(lp0
(dp1
S'line'
p2
S'Moreover, CSTF2, POLA1, HMOX2, and EFNB2 may be associated with the prognosis of bladder cancer patient.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I24
sS'uniprot'
p8
VP30519
p9
sS'lengthInChars'
p10
I5
sS'name'
p11
VHMOX2
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I17
sg8
VP09884
p15
sg10
I5
sg11
VPOLA1
p16
sg13
I1
sa(dp17
g7
I35
sg8
VP52799
p18
sg10
I5
sg11
VEFNB2
p19
sg13
I1
sa(dp20
g7
I10
sg8
VP33240
p21
sg10
I5
sg11
VCSTF2
p22
sg13
I1
sasS'diseases'
p23
(lp24
(dp25
g7
I81
sS'cui'
p26
VC0699885
p27
sg10
I14
sg11
Vbladder cancer
p28
sg13
I2
sasa(dp29
g2
S'Accordingly, RNAi-induced silencing of CSTF2 decreased the proliferative rate of cancer cells.\n'
p30
sg4
(lp31
(dp32
g7
I39
sg8
VP33240
p33
sg10
I5
sg11
VCSTF2
p34
sg13
I1
sasg23
(lp35
(dp36
g7
I81
sg26
VC0006826
p37
sg10
I6
sg11
Vcancer
p38
sg13
I1
sa(dp39
g7
I59
sg26
VC0334094
p40
sg10
I13
sg11
Vproliferative
p41
sg13
I1
sasa(dp42
g2
S'Immunohistochemical staining using tissue microarray consisting of 327 lung cancers was applied to examine the expression of CSTF2 protein and its prognostic value.\n'
p43
sg4
(lp44
(dp45
g7
I125
sg8
VP33240
p46
sg10
I13
sg11
VCSTF2 protein
p47
sg13
I2
sasg23
(lp48
(dp49
g7
I71
sg26
VC0242379
p50
sg10
I12
sg11
Vlung cancers
p51
sg13
I2
sasa(dp52
g2
S'A role of CSTF2 in cancer cell growth was examined by siRNA experiments.\n'
p53
sg4
(lp54
(dp55
g7
I10
sg8
VP33240
p56
sg10
I5
sg11
VCSTF2
p57
sg13
I1
sasg23
(lp58
(dp59
g7
I19
sg26
VC1516170
p60
sg10
I18
sg11
Vcancer cell growth
p61
sg13
I3
sasa(dp62
g2
S'Immunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor.\n'
p63
sg4
(lp64
(dp65
g7
I85
sg8
VP33240
p66
sg10
I5
sg11
VCSTF2
p67
sg13
I1
sa(dp68
g7
I85
sg8
VP33240
p69
sg10
I5
sg11
VCSTF2
p70
sg13
I1
sasg23
(lp71
(dp72
g7
I139
sg26
VC0007131
p73
sg10
I26
sg11
Vnon-small cell lung cancer
p74
sg13
I4
sasa(dp75
g2
S'In addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.\n'
p76
sg4
(lp77
(dp78
g7
I28
sg8
VP33240
p79
sg10
I5
sg11
VCSTF2
p80
sg13
I1
sa(dp81
g7
I28
sg8
VP33240
p82
sg10
I5
sg11
VCSTF2
p83
sg13
I1
sasg23
(lp84
(dp85
g7
I71
sg26
VC1516170
p86
sg10
I18
sg11
Vcancer cell growth
p87
sg13
I3
sa(dp88
g7
I13
sg26
VC0221103
p89
sg10
I11
sg11
Vsuppression
p90
sg13
I1
sa(dp91
g7
I149
sg26
VC2699153
p92
sg10
I8
sg11
Vinvasion
p93
sg13
I1
sasa(dp94
g2
S'Immunohistochemical PD-L1 expression was evaluated in 84 vSCCs with previously defined status of p16 and DNA-HPV, infiltration of immune cells: CD8+, CD4+, FOXP3+, CD56+, CD68+, and GZB+ cells.\n'
p95
sg4
(lp96
(dp97
g7
I97
sg8
VP42771
p98
sg10
I3
sg11
Vp16
p99
sg13
I1
sa(dp100
g7
I144
sg8
VP01732
p101
sg10
I4
sg11
VCD8+
p102
sg13
I1
sa(dp103
g7
I171
sg8
VP34810
p104
sg10
I5
sg11
VCD68+
p105
sg13
I1
sa(dp106
g7
I156
sg8
S''
p107
sg10
I6
sg11
VFOXP3+
p108
sg13
I1
sa(dp109
g7
I150
sg8
VP01730
p110
sg10
I4
sg11
VCD4+
p111
sg13
I1
sa(dp112
g7
I105
sg8
g107
sg10
I7
sg11
VDNA-HPV
p113
sg13
I1
sasg23
(lp114
(dp115
g7
I114
sg26
VC0332448
p116
sg10
I12
sg11
Vinfiltration
p117
sg13
I1
sasa(dp118
g2
S'CD163, as a promising TAMs marker, is superior to CD68 for predicting the malignant transformation and metastatic potential of cervical cancer.\n'
p119
sg4
(lp120
(dp121
g7
I50
sg8
VP34810
p122
sg10
I4
sg11
VCD68
p123
sg13
I1
sa(dp124
g7
I0
sg8
g107
sg10
I5
sg11
VCD163
p125
sg13
I1
sasg23
(lp126
(dp127
g7
I74
sg26
VC1608408
p128
sg10
I24
sg11
Vmalignant transformation
p129
sg13
I2
sa(dp130
g7
I127
sg26
VC0302592
p131
sg10
I15
sg11
Vcervical cancer
p132
sg13
I2
sasa(dp133
g2
S'Immunohistochemistry analysis of cellular immune parameters (CD4+ or CD8+ T cells, CIITA, MHC-II and CD68) was performed on NMU-induced rat mammary tumor nodules, followed by evaluation of the serum level of 34 cytokines using the cytokine antibody array.\n'
p134
sg4
(lp135
(dp136
g7
I90
sg8
VP13747
p137
sg10
I6
sg11
VMHC-II
p138
sg13
I1
sa(dp139
g7
I69
sg8
VP01732
p140
sg10
I4
sg11
VCD8+
p141
sg13
I1
sa(dp142
g7
I83
sg8
VP33076
p143
sg10
I5
sg11
VCIITA
p144
sg13
I1
sa(dp145
g7
I61
sg8
VP01730
p146
sg10
I4
sg11
VCD4+
p147
sg13
I1
sa(dp148
g7
I101
sg8
VP34810
p149
sg10
I4
sg11
VCD68
p150
sg13
I1
sasg23
(lp151
(dp152
g7
I154
sg26
VC0028259
p153
sg10
I7
sg11
Vnodules
p154
sg13
I1
sa(dp155
g7
I140
sg26
VC1458155
p156
sg10
I13
sg11
Vmammary tumor
p157
sg13
I2
sasa(dp158
g2
S'Immunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype.\n'
p159
sg4
(lp160
(dp161
g7
I106
sg8
VP34810
p162
sg10
I4
sg11
VCD68
p163
sg13
I1
sa(dp164
g7
I142
sg8
VP01765
p165
sg10
I3
sg11
VTIL
p166
sg13
I1
sa(dp167
g7
I93
sg8
VP01732
p168
sg10
I3
sg11
VCD8
p169
sg13
I1
sa(dp170
g7
I98
sg8
VP01730
p171
sg10
I3
sg11
VCD4
p172
sg13
I1
sa(dp173
g7
I111
sg8
VP01765
p174
sg10
I29
sg11
Vtumor-infiltrating leucocytes
p175
sg13
I2
sasg23
(lp176
(dp177
g7
I54
sg26
VC0027651
p178
sg10
I5
sg11
Vtumor
p179
sg13
I1
sa(dp180
g7
I54
sg26
VC0027651
p181
sg10
I5
sg11
Vtumor
p182
sg13
I1
sa(dp183
g7
I117
sg26
VC0332448
p184
sg10
I12
sg11
Vinfiltrating
p185
sg13
I1
sa(dp186
g7
I166
sg26
VC0006142
p187
sg10
I14
sg11
Vbreast cancers
p188
sg13
I2
sasa(dp189
g2
S'These findings demonstrate, for the first time, a novel capacity of a P-Alexa647-FA conjugate to colocalize to CD11b+CD68+ TAMs in both primary and metastatic breast tumors.\n'
p190
sg4
(lp191
(dp192
g7
I111
sg8
VP11215
p193
sg10
I16
sg11
VCD11b+CD68+ TAMs
p194
sg13
I2
sasg23
(lp195
(dp196
g7
I159
sg26
VC1458155
p197
sg10
I13
sg11
Vbreast tumors
p198
sg13
I2
sasa(dp199
g2
S'We used breast tumor tissues from each patient to make tissue microarrays that were then stained for leukocyte and myeloid markers including CD4, CD8, CD20, CD25, CD68, and CD163 using immunohistochemical techniques.\n'
p200
sg4
(lp201
(dp202
g7
I151
sg8
VP35900
p203
sg10
I4
sg11
VCD20
p204
sg13
I1
sa(dp205
g7
I173
sg8
g107
sg10
I5
sg11
VCD163
p206
sg13
I1
sa(dp207
g7
I146
sg8
VP01732
p208
sg10
I3
sg11
VCD8
p209
sg13
I1
sa(dp210
g7
I157
sg8
VP01589
p211
sg10
I4
sg11
VCD25
p212
sg13
I1
sa(dp213
g7
I163
sg8
VP34810
p214
sg10
I4
sg11
VCD68
p215
sg13
I1
sa(dp216
g7
I141
sg8
VP01730
p217
sg10
I3
sg11
VCD4
p218
sg13
I1
sasg23
(lp219
(dp220
g7
I8
sg26
VC1458155
p221
sg10
I12
sg11
Vbreast tumor
p222
sg13
I2
sasa(dp223
g2
S'Characterisation of most mutations found in CLCN2 in patients with CC2L leukodystrophy show that they cause a reduction in function of the chloride channel ClC-2.\n'
p224
sg4
(lp225
(dp226
g7
I139
sg8
VP51800
p227
sg10
I22
sg11
Vchloride channel ClC-2
p228
sg13
I3
sasg23
(lp229
(dp230
g7
I72
sg26
VC0023520
p231
sg10
I14
sg11
Vleukodystrophy
p232
sg13
I1
sasa(dp233
g2
S'GlialCAM, a regulatory subunit of ClC-2 in glial cells and involved in the leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC), increases the activity of a ClC-2 mutant by affecting ClC-2 gating and by stabilising the mutant at the plasma membrane.\n'
p234
sg4
(lp235
(dp236
g7
I0
sg8
g107
sg10
I8
sg11
VGlialCAM
p237
sg13
I1
sa(dp238
g7
I184
sg8
VP51788
p239
sg10
I12
sg11
VClC-2 mutant
p240
sg13
I2
sa(dp241
g7
I34
sg8
VP51788
p242
sg10
I5
sg11
VClC-2
p243
sg13
I1
sasg23
(lp244
(dp245
g7
I90
sg26
VC1858854
p246
sg10
I58
sg11
Vmegalencephalic leukoencephalopathy with subcortical cysts
p247
sg13
I5
sa(dp248
g7
I190
sg26
VC0596988
p249
sg10
I6
sg11
Vmutant
p250
sg13
I1
sa(dp251
g7
I75
sg26
VC0023520
p252
sg10
I14
sg11
Vleukodystrophy
p253
sg13
I1
sa(dp254
g7
I190
sg26
VC0596988
p255
sg10
I6
sg11
Vmutant
p256
sg13
I1
sa(dp257
g7
I150
sg26
VC1858854
p258
sg10
I3
sg11
VMLC
p259
sg13
I1
sasa(dp260
g2
S'We suggest that leukodystrophy-causing CLCN2 mutations reduce the functional expression of ClC-2, which is partly counteracted by GlialCAM/MLC1-mediated increase in the gating and stability of the channel.\n'
p261
sg4
(lp262
(dp263
g7
I139
sg8
VP12829
p264
sg10
I4
sg11
VMLC1
p265
sg13
I1
sa(dp266
g7
I130
sg8
g107
sg10
I8
sg11
VGlialCAM
p267
sg13
I1
sa(dp268
g7
I91
sg8
VP51788
p269
sg10
I5
sg11
VClC-2
p270
sg13
I1
sa(dp271
g7
I39
sg8
VP51788
p272
sg10
I15
sg11
VCLCN2 mutations
p273
sg13
I2
sasg23
(lp274
(dp275
g7
I139
sg26
VC1858854
p276
sg10
I4
sg11
VMLC1
p277
sg13
I1
sa(dp278
g7
I16
sg26
VC0023520
p279
sg10
I14
sg11
Vleukodystrophy
p280
sg13
I1
sasa(dp281
g2
S"The review then discusses the diseases associated with ClC-2, including degeneration of the retina, Sjoegren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus.\n"
p282
sg4
(lp283
(dp284
g7
I55
sg8
VP51788
p285
sg10
I5
sg11
VClC-2
p286
sg13
I1
sasg23
(lp287
(dp288
g7
I268
sg26
VC0010674
p289
sg10
I15
sg11
Vcystic fibrosis
p290
sg13
I2
sa(dp291
g7
I306
sg26
VC0014544
p292
sg10
I8
sg11
Vepilepsy
p293
sg13
I1
sa(dp294
g7
I285
sg26
VC0270612
p295
sg10
I19
sg11
Vleukoencephalopathy
p296
sg13
I1
sa(dp297
g7
I133
sg26
VC0521707
p298
sg10
I9
sg11
Vcataracts
p299
sg13
I1
sa(dp300
g7
I72
sg26
VC0011164
p301
sg10
I12
sg11
Vdegeneration
p302
sg13
I1
sa(dp303
g7
I185
sg26
VC0684249
p304
sg10
I11
sg11
Vlung cancer
p305
sg13
I2
sa(dp306
g7
I258
sg26
VC0023418
p307
sg10
I8
sg11
Vleukemia
p308
sg13
I1
sa(dp309
g7
I100
sg26
VC1527336
p310
sg10
I19
sg11
VSjoegren's syndrome
p311
sg13
I2
sa(dp312
g7
I222
sg26
VC0684336
p313
sg10
I8
sg11
Vimpaired
p314
sg13
I1
sa(dp315
g7
I72
sg26
VC0011164
p316
sg10
I12
sg11
Vdegeneration
p317
sg13
I1
sa(dp318
g7
I198
sg26
VC0009806
p319
sg10
I12
sg11
Vconstipation
p320
sg13
I1
sa(dp321
g7
I172
sg26
VC1321542
p322
sg10
I11
sg11
Vazoospermia
p323
sg13
I1
sa(dp324
g7
I319
sg26
VC0011849
p325
sg10
I17
sg11
Vdiabetes mellitus
p326
sg13
I2
sasa(dp327
g2
S'A subset of these genes has been implicated in other neurobehavioral disorders including depression (SLIT3), epilepsy (CLCN2, PRICKLE1), intellectual disability (AP4M1), schizophrenia (WDR60), and Tourette syndrome (OFCC1).\n'
p328
sg4
(lp329
(dp330
g7
I126
sg8
g107
sg10
I8
sg11
VPRICKLE1
p331
sg13
I1
sa(dp332
g7
I162
sg8
g107
sg10
I5
sg11
VAP4M1
p333
sg13
I1
sa(dp334
g7
I101
sg8
g107
sg10
I5
sg11
VSLIT3
p335
sg13
I1
sa(dp336
g7
I185
sg8
g107
sg10
I5
sg11
VWDR60
p337
sg13
I1
sa(dp338
g7
I109
sg8
VP10646
p339
sg10
I8
sg11
Vepilepsy
p340
sg13
I1
sa(dp341
g7
I119
sg8
VP51788
p342
sg10
I5
sg11
VCLCN2
p343
sg13
I1
sasg23
(lp344
(dp345
g7
I137
sg26
VC0025362
p346
sg10
I23
sg11
Vintellectual disability
p347
sg13
I2
sa(dp348
g7
I170
sg26
VC0036341
p349
sg10
I13
sg11
Vschizophrenia
p350
sg13
I1
sa(dp351
g7
I109
sg26
VC0014544
p352
sg10
I8
sg11
Vepilepsy
p353
sg13
I1
sa(dp354
g7
I89
sg26
VC0011581
p355
sg10
I10
sg11
Vdepression
p356
sg13
I1
sa(dp357
g7
I197
sg26
VC0040517
p358
sg10
I17
sg11
VTourette syndrome
p359
sg13
I2
sasa(dp360
g2
S'Epilepsy with grand mal on awakening (EGMA) is a well-defined subtype of idiopathic generalized epilepsy.\n'
p361
sg4
(lp362
sg23
(lp363
(dp364
g7
I73
sg26
VC0270850
p365
sg10
I31
sg11
Vidiopathic generalized epilepsy
p366
sg13
I3
sa(dp367
g7
I0
sg26
VC0014544
p368
sg10
I8
sg11
VEpilepsy
p369
sg13
I1
sa(dp370
g7
I14
sg26
VC0494475
p371
sg10
I9
sg11
Vgrand mal
p372
sg13
I2
sasa(dp373
g2
S'Additionally, using global gene expression analysis of partially reprogrammed cells, we identified SNAI3 as a novel invasion-related marker in human melanoma.\n'
p374
sg4
(lp375
(dp376
g7
I99
sg8
g107
sg10
I5
sg11
VSNAI3
p377
sg13
I1
sasg23
(lp378
(dp379
g7
I149
sg26
VC0025202
p380
sg10
I8
sg11
Vmelanoma
p381
sg13
I1
sa(dp382
g7
I116
sg26
VC2699153
p383
sg10
I8
sg11
Vinvasion
p384
sg13
I1
sasa(dp385
g2
S'SNAI3 expression correlates with tumor thickness in primary melanomas and thus, may be of prognostic value.\n'
p386
sg4
(lp387
(dp388
g7
I0
sg8
g107
sg10
I5
sg11
VSNAI3
p389
sg13
I1
sasg23
(lp390
(dp391
g7
I60
sg26
VC0025202
p392
sg10
I9
sg11
Vmelanomas
p393
sg13
I1
sa(dp394
g7
I33
sg26
VC0027651
p395
sg10
I5
sg11
Vtumor
p396
sg13
I1
sasa(dp397
g2
S'Effective silencing of Runx2 by short interfering RNA (siRNA) demonstrated downregulation of EMT-related molecules (SNAI2, SNAI3 and TWIST1), MMP2 and vasculogenic factors (VEGFA and VEGFC) in thyroid carcinoma cells.\n'
p398
sg4
(lp399
(dp400
g7
I123
sg8
g107
sg10
I5
sg11
VSNAI3
p401
sg13
I1
sa(dp402
g7
I142
sg8
VP08253
p403
sg10
I4
sg11
VMMP2
p404
sg13
I1
sa(dp405
g7
I133
sg8
g107
sg10
I6
sg11
VTWIST1
p406
sg13
I1
sa(dp407
g7
I93
sg8
g107
sg10
I21
sg11
VEMT-related molecules
p408
sg13
I2
sa(dp409
g7
I23
sg8
g107
sg10
I5
sg11
VRunx2
p410
sg13
I1
sa(dp411
g7
I183
sg8
VP49767
p412
sg10
I5
sg11
VVEGFC
p413
sg13
I1
sa(dp414
g7
I116
sg8
g107
sg10
I5
sg11
VSNAI2
p415
sg13
I1
sa(dp416
g7
I151
sg8
VP19883
p417
sg10
I20
sg11
Vvasculogenic factors
p418
sg13
I2
sasg23
(lp419
(dp420
g7
I193
sg26
VC0549473
p421
sg10
I17
sg11
Vthyroid carcinoma
p422
sg13
I2
sasa(dp423
g2
S'Thyroid-stimulating hormone levels, goiter and thyroid dysfunction were higher in children who were anti-TPO1 than in diabetic children without thyroid autoimmunity.\n'
p424
sg4
(lp425
(dp426
g7
I0
sg8
VP01222
p427
sg10
I27
sg11
VThyroid-stimulating hormone
p428
sg13
I2
sa(dp429
g7
I100
sg8
g107
sg10
I9
sg11
Vanti-TPO1
p430
sg13
I1
sasg23
(lp431
(dp432
g7
I36
sg26
VC0018021
p433
sg10
I6
sg11
Vgoiter
p434
sg13
I1
sa(dp435
g7
I152
sg26
VC0004368
p436
sg10
I12
sg11
Vautoimmunity
p437
sg13
I1
sa(dp438
g7
I47
sg26
VC0348024
p439
sg10
I19
sg11
Vthyroid dysfunction
p440
sg13
I2
sasa(dp441
g2
S'Multiplex ligation-dependent probe amplification (MLPA) can be used to detect rearrangements that cause Alfa-thalassemia, particularly large deletions involving the whole Alfa cluster and/or deletions in the HS-40 region.\n'
p442
sg4
(lp443
(dp444
g7
I208
sg8
g107
sg10
I12
sg11
VHS-40 region
p445
sg13
I2
sasg23
(lp446
(dp447
g7
I109
sg26
VC0039730
p448
sg10
I11
sg11
Vthalassemia
p449
sg13
I1
sa(dp450
g7
I35
sg26
VC1705759
p451
sg10
I13
sg11
Vamplification
p452
sg13
I1
sasa(dp453
g2
S'In addition to the -Alfa3.7 deletion identified in the patients with Hb H disease, four different Alfa0 deletions removing 15 to 225 kb DNA segments were found: two of them remove both the Alfa genes, one affects only the regulatory element (HS-40) region, and another one extends over the entire Alfa cluster and the HS-40 region.\n'
p454
sg4
(lp455
(dp456
g7
I318
sg8
g107
sg10
I12
sg11
VHS-40 region
p457
sg13
I2
sasg23
(lp458
(dp459
g7
I72
sg26
VC0018609
p460
sg10
I9
sg11
VH disease
p461
sg13
I2
sasa(dp462
g2
S'The impact of urinary VDBP and KIM-1 on MARE was independent of known CIN risk factors such as anemia, preexisting renal failure, preexisting heart failure, and diabetes.\n'
p463
sg4
(lp464
(dp465
g7
I40
sg8
g107
sg10
I4
sg11
VMARE
p466
sg13
I1
sa(dp467
g7
I31
sg8
g107
sg10
I5
sg11
VKIM-1
p468
sg13
I1
sa(dp469
g7
I22
sg8
VP02774
p470
sg10
I4
sg11
VVDBP
p471
sg13
I1
sasg23
(lp472
(dp473
g7
I95
sg26
VC0002871
p474
sg10
I6
sg11
Vanemia
p475
sg13
I1
sa(dp476
g7
I70
sg26
VC0206708
p477
sg10
I3
sg11
VCIN
p478
sg13
I1
sa(dp479
g7
I142
sg26
VC0018802
p480
sg10
I13
sg11
Vheart failure
p481
sg13
I2
sa(dp482
g7
I115
sg26
VC0035078
p483
sg10
I13
sg11
Vrenal failure
p484
sg13
I2
sa(dp485
g7
I161
sg26
VC0011849
p486
sg10
I8
sg11
Vdiabetes
p487
sg13
I1
sasa(dp488
g2
S'The data show that a tandem Maf recognition element (MARE) in locus control region (LCR) hypersensitive site 2 (HS2) reveals a remarkably high degree of occupancy during differentiation of mouse erythroleukemia cells.\n'
p489
sg4
(lp490
(dp491
g7
I53
sg8
g107
sg10
I4
sg11
VMARE
p492
sg13
I1
sa(dp493
g7
I28
sg8
g107
sg10
I23
sg11
VMaf recognition element
p494
sg13
I3
sasg23
(lp495
(dp496
g7
I195
sg26
VC0023440
p497
sg10
I15
sg11
Verythroleukemia
p498
sg13
I1
sasa(dp499
g2
S'Targeting of an artificial zinc finger DNA-binding domain (ZF-DBD) to the HS2 tandem MARE caused a reduction in the association of MARE-binding proteins and transcription complexes at LCR HS2 and the adult Betamajor-globin gene promoter but did not affect expression of the Betaminor-globin gene.\n'
p500
sg4
(lp501
(dp502
g7
I27
sg8
g107
sg10
I30
sg11
Vzinc finger DNA-binding domain
p503
sg13
I4
sa(dp504
g7
I59
sg8
g107
sg10
I6
sg11
VZF-DBD
p505
sg13
I1
sa(dp506
g7
I131
sg8
g107
sg10
I21
sg11
VMARE-binding proteins
p507
sg13
I2
sasg23
(lp508
sa(dp509
g2
S'The data demonstrate that a stable MARE-associated footprint in LCR HS2 is important for the recruitment of transcription complexes to the adult Betamajor-globin gene promoter during erythroid cell differentiation.\n'
p510
sg4
(lp511
sg23
(lp512
(dp513
g7
I93
sg26
VC0271510
p514
sg10
I11
sg11
Vrecruitment
p515
sg13
I1
sasa(dp516
g2
S'Next, we demonstrate that CD172a(+)Slan DCs that produced IL-1Beta and TNF-Alfa accumulated in mLNs and colons of CD patients.\n'
p517
sg4
(lp518
(dp519
g7
I71
sg8
VP01375
p520
sg10
I8
sg11
VTNF-Alfa
p521
sg13
I1
sa(dp522
g7
I58
sg8
VP01584
p523
sg10
I8
sg11
VIL-1Beta
p524
sg13
I1
sasg23
(lp525
(dp526
g7
I95
sg26
VC0026691
p527
sg10
I4
sg11
VmLNs
p528
sg13
I1
sa(dp529
g7
I40
sg26
VC0268238
p530
sg10
I3
sg11
VDCs
p531
sg13
I1
sasa(dp532
g2
S'In conclusion, we propose that proinflammatory CD14(bright)CD172a(+)Slan DCs are a distinguishing feature between CD and UC, as these cells accumulate uniquely in mLNs and colonic mucosa of CD patients.\n'
p533
sg4
(lp534
(dp535
g7
I47
sg8
VP08571
p536
sg10
I29
sg11
VCD14(bright)CD172a(+)Slan DCs
p537
sg13
I2
sasg23
(lp538
(dp539
g7
I73
sg26
VC0268238
p540
sg10
I3
sg11
VDCs
p541
sg13
I1
sa(dp542
g7
I163
sg26
VC0026691
p543
sg10
I4
sg11
VmLNs
p544
sg13
I1
sasa(dp545
g2
S"Here, we show that CD172a(+)CD11c(+) cells accumulate in the mesenteric lymph nodes (mLNs) and inflamed intestinal mucosa in patients with Crohn's disease (CD).\n"
p546
sg4
(lp547
(dp548
g7
I19
sg8
VP20702
p549
sg10
I14
sg11
VCD172a(+)CD11c
p550
sg13
I1
sasg23
(lp551
(dp552
g7
I85
sg26
VC0026691
p553
sg10
I4
sg11
VmLNs
p554
sg13
I1
sa(dp555
g7
I139
sg26
VC0010346
p556
sg10
I15
sg11
VCrohn's disease
p557
sg13
I2
sa(dp558
g7
I61
sg26
VC0026691
p559
sg10
I22
sg11
Vmesenteric lymph nodes
p560
sg13
I3
sa(dp561
g7
I19
sg26
VC0010346
p562
sg10
I2
sg11
VCD
p563
sg13
I1
sasa(dp564
g2
S'An avidity-improved CD47 fusion protein (CD47-Var1) suppresses the release of a wide array of inflammatory cytokines by CD172a(+) cells, which may include HLA-DR(-)CD172a(+) neutrophils, in inflamed colonic explant cultures and impairs the ability of HLA-DR(+)CD172a(+) cells to activate memory Th17 but not Th1 responses in mLNs.\n'
p565
sg4
(lp566
(dp567
g7
I41
sg8
g107
sg10
I9
sg11
VCD47-Var1
p568
sg13
I1
sa(dp569
g7
I251
sg8
VP30486
p570
sg10
I15
sg11
VHLA-DR(+)CD172a
p571
sg13
I1
sa(dp572
g7
I155
sg8
VP30486
p573
sg10
I15
sg11
VHLA-DR(-)CD172a
p574
sg13
I1
sa(dp575
g7
I20
sg8
g107
sg10
I19
sg11
VCD47 fusion protein
p576
sg13
I3
sasg23
(lp577
(dp578
g7
I325
sg26
VC0026691
p579
sg10
I4
sg11
VmLNs
p580
sg13
I1
sasa(dp581
g2
S'We first show that mucosal CD103(-) DCs selectively express SIRPalpha and that their frequency was augmented in the lamina propria and mLNs of mice that developed Th17-biased colitis in response to trinitrobenzene sulfonic acid.\n'
p582
sg4
(lp583
(dp584
g7
I27
sg8
VP38570
p585
sg10
I12
sg11
VCD103(-) DCs
p586
sg13
I2
sasg23
(lp587
(dp588
g7
I135
sg26
VC0026691
p589
sg10
I4
sg11
VmLNs
p590
sg13
I1
sa(dp591
g7
I36
sg26
VC0268238
p592
sg10
I3
sg11
VDCs
p593
sg13
I1
sa(dp594
g7
I175
sg26
VC0009319
p595
sg10
I7
sg11
Vcolitis
p596
sg13
I1
sasa(dp597
g2
S'CD47 expression was required on the SIRPalpha(+)CD103(-) DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on both DCs and T cells for Th17 polarization in vitro.\n'
p598
sg4
(lp599
(dp600
g7
I36
sg8
VP38570
p601
sg10
I20
sg11
VSIRPalpha(+)CD103(-)
p602
sg13
I1
sa(dp603
g7
I0
sg8
g107
sg10
I4
sg11
VCD47
p604
sg13
I1
sasg23
(lp605
(dp606
g7
I57
sg26
VC0268238
p607
sg10
I3
sg11
VDCs
p608
sg13
I1
sa(dp609
g7
I57
sg26
VC0268238
p610
sg10
I3
sg11
VDCs
p611
sg13
I1
sa(dp612
g7
I90
sg26
VC0026691
p613
sg10
I4
sg11
VmLNs
p614
sg13
I1
sasa(dp615
g2
S'Effects of Ca2+ and calmodulin on the adenylate cyclase activity of a prolactin and growth hormone-producing pituitary tumor cell strain (GH3) were examined.\n'
p616
sg4
(lp617
(dp618
g7
I38
sg8
g107
sg10
I17
sg11
Vadenylate cyclase
p619
sg13
I2
sa(dp620
g7
I84
sg8
VP01242
p621
sg10
I14
sg11
Vgrowth hormone
p622
sg13
I2
sa(dp623
g7
I20
sg8
g107
sg10
I10
sg11
Vcalmodulin
p624
sg13
I1
sa(dp625
g7
I70
sg8
VP01236
p626
sg10
I9
sg11
Vprolactin
p627
sg13
I1
sasg23
(lp628
(dp629
g7
I84
sg26
VC0278864
p630
sg10
I40
sg11
Vgrowth hormone-producing pituitary tumor
p631
sg13
I4
sasa(dp632
g2
S'The control of PTG hyperplasia is most important in the management of secondary hyperparathyroidism (SHPT), because the advanced stage of hyperplasia is considered irreversible.\n'
p633
sg4
(lp634
sg23
(lp635
(dp636
g7
I19
sg26
VC0020507
p637
sg10
I11
sg11
Vhyperplasia
p638
sg13
I1
sa(dp639
g7
I101
sg26
VC0020503
p640
sg10
I4
sg11
VSHPT
p641
sg13
I1
sa(dp642
g7
I19
sg26
VC0020507
p643
sg10
I11
sg11
Vhyperplasia
p644
sg13
I1
sa(dp645
g7
I70
sg26
VC0020503
p646
sg10
I29
sg11
Vsecondary hyperparathyroidism
p647
sg13
I2
sasa(dp648
g2
S'Control of secondary hyperparathyroidism (SHPT) using active vitamin D analogues becomes difficult in advanced SHPT, because the enlarged parathyroid glands (PTGs) are resistant to medical therapy.\n'
p649
sg4
(lp650
sg23
(lp651
(dp652
g7
I11
sg26
VC0020503
p653
sg10
I29
sg11
Vsecondary hyperparathyroidism
p654
sg13
I2
sa(dp655
g7
I42
sg26
VC0020503
p656
sg10
I4
sg11
VSHPT
p657
sg13
I1
sa(dp658
g7
I42
sg26
VC0020503
p659
sg10
I4
sg11
VSHPT
p660
sg13
I1
sasa(dp661
g2
S'The long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT).\n'
p662
sg4
(lp663
sg23
(lp664
(dp665
g7
I193
sg26
VC0020503
p666
sg10
I4
sg11
VSHPT
p667
sg13
I1
sa(dp668
g7
I162
sg26
VC0020503
p669
sg10
I29
sg11
Vsecondary hyperparathyroidism
p670
sg13
I2
sasa(dp671
g2
S'It has been suggested that microRNA-9 (miR-9) is associated with the development of knee osteoarthritis (OA).\n'
p672
sg4
(lp673
(dp674
g7
I27
sg8
g107
sg10
I10
sg11
VmicroRNA-9
p675
sg13
I1
sa(dp676
g7
I39
sg8
g107
sg10
I5
sg11
VmiR-9
p677
sg13
I1
sasg23
(lp678
(dp679
g7
I84
sg26
VC0409959
p680
sg10
I19
sg11
Vknee osteoarthritis
p681
sg13
I2
sasa(dp682
g2
S'X-linked hypophosphatemia (XLH), autosomal dominant HR (ADHR), and autosomal recessive HR (ARHR) are examples of hereditary forms of HR, which are mainly caused by mutations in the phosphate regulating endopeptidase homolog, X-linked (PHEX), FGF23, and, dentin matrix protein-1 (DMP1) and ecto-nucleotide pyro phosphatase/phosphodiesterase 1 (ENPP1) genes, respectively.\n'
p683
sg4
(lp684
(dp685
g7
I242
sg8
g107
sg10
I5
sg11
VFGF23
p686
sg13
I1
sa(dp687
g7
I202
sg8
g107
sg10
I31
sg11
Vendopeptidase homolog, X-linked
p688
sg13
I3
sa(dp689
g7
I33
sg8
VP56715
p690
sg10
I21
sg11
Vautosomal dominant HR
p691
sg13
I3
sa(dp692
g7
I254
sg8
g107
sg10
I23
sg11
Vdentin matrix protein-1
p693
sg13
I3
sa(dp694
g7
I56
sg8
VP30518
p695
sg10
I4
sg11
VADHR
p696
sg13
I1
sa(dp697
g7
I279
sg8
g107
sg10
I4
sg11
VDMP1
p698
sg13
I1
sa(dp699
g7
I343
sg8
VP22413
p700
sg10
I5
sg11
VENPP1
p701
sg13
I1
sa(dp702
g7
I235
sg8
VP78562
p703
sg10
I4
sg11
VPHEX
p704
sg13
I1
sa(dp705
g7
I289
sg8
VP22413
p706
sg10
I52
sg11
Vecto-nucleotide pyro phosphatase/phosphodiesterase 1
p707
sg13
I4
sasg23
(lp708
(dp709
g7
I0
sg26
VC0733682
p710
sg10
I25
sg11
VX-linked hypophosphatemia
p711
sg13
I2
sa(dp712
g7
I91
sg26
VC0342643
p713
sg10
I4
sg11
VARHR
p714
sg13
I1
sa(dp715
g7
I33
sg26
VC0342642
p716
sg10
I21
sg11
Vautosomal dominant HR
p717
sg13
I3
sa(dp718
g7
I56
sg26
VC0342642
p719
sg10
I4
sg11
VADHR
p720
sg13
I1
sa(dp721
g7
I27
sg26
VC0733682
p722
sg10
I3
sg11
VXLH
p723
sg13
I1
sa(dp724
g7
I67
sg26
VC0342643
p725
sg10
I22
sg11
Vautosomal recessive HR
p726
sg13
I3
sasa(dp727
g2
S'Homozygous inactivating mutations in DMP1 (dentin matrix protein 1), the gene encoding a noncollagenous bone matrix protein expressed in osteoblasts and osteocytes, cause autosomal recessive hypophosphatemia (ARHP).\n'
p728
sg4
(lp729
sg23
(lp730
(dp731
g7
I171
sg26
VC0342643
p732
sg10
I36
sg11
Vautosomal recessive hypophosphatemia
p733
sg13
I3
sa(dp734
g7
I209
sg26
VC0342643
p735
sg10
I4
sg11
VARHP
p736
sg13
I1
sasa(dp737
g2
S'An autosomal recessive form of hypophosphatemia (ARHP) was recently shown to be caused by homozygous mutations in DMP1, the gene encoding dentin matrix protein-1 (DMP-1), a non-collagenous bone matrix protein with an important role in the development and mineralization of bone and teeth.\n'
p738
sg4
(lp739
(dp740
g7
I163
sg8
g107
sg10
I5
sg11
VDMP-1
p741
sg13
I1
sa(dp742
g7
I173
sg8
VP63145
p743
sg10
I35
sg11
Vnon-collagenous bone matrix protein
p744
sg13
I4
sa(dp745
g7
I124
sg8
g107
sg10
I37
sg11
Vgene encoding dentin matrix protein-1
p746
sg13
I5
sa(dp747
g7
I114
sg8
g107
sg10
I4
sg11
VDMP1
p748
sg13
I1
sasg23
(lp749
(dp750
g7
I49
sg26
VC0342643
p751
sg10
I4
sg11
VARHP
p752
sg13
I1
sa(dp753
g7
I3
sg26
VC0342643
p754
sg10
I44
sg11
Vautosomal recessive form of hypophosphatemia
p755
sg13
I5
sasa(dp756
g2
S'Among various causes of low serum phosphorous are inherited disorders associated with increased urinary excretion of phosphate, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemia (ARHP), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH).\n'
p757
sg4
(lp758
(dp759
g7
I183
sg8
VP30518
p760
sg10
I4
sg11
VADHR
p761
sg13
I1
sa(dp762
g7
I138
sg8
VP30518
p763
sg10
I43
sg11
Vautosomal dominant hypophosphatemic rickets
p764
sg13
I4
sasg23
(lp765
(dp766
g7
I261
sg26
VC0342643
p767
sg10
I4
sg11
VARHP
p768
sg13
I1
sa(dp769
g7
I138
sg26
VC0342642
p770
sg10
I43
sg11
Vautosomal dominant hypophosphatemic rickets
p771
sg13
I4
sa(dp772
g7
I283
sg26
VC0342645
p773
sg10
I44
sg11
Vhypophosphatemic rickets with hypercalciuria
p774
sg13
I4
sa(dp775
g7
I329
sg26
VC0342645
p776
sg10
I4
sg11
VHHRH
p777
sg13
I1
sa(dp778
g7
I217
sg26
VC0733682
p779
sg10
I3
sg11
VXLH
p780
sg13
I1
sa(dp781
g7
I223
sg26
VC0342643
p782
sg10
I36
sg11
Vautosomal recessive hypophosphatemia
p783
sg13
I3
sa(dp784
g7
I183
sg26
VC0342642
p785
sg10
I4
sg11
VADHR
p786
sg13
I1
sa(dp787
g7
I190
sg26
VC0733682
p788
sg10
I25
sg11
VX-linked hypophosphatemia
p789
sg13
I2
sasa(dp790
g2
S'Recently, positional cloning approaches furthermore led to the identification of homozygous inactivating mutations in dentin matrix protein 1 (DMP1) as the cause of an autosomal recessive form of hypophosphatemia.\n'
p791
sg4
(lp792
(dp793
g7
I118
sg8
VP14222
p794
sg10
I23
sg11
Vdentin matrix protein 1
p795
sg13
I4
sa(dp796
g7
I143
sg8
g107
sg10
I4
sg11
VDMP1
p797
sg13
I1
sasg23
(lp798
(dp799
g7
I196
sg26
VC0085682
p800
sg10
I16
sg11
Vhypophosphatemia
p801
sg13
I1
sasa(dp802
g2
S'Pharmacological treatment of SOD1(G37R) mice with minocycline, a compound that attenuates microgliosis and slows down disease, lessened the dysregulation of Cdk5/Cdk4 and the phosphorylation of Rb.\n'
p803
sg4
(lp804
(dp805
g7
I29
sg8
VP00441
p806
sg10
I4
sg11
VSOD1
p807
sg13
I1
sa(dp808
g7
I157
sg8
g107
sg10
I4
sg11
VCdk5
p809
sg13
I1
sa(dp810
g7
I162
sg8
VP11802
p811
sg10
I4
sg11
VCdk4
p812
sg13
I1
sasg23
(lp813
sa(dp814
g2
S'Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.\n'
p815
sg4
(lp816
(dp817
g7
I57
sg8
VP35398
p818
sg10
I36
sg11
VT-cell-specific transcription factor
p819
sg13
I3
sa(dp820
g7
I276
sg8
VP11473
p821
sg10
I18
sg11
Vvitamin D receptor
p822
sg13
I3
sa(dp823
g7
I109
sg8
VP00519
p824
sg10
I39
sg11
V"proto-oncogene tyrosine-protein kinase
p825
sg13
I3
sa(dp826
g7
I399
sg8
g107
sg10
I31
sg11
VPR domain zinc finger protein 1
p827
sg13
I6
sa(dp828
g7
I322
sg8
VP29323
p829
sg10
I3
sg11
VERK
p830
sg13
I1
sa(dp831
g7
I362
sg8
VP20823
p832
sg10
I35
sg11
Vrunt-related transcription factor 1
p833
sg13
I4
sa(dp834
g7
I477
sg8
VP01584
p835
sg10
I13
sg11
Vinterleukin 1
p836
sg13
I2
sa(dp837
g7
I152
sg8
VP12931
p838
sg10
I8
sg11
Vsarcoma"
p839
sg13
I1
sa(dp840
g7
I163
sg8
VP10914
p841
sg10
I30
sg11
Vinterferon regulatory factor 1
p842
sg13
I4
sa(dp843
g7
I227
sg8
VP49336
p844
sg10
I31
sg11
Vcyclin-dependent kinase (CDK) 4
p845
sg13
I4
sa(dp846
g7
I296
sg8
VP56524
p847
sg10
I19
sg11
Vhistone deacetylase
p848
sg13
I2
sa(dp849
g7
I95
sg8
VP12931
p850
sg10
I3
sg11
VSrc
p851
sg13
I1
sa(dp852
g7
I217
sg8
VP14635
p853
sg10
I8
sg11
Vcyclin B
p854
sg13
I2
sa(dp855
g7
I334
sg8
VP10415
p856
sg10
I26
sg11
Vbcl-2-associated X protein
p857
sg13
I3
sa(dp858
g7
I317
sg8
VP53779
p859
sg10
I4
sg11
VMAPK
p860
sg13
I1
sa(dp861
g7
I432
sg8
VP09619
p862
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p863
sg13
I4
sa(dp864
g7
I265
sg8
VP29466
p865
sg10
I9
sg11
Vcaspase-1
p866
sg13
I1
sa(dp867
g7
I195
sg8
VP04818
p868
sg10
I20
sg11
Vthymidylate synthase
p869
sg13
I2
sa(dp870
g7
I252
sg8
VP24941
p871
sg10
I3
sg11
VCDK
p872
sg13
I1
sasg23
(lp873
(dp874
g7
I152
sg26
VC1261473
p875
sg10
I7
sg11
Vsarcoma
p876
sg13
I1
sa(dp877
g7
I362
sg26
VC0013336
p878
sg10
I4
sg11
Vrunt
p879
sg13
I1
sasa(dp880
g2
S'Therefore, targeting the caspase-1/PPARGamma/MCAD pathway might be a promising therapeutic approach to prevent tumor progression.Tumor associated macrophages (TAMs) promote cancer progression.\n'
p881
sg4
(lp882
(dp883
g7
I45
sg8
VP11310
p884
sg10
I4
sg11
VMCAD
p885
sg13
I1
sa(dp886
g7
I25
sg8
VP29466
p887
sg10
I9
sg11
Vcaspase-1
p888
sg13
I1
sasg23
(lp889
(dp890
g7
I173
sg26
VC0178874
p891
sg10
I18
sg11
Vcancer progression
p892
sg13
I2
sa(dp893
g7
I45
sg26
VC0220710
p894
sg10
I4
sg11
VMCAD
p895
sg13
I1
sa(dp896
g7
I129
sg26
VC0027651
p897
sg10
I5
sg11
VTumor
p898
sg13
I1
sa(dp899
g7
I111
sg26
VC0178874
p900
sg10
I17
sg11
Vtumor progression
p901
sg13
I2
sasa(dp902
g2
S'Here, the author show that caspase-1 promotes TAMs differentiation by attenuating medium-chain acyl-CoA dehydrogenase activity and that inhibition of this axis results in suppression of tumour growth in a transgenic mouse model of breast cancer.\n'
p903
sg4
(lp904
(dp905
g7
I95
sg8
VP49366
p906
sg10
I22
sg11
Vacyl-CoA dehydrogenase
p907
sg13
I2
sa(dp908
g7
I27
sg8
VP29466
p909
sg10
I9
sg11
Vcaspase-1
p910
sg13
I1
sasg23
(lp911
(dp912
g7
I100
sg26
VC2678439
p913
sg10
I3
sg11
VCoA
p914
sg13
I1
sa(dp915
g7
I231
sg26
VC0678222
p916
sg10
I13
sg11
Vbreast cancer
p917
sg13
I2
sa(dp918
g7
I171
sg26
VC0221103
p919
sg10
I11
sg11
Vsuppression
p920
sg13
I1
sa(dp921
g7
I186
sg26
VC0027651
p922
sg10
I6
sg11
Vtumour
p923
sg13
I1
sasa(dp924
g2
S'Ensuing western blotting or immunostaining results showed that Rictor/mTORC2 signaling was activated in kidney interstitial myofibroblasts from mice with unilateral ureteral obstruction.\n'
p925
sg4
(lp926
(dp927
g7
I63
sg8
g107
sg10
I6
sg11
VRictor
p928
sg13
I1
sasg23
(lp929
(dp930
g7
I165
sg26
VC0041956
p931
sg10
I20
sg11
Vureteral obstruction
p932
sg13
I2
sasa(dp933
g2
S'Compared with control littermates, the kidneys of Rictor knockout mice developed less interstitial extracellular matrix deposition and inflammatory cell infiltration at 1 or 2 weeks after ureteral obstruction.\n'
p934
sg4
(lp935
sg23
(lp936
(dp937
g7
I188
sg26
VC0041956
p938
sg10
I20
sg11
Vureteral obstruction
p939
sg13
I2
sa(dp940
g7
I135
sg26
VC0302158
p941
sg10
I30
sg11
Vinflammatory cell infiltration
p942
sg13
I3
sasa(dp943
g2
S'Less progression of Hoffa-synovitis and effusion-synovitis was observed in the TG-C group compared to placebo (9.6% vs. 21.1%, adjusted RR 0.5, 95%CI [0.2,1.2], p = 0.115).\n'
p944
sg4
(lp945
sg23
(lp946
(dp947
g7
I40
sg26
VC0013687
p948
sg10
I8
sg11
Veffusion
p949
sg13
I1
sa(dp950
g7
I26
sg26
VC0039103
p951
sg10
I9
sg11
Vsynovitis
p952
sg13
I1
sa(dp953
g7
I26
sg26
VC0039103
p954
sg10
I9
sg11
Vsynovitis
p955
sg13
I1
sasa(dp956
g2
S'Intraarticular treatment with TG-C showed fewer patients in the treated group with progression in structural OA features and other MRI-defined inflammatory markers such as Hoffa-synovitis and effusion-synovitis.\n'
p957
sg4
(lp958
sg23
(lp959
(dp960
g7
I192
sg26
VC0013687
p961
sg10
I8
sg11
Veffusion
p962
sg13
I1
sa(dp963
g7
I178
sg26
VC0039103
p964
sg10
I9
sg11
Vsynovitis
p965
sg13
I1
sa(dp966
g7
I178
sg26
VC0039103
p967
sg10
I9
sg11
Vsynovitis
p968
sg13
I1
sasa(dp969
g2
S'A total of 104 patients (89.4% females) fulfilling the 1990 ACR criteria for FMS and the Rome III criteria for IBS classification and 125 unrelated age- and sex-matched IBS patients without FMS underwent the following studies: haematological, coagulation and biochemistry tests, serological and genetic markers for CD (i.e., tissue transglutaminase 2 (tTG-2) and major histocompatibility complex HLA-DQ2/HLA-DQ8), multiple gastric and duodenal biopsies, FMS tender points (TPs), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), 36-Item Short Form Health Survey (SF-36) and Visual Analogue Scales (VASs) for tiredness and gastrointestinal complaints.\n'
p970
sg4
(lp971
(dp972
g7
I325
sg8
VP21980
p973
sg10
I25
sg11
Vtissue transglutaminase 2
p974
sg13
I3
sa(dp975
g7
I400
sg8
g107
sg10
I3
sg11
VDQ2
p976
sg13
I1
sa(dp977
g7
I363
sg8
VP18464
p978
sg10
I36
sg11
Vmajor histocompatibility complex HLA
p979
sg13
I4
sa(dp980
g7
I352
sg8
VP21980
p981
sg10
I5
sg11
VtTG-2
p982
sg13
I1
sa(dp983
g7
I404
sg8
VP30486
p984
sg10
I7
sg11
VHLA-DQ8
p985
sg13
I1
sasg23
(lp986
(dp987
g7
I111
sg26
VC0022104
p988
sg10
I3
sg11
VIBS
p989
sg13
I1
sa(dp990
g7
I77
sg26
VC0016053
p991
sg10
I3
sg11
VFMS
p992
sg13
I1
sa(dp993
g7
I638
sg26
VC0015672
p994
sg10
I9
sg11
Vtiredness
p995
sg13
I1
sa(dp996
g7
I479
sg26
VC0016053
p997
sg10
I12
sg11
VFibromyalgia
p998
sg13
I1
sa(dp999
g7
I77
sg26
VC0016053
p1000
sg10
I3
sg11
VFMS
p1001
sg13
I1
sa(dp1002
g7
I77
sg26
VC0016053
p1003
sg10
I3
sg11
VFMS
p1004
sg13
I1
sa(dp1005
g7
I111
sg26
VC0022104
p1006
sg10
I3
sg11
VIBS
p1007
sg13
I1
sasa(dp1008
g2
S'GFD effectiveness was assessed at baseline and after 1 year, examining the score changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness, drug prescriptions and tissue-Trans-Glutaminase (tTG) serum levels.\n'
p1009
sg4
(lp1010
(dp1011
g7
I367
sg8
VP21980
p1012
sg10
I3
sg11
VtTG
p1013
sg13
I1
sa(dp1014
g7
I341
sg8
g107
sg10
I24
sg11
Vtissue-Trans-Glutaminase
p1015
sg13
I1
sasg23
(lp1016
(dp1017
g7
I307
sg26
VC0015672
p1018
sg10
I9
sg11
Vtiredness
p1019
sg13
I1
sa(dp1020
g7
I0
sg26
VC1851112
p1021
sg10
I3
sg11
VGFD
p1022
sg13
I1
sa(dp1023
g7
I122
sg26
VC0016053
p1024
sg10
I12
sg11
VFibromyalgia
p1025
sg13
I1
sasa(dp1026
g2
S"Non-organ specific AAb (ANA, anti-Ro52, anti-Ro60, anti-La, anti-RNP) but not anti-thyroid peroxidase, anti-tissue transglutaminase or myositis-specific antibodies, were more frequent in s-IBM patients, and 14/51 (27%) had another autoimmune disease (Sjoegren's syndrome, thyroiditis, psoriasis, vitiligo).\n"
p1027
sg4
(lp1028
(dp1029
g7
I40
sg8
VP10155
p1030
sg10
I9
sg11
Vanti-Ro60
p1031
sg13
I1
sa(dp1032
g7
I78
sg8
VP40225
p1033
sg10
I23
sg11
Vanti-thyroid peroxidase
p1034
sg13
I2
sa(dp1035
g7
I60
sg8
g107
sg10
I8
sg11
Vanti-RNP
p1036
sg13
I1
sa(dp1037
g7
I135
sg8
VP04280
p1038
sg10
I28
sg11
Vmyositis-specific antibodies
p1039
sg13
I2
sa(dp1040
g7
I24
sg8
g107
sg10
I3
sg11
VANA
p1041
sg13
I1
sa(dp1042
g7
I29
sg8
VP19474
p1043
sg10
I9
sg11
Vanti-Ro52
p1044
sg13
I1
sa(dp1045
g7
I103
sg8
VP21980
p1046
sg10
I28
sg11
Vanti-tissue transglutaminase
p1047
sg13
I2
sasg23
(lp1048
(dp1049
g7
I189
sg26
VC0238190
p1050
sg10
I3
sg11
VIBM
p1051
sg13
I1
sa(dp1052
g7
I251
sg26
VC1527336
p1053
sg10
I19
sg11
VSjoegren's syndrome
p1054
sg13
I2
sa(dp1055
g7
I231
sg26
VC0004364
p1056
sg10
I18
sg11
Vautoimmune disease
p1057
sg13
I2
sa(dp1058
g7
I296
sg26
VC0042900
p1059
sg10
I8
sg11
Vvitiligo
p1060
sg13
I1
sa(dp1061
g7
I135
sg26
VC0027121
p1062
sg10
I8
sg11
Vmyositis
p1063
sg13
I1
sa(dp1064
g7
I272
sg26
VC0040147
p1065
sg10
I11
sg11
Vthyroiditis
p1066
sg13
I1
sa(dp1067
g7
I285
sg26
VC0033860
p1068
sg10
I9
sg11
Vpsoriasis
p1069
sg13
I1
sasa(dp1070
g2
S'By applying CD146 and CD105 antibodies on human retinas from glaucomatous eyes, CD146-positive retinal ganglion cells (RGCs) were found, some being placed in perivascular positions; ongoing processes of neurites extension were related to these neurons.\n'
p1071
sg4
(lp1072
(dp1073
g7
I12
sg8
VP43121
p1074
sg10
I5
sg11
VCD146
p1075
sg13
I1
sa(dp1076
g7
I12
sg8
VP43121
p1077
sg10
I5
sg11
VCD146
p1078
sg13
I1
sa(dp1079
g7
I22
sg8
VP17813
p1080
sg10
I5
sg11
VCD105
p1081
sg13
I1
sasg23
(lp1082
(dp1083
g7
I103
sg26
VC1258666
p1084
sg10
I8
sg11
Vganglion
p1085
sg13
I1
sasa(dp1086
g2
S'These results support the hypothesis that in glaucoma eyes the CD146-positive RGCs result from regenerative processes driven by stem cells in the retinal perivascular niches.\n'
p1087
sg4
(lp1088
(dp1089
g7
I63
sg8
VP43121
p1090
sg10
I19
sg11
VCD146-positive RGCs
p1091
sg13
I2
sasg23
(lp1092
(dp1093
g7
I45
sg26
VC0017601
p1094
sg10
I8
sg11
Vglaucoma
p1095
sg13
I1
sasa(dp1096
g2
S'CD146/MCAM and CD166/ALCAM, previously unreported in cells from fvERMs, were also expressed.\n'
p1097
sg4
(lp1098
(dp1099
g7
I15
sg8
g107
sg10
I5
sg11
VCD166
p1100
sg13
I1
sa(dp1101
g7
I21
sg8
g107
sg10
I5
sg11
VALCAM
p1102
sg13
I1
sa(dp1103
g7
I6
sg8
VP43121
p1104
sg10
I4
sg11
VMCAM
p1105
sg13
I1
sa(dp1106
g7
I0
sg8
VP43121
p1107
sg10
I5
sg11
VCD146
p1108
sg13
I1
sasg23
(lp1109
sa(dp1110
g2
S'Two new and potentially promising melanocytic markers, microphthalmia transcription factor (MiTF) and melanoma cell adhesion molecule (Mel-CAM), have been shown to be sensitive markers of epithelioid melanoma, but have not been tested in desmoplastic/spindle cell melanoma or in other rare melanocytic neuroectodermal tumors such as clear cell sarcoma.\n'
p1111
sg4
(lp1112
(dp1113
g7
I55
sg8
VP35398
p1114
sg10
I35
sg11
Vmicrophthalmia transcription factor
p1115
sg13
I3
sa(dp1116
g7
I135
sg8
VP61006
p1117
sg10
I7
sg11
VMel-CAM
p1118
sg13
I1
sa(dp1119
g7
I92
sg8
g107
sg10
I4
sg11
VMiTF
p1120
sg13
I1
sa(dp1121
g7
I102
sg8
VP43121
p1122
sg10
I31
sg11
Vmelanoma cell adhesion molecule
p1123
sg13
I4
sasg23
(lp1124
(dp1125
g7
I238
sg26
VC1511789
p1126
sg10
I12
sg11
Vdesmoplastic
p1127
sg13
I1
sa(dp1128
g7
I55
sg26
VC0026010
p1129
sg10
I14
sg11
Vmicrophthalmia
p1130
sg13
I1
sa(dp1131
g7
I333
sg26
VC0206651
p1132
sg10
I18
sg11
Vclear cell sarcoma
p1133
sg13
I3
sa(dp1134
g7
I139
sg26
VC1861821
p1135
sg10
I3
sg11
VCAM
p1136
sg13
I1
sa(dp1137
g7
I135
sg26
VC3149631
p1138
sg10
I3
sg11
VMel
p1139
sg13
I1
sa(dp1140
g7
I188
sg26
VC0334443
p1141
sg10
I20
sg11
Vepithelioid melanoma
p1142
sg13
I2
sa(dp1143
g7
I302
sg26
VC0206093
p1144
sg10
I22
sg11
Vneuroectodermal tumors
p1145
sg13
I2
sa(dp1146
g7
I102
sg26
VC0025202
p1147
sg10
I8
sg11
Vmelanoma
p1148
sg13
I1
sa(dp1149
g7
I251
sg26
VC0334444
p1150
sg10
I21
sg11
Vspindle cell melanoma
p1151
sg13
I3
sa(dp1152
g7
I116
sg26
VC0001511
p1153
sg10
I8
sg11
Vadhesion
p1154
sg13
I1
sasa(dp1155
g2
S'We investigated the effect of carnosine as an adjuvant therapy on urinary albumin excretion (UAE), the tubular damage marker alpha 1-microglobulin (A1M), and oxidative stress in pediatric patients with type 1 diabetes and nephropathy.\n'
p1156
sg4
(lp1157
(dp1158
g7
I74
sg8
VP00441
p1159
sg10
I7
sg11
Valbumin
p1160
sg13
I1
sa(dp1161
g7
I125
sg8
VP25100
p1162
sg10
I21
sg11
Valpha 1-microglobulin
p1163
sg13
I2
sa(dp1164
g7
I148
sg8
VP02760
p1165
sg10
I3
sg11
VA1M
p1166
sg13
I1
sasg23
(lp1167
(dp1168
g7
I158
sg26
VC0242606
p1169
sg10
I16
sg11
Voxidative stress
p1170
sg13
I2
sa(dp1171
g7
I202
sg26
VC0011854
p1172
sg10
I15
sg11
Vtype 1 diabetes
p1173
sg13
I3
sa(dp1174
g7
I222
sg26
VC0022658
p1175
sg10
I11
sg11
Vnephropathy
p1176
sg13
I1
sasa(dp1177
g2
S'The following parameters were measured in 377 patients with type 2 diabetes: HbA1c, serum concentrations of 1,5-AG, GA and creatinine, hemoglobin, urinary albumin/creatinine ratio, and urinary excretion of Alfa1 -microglobulin (A1M).\n'
p1178
sg4
(lp1179
(dp1180
g7
I206
sg8
VP02760
p1181
sg10
I20
sg11
VAlfa1 -microglobulin
p1182
sg13
I2
sa(dp1183
g7
I135
sg8
g107
sg10
I10
sg11
Vhemoglobin
p1184
sg13
I1
sa(dp1185
g7
I155
sg8
VP00441
p1186
sg10
I7
sg11
Valbumin
p1187
sg13
I1
sa(dp1188
g7
I228
sg8
VP02760
p1189
sg10
I3
sg11
VA1M
p1190
sg13
I1
sasg23
(lp1191
(dp1192
g7
I60
sg26
VC0011860
p1193
sg10
I15
sg11
Vtype 2 diabetes
p1194
sg13
I3
sasa(dp1195
g2
S'Vonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs).\n'
p1196
sg4
(lp1197
(dp1198
g7
I21
sg8
VP50750
p1199
sg10
I8
sg11
VTAK-438F
p1200
sg13
I1
sasg23
(lp1201
(dp1202
g7
I117
sg26
VC0035222
p1203
sg10
I21
sg11
Vacid-related diseases
p1204
sg13
I2
sa(dp1205
g7
I140
sg26
VC0035222
p1206
sg10
I4
sg11
VARDs
p1207
sg13
I1
sasa(dp1208
g2
S'In many countries, the introduction of generic proton pump inhibitors (PPIs) onto the pharmaceutical market increased the phenomenon of therapeutic substitution in acid-related disorders (ARDs).\n'
p1209
sg4
(lp1210
sg23
(lp1211
(dp1212
g7
I164
sg26
VC0035222
p1213
sg10
I22
sg11
Vacid-related disorders
p1214
sg13
I2
sa(dp1215
g7
I188
sg26
VC0035222
p1216
sg10
I4
sg11
VARDs
p1217
sg13
I1
sasa(dp1218
g2
S'We present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.\n'
p1219
sg4
(lp1220
(dp1221
g7
I120
sg8
g107
sg10
I5
sg11
VPRKRA
p1222
sg13
I1
sa(dp1223
g7
I135
sg8
g107
sg10
I4
sg11
VANO3
p1224
sg13
I1
sasg23
(lp1225
(dp1226
g7
I47
sg26
VC0393593
p1227
sg10
I8
sg11
Vdystonia
p1228
sg13
I1
sasa(dp1229
g2
S'ANO3 encodes anoctamin-3, a Ca+2-dependent phospholipid scramblase expressed in striatal-neurons, that has been implicated in autosomal dominant craniocervical dystonia (Dystonia-24, DYT24, MIM# 615034).\n'
p1230
sg4
(lp1231
(dp1232
g7
I13
sg8
g107
sg10
I11
sg11
Vanoctamin-3
p1233
sg13
I1
sa(dp1234
g7
I0
sg8
g107
sg10
I4
sg11
VANO3
p1235
sg13
I1
sa(dp1236
g7
I28
sg8
VP19525
p1237
sg10
I38
sg11
VCa+2-dependent phospholipid scramblase
p1238
sg13
I3
sasg23
(lp1239
(dp1240
g7
I160
sg26
VC0393593
p1241
sg10
I8
sg11
Vdystonia
p1242
sg13
I1
sa(dp1243
g7
I170
sg26
VC0393593
p1244
sg10
I8
sg11
VDystonia
p1245
sg13
I1
sasa(dp1246
g2
S'Three genes (GCH1, THAP1, TOR1A) were associated with isolated generalized dystonia, whereas 2 (ANO3, ADCY5) gave rise to combined dystonia-myoclonus phenotypes.\n'
p1247
sg4
(lp1248
(dp1249
g7
I102
sg8
g107
sg10
I5
sg11
VADCY5
p1250
sg13
I1
sa(dp1251
g7
I13
sg8
VP30793
p1252
sg10
I4
sg11
VGCH1
p1253
sg13
I1
sa(dp1254
g7
I26
sg8
g107
sg10
I5
sg11
VTOR1A
p1255
sg13
I1
sa(dp1256
g7
I19
sg8
g107
sg10
I5
sg11
VTHAP1
p1257
sg13
I1
sa(dp1258
g7
I96
sg8
g107
sg10
I4
sg11
VANO3
p1259
sg13
I1
sasg23
(lp1260
(dp1261
g7
I75
sg26
VC0393593
p1262
sg10
I8
sg11
Vdystonia
p1263
sg13
I1
sa(dp1264
g7
I63
sg26
VC1848954
p1265
sg10
I20
sg11
Vgeneralized dystonia
p1266
sg13
I2
sa(dp1267
g7
I140
sg26
VC0027066
p1268
sg10
I9
sg11
Vmyoclonus
p1269
sg13
I1
sasa(dp1270
g2
S'Furthermore, it provides confirmatory evidence for a dystonia-relevant role of ANO3 and ADCY5, both of which likely associate with a broader spectrum of dystonic expressions than previously thought.\n'
p1271
sg4
(lp1272
(dp1273
g7
I88
sg8
g107
sg10
I5
sg11
VADCY5
p1274
sg13
I1
sa(dp1275
g7
I79
sg8
g107
sg10
I4
sg11
VANO3
p1276
sg13
I1
sasg23
(lp1277
(dp1278
g7
I53
sg26
VC0393593
p1279
sg10
I8
sg11
Vdystonia
p1280
sg13
I1
sasa(dp1281
g2
S'In the past 4 years, the definition and classification of dystonia have been revised, and new genes have been identified in patients with isolated hereditary dystonia (DYT23, DYT24, and DYT25).\n'
p1282
sg4
(lp1283
sg23
(lp1284
(dp1285
g7
I58
sg26
VC0393593
p1286
sg10
I8
sg11
Vdystonia
p1287
sg13
I1
sa(dp1288
g7
I147
sg26
VC0752207
p1289
sg10
I19
sg11
Vhereditary dystonia
p1290
sg13
I2
sasa(dp1291
g2
S'Compromised anoctamin function is causing a wide range of diseases, such as hearing loss (ANO2), bleeding disorder (ANO6), ataxia and dystonia (ANO3, 10), persistent borrelia and mycobacteria infection (ANO10), skeletal syndromes like gnathodiaphyseal dysplasia and limb girdle muscle dystrophy (ANO5), and cancer (ANO1, 6, 7).\n'
p1292
sg4
(lp1293
(dp1294
g7
I266
sg8
g107
sg10
I35
sg11
Vlimb girdle muscle dystrophy (ANO5)
p1295
sg13
I5
sa(dp1296
g7
I203
sg8
g107
sg10
I5
sg11
VANO10
p1297
sg13
I1
sasg23
(lp1298
(dp1299
g7
I166
sg26
VC0024198
p1300
sg10
I8
sg11
Vborrelia
p1301
sg13
I1
sa(dp1302
g7
I97
sg26
VC0005779
p1303
sg10
I17
sg11
Vbleeding disorder
p1304
sg13
I2
sa(dp1305
g7
I192
sg26
VC0009450
p1306
sg10
I9
sg11
Vinfection
p1307
sg13
I1
sa(dp1308
g7
I134
sg26
VC0393593
p1309
sg10
I8
sg11
Vdystonia
p1310
sg13
I1
sa(dp1311
g7
I123
sg26
VC0004134
p1312
sg10
I6
sg11
Vataxia
p1313
sg13
I1
sa(dp1314
g7
I307
sg26
VC0006826
p1315
sg10
I6
sg11
Vcancer
p1316
sg13
I1
sa(dp1317
g7
I220
sg26
VC0039082
p1318
sg10
I9
sg11
Vsyndromes
p1319
sg13
I1
sa(dp1320
g7
I235
sg26
VC1833736
p1321
sg10
I26
sg11
Vgnathodiaphyseal dysplasia
p1322
sg13
I2
sa(dp1323
g7
I76
sg26
VC0011053
p1324
sg10
I12
sg11
Vhearing loss
p1325
sg13
I2
sa(dp1326
g7
I285
sg26
VC0333606
p1327
sg10
I9
sg11
Vdystrophy
p1328
sg13
I1
sasa(dp1329
g2
S'Some genes, such as ANO3, GNAL and CIZ1, have been discovered for isolated dystonia, but they are probably not a common cause of classic cervical dystonia.\n'
p1330
sg4
(lp1331
(dp1332
g7
I20
sg8
g107
sg10
I4
sg11
VANO3
p1333
sg13
I1
sa(dp1334
g7
I35
sg8
g107
sg10
I4
sg11
VCIZ1
p1335
sg13
I1
sa(dp1336
g7
I26
sg8
VP38405
p1337
sg10
I4
sg11
VGNAL
p1338
sg13
I1
sasg23
(lp1339
(dp1340
g7
I75
sg26
VC0393593
p1341
sg10
I8
sg11
Vdystonia
p1342
sg13
I1
sa(dp1343
g7
I137
sg26
VC0949445
p1344
sg10
I17
sg11
Vcervical dystonia
p1345
sg13
I2
sasa(dp1346
g2
S'Clinical and genetic heterogeneity also characterizes myoclonus-dystonia, which includes not only the classical phenotype associated with epsilon-sarcoglycan mutations but rarely also presentation of ANO3 gene mutations, TITF1 gene mutations typically underlying benign hereditary chorea, and some dopamine synthesis pathway conditions due to GCH1 and TH mutations.\n'
p1347
sg4
(lp1348
(dp1349
g7
I221
sg8
VP43699
p1350
sg10
I10
sg11
VTITF1 gene
p1351
sg13
I2
sa(dp1352
g7
I200
sg8
g107
sg10
I9
sg11
VANO3 gene
p1353
sg13
I2
sa(dp1354
g7
I343
sg8
VP30793
p1355
sg10
I4
sg11
VGCH1
p1356
sg13
I1
sasg23
(lp1357
(dp1358
g7
I54
sg26
VC0027066
p1359
sg10
I9
sg11
Vmyoclonus
p1360
sg13
I1
sa(dp1361
g7
I64
sg26
VC0393593
p1362
sg10
I8
sg11
Vdystonia
p1363
sg13
I1
sa(dp1364
g7
I263
sg26
VC0393584
p1365
sg10
I24
sg11
Vbenign hereditary chorea
p1366
sg13
I3
sasa(dp1367
g2
S'When 10 cases of M5 were subdivided by the differential level into undifferentiated (M5a) and differentiated monocytic leukemia (M5b), expression of CD45RA and CD45RO was strictly restricted to cases with M5a and M5b, respectively.\n'
p1368
sg4
(lp1369
sg23
(lp1370
(dp1371
g7
I129
sg26
VC0598894
p1372
sg10
I3
sg11
VM5b
p1373
sg13
I1
sa(dp1374
g7
I109
sg26
VC0598894
p1375
sg10
I18
sg11
Vmonocytic leukemia
p1376
sg13
I2
sa(dp1377
g7
I129
sg26
VC0598894
p1378
sg10
I3
sg11
VM5b
p1379
sg13
I1
sasa(dp1380
g2
S'In this review, we describe the fusion genes recently reported in bone and soft-tissue tumors such as solitary fibrous tumor, aneurysmal bone cyst, nodular fasciitis, CIC-DUX4 fusion gene-positive small round cell tumors, or BCOR-CCNB3-positive sarcoma as well as other genetic aberrations in dedifferentiated liposarcoma, malignant rhabdoid tumor, cartilaginous tumor, Langerhans cell histiocytosis chondroblastoma, or giant cell tumor of the bone.\n'
p1381
sg4
(lp1382
(dp1383
g7
I171
sg8
g107
sg10
I4
sg11
VDUX4
p1384
sg13
I1
sa(dp1385
g7
I225
sg8
g107
sg10
I10
sg11
VBCOR-CCNB3
p1386
sg13
I1
sa(dp1387
g7
I167
sg8
g107
sg10
I3
sg11
VCIC
p1388
sg13
I1
sasg23
(lp1389
(dp1390
g7
I245
sg26
VC1261473
p1391
sg10
I7
sg11
Vsarcoma
p1392
sg13
I1
sa(dp1393
g7
I87
sg26
VC0027651
p1394
sg10
I6
sg11
Vtumors
p1395
sg13
I1
sa(dp1396
g7
I420
sg26
VC0017547
p1397
sg10
I5
sg11
Vgiant
p1398
sg13
I1
sa(dp1399
g7
I349
sg26
VC0476147
p1400
sg10
I19
sg11
Vcartilaginous tumor
p1401
sg13
I2
sa(dp1402
g7
I148
sg26
VC0410005
p1403
sg10
I17
sg11
Vnodular fasciitis
p1404
sg13
I2
sa(dp1405
g7
I370
sg26
VC0019621
p1406
sg10
I29
sg11
VLangerhans cell histiocytosis
p1407
sg13
I3
sa(dp1408
g7
I87
sg26
VC0027651
p1409
sg10
I6
sg11
Vtumors
p1410
sg13
I1
sa(dp1411
g7
I293
sg26
VC0205824
p1412
sg10
I28
sg11
Vdedifferentiated liposarcoma
p1413
sg13
I2
sa(dp1414
g7
I400
sg26
VC0008441
p1415
sg10
I15
sg11
Vchondroblastoma
p1416
sg13
I1
sa(dp1417
g7
I323
sg26
VC0206743
p1418
sg10
I24
sg11
Vmalignant rhabdoid tumor
p1419
sg13
I3
sa(dp1420
g7
I102
sg26
VC1266119
p1421
sg10
I22
sg11
Vsolitary fibrous tumor
p1422
sg13
I3
sa(dp1423
g7
I431
sg26
VC0005967
p1424
sg10
I17
sg11
Vtumor of the bone
p1425
sg13
I4
sa(dp1426
g7
I126
sg26
VC0152244
p1427
sg10
I20
sg11
Vaneurysmal bone cyst
p1428
sg13
I3
sasa(dp1429
g2
S'The individual diagnostic marker positivity was 98% for GATA-binding protein 3, 95% for androgen receptor, 90% for progesterone receptor, 88% for deleted in pancreatic cancer 4, 75% for gross cystic disease fluid protein 15, 72% for cytokeratin 7, 55% for mammaglobin, and 15% for vimentin and Wilms tumor protein 1.\n'
p1430
sg4
(lp1431
(dp1432
g7
I56
sg8
VP23771
p1433
sg10
I22
sg11
VGATA-binding protein 3
p1434
sg13
I3
sa(dp1435
g7
I256
sg8
g107
sg10
I11
sg11
Vmammaglobin
p1436
sg13
I1
sa(dp1437
g7
I115
sg8
VP06401
p1438
sg10
I21
sg11
Vprogesterone receptor
p1439
sg13
I2
sa(dp1440
g7
I88
sg8
VP10275
p1441
sg10
I17
sg11
Vandrogen receptor
p1442
sg13
I2
sa(dp1443
g7
I294
sg8
VP14222
p1444
sg10
I21
sg11
VWilms tumor protein 1
p1445
sg13
I4
sasg23
(lp1446
(dp1447
g7
I192
sg26
VC0334054
p1448
sg10
I14
sg11
Vcystic disease
p1449
sg13
I2
sa(dp1450
g7
I157
sg26
VC0235974
p1451
sg10
I17
sg11
Vpancreatic cancer
p1452
sg13
I2
sa(dp1453
g7
I294
sg26
VC0027708
p1454
sg10
I11
sg11
VWilms tumor
p1455
sg13
I2
sasa(dp1456
g2
S'Astrocyte loss may be caused by cytotoxic T cells as seen in Rasmussen encephalitis, auto-antibodies such as in neuromyelitis optica (aquaporin-4 antibodies), or cytokines such as TNF-Alfa in major depressive disorder.\n'
p1457
sg4
(lp1458
(dp1459
g7
I180
sg8
VP01375
p1460
sg10
I8
sg11
VTNF-Alfa
p1461
sg13
I1
sa(dp1462
g7
I134
sg8
VP55087
p1463
sg10
I22
sg11
Vaquaporin-4 antibodies
p1464
sg13
I2
sasg23
(lp1465
(dp1466
g7
I112
sg26
VC0027873
p1467
sg10
I20
sg11
Vneuromyelitis optica
p1468
sg13
I2
sa(dp1469
g7
I61
sg26
VC0393484
p1470
sg10
I22
sg11
VRasmussen encephalitis
p1471
sg13
I2
sa(dp1472
g7
I192
sg26
VC1269683
p1473
sg10
I25
sg11
Vmajor depressive disorder
p1474
sg13
I3
sasa(dp1475
g2
S'Mutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism (FH).\n'
p1476
sg4
(lp1477
(dp1478
g7
I13
sg8
VP48544
p1479
sg10
I5
sg11
VKCNJ5
p1480
sg13
I1
sa(dp1481
g7
I39
sg8
g107
sg10
I7
sg11
VCACNA1D
p1482
sg13
I1
sa(dp1483
g7
I20
sg8
VP05023
p1484
sg10
I6
sg11
VATP1A1
p1485
sg13
I1
sa(dp1486
g7
I28
sg8
g107
sg10
I6
sg11
VATP2B3
p1487
sg13
I1
sasg23
(lp1488
(dp1489
g7
I82
sg26
VC0001430
p1490
sg10
I7
sg11
Vadenoma
p1491
sg13
I1
sa(dp1492
g7
I109
sg26
VC0020428
p1493
sg10
I18
sg11
Vhyperaldosteronism
p1494
sg13
I1
sasa(dp1495
g2
S"Our results suggest that these mutations, in addition to mutations in the KCNJ5 gene and other genes such as ATP1A1, ATP2B3 and CACNA1D, may be responsible for the tumorigenesis of APAs and CPAs with subclinical Cushing's syndrome.\n"
p1496
sg4
(lp1497
(dp1498
g7
I74
sg8
VP48544
p1499
sg10
I10
sg11
VKCNJ5 gene
p1500
sg13
I2
sa(dp1501
g7
I117
sg8
g107
sg10
I6
sg11
VATP2B3
p1502
sg13
I1
sa(dp1503
g7
I128
sg8
g107
sg10
I7
sg11
VCACNA1D
p1504
sg13
I1
sa(dp1505
g7
I109
sg8
VP05023
p1506
sg10
I6
sg11
VATP1A1
p1507
sg13
I1
sasg23
(lp1508
(dp1509
g7
I164
sg26
VC0007621
p1510
sg10
I13
sg11
Vtumorigenesis
p1511
sg13
I1
sa(dp1512
g7
I212
sg26
VC0010481
p1513
sg10
I18
sg11
VCushing's syndrome
p1514
sg13
I2
sasa(dp1515
g2
S'Screening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye disorders (14).\n'
p1516
sg4
(lp1517
(dp1518
g7
I13
sg8
VP48431
p1519
sg10
I4
sg11
VSOX2
p1520
sg13
I1
sasg23
(lp1521
(dp1522
g7
I218
sg26
VC0015397
p1523
sg10
I13
sg11
Veye disorders
p1524
sg13
I2
sa(dp1525
g7
I195
sg26
VC0009363
p1526
sg10
I8
sg11
Vcoloboma
p1527
sg13
I1
sa(dp1528
g7
I137
sg26
VC0266525
p1529
sg10
I27
sg11
Vanterior segment dysgenesis
p1530
sg13
I3
sa(dp1531
g7
I171
sg26
VC0086543
p1532
sg10
I8
sg11
Vcataract
p1533
sg13
I1
sasa(dp1534
g2
S'The overexpression of Kir3.2, a subunit of the G protein-gated inwardly rectifying K(+) channel, is implicated in some of the neurological phenotypes of Down syndrome (DS).\n'
p1535
sg4
(lp1536
(dp1537
g7
I47
sg8
g107
sg10
I9
sg11
VG protein
p1538
sg13
I2
sa(dp1539
g7
I22
sg8
VP48051
p1540
sg10
I6
sg11
VKir3.2
p1541
sg13
I1
sasg23
(lp1542
(dp1543
g7
I153
sg26
VC0013080
p1544
sg10
I13
sg11
VDown syndrome
p1545
sg13
I2
sa(dp1546
g7
I168
sg26
VC0013080
p1547
sg10
I2
sg11
VDS
p1548
sg13
I1
sasa(dp1549
g2
S'Keppen-Lubinsky syndrome (KPLBS) is a rare disease mainly characterized by severe developmental delay and intellectual disability, microcephaly, large prominent eyes, a narrow nasal bridge, a tented upper lip, a high palate, an open mouth, tightly adherent skin, an aged appearance, and severe generalized lipodystrophy.\n'
p1550
sg4
(lp1551
sg23
(lp1552
(dp1553
g7
I131
sg26
VC0025958
p1554
sg10
I12
sg11
Vmicrocephaly
p1555
sg13
I1
sa(dp1556
g7
I82
sg26
VC0424605
p1557
sg10
I19
sg11
Vdevelopmental delay
p1558
sg13
I2
sa(dp1559
g7
I0
sg26
VC3279800
p1560
sg10
I24
sg11
VKeppen-Lubinsky syndrome
p1561
sg13
I2
sa(dp1562
g7
I294
sg26
VC0221032
p1563
sg10
I25
sg11
Vgeneralized lipodystrophy
p1564
sg13
I2
sa(dp1565
g7
I212
sg26
VC1398297
p1566
sg10
I11
sg11
Vhigh palate
p1567
sg13
I2
sa(dp1568
g7
I38
sg26
VC0678236
p1569
sg10
I12
sg11
Vrare disease
p1570
sg13
I2
sa(dp1571
g7
I106
sg26
VC0025362
p1572
sg10
I23
sg11
Vintellectual disability
p1573
sg13
I2
sa(dp1574
g7
I26
sg26
VC3279800
p1575
sg10
I5
sg11
VKPLBS
p1576
sg13
I1
sa(dp1577
g7
I205
sg26
VC0264511
p1578
sg10
I3
sg11
Vlip
p1579
sg13
I1
sasa(dp1580
g2
S'We sequenced the exomes of three unrelated individuals affected by KPLBS and found de novo heterozygous mutations in KCNJ6 (GIRK2), which encodes an inwardly rectifying potassium channel and maps to the Down syndrome critical region between DIRK1A and DSCR4.\n'
p1581
sg4
(lp1582
(dp1583
g7
I104
sg8
VP48051
p1584
sg10
I18
sg11
Vmutations in KCNJ6
p1585
sg13
I3
sa(dp1586
g7
I252
sg8
VP56555
p1587
sg10
I5
sg11
VDSCR4
p1588
sg13
I1
sa(dp1589
g7
I124
sg8
VP48051
p1590
sg10
I5
sg11
VGIRK2
p1591
sg13
I1
sasg23
(lp1592
(dp1593
g7
I67
sg26
VC3279800
p1594
sg10
I5
sg11
VKPLBS
p1595
sg13
I1
sa(dp1596
g7
I203
sg26
VC1860787
p1597
sg10
I29
sg11
VDown syndrome critical region
p1598
sg13
I4
sasa(dp1599
g2
S'We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water.\n'
p1600
sg4
(lp1601
(dp1602
g7
I27
sg8
g107
sg10
I41
sg11
Vglucose-lysine Maillard reaction products
p1603
sg13
I4
sa(dp1604
g7
I70
sg8
g107
sg10
I12
sg11
VGlc-Lys MRPs
p1605
sg13
I2
sasg23
(lp1606
(dp1607
g7
I139
sg26
VC0011195
p1608
sg10
I22
sg11
Vdextran sulfate sodium
p1609
sg13
I3
sa(dp1610
g7
I163
sg26
VC0011195
p1611
sg10
I3
sg11
VDSS
p1612
sg13
I1
sa(dp1613
g7
I87
sg26
VC0009319
p1614
sg10
I7
sg11
Vcolitis
p1615
sg13
I1
sasa(dp1616
g2
S'Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels.\n'
p1617
sg4
(lp1618
(dp1619
g7
I0
sg8
g107
sg10
I12
sg11
VGlc-Lys MRPs
p1620
sg13
I2
sa(dp1621
g7
I187
sg8
VP61626
p1622
sg10
I31
sg11
Vcolon length and serum lysozyme
p1623
sg13
I5
sasg23
(lp1624
(dp1625
g7
I24
sg26
VC0011195
p1626
sg10
I3
sg11
VDSS
p1627
sg13
I1
sa(dp1628
g7
I36
sg26
VC0009319
p1629
sg10
I7
sg11
Vcolitis
p1630
sg13
I1
sasa(dp1631
g2
S'This study was aimed at determining whether repeated low-level exposure to MRPs, generated via two different heat treatments, can contribute to the modulation of experimental colitis in mice.\n'
p1632
sg4
(lp1633
sg23
(lp1634
(dp1635
g7
I175
sg26
VC0009319
p1636
sg10
I7
sg11
Vcolitis
p1637
sg13
I1
sasa(dp1638
g2
S"Furthermore, we used a sandwich immunoassay to measure serum concentrations of MRPs in 62 patients were simultaneously assessed by the Crohn's disease activity index (CDAI) and the severity activity index of Goebell (SAI).\n"
p1639
sg4
(lp1640
(dp1641
g7
I135
sg8
g107
sg10
I30
sg11
VCrohn's disease activity index
p1642
sg13
I4
sa(dp1643
g7
I167
sg8
g107
sg10
I4
sg11
VCDAI
p1644
sg13
I1
sasg23
(lp1645
(dp1646
g7
I135
sg26
VC0010346
p1647
sg10
I15
sg11
VCrohn's disease
p1648
sg13
I2
sasa(dp1649
g2
S'In the present study monospecific antibodies against MRPs were used to investigate immunohistochemically the distribution of these proteins in routinely processed bowel tissues from 23 patients with ulcerative colitis (UC).\n'
p1650
sg4
(lp1651
sg23
(lp1652
(dp1653
g7
I219
sg26
VC0009324
p1654
sg10
I2
sg11
VUC
p1655
sg13
I1
sa(dp1656
g7
I199
sg26
VC0009324
p1657
sg10
I18
sg11
Vulcerative colitis
p1658
sg13
I2
sasa(dp1659
g2
S"The dimeric hybrid-IgG/IgA inhibited the binding of digoxigenin-conjugated Stx1B to natural ligands (CD77) displayed on Burkitt's lymphoma cell line Ramos.\n"
p1660
sg4
(lp1661
(dp1662
g7
I75
sg8
VP61266
p1663
sg10
I5
sg11
VStx1B
p1664
sg13
I1
sa(dp1665
g7
I23
sg8
VP11912
p1666
sg10
I3
sg11
VIgA
p1667
sg13
I1
sasg23
(lp1668
(dp1669
g7
I120
sg26
VC0006413
p1670
sg10
I18
sg11
VBurkitt's lymphoma
p1671
sg13
I2
sasa(dp1672
g2
S"Furthermore, the purified Stx1 B subunit was able to bind specifically to Gb3Cer expressed on Burkitt's lymphoma cells.\n"
p1673
sg4
(lp1674
(dp1675
g7
I26
sg8
g107
sg10
I14
sg11
VStx1 B subunit
p1676
sg13
I3
sasg23
(lp1677
(dp1678
g7
I94
sg26
VC0006413
p1679
sg10
I18
sg11
VBurkitt's lymphoma
p1680
sg13
I2
sasa(dp1681
g2
S'Furthermore, we found that Mcl-1 could be a potential therapeutic target of MECK-induced apoptosis and its stability is regulated by extracellular signal-regulated kinases 1/2 (ERK1/2) signaling MECK can be used as a safe and efficient therapeutic alternative for the treatment of salivary gland cancer.\n'
p1682
sg4
(lp1683
(dp1684
g7
I177
sg8
VP27361
p1685
sg10
I6
sg11
VERK1/2
p1686
sg13
I1
sa(dp1687
g7
I133
sg8
g107
sg10
I42
sg11
Vextracellular signal-regulated kinases 1/2
p1688
sg13
I4
sa(dp1689
g7
I27
sg8
VP07954
p1690
sg10
I5
sg11
VMcl-1
p1691
sg13
I1
sasg23
(lp1692
(dp1693
g7
I281
sg26
VC0220636
p1694
sg10
I21
sg11
Vsalivary gland cancer
p1695
sg13
I3
sa(dp1696
g7
I27
sg26
VC1708350
p1697
sg10
I3
sg11
VMcl
p1698
sg13
I1
sasa(dp1699
g2
S'RelA-/-Fadd-/-Rip3-/- triple-knockout (TKO) and RelA-/-Rip1K45A/K45A mice displayed bacterial pneumonia leading to death ~2 wk after birth.\n'
p1700
sg4
(lp1701
(dp1702
g7
I14
sg8
g107
sg10
I4
sg11
VRip3
p1703
sg13
I1
sa(dp1704
g7
I48
sg8
g107
sg10
I15
sg11
VRelA-/-Rip1K45A
p1705
sg13
I1
sa(dp1706
g7
I0
sg8
g107
sg10
I11
sg11
VRelA-/-Fadd
p1707
sg13
I1
sasg23
(lp1708
(dp1709
g7
I84
sg26
VC0004626
p1710
sg10
I19
sg11
Vbacterial pneumonia
p1711
sg13
I2
sasa(dp1712
g2
S'Antibiotic treatment improved bacterial pneumonia, extended the lifespan of TKO and RelA-/-Rip1K45A/K45A mice, and alleviated skin inflammation in RelA-/-Rip1K45A/K45A mice.\n'
p1713
sg4
(lp1714
(dp1715
g7
I84
sg8
g107
sg10
I15
sg11
VRelA-/-Rip1K45A
p1716
sg13
I1
sa(dp1717
g7
I84
sg8
g107
sg10
I15
sg11
VRelA-/-Rip1K45A
p1718
sg13
I1
sasg23
(lp1719
(dp1720
g7
I30
sg26
VC0004626
p1721
sg10
I19
sg11
Vbacterial pneumonia
p1722
sg13
I2
sa(dp1723
g7
I126
sg26
VC0011603
p1724
sg10
I17
sg11
Vskin inflammation
p1725
sg13
I2
sasa(dp1726
g2
S'Although NF-KB RelA (p65) is essential for the expression of many cytokines during pneumonia, its targeted mutation in the lung epithelium was inconsequential for pneumonia-driven LIF induction.\n'
p1727
sg4
(lp1728
(dp1729
g7
I9
sg8
g107
sg10
I10
sg11
VNF-KB RelA
p1730
sg13
I2
sa(dp1731
g7
I21
sg8
VP21579
p1732
sg10
I3
sg11
Vp65
p1733
sg13
I1
sasg23
(lp1734
(dp1735
g7
I83
sg26
VC0032285
p1736
sg10
I9
sg11
Vpneumonia
p1737
sg13
I1
sa(dp1738
g7
I83
sg26
VC0032285
p1739
sg10
I9
sg11
Vpneumonia
p1740
sg13
I1
sasa(dp1741
g2
S'Overall, our data suggest a signaling axis whereby activation of NF-KB RelA in myeloid cells promotes epithelial LIF induction during lung infections, representing a means through which these two cell types collaborate to improve tissue resilience during pneumonia.\n'
p1742
sg4
(lp1743
(dp1744
g7
I102
sg8
VP15018
p1745
sg10
I14
sg11
Vepithelial LIF
p1746
sg13
I2
sa(dp1747
g7
I65
sg8
g107
sg10
I10
sg11
VNF-KB RelA
p1748
sg13
I2
sasg23
(lp1749
(dp1750
g7
I139
sg26
VC0021311
p1751
sg10
I10
sg11
Vinfections
p1752
sg13
I1
sa(dp1753
g7
I255
sg26
VC0032285
p1754
sg10
I9
sg11
Vpneumonia
p1755
sg13
I1
sasa(dp1756
g2
S'Sectm1 was induced during the early stages of pneumococcal pneumonia, and mutation of NF-KB RelA in epithelial cells did not diminish its expression.\n'
p1757
sg4
(lp1758
(dp1759
g7
I86
sg8
g107
sg10
I10
sg11
VNF-KB RelA
p1760
sg13
I2
sa(dp1761
g7
I0
sg8
g107
sg10
I6
sg11
VSectm1
p1762
sg13
I1
sasg23
(lp1763
(dp1764
g7
I46
sg26
VC0155862
p1765
sg10
I22
sg11
Vpneumococcal pneumonia
p1766
sg13
I2
sasa(dp1767
g2
S'To determine the functional significance of the hepatic APR during pneumonia, we challenged APR-null mice lacking hepatocyte signal transducer and activator of transcription 3 (STAT3) and v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) with Escherichia coli in the airspaces.\n'
p1768
sg4
(lp1769
(dp1770
g7
I114
sg8
VP40763
p1771
sg10
I61
sg11
Vhepatocyte signal transducer and activator of transcription 3
p1772
sg13
I8
sa(dp1773
g7
I188
sg8
g107
sg10
I58
sg11
Vv-rel avian reticuloendotheliosis viral oncogene homolog A
p1774
sg13
I7
sa(dp1775
g7
I248
sg8
g107
sg10
I4
sg11
VRelA
p1776
sg13
I1
sa(dp1777
g7
I177
sg8
VP40763
p1778
sg10
I5
sg11
VSTAT3
p1779
sg13
I1
sasg23
(lp1780
(dp1781
g7
I67
sg26
VC0032285
p1782
sg10
I9
sg11
Vpneumonia
p1783
sg13
I1
sa(dp1784
g7
I194
sg26
VC0276487
p1785
sg10
I27
sg11
Vavian reticuloendotheliosis
p1786
sg13
I2
sasa(dp1787
g2
S'Epithelial cells expressed multiple neutrophil-stimulating cytokines during pneumonia, all of which depended on RelA.\n'
p1788
sg4
(lp1789
(dp1790
g7
I112
sg8
g107
sg10
I4
sg11
VRelA
p1791
sg13
I1
sasg23
(lp1792
(dp1793
g7
I76
sg26
VC0032285
p1794
sg10
I9
sg11
Vpneumonia
p1795
sg13
I1
sasa(dp1796
g2
S'Epithelial RelA mutation decreased whole lung levels of CXCL5 and GM-CSF during pneumococcal pneumonia, whereas lung levels of other neutrophil-recruiting factors were unaffected.\n'
p1797
sg4
(lp1798
(dp1799
g7
I66
sg8
VP04141
p1800
sg10
I6
sg11
VGM-CSF
p1801
sg13
I1
sa(dp1802
g7
I56
sg8
VP42830
p1803
sg10
I5
sg11
VCXCL5
p1804
sg13
I1
sa(dp1805
g7
I11
sg8
g107
sg10
I4
sg11
VRelA
p1806
sg13
I1
sasg23
(lp1807
(dp1808
g7
I80
sg26
VC0155862
p1809
sg10
I22
sg11
Vpneumococcal pneumonia
p1810
sg13
I2
sasa(dp1811
g2
S'We demonstrate that RelA-P-Ser536 is a feature of human lung and skin fibroblasts, but not lung epithelial cells, in vitro and is present in sclerotic skin and diseased lungs of patients suffering from idiopathic pulmonary fibrosis.\n'
p1812
sg4
(lp1813
(dp1814
g7
I20
sg8
g107
sg10
I6
sg11
VRelA-P
p1815
sg13
I1
sasg23
(lp1816
(dp1817
g7
I202
sg26
VC3161101
p1818
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p1819
sg13
I3
sa(dp1820
g7
I187
sg26
VC0683278
p1821
sg10
I9
sg11
Vsuffering
p1822
sg13
I1
sa(dp1823
g7
I141
sg26
VC0036429
p1824
sg10
I9
sg11
Vsclerotic
p1825
sg13
I1
sasa(dp1826
g2
S'Because innate immunity gene induction depends on NF-KB RelA (also known as p65) during pneumonia, we generated a murine model of RelA mutated throughout the alveolar epithelium.\n'
p1827
sg4
(lp1828
(dp1829
g7
I76
sg8
VP21579
p1830
sg10
I3
sg11
Vp65
p1831
sg13
I1
sa(dp1832
g7
I56
sg8
g107
sg10
I4
sg11
VRelA
p1833
sg13
I1
sa(dp1834
g7
I50
sg8
g107
sg10
I10
sg11
VNF-KB RelA
p1835
sg13
I2
sasg23
(lp1836
(dp1837
g7
I88
sg26
VC0032285
p1838
sg10
I9
sg11
Vpneumonia
p1839
sg13
I1
sasa(dp1840
g2
S'Sorted cell populations from mouse lungs revealed that CXCL5 was induced during pneumonia in type I cells, which did not require RelA.\n'
p1841
sg4
(lp1842
(dp1843
g7
I129
sg8
g107
sg10
I4
sg11
VRelA
p1844
sg13
I1
sa(dp1845
g7
I55
sg8
VP42830
p1846
sg10
I5
sg11
VCXCL5
p1847
sg13
I1
sasg23
(lp1848
(dp1849
g7
I80
sg26
VC0032285
p1850
sg10
I9
sg11
Vpneumonia
p1851
sg13
I1
sasa(dp1852
g2
S'These are also, to our knowledge, the first evidence for entirely RelA-independent pathways of innate immunity gene induction in any cell during pneumonia.\n'
p1853
sg4
(lp1854
(dp1855
g7
I66
sg8
g107
sg10
I4
sg11
VRelA
p1856
sg13
I1
sasg23
(lp1857
(dp1858
g7
I145
sg26
VC0032285
p1859
sg10
I9
sg11
Vpneumonia
p1860
sg13
I1
sasa(dp1861
g2
S'We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).\n'
p1862
sg4
(lp1863
(dp1864
g7
I421
sg8
g107
sg10
I6
sg11
VRAB39B
p1865
sg13
I1
sa(dp1866
g7
I204
sg8
g107
sg10
I5
sg11
VPINK1
p1867
sg13
I1
sa(dp1868
g7
I440
sg8
g107
sg10
I4
sg11
VSCA2
p1869
sg13
I1
sa(dp1870
g7
I267
sg8
g107
sg10
I5
sg11
VLRRK2
p1871
sg13
I1
sa(dp1872
g7
I349
sg8
VP30793
p1873
sg10
I4
sg11
VGCH1
p1874
sg13
I1
sa(dp1875
g7
I414
sg8
g107
sg10
I5
sg11
VFBXO7
p1876
sg13
I1
sa(dp1877
g7
I355
sg8
g107
sg10
I7
sg11
VATP13A2
p1878
sg13
I1
sa(dp1879
g7
I364
sg8
g107
sg10
I6
sg11
VPLA2G6
p1880
sg13
I1
sa(dp1881
g7
I433
sg8
g107
sg10
I5
sg11
VATXN2
p1882
sg13
I1
sasg23
(lp1883
(dp1884
g7
I295
sg26
VC0017205
p1885
sg10
I15
sg11
VGaucher disease
p1886
sg13
I2
sa(dp1887
g7
I93
sg26
VC0242422
p1888
sg10
I12
sg11
Vparkinsonism
p1889
sg13
I1
sa(dp1890
g7
I461
sg26
VC0795880
p1891
sg10
I21
sg11
V22q deletion syndrome
p1892
sg13
I3
sa(dp1893
g7
I93
sg26
VC0242422
p1894
sg10
I12
sg11
Vparkinsonism
p1895
sg13
I1
sa(dp1896
g7
I440
sg26
VC0752121
p1897
sg10
I4
sg11
VSCA2
p1898
sg13
I1
sasa(dp1899
g2
S"We performed genetic testing consisting of C9orf72 hexanucleotide expansion, ATXN2 polyglutamine (polyQ) expansion, and targeted next generation sequencing using the ONDRISeq, a gene panel consisting of 80 genes known to be associated with neurodegenerative diseases such as ALS, FTD, Alzheimer's disease, Parkinson's disease, and vascular cognitive impairment.\n"
p1900
sg4
(lp1901
(dp1902
g7
I77
sg8
g107
sg10
I5
sg11
VATXN2
p1903
sg13
I1
sasg23
(lp1904
(dp1905
g7
I340
sg26
VC0338656
p1906
sg10
I20
sg11
Vcognitive impairment
p1907
sg13
I2
sa(dp1908
g7
I306
sg26
VC0030567
p1909
sg10
I19
sg11
VParkinson's disease
p1910
sg13
I2
sa(dp1911
g7
I240
sg26
VC0524851
p1912
sg10
I26
sg11
Vneurodegenerative diseases
p1913
sg13
I2
sa(dp1914
g7
I285
sg26
VC1521724
p1915
sg10
I19
sg11
VAlzheimer's disease
p1916
sg13
I2
sa(dp1917
g7
I280
sg26
VC0338451
p1918
sg10
I3
sg11
VFTD
p1919
sg13
I1
sa(dp1920
g7
I275
sg26
VC0002736
p1921
sg10
I3
sg11
VALS
p1922
sg13
I1
sasa(dp1923
g2
S'Pathological developments leading to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are associated with misbehavior of several key proteins, such as SOD1 (superoxide dismutase 1), TARDBP/TDP-43, FUS, C9orf72, and dipeptide repeat proteins generated as a result of the translation of the intronic hexanucleotide expansions in the C9orf72 gene, PFN1 (profilin 1), GLE1 (GLE1, RNA export mediator), PURA (purine rich element binding protein A), FLCN (folliculin), RBM45 (RNA binding motif protein 45), SS18L1/CREST, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1), HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1), ATXN2 (ataxin 2), MAPT (microtubule associated protein tau), and TIA1 (TIA1 cytotoxic granule associated RNA binding protein).\n'
p1924
sg4
(lp1925
(dp1926
g7
I556
sg8
VP09651
p1927
sg10
I42
sg11
Vheterogeneous nuclear ribonucleoprotein A1
p1928
sg13
I4
sa(dp1929
g7
I684
sg8
g107
sg10
I34
sg11
Vmicrotubule associated protein tau
p1930
sg13
I4
sa(dp1931
g7
I396
sg8
g107
sg10
I4
sg11
VGLE1
p1932
sg13
I1
sa(dp1933
g7
I430
sg8
g107
sg10
I4
sg11
VPURA
p1934
sg13
I1
sa(dp1935
g7
I383
sg8
VP07737
p1936
sg10
I10
sg11
Vprofilin 1
p1937
sg13
I2
sa(dp1938
g7
I482
sg8
g107
sg10
I10
sg11
Vfolliculin
p1939
sg13
I1
sa(dp1940
g7
I436
sg8
g107
sg10
I37
sg11
Vpurine rich element binding protein A
p1941
sg13
I6
sa(dp1942
g7
I725
sg8
VP31483
p1943
sg10
I4
sg11
VTIA1
p1944
sg13
I1
sa(dp1945
g7
I183
sg8
VP00441
p1946
sg10
I4
sg11
VSOD1
p1947
sg13
I1
sa(dp1948
g7
I229
sg8
VP35637
p1949
sg10
I3
sg11
VFUS
p1950
sg13
I1
sa(dp1951
g7
I189
sg8
VP00441
p1952
sg10
I22
sg11
Vsuperoxide dismutase 1
p1953
sg13
I3
sa(dp1954
g7
I678
sg8
g107
sg10
I4
sg11
VMAPT
p1955
sg13
I1
sa(dp1956
g7
I396
sg8
g107
sg10
I4
sg11
VGLE1
p1957
sg13
I1
sa(dp1958
g7
I667
sg8
g107
sg10
I8
sg11
Vataxin 2
p1959
sg13
I2
sa(dp1960
g7
I612
sg8
VP22626
p1961
sg10
I45
sg11
Vheterogeneous nuclear ribonucleoprotein A2/B1
p1962
sg13
I4
sa(dp1963
g7
I234
sg8
g107
sg10
I7
sg11
VC9orf72
p1964
sg13
I1
sa(dp1965
g7
I214
sg8
g107
sg10
I13
sg11
VTARDBP/TDP-43
p1966
sg13
I1
sa(dp1967
g7
I731
sg8
VP00390
p1968
sg10
I53
sg11
VTIA1 cytotoxic granule associated RNA binding protein
p1969
sg13
I7
sa(dp1970
g7
I601
sg8
VP22626
p1971
sg10
I9
sg11
VHNRNPA2B1
p1972
sg13
I1
sa(dp1973
g7
I377
sg8
VP07737
p1974
sg10
I4
sg11
VPFN1
p1975
sg13
I1
sa(dp1976
g7
I363
sg8
g107
sg10
I12
sg11
VC9orf72 gene
p1977
sg13
I2
sa(dp1978
g7
I476
sg8
g107
sg10
I4
sg11
VFLCN
p1979
sg13
I1
sa(dp1980
g7
I660
sg8
g107
sg10
I5
sg11
VATXN2
p1981
sg13
I1
sa(dp1982
g7
I547
sg8
VP09651
p1983
sg10
I7
sg11
VHNRNPA1
p1984
sg13
I1
sasg23
(lp1985
(dp1986
g7
I68
sg26
VC0002736
p1987
sg10
I3
sg11
VALS
p1988
sg13
I1
sa(dp1989
g7
I77
sg26
VC0751072
p1990
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p1991
sg13
I3
sa(dp1992
g7
I540
sg26
VC0206138
p1993
sg10
I5
sg11
VCREST
p1994
sg13
I1
sa(dp1995
g7
I112
sg26
VC0751072
p1996
sg10
I4
sg11
VFTLD
p1997
sg13
I1
sa(dp1998
g7
I37
sg26
VC0002736
p1999
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p2000
sg13
I3
sasa(dp2001
g2
S'Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant cerebellar ataxia that occurs as a consequence of abnormal CAG expansions in the ATXN2 gene.\n'
p2002
sg4
(lp2003
(dp2004
g7
I143
sg8
g107
sg10
I10
sg11
VATXN2 gene
p2005
sg13
I2
sa(dp2006
g7
I0
sg8
g107
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p2007
sg13
I4
sa(dp2008
g7
I31
sg8
g107
sg10
I4
sg11
VSCA2
p2009
sg13
I1
sasg23
(lp2010
(dp2011
g7
I5
sg26
VC0007758
p2012
sg10
I17
sg11
Vcerebellar ataxia
p2013
sg13
I2
sa(dp2014
g7
I0
sg26
VC0752121
p2015
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p2016
sg13
I4
sa(dp2017
g7
I31
sg26
VC0752121
p2018
sg10
I4
sg11
VSCA2
p2019
sg13
I1
sasa(dp2020
g2
S'Recent findings linking ataxin-2 intermediate expansions to other neurodegenerative diseases such as amyotrophic lateral sclerosis have provided insights into the ataxin-2-related toxicity mechanism in neurodegenerative diseases and have raised new ethical challenges to molecular predictive diagnosis of SCA2.\n'
p2021
sg4
(lp2022
(dp2023
g7
I305
sg8
g107
sg10
I4
sg11
VSCA2
p2024
sg13
I1
sasg23
(lp2025
(dp2026
g7
I101
sg26
VC0002736
p2027
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p2028
sg13
I3
sa(dp2029
g7
I66
sg26
VC0524851
p2030
sg10
I26
sg11
Vneurodegenerative diseases
p2031
sg13
I2
sa(dp2032
g7
I66
sg26
VC0524851
p2033
sg10
I26
sg11
Vneurodegenerative diseases
p2034
sg13
I2
sa(dp2035
g7
I305
sg26
VC0752121
p2036
sg10
I4
sg11
VSCA2
p2037
sg13
I1
sasa(dp2038
g2
S'Spinocerebellar ataxia type 2 (SCA2) is among the most common forms of autosomal dominant ataxias, accounting for 15% of the total families.\n'
p2039
sg4
(lp2040
(dp2041
g7
I0
sg8
g107
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p2042
sg13
I4
sa(dp2043
g7
I31
sg8
g107
sg10
I4
sg11
VSCA2
p2044
sg13
I1
sasg23
(lp2045
(dp2046
g7
I90
sg26
VC0004134
p2047
sg10
I7
sg11
Vataxias
p2048
sg13
I1
sa(dp2049
g7
I0
sg26
VC0752121
p2050
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p2051
sg13
I4
sa(dp2052
g7
I31
sg26
VC0752121
p2053
sg10
I4
sg11
VSCA2
p2054
sg13
I1
sasa(dp2055
g2
S'Spinocerebellar ataxia type 2 (SCA2) is due to a CAG expansion (CAGexp) at ATXN2.\n'
p2056
sg4
(lp2057
(dp2058
g7
I75
sg8
g107
sg10
I5
sg11
VATXN2
p2059
sg13
I1
sa(dp2060
g7
I0
sg8
g107
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p2061
sg13
I4
sa(dp2062
g7
I31
sg8
g107
sg10
I4
sg11
VSCA2
p2063
sg13
I1
sasg23
(lp2064
(dp2065
g7
I0
sg26
VC0752121
p2066
sg10
I29
sg11
VSpinocerebellar ataxia type 2
p2067
sg13
I4
sa(dp2068
g7
I31
sg26
VC0752121
p2069
sg10
I4
sg11
VSCA2
p2070
sg13
I1
sasa(dp2071
g2
S'Expansion of polyglutamine trinucleotide (CAG) within ATXN2 gene with 35 or more repeats, results in spinocerebellar ataxia type-2.\n'
p2072
sg4
(lp2073
(dp2074
g7
I54
sg8
g107
sg10
I10
sg11
VATXN2 gene
p2075
sg13
I2
sasg23
(lp2076
(dp2077
g7
I101
sg26
VC0087012
p2078
sg10
I22
sg11
Vspinocerebellar ataxia
p2079
sg13
I2
sasa(dp2080
g2
S'Recent studies have identified the RNA-binding protein Ataxin-2 as a genetic determinant or risk factor for various diseases including spinocerebellar ataxia type II (SCA2) and amyotrophic lateral sclerosis (ALS), amongst others.\n'
p2081
sg4
(lp2082
(dp2083
g7
I167
sg8
g107
sg10
I4
sg11
VSCA2
p2084
sg13
I1
sa(dp2085
g7
I55
sg8
g107
sg10
I8
sg11
VAtaxin-2
p2086
sg13
I1
sa(dp2087
g7
I151
sg8
VP27037
p2088
sg10
I14
sg11
Vataxia type II
p2089
sg13
I3
sasg23
(lp2090
(dp2091
g7
I167
sg26
VC0752121
p2092
sg10
I4
sg11
VSCA2
p2093
sg13
I1
sa(dp2094
g7
I177
sg26
VC0002736
p2095
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p2096
sg13
I3
sa(dp2097
g7
I208
sg26
VC0002736
p2098
sg10
I3
sg11
VALS
p2099
sg13
I1
sa(dp2100
g7
I135
sg26
VC0087012
p2101
sg10
I22
sg11
Vspinocerebellar ataxia
p2102
sg13
I2
sasa(dp2103
g2
S'Here we show that synaptobrevin 2 sorting involves determinants within its SNARE motif that are recognized by the ANTH domains of the endocytic adaptors AP180 and clathrin assembly lymphoid myeloid leukemia (CALM).\n'
p2104
sg4
(lp2105
(dp2106
g7
I18
sg8
VP63027
p2107
sg10
I15
sg11
Vsynaptobrevin 2
p2108
sg13
I2
sa(dp2109
g7
I153
sg8
g107
sg10
I5
sg11
VAP180
p2110
sg13
I1
sasg23
(lp2111
(dp2112
g7
I190
sg26
VC0023470
p2113
sg10
I16
sg11
Vmyeloid leukemia
p2114
sg13
I2
sasa(dp2115
g2
S'Specifically, fibroblast growth factor receptor 3 (FGFR3), desmoglein 2 (DSG2), E3 ubiquitin ligase c-CBL (casitas B-cell lymphoma), cancer/testis antigen NY-ESO-1 (CTAG1A/B), undifferentiated embryonic cell transcription factor 1 (UTF1) and synaptosomal-associated protein, 91 kDa homolog (SNAP91) were shown to represent specific biomarkers of human spermatogonia.\n'
p2116
sg4
(lp2117
(dp2118
g7
I51
sg8
VP22607
p2119
sg10
I5
sg11
VFGFR3
p2120
sg13
I1
sa(dp2121
g7
I100
sg8
VP22681
p2122
sg10
I5
sg11
Vc-CBL
p2123
sg13
I1
sa(dp2124
g7
I59
sg8
g107
sg10
I12
sg11
Vdesmoglein 2
p2125
sg13
I2
sa(dp2126
g7
I155
sg8
VP78358
p2127
sg10
I8
sg11
VNY-ESO-1
p2128
sg13
I1
sa(dp2129
g7
I80
sg8
VP62979
p2130
sg10
I12
sg11
VE3 ubiquitin
p2131
sg13
I2
sa(dp2132
g7
I14
sg8
g107
sg10
I35
sg11
Vfibroblast growth factor receptor 3
p2133
sg13
I5
sa(dp2134
g7
I176
sg8
g107
sg10
I54
sg11
Vundifferentiated embryonic cell transcription factor 1
p2135
sg13
I6
sa(dp2136
g7
I291
sg8
g107
sg10
I6
sg11
VSNAP91
p2137
sg13
I1
sa(dp2138
g7
I73
sg8
g107
sg10
I4
sg11
VDSG2
p2139
sg13
I1
sa(dp2140
g7
I275
sg8
g107
sg10
I14
sg11
V91 kDa homolog
p2141
sg13
I3
sa(dp2142
g7
I165
sg8
VP78358
p2143
sg10
I8
sg11
VCTAG1A/B
p2144
sg13
I1
sa(dp2145
g7
I232
sg8
g107
sg10
I4
sg11
VUTF1
p2146
sg13
I1
sasg23
(lp2147
(dp2148
g7
I115
sg26
VC0079731
p2149
sg10
I15
sg11
VB-cell lymphoma
p2150
sg13
I2
sa(dp2151
g7
I133
sg26
VC0006826
p2152
sg10
I6
sg11
Vcancer
p2153
sg13
I1
sasa(dp2154
g2
S'Recently, the gene encoding clathrin assembly protein of lymphoid myeloid leukemia (CALM), which is homologous to the AP180, was cloned from rat brain, and its expression differential to AP180 was reported (Kim and Lee, 1999).\n'
p2155
sg4
(lp2156
(dp2157
g7
I118
sg8
g107
sg10
I5
sg11
VAP180
p2158
sg13
I1
sasg23
(lp2159
(dp2160
g7
I66
sg26
VC0023470
p2161
sg10
I16
sg11
Vmyeloid leukemia
p2162
sg13
I2
sasa(dp2163
g2
S'The clathrin assembly protein lymphoid myeloid leukemia (CALM) gene, encodes a homologoue of the neuronal clathrin assembly protein AP180.\n'
p2164
sg4
(lp2165
sg23
(lp2166
(dp2167
g7
I39
sg26
VC0023470
p2168
sg10
I16
sg11
Vmyeloid leukemia
p2169
sg13
I2
sasa(dp2170
g2
S'The clathrin assembly lymphoid myeloid leukemia (CALM) gene encodes a putative homologue of the clathrin assembly synaptic protein AP180.\n'
p2171
sg4
(lp2172
sg23
(lp2173
(dp2174
g7
I31
sg26
VC0023470
p2175
sg10
I16
sg11
Vmyeloid leukemia
p2176
sg13
I2
sasa(dp2177
g2
S'The expression level of ERp57 was also elevated in rat insulinoma INS-1 cells by inducible knock-down of the atg7-gene.\n'
p2178
sg4
(lp2179
(dp2180
g7
I51
sg8
VP01308
p2181
sg10
I20
sg11
Vrat insulinoma INS-1
p2182
sg13
I3
sa(dp2183
g7
I109
sg8
g107
sg10
I9
sg11
Vatg7-gene
p2184
sg13
I1
sa(dp2185
g7
I24
sg8
VP30101
p2186
sg10
I5
sg11
VERp57
p2187
sg13
I1
sasg23
(lp2188
(dp2189
g7
I66
sg26
VC1533172
p2190
sg10
I3
sg11
VINS
p2191
sg13
I1
sa(dp2192
g7
I55
sg26
VC0021670
p2193
sg10
I10
sg11
Vinsulinoma
p2194
sg13
I1
sasa(dp2195
g2
S'Tissue specimens of nine dental follicles and 69 ameloblastomas were immunohistochemically examined with antibodies against ATG7, LC3, and p62.\n'
p2196
sg4
(lp2197
(dp2198
g7
I130
sg8
g107
sg10
I3
sg11
VLC3
p2199
sg13
I1
sa(dp2200
g7
I139
sg8
VP37198
p2201
sg10
I3
sg11
Vp62
p2202
sg13
I1
sa(dp2203
g7
I124
sg8
g107
sg10
I4
sg11
VATG7
p2204
sg13
I1
sasg23
(lp2205
(dp2206
g7
I49
sg26
VC0002448
p2207
sg10
I14
sg11
Vameloblastomas
p2208
sg13
I1
sasa(dp2209
g2
S'Immunohistochemical reactivity for ATG7, LC3, and p62 was detected in many odontogenic epithelial cells and several endothelial cells and fibroblasts in dental follicles and ameloblastomas.\n'
p2210
sg4
(lp2211
(dp2212
g7
I35
sg8
g107
sg10
I4
sg11
VATG7
p2213
sg13
I1
sa(dp2214
g7
I41
sg8
g107
sg10
I3
sg11
VLC3
p2215
sg13
I1
sa(dp2216
g7
I50
sg8
VP37198
p2217
sg10
I3
sg11
Vp62
p2218
sg13
I1
sasg23
(lp2219
(dp2220
g7
I174
sg26
VC0002448
p2221
sg10
I14
sg11
Vameloblastomas
p2222
sg13
I1
sasa(dp2223
g2
S'Expression of ATG7, LC3, and p62 was found markedly in neoplastic cells near the basement membrane rather than central polyhedral cells in ameloblastomas.\n'
p2224
sg4
(lp2225
(dp2226
g7
I29
sg8
VP37198
p2227
sg10
I3
sg11
Vp62
p2228
sg13
I1
sa(dp2229
g7
I20
sg8
g107
sg10
I3
sg11
VLC3
p2230
sg13
I1
sa(dp2231
g7
I14
sg8
g107
sg10
I4
sg11
VATG7
p2232
sg13
I1
sasg23
(lp2233
(dp2234
g7
I139
sg26
VC0002448
p2235
sg10
I14
sg11
Vameloblastomas
p2236
sg13
I1
sasa(dp2237
g2
S'Expression of ATG7, LC3, and p62 in dental follicles and ameloblastomas suggests that autophagy regulation might be affected by microenvironment alterations during tumorigenesis.\n'
p2238
sg4
(lp2239
(dp2240
g7
I29
sg8
VP37198
p2241
sg10
I3
sg11
Vp62
p2242
sg13
I1
sa(dp2243
g7
I20
sg8
g107
sg10
I3
sg11
VLC3
p2244
sg13
I1
sa(dp2245
g7
I14
sg8
g107
sg10
I4
sg11
VATG7
p2246
sg13
I1
sasg23
(lp2247
(dp2248
g7
I164
sg26
VC0007621
p2249
sg10
I13
sg11
Vtumorigenesis
p2250
sg13
I1
sa(dp2251
g7
I57
sg26
VC0002448
p2252
sg10
I14
sg11
Vameloblastomas
p2253
sg13
I1
sasa(dp2254
g2
S'Atg7 deficiency alters progression of Braf(V600E)-driven tumors from adenomas (Braf(V600E); atg7(-/-)) and adenocarcinomas (trp53(-/-); Braf(V600E); atg7(-/-)) to benign oncocytomas that accumulated morphologically and functionally defective mitochondria, suggesting that defects in mitochondrial metabolism may compromise continued tumor growth.\n'
p2255
sg4
(lp2256
(dp2257
g7
I124
sg8
VP42771
p2258
sg10
I5
sg11
Vtrp53
p2259
sg13
I1
sa(dp2260
g7
I0
sg8
g107
sg10
I4
sg11
VAtg7
p2261
sg13
I1
sasg23
(lp2262
(dp2263
g7
I170
sg26
VC0949541
p2264
sg10
I11
sg11
Voncocytomas
p2265
sg13
I1
sa(dp2266
g7
I57
sg26
VC0027651
p2267
sg10
I6
sg11
Vtumors
p2268
sg13
I1
sa(dp2269
g7
I107
sg26
VC0001418
p2270
sg10
I15
sg11
Vadenocarcinomas
p2271
sg13
I1
sa(dp2272
g7
I69
sg26
VC0001430
p2273
sg10
I8
sg11
Vadenomas
p2274
sg13
I1
sa(dp2275
g7
I333
sg26
VC0598934
p2276
sg10
I12
sg11
Vtumor growth
p2277
sg13
I2
sasa(dp2278
g2
S'At later stages of tumorigenesis, Atg7 deficiency resulted in an accumulation of defective mitochondria, proliferative defects, reduced tumor burden, conversion of adenomas and adenocarcinomas to oncocytomas, and increased mouse life span.\n'
p2279
sg4
(lp2280
(dp2281
g7
I34
sg8
g107
sg10
I4
sg11
VAtg7
p2282
sg13
I1
sasg23
(lp2283
(dp2284
g7
I19
sg26
VC0027651
p2285
sg10
I5
sg11
Vtumor
p2286
sg13
I1
sa(dp2287
g7
I196
sg26
VC0949541
p2288
sg10
I11
sg11
Voncocytomas
p2289
sg13
I1
sa(dp2290
g7
I177
sg26
VC0001418
p2291
sg10
I15
sg11
Vadenocarcinomas
p2292
sg13
I1
sa(dp2293
g7
I19
sg26
VC0007621
p2294
sg10
I13
sg11
Vtumorigenesis
p2295
sg13
I1
sa(dp2296
g7
I164
sg26
VC0001430
p2297
sg10
I8
sg11
Vadenomas
p2298
sg13
I1
sa(dp2299
g7
I105
sg26
VC0334094
p2300
sg10
I13
sg11
Vproliferative
p2301
sg13
I1
sasa(dp2302
g2
S'Using genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.\n'
p2303
sg4
(lp2304
(dp2305
g7
I152
sg8
g107
sg10
I4
sg11
VAtg7
p2306
sg13
I1
sa(dp2307
g7
I161
sg8
VP01116
p2308
sg10
I4
sg11
VKRAS
p2309
sg13
I1
sasg23
(lp2310
(dp2311
g7
I194
sg26
VC0598934
p2312
sg10
I12
sg11
Vtumor growth
p2313
sg13
I2
sa(dp2314
g7
I88
sg26
VC0007131
p2315
sg10
I5
sg11
VNSCLC
p2316
sg13
I1
sa(dp2317
g7
I220
sg26
VC0001430
p2318
sg10
I8
sg11
Vadenomas
p2319
sg13
I1
sa(dp2320
g7
I259
sg26
VC0949541
p2321
sg10
I11
sg11
Voncocytomas
p2322
sg13
I1
sa(dp2323
g7
I88
sg26
VC0007131
p2324
sg10
I5
sg11
VNSCLC
p2325
sg13
I1
sa(dp2326
g7
I60
sg26
VC0007131
p2327
sg10
I26
sg11
Vnon-small-cell lung cancer
p2328
sg13
I3
sa(dp2329
g7
I233
sg26
VC0001418
p2330
sg10
I15
sg11
Vadenocarcinomas
p2331
sg13
I1
sasa(dp2332
g2
S'atg7 loss altered tumor fate from adenomas and carcinomas to oncocytomas-rare, predominantly benign tumors characterized by the accumulation of defective mitochondria.\n'
p2333
sg4
(lp2334
(dp2335
g7
I0
sg8
g107
sg10
I4
sg11
Vatg7
p2336
sg13
I1
sasg23
(lp2337
(dp2338
g7
I18
sg26
VC0027651
p2339
sg10
I5
sg11
Vtumor
p2340
sg13
I1
sa(dp2341
g7
I61
sg26
VC0949541
p2342
sg10
I11
sg11
Voncocytomas
p2343
sg13
I1
sa(dp2344
g7
I34
sg26
VC0001430
p2345
sg10
I8
sg11
Vadenomas
p2346
sg13
I1
sa(dp2347
g7
I47
sg26
VC0007097
p2348
sg10
I10
sg11
Vcarcinomas
p2349
sg13
I1
sa(dp2350
g7
I93
sg26
VC0086692
p2351
sg10
I13
sg11
Vbenign tumors
p2352
sg13
I2
sasa(dp2353
g2
S'Subsequent studies demonstrated that Atg5(-/-) and Atg7(-/-) livers give rise to adenomas, Atg4C(-/-) mice are susceptible to chemical carcinogenesis, and Bif1(-/-) mice are prone to spontaneous tumors, indicating that autophagy defects promote tumorigenesis.\n'
p2354
sg4
(lp2355
(dp2356
g7
I91
sg8
g107
sg10
I5
sg11
VAtg4C
p2357
sg13
I1
sa(dp2358
g7
I155
sg8
g107
sg10
I4
sg11
VBif1
p2359
sg13
I1
sa(dp2360
g7
I37
sg8
g107
sg10
I4
sg11
VAtg5
p2361
sg13
I1
sa(dp2362
g7
I51
sg8
g107
sg10
I4
sg11
VAtg7
p2363
sg13
I1
sasg23
(lp2364
(dp2365
g7
I126
sg26
VC0596321
p2366
sg10
I23
sg11
Vchemical carcinogenesis
p2367
sg13
I2
sa(dp2368
g7
I245
sg26
VC0007621
p2369
sg10
I13
sg11
Vtumorigenesis
p2370
sg13
I1
sa(dp2371
g7
I81
sg26
VC0001430
p2372
sg10
I8
sg11
Vadenomas
p2373
sg13
I1
sa(dp2374
g7
I195
sg26
VC0027651
p2375
sg10
I6
sg11
Vtumors
p2376
sg13
I1
sasa(dp2377
g2
S'Scavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.\n'
p2378
sg4
(lp2379
(dp2380
g7
I38
sg8
g107
sg10
I6
sg11
VSCARA3
p2381
sg13
I1
sa(dp2382
g7
I0
sg8
g107
sg10
I36
sg11
VScavenger receptor class A, member 3
p2383
sg13
I6
sasg23
(lp2384
(dp2385
g7
I150
sg26
VC0678222
p2386
sg10
I16
sg11
Vbreast carcinoma
p2387
sg13
I2
sa(dp2388
g7
I167
sg26
VC0013687
p2389
sg10
I9
sg11
Veffusions
p2390
sg13
I1
sa(dp2391
g7
I98
sg26
VC1514428
p2392
sg10
I28
sg11
Vprimary peritoneal carcinoma
p2393
sg13
I3
sasa(dp2394
g2
S'p15RS is a ubiquitously expressed nuclear protein that is positively regulated by p15 and, in turn, inhibits the expression of cyclin D and cyclin E. To determine whether p15RS has malignancy inhibitory functions in addition to its inhibitory effects on cell cycle entry, we ectopically expressed p15RS in metastatic melanoma A375 cells, in which p15 gene is deleted and p15RS expression is dramatically downregulated, and examined the effect on various malignant phenotypes.\n'
p2395
sg4
(lp2396
(dp2397
g7
I0
sg8
g107
sg10
I5
sg11
Vp15RS
p2398
sg13
I1
sa(dp2399
g7
I0
sg8
g107
sg10
I5
sg11
Vp15RS
p2400
sg13
I1
sa(dp2401
g7
I0
sg8
g107
sg10
I5
sg11
Vp15RS
p2402
sg13
I1
sa(dp2403
g7
I0
sg8
g107
sg10
I5
sg11
Vp15RS
p2404
sg13
I1
sa(dp2405
g7
I347
sg8
VP53999
p2406
sg10
I8
sg11
Vp15 gene
p2407
sg13
I2
sa(dp2408
g7
I0
sg8
VP53999
p2409
sg10
I3
sg11
Vp15
p2410
sg13
I1
sa(dp2411
g7
I140
sg8
VP24864
p2412
sg10
I8
sg11
Vcyclin E
p2413
sg13
I2
sa(dp2414
g7
I127
sg8
VP24385
p2415
sg10
I8
sg11
Vcyclin D
p2416
sg13
I2
sasg23
(lp2417
(dp2418
g7
I181
sg26
VC0006826
p2419
sg10
I10
sg11
Vmalignancy
p2420
sg13
I1
sa(dp2421
g7
I306
sg26
VC0278883
p2422
sg10
I19
sg11
Vmetastatic melanoma
p2423
sg13
I2
sasa(dp2424
g2
S"Wilms' tumor 1-associating protein (WTAP) has been reported to be a ubiquitously expressed nuclear protein.\n"
p2425
sg4
(lp2426
(dp2427
g7
I0
sg8
g107
sg10
I34
sg11
VWilms' tumor 1-associating protein
p2428
sg13
I4
sa(dp2429
g7
I36
sg8
g107
sg10
I4
sg11
VWTAP
p2430
sg13
I1
sasg23
(lp2431
(dp2432
g7
I0
sg26
VC0027708
p2433
sg10
I12
sg11
VWilms' tumor
p2434
sg13
I2
sasa(dp2435
g2
S'The results showed that TCF7L2 polymorphism was associated with breast cancer (Homogeneous model: OR=1.17, 95%CI=1.02-1.35, I (2) =21.8%, p for heterogeneity=0.276; Heterogeneous model: OR=1.11, 95%CI=1.03-1.20, I (2) =0.0%, p for heterogeneity=0.543), prostate cancer (Homogeneous model: OR=0.89, 95%CI=0.84-0.96, I (2) =0.0%, p for heterogeneity=0.640; Heterogeneous model: OR=0.89, 95%CI=0.84-0.95, I (2) =0.0%, p for heterogeneity=0.871), and colon cancer (Heterogeneous model: OR=1.15, 95%CI=1.01-1.31, I (2) =0.0%, p for heterogeneity=0.658), but not with colorectal cancer, lung cancer, and ovarian cancer.\n'
p2436
sg4
(lp2437
sg23
(lp2438
(dp2439
g7
I598
sg26
VC1140680
p2440
sg10
I14
sg11
Vovarian cancer
p2441
sg13
I2
sa(dp2442
g7
I253
sg26
VC0600139
p2443
sg10
I15
sg11
Vprostate cancer
p2444
sg13
I2
sa(dp2445
g7
I64
sg26
VC0678222
p2446
sg10
I13
sg11
Vbreast cancer
p2447
sg13
I2
sa(dp2448
g7
I447
sg26
VC0699790
p2449
sg10
I12
sg11
Vcolon cancer
p2450
sg13
I2
sa(dp2451
g7
I562
sg26
VC1527249
p2452
sg10
I17
sg11
Vcolorectal cancer
p2453
sg13
I2
sa(dp2454
g7
I581
sg26
VC0684249
p2455
sg10
I11
sg11
Vlung cancer
p2456
sg13
I2
sasa(dp2457
g2
S'The present meta-analysis indicated that there were significantly associations between the TCF7L2 rs7903146 polymorphism and risk of breast, prostate and colon cancers, rather than colorectal cancer, lung cancer, and ovarian cancer.\n'
p2458
sg4
(lp2459
sg23
(lp2460
(dp2461
g7
I200
sg26
VC0684249
p2462
sg10
I11
sg11
Vlung cancer
p2463
sg13
I2
sa(dp2464
g7
I154
sg26
VC0007102
p2465
sg10
I13
sg11
Vcolon cancers
p2466
sg13
I2
sa(dp2467
g7
I217
sg26
VC1140680
p2468
sg10
I14
sg11
Vovarian cancer
p2469
sg13
I2
sa(dp2470
g7
I181
sg26
VC1527249
p2471
sg10
I17
sg11
Vcolorectal cancer
p2472
sg13
I2
sasa(dp2473
g2
S'Mutations in the gene encoding comparative gene identification 58 (CGI-58), also known as Alfa Beta hydrolase domain-containing 5 (ABHD5), cause neutral lipid storage disorder with ichthyosis (NLSDI).\n'
p2474
sg4
(lp2475
(dp2476
g7
I90
sg8
g107
sg10
I39
sg11
VAlfa Beta hydrolase domain-containing 5
p2477
sg13
I5
sa(dp2478
g7
I131
sg8
g107
sg10
I5
sg11
VABHD5
p2479
sg13
I1
sasg23
(lp2480
(dp2481
g7
I193
sg26
VC0268238
p2482
sg10
I5
sg11
VNLSDI
p2483
sg13
I1
sa(dp2484
g7
I145
sg26
VC0268238
p2485
sg10
I46
sg11
Vneutral lipid storage disorder with ichthyosis
p2486
sg13
I6
sasa(dp2487
g2
S'It has been elucidated that, of the ichthyosis-causative genes, ABCA12, ALOXE3, ALOX12B, CYP4F22, CERS3, ABHD5, PNPLA1 and ELOVL4 work in the formation of the corneocyte lipid envelope (CLE), a structure that is essential to sound skin barrier function.\n'
p2488
sg4
(lp2489
(dp2490
g7
I72
sg8
g107
sg10
I6
sg11
VALOXE3
p2491
sg13
I1
sa(dp2492
g7
I89
sg8
g107
sg10
I7
sg11
VCYP4F22
p2493
sg13
I1
sa(dp2494
g7
I186
sg8
g107
sg10
I3
sg11
VCLE
p2495
sg13
I1
sa(dp2496
g7
I80
sg8
g107
sg10
I7
sg11
VALOX12B
p2497
sg13
I1
sa(dp2498
g7
I64
sg8
g107
sg10
I6
sg11
VABCA12
p2499
sg13
I1
sa(dp2500
g7
I105
sg8
g107
sg10
I5
sg11
VABHD5
p2501
sg13
I1
sa(dp2502
g7
I98
sg8
g107
sg10
I5
sg11
VCERS3
p2503
sg13
I1
sa(dp2504
g7
I123
sg8
g107
sg10
I6
sg11
VELOVL4
p2505
sg13
I1
sa(dp2506
g7
I159
sg8
g107
sg10
I25
sg11
Vcorneocyte lipid envelope
p2507
sg13
I3
sa(dp2508
g7
I112
sg8
g107
sg10
I6
sg11
VPNPLA1
p2509
sg13
I1
sasg23
(lp2510
(dp2511
g7
I159
sg26
VC2931489
p2512
sg10
I25
sg11
Vcorneocyte lipid envelope
p2513
sg13
I3
sa(dp2514
g7
I186
sg26
VC2931489
p2515
sg10
I3
sg11
VCLE
p2516
sg13
I1
sa(dp2517
g7
I36
sg26
VC0020758
p2518
sg10
I10
sg11
Vichthyosis
p2519
sg13
I1
sasa(dp2520
g2
S'We discuss known inborn errors of CTGM, including deficiencies of: AGPAT2 (a form of generalized lipodystrophy), LPIN1 (childhood rhabdomyolysis), LPIN2 (an inflammatory condition, Majeed syndrome, described elsewhere in this issue), DGAT1 (protein loosing enteropathy), perilipin 1 (partial lipodystrophy), CGI-58 (gene ABHD5, neutral lipid storage disease (NLSD) with ichthyosis and "Jordan\'s anomaly" of vacuolated polymorphonuclear leukocytes), adipose triglyceride lipase (ATGL, gene PNPLA2, NLSD with myopathy, cardiomyopathy and Jordan\'s anomaly), hormone-sensitive lipase (HSL, gene LIPE, hypertriglyceridemia, and insulin resistance).\n'
p2521
sg4
(lp2522
(dp2523
g7
I623
sg8
VP01308
p2524
sg10
I7
sg11
Vinsulin
p2525
sg13
I1
sa(dp2526
g7
I586
sg8
g107
sg10
I9
sg11
Vgene LIPE
p2527
sg13
I2
sa(dp2528
g7
I478
sg8
g107
sg10
I4
sg11
VATGL
p2529
sg13
I1
sa(dp2530
g7
I581
sg8
g107
sg10
I3
sg11
VHSL
p2531
sg13
I1
sa(dp2532
g7
I484
sg8
g107
sg10
I11
sg11
Vgene PNPLA2
p2533
sg13
I2
sa(dp2534
g7
I555
sg8
g107
sg10
I24
sg11
Vhormone-sensitive lipase
p2535
sg13
I2
sa(dp2536
g7
I321
sg8
g107
sg10
I5
sg11
VABHD5
p2537
sg13
I1
sa(dp2538
g7
I271
sg8
g107
sg10
I11
sg11
Vperilipin 1
p2539
sg13
I2
sa(dp2540
g7
I234
sg8
g107
sg10
I5
sg11
VDGAT1
p2541
sg13
I1
sa(dp2542
g7
I67
sg8
g107
sg10
I6
sg11
VAGPAT2
p2543
sg13
I1
sa(dp2544
g7
I449
sg8
VP04118
p2545
sg10
I27
sg11
Vadipose triglyceride lipase
p2546
sg13
I3
sa(dp2547
g7
I113
sg8
g107
sg10
I5
sg11
VLPIN1
p2548
sg13
I1
sasg23
(lp2549
(dp2550
g7
I507
sg26
VC0026848
p2551
sg10
I8
sg11
Vmyopathy
p2552
sg13
I1
sa(dp2553
g7
I359
sg26
VC0268238
p2554
sg10
I4
sg11
VNLSD
p2555
sg13
I1
sa(dp2556
g7
I181
sg26
VC1864997
p2557
sg10
I15
sg11
VMajeed syndrome
p2558
sg13
I2
sa(dp2559
g7
I359
sg26
VC0268238
p2560
sg10
I4
sg11
VNLSD
p2561
sg13
I1
sa(dp2562
g7
I370
sg26
VC0020758
p2563
sg10
I10
sg11
Vichthyosis
p2564
sg13
I1
sa(dp2565
g7
I328
sg26
VC0268238
p2566
sg10
I29
sg11
Vneutral lipid storage disease
p2567
sg13
I4
sa(dp2568
g7
I517
sg26
VC0878544
p2569
sg10
I14
sg11
Vcardiomyopathy
p2570
sg13
I1
sa(dp2571
g7
I130
sg26
VC0035410
p2572
sg10
I14
sg11
Vrhabdomyolysis
p2573
sg13
I1
sa(dp2574
g7
I85
sg26
VC0221032
p2575
sg10
I25
sg11
Vgeneralized lipodystrophy
p2576
sg13
I2
sa(dp2577
g7
I257
sg26
VC0021831
p2578
sg10
I11
sg11
Venteropathy
p2579
sg13
I1
sa(dp2580
g7
I170
sg26
VC0012634
p2581
sg10
I9
sg11
Vcondition
p2582
sg13
I1
sa(dp2583
g7
I284
sg26
VC0220989
p2584
sg10
I21
sg11
Vpartial lipodystrophy
p2585
sg13
I2
sa(dp2586
g7
I623
sg26
VC0021655
p2587
sg10
I18
sg11
Vinsulin resistance
p2588
sg13
I2
sasa(dp2589
g2
S'In current study, we have discovered, using a comprehensive investigative regimen, a novel and tissue-specific role of claudin-3, a tight junction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of Stat-3 and Wnt-signaling activation.\n'
p2590
sg4
(lp2591
(dp2592
g7
I119
sg8
g107
sg10
I9
sg11
Vclaudin-3
p2593
sg13
I1
sa(dp2594
g7
I241
sg8
g107
sg10
I6
sg11
VStat-3
p2595
sg13
I1
sasg23
(lp2596
(dp2597
g7
I185
sg26
VC0178874
p2598
sg10
I18
sg11
Vcancer progression
p2599
sg13
I2
sasa(dp2600
g2
S'Claudin-3-/- mice revealed dedifferentiated and leaky colonic epithelium, and developed invasive adenocarcinoma when subjected to colon cancer.\n'
p2601
sg4
(lp2602
sg23
(lp2603
(dp2604
g7
I97
sg26
VC0001418
p2605
sg10
I14
sg11
Vadenocarcinoma
p2606
sg13
I1
sa(dp2607
g7
I130
sg26
VC0699790
p2608
sg10
I12
sg11
Vcolon cancer
p2609
sg13
I2
sasa(dp2610
g2
S'Wnt-signaling hyperactivation, albeit in GSK-3Beta independent manner, differentiated colon cancer in claudin-3-/- mice versus WT-mice.\n'
p2611
sg4
(lp2612
(dp2613
g7
I41
sg8
VP49841
p2614
sg10
I9
sg11
VGSK-3Beta
p2615
sg13
I1
sasg23
(lp2616
(dp2617
g7
I86
sg26
VC0699790
p2618
sg10
I12
sg11
Vcolon cancer
p2619
sg13
I2
sasa(dp2620
g2
S'Genetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/Beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer.\n'
p2621
sg4
(lp2622
(dp2623
g7
I51
sg8
g107
sg10
I14
sg11
Vclaudin-3 loss
p2624
sg13
I2
sa(dp2625
g7
I135
sg8
g107
sg10
I6
sg11
VStat-3
p2626
sg13
I1
sa(dp2627
g7
I78
sg8
VP35222
p2628
sg10
I12
sg11
VBeta-catenin
p2629
sg13
I1
sasg23
(lp2630
(dp2631
g7
I170
sg26
VC0699790
p2632
sg10
I12
sg11
Vcolon cancer
p2633
sg13
I2
sasa(dp2634
g2
S'Among the paradoxical claudin reaction nuclear localization of marker was observed relatively rarely: claudin-3 in 2.5% cases of colon cancer; claudin-4 in 8.5% of colon polyps.\n'
p2635
sg4
(lp2636
sg23
(lp2637
(dp2638
g7
I129
sg26
VC0699790
p2639
sg10
I12
sg11
Vcolon cancer
p2640
sg13
I2
sa(dp2641
g7
I164
sg26
VC0009376
p2642
sg10
I12
sg11
Vcolon polyps
p2643
sg13
I2
sasa(dp2644
g2
S'Mislocalization claudin-3 to nucleus in colon cancer and mislocalization claudin-4 to nucleus in adenomas of the colon were detected for the first time.\n'
p2645
sg4
(lp2646
(dp2647
g7
I0
sg8
g107
sg10
I25
sg11
VMislocalization claudin-3
p2648
sg13
I2
sa(dp2649
g7
I73
sg8
g107
sg10
I9
sg11
Vclaudin-4
p2650
sg13
I1
sasg23
(lp2651
(dp2652
g7
I97
sg26
VC0001430
p2653
sg10
I8
sg11
Vadenomas
p2654
sg13
I1
sa(dp2655
g7
I40
sg26
VC0699790
p2656
sg10
I12
sg11
Vcolon cancer
p2657
sg13
I2
sasa(dp2658
g2
S'Our approach aimed at evaluation of a selective and targeted cancer gene therapy of claudin-3- and/or claudin-4- expressing colon carcinoma in vitro and in vivo by using translation optimized CPE expressing vector.\n'
p2659
sg4
(lp2660
sg23
(lp2661
(dp2662
g7
I124
sg26
VC0699790
p2663
sg10
I15
sg11
Vcolon carcinoma
p2664
sg13
I2
sa(dp2665
g7
I61
sg26
VC0006826
p2666
sg10
I6
sg11
Vcancer
p2667
sg13
I1
sasa(dp2668
g2
S'In this study the recombinant CPE and a translation optimized CPE expressing vector (optCPE) was used for targeted gene therapy of claudin-3 and/or -4 overexpressing colon cancer cell lines.\n'
p2669
sg4
(lp2670
sg23
(lp2671
(dp2672
g7
I166
sg26
VC0699790
p2673
sg10
I12
sg11
Vcolon cancer
p2674
sg13
I2
sasa(dp2675
g2
S'All experiments were performed in the human SW480, SW620, HCT116, CaCo-2 and HT-29 colon cancer and the isogenic Sk-Mel5 and Sk-Mel5 Cldn-3-YFP melanoma cell lines.\n'
p2676
sg4
(lp2677
sg23
(lp2678
(dp2679
g7
I83
sg26
VC0699790
p2680
sg10
I12
sg11
Vcolon cancer
p2681
sg13
I2
sa(dp2682
g7
I144
sg26
VC0025202
p2683
sg10
I8
sg11
Vmelanoma
p2684
sg13
I1
sasa(dp2685
g2
S'Claudin-3 and -4 overexpressing colon carcinoma lines showed high sensitivity towards both recCPE application and optCPE gene transfer.\n'
p2686
sg4
(lp2687
(dp2688
g7
I0
sg8
g107
sg10
I16
sg11
VClaudin-3 and -4
p2689
sg13
I3
sasg23
(lp2690
(dp2691
g7
I32
sg26
VC0699790
p2692
sg10
I15
sg11
Vcolon carcinoma
p2693
sg13
I2
sasa(dp2694
g2
S'This novel approach demonstrates that optCPE gene transfer represents a promising and efficient therapeutic option for a targeted suicide gene therapy of claudin-3 and/or claudin-4 overexpressing colon carcinomas, leading to rapid and effective tumor cell killing in vitro and in vivo.\n'
p2695
sg4
(lp2696
(dp2697
g7
I171
sg8
g107
sg10
I9
sg11
Vclaudin-4
p2698
sg13
I1
sasg23
(lp2699
(dp2700
g7
I245
sg26
VC0027651
p2701
sg10
I5
sg11
Vtumor
p2702
sg13
I1
sa(dp2703
g7
I202
sg26
VC0007097
p2704
sg10
I10
sg11
Vcarcinomas
p2705
sg13
I1
sasa(dp2706
g2
S'To investigate the expression of claudin-3 in colorectal carcinoma and its association with the occurrence, progression and prognosis of colorectal cancer.\n'
p2707
sg4
(lp2708
(dp2709
g7
I33
sg8
g107
sg10
I9
sg11
Vclaudin-3
p2710
sg13
I1
sasg23
(lp2711
(dp2712
g7
I46
sg26
VC0009402
p2713
sg10
I20
sg11
Vcolorectal carcinoma
p2714
sg13
I2
sa(dp2715
g7
I137
sg26
VC0009402
p2716
sg10
I17
sg11
Vcolorectal cancer
p2717
sg13
I2
sasa(dp2718
g2
S'Claudin-3 is over-expressed in colorectal cancer tissues, and its high expression may promote the occurrence and progression of colorectal cancer.\n'
p2719
sg4
(lp2720
(dp2721
g7
I0
sg8
g107
sg10
I9
sg11
VClaudin-3
p2722
sg13
I1
sasg23
(lp2723
(dp2724
g7
I31
sg26
VC1527249
p2725
sg10
I17
sg11
Vcolorectal cancer
p2726
sg13
I2
sa(dp2727
g7
I31
sg26
VC1527249
p2728
sg10
I17
sg11
Vcolorectal cancer
p2729
sg13
I2
sasa(dp2730
g2
S'Here, we report that epidermal growth factor (EGF) increases the expression of claudin-3 in human colorectal adenocarcinoma HT-29 cells.\n'
p2731
sg4
(lp2732
(dp2733
g7
I79
sg8
g107
sg10
I9
sg11
Vclaudin-3
p2734
sg13
I1
sa(dp2735
g7
I46
sg8
VP01133
p2736
sg10
I3
sg11
VEGF
p2737
sg13
I1
sa(dp2738
g7
I21
sg8
VP01133
p2739
sg10
I23
sg11
Vepidermal growth factor
p2740
sg13
I3
sasg23
(lp2741
(dp2742
g7
I98
sg26
VC1319315
p2743
sg10
I25
sg11
Vcolorectal adenocarcinoma
p2744
sg13
I2
sasa(dp2745
g2
S'In conclusion, our results show a novel role for claudin-3 overexpression in promoting the malignant potential of colorectal cancer cells, which is potentially regulated by the EGF-activated ERK1/2 and PI3K-Akt pathways.\n'
p2746
sg4
(lp2747
(dp2748
g7
I49
sg8
g107
sg10
I9
sg11
Vclaudin-3
p2749
sg13
I1
sa(dp2750
g7
I177
sg8
VP01133
p2751
sg10
I3
sg11
VEGF
p2752
sg13
I1
sa(dp2753
g7
I202
sg8
VP42336
p2754
sg10
I4
sg11
VPI3K
p2755
sg13
I1
sa(dp2756
g7
I207
sg8
g107
sg10
I3
sg11
VAkt
p2757
sg13
I1
sa(dp2758
g7
I191
sg8
VP27361
p2759
sg10
I6
sg11
VERK1/2
p2760
sg13
I1
sasg23
(lp2761
(dp2762
g7
I114
sg26
VC1527249
p2763
sg10
I17
sg11
Vcolorectal cancer
p2764
sg13
I2
sasa(dp2765
g2
S'Patients with essential thrombocythemia (ET) and polycythemia vera (PV), complicated by microvascular ischemic or thrombotic events, have shortened platelet survival, increased beta-thromboglobulin, platelet factor 4, and thrombomodulin levels, and increased urinary thromboxane B2 excretion.\n'
p2766
sg4
(lp2767
(dp2768
g7
I177
sg8
VP02775
p2769
sg10
I20
sg11
Vbeta-thromboglobulin
p2770
sg13
I1
sa(dp2771
g7
I199
sg8
VP02776
p2772
sg10
I17
sg11
Vplatelet factor 4
p2773
sg13
I3
sa(dp2774
g7
I222
sg8
VP07204
p2775
sg10
I14
sg11
Vthrombomodulin
p2776
sg13
I1
sasg23
(lp2777
(dp2778
g7
I68
sg26
VC0032463
p2779
sg10
I2
sg11
VPV
p2780
sg13
I1
sa(dp2781
g7
I14
sg26
VC0040028
p2782
sg10
I25
sg11
Vessential thrombocythemia
p2783
sg13
I2
sa(dp2784
g7
I41
sg26
VC0040028
p2785
sg10
I2
sg11
VET
p2786
sg13
I1
sa(dp2787
g7
I49
sg26
VC0032463
p2788
sg10
I17
sg11
Vpolycythemia vera
p2789
sg13
I2
sasa(dp2790
g2
S'Our results suggest that CEP68 gene variants may play an important role in MNSAID-UA susceptibility and, despite the different regulatory mechanisms involved depending on the specific affected organ, in the development of hypersensitivity reactions to NSAIDs.\n'
p2791
sg4
(lp2792
(dp2793
g7
I25
sg8
g107
sg10
I19
sg11
VCEP68 gene variants
p2794
sg13
I3
sasg23
(lp2795
(dp2796
g7
I222
sg26
VC0020517
p2797
sg10
I26
sg11
Vhypersensitivity reactions
p2798
sg13
I2
sasa(dp2799
g2
S'Baboon anti-pig antibody (Ab) was measured before CPB, before circulatory arrest, during AbA, at the end of CPB, and daily after HTx.\n'
p2800
sg4
(lp2801
sg23
(lp2802
(dp2803
g7
I62
sg26
VC0444720
p2804
sg10
I18
sg11
Vcirculatory arrest
p2805
sg13
I2
sasa(dp2806
g2
S'At 4 dpi a severe fibrinosuppurative bronchopneumonia had developed.\n'
p2807
sg4
(lp2808
sg23
(lp2809
(dp2810
g7
I37
sg26
VC0006285
p2811
sg10
I16
sg11
Vbronchopneumonia
p2812
sg13
I1
sasa(dp2813
g2
S'However, the SrGAP3-deficient mice showed little to no interest in burying marbles; a behavior that is seen in some animal models related to autism, supporting the view that SrGAP3 plays a role in neurodevelopmental disorders.\n'
p2814
sg4
(lp2815
(dp2816
g7
I13
sg8
g107
sg10
I6
sg11
VSrGAP3
p2817
sg13
I1
sa(dp2818
g7
I13
sg8
g107
sg10
I6
sg11
VSrGAP3
p2819
sg13
I1
sasg23
(lp2820
(dp2821
g7
I141
sg26
VC0004352
p2822
sg10
I6
sg11
Vautism
p2823
sg13
I1
sasa(dp2824
g2
S'BA synthesis was directly quantified by measuring serum concentrations of 7alpha-hydroxycholest-4-en-3-one (C4), along with serum FGF19 and other parameters, in 44 patients with primary biliary cirrhosis (PBC) and 10 healthy subjects.\n'
p2825
sg4
(lp2826
(dp2827
g7
I130
sg8
g107
sg10
I5
sg11
VFGF19
p2828
sg13
I1
sasg23
(lp2829
(dp2830
g7
I178
sg26
VC0008312
p2831
sg10
I25
sg11
Vprimary biliary cirrhosis
p2832
sg13
I3
sa(dp2833
g7
I205
sg26
VC0008312
p2834
sg10
I3
sg11
VPBC
p2835
sg13
I1
sasa(dp2836
g2
S'Whether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are involved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.\n'
p2837
sg4
(lp2838
(dp2839
g7
I8
sg8
g107
sg10
I27
sg11
Vfibroblast growth factor 19
p2840
sg13
I4
sa(dp2841
g7
I69
sg8
VP23945
p2842
sg10
I3
sg11
VFXR
p2843
sg13
I1
sa(dp2844
g7
I47
sg8
g107
sg10
I20
sg11
Vfarnesoid X receptor
p2845
sg13
I3
sa(dp2846
g7
I37
sg8
g107
sg10
I5
sg11
VFGF19
p2847
sg13
I1
sasg23
(lp2848
(dp2849
g7
I173
sg26
VC0008312
p2850
sg10
I3
sg11
VPBC
p2851
sg13
I1
sa(dp2852
g7
I146
sg26
VC0008312
p2853
sg10
I25
sg11
Vprimary biliary cirrhosis
p2854
sg13
I3
sasa(dp2855
g2
S'Our results provide further insight into the specific relationship between histone H4 modification and gene expression during spermatogenesis, which could help to elucidate the epigenetic disorders underlying male infertility.\n'
p2856
sg4
(lp2857
(dp2858
g7
I75
sg8
VP62805
p2859
sg10
I10
sg11
Vhistone H4
p2860
sg13
I2
sasg23
(lp2861
(dp2862
g7
I209
sg26
VC0021364
p2863
sg10
I16
sg11
Vmale infertility
p2864
sg13
I2
sasa(dp2865
g2
S'Previous studies have resulted in the isolation of the human HSST gene from within the Treacher Collins syndrome locus (TCOF1) critical region on 5q.\n'
p2866
sg4
(lp2867
(dp2868
g7
I120
sg8
g107
sg10
I5
sg11
VTCOF1
p2869
sg13
I1
sa(dp2870
g7
I55
sg8
VP52848
p2871
sg10
I15
sg11
Vhuman HSST gene
p2872
sg13
I3
sasg23
(lp2873
(dp2874
g7
I87
sg26
VC0242387
p2875
sg10
I25
sg11
VTreacher Collins syndrome
p2876
sg13
I3
sasa(dp2877
g2
S'As a result of these studies, mutations within the coding sequence and adjacent splice junctions of HSST can be excluded from a causative role in the pathogenesis of Treacher Collins syndrome.\n'
p2878
sg4
(lp2879
sg23
(lp2880
(dp2881
g7
I150
sg26
VC0699748
p2882
sg10
I12
sg11
Vpathogenesis
p2883
sg13
I1
sa(dp2884
g7
I166
sg26
VC0242387
p2885
sg10
I25
sg11
VTreacher Collins syndrome
p2886
sg13
I3
sasa(dp2887
g2
S'In univariate analyses, diabetes mellitus, chronic kidney disease, ischemic etiology of LBBB, dilated left atrium, reduced LVEF, dilated left ventricle, and impaired LV global strain (GLS &gt; -12.2%, global circumferential strain &gt; -11.8%, and twist &lt; 6.5) showed associations with the composite end point.\n'
p2888
sg4
(lp2889
sg23
(lp2890
(dp2891
g7
I157
sg26
VC0684336
p2892
sg10
I8
sg11
Vimpaired
p2893
sg13
I1
sa(dp2894
g7
I24
sg26
VC0011849
p2895
sg10
I17
sg11
Vdiabetes mellitus
p2896
sg13
I2
sa(dp2897
g7
I129
sg26
VC0745674
p2898
sg10
I22
sg11
Vdilated left ventricle
p2899
sg13
I3
sa(dp2900
g7
I88
sg26
VC0023211
p2901
sg10
I4
sg11
VLBBB
p2902
sg13
I1
sa(dp2903
g7
I43
sg26
VC1561643
p2904
sg10
I22
sg11
Vchronic kidney disease
p2905
sg13
I3
sasa(dp2906
g2
S'Individuals with T1D had increased systolic torsion (P = 0.035), systolic torsion rate (P = 0.032), peak Ecl (P = 0.001), and rates of change of systolic (P = 0.007) and diastolic (P = 0.007) Ecl Individuals with T1D, with normal structure, LVEF, and strain, have increased extracellular volume and increased native T1 values with associated augmented torsion and Ecl These measures may be useful in detecting the early stages of diabetic cardiomyopathy and warrant larger prospective studies.NEW &amp; NOTEWORTHY Individuals with type 1 diabetes, with normal left ventricular structure and function (ejection fraction and strain), have signs of interstitial fibrosis, measured with MRI as increased extracellular volume fraction and increased native myocardial T1, which significantly correlated with a number of measures of augmented left ventricular twist function.\n'
p2907
sg4
(lp2908
sg23
(lp2909
(dp2910
g7
I531
sg26
VC0011854
p2911
sg10
I15
sg11
Vtype 1 diabetes
p2912
sg13
I3
sa(dp2913
g7
I44
sg26
VC1265748
p2914
sg10
I7
sg11
Vtorsion
p2915
sg13
I1
sa(dp2916
g7
I646
sg26
VC0240035
p2917
sg10
I21
sg11
Vinterstitial fibrosis
p2918
sg13
I2
sa(dp2919
g7
I44
sg26
VC1265748
p2920
sg10
I7
sg11
Vtorsion
p2921
sg13
I1
sa(dp2922
g7
I430
sg26
VC0853897
p2923
sg10
I23
sg11
Vdiabetic cardiomyopathy
p2924
sg13
I2
sa(dp2925
g7
I44
sg26
VC1265748
p2926
sg10
I7
sg11
Vtorsion
p2927
sg13
I1
sasa(dp2928
g2
S'In this study, we show that hyperinsulinemia in the Rag/MKR mice increases the expression of mesenchymal transcription factors, TWIST1 and ZEB1, and increases the expression of the angiogenesis marker, vascular endothelial growth factor A (VEGFA).\n'
p2929
sg4
(lp2930
(dp2931
g7
I240
sg8
g107
sg10
I5
sg11
VVEGFA
p2932
sg13
I1
sa(dp2933
g7
I52
sg8
VP52803
p2934
sg10
I3
sg11
VRag
p2935
sg13
I1
sa(dp2936
g7
I139
sg8
VP37275
p2937
sg10
I4
sg11
VZEB1
p2938
sg13
I1
sa(dp2939
g7
I56
sg8
VP33032
p2940
sg10
I3
sg11
VMKR
p2941
sg13
I1
sa(dp2942
g7
I128
sg8
g107
sg10
I6
sg11
VTWIST1
p2943
sg13
I1
sa(dp2944
g7
I202
sg8
g107
sg10
I36
sg11
Vvascular endothelial growth factor A
p2945
sg13
I5
sasg23
(lp2946
(dp2947
g7
I28
sg26
VC0020459
p2948
sg10
I16
sg11
Vhyperinsulinemia
p2949
sg13
I1
sasa(dp2950
g2
S"Aortic PWV correlated crudely with age (p &lt; 0.001), the presence of diabetes (p &lt; 0.001), hypertension (p &lt; 0.001), eGFR (p &lt; 0.001), LVMI (p = 0.01), e/e' (p &lt; 0.001) and LV twist (p = 0.003).\n"
p2951
sg4
(lp2952
sg23
(lp2953
(dp2954
g7
I96
sg26
VC0020538
p2955
sg10
I12
sg11
Vhypertension
p2956
sg13
I1
sa(dp2957
g7
I71
sg26
VC0011849
p2958
sg10
I8
sg11
Vdiabetes
p2959
sg13
I1
sasa(dp2960
g2
S'There is limited information regarding the role of left ventricular (LV) twist and the effect of exercise in type 2 diabetes (T2D).\n'
p2961
sg4
(lp2962
sg23
(lp2963
(dp2964
g7
I126
sg26
VC0011860
p2965
sg10
I3
sg11
VT2D
p2966
sg13
I1
sa(dp2967
g7
I109
sg26
VC0011860
p2968
sg10
I15
sg11
Vtype 2 diabetes
p2969
sg13
I3
sasa(dp2970
g2
S'These results demonstrated that quercetin ameliorates the EMT of HK-2 and NRK-52E cells induced by high glucose and renal fibrosis induced by diabetes, and these effects have been associated with the inhibition of the two transcriptional factors (snail and twist) and the activation of mTORC1/p70S6K.\n'
p2971
sg4
(lp2972
(dp2973
g7
I74
sg8
g107
sg10
I7
sg11
VNRK-52E
p2974
sg13
I1
sasg23
(lp2975
(dp2976
g7
I142
sg26
VC0011849
p2977
sg10
I8
sg11
Vdiabetes
p2978
sg13
I1
sa(dp2979
g7
I116
sg26
VC0151650
p2980
sg10
I14
sg11
Vrenal fibrosis
p2981
sg13
I2
sasa(dp2982
g2
S'Activin Receptor-Like Kinase 5 (ALK-5) is related to some types of cancer, such as breast, lung and pancreas.\n'
p2983
sg4
(lp2984
(dp2985
g7
I0
sg8
VP36897
p2986
sg10
I30
sg11
VActivin Receptor-Like Kinase 5
p2987
sg13
I4
sa(dp2988
g7
I32
sg8
VP36897
p2989
sg10
I5
sg11
VALK-5
p2990
sg13
I1
sasg23
(lp2991
(dp2992
g7
I67
sg26
VC0006826
p2993
sg10
I6
sg11
Vcancer
p2994
sg13
I1
sasa(dp2995
g2
S'Overall, we discussed about the main interactions between ALK-5 and six inhibitors that may be used as starting point for designing of new molecules to the cancer treatment.\n'
p2996
sg4
(lp2997
(dp2998
g7
I58
sg8
VP36897
p2999
sg10
I5
sg11
VALK-5
p3000
sg13
I1
sasg23
(lp3001
(dp3002
g7
I156
sg26
VC0006826
p3003
sg10
I6
sg11
Vcancer
p3004
sg13
I1
sasa(dp3005
g2
S'In summary, the results suggest that eupatolide suppresses the migration and invasion of breast cancer cells by blocking the canonical ALK5-SMAD3 signaling pathway and the non-canonical ERK and AKT signaling pathways.\n'
p3006
sg4
(lp3007
(dp3008
g7
I186
sg8
VP29323
p3009
sg10
I3
sg11
VERK
p3010
sg13
I1
sa(dp3011
g7
I135
sg8
VP36897
p3012
sg10
I4
sg11
VALK5
p3013
sg13
I1
sa(dp3014
g7
I194
sg8
g107
sg10
I3
sg11
VAKT
p3015
sg13
I1
sasg23
(lp3016
(dp3017
g7
I77
sg26
VC2699153
p3018
sg10
I8
sg11
Vinvasion
p3019
sg13
I1
sa(dp3020
g7
I112
sg26
VC0233660
p3021
sg10
I8
sg11
Vblocking
p3022
sg13
I1
sa(dp3023
g7
I89
sg26
VC0678222
p3024
sg10
I13
sg11
Vbreast cancer
p3025
sg13
I2
sasa(dp3026
g2
S'Expression of a mutant TBetaRI that signals but does not interact with Smad7 prevented the CerS4-mediated inhibition of migration in various cancer cells.\n'
p3027
sg4
(lp3028
(dp3029
g7
I71
sg8
g107
sg10
I5
sg11
VSmad7
p3030
sg13
I1
sa(dp3031
g7
I91
sg8
g107
sg10
I5
sg11
VCerS4
p3032
sg13
I1
sasg23
(lp3033
(dp3034
g7
I141
sg26
VC0006826
p3035
sg10
I6
sg11
Vcancer
p3036
sg13
I1
sa(dp3037
g7
I16
sg26
VC0596988
p3038
sg10
I6
sg11
Vmutant
p3039
sg13
I1
sasa(dp3040
g2
S'TBetaRI-Smo cross-talk at the cilia in CerS4-deficient 4T1 mammary cancer cells induced liver metastasis from orthotopic allografts in both wild-type and CerS4-deficient mice, which was prevented by overexpression of Smad7 or knockdown of intraflagellar transport protein 88 (IFT88).\n'
p3041
sg4
(lp3042
(dp3043
g7
I239
sg8
g107
sg10
I35
sg11
Vintraflagellar transport protein 88
p3044
sg13
I4
sa(dp3045
g7
I39
sg8
g107
sg10
I5
sg11
VCerS4
p3046
sg13
I1
sa(dp3047
g7
I8
sg8
g107
sg10
I3
sg11
VSmo
p3048
sg13
I1
sa(dp3049
g7
I276
sg8
g107
sg10
I5
sg11
VIFT88
p3050
sg13
I1
sa(dp3051
g7
I39
sg8
g107
sg10
I5
sg11
VCerS4
p3052
sg13
I1
sa(dp3053
g7
I217
sg8
g107
sg10
I5
sg11
VSmad7
p3054
sg13
I1
sasg23
(lp3055
(dp3056
g7
I67
sg26
VC0006826
p3057
sg10
I6
sg11
Vcancer
p3058
sg13
I1
sa(dp3059
g7
I88
sg26
VC0494165
p3060
sg10
I16
sg11
Vliver metastasis
p3061
sg13
I2
sasa(dp3062
g2
S'Transforming growth factor type 1 receptor (ALK5) is kinase associated with a wide variety of pathological processes, and inhibition of ALK5 is a good strategy to treat many kinds of cancer and fibrotic diseases.\n'
p3063
sg4
(lp3064
(dp3065
g7
I0
sg8
g107
sg10
I42
sg11
VTransforming growth factor type 1 receptor
p3066
sg13
I6
sa(dp3067
g7
I44
sg8
VP36897
p3068
sg10
I4
sg11
VALK5
p3069
sg13
I1
sa(dp3070
g7
I44
sg8
VP36897
p3071
sg10
I4
sg11
VALK5
p3072
sg13
I1
sasg23
(lp3073
(dp3074
g7
I94
sg26
VC0030660
p3075
sg10
I22
sg11
Vpathological processes
p3076
sg13
I2
sa(dp3077
g7
I183
sg26
VC0006826
p3078
sg10
I6
sg11
Vcancer
p3079
sg13
I1
sasa(dp3080
g2
S'The high mortality rates observed in patients with invasive aspergillosis caused by azole-resistant A. fumigatus (ARAF) isolates pose serious challenges to the clinical microbiologist for timely identification of resistance and appropriate therapeutic interventions.\n'
p3081
sg4
(lp3082
sg23
(lp3083
(dp3084
g7
I51
sg26
VC0238013
p3085
sg10
I22
sg11
Vinvasive aspergillosis
p3086
sg13
I2
sasa(dp3087
g2
S'MKL/myocardin-like 2 (MKL2) encodes myocardin-related transcription factor B in a megakaryoblastic leukemia gene family, and C11orf95 (chromosome 11 open reading frame 95) is a hypothetical protein.\n'
p3088
sg4
(lp3089
(dp3090
g7
I0
sg8
g107
sg10
I20
sg11
VMKL/myocardin-like 2
p3091
sg13
I2
sa(dp3092
g7
I36
sg8
g107
sg10
I40
sg11
Vmyocardin-related transcription factor B
p3093
sg13
I4
sa(dp3094
g7
I22
sg8
g107
sg10
I4
sg11
VMKL2
p3095
sg13
I1
sasg23
(lp3096
(dp3097
g7
I82
sg26
VC0023462
p3098
sg10
I25
sg11
Vmegakaryoblastic leukemia
p3099
sg13
I2
sasa(dp3100
g2
S'Serum levels of IL-16, IL-33 and the decoy receptor of IL-33, soluble ST2, are elevated in allergic rhinitis.\n'
p3101
sg4
(lp3102
(dp3103
g7
I16
sg8
g107
sg10
I5
sg11
VIL-16
p3104
sg13
I1
sasg23
(lp3105
(dp3106
g7
I91
sg26
VC2607914
p3107
sg10
I17
sg11
Vallergic rhinitis
p3108
sg13
I2
sasa(dp3109
g2
S'Recent studies show that IL-16, soluble ST2 or anti-IL-33 reduce type 2 cytokines (such as IL-5) and eosinophilia in murine models of allergic asthma or allergic rhinitis respectively.\n'
p3110
sg4
(lp3111
(dp3112
g7
I65
sg8
VP01374
p3113
sg10
I16
sg11
Vtype 2 cytokines
p3114
sg13
I3
sa(dp3115
g7
I91
sg8
VP05113
p3116
sg10
I4
sg11
VIL-5
p3117
sg13
I1
sa(dp3118
g7
I25
sg8
g107
sg10
I18
sg11
VIL-16, soluble ST2
p3119
sg13
I3
sasg23
(lp3120
(dp3121
g7
I134
sg26
VC0155877
p3122
sg10
I15
sg11
Vallergic asthma
p3123
sg13
I2
sa(dp3124
g7
I153
sg26
VC2607914
p3125
sg10
I17
sg11
Vallergic rhinitis
p3126
sg13
I2
sa(dp3127
g7
I101
sg26
VC0014457
p3128
sg10
I12
sg11
Veosinophilia
p3129
sg13
I1
sasa(dp3130
g2
S'In this study, we studied the release of IL-5, IL-16, IL-33 and soluble ST2 in allergic rhinitis patients after nasal allergen challenge and natural pollen exposure.\n'
p3131
sg4
(lp3132
(dp3133
g7
I47
sg8
g107
sg10
I5
sg11
VIL-16
p3134
sg13
I1
sa(dp3135
g7
I41
sg8
VP05113
p3136
sg10
I4
sg11
VIL-5
p3137
sg13
I1
sasg23
(lp3138
(dp3139
g7
I79
sg26
VC2607914
p3140
sg10
I17
sg11
Vallergic rhinitis
p3141
sg13
I2
sasa(dp3142
g2
S'The observed upregulation of soluble ST2 and IL-16 after nasal allergen challenge and during peak pollination season suggests potential regulatory roles of these cytokines in the inflammatory reaction in allergic rhinitis.\n'
p3143
sg4
(lp3144
(dp3145
g7
I45
sg8
g107
sg10
I5
sg11
VIL-16
p3146
sg13
I1
sa(dp3147
g7
I37
sg8
VP10767
p3148
sg10
I3
sg11
VST2
p3149
sg13
I1
sasg23
(lp3150
(dp3151
g7
I204
sg26
VC2607914
p3152
sg10
I17
sg11
Vallergic rhinitis
p3153
sg13
I2
sa(dp3154
g7
I179
sg26
VC0021368
p3155
sg10
I21
sg11
Vinflammatory reaction
p3156
sg13
I2
sasa(dp3157
g2
S'To detect the expression and distribution of the lung surfactant protein D (surfactant protein D,SP-D ) and IL-16 in nasal mucosa of allergic rhinitis and nasal polyps, and then probe into their significance in the pathology of allergic rhinitis and nasal polyps.\n'
p3158
sg4
(lp3159
(dp3160
g7
I97
sg8
VP35247
p3161
sg10
I4
sg11
VSP-D
p3162
sg13
I1
sa(dp3163
g7
I54
sg8
VP35247
p3164
sg10
I20
sg11
Vsurfactant protein D
p3165
sg13
I3
sa(dp3166
g7
I54
sg8
VP35247
p3167
sg10
I20
sg11
Vsurfactant protein D
p3168
sg13
I3
sa(dp3169
g7
I108
sg8
g107
sg10
I5
sg11
VIL-16
p3170
sg13
I1
sasg23
(lp3171
(dp3172
g7
I215
sg26
VC0677042
p3173
sg10
I9
sg11
Vpathology
p3174
sg13
I1
sa(dp3175
g7
I155
sg26
VC0027430
p3176
sg10
I12
sg11
Vnasal polyps
p3177
sg13
I2
sa(dp3178
g7
I133
sg26
VC2607914
p3179
sg10
I17
sg11
Vallergic rhinitis
p3180
sg13
I2
sa(dp3181
g7
I155
sg26
VC0027430
p3182
sg10
I12
sg11
Vnasal polyps
p3183
sg13
I2
sa(dp3184
g7
I133
sg26
VC2607914
p3185
sg10
I17
sg11
Vallergic rhinitis
p3186
sg13
I2
sasa(dp3187
g2
S'Fifteen cases of allergic rhinitis, fifteen cases of nasal polyps and fifteen cases of inferior turbinate mucosa were studied to detect the expression of SP-D and IL-16 by immunohistochemistry method.\n'
p3188
sg4
(lp3189
(dp3190
g7
I154
sg8
VP35247
p3191
sg10
I4
sg11
VSP-D
p3192
sg13
I1
sa(dp3193
g7
I163
sg8
g107
sg10
I5
sg11
VIL-16
p3194
sg13
I1
sasg23
(lp3195
(dp3196
g7
I17
sg26
VC2607914
p3197
sg10
I17
sg11
Vallergic rhinitis
p3198
sg13
I2
sa(dp3199
g7
I53
sg26
VC0027430
p3200
sg10
I12
sg11
Vnasal polyps
p3201
sg13
I2
sasa(dp3202
g2
S'The expression of SP-D and IL-16 in allergic rhinitis and nasal polyps were dramatically higher in controls (P &lt; 0.01).\n'
p3203
sg4
(lp3204
(dp3205
g7
I27
sg8
g107
sg10
I5
sg11
VIL-16
p3206
sg13
I1
sa(dp3207
g7
I18
sg8
VP35247
p3208
sg10
I4
sg11
VSP-D
p3209
sg13
I1
sasg23
(lp3210
(dp3211
g7
I36
sg26
VC2607914
p3212
sg10
I17
sg11
Vallergic rhinitis
p3213
sg13
I2
sa(dp3214
g7
I58
sg26
VC0027430
p3215
sg10
I12
sg11
Vnasal polyps
p3216
sg13
I2
sasa(dp3217
g2
S'There was no remarkable difference in the expression of SP-D and IL-16 between allergic rhinitis and nasal polyps (P &gt; 0.05).\n'
p3218
sg4
(lp3219
(dp3220
g7
I65
sg8
g107
sg10
I5
sg11
VIL-16
p3221
sg13
I1
sa(dp3222
g7
I56
sg8
VP35247
p3223
sg10
I4
sg11
VSP-D
p3224
sg13
I1
sasg23
(lp3225
(dp3226
g7
I101
sg26
VC0027430
p3227
sg10
I12
sg11
Vnasal polyps
p3228
sg13
I2
sa(dp3229
g7
I79
sg26
VC2607914
p3230
sg10
I17
sg11
Vallergic rhinitis
p3231
sg13
I2
sasa(dp3232
g2
S'IL-16 is an important eosinophil chemokine in the process of allergic rhinitis and nasal polyps,and it can also enhance the local role of eosinophils,thus it can involve in the process of allergic rhinitis and nasal polyps disease.\n'
p3233
sg4
(lp3234
(dp3235
g7
I0
sg8
g107
sg10
I5
sg11
VIL-16
p3236
sg13
I1
sasg23
(lp3237
(dp3238
g7
I61
sg26
VC2607914
p3239
sg10
I17
sg11
Vallergic rhinitis
p3240
sg13
I2
sa(dp3241
g7
I61
sg26
VC2607914
p3242
sg10
I17
sg11
Vallergic rhinitis
p3243
sg13
I2
sa(dp3244
g7
I83
sg26
VC0027430
p3245
sg10
I12
sg11
Vnasal polyps
p3246
sg13
I2
sa(dp3247
g7
I83
sg26
VC0027430
p3248
sg10
I12
sg11
Vnasal polyps
p3249
sg13
I2
sasa(dp3250
g2
S'Though a chemotactin for CD4(+) cells and eosinophils, IL-16 also modulates their production of factors that influence inflammatory lung diseases, e.g., asthma and allergic rhinitis.\n'
p3251
sg4
(lp3252
(dp3253
g7
I55
sg8
g107
sg10
I5
sg11
VIL-16
p3254
sg13
I1
sa(dp3255
g7
I25
sg8
VP01730
p3256
sg10
I3
sg11
VCD4
p3257
sg13
I1
sasg23
(lp3258
(dp3259
g7
I153
sg26
VC0004096
p3260
sg10
I6
sg11
Vasthma
p3261
sg13
I1
sa(dp3262
g7
I132
sg26
VC0024115
p3263
sg10
I13
sg11
Vlung diseases
p3264
sg13
I2
sa(dp3265
g7
I164
sg26
VC2607914
p3266
sg10
I17
sg11
Vallergic rhinitis
p3267
sg13
I2
sasa(dp3268
g2
S'Interleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis.\n'
p3269
sg4
(lp3270
(dp3271
g7
I16
sg8
g107
sg10
I5
sg11
VIL-16
p3272
sg13
I1
sa(dp3273
g7
I0
sg8
g107
sg10
I14
sg11
VInterleukin-16
p3274
sg13
I1
sa(dp3275
g7
I73
sg8
VP01730
p3276
sg10
I4
sg11
VCD4+
p3277
sg13
I1
sasg23
(lp3278
(dp3279
g7
I136
sg26
VC2607914
p3280
sg10
I17
sg11
Vallergic rhinitis
p3281
sg13
I2
sasa(dp3282
g2
S'We evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.\n'
p3283
sg4
(lp3284
(dp3285
g7
I32
sg8
g107
sg10
I5
sg11
VIL-16
p3286
sg13
I1
sa(dp3287
g7
I32
sg8
g107
sg10
I5
sg11
VIL-16
p3288
sg13
I1
sasg23
(lp3289
(dp3290
g7
I195
sg26
VC2607914
p3291
sg10
I17
sg11
Vallergic rhinitis
p3292
sg13
I2
sasa(dp3293
g2
S'These results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.\n'
p3294
sg4
(lp3295
(dp3296
g7
I27
sg8
g107
sg10
I5
sg11
VIL-16
p3297
sg13
I1
sa(dp3298
g7
I27
sg8
g107
sg10
I5
sg11
VIL-16
p3299
sg13
I1
sasg23
(lp3300
(dp3301
g7
I155
sg26
VC0020517
p3302
sg10
I14
sg11
Vallergic state
p3303
sg13
I2
sa(dp3304
g7
I93
sg26
VC2607914
p3305
sg10
I17
sg11
Vallergic rhinitis
p3306
sg13
I2
sasa(dp3307
g2
S'The results showed abnormally increased levels of IL-16 (294.4 +/- 15.24 pg/ml), serum eosinophils with absolute count (510.0 +/- 93.57, P&gt;0.05), and total serum IgE (287.9 +/- 61.22 IU/ml) using ELFA in patients of combined asthma and rhinitis, than in each of them alone.\n'
p3308
sg4
(lp3309
(dp3310
g7
I159
sg8
VP01854
p3311
sg10
I9
sg11
Vserum IgE
p3312
sg13
I2
sa(dp3313
g7
I50
sg8
g107
sg10
I5
sg11
VIL-16
p3314
sg13
I1
sasg23
(lp3315
(dp3316
g7
I239
sg26
VC0035455
p3317
sg10
I8
sg11
Vrhinitis
p3318
sg13
I1
sa(dp3319
g7
I165
sg26
VC0270850
p3320
sg10
I3
sg11
VIgE
p3321
sg13
I1
sa(dp3322
g7
I228
sg26
VC0004096
p3323
sg10
I6
sg11
Vasthma
p3324
sg13
I1
sasa(dp3325
g2
S'We first examined the IL-16 expression of serum and mucosal tissue in patients with allergic rhinitis.\n'
p3326
sg4
(lp3327
(dp3328
g7
I22
sg8
g107
sg10
I5
sg11
VIL-16
p3329
sg13
I1
sasg23
(lp3330
(dp3331
g7
I84
sg26
VC2607914
p3332
sg10
I17
sg11
Vallergic rhinitis
p3333
sg13
I2
sasa(dp3334
g2
S'IL-16 levels were elevated in the serum of patients with allergic rhinitis compared with normal controls.\n'
p3335
sg4
(lp3336
(dp3337
g7
I0
sg8
g107
sg10
I5
sg11
VIL-16
p3338
sg13
I1
sasg23
(lp3339
(dp3340
g7
I57
sg26
VC2607914
p3341
sg10
I17
sg11
Vallergic rhinitis
p3342
sg13
I2
sasa(dp3343
g2
S'IL-16 was significantly correlated with eosinophils in the peripheral blood of allergic rhinitis patients.\n'
p3344
sg4
(lp3345
(dp3346
g7
I0
sg8
g107
sg10
I5
sg11
VIL-16
p3347
sg13
I1
sasg23
(lp3348
(dp3349
g7
I79
sg26
VC2607914
p3350
sg10
I17
sg11
Vallergic rhinitis
p3351
sg13
I2
sasa(dp3352
g2
S'This IL-16 cytokine may be strongly associated with the developmental mechanism of allergic rhinitis.\n'
p3353
sg4
(lp3354
(dp3355
g7
I5
sg8
g107
sg10
I14
sg11
VIL-16 cytokine
p3356
sg13
I2
sasg23
(lp3357
(dp3358
g7
I83
sg26
VC2607914
p3359
sg10
I17
sg11
Vallergic rhinitis
p3360
sg13
I2
sasa(dp3361
g2
S'Speech fluency was assessed in 35 patients with frontotemporal lobar degeneration (FTLD) who presented with progressive non-fluent aphasia (PNFA, n=11), semantic dementia (SemD, n=12), or a social and executive disorder without aphasia (SOC/EXEC, n=12).\n'
p3362
sg4
(lp3363
(dp3364
g7
I172
sg8
g107
sg10
I4
sg11
VSemD
p3365
sg13
I1
sa(dp3366
g7
I153
sg8
g107
sg10
I17
sg11
Vsemantic dementia
p3367
sg13
I2
sasg23
(lp3368
(dp3369
g7
I48
sg26
VC0751072
p3370
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p3371
sg13
I3
sa(dp3372
g7
I153
sg26
VC0338462
p3373
sg10
I17
sg11
Vsemantic dementia
p3374
sg13
I2
sa(dp3375
g7
I172
sg26
VC0338462
p3376
sg10
I4
sg11
VSemD
p3377
sg13
I1
sa(dp3378
g7
I83
sg26
VC0751072
p3379
sg10
I4
sg11
VFTLD
p3380
sg13
I1
sa(dp3381
g7
I131
sg26
VC0003537
p3382
sg10
I7
sg11
Vaphasia
p3383
sg13
I1
sa(dp3384
g7
I120
sg26
VC0349390
p3385
sg10
I18
sg11
Vnon-fluent aphasia
p3386
sg13
I2
sasa(dp3387
g2
S'Two subtypes commonly present with a language disorder: semantic dementia (SemD) and progressive nonfluent aphasia (PNFA).\n'
p3388
sg4
(lp3389
(dp3390
g7
I56
sg8
g107
sg10
I17
sg11
Vsemantic dementia
p3391
sg13
I2
sa(dp3392
g7
I75
sg8
g107
sg10
I4
sg11
VSemD
p3393
sg13
I1
sasg23
(lp3394
(dp3395
g7
I37
sg26
VC0023015
p3396
sg10
I17
sg11
Vlanguage disorder
p3397
sg13
I2
sa(dp3398
g7
I56
sg26
VC0338462
p3399
sg10
I17
sg11
Vsemantic dementia
p3400
sg13
I2
sa(dp3401
g7
I85
sg26
VC0751706
p3402
sg10
I29
sg11
Vprogressive nonfluent aphasia
p3403
sg13
I3
sa(dp3404
g7
I116
sg26
VC0751706
p3405
sg10
I4
sg11
VPNFA
p3406
sg13
I1
sa(dp3407
g7
I75
sg26
VC0338462
p3408
sg10
I4
sg11
VSemD
p3409
sg13
I1
sasa(dp3410
g2
S'Expression of several genes associated with schizophrenia or autism including Sema3a, Trfr2 and Vldlr were found to be altered as were protein levels of Foxp2.\n'
p3411
sg4
(lp3412
(dp3413
g7
I96
sg8
VP98155
p3414
sg10
I5
sg11
VVldlr
p3415
sg13
I1
sa(dp3416
g7
I78
sg8
g107
sg10
I6
sg11
VSema3a
p3417
sg13
I1
sasg23
(lp3418
(dp3419
g7
I44
sg26
VC0036341
p3420
sg10
I13
sg11
Vschizophrenia
p3421
sg13
I1
sa(dp3422
g7
I61
sg26
VC0004352
p3423
sg10
I6
sg11
Vautism
p3424
sg13
I1
sasa(dp3425
g2
S'We classified 67 patients with PPA into three clinical variants: semantic dementia (SEMD), progressive nonfluent aphasia (PNFA), and logopenic progressive aphasia (LPA), and we compared the severity of behavioral dysfunction, as measured by the Neuropsychiatric Inventory, in these groups and patients with frontotemporal dementia (FTD) and Alzheimer disease (AD).\n'
p3426
sg4
(lp3427
sg23
(lp3428
(dp3429
g7
I65
sg26
VC0338462
p3430
sg10
I17
sg11
Vsemantic dementia
p3431
sg13
I2
sa(dp3432
g7
I332
sg26
VC0338451
p3433
sg10
I3
sg11
VFTD
p3434
sg13
I1
sa(dp3435
g7
I91
sg26
VC0751706
p3436
sg10
I29
sg11
Vprogressive nonfluent aphasia
p3437
sg13
I3
sa(dp3438
g7
I341
sg26
VC0002395
p3439
sg10
I17
sg11
VAlzheimer disease
p3440
sg13
I2
sa(dp3441
g7
I84
sg26
VC0338462
p3442
sg10
I4
sg11
VSEMD
p3443
sg13
I1
sa(dp3444
g7
I122
sg26
VC0751706
p3445
sg10
I4
sg11
VPNFA
p3446
sg13
I1
sa(dp3447
g7
I307
sg26
VC0338451
p3448
sg10
I23
sg11
Vfrontotemporal dementia
p3449
sg13
I2
sa(dp3450
g7
I143
sg26
VC0338457
p3451
sg10
I19
sg11
Vprogressive aphasia
p3452
sg13
I2
sa(dp3453
g7
I360
sg26
VC0002395
p3454
sg10
I2
sg11
VAD
p3455
sg13
I1
sa(dp3456
g7
I31
sg26
VC0282513
p3457
sg10
I3
sg11
VPPA
p3458
sg13
I1
sasa(dp3459
g2
S"The authors asked patients with progressive nonfluent aphasia (PNFA), patients with semantic dementia (SemD), and nonaphasic patients with a disorder of social comportment and executive functioning (SOC/EXEC) to narrate the story of a wordless children's picture book.\n"
p3460
sg4
(lp3461
(dp3462
g7
I84
sg8
g107
sg10
I17
sg11
Vsemantic dementia
p3463
sg13
I2
sa(dp3464
g7
I199
sg8
g107
sg10
I3
sg11
VSOC
p3465
sg13
I1
sa(dp3466
g7
I103
sg8
g107
sg10
I4
sg11
VSemD
p3467
sg13
I1
sasg23
(lp3468
(dp3469
g7
I32
sg26
VC0751706
p3470
sg10
I29
sg11
Vprogressive nonfluent aphasia
p3471
sg13
I3
sa(dp3472
g7
I63
sg26
VC0751706
p3473
sg10
I4
sg11
VPNFA
p3474
sg13
I1
sa(dp3475
g7
I103
sg26
VC0338462
p3476
sg10
I4
sg11
VSemD
p3477
sg13
I1
sa(dp3478
g7
I84
sg26
VC0338462
p3479
sg10
I17
sg11
Vsemantic dementia
p3480
sg13
I2
sasa(dp3481
g2
S'Each sequence is manually annotated with primary function, subfunction and subcellular location, and extensively annotated in an automated process with data extracted from external databases, including gene information from LocusLink and Ensembl; disease information from OMIM; protein-protein interaction data from MINT and DIP; functional domain information from Pfam; protein fingerprints from PRINTS; protein family and family-specific signatures from InterPro; structure data from PDB; mutation data from PMD; BLAST homology data from NCBI NR; and proteins found to be related based on LocusLink and SWISS-PROT references and sequence and taxonomy data.\n'
p3482
sg4
(lp3483
sg23
(lp3484
(dp3485
g7
I510
sg26
VC1832661
p3486
sg10
I3
sg11
VPMD
p3487
sg13
I1
sa(dp3488
g7
I325
sg26
VC0238378
p3489
sg10
I3
sg11
VDIP
p3490
sg13
I1
sa(dp3491
g7
I486
sg26
VC0029401
p3492
sg10
I3
sg11
VPDB
p3493
sg13
I1
sasa(dp3494
g2
S'High fat diet-induced activation of insulin receptor substrate 1/Forkhead box protein O1 (IRS1/FOXO1), Janus kinase 2 gene/signal transducer and activator of transcription (JAK2/STAT3) and Protein Kinase B/Glycogen synthase kinase 3 beta (AKT/GSK3Beta) pathways in liver was inhibited by actein, a potential mechanism by which hyperinsulinemia, hyperleptindemia and dyslipidemia were attenuated.\n'
p3495
sg4
(lp3496
(dp3497
g7
I173
sg8
g107
sg10
I4
sg11
VJAK2
p3498
sg13
I1
sa(dp3499
g7
I36
sg8
VP35568
p3500
sg10
I52
sg11
Vinsulin receptor substrate 1/Forkhead box protein O1
p3501
sg13
I7
sa(dp3502
g7
I178
sg8
VP40763
p3503
sg10
I5
sg11
VSTAT3
p3504
sg13
I1
sa(dp3505
g7
I239
sg8
g107
sg10
I3
sg11
VAKT
p3506
sg13
I1
sa(dp3507
g7
I123
sg8
VP35555
p3508
sg10
I48
sg11
Vsignal transducer and activator of transcription
p3509
sg13
I6
sa(dp3510
g7
I90
sg8
VP35568
p3511
sg10
I10
sg11
VIRS1/FOXO1
p3512
sg13
I1
sa(dp3513
g7
I206
sg8
VP49841
p3514
sg10
I31
sg11
VGlycogen synthase kinase 3 beta
p3515
sg13
I5
sa(dp3516
g7
I189
sg8
VP31749
p3517
sg10
I16
sg11
VProtein Kinase B
p3518
sg13
I3
sa(dp3519
g7
I103
sg8
g107
sg10
I19
sg11
VJanus kinase 2 gene
p3520
sg13
I4
sasg23
(lp3521
(dp3522
g7
I103
sg26
VC0266700
p3523
sg10
I5
sg11
VJanus
p3524
sg13
I1
sa(dp3525
g7
I327
sg26
VC0020459
p3526
sg10
I16
sg11
Vhyperinsulinemia
p3527
sg13
I1
sa(dp3528
g7
I366
sg26
VC0242339
p3529
sg10
I12
sg11
Vdyslipidemia
p3530
sg13
I1
sasa(dp3531
g2
S"An increase in the ratio of Abeta(WT)/Abeta(MUT(Arctic)), therefore, may result in the accumulation of potential neurotoxic protofibrils and acceleration of disease progression in familial Alzheimer's disease mutation carriers.\n"
p3532
sg4
(lp3533
(dp3534
g7
I44
sg8
VP22033
p3535
sg10
I3
sg11
VMUT
p3536
sg13
I1
sa(dp3537
g7
I28
sg8
g107
sg10
I5
sg11
VAbeta
p3538
sg13
I1
sa(dp3539
g7
I28
sg8
g107
sg10
I5
sg11
VAbeta
p3540
sg13
I1
sasg23
(lp3541
(dp3542
g7
I157
sg26
VC0242656
p3543
sg10
I19
sg11
Vdisease progression
p3544
sg13
I2
sa(dp3545
g7
I180
sg26
VC0276496
p3546
sg10
I28
sg11
Vfamilial Alzheimer's disease
p3547
sg13
I3
sasa(dp3548
g2
S'To gain insight into the pathogenesis of these tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, b-catenin, SMARCB1, synaptophysin, chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated endometrial carcinomas with strong and diffuse neuroendocrine expression.\n'
p3549
sg4
(lp3550
(dp3551
g7
I140
sg8
g107
sg10
I7
sg11
VSMARCB1
p3552
sg13
I1
sa(dp3553
g7
I112
sg8
VP43246
p3554
sg10
I4
sg11
VMSH2
p3555
sg13
I1
sa(dp3556
g7
I164
sg8
VP10645
p3557
sg10
I14
sg11
Vchromogranin A
p3558
sg13
I2
sa(dp3559
g7
I149
sg8
VP08247
p3560
sg10
I13
sg11
Vsynaptophysin
p3561
sg13
I1
sa(dp3562
g7
I100
sg8
VP40692
p3563
sg10
I4
sg11
VMLH1
p3564
sg13
I1
sa(dp3565
g7
I124
sg8
VP42771
p3566
sg10
I3
sg11
Vp53
p3567
sg13
I1
sa(dp3568
g7
I225
sg8
VP42336
p3569
sg10
I6
sg11
VPIK3CA
p3570
sg13
I1
sa(dp3571
g7
I118
sg8
VP52701
p3572
sg10
I4
sg11
VMSH6
p3573
sg13
I1
sa(dp3574
g7
I106
sg8
VP25054
p3575
sg10
I4
sg11
VPMS2
p3576
sg13
I1
sa(dp3577
g7
I213
sg8
VP60484
p3578
sg10
I4
sg11
VPTEN
p3579
sg13
I1
sa(dp3580
g7
I219
sg8
VP01116
p3581
sg10
I4
sg11
VKRAS
p3582
sg13
I1
sa(dp3583
g7
I242
sg8
g107
sg10
I4
sg11
VPOLE
p3584
sg13
I1
sasg23
(lp3585
(dp3586
g7
I270
sg26
VC0476089
p3587
sg10
I22
sg11
Vendometrial carcinomas
p3588
sg13
I2
sa(dp3589
g7
I47
sg26
VC0027651
p3590
sg10
I6
sg11
Vtumors
p3591
sg13
I1
sa(dp3592
g7
I25
sg26
VC0699748
p3593
sg10
I12
sg11
Vpathogenesis
p3594
sg13
I1
sasa(dp3595
g2
S'In gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma.\n'
p3596
sg4
(lp3597
sg23
(lp3598
(dp3599
g7
I76
sg26
VC0206681
p3600
sg10
I20
sg11
Vclear cell carcinoma
p3601
sg13
I3
sa(dp3602
g7
I17
sg26
VC0006826
p3603
sg10
I6
sg11
Vcancer
p3604
sg13
I1
sa(dp3605
g7
I108
sg26
VC0206687
p3606
sg10
I22
sg11
Vendometrioid carcinoma
p3607
sg13
I2
sasa(dp3608
g2
S'We recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.\n'
p3609
sg4
(lp3610
(dp3611
g7
I89
sg8
VP28370
p3612
sg10
I3
sg11
VSWI
p3613
sg13
I1
sa(dp3614
g7
I120
sg8
VP51532
p3615
sg10
I4
sg11
VBRG1
p3616
sg13
I1
sa(dp3617
g7
I139
sg8
g107
sg10
I4
sg11
VINI1
p3618
sg13
I1
sa(dp3619
g7
I167
sg8
g107
sg10
I6
sg11
VARID1B
p3620
sg13
I1
sa(dp3621
g7
I93
sg8
g107
sg10
I3
sg11
VSNF
p3622
sg13
I1
sasg23
(lp3623
(dp3624
g7
I106
sg26
VC0544461
p3625
sg10
I12
sg11
Vinactivation
p3626
sg13
I1
sa(dp3627
g7
I281
sg26
VC0476089
p3628
sg10
I21
sg11
Vendometrial carcinoma
p3629
sg13
I2
sa(dp3630
g7
I106
sg26
VC0544461
p3631
sg10
I12
sg11
Vinactivation
p3632
sg13
I1
sa(dp3633
g7
I227
sg26
VC0002793
p3634
sg10
I17
sg11
Vdedifferentiation
p3635
sg13
I1
sa(dp3636
g7
I106
sg26
VC0544461
p3637
sg10
I12
sg11
Vinactivation
p3638
sg13
I1
sa(dp3639
g7
I106
sg26
VC0544461
p3640
sg10
I12
sg11
Vinactivation
p3641
sg13
I1
sasa(dp3642
g2
S'The tumor suppressor gene, AT Rich Interactive Domain 1A (ARID1A) mutation has been reported in a variety of cancers, especially the endometrium-related gynecological cancers, including the ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma.\n'
p3643
sg4
(lp3644
(dp3645
g7
I27
sg8
g107
sg10
I29
sg11
VAT Rich Interactive Domain 1A
p3646
sg13
I5
sa(dp3647
g7
I58
sg8
g107
sg10
I6
sg11
VARID1A
p3648
sg13
I1
sasg23
(lp3649
(dp3650
g7
I109
sg26
VC0006826
p3651
sg10
I7
sg11
Vcancers
p3652
sg13
I1
sa(dp3653
g7
I198
sg26
VC0206681
p3654
sg10
I20
sg11
Vclear cell carcinoma
p3655
sg13
I3
sa(dp3656
g7
I220
sg26
VC0346163
p3657
sg10
I30
sg11
Vovarian endometrioid carcinoma
p3658
sg13
I3
sa(dp3659
g7
I228
sg26
VC0206687
p3660
sg10
I22
sg11
Vendometrioid carcinoma
p3661
sg13
I2
sa(dp3662
g7
I109
sg26
VC0006826
p3663
sg10
I7
sg11
Vcancers
p3664
sg13
I1
sa(dp3665
g7
I4
sg26
VC0027651
p3666
sg10
I5
sg11
Vtumor
p3667
sg13
I1
sasa(dp3668
g2
S'The current study aimed to evaluate serum levels of MFAP4 in patients with pulmonary fibrosis in order to test its potential as biomarker in clinical practice.\n'
p3669
sg4
(lp3670
(dp3671
g7
I52
sg8
VP55083
p3672
sg10
I5
sg11
VMFAP4
p3673
sg13
I1
sasg23
(lp3674
(dp3675
g7
I75
sg26
VC0034069
p3676
sg10
I18
sg11
Vpulmonary fibrosis
p3677
sg13
I2
sasa(dp3678
g2
S'A further aim was to determine whether MFAP4 deficiency in mice affects the formation of pulmonary fibrosis in the bleomycin model of lung fibrosis.\n'
p3679
sg4
(lp3680
(dp3681
g7
I39
sg8
VP55083
p3682
sg10
I5
sg11
VMFAP4
p3683
sg13
I1
sasg23
(lp3684
(dp3685
g7
I89
sg26
VC0034069
p3686
sg10
I18
sg11
Vpulmonary fibrosis
p3687
sg13
I2
sa(dp3688
g7
I134
sg26
VC0034069
p3689
sg10
I13
sg11
Vlung fibrosis
p3690
sg13
I2
sasa(dp3691
g2
S'MFAP4 levels were increased in BAL of bleomycin treated mice with pulmonary fibrosis.\n'
p3692
sg4
(lp3693
(dp3694
g7
I0
sg8
VP55083
p3695
sg10
I5
sg11
VMFAP4
p3696
sg13
I1
sasg23
(lp3697
(dp3698
g7
I66
sg26
VC0034069
p3699
sg10
I18
sg11
Vpulmonary fibrosis
p3700
sg13
I2
sasa(dp3701
g2
S'MFAP4 is not elevated in sera of patients with pulmonary fibrosis or bleomycin treated mice with pulmonary fibrosis.\n'
p3702
sg4
(lp3703
(dp3704
g7
I0
sg8
VP55083
p3705
sg10
I5
sg11
VMFAP4
p3706
sg13
I1
sasg23
(lp3707
(dp3708
g7
I47
sg26
VC0034069
p3709
sg10
I18
sg11
Vpulmonary fibrosis
p3710
sg13
I2
sa(dp3711
g7
I47
sg26
VC0034069
p3712
sg10
I18
sg11
Vpulmonary fibrosis
p3713
sg13
I2
sasa(dp3714
g2
S'The aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).\n'
p3715
sg4
(lp3716
(dp3717
g7
I61
sg8
VP55083
p3718
sg10
I5
sg11
VMFAP4
p3719
sg13
I1
sasg23
(lp3720
(dp3721
g7
I145
sg26
VC0024117
p3722
sg10
I4
sg11
VCOPD
p3723
sg13
I1
sa(dp3724
g7
I106
sg26
VC0024117
p3725
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p3726
sg13
I4
sasa(dp3727
g2
S'Multiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p &lt; 0.0001) and BODE index (p = 0.04).\n'
p3728
sg4
(lp3729
sg23
(lp3730
(dp3731
g7
I16
sg26
VC0684320
p3732
sg10
I11
sg11
Vregressions
p3733
sg13
I1
sa(dp3734
g7
I102
sg26
VC0600260
p3735
sg10
I24
sg11
VObstructive Lung Disease
p3736
sg13
I3
sasa(dp3737
g2
S'For essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.\n'
p3738
sg4
(lp3739
(dp3740
g7
I598
sg8
VP49715
p3741
sg10
I5
sg11
VCEBPA
p3742
sg13
I1
sa(dp3743
g7
I200
sg8
g107
sg10
I4
sg11
VEZH2
p3744
sg13
I1
sa(dp3745
g7
I362
sg8
VP48735
p3746
sg10
I4
sg11
VIDH2
p3747
sg13
I1
sa(dp3748
g7
I609
sg8
g107
sg10
I5
sg11
VSH2B3
p3749
sg13
I1
sasg23
(lp3750
(dp3751
g7
I265
sg26
VC0032463
p3752
sg10
I17
sg11
Vpolycythemia vera
p3753
sg13
I2
sa(dp3754
g7
I4
sg26
VC0040028
p3755
sg10
I25
sg11
Vessential thrombocythemia
p3756
sg13
I2
sa(dp3757
g7
I66
sg26
VC1510411
p3758
sg10
I14
sg11
Vtransformation
p3759
sg13
I1
sa(dp3760
g7
I135
sg26
VC0023518
p3761
sg10
I12
sg11
Vleukocytosis
p3762
sg13
I1
sa(dp3763
g7
I127
sg26
VC0002871
p3764
sg10
I6
sg11
Vanemia
p3765
sg13
I1
sa(dp3766
g7
I135
sg26
VC0023518
p3767
sg10
I12
sg11
Vleukocytosis
p3768
sg13
I1
sa(dp3769
g7
I111
sg26
VC0836924
p3770
sg10
I14
sg11
Vthrombocytosis
p3771
sg13
I1
sasa(dp3772
g2
S'In the present case, i(17q)/-17, der(12p), del(5q26), del(7q36), and del(20q11) indicate possible alterations in TP53, ETV6, IDH2, EZH2, and SRSF2 genes, which are responsible for pathomechanism, genetic instability, clonal evolution, and advancement of disease condition.\n'
p3773
sg4
(lp3774
(dp3775
g7
I119
sg8
VP41212
p3776
sg10
I4
sg11
VETV6
p3777
sg13
I1
sa(dp3778
g7
I125
sg8
VP48735
p3779
sg10
I4
sg11
VIDH2
p3780
sg13
I1
sa(dp3781
g7
I141
sg8
VP01893
p3782
sg10
I11
sg11
VSRSF2 genes
p3783
sg13
I2
sa(dp3784
g7
I131
sg8
g107
sg10
I4
sg11
VEZH2
p3785
sg13
I1
sasg23
(lp3786
(dp3787
g7
I262
sg26
VC0012634
p3788
sg10
I9
sg11
Vcondition
p3789
sg13
I1
sa(dp3790
g7
I217
sg26
VC1516669
p3791
sg10
I16
sg11
Vclonal evolution
p3792
sg13
I2
sasa(dp3793
g2
S'Accumulating evidence indicates that enhancer of zeste homolog 2 (EZH2) promotes the metastatic ability of solid tumors, but the role of EZH2 in extramedullary infiltration (EMI) in acute myeloid leukemia (AML) has not been thoroughly explored.\n'
p3794
sg4
(lp3795
(dp3796
g7
I66
sg8
g107
sg10
I4
sg11
VEZH2
p3797
sg13
I1
sa(dp3798
g7
I37
sg8
g107
sg10
I27
sg11
Venhancer of zeste homolog 2
p3799
sg13
I5
sa(dp3800
g7
I66
sg8
g107
sg10
I4
sg11
VEZH2
p3801
sg13
I1
sasg23
(lp3802
(dp3803
g7
I182
sg26
VC0023467
p3804
sg10
I22
sg11
Vacute myeloid leukemia
p3805
sg13
I3
sa(dp3806
g7
I160
sg26
VC0332448
p3807
sg10
I12
sg11
Vinfiltration
p3808
sg13
I1
sa(dp3809
g7
I107
sg26
VC0280100
p3810
sg10
I12
sg11
Vsolid tumors
p3811
sg13
I2
sa(dp3812
g7
I206
sg26
VC0023467
p3813
sg10
I3
sg11
VAML
p3814
sg13
I1
sasa(dp3815
g2
S'We found that the messenger RNA (mRNA) and protein expression levels of EZH2 in AML patients were both significantly higher than in idiopathic thrombocytopenic purpura (ITP) patients.\n'
p3816
sg4
(lp3817
(dp3818
g7
I72
sg8
g107
sg10
I4
sg11
VEZH2
p3819
sg13
I1
sasg23
(lp3820
(dp3821
g7
I80
sg26
VC0023467
p3822
sg10
I3
sg11
VAML
p3823
sg13
I1
sa(dp3824
g7
I169
sg26
VC0043117
p3825
sg10
I3
sg11
VITP
p3826
sg13
I1
sa(dp3827
g7
I132
sg26
VC0043117
p3828
sg10
I35
sg11
Vidiopathic thrombocytopenic purpura
p3829
sg13
I3
sasa(dp3830
g2
S'Histopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.\n'
p3831
sg4
(lp3832
(dp3833
g7
I225
sg8
VP55786
p3834
sg10
I3
sg11
VPSA
p3835
sg13
I1
sa(dp3836
g7
I198
sg8
g107
sg10
I13
sg11
Vthyroglobulin
p3837
sg13
I1
sasg23
(lp3838
(dp3839
g7
I225
sg26
VC1519176
p3840
sg10
I3
sg11
VPSA
p3841
sg13
I1
sa(dp3842
g7
I135
sg26
VC0238463
p3843
sg10
I27
sg11
Vpapillary thyroid carcinoma
p3844
sg13
I3
sa(dp3845
g7
I82
sg26
VC0001430
p3846
sg10
I8
sg11
Vadenomas
p3847
sg13
I1
sasa(dp3848
g2
S'Univariate analysis showed that male gender, thyroglobulin concentrations &gt;=300 ng/ml and tumor diameter &gt;30 mm were significantly more frequent in patients with oxyphile carcinoma compared to patients with oxyphile adenoma, while coexisting Hashimoto thyreoiditis and positive AntiTPO antibodies appeared significantly less frequent in the carcinoma group.\n'
p3849
sg4
(lp3850
(dp3851
g7
I45
sg8
g107
sg10
I13
sg11
Vthyroglobulin
p3852
sg13
I1
sasg23
(lp3853
(dp3854
g7
I93
sg26
VC0027651
p3855
sg10
I5
sg11
Vtumor
p3856
sg13
I1
sa(dp3857
g7
I177
sg26
VC0007097
p3858
sg10
I9
sg11
Vcarcinoma
p3859
sg13
I1
sa(dp3860
g7
I177
sg26
VC0007097
p3861
sg10
I9
sg11
Vcarcinoma
p3862
sg13
I1
sa(dp3863
g7
I222
sg26
VC0001430
p3864
sg10
I7
sg11
Vadenoma
p3865
sg13
I1
sasa(dp3866
g2
S'The histologic appearance together with the immune profile was diagnostic of WCCA, with diffuse positivity for GATA3, focal weak positivity for parathyroid hormone, and negativity for PAX8, thyroglobulin, TTF1, synaptophysin, chromogranin, and S100p.\n'
p3867
sg4
(lp3868
(dp3869
g7
I205
sg8
VP43699
p3870
sg10
I4
sg11
VTTF1
p3871
sg13
I1
sa(dp3872
g7
I226
sg8
VP08311
p3873
sg10
I12
sg11
Vchromogranin
p3874
sg13
I1
sa(dp3875
g7
I190
sg8
g107
sg10
I13
sg11
Vthyroglobulin
p3876
sg13
I1
sa(dp3877
g7
I211
sg8
VP08247
p3878
sg10
I13
sg11
Vsynaptophysin
p3879
sg13
I1
sa(dp3880
g7
I184
sg8
g107
sg10
I4
sg11
VPAX8
p3881
sg13
I1
sa(dp3882
g7
I144
sg8
VP01270
p3883
sg10
I19
sg11
Vparathyroid hormone
p3884
sg13
I2
sa(dp3885
g7
I244
sg8
VP25815
p3886
sg10
I5
sg11
VS100p
p3887
sg13
I1
sa(dp3888
g7
I111
sg8
VP23771
p3889
sg10
I5
sg11
VGATA3
p3890
sg13
I1
sasg23
(lp3891
sa(dp3892
g2
S'After immunohistochemical characterization using a panel of chromogranin A, thyroglobulin, and calcitonin, 7 of the former thyroid neoplasms were diagnosed as thyroid adenomas, 1 was diagnosed as a thyroid carcinoma, and 4 were diagnosed as parathyroid adenomas.\n'
p3893
sg4
(lp3894
(dp3895
g7
I95
sg8
VP06881
p3896
sg10
I10
sg11
Vcalcitonin
p3897
sg13
I1
sa(dp3898
g7
I60
sg8
VP10645
p3899
sg10
I14
sg11
Vchromogranin A
p3900
sg13
I2
sa(dp3901
g7
I76
sg8
g107
sg10
I13
sg11
Vthyroglobulin
p3902
sg13
I1
sasg23
(lp3903
(dp3904
g7
I123
sg26
VC0040136
p3905
sg10
I17
sg11
Vthyroid neoplasms
p3906
sg13
I2
sa(dp3907
g7
I198
sg26
VC0549473
p3908
sg10
I17
sg11
Vthyroid carcinoma
p3909
sg13
I2
sa(dp3910
g7
I241
sg26
VC0262587
p3911
sg10
I20
sg11
Vparathyroid adenomas
p3912
sg13
I2
sa(dp3913
g7
I167
sg26
VC0001430
p3914
sg10
I8
sg11
Vadenomas
p3915
sg13
I1
sasa(dp3916
g2
S'The findings obtained using these cell lines derived from ovarian clear cell adenocarcinoma indicate that integrin alpha3 may associated with the acquisition of malignant potential by clear cell adenocarcinoma.\n'
p3917
sg4
(lp3918
sg23
(lp3919
(dp3920
g7
I66
sg26
VC0206681
p3921
sg10
I25
sg11
Vclear cell adenocarcinoma
p3922
sg13
I3
sa(dp3923
g7
I58
sg26
VC1518693
p3924
sg10
I33
sg11
Vovarian clear cell adenocarcinoma
p3925
sg13
I4
sasa(dp3926
g2
S'No entanto, a existencia de uma patologia cronica pode determinar um elevado nivel de cuidados preventivos gerais, inclusivamente resultando numa melhoria global do seu nivel de saude oral, o que podera justificar os resultados obtidos.Conclusao: A presenca de diabetes mellitus tipo 1 em doentes tratados com bomba de insulina nao esta associada a um aumento da prevalencia de lesoes de carie dentaria.\n'
p3927
sg4
(lp3928
sg23
(lp3929
(dp3930
g7
I261
sg26
VC0011849
p3931
sg10
I17
sg11
Vdiabetes mellitus
p3932
sg13
I2
sasa(dp3933
g2
S'Few of the substrates of Tankyrases are Telomeric Repeat binding Factor protein (TRF1), Axis Inhibitory protein (AXIN 1&amp;amp;2), Insulin Responsive Amino Peptidase (IRAP), Nuclear Mitotic Apparatus protein (NuMa), that become aberrantly active due to the apparent overexpression of the enzyme during hyper proliferative disease conditions like cancer, fibrosis and metabolic disorders like diabetes.\n'
p3934
sg4
(lp3935
(dp3936
g7
I168
sg8
g107
sg10
I4
sg11
VIRAP
p3937
sg13
I1
sa(dp3938
g7
I25
sg8
g107
sg10
I10
sg11
VTankyrases
p3939
sg13
I1
sa(dp3940
g7
I132
sg8
g107
sg10
I34
sg11
VInsulin Responsive Amino Peptidase
p3941
sg13
I4
sa(dp3942
g7
I40
sg8
VP54274
p3943
sg10
I39
sg11
VTelomeric Repeat binding Factor protein
p3944
sg13
I5
sa(dp3945
g7
I-1
sg8
g107
sg10
I8
sg11
VAXIN 1&2
p3946
sg13
I2
sa(dp3947
g7
I81
sg8
VP54274
p3948
sg10
I4
sg11
VTRF1
p3949
sg13
I1
sasg23
(lp3950
(dp3951
g7
I309
sg26
VC0334094
p3952
sg10
I13
sg11
Vproliferative
p3953
sg13
I1
sa(dp3954
g7
I368
sg26
VC0025517
p3955
sg10
I19
sg11
Vmetabolic disorders
p3956
sg13
I2
sa(dp3957
g7
I355
sg26
VC0016059
p3958
sg10
I8
sg11
Vfibrosis
p3959
sg13
I1
sa(dp3960
g7
I393
sg26
VC0011849
p3961
sg10
I8
sg11
Vdiabetes
p3962
sg13
I1
sa(dp3963
g7
I347
sg26
VC0006826
p3964
sg10
I6
sg11
Vcancer
p3965
sg13
I1
sasa(dp3966
g2
S'O objetivo deste estudo foi avaliar a utilidade deste exame numa populacao de criancas e adolescentes obesos, maioritariamente de etnia caucasiana.Material e Metodos: Foram recrutados 226 doentes [indice de massa corporal z-score 3,35 A+/- 0,59, 90% caucasianos, 55% do sexo feminino, idade mediana de 12,3 (ambito: 8,9 a 17,6) anos] referenciados a consulta de obesidade pediatrica de um hospital terciario, com criterios para rastreio de diabetes mellitus tipo 2.\n'
p3967
sg4
(lp3968
sg23
(lp3969
(dp3970
g7
I440
sg26
VC0011849
p3971
sg10
I17
sg11
Vdiabetes mellitus
p3972
sg13
I2
sasa(dp3973
g2
S'Finally, we speculate on the potential benefits of the inhibition of Sin3B-containing complexes for the treatment of cancer.\n'
p3974
sg4
(lp3975
(dp3976
g7
I69
sg8
g107
sg10
I5
sg11
VSin3B
p3977
sg13
I1
sasg23
(lp3978
(dp3979
g7
I117
sg26
VC0006826
p3980
sg10
I6
sg11
Vcancer
p3981
sg13
I1
sasa(dp3982
g2
S'Expert opinion: Further identification and characterization of specific Sin3B-containing complexes provide a unique opportunity to prevent the pro-tumorigenic effects of the senescence-associated secretory phenotype, and to abrogate cancer stem cell quiescence and the associated resistance to therapy.\n'
p3983
sg4
(lp3984
(dp3985
g7
I72
sg8
g107
sg10
I5
sg11
VSin3B
p3986
sg13
I1
sasg23
(lp3987
(dp3988
g7
I233
sg26
VC0006826
p3989
sg10
I6
sg11
Vcancer
p3990
sg13
I1
sasa(dp3991
g2
S'SIN3B has been implicated in the initiation of senescence in vitro Here we show that in a mouse model of prostate cancer, SIN3B provides a barrier to malignant progression.\n'
p3992
sg4
(lp3993
(dp3994
g7
I0
sg8
g107
sg10
I5
sg11
VSIN3B
p3995
sg13
I1
sa(dp3996
g7
I0
sg8
g107
sg10
I5
sg11
VSIN3B
p3997
sg13
I1
sasg23
(lp3998
(dp3999
g7
I105
sg26
VC0600139
p4000
sg10
I15
sg11
Vprostate cancer
p4001
sg13
I2
sasa(dp4002
g2
S'SIN3B was required for PTEN-induced cellular senescence and prevented progression to invasive prostate adenocarcinoma.\n'
p4003
sg4
(lp4004
(dp4005
g7
I0
sg8
g107
sg10
I5
sg11
VSIN3B
p4006
sg13
I1
sa(dp4007
g7
I23
sg8
VP60484
p4008
sg10
I4
sg11
VPTEN
p4009
sg13
I1
sasg23
(lp4010
(dp4011
g7
I94
sg26
VC0007112
p4012
sg10
I23
sg11
Vprostate adenocarcinoma
p4013
sg13
I2
sasa(dp4014
g2
S'Furthermore, SIN3B was downregulated in human prostate adenocarcinoma correlating with upregulation of its target genes.\n'
p4015
sg4
(lp4016
(dp4017
g7
I13
sg8
g107
sg10
I5
sg11
VSIN3B
p4018
sg13
I1
sasg23
(lp4019
(dp4020
g7
I46
sg26
VC0007112
p4021
sg10
I23
sg11
Vprostate adenocarcinoma
p4022
sg13
I2
sasa(dp4023
g2
S'Our results suggest a tumor suppressor function for SIN3B that limits prostate adenocarcinoma progression, with potential implications for the use of SIN3B and its target genes as candidate diagnostic markers to distinguish indolent from aggressive disease.\n'
p4024
sg4
(lp4025
(dp4026
g7
I52
sg8
g107
sg10
I5
sg11
VSIN3B
p4027
sg13
I1
sa(dp4028
g7
I52
sg8
g107
sg10
I5
sg11
VSIN3B
p4029
sg13
I1
sasg23
(lp4030
(dp4031
g7
I22
sg26
VC0027651
p4032
sg10
I5
sg11
Vtumor
p4033
sg13
I1
sa(dp4034
g7
I70
sg26
VC0007112
p4035
sg10
I23
sg11
Vprostate adenocarcinoma
p4036
sg13
I2
sa(dp4037
g7
I238
sg26
VC0001807
p4038
sg10
I10
sg11
Vaggressive
p4039
sg13
I1
sasa(dp4040
g2
S'However, specific roles for SIN3A and SIN3B in breast cancer progression have not been characterized.\n'
p4041
sg4
(lp4042
(dp4043
g7
I38
sg8
g107
sg10
I5
sg11
VSIN3B
p4044
sg13
I1
sa(dp4045
g7
I28
sg8
g107
sg10
I5
sg11
VSIN3A
p4046
sg13
I1
sasg23
(lp4047
(dp4048
g7
I54
sg26
VC0178874
p4049
sg10
I18
sg11
Vcancer progression
p4050
sg13
I2
sasa(dp4051
g2
S'Additionally, we analyzed microarray data sets to identify correlations of SIN3A and SIN3B expression with survival in patients with breast cancer.\n'
p4052
sg4
(lp4053
(dp4054
g7
I85
sg8
g107
sg10
I5
sg11
VSIN3B
p4055
sg13
I1
sa(dp4056
g7
I75
sg8
g107
sg10
I5
sg11
VSIN3A
p4057
sg13
I1
sasg23
(lp4058
(dp4059
g7
I133
sg26
VC0678222
p4060
sg10
I13
sg11
Vbreast cancer
p4061
sg13
I2
sasa(dp4062
g2
S'These data sets indicated that high mRNA expression of SIN3A as well as low mRNA expression of SIN3B correlates with longer relapse free survival specifically in patients with triple negative breast cancer which corresponds with our in vitro and in vivo data.\n'
p4063
sg4
(lp4064
(dp4065
g7
I95
sg8
g107
sg10
I5
sg11
VSIN3B
p4066
sg13
I1
sa(dp4067
g7
I55
sg8
g107
sg10
I5
sg11
VSIN3A
p4068
sg13
I1
sasg23
(lp4069
(dp4070
g7
I124
sg26
VC0277556
p4071
sg10
I7
sg11
Vrelapse
p4072
sg13
I1
sa(dp4073
g7
I192
sg26
VC0678222
p4074
sg10
I13
sg11
Vbreast cancer
p4075
sg13
I2
sasa(dp4076
g2
S'These results demonstrate key functional differences between SIN3 paralogs in regulating the process of breast cancer metastasis and suggest metastasis suppressive roles of SIN3A and metastasis promoting roles of SIN3B.\n'
p4077
sg4
(lp4078
(dp4079
g7
I173
sg8
g107
sg10
I5
sg11
VSIN3A
p4080
sg13
I1
sa(dp4081
g7
I213
sg8
g107
sg10
I5
sg11
VSIN3B
p4082
sg13
I1
sa(dp4083
g7
I61
sg8
g107
sg10
I4
sg11
VSIN3
p4084
sg13
I1
sasg23
(lp4085
(dp4086
g7
I118
sg26
VC0027627
p4087
sg10
I10
sg11
Vmetastasis
p4088
sg13
I1
sa(dp4089
g7
I104
sg26
VC0678222
p4090
sg10
I13
sg11
Vbreast cancer
p4091
sg13
I2
sa(dp4092
g7
I118
sg26
VC0027627
p4093
sg10
I10
sg11
Vmetastasis
p4094
sg13
I1
sa(dp4095
g7
I118
sg26
VC0027627
p4096
sg10
I10
sg11
Vmetastasis
p4097
sg13
I1
sasa(dp4098
g2
S'Finally, by immunohistochemical staining of primary breast tissue microarrays we find that EMSY/KDM5A/SIN3B complex subunits are frequently overexpressed in primary breast cancer cases in a correlative manner.\n'
p4099
sg4
(lp4100
(dp4101
g7
I96
sg8
VP29375
p4102
sg10
I5
sg11
VKDM5A
p4103
sg13
I1
sa(dp4104
g7
I102
sg8
g107
sg10
I5
sg11
VSIN3B
p4105
sg13
I1
sa(dp4106
g7
I91
sg8
g107
sg10
I4
sg11
VEMSY
p4107
sg13
I1
sasg23
(lp4108
(dp4109
g7
I165
sg26
VC0678222
p4110
sg10
I13
sg11
Vbreast cancer
p4111
sg13
I2
sasa(dp4112
g2
S'Here, using a mouse model of pancreatic cancer, we have demonstrated that SIN3B is required for activated KRAS-induced senescence in vivo.\n'
p4113
sg4
(lp4114
(dp4115
g7
I106
sg8
VP01116
p4116
sg10
I4
sg11
VKRAS
p4117
sg13
I1
sa(dp4118
g7
I74
sg8
g107
sg10
I5
sg11
VSIN3B
p4119
sg13
I1
sasg23
(lp4120
(dp4121
g7
I29
sg26
VC0235974
p4122
sg10
I17
sg11
Vpancreatic cancer
p4123
sg13
I2
sasa(dp4124
g2
S'Furthermore, evaluation of human pancreatic tissue and cancer cells revealed that Sin3B was decreased in control and PDAC samples, compared with samples from patients with pancreatic inflammation.\n'
p4125
sg4
(lp4126
(dp4127
g7
I82
sg8
g107
sg10
I5
sg11
VSin3B
p4128
sg13
I1
sasg23
(lp4129
(dp4130
g7
I183
sg26
VC0021368
p4131
sg10
I12
sg11
Vinflammation
p4132
sg13
I1
sa(dp4133
g7
I55
sg26
VC0006826
p4134
sg10
I6
sg11
Vcancer
p4135
sg13
I1
sasa(dp4136
g2
S'Among proteins in the c-Myc/Max/Mad/Sin3 regulatory complex, Mad4 and Sin3B are routinely detected in human glioblastoma multiforme (GBM) cell lines.\n'
p4137
sg4
(lp4138
(dp4139
g7
I36
sg8
g107
sg10
I4
sg11
VSin3
p4140
sg13
I1
sa(dp4141
g7
I61
sg8
g107
sg10
I4
sg11
VMad4
p4142
sg13
I1
sa(dp4143
g7
I22
sg8
VP12524
p4144
sg10
I5
sg11
Vc-Myc
p4145
sg13
I1
sa(dp4146
g7
I70
sg8
g107
sg10
I5
sg11
VSin3B
p4147
sg13
I1
sa(dp4148
g7
I32
sg8
VP23109
p4149
sg10
I3
sg11
VMad
p4150
sg13
I1
sasg23
(lp4151
(dp4152
g7
I133
sg26
VC1621958
p4153
sg10
I3
sg11
VGBM
p4154
sg13
I1
sa(dp4155
g7
I108
sg26
VC1621958
p4156
sg10
I23
sg11
Vglioblastoma multiforme
p4157
sg13
I2
sasa(dp4158
g2
S'In response to gamma radiation, the expression of Sin3B and Mad4 in GBM cells was upregulated in parallel over time, suggesting that Sin3B may play a role in the regulation of Mad4 stability.\n'
p4159
sg4
(lp4160
(dp4161
g7
I50
sg8
g107
sg10
I5
sg11
VSin3B
p4162
sg13
I1
sa(dp4163
g7
I60
sg8
g107
sg10
I4
sg11
VMad4
p4164
sg13
I1
sa(dp4165
g7
I60
sg8
g107
sg10
I4
sg11
VMad4
p4166
sg13
I1
sa(dp4167
g7
I50
sg8
g107
sg10
I5
sg11
VSin3B
p4168
sg13
I1
sasg23
(lp4169
(dp4170
g7
I68
sg26
VC0017636
p4171
sg10
I3
sg11
VGBM
p4172
sg13
I1
sasa(dp4173
g2
S'Using the Drosophila heart as a platform for identifying novel gene interactions leading to heart disease, we found that the Rho-GTPase Cdc42 cooperates with the cardiac transcription factor Tinman/Nkx2-5.\n'
p4174
sg4
(lp4175
(dp4176
g7
I198
sg8
VP52952
p4177
sg10
I6
sg11
VNkx2-5
p4178
sg13
I1
sa(dp4179
g7
I125
sg8
VP08100
p4180
sg10
I10
sg11
VRho-GTPase
p4181
sg13
I1
sa(dp4182
g7
I136
sg8
VP60953
p4183
sg10
I5
sg11
VCdc42
p4184
sg13
I1
sa(dp4185
g7
I162
sg8
VP35398
p4186
sg10
I28
sg11
Vcardiac transcription factor
p4187
sg13
I3
sasg23
(lp4188
(dp4189
g7
I92
sg26
VC0018799
p4190
sg10
I13
sg11
Vheart disease
p4191
sg13
I2
sasa(dp4192
g2
S'What is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.\n'
p4193
sg4
(lp4194
(dp4195
g7
I105
sg8
g107
sg10
I6
sg11
VSnapin
p4196
sg13
I1
sa(dp4197
g7
I59
sg8
g107
sg10
I6
sg11
VCav1.3
p4198
sg13
I1
sasg23
(lp4199
(dp4200
g7
I171
sg26
VC0004238
p4201
sg10
I2
sg11
VAF
p4202
sg13
I1
sa(dp4203
g7
I150
sg26
VC0004238
p4204
sg10
I19
sg11
Vatrial fibrillation
p4205
sg13
I2
sasa(dp4206
g2
S'Furthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.\n'
p4207
sg4
(lp4208
(dp4209
g7
I29
sg8
g107
sg10
I15
sg11
VCav1.3 channels
p4210
sg13
I2
sasg23
(lp4211
(dp4212
g7
I59
sg26
VC0155709
p4213
sg10
I31
sg11
Vatrial fibrillation and flutter
p4214
sg13
I4
sa(dp4215
g7
I13
sg26
VC0544461
p4216
sg10
I12
sg11
Vinactivation
p4217
sg13
I1
sasa(dp4218
g2
S'The significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.\n'
p4219
sg4
(lp4220
(dp4221
g7
I139
sg8
g107
sg10
I6
sg11
VCav1.3
p4222
sg13
I1
sasg23
(lp4223
(dp4224
g7
I151
sg26
VC0596988
p4225
sg10
I6
sg11
Vmutant
p4226
sg13
I1
sa(dp4227
g7
I114
sg26
VC0004238
p4228
sg10
I19
sg11
Vatrial fibrillation
p4229
sg13
I2
sasa(dp4230
g2
S'The novel Cav1.3 (Alfa1D) L-type Ca^2+ channel plays a significant role in sinoatrial (SA) and atrioventricular (AV) nodes function and in atrial fibrillation.\n'
p4231
sg4
(lp4232
(dp4233
g7
I10
sg8
g107
sg10
I6
sg11
VCav1.3
p4234
sg13
I1
sasg23
(lp4235
(dp4236
g7
I139
sg26
VC0004238
p4237
sg10
I19
sg11
Vatrial fibrillation
p4238
sg13
I2
sasa(dp4239
g2
S'Interestingly, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(Ub)n-Bcl10 production to extents that correlate with their abilities to activate NF-KB and with their enhanced abilities to bind HOIP and Bcl10.\n'
p4240
sg4
(lp4241
(dp4242
g7
I15
sg8
g107
sg10
I25
sg11
Voncogenic CARD11 variants
p4243
sg13
I3
sa(dp4244
g7
I117
sg8
g107
sg10
I5
sg11
VBcl10
p4245
sg13
I1
sasg23
(lp4246
(dp4247
g7
I57
sg26
VC0079744
p4248
sg10
I29
sg11
Vdiffuse large B cell lymphoma
p4249
sg13
I5
sasa(dp4250
g2
S'Our previous studies showed important regulatory functions of RNF31 in controlling important oncogenic pathways in breast cancer, such as ERAlfa and p53.\n'
p4251
sg4
(lp4252
(dp4253
g7
I62
sg8
g107
sg10
I5
sg11
VRNF31
p4254
sg13
I1
sa(dp4255
g7
I149
sg8
VP42771
p4256
sg10
I3
sg11
Vp53
p4257
sg13
I1
sasg23
(lp4258
(dp4259
g7
I115
sg26
VC0678222
p4260
sg10
I13
sg11
Vbreast cancer
p4261
sg13
I2
sasa(dp4262
g2
S'This review highlights recent discoveries on RNF31 functions in nuclear factor modifications, breast cancer progression and possible therapeutic inhibitors targeting RNF31.\n'
p4263
sg4
(lp4264
(dp4265
g7
I45
sg8
g107
sg10
I5
sg11
VRNF31
p4266
sg13
I1
sa(dp4267
g7
I45
sg8
g107
sg10
I5
sg11
VRNF31
p4268
sg13
I1
sasg23
(lp4269
(dp4270
g7
I101
sg26
VC0178874
p4271
sg10
I18
sg11
Vcancer progression
p4272
sg13
I2
sasa(dp4273
g2
S'The atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women.\n'
p4274
sg4
(lp4275
(dp4276
g7
I13
sg8
VP62979
p4277
sg10
I12
sg11
VE3 ubiquitin
p4278
sg13
I2
sa(dp4279
g7
I33
sg8
g107
sg10
I5
sg11
VRNF31
p4280
sg13
I1
sasg23
(lp4281
(dp4282
g7
I68
sg26
VC0678222
p4283
sg10
I13
sg11
Vbreast cancer
p4284
sg13
I2
sasa(dp4285
g2
S'Here, RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 (TP53) signaling as a potential RNF31 target.\n'
p4286
sg4
(lp4287
(dp4288
g7
I107
sg8
VP42771
p4289
sg10
I3
sg11
Vp53
p4290
sg13
I1
sa(dp4291
g7
I6
sg8
g107
sg10
I5
sg11
VRNF31
p4292
sg13
I1
sa(dp4293
g7
I6
sg8
g107
sg10
I5
sg11
VRNF31
p4294
sg13
I1
sasg23
(lp4295
(dp4296
g7
I25
sg26
VC0678222
p4297
sg10
I13
sg11
Vbreast cancer
p4298
sg13
I2
sasa(dp4299
g2
S'Interestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner.\n'
p4300
sg4
(lp4301
(dp4302
g7
I15
sg8
g107
sg10
I5
sg11
VRNF31
p4303
sg13
I1
sa(dp4304
g7
I31
sg8
VP42771
p4305
sg10
I3
sg11
Vp53
p4306
sg13
I1
sa(dp4307
g7
I31
sg8
VP42771
p4308
sg10
I3
sg11
Vp53
p4309
sg13
I1
sa(dp4310
g7
I15
sg8
g107
sg10
I5
sg11
VRNF31
p4311
sg13
I1
sasg23
(lp4312
(dp4313
g7
I76
sg26
VC0678222
p4314
sg10
I13
sg11
Vbreast cancer
p4315
sg13
I2
sasa(dp4316
g2
S'Together, our findings suggest RNF31 as a potential therapeutic target to restore p53 function in breast cancer.\n'
p4317
sg4
(lp4318
(dp4319
g7
I82
sg8
VP42771
p4320
sg10
I3
sg11
Vp53
p4321
sg13
I1
sa(dp4322
g7
I31
sg8
g107
sg10
I5
sg11
VRNF31
p4323
sg13
I1
sasg23
(lp4324
(dp4325
g7
I98
sg26
VC0678222
p4326
sg10
I13
sg11
Vbreast cancer
p4327
sg13
I2
sasa(dp4328
g2
S'By examining the kinetics of pathway activation in TRAIL-sensitive lymphoma cells wild-type or deficient for RIP1, TRAF2, cIAP1/2 or HOIP, we report here that TRAIL induces two phases of JNK and NF-KB activation.\n'
p4329
sg4
(lp4330
(dp4331
g7
I115
sg8
g107
sg10
I5
sg11
VTRAF2
p4332
sg13
I1
sa(dp4333
g7
I109
sg8
VP47985
p4334
sg10
I4
sg11
VRIP1
p4335
sg13
I1
sa(dp4336
g7
I122
sg8
g107
sg10
I7
sg11
VcIAP1/2
p4337
sg13
I1
sa(dp4338
g7
I187
sg8
VP53779
p4339
sg10
I3
sg11
VJNK
p4340
sg13
I1
sa(dp4341
g7
I51
sg8
VP50591
p4342
sg10
I5
sg11
VTRAIL
p4343
sg13
I1
sasg23
(lp4344
(dp4345
g7
I67
sg26
VC0024299
p4346
sg10
I8
sg11
Vlymphoma
p4347
sg13
I1
sasa(dp4348
g2
S'Literature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).\n'
p4349
sg4
(lp4350
(dp4351
g7
I102
sg8
VP23975
p4352
sg10
I26
sg11
Vnorepinephrine transporter
p4353
sg13
I2
sasg23
(lp4354
(dp4355
g7
I170
sg26
VC0332875
p4356
sg10
I3
sg11
VWeb
p4357
sg13
I1
sa(dp4358
g7
I86
sg26
VC0344307
p4359
sg10
I9
sg11
Vanalgesia
p4360
sg13
I1
sasa(dp4361
g2
S'Norepinephrine transporter blockade seems to be essential for analgesia, but optimal concentrations are unknown.\n'
p4362
sg4
(lp4363
sg23
(lp4364
(dp4365
g7
I62
sg26
VC0344307
p4366
sg10
I9
sg11
Vanalgesia
p4367
sg13
I1
sasa(dp4368
g2
S'The third type is the secondary PHA1, which is strongly associated with urinary tract infections and/or urinary tract malformations.\n'
p4369
sg4
(lp4370
sg23
(lp4371
(dp4372
g7
I118
sg26
VC0000768
p4373
sg10
I13
sg11
Vmalformations
p4374
sg13
I1
sa(dp4375
g7
I72
sg26
VC0042029
p4376
sg10
I24
sg11
Vurinary tract infections
p4377
sg13
I3
sasa(dp4378
g2
S'To identify mutation in SCNN1B and SCNN1G genes in an adolescent with suspicious Liddle syndrome and his family members and to explore the screening target subjects of Liddle syndrome.\n'
p4379
sg4
(lp4380
(dp4381
g7
I24
sg8
VP51168
p4382
sg10
I6
sg11
VSCNN1B
p4383
sg13
I1
sa(dp4384
g7
I35
sg8
VP51168
p4385
sg10
I12
sg11
VSCNN1G genes
p4386
sg13
I2
sasg23
(lp4387
(dp4388
g7
I81
sg26
VC0221043
p4389
sg10
I15
sg11
VLiddle syndrome
p4390
sg13
I2
sa(dp4391
g7
I81
sg26
VC0221043
p4392
sg10
I15
sg11
VLiddle syndrome
p4393
sg13
I2
sasa(dp4394
g2
S'Genetic analysis of the C-terminus of SCNN1B and SCNN1G genes was conducted in an adolescent, with treatment-resistant hypertension and hypokalemia, who was suspected of having Liddle syndrome, and his family members.\n'
p4395
sg4
(lp4396
(dp4397
g7
I38
sg8
VP51168
p4398
sg10
I6
sg11
VSCNN1B
p4399
sg13
I1
sa(dp4400
g7
I49
sg8
VP51168
p4401
sg10
I12
sg11
VSCNN1G genes
p4402
sg13
I2
sasg23
(lp4403
(dp4404
g7
I119
sg26
VC0020538
p4405
sg10
I12
sg11
Vhypertension
p4406
sg13
I1
sa(dp4407
g7
I177
sg26
VC0221043
p4408
sg10
I15
sg11
VLiddle syndrome
p4409
sg13
I2
sasa(dp4410
g2
S'In adulthood, an induced nephron-specific deficiency of AlfaENaC (Scnn1a) resulted in pseudohypoaldosteronism type 1 (PHA-1) with sodium loss, hyperkalemia, and metabolic acidosis that is rescued through high-sodium/low-potassium (HNa+/LK+) diet.\n'
p4411
sg4
(lp4412
(dp4413
g7
I86
sg8
VP37088
p4414
sg10
I30
sg11
Vpseudohypoaldosteronism type 1
p4415
sg13
I3
sa(dp4416
g7
I66
sg8
VP37088
p4417
sg10
I6
sg11
VScnn1a
p4418
sg13
I1
sa(dp4419
g7
I118
sg8
g107
sg10
I5
sg11
VPHA-1
p4420
sg13
I1
sasg23
(lp4421
(dp4422
g7
I86
sg26
VC0268436
p4423
sg10
I30
sg11
Vpseudohypoaldosteronism type 1
p4424
sg13
I3
sa(dp4425
g7
I118
sg26
VC0268436
p4426
sg10
I5
sg11
VPHA-1
p4427
sg13
I1
sa(dp4428
g7
I161
sg26
VC0220981
p4429
sg10
I18
sg11
Vmetabolic acidosis
p4430
sg13
I2
sasa(dp4431
g2
S'Liddle syndrome is an autosomal dominant genetic condition that causes hypertension and hypokalemia due to a gain-of-function mutation in the SCNN1B or SCNN1G genes which code for the epithelial sodium channel in the kidney.\n'
p4432
sg4
(lp4433
(dp4434
g7
I142
sg8
VP51168
p4435
sg10
I6
sg11
VSCNN1B
p4436
sg13
I1
sa(dp4437
g7
I152
sg8
VP51168
p4438
sg10
I12
sg11
VSCNN1G genes
p4439
sg13
I2
sasg23
(lp4440
(dp4441
g7
I41
sg26
VC0019247
p4442
sg10
I17
sg11
Vgenetic condition
p4443
sg13
I2
sa(dp4444
g7
I0
sg26
VC0221043
p4445
sg10
I15
sg11
VLiddle syndrome
p4446
sg13
I2
sa(dp4447
g7
I71
sg26
VC0020538
p4448
sg10
I12
sg11
Vhypertension
p4449
sg13
I1
sasa(dp4450
g2
S'Loss-of-function mutations of the MR are responsible for renal pseudohypoaldosteronism type 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with weight loss, failure to thrive, vomiting and dehydration, associated with hyperkalemia and metabolic acidosis, despite extremely elevated levels of plasma renin and aldosterone.\n'
p4451
sg4
(lp4452
(dp4453
g7
I57
sg8
VP37088
p4454
sg10
I36
sg11
Vrenal pseudohypoaldosteronism type 1
p4455
sg13
I4
sa(dp4456
g7
I328
sg8
VP00797
p4457
sg10
I12
sg11
Vplasma renin
p4458
sg13
I2
sa(dp4459
g7
I95
sg8
VP37088
p4460
sg10
I4
sg11
VPHA1
p4461
sg13
I1
sasg23
(lp4462
(dp4463
g7
I212
sg26
VC0042963
p4464
sg10
I8
sg11
Vvomiting
p4465
sg13
I1
sa(dp4466
g7
I104
sg26
VC0678236
p4467
sg10
I12
sg11
Vrare disease
p4468
sg13
I2
sa(dp4469
g7
I271
sg26
VC0220981
p4470
sg10
I18
sg11
Vmetabolic acidosis
p4471
sg13
I2
sa(dp4472
g7
I193
sg26
VC0015544
p4473
sg10
I17
sg11
Vfailure to thrive
p4474
sg13
I3
sa(dp4475
g7
I95
sg26
VC0268436
p4476
sg10
I4
sg11
VPHA1
p4477
sg13
I1
sa(dp4478
g7
I63
sg26
VC0268436
p4479
sg10
I30
sg11
Vpseudohypoaldosteronism type 1
p4480
sg13
I3
sa(dp4481
g7
I225
sg26
VC0011175
p4482
sg10
I11
sg11
Vdehydration
p4483
sg13
I1
sasa(dp4484
g2
S'In the presence of pyelonephritis, the same biochemical picture can occur with transient type 1 pseudohypoaldosteronism (PHA-1) also termed type 4 renal tubular acidosis.\n'
p4485
sg4
(lp4486
(dp4487
g7
I121
sg8
g107
sg10
I5
sg11
VPHA-1
p4488
sg13
I1
sa(dp4489
g7
I56
sg8
g107
sg10
I63
sg11
Vpicture can occur with transient type 1 pseudohypoaldosteronism
p4490
sg13
I8
sasg23
(lp4491
(dp4492
g7
I147
sg26
VC0001126
p4493
sg10
I22
sg11
Vrenal tubular acidosis
p4494
sg13
I3
sa(dp4495
g7
I96
sg26
VC0033805
p4496
sg10
I23
sg11
Vpseudohypoaldosteronism
p4497
sg13
I1
sa(dp4498
g7
I121
sg26
VC0030779
p4499
sg10
I3
sg11
VPHA
p4500
sg13
I1
sa(dp4501
g7
I19
sg26
VC0034186
p4502
sg10
I14
sg11
Vpyelonephritis
p4503
sg13
I1
sasa(dp4504
g2
S'Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease characterized by resistance to aldosterone, and the renal form of PHA1 is associated with heterozygous inactivating mutations in NR3C2, which encodes mineralocorticoid receptor (MR).\n'
p4505
sg4
(lp4506
(dp4507
g7
I32
sg8
VP37088
p4508
sg10
I4
sg11
VPHA1
p4509
sg13
I1
sa(dp4510
g7
I32
sg8
VP37088
p4511
sg10
I4
sg11
VPHA1
p4512
sg13
I1
sa(dp4513
g7
I193
sg8
VP08235
p4514
sg10
I5
sg11
VNR3C2
p4515
sg13
I1
sa(dp4516
g7
I0
sg8
VP37088
p4517
sg10
I30
sg11
VPseudohypoaldosteronism type 1
p4518
sg13
I3
sasg23
(lp4519
(dp4520
g7
I32
sg26
VC0268436
p4521
sg10
I4
sg11
VPHA1
p4522
sg13
I1
sa(dp4523
g7
I32
sg26
VC0268436
p4524
sg10
I4
sg11
VPHA1
p4525
sg13
I1
sa(dp4526
g7
I0
sg26
VC0268436
p4527
sg10
I30
sg11
VPseudohypoaldosteronism type 1
p4528
sg13
I3
sa(dp4529
g7
I48
sg26
VC0019247
p4530
sg10
I15
sg11
Vgenetic disease
p4531
sg13
I2
sasa(dp4532
g2
S'Recent work has identified cancer-associated U2AF35 missense mutations in two zinc-finger (ZnF) domains, but little is known about Q157R/P substitutions within the second ZnF.\n'
p4533
sg4
(lp4534
(dp4535
g7
I45
sg8
g107
sg10
I6
sg11
VU2AF35
p4536
sg13
I1
sasg23
(lp4537
(dp4538
g7
I27
sg26
VC0006826
p4539
sg10
I6
sg11
Vcancer
p4540
sg13
I1
sasa(dp4541
g2
S'Zinc finger (ZNF) proteins, a diverse family of proteins, have multiple biological functions in cancer.\n'
p4542
sg4
(lp4543
(dp4544
g7
I0
sg8
g107
sg10
I26
sg11
VZinc finger (ZNF) proteins
p4545
sg13
I4
sasg23
(lp4546
(dp4547
g7
I96
sg26
VC0006826
p4548
sg10
I6
sg11
Vcancer
p4549
sg13
I1
sasa(dp4550
g2
S'However, the function and underlying mechanisms of ZNF185 in the tumorigenesis of lung adenocarcinoma (LAC) remain unclear.\n'
p4551
sg4
(lp4552
(dp4553
g7
I51
sg8
g107
sg10
I6
sg11
VZNF185
p4554
sg13
I1
sasg23
(lp4555
(dp4556
g7
I103
sg26
VC0152013
p4557
sg10
I3
sg11
VLAC
p4558
sg13
I1
sa(dp4559
g7
I82
sg26
VC0152013
p4560
sg10
I19
sg11
Vlung adenocarcinoma
p4561
sg13
I2
sa(dp4562
g7
I65
sg26
VC0007621
p4563
sg10
I13
sg11
Vtumorigenesis
p4564
sg13
I1
sasa(dp4565
g2
S'We found that the protein expression of ZNF185 was significantly downregulated in LAC tissues compared with the adjacent non-cancerous tissues (ANCT) (37.10% vs 58.06%, P=0.015), and was negatively correlated with the lymph node metastasis of the LAC patients (P=0.005).\n'
p4566
sg4
(lp4567
(dp4568
g7
I40
sg8
g107
sg10
I6
sg11
VZNF185
p4569
sg13
I1
sasg23
(lp4570
(dp4571
g7
I218
sg26
VC0686619
p4572
sg10
I21
sg11
Vlymph node metastasis
p4573
sg13
I3
sasa(dp4574
g2
S'In view of the exploitation of tetraspanins by organisms for survival, these proteins could be targeted using specific antibodies, recombinant large extracellular loop (LEL) domains, small-molecule mimetics and siRNAs as potential novel and efficacious putative targets to combat African trypanosomiasis by killing the tsetse fly vector.\n'
p4575
sg4
(lp4576
sg23
(lp4577
(dp4578
g7
I280
sg26
VC0041228
p4579
sg10
I23
sg11
VAfrican trypanosomiasis
p4580
sg13
I2
sa(dp4581
g7
I143
sg26
VC1846721
p4582
sg10
I24
sg11
Vlarge extracellular loop
p4583
sg13
I3
sa(dp4584
g7
I169
sg26
VC1846721
p4585
sg10
I3
sg11
VLEL
p4586
sg13
I1
sasa(dp4587
g2
S'Infection of hepatocytic cells by two major pathogens, the hepatitis C virus and the malaria parasite, also requires the tetraspanin CD81.\n'
p4588
sg4
(lp4589
(dp4590
g7
I121
sg8
g107
sg10
I16
sg11
Vtetraspanin CD81
p4591
sg13
I2
sasg23
(lp4592
(dp4593
g7
I0
sg26
VC0009450
p4594
sg10
I9
sg11
VInfection
p4595
sg13
I1
sa(dp4596
g7
I59
sg26
VC0019196
p4597
sg10
I11
sg11
Vhepatitis C
p4598
sg13
I2
sa(dp4599
g7
I85
sg26
VC0024530
p4600
sg10
I7
sg11
Vmalaria
p4601
sg13
I1
sasa(dp4602
g2
S'Our results unravel a functional link between CD81 and cholesterol during infection by malaria parasites, and illustrate that tetraspanin microdomains constitute a novel type of membrane microdomains that could be used by pathogens for infection.\n'
p4603
sg4
(lp4604
(dp4605
g7
I46
sg8
VP60033
p4606
sg10
I4
sg11
VCD81
p4607
sg13
I1
sa(dp4608
g7
I126
sg8
g107
sg10
I24
sg11
Vtetraspanin microdomains
p4609
sg13
I2
sasg23
(lp4610
(dp4611
g7
I87
sg26
VC0024530
p4612
sg10
I7
sg11
Vmalaria
p4613
sg13
I1
sa(dp4614
g7
I74
sg26
VC0009450
p4615
sg10
I9
sg11
Vinfection
p4616
sg13
I1
sa(dp4617
g7
I74
sg26
VC0009450
p4618
sg10
I9
sg11
Vinfection
p4619
sg13
I1
sasa(dp4620
g2
S'The CXCL11 gene may also play a role in BK polyomavirus-associated nephropathy.\n'
p4621
sg4
(lp4622
(dp4623
g7
I4
sg8
g107
sg10
I11
sg11
VCXCL11 gene
p4624
sg13
I2
sasg23
(lp4625
(dp4626
g7
I43
sg26
VC1696946
p4627
sg10
I35
sg11
Vpolyomavirus-associated nephropathy
p4628
sg13
I2
sasa(dp4629
g2
S'Our aim was to compare expression levels of CXCL11 in BK polyomavirus-infected versus noninfected kidney transplant patients with nephropathy and healthy controls.\n'
p4630
sg4
(lp4631
(dp4632
g7
I44
sg8
g107
sg10
I6
sg11
VCXCL11
p4633
sg13
I1
sasg23
(lp4634
(dp4635
g7
I130
sg26
VC0022658
p4636
sg10
I11
sg11
Vnephropathy
p4637
sg13
I1
sasa(dp4638
g2
S'Taken together, the results indicated that sorafenib had protective effects against renal fibrosis; its mechanism of action was associated with inhibition of macrophage infiltration via the CXCR3/CXCL11 pathway.\n'
p4639
sg4
(lp4640
(dp4641
g7
I190
sg8
VP49682
p4642
sg10
I5
sg11
VCXCR3
p4643
sg13
I1
sa(dp4644
g7
I196
sg8
g107
sg10
I6
sg11
VCXCL11
p4645
sg13
I1
sasg23
(lp4646
(dp4647
g7
I169
sg26
VC0332448
p4648
sg10
I12
sg11
Vinfiltration
p4649
sg13
I1
sa(dp4650
g7
I84
sg26
VC0151650
p4651
sg10
I14
sg11
Vrenal fibrosis
p4652
sg13
I2
sasa(dp4653
g2
S'Urinary mRNA levels of CXCL10 and CXCL11 are decreased, and those of collagen I A1 chain and fibronectin are increased in diabetic nephropathy.\n'
p4654
sg4
(lp4655
(dp4656
g7
I23
sg8
VP02778
p4657
sg10
I6
sg11
VCXCL10
p4658
sg13
I1
sa(dp4659
g7
I34
sg8
g107
sg10
I6
sg11
VCXCL11
p4660
sg13
I1
sasg23
(lp4661
(dp4662
g7
I122
sg26
VC0011881
p4663
sg10
I20
sg11
Vdiabetic nephropathy
p4664
sg13
I2
sasa(dp4665
g2
S'For this purpose, serum concentration of interleukin 2 (IL2), interleukin 10 (IL10), interferon-gamma (IFNG), Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9) were measured in blood samples obtained from F(2) piglets (n = 334) of a Duroc x Pietrain resource population (DUPI) after Mycoplasma hypopneumoniae (Mh), tetanus toxoid (TT) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccination at 6, 9 and 15 weeks of age.\n'
p4666
sg4
(lp4667
(dp4668
g7
I78
sg8
VP22301
p4669
sg10
I4
sg11
VIL10
p4670
sg13
I1
sa(dp4671
g7
I164
sg8
g107
sg10
I4
sg11
VTLR9
p4672
sg13
I1
sa(dp4673
g7
I56
sg8
VP60568
p4674
sg10
I3
sg11
VIL2
p4675
sg13
I1
sa(dp4676
g7
I142
sg8
g107
sg10
I20
sg11
VToll-like receptor 9
p4677
sg13
I3
sa(dp4678
g7
I41
sg8
VP60568
p4679
sg10
I13
sg11
Vinterleukin 2
p4680
sg13
I2
sa(dp4681
g7
I110
sg8
g107
sg10
I20
sg11
VToll-like receptor 2
p4682
sg13
I3
sa(dp4683
g7
I132
sg8
g107
sg10
I4
sg11
VTLR2
p4684
sg13
I1
sa(dp4685
g7
I85
sg8
VP01579
p4686
sg10
I16
sg11
Vinterferon-gamma
p4687
sg13
I1
sa(dp4688
g7
I103
sg8
VP01579
p4689
sg10
I4
sg11
VIFNG
p4690
sg13
I1
sa(dp4691
g7
I62
sg8
VP22301
p4692
sg10
I14
sg11
Vinterleukin 10
p4693
sg13
I2
sasg23
(lp4694
(dp4695
g7
I325
sg26
VC0039614
p4696
sg10
I7
sg11
Vtetanus
p4697
sg13
I1
sa(dp4698
g7
I349
sg26
VC0376538
p4699
sg10
I45
sg11
VPorcine Reproductive and Respiratory Syndrome
p4700
sg13
I5
sa(dp4701
g7
I293
sg26
VC0026936
p4702
sg10
I10
sg11
VMycoplasma
p4703
sg13
I1
sasa(dp4704
g2
S'Not only TLR-2 gene polymorphisms but also immunoglobulins (IgG, IgM, IgA), IgG subsets (G1, G2, G3), and specific antibody levels (anti-tetanus and anti-hemophilus influenza) were determined to exclude humoral immunodeficiencies.\n'
p4705
sg4
(lp4706
(dp4707
g7
I65
sg8
VP29965
p4708
sg10
I3
sg11
VIgM
p4709
sg13
I1
sa(dp4710
g7
I9
sg8
g107
sg10
I10
sg11
VTLR-2 gene
p4711
sg13
I2
sa(dp4712
g7
I70
sg8
VP11912
p4713
sg10
I3
sg11
VIgA
p4714
sg13
I1
sa(dp4715
g7
I43
sg8
g107
sg10
I15
sg11
Vimmunoglobulins
p4716
sg13
I1
sasg23
(lp4717
(dp4718
g7
I165
sg26
VC0021400
p4719
sg10
I9
sg11
Vinfluenza
p4720
sg13
I1
sa(dp4721
g7
I211
sg26
VC0021051
p4722
sg10
I18
sg11
Vimmunodeficiencies
p4723
sg13
I1
sa(dp4724
g7
I137
sg26
VC0039614
p4725
sg10
I7
sg11
Vtetanus
p4726
sg13
I1
sasa(dp4727
g2
S'While glutamate is not a known OAT4 or OATP2B1 substrate, we propose that its high intracellular concentration has the potential to drive accumulation of substrates from the fetal circulation.\n'
p4728
sg4
(lp4729
(dp4730
g7
I39
sg8
g107
sg10
I7
sg11
VOATP2B1
p4731
sg13
I1
sa(dp4732
g7
I31
sg8
g107
sg10
I4
sg11
VOAT4
p4733
sg13
I1
sasg23
(lp4734
sa(dp4735
g2
S'Cycling of glutamate across the placenta involving efflux via OAT4 and OATP2B1 and subsequent reuptake will drive placental uptake of organic anions from the fetal circulation.\n'
p4736
sg4
(lp4737
(dp4738
g7
I71
sg8
g107
sg10
I7
sg11
VOATP2B1
p4739
sg13
I1
sa(dp4740
g7
I62
sg8
g107
sg10
I4
sg11
VOAT4
p4741
sg13
I1
sasg23
(lp4742
sa(dp4743
g2
S'Efflux transport of olmesartan via OAT4 from syncytiotrophoblasts to the fetal circulation might be facilitated in the presence of an inwardly directed physiological chloride gradient and extracellular DHEAS.\n'
p4744
sg4
(lp4745
(dp4746
g7
I35
sg8
g107
sg10
I4
sg11
VOAT4
p4747
sg13
I1
sasg23
(lp4748
sa(dp4749
g2
S'This is probably the first case report of cobalamin intracellular metabolism defect (CblC/CblD/CblF/CblJ or ABCD4) presenting as diabetic ketoacidosis.\n'
p4750
sg4
(lp4751
(dp4752
g7
I85
sg8
g107
sg10
I4
sg11
VCblC
p4753
sg13
I1
sa(dp4754
g7
I108
sg8
g107
sg10
I5
sg11
VABCD4
p4755
sg13
I1
sa(dp4756
g7
I90
sg8
g107
sg10
I4
sg11
VCblD
p4757
sg13
I1
sa(dp4758
g7
I95
sg8
g107
sg10
I4
sg11
VCblF
p4759
sg13
I1
sasg23
(lp4760
(dp4761
g7
I129
sg26
VC0011880
p4762
sg10
I21
sg11
Vdiabetic ketoacidosis
p4763
sg13
I2
sa(dp4764
g7
I95
sg26
VC1848578
p4765
sg10
I4
sg11
VCblF
p4766
sg13
I1
sasa(dp4767
g2
S'Moderate to severe sensorineural hearing loss and progressive RP characterizes Usher syndrome type IIa (USH2A), which maps to the long arm of chromosome 1q41.\n'
p4768
sg4
(lp4769
(dp4770
g7
I104
sg8
g107
sg10
I5
sg11
VUSH2A
p4771
sg13
I1
sasg23
(lp4772
(dp4773
g7
I104
sg26
VC1848634
p4774
sg10
I5
sg11
VUSH2A
p4775
sg13
I1
sa(dp4776
g7
I79
sg26
VC0271097
p4777
sg10
I14
sg11
VUsher syndrome
p4778
sg13
I2
sa(dp4779
g7
I19
sg26
VC0018784
p4780
sg10
I26
sg11
Vsensorineural hearing loss
p4781
sg13
I3
sasa(dp4782
g2
S'Usher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2.\n'
p4783
sg4
(lp4784
sg23
(lp4785
(dp4786
g7
I150
sg26
VC0035334
p4787
sg10
I20
sg11
Vretinitis pigmentosa
p4788
sg13
I2
sa(dp4789
g7
I0
sg26
VC0271097
p4790
sg10
I14
sg11
VUsher syndrome
p4791
sg13
I2
sa(dp4792
g7
I107
sg26
VC0018784
p4793
sg10
I26
sg11
Vsensorineural hearing loss
p4794
sg13
I3
sasa(dp4795
g2
S'Moderate to severe non-progressive high frequency hearing loss with RP and normal vestibular function describes Usher syndrome type IIa, which has been localized to 1q41.\n'
p4796
sg4
(lp4797
sg23
(lp4798
(dp4799
g7
I35
sg26
VC0018780
p4800
sg10
I27
sg11
Vhigh frequency hearing loss
p4801
sg13
I4
sa(dp4802
g7
I112
sg26
VC0271097
p4803
sg10
I14
sg11
VUsher syndrome
p4804
sg13
I2
sasa(dp4805
g2
S'As one subtype of the class IIa HDACs, HDAC9 is capable to repress/de-repress their target genes in tumor, inflammation, atherosclerosis and metabolic diseases.\n'
p4806
sg4
(lp4807
(dp4808
g7
I22
sg8
g107
sg10
I15
sg11
Vclass IIa HDACs
p4809
sg13
I3
sa(dp4810
g7
I39
sg8
g107
sg10
I5
sg11
VHDAC9
p4811
sg13
I1
sasg23
(lp4812
(dp4813
g7
I100
sg26
VC0027651
p4814
sg10
I5
sg11
Vtumor
p4815
sg13
I1
sa(dp4816
g7
I107
sg26
VC0021368
p4817
sg10
I12
sg11
Vinflammation
p4818
sg13
I1
sa(dp4819
g7
I141
sg26
VC0025517
p4820
sg10
I18
sg11
Vmetabolic diseases
p4821
sg13
I2
sa(dp4822
g7
I121
sg26
VC0004153
p4823
sg10
I15
sg11
Vatherosclerosis
p4824
sg13
I1
sasa(dp4825
g2
S'Taken together, our data suggest that SNP rs2107595 may contribute to coronary atherosclerosis and CAD risk through a possible mechanism of regulating HDAC9 expression and gene-environment interactions.\n'
p4826
sg4
(lp4827
(dp4828
g7
I151
sg8
g107
sg10
I5
sg11
VHDAC9
p4829
sg13
I1
sasg23
(lp4830
(dp4831
g7
I99
sg26
VC0010054
p4832
sg10
I3
sg11
VCAD
p4833
sg13
I1
sa(dp4834
g7
I70
sg26
VC0010054
p4835
sg10
I24
sg11
Vcoronary atherosclerosis
p4836
sg13
I2
sasa(dp4837
g2
S'These results suggest that HDAC9 may participate in ox-LDL-induced endothelial damage and inflammation during atherosclerosis development.\n'
p4838
sg4
(lp4839
(dp4840
g7
I27
sg8
g107
sg10
I5
sg11
VHDAC9
p4841
sg13
I1
sasg23
(lp4842
(dp4843
g7
I90
sg26
VC0021368
p4844
sg10
I12
sg11
Vinflammation
p4845
sg13
I1
sa(dp4846
g7
I110
sg26
VC0004153
p4847
sg10
I15
sg11
Vatherosclerosis
p4848
sg13
I1
sasa(dp4849
g2
S'Our results also supported robust associations with ischaemic stroke for four other loci that have been reported in previous studies, including PITX2 (first stage OR 1*39, 1*29-1*49, p=3*26 x 10-19; joint OR 1*37, 1*30-1*45, p=2*79 x 10-32) and ZFHX3 (first stage OR 1*19, 1*11-1*27, p=2*93 x 10-7; joint OR 1*17, 1*11-1*23, p=2*29 x 10-10) for cardioembolic stroke, and HDAC9 (first stage OR 1*29, 1*18-1*42, p=3*50 x 10-8; joint OR 1*24, 1*15-1*33, p=4*52 x 10-9) for large artery atherosclerosis stroke.\n'
p4850
sg4
(lp4851
(dp4852
g7
I144
sg8
g107
sg10
I5
sg11
VPITX2
p4853
sg13
I1
sa(dp4854
g7
I371
sg8
g107
sg10
I5
sg11
VHDAC9
p4855
sg13
I1
sa(dp4856
g7
I245
sg8
g107
sg10
I5
sg11
VZFHX3
p4857
sg13
I1
sasg23
(lp4858
(dp4859
g7
I62
sg26
VC0038454
p4860
sg10
I6
sg11
Vstroke
p4861
sg13
I1
sa(dp4862
g7
I52
sg26
VC0948008
p4863
sg10
I16
sg11
Vischaemic stroke
p4864
sg13
I2
sa(dp4865
g7
I483
sg26
VC0004153
p4866
sg10
I15
sg11
Vatherosclerosis
p4867
sg13
I1
sa(dp4868
g7
I345
sg26
VC1531624
p4869
sg10
I20
sg11
Vcardioembolic stroke
p4870
sg13
I2
sasa(dp4871
g2
S'In this study, we investigated the candidacy and directionality of HDAC9 in atherosclerosis and analyzed associations between risk alleles at 7p21.1 and plaque characteristics.\n'
p4872
sg4
(lp4873
(dp4874
g7
I67
sg8
g107
sg10
I5
sg11
VHDAC9
p4875
sg13
I1
sasg23
(lp4876
(dp4877
g7
I76
sg26
VC0004153
p4878
sg10
I15
sg11
Vatherosclerosis
p4879
sg13
I1
sa(dp4880
g7
I153
sg26
VC0011389
p4881
sg10
I6
sg11
Vplaque
p4882
sg13
I1
sasa(dp4883
g2
S'Targeted inhibition of HDAC9 might be a viable strategy to prevent atherosclerosis.\n'
p4884
sg4
(lp4885
(dp4886
g7
I23
sg8
g107
sg10
I5
sg11
VHDAC9
p4887
sg13
I1
sasg23
(lp4888
(dp4889
g7
I67
sg26
VC0004153
p4890
sg10
I15
sg11
Vatherosclerosis
p4891
sg13
I1
sasa(dp4892
g2
S'The ability of a pulsed oxygen delivery system (Puritan-Bennett Companion Oxygen Saver (COS-5) to track respiratory rate during exercise and the oxygenation achieved during the exercise while oxygen was being delivered by this system was compared to that attained while oxygen was delivered continuously in six patients with chronic obstructive pulmonary disease (COPD) and six patients with idiopathic pulmonary fibrosis (IPF).\n'
p4893
sg4
(lp4894
sg23
(lp4895
(dp4896
g7
I325
sg26
VC0024117
p4897
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p4898
sg13
I4
sa(dp4899
g7
I392
sg26
VC3161101
p4900
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p4901
sg13
I3
sa(dp4902
g7
I423
sg26
VC3161101
p4903
sg10
I3
sg11
VIPF
p4904
sg13
I1
sa(dp4905
g7
I364
sg26
VC0024117
p4906
sg10
I4
sg11
VCOPD
p4907
sg13
I1
sasa(dp4908
g2
S'Peripheral blood monocyte surface marker (CD14, CD16, CD163, CSF1R, CCR2, CCR4, CCR5, CXCR3, CXCR4, CX3CR1, HLA-DR, CD62L, SIGLEC-1) expression and capacity for phagocytosis, oxidative burst and LPS-stimulated TNF production were assessed in patients with hepatitis C (HCV) (n = 39) or non-alcoholic fatty liver disease (NAFLD) (n = 34) (classified as non-advanced disease, compensated cirrhosis and decompensated cirrhosis) and healthy controls (n = 11) by flow cytometry.\n'
p4909
sg4
(lp4910
(dp4911
g7
I48
sg8
VP08637
p4912
sg10
I4
sg11
VCD16
p4913
sg13
I1
sa(dp4914
g7
I100
sg8
VP78423
p4915
sg10
I6
sg11
VCX3CR1
p4916
sg13
I1
sa(dp4917
g7
I80
sg8
VP32302
p4918
sg10
I4
sg11
VCCR5
p4919
sg13
I1
sa(dp4920
g7
I74
sg8
VP51679
p4921
sg10
I4
sg11
VCCR4
p4922
sg13
I1
sa(dp4923
g7
I86
sg8
VP49682
p4924
sg10
I5
sg11
VCXCR3
p4925
sg13
I1
sa(dp4926
g7
I54
sg8
g107
sg10
I5
sg11
VCD163
p4927
sg13
I1
sa(dp4928
g7
I210
sg8
VP01375
p4929
sg10
I3
sg11
VTNF
p4930
sg13
I1
sa(dp4931
g7
I61
sg8
VP09619
p4932
sg10
I5
sg11
VCSF1R
p4933
sg13
I1
sa(dp4934
g7
I108
sg8
VP30486
p4935
sg10
I6
sg11
VHLA-DR
p4936
sg13
I1
sa(dp4937
g7
I93
sg8
VP61073
p4938
sg10
I5
sg11
VCXCR4
p4939
sg13
I1
sa(dp4940
g7
I123
sg8
g107
sg10
I8
sg11
VSIGLEC-1
p4941
sg13
I1
sa(dp4942
g7
I116
sg8
VP14151
p4943
sg10
I5
sg11
VCD62L
p4944
sg13
I1
sa(dp4945
g7
I68
sg8
VP41597
p4946
sg10
I4
sg11
VCCR2
p4947
sg13
I1
sa(dp4948
g7
I42
sg8
VP08571
p4949
sg10
I4
sg11
VCD14
p4950
sg13
I1
sasg23
(lp4951
(dp4952
g7
I374
sg26
VC1608426
p4953
sg10
I21
sg11
Vcompensated cirrhosis
p4954
sg13
I2
sa(dp4955
g7
I400
sg26
VC1619727
p4956
sg10
I23
sg11
Vdecompensated cirrhosis
p4957
sg13
I2
sa(dp4958
g7
I321
sg26
VC0400966
p4959
sg10
I5
sg11
VNAFLD
p4960
sg13
I1
sa(dp4961
g7
I195
sg26
VC0175697
p4962
sg10
I3
sg11
VLPS
p4963
sg13
I1
sa(dp4964
g7
I256
sg26
VC0019196
p4965
sg10
I11
sg11
Vhepatitis C
p4966
sg13
I2
sa(dp4967
g7
I286
sg26
VC0400966
p4968
sg10
I33
sg11
Vnon-alcoholic fatty liver disease
p4969
sg13
I4
sasa(dp4970
g2
S'Soluble CD163 (sCD163), a marker of Kupffer cell activation detectable in serum, correlates with inflammation and fibrosis in chronic viral hepatitis, but its role in nonalcoholic fatty liver disease is unknown.\n'
p4971
sg4
(lp4972
(dp4973
g7
I15
sg8
g107
sg10
I6
sg11
VsCD163
p4974
sg13
I1
sa(dp4975
g7
I0
sg8
g107
sg10
I13
sg11
VSoluble CD163
p4976
sg13
I2
sasg23
(lp4977
(dp4978
g7
I126
sg26
VC0276623
p4979
sg10
I23
sg11
Vchronic viral hepatitis
p4980
sg13
I3
sa(dp4981
g7
I114
sg26
VC0016059
p4982
sg10
I8
sg11
Vfibrosis
p4983
sg13
I1
sa(dp4984
g7
I97
sg26
VC0021368
p4985
sg10
I12
sg11
Vinflammation
p4986
sg13
I1
sa(dp4987
g7
I167
sg26
VC0400966
p4988
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p4989
sg13
I4
sasa(dp4990
g2
S'We hypothesized that sCD163 would correlate with nonalcoholic fatty liver disease activity and fibrosis.\n'
p4991
sg4
(lp4992
(dp4993
g7
I21
sg8
g107
sg10
I6
sg11
VsCD163
p4994
sg13
I1
sasg23
(lp4995
(dp4996
g7
I49
sg26
VC0400966
p4997
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p4998
sg13
I4
sa(dp4999
g7
I95
sg26
VC0016059
p5000
sg10
I8
sg11
Vfibrosis
p5001
sg13
I1
sasa(dp5002
g2
S"dermatoses presenting with erythematous-desquamative patches/plaques (plaque psoriasis, eczematous dermatitis, pityriasis rosea, mycosis fungoides and subacute cutaneous lupus erythematosus), papulosquamous/papulokeratotic dermatoses (lichen planus, pityriasis rosea, papulosquamous sarcoidosis, guttate psoriasis, pityriasis lichenoides chronica, classical pityriasis rubra pilaris, porokeratosis, lymphomatoid papulosis, papulosquamous chronic GVHD, parakeratosis variegata, Grover disease, Darier disease and BRAF-inhibitor-induced acantholytic dyskeratosis), facial inflammatory skin diseases (rosacea, seborrheic dermatitis, discoid lupus erythematosus, sarcoidosis, cutaneous leishmaniasis, lupus vulgaris, granuloma faciale and demodicidosis), acquired keratodermas (chronic hand eczema, palmar psoriasis, keratoderma due to mycosis fungoides, keratoderma resulting from pityriasis rubra pilaris, tinea manuum, palmar lichen planus and aquagenic palmar keratoderma), sclero-atrophic dermatoses (necrobiosis lipoidica, morphea and cutaneous lichen sclerosus), hypopigmented macular diseases (extragenital guttate lichen sclerosus, achromic pityriasis versicolor, guttate vitiligo, idiopathic guttate hypomelanosis, progressive macular hypomelanosis and postinflammatory hypopigmentations), hyperpigmented maculopapular diseases (pityriasis versicolor, lichen planus pigmentosus, Gougerot-Carteaud syndrome, Dowling-Degos disease, erythema ab igne, macular amyloidosis, lichen amyloidosus, friction melanosis, terra firma-forme dermatosis, urticaria pigmentosa and telangiectasia macularis eruptiva perstans), itchy papulonodular dermatoses (hypertrophic lichen planus, prurigo nodularis, nodular scabies and acquired perforating dermatosis), erythrodermas (due to psoriasis, atopic dermatitis, mycosis fungoides, pityriasis rubra pilaris and scabies), noninfectious balanitis (Zoon's plasma cell balanitis, psoriatic balanitis, seborrheic dermatitis and non-specific balanitis) and erythroplasia of Queyrat, inflammatory cicatricial alopecias (scalp discoid lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia and folliculitis decalvans), nonscarring alopecias (alopecia areata, trichotillomania, androgenetic alopecia and telogen effluvium) and scaling disorders of the scalp (tinea capitis, scalp psoriasis, seborrheic dermatitis and pityriasis amiantacea).\n"
p5003
sg4
(lp5004
sg23
(lp5005
(dp5006
g7
I77
sg26
VC0033860
p5007
sg10
I9
sg11
Vpsoriasis
p5008
sg13
I1
sa(dp5009
g7
I88
sg26
VC0013595
p5010
sg10
I21
sg11
Veczematous dermatitis
p5011
sg13
I2
sa(dp5012
g7
I607
sg26
VC0036508
p5013
sg10
I21
sg11
Vseborrheic dermatitis
p5014
sg13
I2
sa(dp5015
g7
I2316
sg26
VC0406326
p5016
sg10
I15
sg11
Vscalp psoriasis
p5017
sg13
I2
sa(dp5018
g7
I129
sg26
VC0026948
p5019
sg10
I17
sg11
Vmycosis fungoides
p5020
sg13
I2
sa(dp5021
g7
I358
sg26
VC0032027
p5022
sg10
I24
sg11
Vpityriasis rubra pilaris
p5023
sg13
I3
sa(dp5024
g7
I1413
sg26
VC0406811
p5025
sg10
I21
sg11
VDowling-Degos disease
p5026
sg13
I2
sa(dp5027
g7
I235
sg26
VC0023646
p5028
sg10
I13
sg11
Vlichen planus
p5029
sg13
I2
sa(dp5030
g7
I1111
sg26
VC0406644
p5031
sg10
I24
sg11
Vguttate lichen sclerosus
p5032
sg13
I3
sa(dp5033
g7
I1694
sg26
VC0344064
p5034
sg10
I15
sg11
Vnodular scabies
p5035
sg13
I2
sa(dp5036
g7
I1177
sg26
VC0042900
p5037
sg10
I8
sg11
Vvitiligo
p5038
sg13
I1
sa(dp5039
g7
I1723
sg26
VC1304435
p5040
sg10
I22
sg11
Vperforating dermatosis
p5041
sg13
I2
sa(dp5042
g7
I283
sg26
VC0036202
p5043
sg10
I11
sg11
Vsarcoidosis
p5044
sg13
I1
sa(dp5045
g7
I1025
sg26
VC0036420
p5046
sg10
I7
sg11
Vmorphea
p5047
sg13
I1
sa(dp5048
g7
I0
sg26
VC0037274
p5049
sg10
I10
sg11
Vdermatoses
p5050
sg13
I1
sa(dp5051
g7
I2301
sg26
VC0040250
p5052
sg10
I13
sg11
Vtinea capitis
p5053
sg13
I2
sa(dp5054
g7
I1146
sg26
VC0040262
p5055
sg10
I21
sg11
Vpityriasis versicolor
p5056
sg13
I2
sa(dp5057
g7
I981
sg26
VC0333641
p5058
sg10
I8
sg11
Vatrophic
p5059
sg13
I1
sa(dp5060
g7
I2185
sg26
VC0002171
p5061
sg10
I15
sg11
Valopecia areata
p5062
sg13
I2
sa(dp5063
g7
I1475
sg26
VC0268397
p5064
sg10
I18
sg11
Vlichen amyloidosus
p5065
sg13
I2
sa(dp5066
g7
I630
sg26
VC0024138
p5067
sg10
I27
sg11
Vdiscoid lupus erythematosus
p5068
sg13
I3
sa(dp5069
g7
I774
sg26
VC1276092
p5070
sg10
I19
sg11
Vchronic hand eczema
p5071
sg13
I3
sa(dp5072
g7
I2106
sg26
VC1274700
p5073
sg10
I26
sg11
Vfrontal fibrosing alopecia
p5074
sg13
I3
sa(dp5075
g7
I1462
sg26
VC0002726
p5076
sg10
I11
sg11
Vamyloidosis
p5077
sg13
I1
sa(dp5078
g7
I1146
sg26
VC0040262
p5079
sg10
I21
sg11
Vpityriasis versicolor
p5080
sg13
I2
sa(dp5081
g7
I713
sg26
VC0239495
p5082
sg10
I17
sg11
Vgranuloma faciale
p5083
sg13
I2
sa(dp5084
g7
I1988
sg26
VC0154089
p5085
sg10
I24
sg11
Verythroplasia of Queyrat
p5086
sg13
I3
sa(dp5087
g7
I672
sg26
VC0023283
p5088
sg10
I23
sg11
Vcutaneous leishmaniasis
p5089
sg13
I2
sa(dp5090
g7
I0
sg26
VC0037274
p5091
sg10
I10
sg11
Vdermatoses
p5092
sg13
I1
sa(dp5093
g7
I151
sg26
VC0024140
p5094
sg10
I38
sg11
Vsubacute cutaneous lupus erythematosus
p5095
sg13
I4
sa(dp5096
g7
I1570
sg26
VC0263402
p5097
sg10
I42
sg11
Vtelangiectasia macularis eruptiva perstans
p5098
sg13
I4
sa(dp5099
g7
I0
sg26
VC0037274
p5100
sg10
I10
sg11
Vdermatoses
p5101
sg13
I1
sa(dp5102
g7
I607
sg26
VC0036508
p5103
sg10
I21
sg11
Vseborrheic dermatitis
p5104
sg13
I2
sa(dp5105
g7
I1436
sg26
VC0494853
p5106
sg10
I16
sg11
Verythema ab igne
p5107
sg13
I3
sa(dp5108
g7
I77
sg26
VC0033860
p5109
sg10
I9
sg11
Vpsoriasis
p5110
sg13
I1
sa(dp5111
g7
I1702
sg26
VC0036262
p5112
sg10
I7
sg11
Vscabies
p5113
sg13
I1
sa(dp5114
g7
I358
sg26
VC0032027
p5115
sg10
I24
sg11
Vpityriasis rubra pilaris
p5116
sg13
I3
sa(dp5117
g7
I399
sg26
VC0206182
p5118
sg10
I22
sg11
Vlymphomatoid papulosis
p5119
sg13
I2
sa(dp5120
g7
I0
sg26
VC0037274
p5121
sg10
I10
sg11
Vdermatoses
p5122
sg13
I1
sa(dp5123
g7
I1206
sg26
VC0162835
p5124
sg10
I13
sg11
Vhypomelanosis
p5125
sg13
I1
sa(dp5126
g7
I607
sg26
VC0036508
p5127
sg10
I21
sg11
Vseborrheic dermatitis
p5128
sg13
I2
sa(dp5129
g7
I760
sg26
VC0022579
p5130
sg10
I11
sg11
Vkeratoderma
p5131
sg13
I1
sa(dp5132
g7
I1187
sg26
VC0263583
p5133
sg10
I32
sg11
Vidiopathic guttate hypomelanosis
p5134
sg13
I3
sa(dp5135
g7
I1647
sg26
VC0023649
p5136
sg10
I26
sg11
Vhypertrophic lichen planus
p5137
sg13
I3
sa(dp5138
g7
I1358
sg26
VC0406366
p5139
sg10
I25
sg11
Vlichen planus pigmentosus
p5140
sg13
I3
sa(dp5141
g7
I598
sg26
VC0035854
p5142
sg10
I7
sg11
Vrosacea
p5143
sg13
I1
sa(dp5144
g7
I1002
sg26
VC0027538
p5145
sg10
I21
sg11
Vnecrobiosis lipoidica
p5146
sg13
I2
sa(dp5147
g7
I1047
sg26
VC0023652
p5148
sg10
I16
sg11
Vlichen sclerosus
p5149
sg13
I2
sa(dp5150
g7
I2202
sg26
VC0040953
p5151
sg10
I16
sg11
Vtrichotillomania
p5152
sg13
I1
sa(dp5153
g7
I2246
sg26
VC0263518
p5154
sg10
I17
sg11
Vtelogen effluvium
p5155
sg13
I2
sa(dp5156
g7
I111
sg26
VC0032026
p5157
sg10
I16
sg11
Vpityriasis rosea
p5158
sg13
I2
sa(dp5159
g7
I1872
sg26
VC0004690
p5160
sg10
I9
sg11
Vbalanitis
p5161
sg13
I1
sa(dp5162
g7
I760
sg26
VC0022579
p5163
sg10
I11
sg11
Vkeratoderma
p5164
sg13
I1
sa(dp5165
g7
I2085
sg26
VC0023645
p5166
sg10
I19
sg11
Vlichen planopilaris
p5167
sg13
I2
sa(dp5168
g7
I315
sg26
VC0162851
p5169
sg10
I31
sg11
Vpityriasis lichenoides chronica
p5170
sg13
I3
sa(dp5171
g7
I452
sg26
VC0030437
p5172
sg10
I23
sg11
Vparakeratosis variegata
p5173
sg13
I2
sa(dp5174
g7
I2137
sg26
VC0263503
p5175
sg10
I22
sg11
Vfolliculitis decalvans
p5176
sg13
I2
sa(dp5177
g7
I1615
sg26
VC0033774
p5178
sg10
I5
sg11
Vitchy
p5179
sg13
I1
sa(dp5180
g7
I235
sg26
VC0023646
p5181
sg10
I13
sg11
Vlichen planus
p5182
sg13
I2
sa(dp5183
g7
I129
sg26
VC0026948
p5184
sg10
I17
sg11
Vmycosis fungoides
p5185
sg13
I2
sa(dp5186
g7
I548
sg26
VC0334061
p5187
sg10
I12
sg11
Vdyskeratosis
p5188
sg13
I1
sa(dp5189
g7
I358
sg26
VC0032027
p5190
sg10
I24
sg11
Vpityriasis rubra pilaris
p5191
sg13
I3
sa(dp5192
g7
I1385
sg26
VC0263385
p5193
sg10
I26
sg11
VGougerot-Carteaud syndrome
p5194
sg13
I2
sa(dp5195
g7
I2220
sg26
VC0162311
p5196
sg10
I21
sg11
Vandrogenetic alopecia
p5197
sg13
I2
sa(dp5198
g7
I484
sg26
VC0022595
p5199
sg10
I15
sg11
Vdisease, Darier
p5200
sg13
I2
sa(dp5201
g7
I1545
sg26
VC0042111
p5202
sg10
I20
sg11
Vurticaria pigmentosa
p5203
sg13
I2
sa(dp5204
g7
I1872
sg26
VC0004690
p5205
sg10
I9
sg11
Vbalanitis
p5206
sg13
I1
sa(dp5207
g7
I438
sg26
VC0867389
p5208
sg10
I12
sg11
Vchronic GVHD
p5209
sg13
I2
sa(dp5210
g7
I697
sg26
VC0024131
p5211
sg10
I14
sg11
Vlupus vulgaris
p5212
sg13
I2
sa(dp5213
g7
I384
sg26
VC0162839
p5214
sg10
I13
sg11
Vporokeratosis
p5215
sg13
I1
sa(dp5216
g7
I904
sg26
VC0153246
p5217
sg10
I12
sg11
Vtinea manuum
p5218
sg13
I2
sa(dp5219
g7
I70
sg26
VC0406317
p5220
sg10
I16
sg11
Vplaque psoriasis
p5221
sg13
I2
sa(dp5222
g7
I1675
sg26
VC0263353
p5223
sg10
I17
sg11
Vprurigo nodularis
p5224
sg13
I2
sa(dp5225
g7
I1781
sg26
VC0011615
p5226
sg10
I17
sg11
Vatopic dermatitis
p5227
sg13
I2
sa(dp5228
g7
I1748
sg26
VC0011606
p5229
sg10
I13
sg11
Verythrodermas
p5230
sg13
I1
sa(dp5231
g7
I583
sg26
VC0037274
p5232
sg10
I13
sg11
Vskin diseases
p5233
sg13
I2
sa(dp5234
g7
I2359
sg26
VC0343100
p5235
sg10
I21
sg11
Vpityriasis amiantacea
p5236
sg13
I2
sa(dp5237
g7
I283
sg26
VC0036202
p5238
sg10
I11
sg11
Vsarcoidosis
p5239
sg13
I1
sa(dp5240
g7
I1515
sg26
VC2721650
p5241
sg10
I28
sg11
Vterra firma-forme dermatosis
p5242
sg13
I3
sa(dp5243
g7
I111
sg26
VC0032026
p5244
sg10
I16
sg11
Vpityriasis rosea
p5245
sg13
I2
sa(dp5246
g7
I630
sg26
VC0024138
p5247
sg10
I27
sg11
Vdiscoid lupus erythematosus
p5248
sg13
I3
sa(dp5249
g7
I1210
sg26
VC0221391
p5250
sg10
I9
sg11
Vmelanosis
p5251
sg13
I1
sa(dp5252
g7
I61
sg26
VC0333463
p5253
sg10
I7
sg11
Vplaques
p5254
sg13
I1
sa(dp5255
g7
I129
sg26
VC0026948
p5256
sg10
I17
sg11
Vmycosis fungoides
p5257
sg13
I2
sa(dp5258
g7
I1890
sg26
VC0403761
p5259
sg10
I21
sg11
Vplasma cell balanitis
p5260
sg13
I3
sa(dp5261
g7
I296
sg26
VC0343052
p5262
sg10
I17
sg11
Vguttate psoriasis
p5263
sg13
I2
sa(dp5264
g7
I760
sg26
VC0022579
p5265
sg10
I11
sg11
Vkeratoderma
p5266
sg13
I1
sa(dp5267
g7
I1872
sg26
VC0004690
p5268
sg10
I9
sg11
Vbalanitis
p5269
sg13
I1
sa(dp5270
g7
I760
sg26
VC0022579
p5271
sg10
I12
sg11
Vkeratodermas
p5272
sg13
I1
sasa(dp5273
g2
S'Kaposi varicelliform eruption or eczema herpeticum is well known to be associated with several chronic dermatoses, including atopic dermatitis, foliaceus pemphigus, seborrheic dermatitis, Darier disease, and congenital ichthyosiform erythroderma.\n'
p5274
sg4
(lp5275
sg23
(lp5276
(dp5277
g7
I208
sg26
VC0079583
p5278
sg10
I37
sg11
Vcongenital ichthyosiform erythroderma
p5279
sg13
I3
sa(dp5280
g7
I0
sg26
VC0022504
p5281
sg10
I29
sg11
VKaposi varicelliform eruption
p5282
sg13
I3
sa(dp5283
g7
I165
sg26
VC0036508
p5284
sg10
I21
sg11
Vseborrheic dermatitis
p5285
sg13
I2
sa(dp5286
g7
I188
sg26
VC0022595
p5287
sg10
I14
sg11
VDarier disease
p5288
sg13
I2
sa(dp5289
g7
I154
sg26
VC0030807
p5290
sg10
I9
sg11
Vpemphigus
p5291
sg13
I1
sa(dp5292
g7
I103
sg26
VC0037274
p5293
sg10
I10
sg11
Vdermatoses
p5294
sg13
I1
sa(dp5295
g7
I33
sg26
VC0936250
p5296
sg10
I17
sg11
Veczema herpeticum
p5297
sg13
I2
sa(dp5298
g7
I125
sg26
VC0011615
p5299
sg10
I17
sg11
Vatopic dermatitis
p5300
sg13
I2
sasa(dp5301
g2
S'MCI-186, a dose that prevents ischemic brain edema, had no significant effect on brain concentrations of dopamine, norepinephrine, 5-hydroxytryptamine, or their metabolites.\n'
p5302
sg4
(lp5303
sg23
(lp5304
(dp5305
g7
I39
sg26
VC1527311
p5306
sg10
I11
sg11
Vbrain edema
p5307
sg13
I2
sa(dp5308
g7
I0
sg26
VC1270972
p5309
sg10
I3
sg11
VMCI
p5310
sg13
I1
sasa(dp5311
g2
S'Pretreatments with dexamethasone, parachlorophenylalanine (an inhibitor of 5-hydroxytryptamine synthesis), mepyramine and metiamide (H1 and H2 histamine receptor antagonists) or aminophylline did not influence significantly the development of brain edema evaluated 24 h after embolization.\n'
p5312
sg4
(lp5313
(dp5314
g7
I140
sg8
g107
sg10
I21
sg11
VH2 histamine receptor
p5315
sg13
I3
sasg23
(lp5316
(dp5317
g7
I243
sg26
VC1527311
p5318
sg10
I11
sg11
Vbrain edema
p5319
sg13
I2
sasa(dp5320
g2
S'To study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.\n'
p5321
sg4
(lp5322
(dp5323
g7
I61
sg8
g107
sg10
I6
sg11
VBlimp1
p5324
sg13
I1
sa(dp5325
g7
I44
sg8
VP17980
p5326
sg10
I16
sg11
Vmature protein-1
p5327
sg13
I2
sasg23
(lp5328
(dp5329
g7
I147
sg26
VC0026764
p5330
sg10
I16
sg11
Vmultiple myeloma
p5331
sg13
I2
sasa(dp5332
g2
S'Here we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC.\n'
p5333
sg4
(lp5334
(dp5335
g7
I64
sg8
g107
sg10
I4
sg11
VEZH2
p5336
sg13
I1
sa(dp5337
g7
I187
sg8
VP17861
p5338
sg10
I5
sg11
VXBP-1
p5339
sg13
I1
sa(dp5340
g7
I64
sg8
g107
sg10
I4
sg11
VEZH2
p5341
sg13
I1
sa(dp5342
g7
I194
sg8
g107
sg10
I5
sg11
VPRDM1
p5343
sg13
I1
sa(dp5344
g7
I212
sg8
VP12524
p5345
sg10
I5
sg11
Vc-MYC
p5346
sg13
I1
sa(dp5347
g7
I200
sg8
g107
sg10
I7
sg11
VBLIMP-1
p5348
sg13
I1
sa(dp5349
g7
I180
sg8
g107
sg10
I5
sg11
VIRF-4
p5350
sg13
I1
sasg23
(lp5351
(dp5352
g7
I33
sg26
VC0026764
p5353
sg10
I7
sg11
Vmyeloma
p5354
sg13
I1
sasa(dp5355
g2
S'To investigate the expression level of B lymphocyte-induced maturation protein-1(Blimp-1) mRNA in bone marrow mononuclear cells(BMMNC) of multiple myeloma(MM) patients and its clinical significance.\n'
p5356
sg4
(lp5357
(dp5358
g7
I60
sg8
VP17980
p5359
sg10
I20
sg11
Vmaturation protein-1
p5360
sg13
I2
sasg23
(lp5361
(dp5362
g7
I138
sg26
VC0026764
p5363
sg10
I16
sg11
Vmultiple myeloma
p5364
sg13
I2
sasa(dp5365
g2
S'Meanwhile, plasma could promote myeloma differentiation by up-regulating Blimp-1 and XBP-1 expression.\n'
p5366
sg4
(lp5367
(dp5368
g7
I85
sg8
VP17861
p5369
sg10
I5
sg11
VXBP-1
p5370
sg13
I1
sa(dp5371
g7
I73
sg8
g107
sg10
I7
sg11
VBlimp-1
p5372
sg13
I1
sasg23
(lp5373
(dp5374
g7
I32
sg26
VC0026764
p5375
sg10
I7
sg11
Vmyeloma
p5376
sg13
I1
sasa(dp5377
g2
S'However, how Blimp-1 ensures the survival of plasma cell malignancy, multiple myeloma (MM), has remained elusive.\n'
p5378
sg4
(lp5379
sg23
(lp5380
(dp5381
g7
I57
sg26
VC0006826
p5382
sg10
I10
sg11
Vmalignancy
p5383
sg13
I1
sa(dp5384
g7
I69
sg26
VC0026764
p5385
sg10
I16
sg11
Vmultiple myeloma
p5386
sg13
I2
sasa(dp5387
g2
S'The finding that Blimp-1/PRDM1 enhances transcription of CS1 gene in multiple myeloma cells may help in developing novel strategies for therapeutic intervention in multiple myeloma.\n'
p5388
sg4
(lp5389
(dp5390
g7
I57
sg8
g107
sg10
I8
sg11
VCS1 gene
p5391
sg13
I2
sa(dp5392
g7
I17
sg8
g107
sg10
I7
sg11
VBlimp-1
p5393
sg13
I1
sa(dp5394
g7
I25
sg8
g107
sg10
I5
sg11
VPRDM1
p5395
sg13
I1
sasg23
(lp5396
(dp5397
g7
I69
sg26
VC0026764
p5398
sg10
I16
sg11
Vmultiple myeloma
p5399
sg13
I2
sa(dp5400
g7
I69
sg26
VC0026764
p5401
sg10
I16
sg11
Vmultiple myeloma
p5402
sg13
I2
sasa(dp5403
g2
S'Lhx9 is an LIM (named for the first three proteins in which the domain was found, Lin-11, Isl1 and Mec-3) homeodomain protein involved in development and differentiation of the gonad.\n'
p5404
sg4
(lp5405
(dp5406
g7
I106
sg8
g107
sg10
I11
sg11
Vhomeodomain
p5407
sg13
I1
sa(dp5408
g7
I99
sg8
g107
sg10
I5
sg11
VMec-3
p5409
sg13
I1
sa(dp5410
g7
I11
sg8
g107
sg10
I3
sg11
VLIM
p5411
sg13
I1
sa(dp5412
g7
I90
sg8
VP61371
p5413
sg10
I4
sg11
VIsl1
p5414
sg13
I1
sa(dp5415
g7
I0
sg8
g107
sg10
I4
sg11
VLhx9
p5416
sg13
I1
sasg23
(lp5417
sa(dp5418
g2
S'We report that CCRL2-deficient mice have a defect in neutrophil recruitment and are protected in 2 models of inflammatory arthritis.\n'
p5419
sg4
(lp5420
(dp5421
g7
I15
sg8
g107
sg10
I5
sg11
VCCRL2
p5422
sg13
I1
sasg23
(lp5423
(dp5424
g7
I64
sg26
VC0271510
p5425
sg10
I11
sg11
Vrecruitment
p5426
sg13
I1
sa(dp5427
g7
I109
sg26
VC0003864
p5428
sg10
I22
sg11
Vinflammatory arthritis
p5429
sg13
I2
sasa(dp5430
g2
S'The concurrence of PJS and feminizing SCTs of the testes is an increasingly recognized cause of prepubertal gynecomastia.\n'
p5431
sg4
(lp5432
(dp5433
g7
I19
sg8
g107
sg10
I23
sg11
VPJS and feminizing SCTs
p5434
sg13
I4
sasg23
(lp5435
(dp5436
g7
I38
sg26
VC0796149
p5437
sg10
I4
sg11
VSCTs
p5438
sg13
I1
sa(dp5439
g7
I108
sg26
VC0018418
p5440
sg10
I12
sg11
Vgynecomastia
p5441
sg13
I1
sa(dp5442
g7
I19
sg26
VC0031269
p5443
sg10
I3
sg11
VPJS
p5444
sg13
I1
sasa(dp5445
g2
S'Most IgAD and CVID patients in our clinic population in the Southeastern United States have inherited part or all of two extended MHC haplotypes, referred to as haplotype 1 (HLA-DQB1 0201, HLA-DR3, C4B-Sf, C4A-0, G1-15, Bf-0.4, C2-a, HSP-7.5, TNF alpha-5, HLA-B8, HLA-A1) and haplotype 2 (HLA-DQB1 0201, HLA-DR-7, C4B-S, C4A-L, G11-4.5, Bf-0.6, C2-b, HSP-9, TNF alpha-9, HLA-B44, HLA-A29).\n'
p5446
sg4
(lp5447
(dp5448
g7
I371
sg8
VP30486
p5449
sg10
I7
sg11
VHLA-B44
p5450
sg13
I1
sa(dp5451
g7
I243
sg8
VP01375
p5452
sg10
I11
sg11
VTNF alpha-5
p5453
sg13
I2
sa(dp5454
g7
I351
sg8
g107
sg10
I5
sg11
VHSP-9
p5455
sg13
I1
sa(dp5456
g7
I358
sg8
VP01375
p5457
sg10
I11
sg11
VTNF alpha-9
p5458
sg13
I2
sa(dp5459
g7
I174
sg8
VP09471
p5460
sg10
I13
sg11
VHLA-DQB1 0201
p5461
sg13
I2
sa(dp5462
g7
I380
sg8
VP30486
p5463
sg10
I7
sg11
VHLA-A29
p5464
sg13
I1
sa(dp5465
g7
I130
sg8
VP13747
p5466
sg10
I14
sg11
VMHC haplotypes
p5467
sg13
I2
sa(dp5468
g7
I198
sg8
VP04003
p5469
sg10
I3
sg11
VC4B
p5470
sg13
I1
sa(dp5471
g7
I189
sg8
VP30486
p5472
sg10
I7
sg11
VHLA-DR3
p5473
sg13
I1
sa(dp5474
g7
I198
sg8
VP04003
p5475
sg10
I5
sg11
VC4B-S
p5476
sg13
I1
sa(dp5477
g7
I234
sg8
g107
sg10
I7
sg11
VHSP-7.5
p5478
sg13
I1
sa(dp5479
g7
I304
sg8
VP30486
p5480
sg10
I8
sg11
VHLA-DR-7
p5481
sg13
I1
sa(dp5482
g7
I256
sg8
VP30486
p5483
sg10
I6
sg11
VHLA-B8
p5484
sg13
I1
sa(dp5485
g7
I174
sg8
VP09471
p5486
sg10
I13
sg11
VHLA-DQB1 0201
p5487
sg13
I2
sa(dp5488
g7
I328
sg8
VP56715
p5489
sg10
I7
sg11
VG11-4.5
p5490
sg13
I1
sasg23
(lp5491
(dp5492
g7
I234
sg26
VC0034152
p5493
sg10
I3
sg11
VHSP
p5494
sg13
I1
sa(dp5495
g7
I234
sg26
VC0034152
p5496
sg10
I3
sg11
VHSP
p5497
sg13
I1
sa(dp5498
g7
I14
sg26
VC0009447
p5499
sg10
I4
sg11
VCVID
p5500
sg13
I1
sasa(dp5501
g2
S'In search of a genetic linkage between the two immunodeficiencies, we examined the major histocompatibility complex (MHC) class III genes encoding complement components C2, C4A, and C4B and steroid 21-hydroxylase in addition to the HLA serotypes in individuals with either common variable immunodeficiency or IgA deficiency.\n'
p5502
sg4
(lp5503
(dp5504
g7
I232
sg8
VP30486
p5505
sg10
I3
sg11
VHLA
p5506
sg13
I1
sa(dp5507
g7
I309
sg8
VP11912
p5508
sg10
I3
sg11
VIgA
p5509
sg13
I1
sa(dp5510
g7
I182
sg8
VP04003
p5511
sg10
I3
sg11
VC4B
p5512
sg13
I1
sa(dp5513
g7
I190
sg8
VP08686
p5514
sg10
I22
sg11
Vsteroid 21-hydroxylase
p5515
sg13
I2
sa(dp5516
g7
I83
sg8
g107
sg10
I74
sg11
Vmajor histocompatibility complex (MHC) class III genes encoding complement
p5517
sg13
I9
sasg23
(lp5518
(dp5519
g7
I47
sg26
VC0021051
p5520
sg10
I18
sg11
Vimmunodeficiencies
p5521
sg13
I1
sa(dp5522
g7
I273
sg26
VC0009447
p5523
sg10
I32
sg11
Vcommon variable immunodeficiency
p5524
sg13
I3
sa(dp5525
g7
I309
sg26
VC0162538
p5526
sg10
I14
sg11
VIgA deficiency
p5527
sg13
I2
sasa(dp5528
g2
S'Twelve of 19 patients with common variable immunodeficiency (63%, P less than 0.001) and 9 of 16 patients with IgA deficiency (56%, P less than 0.01) had rare C2 alleles and/or C4A and 21-hydroxylase A deletions, whereas these gene features were seen in only 5 of 34 healthy individuals (15%) in the control group.\n'
p5529
sg4
(lp5530
(dp5531
g7
I185
sg8
VP08686
p5532
sg10
I16
sg11
V21-hydroxylase A
p5533
sg13
I2
sa(dp5534
g7
I111
sg8
VP11912
p5535
sg10
I3
sg11
VIgA
p5536
sg13
I1
sasg23
(lp5537
(dp5538
g7
I27
sg26
VC0009447
p5539
sg10
I32
sg11
Vcommon variable immunodeficiency
p5540
sg13
I3
sa(dp5541
g7
I111
sg26
VC0162538
p5542
sg10
I14
sg11
VIgA deficiency
p5543
sg13
I2
sasa(dp5544
g2
S'Totally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.)'
p5545
sg4
(lp5546
sg23
(lp5547
(dp5548
g7
I107
sg26
VC0006826
p5549
sg10
I6
sg11
Vcancer
p5550
sg13
I1
sa(dp5551
g7
I55
sg26
VC0021311
p5552
sg10
I10
sg11
Vinfections
p5553
sg13
I1
sasa(dp5554
g2
S'Furthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer.\n'
p5555
sg4
(lp5556
sg23
(lp5557
(dp5558
g7
I117
sg26
VC0006826
p5559
sg10
I6
sg11
Vcancer
p5560
sg13
I1
sasa(dp5561
g2
S'Liver sections from patients with biliary atresia were evaluated to detect antigen for the BECs marker 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblasts marker a-smooth muscle actin (a-SMA).\n'
p5562
sg4
(lp5563
(dp5564
g7
I124
sg8
VP14222
p5565
sg10
I46
sg11
VCK-7), proteins (fibroblast-specific protein 1
p5566
sg13
I5
sa(dp5567
g7
I109
sg8
VP08729
p5568
sg10
I13
sg11
Vcytokeratin-7
p5569
sg13
I1
sa(dp5570
g7
I237
sg8
VP50454
p5571
sg10
I5
sg11
VHSP47
p5572
sg13
I1
sa(dp5573
g7
I195
sg8
VP34931
p5574
sg10
I40
sg11
Vcollagen chaperone heat shock protein 47
p5575
sg13
I6
sa(dp5576
g7
I183
sg8
VP26447
p5577
sg10
I6
sg11
VS100A4
p5578
sg13
I1
sa(dp5579
g7
I354
sg8
g107
sg10
I5
sg11
Va-SMA
p5580
sg13
I1
sa(dp5581
g7
I331
sg8
g107
sg10
I21
sg11
Va-smooth muscle actin
p5582
sg13
I3
sasg23
(lp5583
(dp5584
g7
I34
sg26
VC0005411
p5585
sg10
I15
sg11
Vbiliary atresia
p5586
sg13
I2
sa(dp5587
g7
I356
sg26
VC0026847
p5588
sg10
I3
sg11
VSMA
p5589
sg13
I1
sasa(dp5590
g2
S'However, BECs from biliary atresia resulted in increased expression of a-SMA, S100A4, with concurrent transition to a fibroblast-like morphology and decreased expression of AK-7.\n'
p5591
sg4
(lp5592
(dp5593
g7
I173
sg8
VP55263
p5594
sg10
I4
sg11
VAK-7
p5595
sg13
I1
sa(dp5596
g7
I78
sg8
VP26447
p5597
sg10
I6
sg11
VS100A4
p5598
sg13
I1
sa(dp5599
g7
I73
sg8
g107
sg10
I3
sg11
VSMA
p5600
sg13
I1
sasg23
(lp5601
(dp5602
g7
I102
sg26
VC0599156
p5603
sg10
I10
sg11
Vtransition
p5604
sg13
I1
sa(dp5605
g7
I19
sg26
VC0005411
p5606
sg10
I15
sg11
Vbiliary atresia
p5607
sg13
I2
sa(dp5608
g7
I73
sg26
VC0026847
p5609
sg10
I3
sg11
VSMA
p5610
sg13
I1
sasa(dp5611
g2
S'Consequently, there has been considerable interest in the pharmaceutical industry to develop selective TPL-2 inhibitors as drugs for the treatment of TNF-dependent inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.\n'
p5612
sg4
(lp5613
(dp5614
g7
I150
sg8
VP01375
p5615
sg10
I3
sg11
VTNF
p5616
sg13
I1
sa(dp5617
g7
I103
sg8
VP41279
p5618
sg10
I5
sg11
VTPL-2
p5619
sg13
I1
sasg23
(lp5620
(dp5621
g7
I220
sg26
VC0021390
p5622
sg10
I26
sg11
Vinflammatory bowel disease
p5623
sg13
I3
sa(dp5624
g7
I195
sg26
VC0003873
p5625
sg10
I20
sg11
Vrheumatoid arthritis
p5626
sg13
I2
sasa(dp5627
g2
S'Thus, pharmacologic inhibition of Tpl2 should be a valid approach to therapeutic intervention in the pathogenesis of rheumatoid arthritis and other inflammatory diseases in humans.\n'
p5628
sg4
(lp5629
(dp5630
g7
I34
sg8
VP41279
p5631
sg10
I4
sg11
VTpl2
p5632
sg13
I1
sasg23
(lp5633
(dp5634
g7
I117
sg26
VC0003873
p5635
sg10
I20
sg11
Vrheumatoid arthritis
p5636
sg13
I2
sa(dp5637
g7
I101
sg26
VC0699748
p5638
sg10
I12
sg11
Vpathogenesis
p5639
sg13
I1
sasa(dp5640
g2
S'Taken together, our results show that inhibition of Tpl2 in primary human cell types can decrease the production of TNFalpha and other pro-inflammatory mediators during inflammatory events, and they further support the notion that Tpl2 is an appropriate therapeutic target for rheumatoid arthritis and other human inflammatory diseases.\n'
p5641
sg4
(lp5642
(dp5643
g7
I116
sg8
VP01375
p5644
sg10
I8
sg11
VTNFalpha
p5645
sg13
I1
sa(dp5646
g7
I52
sg8
VP41279
p5647
sg10
I4
sg11
VTpl2
p5648
sg13
I1
sa(dp5649
g7
I52
sg8
VP41279
p5650
sg10
I4
sg11
VTpl2
p5651
sg13
I1
sasg23
(lp5652
(dp5653
g7
I277
sg26
VC0003873
p5654
sg10
I20
sg11
Vrheumatoid arthritis
p5655
sg13
I2
sasa(dp5656
g2
S'Recent studies using Tpl2 knockout mice have indicated an important role for Tpl2 in the lipopolysaccharide (LPS) induced production of tumor necrosis factor alpha (TNF-alpha) and other proinflammatory cytokines involved in diseases such as rheumatoid arthritis.\n'
p5657
sg4
(lp5658
(dp5659
g7
I136
sg8
VP01375
p5660
sg10
I27
sg11
Vtumor necrosis factor alpha
p5661
sg13
I4
sa(dp5662
g7
I21
sg8
VP41279
p5663
sg10
I4
sg11
VTpl2
p5664
sg13
I1
sa(dp5665
g7
I21
sg8
VP41279
p5666
sg10
I4
sg11
VTpl2
p5667
sg13
I1
sa(dp5668
g7
I165
sg8
VP01375
p5669
sg10
I9
sg11
VTNF-alpha
p5670
sg13
I1
sasg23
(lp5671
(dp5672
g7
I136
sg26
VC0333516
p5673
sg10
I14
sg11
Vtumor necrosis
p5674
sg13
I2
sa(dp5675
g7
I89
sg26
VC0175697
p5676
sg10
I18
sg11
Vlipopolysaccharide
p5677
sg13
I1
sa(dp5678
g7
I109
sg26
VC0175697
p5679
sg10
I3
sg11
VLPS
p5680
sg13
I1
sa(dp5681
g7
I241
sg26
VC0003873
p5682
sg10
I20
sg11
Vrheumatoid arthritis
p5683
sg13
I2
sasa(dp5684
g2
S'In all, 78.08% had stage 1 HTN while 22% had stage 2 HTN.\n'
p5685
sg4
(lp5686
sg23
(lp5687
(dp5688
g7
I27
sg26
VC0020538
p5689
sg10
I3
sg11
VHTN
p5690
sg13
I1
sa(dp5691
g7
I27
sg26
VC0020538
p5692
sg10
I3
sg11
VHTN
p5693
sg13
I1
sasa(dp5694
g2
S'Moreover, ba-PWV showed a significant increase with increasing plasma tHcy level in subjects with both high normal BP and grade 1 HTN (p &lt; 0.05).\n'
p5695
sg4
(lp5696
sg23
(lp5697
(dp5698
g7
I130
sg26
VC0020538
p5699
sg10
I3
sg11
VHTN
p5700
sg13
I1
sasa(dp5701
g2
S'Compared with optimal BP stage, ba-PWV was significantly associated with high normal BP stage (Beta = 193, p &lt; 0.001) and grade 1 HTN (Beta = 413, p &lt; 0.001).There was a statistical interaction effect between high normal BP stage and optimal BP stage (p = 0.045).\n'
p5702
sg4
(lp5703
sg23
(lp5704
(dp5705
g7
I133
sg26
VC0020538
p5706
sg10
I3
sg11
VHTN
p5707
sg13
I1
sasa(dp5708
g2
S'The similar result was found between subjects with optimal BP and those with grade 1 HTN (p = 0.037).\n'
p5709
sg4
(lp5710
sg23
(lp5711
(dp5712
g7
I85
sg26
VC0020538
p5713
sg10
I3
sg11
VHTN
p5714
sg13
I1
sasa(dp5715
g2
S'In conclusion, tHcy was independently correlated with ba-PWV in subjects with high normal BP and grade 1 HTN.\n'
p5716
sg4
(lp5717
sg23
(lp5718
(dp5719
g7
I105
sg26
VC0020538
p5720
sg10
I3
sg11
VHTN
p5721
sg13
I1
sasa(dp5722
g2
S'High normal BP and grade 1 HTN may worsen the impact of tHcy on arterial stiffness in a Chinese rural community population.\n'
p5723
sg4
(lp5724
sg23
(lp5725
(dp5726
g7
I73
sg26
VC0427008
p5727
sg10
I9
sg11
Vstiffness
p5728
sg13
I1
sa(dp5729
g7
I27
sg26
VC0020538
p5730
sg10
I3
sg11
VHTN
p5731
sg13
I1
sasa(dp5732
g2
S'NpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA, ocTpoN oKKnh3NeN BHyTpeHHeN coHHoN apTepNN.\n'
p5733
sg4
(lp5734
(dp5735
g7
I0
sg8
VP05452
p5736
sg10
I149
sg11
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA
p5737
sg13
I17
sasg23
(lp5738
sa(dp5739
g2
S'The upper bound of a 95% confidence interval for the difference in prevalence of Stage 1 and 2 HTN between study arms indicates that discontinuation of study medication is unlikely to be associated with an increase in Stage 1 HTN of &gt;4.8 percentage points and in Stage 2 HTN of no &gt;5.8 percentage points.\n'
p5740
sg4
(lp5741
sg23
(lp5742
(dp5743
g7
I95
sg26
VC0020538
p5744
sg10
I3
sg11
VHTN
p5745
sg13
I1
sa(dp5746
g7
I113
sg26
VC0206655
p5747
sg10
I4
sg11
Varms
p5748
sg13
I1
sa(dp5749
g7
I95
sg26
VC0020538
p5750
sg10
I3
sg11
VHTN
p5751
sg13
I1
sa(dp5752
g7
I95
sg26
VC0020538
p5753
sg10
I3
sg11
VHTN
p5754
sg13
I1
sasa(dp5755
g2
S'Target genes (e.g., cyclin-dependent kinase 6) of hsa-miR-942-5p were mainly enriched in cancer-related pathways, whereas target genes (e.g., CRK-Like Proto-Oncogene, Adaptor Protein) of hsa-miR-940 were enriched in the ErbB signaling pathway.\n'
p5756
sg4
(lp5757
(dp5758
g7
I142
sg8
VP46108
p5759
sg10
I40
sg11
VCRK-Like Proto-Oncogene, Adaptor Protein
p5760
sg13
I4
sa(dp5761
g7
I187
sg8
g107
sg10
I11
sg11
Vhsa-miR-940
p5762
sg13
I1
sa(dp5763
g7
I50
sg8
g107
sg10
I14
sg11
Vhsa-miR-942-5p
p5764
sg13
I1
sa(dp5765
g7
I220
sg8
g107
sg10
I4
sg11
VErbB
p5766
sg13
I1
sa(dp5767
g7
I20
sg8
g107
sg10
I25
sg11
Vcyclin-dependent kinase 6
p5768
sg13
I3
sasg23
(lp5769
(dp5770
g7
I89
sg26
VC0006826
p5771
sg10
I6
sg11
Vcancer
p5772
sg13
I1
sa(dp5773
g7
I50
sg26
VC0393754
p5774
sg10
I3
sg11
Vhsa
p5775
sg13
I1
sa(dp5776
g7
I50
sg26
VC0393754
p5777
sg10
I3
sg11
Vhsa
p5778
sg13
I1
sasa(dp5779
g2
S'Herein, we demonstrated that hypoxia induces the high expression of microRNA-940 (miR-940) in exosomes derived from epithelial ovarian cancer (EOC).\n'
p5780
sg4
(lp5781
sg23
(lp5782
(dp5783
g7
I143
sg26
VC0677886
p5784
sg10
I3
sg11
VEOC
p5785
sg13
I1
sa(dp5786
g7
I29
sg26
VC0242184
p5787
sg10
I7
sg11
Vhypoxia
p5788
sg13
I1
sa(dp5789
g7
I116
sg26
VC0677886
p5790
sg10
I25
sg11
Vepithelial ovarian cancer
p5791
sg13
I3
sasa(dp5792
g2
S'Results: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).\n'
p5793
sg4
(lp5794
(dp5795
g7
I24
sg8
g107
sg10
I3
sg11
Vhsa
p5796
sg13
I1
sa(dp5797
g7
I38
sg8
g107
sg10
I11
sg11
Vhsa-mir-149
p5798
sg13
I1
sa(dp5799
g7
I51
sg8
g107
sg10
I11
sg11
Vhsa-mir-744
p5800
sg13
I1
sa(dp5801
g7
I24
sg8
g107
sg10
I12
sg11
Vhsa-mir-1180
p5802
sg13
I1
sasg23
(lp5803
(dp5804
g7
I24
sg26
VC0393754
p5805
sg10
I3
sg11
Vhsa
p5806
sg13
I1
sa(dp5807
g7
I24
sg26
VC0393754
p5808
sg10
I3
sg11
Vhsa
p5809
sg13
I1
sa(dp5810
g7
I24
sg26
VC0393754
p5811
sg10
I3
sg11
Vhsa
p5812
sg13
I1
sa(dp5813
g7
I24
sg26
VC0393754
p5814
sg10
I3
sg11
Vhsa
p5815
sg13
I1
sa(dp5816
g7
I109
sg26
VC2699153
p5817
sg10
I8
sg11
Vinvasion
p5818
sg13
I1
sa(dp5819
g7
I190
sg26
VC1512411
p5820
sg10
I24
sg11
Vhepatocellular carcinoma
p5821
sg13
I2
sa(dp5822
g7
I109
sg26
VC2699153
p5823
sg10
I8
sg11
Vinvasion
p5824
sg13
I1
sasa(dp5825
g2
S'Results from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).\n'
p5826
sg4
(lp5827
(dp5828
g7
I47
sg8
g107
sg10
I3
sg11
Vhsa
p5829
sg13
I1
sa(dp5830
g7
I47
sg8
g107
sg10
I3
sg11
Vhsa
p5831
sg13
I1
sa(dp5832
g7
I47
sg8
g107
sg10
I3
sg11
Vhsa
p5833
sg13
I1
sasg23
(lp5834
(dp5835
g7
I47
sg26
VC0393754
p5836
sg10
I3
sg11
Vhsa
p5837
sg13
I1
sa(dp5838
g7
I47
sg26
VC0393754
p5839
sg10
I3
sg11
Vhsa
p5840
sg13
I1
sa(dp5841
g7
I266
sg26
VC1512411
p5842
sg10
I24
sg11
Vhepatocellular carcinoma
p5843
sg13
I2
sa(dp5844
g7
I47
sg26
VC0393754
p5845
sg10
I3
sg11
Vhsa
p5846
sg13
I1
sasa(dp5847
g2
S'Conclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.\n'
p5848
sg4
(lp5849
(dp5850
g7
I57
sg8
g107
sg10
I12
sg11
Vhsa-mir-1180
p5851
sg13
I1
sa(dp5852
g7
I71
sg8
g107
sg10
I11
sg11
Vhsa-mir-149
p5853
sg13
I1
sa(dp5854
g7
I84
sg8
g107
sg10
I11
sg11
Vhsa-mir-744
p5855
sg13
I1
sa(dp5856
g7
I57
sg8
g107
sg10
I3
sg11
Vhsa
p5857
sg13
I1
sasg23
(lp5858
(dp5859
g7
I57
sg26
VC0393754
p5860
sg10
I3
sg11
Vhsa
p5861
sg13
I1
sa(dp5862
g7
I156
sg26
VC1512411
p5863
sg10
I24
sg11
Vhepatocellular carcinoma
p5864
sg13
I2
sa(dp5865
g7
I156
sg26
VC1512411
p5866
sg10
I24
sg11
Vhepatocellular carcinoma
p5867
sg13
I2
sa(dp5868
g7
I57
sg26
VC0393754
p5869
sg10
I3
sg11
Vhsa
p5870
sg13
I1
sa(dp5871
g7
I57
sg26
VC0393754
p5872
sg10
I3
sg11
Vhsa
p5873
sg13
I1
sa(dp5874
g7
I57
sg26
VC0393754
p5875
sg10
I3
sg11
Vhsa
p5876
sg13
I1
sasa(dp5877
g2
S'### ###GEO (Gene Expression Omnibus) #TCGA (The Cancer Genome Atlas) #####, ###########microRNA, ############ ### ##GEO###########microRNA#### (GSE67140) , #5########### (SNU423#SNU449#HepG2#Hep3B#SNU398) #########, ##81############91#######################TCGA####362############, ##microRNA########GO#KEGG### ### hsa-mir-1180#hsa-mir-149#hsa-mir-744#hsa-mir-940########################### (logFC&gt;1, P&lt;0.05) #######, hsa-mir-1180 (HR=1.623, 95%CI#1.114~2.365, P=0.012) #hsa-mir-149 (HR=2.400, 95% CI#1.639~3.514, P&lt;0.001) #hsa-mir-744 (HR=1.679, 95%CI#1.161~2.427, P=0.006) #hsa-mir-940 (HR=1.704, 95%CI#1.188~2.443, P=0.004) #############, ############### (P&lt;0.05) #GO#KEGG############################## ### ###TCGA#GEO######, ####hsa-mir-1180#hsa-mir-149#hsa-mir-744#hsa-mir-940#########, ##############.\n'
p5878
sg4
(lp5879
(dp5880
g7
I315
sg8
g107
sg10
I3
sg11
Vhsa
p5881
sg13
I1
sa(dp5882
g7
I315
sg8
g107
sg10
I3
sg11
Vhsa
p5883
sg13
I1
sa(dp5884
g7
I315
sg8
g107
sg10
I3
sg11
Vhsa
p5885
sg13
I1
sasg23
(lp5886
(dp5887
g7
I315
sg26
VC0393754
p5888
sg10
I3
sg11
Vhsa
p5889
sg13
I1
sa(dp5890
g7
I315
sg26
VC0393754
p5891
sg10
I3
sg11
Vhsa
p5892
sg13
I1
sa(dp5893
g7
I315
sg26
VC0393754
p5894
sg10
I3
sg11
Vhsa
p5895
sg13
I1
sa(dp5896
g7
I315
sg26
VC0393754
p5897
sg10
I3
sg11
Vhsa
p5898
sg13
I1
sa(dp5899
g7
I315
sg26
VC0393754
p5900
sg10
I3
sg11
Vhsa
p5901
sg13
I1
sa(dp5902
g7
I315
sg26
VC0393754
p5903
sg10
I3
sg11
Vhsa
p5904
sg13
I1
sa(dp5905
g7
I315
sg26
VC0393754
p5906
sg10
I3
sg11
Vhsa
p5907
sg13
I1
sa(dp5908
g7
I48
sg26
VC0006826
p5909
sg10
I6
sg11
VCancer
p5910
sg13
I1
sa(dp5911
g7
I315
sg26
VC0393754
p5912
sg10
I3
sg11
Vhsa
p5913
sg13
I1
sa(dp5914
g7
I315
sg26
VC0393754
p5915
sg10
I3
sg11
Vhsa
p5916
sg13
I1
sa(dp5917
g7
I315
sg26
VC0393754
p5918
sg10
I3
sg11
Vhsa
p5919
sg13
I1
sa(dp5920
g7
I315
sg26
VC0393754
p5921
sg10
I3
sg11
Vhsa
p5922
sg13
I1
sa(dp5923
g7
I315
sg26
VC0393754
p5924
sg10
I3
sg11
Vhsa
p5925
sg13
I1
sasa(dp5926
g2
S'The high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma.\n'
p5927
sg4
(lp5928
(dp5929
g7
I23
sg8
g107
sg10
I7
sg11
VmiR-940
p5930
sg13
I1
sasg23
(lp5931
(dp5932
g7
I83
sg26
VC0279663
p5933
sg10
I33
sg11
Vovarian serous cystadenocarcinoma
p5934
sg13
I3
sasa(dp5935
g2
S'In our study, real-time (RT) quantitative PCR indicated that miR-940 levels were upregulated in human cervical cancer tissue samples and cell lines.\n'
p5936
sg4
(lp5937
sg23
(lp5938
(dp5939
g7
I102
sg26
VC0302592
p5940
sg10
I15
sg11
Vcervical cancer
p5941
sg13
I2
sasa(dp5942
g2
S'Ectopic miR-940 accelerated cervical cancer cell growth, proliferation and cell cycle arrest in vitro as well as tumor formation in vivo.\n'
p5943
sg4
(lp5944
sg23
(lp5945
(dp5946
g7
I37
sg26
VC1516170
p5947
sg10
I18
sg11
Vcancer cell growth
p5948
sg13
I3
sa(dp5949
g7
I113
sg26
VC0027651
p5950
sg10
I5
sg11
Vtumor
p5951
sg13
I1
sa(dp5952
g7
I57
sg26
VC0334094
p5953
sg10
I13
sg11
Vproliferation
p5954
sg13
I1
sasa(dp5955
g2
S'p27 and PTEN were evidenced as direct targets for miR-940 and inhibition of p27 and PTEN recovered the suppressive function of miR-940-silenced cell towards to proliferation and tumorigenicity in cervical cancer cells.\n'
p5956
sg4
(lp5957
(dp5958
g7
I0
sg8
VP40305
p5959
sg10
I3
sg11
Vp27
p5960
sg13
I1
sa(dp5961
g7
I8
sg8
VP60484
p5962
sg10
I4
sg11
VPTEN
p5963
sg13
I1
sa(dp5964
g7
I0
sg8
VP40305
p5965
sg10
I3
sg11
Vp27
p5966
sg13
I1
sa(dp5967
g7
I8
sg8
VP60484
p5968
sg10
I4
sg11
VPTEN
p5969
sg13
I1
sasg23
(lp5970
(dp5971
g7
I196
sg26
VC0302592
p5972
sg10
I15
sg11
Vcervical cancer
p5973
sg13
I2
sa(dp5974
g7
I160
sg26
VC0334094
p5975
sg10
I13
sg11
Vproliferation
p5976
sg13
I1
sa(dp5977
g7
I178
sg26
VC1519697
p5978
sg10
I14
sg11
Vtumorigenicity
p5979
sg13
I1
sasa(dp5980
g2
S'In addition, miR-940 expression was inversely associated with p27 and PTEN expression levels and actively with cyclin D1 in cervical cancer specimens.\n'
p5981
sg4
(lp5982
(dp5983
g7
I111
sg8
VP24385
p5984
sg10
I9
sg11
Vcyclin D1
p5985
sg13
I2
sa(dp5986
g7
I62
sg8
VP40305
p5987
sg10
I3
sg11
Vp27
p5988
sg13
I1
sa(dp5989
g7
I70
sg8
VP60484
p5990
sg10
I4
sg11
VPTEN
p5991
sg13
I1
sasg23
(lp5992
(dp5993
g7
I124
sg26
VC0302592
p5994
sg10
I15
sg11
Vcervical cancer
p5995
sg13
I2
sasa(dp5996
g2
S'The results from our study demonstrated that miR-940 regulated p27 and PTEN post-transcriptionally and might play a significant role in cervical cancer development and progression.\n'
p5997
sg4
(lp5998
(dp5999
g7
I45
sg8
g107
sg10
I7
sg11
VmiR-940
p6000
sg13
I1
sa(dp6001
g7
I71
sg8
VP60484
p6002
sg10
I4
sg11
VPTEN
p6003
sg13
I1
sa(dp6004
g7
I63
sg8
VP40305
p6005
sg10
I3
sg11
Vp27
p6006
sg13
I1
sasg23
(lp6007
(dp6008
g7
I136
sg26
VC0302592
p6009
sg10
I15
sg11
Vcervical cancer
p6010
sg13
I2
sasa(dp6011
g2
S'Thus, miR-940 might provide a potential value as therapeutic target for cervical cancer treatment in future.\n'
p6012
sg4
(lp6013
(dp6014
g7
I6
sg8
g107
sg10
I7
sg11
VmiR-940
p6015
sg13
I1
sasg23
(lp6016
(dp6017
g7
I72
sg26
VC0302592
p6018
sg10
I15
sg11
Vcervical cancer
p6019
sg13
I2
sasa(dp6020
g2
S'We aimed to explore the roles and regulatory mechanism of microRNA-940 (miR-940) in bladder cancer development.\n'
p6021
sg4
(lp6022
sg23
(lp6023
(dp6024
g7
I84
sg26
VC0699885
p6025
sg10
I14
sg11
Vbladder cancer
p6026
sg13
I2
sasa(dp6027
g2
S'The expressions of miR-940 in bladder cancer tissues and cells were measured.\n'
p6028
sg4
(lp6029
sg23
(lp6030
(dp6031
g7
I30
sg26
VC0699885
p6032
sg10
I14
sg11
Vbladder cancer
p6033
sg13
I2
sasa(dp6034
g2
S'miR-940 was up-regulated in bladder cancer tissues and cells.\n'
p6035
sg4
(lp6036
sg23
(lp6037
(dp6038
g7
I28
sg26
VC0699885
p6039
sg10
I14
sg11
Vbladder cancer
p6040
sg13
I2
sasa(dp6041
g2
S'Overexpression of miR-940 significantly increased bladder cancer cell proliferation, promoted migration and invasion, and inhibited cell apoptosis.\n'
p6042
sg4
(lp6043
sg23
(lp6044
(dp6045
g7
I108
sg26
VC2699153
p6046
sg10
I8
sg11
Vinvasion
p6047
sg13
I1
sa(dp6048
g7
I50
sg26
VC0699885
p6049
sg10
I14
sg11
Vbladder cancer
p6050
sg13
I2
sa(dp6051
g7
I70
sg26
VC0334094
p6052
sg10
I13
sg11
Vproliferation
p6053
sg13
I1
sasa(dp6054
g2
S'INPP4A and GSK3Beta were the direct targets of miR-940, and knockdown of INPP4A or GSK3Beta significantly increased cancer cell proliferation, migration and invasion, and inhibited cell apoptosis.\n'
p6055
sg4
(lp6056
(dp6057
g7
I0
sg8
g107
sg10
I6
sg11
VINPP4A
p6058
sg13
I1
sa(dp6059
g7
I0
sg8
g107
sg10
I6
sg11
VINPP4A
p6060
sg13
I1
sasg23
(lp6061
(dp6062
g7
I128
sg26
VC0334094
p6063
sg10
I13
sg11
Vproliferation
p6064
sg13
I1
sa(dp6065
g7
I157
sg26
VC2699153
p6066
sg10
I8
sg11
Vinvasion
p6067
sg13
I1
sa(dp6068
g7
I116
sg26
VC0006826
p6069
sg10
I6
sg11
Vcancer
p6070
sg13
I1
sasa(dp6071
g2
S'Our results indicate that overexpression of miR-940 may promote bladder cancer cell proliferation, migration and invasion, and inhibited cell apoptosis via targeting INPP4A or GSK3Beta and activating Wnt/Beta-catenin pathway.\n'
p6072
sg4
(lp6073
(dp6074
g7
I44
sg8
g107
sg10
I7
sg11
VmiR-940
p6075
sg13
I1
sa(dp6076
g7
I166
sg8
g107
sg10
I6
sg11
VINPP4A
p6077
sg13
I1
sasg23
(lp6078
(dp6079
g7
I113
sg26
VC2699153
p6080
sg10
I8
sg11
Vinvasion
p6081
sg13
I1
sa(dp6082
g7
I64
sg26
VC0699885
p6083
sg10
I14
sg11
Vbladder cancer
p6084
sg13
I2
sa(dp6085
g7
I84
sg26
VC0334094
p6086
sg10
I13
sg11
Vproliferation
p6087
sg13
I1
sasa(dp6088
g2
S'Expressions of miR-940, miR-15a, miR-16 and IL-23 in PTC tissues might be useful biomarkers and promising targets in the diagnosis of papillary thyroid carcinoma.\n'
p6089
sg4
(lp6090
(dp6091
g7
I24
sg8
g107
sg10
I7
sg11
VmiR-15a
p6092
sg13
I1
sa(dp6093
g7
I44
sg8
g107
sg10
I5
sg11
VIL-23
p6094
sg13
I1
sa(dp6095
g7
I15
sg8
g107
sg10
I7
sg11
VmiR-940
p6096
sg13
I1
sa(dp6097
g7
I33
sg8
g107
sg10
I6
sg11
VmiR-16
p6098
sg13
I1
sa(dp6099
g7
I53
sg8
g107
sg10
I3
sg11
VPTC
p6100
sg13
I1
sasg23
(lp6101
(dp6102
g7
I134
sg26
VC0238463
p6103
sg10
I27
sg11
Vpapillary thyroid carcinoma
p6104
sg13
I3
sa(dp6105
g7
I53
sg26
VC0238463
p6106
sg10
I3
sg11
VPTC
p6107
sg13
I1
sasa(dp6108
g2
S'This study investigated the pivotal role of miR-940 in the progression of ovarian cancer and to reveal the possible molecular mechanism of its action.\n'
p6109
sg4
(lp6110
sg23
(lp6111
(dp6112
g7
I74
sg26
VC1140680
p6113
sg10
I14
sg11
Vovarian cancer
p6114
sg13
I2
sasa(dp6115
g2
S'Ovarian cancer OVCAR3 cells were transfected with the miR-940 vector, miR-940 inhibitor, and/or small interfering RNA (siRNA) targeting PKC-Delta (si-PKC-Delta), respectively.\n'
p6116
sg4
(lp6117
(dp6118
g7
I147
sg8
VP17252
p6119
sg10
I12
sg11
Vsi-PKC-Delta
p6120
sg13
I1
sa(dp6121
g7
I136
sg8
VP17252
p6122
sg10
I9
sg11
VPKC-Delta
p6123
sg13
I1
sasg23
(lp6124
(dp6125
g7
I0
sg26
VC1140680
p6126
sg10
I14
sg11
VOvarian cancer
p6127
sg13
I2
sa(dp6128
g7
I136
sg26
VC1868682
p6129
sg10
I3
sg11
VPKC
p6130
sg13
I1
sa(dp6131
g7
I136
sg26
VC1868682
p6132
sg10
I3
sg11
VPKC
p6133
sg13
I1
sasa(dp6134
g2
S'Taken together, the results of our study suggest that upregulation of miR-940 may function as a suppressor in the progression of ovarian cancer by inhibiting cell proliferation and inducing apoptosis by targeting PKC-Delta.\n'
p6135
sg4
(lp6136
(dp6137
g7
I213
sg8
VP17252
p6138
sg10
I9
sg11
VPKC-Delta
p6139
sg13
I1
sa(dp6140
g7
I70
sg8
g107
sg10
I7
sg11
VmiR-940
p6141
sg13
I1
sasg23
(lp6142
(dp6143
g7
I129
sg26
VC1140680
p6144
sg10
I14
sg11
Vovarian cancer
p6145
sg13
I2
sa(dp6146
g7
I213
sg26
VC1868682
p6147
sg10
I3
sg11
VPKC
p6148
sg13
I1
sa(dp6149
g7
I163
sg26
VC0334094
p6150
sg10
I13
sg11
Vproliferation
p6151
sg13
I1
sasa(dp6152
g2
S'This study may provide a basis for the possible application of miR-940 in illustrating the molecular pathogenic mechanism of ovarian cancer.\n'
p6153
sg4
(lp6154
sg23
(lp6155
(dp6156
g7
I125
sg26
VC1140680
p6157
sg10
I14
sg11
Vovarian cancer
p6158
sg13
I2
sasa(dp6159
g2
S'To investigate the expression of miR-940 in the hepatocellular carcinoma (HCC) and its impact on function and biological mechanism in the HCC cells.\n'
p6160
sg4
(lp6161
sg23
(lp6162
(dp6163
g7
I74
sg26
VC2239176
p6164
sg10
I3
sg11
VHCC
p6165
sg13
I1
sa(dp6166
g7
I74
sg26
VC2239176
p6167
sg10
I3
sg11
VHCC
p6168
sg13
I1
sa(dp6169
g7
I48
sg26
VC2239176
p6170
sg10
I24
sg11
Vhepatocellular carcinoma
p6171
sg13
I2
sasa(dp6172
g2
S"This meta-analysis demonstrates that within the Caucasian population, the NLRP1 rs12150220 polymorphism may correlate with a decreased risk of vitiligo-associated autoimmune diseases, especially autoimmune Addison's disease, type 1 diabetes, or systemic lupus erythematosus.\n"
p6173
sg4
(lp6174
(dp6175
g7
I74
sg8
g107
sg10
I16
sg11
VNLRP1 rs12150220
p6176
sg13
I2
sasg23
(lp6177
(dp6178
g7
I163
sg26
VC0004364
p6179
sg10
I19
sg11
Vautoimmune diseases
p6180
sg13
I2
sa(dp6181
g7
I225
sg26
VC0011854
p6182
sg10
I15
sg11
Vtype 1 diabetes
p6183
sg13
I3
sa(dp6184
g7
I143
sg26
VC0042900
p6185
sg10
I8
sg11
Vvitiligo
p6186
sg13
I1
sa(dp6187
g7
I245
sg26
VC0024141
p6188
sg10
I28
sg11
Vsystemic lupus erythematosus
p6189
sg13
I3
sa(dp6190
g7
I195
sg26
VC0271737
p6191
sg10
I28
sg11
Vautoimmune Addison's disease
p6192
sg13
I3
sasa(dp6193
g2
S"Gene variants known to contribute to Autoimmune Addison's disease (AAD) susceptibility include those at the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci.\n"
p6194
sg4
(lp6195
(dp6196
g7
I108
sg8
VP13747
p6197
sg10
I3
sg11
VMHC
p6198
sg13
I1
sa(dp6199
g7
I161
sg8
g107
sg10
I10
sg11
VCD274 loci
p6200
sg13
I2
sa(dp6201
g7
I126
sg8
VP16410
p6202
sg10
I5
sg11
VCTLA4
p6203
sg13
I1
sa(dp6204
g7
I141
sg8
g107
sg10
I7
sg11
VCYP27B1
p6205
sg13
I1
sa(dp6206
g7
I150
sg8
g107
sg10
I6
sg11
VNLRP-1
p6207
sg13
I1
sa(dp6208
g7
I119
sg8
VP33076
p6209
sg10
I5
sg11
VCIITA
p6210
sg13
I1
sa(dp6211
g7
I133
sg8
g107
sg10
I6
sg11
VPTPN22
p6212
sg13
I1
sasg23
(lp6213
(dp6214
g7
I67
sg26
VC0271737
p6215
sg10
I3
sg11
VAAD
p6216
sg13
I1
sa(dp6217
g7
I37
sg26
VC0271737
p6218
sg10
I28
sg11
VAutoimmune Addison's disease
p6219
sg13
I3
sa(dp6220
g7
I113
sg26
VC0700319
p6221
sg10
I4
sg11
VMICA
p6222
sg13
I1
sasa(dp6223
g2
S'NLRP1 is genetically associated with risk of several autoimmune diseases including generalized vitiligo, Addison disease, type 1 diabetes, rheumatoid arthritis, and others.\n'
p6224
sg4
(lp6225
(dp6226
g7
I0
sg8
g107
sg10
I5
sg11
VNLRP1
p6227
sg13
I1
sasg23
(lp6228
(dp6229
g7
I83
sg26
VC1304470
p6230
sg10
I20
sg11
Vgeneralized vitiligo
p6231
sg13
I2
sa(dp6232
g7
I122
sg26
VC0011854
p6233
sg10
I15
sg11
Vtype 1 diabetes
p6234
sg13
I3
sa(dp6235
g7
I53
sg26
VC0004364
p6236
sg10
I19
sg11
Vautoimmune diseases
p6237
sg13
I2
sa(dp6238
g7
I105
sg26
VC0266273
p6239
sg10
I15
sg11
VAddison disease
p6240
sg13
I2
sa(dp6241
g7
I139
sg26
VC0003873
p6242
sg10
I20
sg11
Vrheumatoid arthritis
p6243
sg13
I2
sasa(dp6244
g2
S"Investigating large patient cohorts from six different autoimmune diseases, that is autoimmune Addison's disease (n=333), type 1 diabetes (n=1086), multiple sclerosis (n=502), rheumatoid arthritis (n=945), systemic lupus erythematosus (n=156) and juvenile idiopathic arthritis (n=505), against 3273 healthy controls, we analyzed four single nucleotide polymorphisms (SNPs) in NALP1.\n"
p6245
sg4
(lp6246
(dp6247
g7
I376
sg8
g107
sg10
I5
sg11
VNALP1
p6248
sg13
I1
sasg23
(lp6249
(dp6250
g7
I122
sg26
VC0011854
p6251
sg10
I15
sg11
Vtype 1 diabetes
p6252
sg13
I3
sa(dp6253
g7
I148
sg26
VC0026769
p6254
sg10
I18
sg11
Vmultiple sclerosis
p6255
sg13
I2
sa(dp6256
g7
I176
sg26
VC0003873
p6257
sg10
I20
sg11
Vrheumatoid arthritis
p6258
sg13
I2
sa(dp6259
g7
I206
sg26
VC0024141
p6260
sg10
I28
sg11
Vsystemic lupus erythematosus
p6261
sg13
I3
sa(dp6262
g7
I55
sg26
VC0004364
p6263
sg10
I19
sg11
Vautoimmune diseases
p6264
sg13
I2
sa(dp6265
g7
I247
sg26
VC0553662
p6266
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p6267
sg13
I3
sa(dp6268
g7
I84
sg26
VC0271737
p6269
sg10
I28
sg11
Vautoimmune Addison's disease
p6270
sg13
I3
sasa(dp6271
g2
S'Forty-four formalin-fixed, paraffin-embedded MRCL samples and 60 control cases (atypical/well-differentiated liposarcoma, pleomorphic liposarcoma, low-grade myofibrosarcoma, etc.)'
p6272
sg4
(lp6273
sg23
(lp6274
(dp6275
g7
I109
sg26
VC0205825
p6276
sg10
I24
sg11
Vliposarcoma, pleomorphic
p6277
sg13
I2
sa(dp6278
g7
I109
sg26
VC0023827
p6279
sg10
I11
sg11
Vliposarcoma
p6280
sg13
I1
sa(dp6281
g7
I157
sg26
VC1708751
p6282
sg10
I15
sg11
Vmyofibrosarcoma
p6283
sg13
I1
sasa(dp6284
g2
S'The most frequent acupoints of acupuncture for PCOS were Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongji (CV 3) and Qihai (CV 6).\n'
p6285
sg4
(lp6286
(dp6287
g7
I101
sg8
VP00915
p6288
sg10
I7
sg11
VEX-CA 1
p6289
sg13
I2
sasg23
(lp6290
(dp6291
g7
I47
sg26
VC0032460
p6292
sg10
I4
sg11
VPCOS
p6293
sg13
I1
sasa(dp6294
g2
S'In the modern treatment of acupuncture for PCOS, Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongii (CV 3) and Qihai (CV 6) are most used.\n'
p6295
sg4
(lp6296
(dp6297
g7
I93
sg8
VP00915
p6298
sg10
I7
sg11
VEX-CA 1
p6299
sg13
I2
sasg23
(lp6300
(dp6301
g7
I43
sg26
VC0032460
p6302
sg10
I4
sg11
VPCOS
p6303
sg13
I1
sasa(dp6304
g2
S"Carbonic anhydrase II (CA II) has an important role in thyroid hormone synthesis via regulating iodide (I-) transport across thyroidal cell membranes and the existence of autoantibodies against CA I and/or CA II have been shown in sera from patient with various autoimmune diseases such as Sjoegren's Syndrome, Systemic Lupus Erythmatosus, type 1 diabetes, primary biliary cirrhosis and ulcerative colitis.\n"
p6305
sg4
(lp6306
(dp6307
g7
I23
sg8
VP00915
p6308
sg10
I4
sg11
VCA I
p6309
sg13
I2
sa(dp6310
g7
I0
sg8
VP00918
p6311
sg10
I21
sg11
VCarbonic anhydrase II
p6312
sg13
I3
sa(dp6313
g7
I23
sg8
VP00918
p6314
sg10
I5
sg11
VCA II
p6315
sg13
I2
sa(dp6316
g7
I23
sg8
VP00918
p6317
sg10
I5
sg11
VCA II
p6318
sg13
I2
sasg23
(lp6319
(dp6320
g7
I340
sg26
VC0011854
p6321
sg10
I15
sg11
Vtype 1 diabetes
p6322
sg13
I3
sa(dp6323
g7
I387
sg26
VC0009324
p6324
sg10
I18
sg11
Vulcerative colitis
p6325
sg13
I2
sa(dp6326
g7
I320
sg26
VC0024131
p6327
sg10
I5
sg11
VLupus
p6328
sg13
I1
sa(dp6329
g7
I290
sg26
VC1527336
p6330
sg10
I19
sg11
VSjoegren's Syndrome
p6331
sg13
I2
sa(dp6332
g7
I262
sg26
VC0004364
p6333
sg10
I19
sg11
Vautoimmune diseases
p6334
sg13
I2
sa(dp6335
g7
I357
sg26
VC0008312
p6336
sg10
I25
sg11
Vprimary biliary cirrhosis
p6337
sg13
I3
sasa(dp6338
g2
S"Efforts to inhibit the chemokine receptor CCR9 using the agent CCX282-B in Crohn's disease were not successful.\n"
p6339
sg4
(lp6340
(dp6341
g7
I23
sg8
VP51686
p6342
sg10
I23
sg11
Vchemokine receptor CCR9
p6343
sg13
I3
sasg23
(lp6344
(dp6345
g7
I75
sg26
VC0010346
p6346
sg10
I15
sg11
VCrohn's disease
p6347
sg13
I2
sasa(dp6348
g2
S"Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.\n"
p6349
sg4
(lp6350
(dp6351
g7
I112
sg8
g107
sg10
I32
sg11
Vaddressin cell adhesion molecule
p6352
sg13
I4
sa(dp6353
g7
I213
sg8
VP51686
p6354
sg10
I4
sg11
VCCR9
p6355
sg13
I1
sa(dp6356
g7
I269
sg8
g107
sg10
I31
sg11
VSMAD7 antisense oligonucleotide
p6357
sg13
I3
sasg23
(lp6358
(dp6359
g7
I127
sg26
VC0001511
p6360
sg10
I8
sg11
Vadhesion
p6361
sg13
I1
sa(dp6362
g7
I333
sg26
VC0010346
p6363
sg10
I15
sg11
VCrohn's disease
p6364
sg13
I2
sasa(dp6365
g2
S"The chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development.\n"
p6366
sg4
(lp6367
(dp6368
g7
I14
sg8
g107
sg10
I5
sg11
VCCL25
p6369
sg13
I1
sa(dp6370
g7
I38
sg8
VP51686
p6371
sg10
I4
sg11
VCCR9
p6372
sg13
I1
sasg23
(lp6373
(dp6374
g7
I232
sg26
VC0010346
p6375
sg10
I15
sg11
VCrohn's disease
p6376
sg13
I2
sasa(dp6377
g2
S"Vercirnon is a CCR9 chemokine receptor antagonist being developed for the treatment of Crohn's disease.\n"
p6378
sg4
(lp6379
(dp6380
g7
I15
sg8
VP51686
p6381
sg10
I23
sg11
VCCR9 chemokine receptor
p6382
sg13
I3
sasg23
(lp6383
(dp6384
g7
I87
sg26
VC0010346
p6385
sg10
I15
sg11
VCrohn's disease
p6386
sg13
I2
sasa(dp6387
g2
S'It is well established that the passive trans-placental passage of anti-Ro/SSA antibodies from mother to foetus is associated with the risk to develop an uncommon syndrome named neonatal lupus (NLE), where the congenital heart block represents the most severe clinical feature.\n'
p6388
sg4
(lp6389
(dp6390
g7
I67
sg8
VP19474
p6391
sg10
I22
sg11
Vanti-Ro/SSA antibodies
p6392
sg13
I2
sasg23
(lp6393
(dp6394
g7
I178
sg26
VC0409979
p6395
sg10
I14
sg11
Vneonatal lupus
p6396
sg13
I2
sa(dp6397
g7
I210
sg26
VC0149530
p6398
sg10
I22
sg11
Vcongenital heart block
p6399
sg13
I3
sa(dp6400
g7
I163
sg26
VC0039082
p6401
sg10
I8
sg11
Vsyndrome
p6402
sg13
I1
sasa(dp6403
g2
S'The characteristics of NLE that were studied included congenital complete heart block (CCHB), second degree heart block, and hepatic fibrosis.\n'
p6404
sg4
(lp6405
sg23
(lp6406
(dp6407
g7
I54
sg26
VC0340496
p6408
sg10
I31
sg11
Vcongenital complete heart block
p6409
sg13
I4
sa(dp6410
g7
I94
sg26
VC0264906
p6411
sg10
I25
sg11
Vsecond degree heart block
p6412
sg13
I4
sa(dp6413
g7
I87
sg26
VC0340496
p6414
sg10
I4
sg11
VCCHB
p6415
sg13
I1
sa(dp6416
g7
I125
sg26
VC0239946
p6417
sg10
I16
sg11
Vhepatic fibrosis
p6418
sg13
I2
sasa(dp6419
g2
S"Sera from patients known to frequently produce precipitating anti-SS-A/Ro antibody (subacute cutaneous lupus erythematosus [SCLE], 56 patients; Sjoegren's syndrome [SS], 41 patients; mothers of infants with neonatal LE [NLE], 10 individuals; infants with congenital heart block [CHB], 5 patients) were tested for reactivity to RoSP7-24 in ELISA.\n"
p6420
sg4
(lp6421
(dp6422
g7
I61
sg8
VP37268
p6423
sg10
I21
sg11
Vanti-SS-A/Ro antibody
p6424
sg13
I2
sasg23
(lp6425
(dp6426
g7
I279
sg26
VC0151517
p6427
sg10
I3
sg11
VCHB
p6428
sg13
I1
sa(dp6429
g7
I144
sg26
VC1527336
p6430
sg10
I19
sg11
VSjoegren's syndrome
p6431
sg13
I2
sa(dp6432
g7
I255
sg26
VC0149530
p6433
sg10
I22
sg11
Vcongenital heart block
p6434
sg13
I3
sa(dp6435
g7
I84
sg26
VC0024140
p6436
sg10
I38
sg11
Vsubacute cutaneous lupus erythematosus
p6437
sg13
I4
sasa(dp6438
g2
S'NLE is manifested most typically as transient subacute cutaneous lupus lesions or isolated complete congenital heart block.\n'
p6439
sg4
(lp6440
(dp6441
g7
I0
sg8
g107
sg10
I3
sg11
VNLE
p6442
sg13
I1
sasg23
(lp6443
(dp6444
g7
I46
sg26
VC2362320
p6445
sg10
I24
sg11
Vsubacute cutaneous lupus
p6446
sg13
I3
sa(dp6447
g7
I100
sg26
VC0149530
p6448
sg10
I22
sg11
Vcongenital heart block
p6449
sg13
I3
sasa(dp6450
g2
S'Our findings also suggested that the inhibitory effects of AC-93253 iodide on lung cancer progression may be attributable to its ability to modulate multiple proteins, including Src, PI3K, JNK, Paxillin, p130cas, MEK, ERK, and EGFR.\n'
p6451
sg4
(lp6452
(dp6453
g7
I178
sg8
VP12931
p6454
sg10
I3
sg11
VSrc
p6455
sg13
I1
sa(dp6456
g7
I204
sg8
VP56945
p6457
sg10
I7
sg11
Vp130cas
p6458
sg13
I1
sa(dp6459
g7
I183
sg8
VP42336
p6460
sg10
I4
sg11
VPI3K
p6461
sg13
I1
sa(dp6462
g7
I189
sg8
VP53779
p6463
sg10
I3
sg11
VJNK
p6464
sg13
I1
sa(dp6465
g7
I218
sg8
VP29323
p6466
sg10
I3
sg11
VERK
p6467
sg13
I1
sa(dp6468
g7
I194
sg8
VP49023
p6469
sg10
I8
sg11
VPaxillin
p6470
sg13
I1
sa(dp6471
g7
I213
sg8
VP45985
p6472
sg10
I3
sg11
VMEK
p6473
sg13
I1
sasg23
(lp6474
(dp6475
g7
I83
sg26
VC0178874
p6476
sg10
I18
sg11
Vcancer progression
p6477
sg13
I2
sasa(dp6478
g2
S'Paxillin and FAK activity are reduced in lung cancer cell lines following wiskostatin and nWASP knockdown as shown by immunofluorescence and western blot.\n'
p6479
sg4
(lp6480
(dp6481
g7
I13
sg8
g107
sg10
I3
sg11
VFAK
p6482
sg13
I1
sa(dp6483
g7
I90
sg8
g107
sg10
I5
sg11
VnWASP
p6484
sg13
I1
sa(dp6485
g7
I0
sg8
VP49023
p6486
sg10
I8
sg11
VPaxillin
p6487
sg13
I1
sasg23
(lp6488
(dp6489
g7
I41
sg26
VC0684249
p6490
sg10
I11
sg11
Vlung cancer
p6491
sg13
I2
sasa(dp6492
g2
S'Taken together, these results suggested that treatment with DBL may act as a potential candidate to inhibit lung cancer metastasis by inhibiting MMP-2 and -9 via affecting PI3K/AKT, MAPKs, FAK/paxillin, EMT/Snail and Slug, Nrf2/antioxidant enzymes, and NFKB signaling pathways.\n'
p6493
sg4
(lp6494
(dp6495
g7
I189
sg8
g107
sg10
I3
sg11
VFAK
p6496
sg13
I1
sa(dp6497
g7
I145
sg8
VP08253
p6498
sg10
I5
sg11
VMMP-2
p6499
sg13
I1
sa(dp6500
g7
I217
sg8
g107
sg10
I4
sg11
VSlug
p6501
sg13
I1
sa(dp6502
g7
I177
sg8
g107
sg10
I3
sg11
VAKT
p6503
sg13
I1
sa(dp6504
g7
I203
sg8
g107
sg10
I3
sg11
VEMT
p6505
sg13
I1
sa(dp6506
g7
I172
sg8
VP42336
p6507
sg10
I4
sg11
VPI3K
p6508
sg13
I1
sa(dp6509
g7
I223
sg8
g107
sg10
I4
sg11
VNrf2
p6510
sg13
I1
sa(dp6511
g7
I253
sg8
g107
sg10
I4
sg11
VNFKB
p6512
sg13
I1
sa(dp6513
g7
I182
sg8
g107
sg10
I5
sg11
VMAPKs
p6514
sg13
I1
sa(dp6515
g7
I207
sg8
g107
sg10
I5
sg11
VSnail
p6516
sg13
I1
sa(dp6517
g7
I193
sg8
VP49023
p6518
sg10
I8
sg11
Vpaxillin
p6519
sg13
I1
sasg23
(lp6520
(dp6521
g7
I108
sg26
VC0684249
p6522
sg10
I11
sg11
Vlung cancer
p6523
sg13
I2
sa(dp6524
g7
I120
sg26
VC0027627
p6525
sg10
I10
sg11
Vmetastasis
p6526
sg13
I1
sasa(dp6527
g2
S'EL decreased phosphorylation of FAK and its downstream targets, Src, paxillin, and decreased mRNA expression of cell motility-related genes, RhoA, Rac1, and Cdc42 in lung cancer cells.\n'
p6528
sg4
(lp6529
(dp6530
g7
I147
sg8
VP63000
p6531
sg10
I4
sg11
VRac1
p6532
sg13
I1
sa(dp6533
g7
I141
sg8
VP61586
p6534
sg10
I4
sg11
VRhoA
p6535
sg13
I1
sa(dp6536
g7
I32
sg8
g107
sg10
I3
sg11
VFAK
p6537
sg13
I1
sa(dp6538
g7
I64
sg8
VP12931
p6539
sg10
I3
sg11
VSrc
p6540
sg13
I1
sa(dp6541
g7
I157
sg8
VP60953
p6542
sg10
I5
sg11
VCdc42
p6543
sg13
I1
sa(dp6544
g7
I69
sg8
VP49023
p6545
sg10
I8
sg11
Vpaxillin
p6546
sg13
I1
sasg23
(lp6547
(dp6548
g7
I166
sg26
VC0684249
p6549
sg10
I11
sg11
Vlung cancer
p6550
sg13
I2
sasa(dp6551
g2
S'It efficiently inhibits metastasis on NSCLC by reducing vascularization, and eliciting depression of the PI3K-AKT and FAK-Paxillin signaling pathways.\n'
p6552
sg4
(lp6553
(dp6554
g7
I122
sg8
VP49023
p6555
sg10
I8
sg11
VPaxillin
p6556
sg13
I1
sa(dp6557
g7
I110
sg8
g107
sg10
I3
sg11
VAKT
p6558
sg13
I1
sa(dp6559
g7
I105
sg8
VP42336
p6560
sg10
I4
sg11
VPI3K
p6561
sg13
I1
sa(dp6562
g7
I118
sg8
g107
sg10
I3
sg11
VFAK
p6563
sg13
I1
sasg23
(lp6564
(dp6565
g7
I38
sg26
VC0007131
p6566
sg10
I5
sg11
VNSCLC
p6567
sg13
I1
sa(dp6568
g7
I24
sg26
VC0027627
p6569
sg10
I10
sg11
Vmetastasis
p6570
sg13
I1
sa(dp6571
g7
I87
sg26
VC0011581
p6572
sg10
I10
sg11
Vdepression
p6573
sg13
I1
sa(dp6574
g7
I56
sg26
VC0027686
p6575
sg10
I15
sg11
Vvascularization
p6576
sg13
I1
sasa(dp6577
g2
S'Here, we assessed the impact of CD101 on the course of inflammatory bowel disease (IBD).\n'
p6578
sg4
(lp6579
(dp6580
g7
I32
sg8
g107
sg10
I5
sg11
VCD101
p6581
sg13
I1
sasg23
(lp6582
(dp6583
g7
I83
sg26
VC0021390
p6584
sg10
I3
sg11
VIBD
p6585
sg13
I1
sa(dp6586
g7
I55
sg26
VC0021390
p6587
sg10
I26
sg11
Vinflammatory bowel disease
p6588
sg13
I3
sasa(dp6589
g2
S'Using a T-cell transfer model of chronic colitis, we found that in recipients of naive T cells from CD101(+/+) donors up to 30% of the recovered lymphocytes expressed CD101, correlating with an increased interleukin (IL)-2-mediated FoxP3 expression.\n'
p6590
sg4
(lp6591
(dp6592
g7
I204
sg8
VP60568
p6593
sg10
I18
sg11
Vinterleukin (IL)-2
p6594
sg13
I2
sa(dp6595
g7
I232
sg8
g107
sg10
I5
sg11
VFoxP3
p6596
sg13
I1
sa(dp6597
g7
I100
sg8
g107
sg10
I5
sg11
VCD101
p6598
sg13
I1
sasg23
(lp6599
(dp6600
g7
I33
sg26
VC0267375
p6601
sg10
I15
sg11
Vchronic colitis
p6602
sg13
I2
sasa(dp6603
g2
S'Transfer of CD101(-/-) T cells caused more severe colitis and was associated with an expansion of IL-17-producing T cells and an enhanced expression of IL-2RAlfa/Beta independently of FoxP3.\n'
p6604
sg4
(lp6605
(dp6606
g7
I184
sg8
g107
sg10
I5
sg11
VFoxP3
p6607
sg13
I1
sasg23
(lp6608
(dp6609
g7
I50
sg26
VC0009319
p6610
sg10
I7
sg11
Vcolitis
p6611
sg13
I1
sasa(dp6612
g2
S'The co-transfer of naive and regulatory T cells (Treg) protected most effectively from colitis, when both donor and recipient mice expressed CD101.\n'
p6613
sg4
(lp6614
(dp6615
g7
I141
sg8
g107
sg10
I5
sg11
VCD101
p6616
sg13
I1
sasg23
(lp6617
(dp6618
g7
I87
sg26
VC0009319
p6619
sg10
I7
sg11
Vcolitis
p6620
sg13
I1
sasa(dp6621
g2
S'Thus, CD101 deficiency is a novel marker for progressive colitis and potential target for therapeutic intervention.\n'
p6622
sg4
(lp6623
(dp6624
g7
I6
sg8
g107
sg10
I5
sg11
VCD101
p6625
sg13
I1
sasg23
(lp6626
(dp6627
g7
I57
sg26
VC0009319
p6628
sg10
I7
sg11
Vcolitis
p6629
sg13
I1
sasa(dp6630
g2
S'Subgroups of T cells (Th : CD4(+) or Tc : CD8(+) ); naive (CD27(+) CD28(+) CD45RA(+) CCR7(+) ), central memory (CD27(+) CD28(+) CD45RA(-) CCR7(+) ), effector memory (early differentiated; CD27(+) CD28(+) CD45RA(-) CCR7(-) and late differentiated; CD27(-) CD28(-) CD45RA(-) CCR7(-) ), terminally differentiated effector cells (TEMRA; CD27(-) CD28(-) CD45RA(+) CCR7(-) ) and Treg (CD4(+) CD25(+) FOXP3(+) CD127(-) ) cells, and their expression of CD39, CD45RA, CD101 and CD129, were studied by flow cytometry in T1D and/or coeliac disease children or without any of these diseases (reference group).\n'
p6631
sg4
(lp6632
(dp6633
g7
I247
sg8
VP26842
p6634
sg10
I7
sg11
VCD27(-)
p6635
sg13
I1
sa(dp6636
g7
I445
sg8
VP49961
p6637
sg10
I4
sg11
VCD39
p6638
sg13
I1
sa(dp6639
g7
I255
sg8
VP33681
p6640
sg10
I22
sg11
VCD28(-) CD45RA(-) CCR7
p6641
sg13
I3
sa(dp6642
g7
I27
sg8
VP01730
p6643
sg10
I3
sg11
VCD4
p6644
sg13
I1
sa(dp6645
g7
I341
sg8
VP33681
p6646
sg10
I22
sg11
VCD28(-) CD45RA(+) CCR7
p6647
sg13
I3
sa(dp6648
g7
I247
sg8
VP26842
p6649
sg10
I7
sg11
VCD27(-)
p6650
sg13
I1
sa(dp6651
g7
I112
sg8
VP26842
p6652
sg10
I30
sg11
VCD27(+) CD28(+) CD45RA(-) CCR7
p6653
sg13
I4
sa(dp6654
g7
I42
sg8
VP01732
p6655
sg10
I3
sg11
VCD8
p6656
sg13
I1
sa(dp6657
g7
I59
sg8
VP26842
p6658
sg10
I30
sg11
VCD27(+) CD28(+) CD45RA(+) CCR7
p6659
sg13
I4
sa(dp6660
g7
I188
sg8
VP26842
p6661
sg10
I33
sg11
VCD27(+) CD28(+) CD45RA(-) CCR7(-)
p6662
sg13
I4
sa(dp6663
g7
I459
sg8
g107
sg10
I5
sg11
VCD101
p6664
sg13
I1
sa(dp6665
g7
I469
sg8
g107
sg10
I5
sg11
VCD129
p6666
sg13
I1
sa(dp6667
g7
I379
sg8
VP01730
p6668
sg10
I29
sg11
VCD4(+) CD25(+) FOXP3(+) CD127
p6669
sg13
I4
sasg23
(lp6670
(dp6671
g7
I521
sg26
VC0007570
p6672
sg10
I15
sg11
Vcoeliac disease
p6673
sg13
I2
sasa(dp6674
g2
S'Children with exclusively coeliac disease had a higher MFI of CD101 (P &lt; 0*01), as well as a higher percentage of CD129(+) (P &lt; 0*05), in the CD4(+) CD25(hi) lymphocyte population, compared to references.\n'
p6675
sg4
(lp6676
(dp6677
g7
I62
sg8
g107
sg10
I5
sg11
VCD101
p6678
sg13
I1
sa(dp6679
g7
I148
sg8
VP01730
p6680
sg10
I11
sg11
VCD4(+) CD25
p6681
sg13
I2
sasg23
(lp6682
(dp6683
g7
I26
sg26
VC0007570
p6684
sg10
I15
sg11
Vcoeliac disease
p6685
sg13
I2
sasa(dp6686
g2
S'Conversely, children with coeliac disease show signs of CD101(+) /CD129(+) Treg cells that may indicate suppressor activity.\n'
p6687
sg4
(lp6688
(dp6689
g7
I66
sg8
g107
sg10
I5
sg11
VCD129
p6690
sg13
I1
sasg23
(lp6691
(dp6692
g7
I26
sg26
VC0007570
p6693
sg10
I15
sg11
Vcoeliac disease
p6694
sg13
I2
sasa(dp6695
g2
S'Further, to define the mechanism of action that explains the differential ability of C57BL/6 Treg versus dnTGF-BetaRII Treg on the ability to down-regulate autoimmune cholangitis, we noted significant differential expression of glycoprotein A repetitions predominant (GARP), CD73, CD101 and CD103 and a functionally significant increase in interleukin (IL)-10 in Treg from C57BL/6 compared to dnTGF-BetaRII mice.\n'
p6696
sg4
(lp6697
(dp6698
g7
I340
sg8
VP60568
p6699
sg10
I19
sg11
Vinterleukin (IL)-10
p6700
sg13
I2
sa(dp6701
g7
I275
sg8
VP21589
p6702
sg10
I4
sg11
VCD73
p6703
sg13
I1
sa(dp6704
g7
I291
sg8
VP38570
p6705
sg10
I5
sg11
VCD103
p6706
sg13
I1
sa(dp6707
g7
I281
sg8
g107
sg10
I5
sg11
VCD101
p6708
sg13
I1
sa(dp6709
g7
I228
sg8
VP55822
p6710
sg10
I38
sg11
Vglycoprotein A repetitions predominant
p6711
sg13
I4
sa(dp6712
g7
I268
sg8
VP55822
p6713
sg10
I4
sg11
VGARP
p6714
sg13
I1
sasg23
(lp6715
(dp6716
g7
I167
sg26
VC0008311
p6717
sg10
I11
sg11
Vcholangitis
p6718
sg13
I1
sa(dp6719
g7
I156
sg26
VC0443146
p6720
sg10
I10
sg11
Vautoimmune
p6721
sg13
I1
sasa(dp6722
g2
S'CD101-knockout mice generated on the B6 background also exhibit substantially more severe N. aromaticivorans-induced liver disease correlating with increased IFN-Gamma and IL-17 responses compared with wild-type mice.\n'
p6723
sg4
(lp6724
(dp6725
g7
I0
sg8
g107
sg10
I5
sg11
VCD101
p6726
sg13
I1
sa(dp6727
g7
I158
sg8
VP01579
p6728
sg10
I9
sg11
VIFN-Gamma
p6729
sg13
I1
sasg23
(lp6730
(dp6731
g7
I117
sg26
VC0023895
p6732
sg10
I13
sg11
Vliver disease
p6733
sg13
I2
sasa(dp6734
g2
S'Gastric juice from 15 normals, 20 patients with gastric ulcer and 14 patients with erosive haemorrhagic gastroduodenitis was investigated in respect of its activity on unheated and heated fibrin plates and its content of FDP and plasminogen or plasmin with immunochemical methods.\n'
p6735
sg4
(lp6736
(dp6737
g7
I188
sg8
VP22087
p6738
sg10
I6
sg11
Vfibrin
p6739
sg13
I1
sa(dp6740
g7
I221
sg8
g107
sg10
I3
sg11
VFDP
p6741
sg13
I1
sa(dp6742
g7
I229
sg8
VP00747
p6743
sg10
I11
sg11
Vplasminogen
p6744
sg13
I1
sa(dp6745
g7
I229
sg8
VP00747
p6746
sg10
I7
sg11
Vplasmin
p6747
sg13
I1
sasg23
(lp6748
(dp6749
g7
I48
sg26
VC0038358
p6750
sg10
I13
sg11
Vgastric ulcer
p6751
sg13
I2
sa(dp6752
g7
I104
sg26
VC0267166
p6753
sg10
I16
sg11
Vgastroduodenitis
p6754
sg13
I1
sasa(dp6755
g2
S'The patients with erosive haemorrhagic gastroduodenitis showed no increase in fibrinolysis in the blood, but low values for plasminogen and alpha2-M, and the serum contained FDP.\n'
p6756
sg4
(lp6757
(dp6758
g7
I174
sg8
g107
sg10
I3
sg11
VFDP
p6759
sg13
I1
sa(dp6760
g7
I124
sg8
VP00747
p6761
sg10
I11
sg11
Vplasminogen
p6762
sg13
I1
sasg23
(lp6763
(dp6764
g7
I39
sg26
VC0267166
p6765
sg10
I16
sg11
Vgastroduodenitis
p6766
sg13
I1
sasa(dp6767
g2
S"In the patient's lymphocytes, mRNA expression of TGFBeta2 was lower than control, and might cause DORV as it does in TGFBeta2-deficient mice.\n"
p6768
sg4
(lp6769
sg23
(lp6770
(dp6771
g7
I98
sg26
VC0013069
p6772
sg10
I4
sg11
VDORV
p6773
sg13
I1
sasa(dp6774
g2
S'Activin BA, follistatin, and activin receptor type IIA proteins were observed in normal and cleft palate tissues throughout pregnancy (gestational weeks 11 to 40).\n'
p6775
sg4
(lp6776
(dp6777
g7
I0
sg8
VP58166
p6778
sg10
I7
sg11
VActivin
p6779
sg13
I1
sa(dp6780
g7
I29
sg8
VP27037
p6781
sg10
I34
sg11
Vactivin receptor type IIA proteins
p6782
sg13
I5
sasg23
(lp6783
(dp6784
g7
I92
sg26
VC0008925
p6785
sg10
I12
sg11
Vcleft palate
p6786
sg13
I2
sasa(dp6787
g2
S'We have previously shown that follistatin-deficient mice have numerous embryonic defects including shiny, taut skin, growth retardation, and cleft palate leading to death within hours of birth.\n'
p6788
sg4
(lp6789
(dp6790
g7
I30
sg8
VP19883
p6791
sg10
I11
sg11
Vfollistatin
p6792
sg13
I1
sasg23
(lp6793
(dp6794
g7
I117
sg26
VC0151686
p6795
sg10
I18
sg11
Vgrowth retardation
p6796
sg13
I2
sa(dp6797
g7
I141
sg26
VC0008925
p6798
sg10
I12
sg11
Vcleft palate
p6799
sg13
I2
sasa(dp6800
g2
S'Two rheumatic disease patients had a relatively high titer of IgG(2)anti-p80-coilin antibodies.\n'
p6801
sg4
(lp6802
(dp6803
g7
I62
sg8
VP38432
p6804
sg10
I32
sg11
VIgG(2)anti-p80-coilin antibodies
p6805
sg13
I2
sasg23
(lp6806
(dp6807
g7
I4
sg26
VC0035435
p6808
sg10
I17
sg11
Vrheumatic disease
p6809
sg13
I2
sasa(dp6810
g2
S'The IgG(2)subclass of anti-p80-coilin antibodies may be a specific marker for systemic autoimmune disease.\n'
p6811
sg4
(lp6812
(dp6813
g7
I22
sg8
VP38432
p6814
sg10
I26
sg11
Vanti-p80-coilin antibodies
p6815
sg13
I2
sasg23
(lp6816
(dp6817
g7
I78
sg26
VC2895206
p6818
sg10
I27
sg11
Vsystemic autoimmune disease
p6819
sg13
I3
sasa(dp6820
g2
S'The patients with localized scleroderma who were positive for anti-p80-coilin antibody had all been classified as having linear scleroderma.\n'
p6821
sg4
(lp6822
(dp6823
g7
I62
sg8
VP38432
p6824
sg10
I24
sg11
Vanti-p80-coilin antibody
p6825
sg13
I2
sasg23
(lp6826
(dp6827
g7
I18
sg26
VC0036420
p6828
sg10
I21
sg11
Vlocalized scleroderma
p6829
sg13
I2
sa(dp6830
g7
I121
sg26
VC0263409
p6831
sg10
I18
sg11
Vlinear scleroderma
p6832
sg13
I2
sasa(dp6833
g2
S'Our data indicate that anti-p80-coilin antibody is uncommon in skin diseases: however, this antibody is present in patients with a milder form of linear scleroderma, although the incidence of positivity may not be high.\n'
p6834
sg4
(lp6835
(dp6836
g7
I23
sg8
VP38432
p6837
sg10
I24
sg11
Vanti-p80-coilin antibody
p6838
sg13
I2
sasg23
(lp6839
(dp6840
g7
I63
sg26
VC0037274
p6841
sg10
I13
sg11
Vskin diseases
p6842
sg13
I2
sa(dp6843
g7
I146
sg26
VC0263409
p6844
sg10
I18
sg11
Vlinear scleroderma
p6845
sg13
I2
sasa(dp6846
g2
S'We also discuss several of the antigen-autoantibody systems found in systemic lupus erythematosus (Smith antigen, U1-nuclear ribonucleoprotein, SS-A/Ro, SS-B/La, proliferating cell nuclear antigen ribosomal ribonucleoprotein, double-strand DNA, histones, antiphospholipids, Ku, Ki/SL), systemic sclerosis (centromere, topo I, RNA polymerases, fibrillarin, polymyositis-Scl, Th/To), polymyositis/dermatomyositis (transferRNA synthetases, signal recognition particle, and others), and SS (SS-A/Ro, SS-B/La, nucleolar organizing region-90, p80-coilin), addressing their clinical significance, common detection methods, immunogenetic associations, and the molecular and cellular biology of the cognate antigens.\n'
p6847
sg4
(lp6848
(dp6849
g7
I162
sg8
VP12004
p6850
sg10
I62
sg11
Vproliferating cell nuclear antigen ribosomal ribonucleoprotein
p6851
sg13
I6
sa(dp6852
g7
I144
sg8
VP37268
p6853
sg10
I4
sg11
VSS-A
p6854
sg13
I1
sa(dp6855
g7
I326
sg8
g107
sg10
I15
sg11
VRNA polymerases
p6856
sg13
I2
sa(dp6857
g7
I343
sg8
VP22087
p6858
sg10
I11
sg11
Vfibrillarin
p6859
sg13
I1
sa(dp6860
g7
I537
sg8
VP20333
p6861
sg10
I3
sg11
Vp80
p6862
sg13
I1
sa(dp6863
g7
I153
sg8
VP37268
p6864
sg10
I4
sg11
VSS-B
p6865
sg13
I1
sa(dp6866
g7
I114
sg8
VP26599
p6867
sg10
I28
sg11
VU1-nuclear ribonucleoprotein
p6868
sg13
I2
sa(dp6869
g7
I541
sg8
VP38432
p6870
sg10
I6
sg11
Vcoilin
p6871
sg13
I1
sa(dp6872
g7
I99
sg8
VP14209
p6873
sg10
I13
sg11
VSmith antigen
p6874
sg13
I2
sa(dp6875
g7
I153
sg8
VP37268
p6876
sg10
I4
sg11
VSS-B
p6877
sg13
I1
sasg23
(lp6878
(dp6879
g7
I286
sg26
VC0036421
p6880
sg10
I18
sg11
Vsystemic sclerosis
p6881
sg13
I2
sa(dp6882
g7
I356
sg26
VC0085655
p6883
sg10
I12
sg11
Vpolymyositis
p6884
sg13
I1
sa(dp6885
g7
I69
sg26
VC0024141
p6886
sg10
I28
sg11
Vsystemic lupus erythematosus
p6887
sg13
I3
sa(dp6888
g7
I356
sg26
VC0085655
p6889
sg10
I12
sg11
Vpolymyositis
p6890
sg13
I1
sa(dp6891
g7
I395
sg26
VC0221056
p6892
sg10
I15
sg11
Vdermatomyositis
p6893
sg13
I1
sasa(dp6894
g2
S'However, IL-17 deficiency did not affect the development of dermatitis at all, in clear contrast to that of arthritis and aortitis.\n'
p6895
sg4
(lp6896
sg23
(lp6897
(dp6898
g7
I108
sg26
VC0003864
p6899
sg10
I9
sg11
Varthritis
p6900
sg13
I1
sa(dp6901
g7
I122
sg26
VC0003509
p6902
sg10
I8
sg11
Vaortitis
p6903
sg13
I1
sa(dp6904
g7
I60
sg26
VC0011603
p6905
sg10
I10
sg11
Vdermatitis
p6906
sg13
I1
sasa(dp6907
g2
S'The development of arthritis and aortitis was significantly suppressed by the deficiency of TNFalpha or IL-17.\n'
p6908
sg4
(lp6909
(dp6910
g7
I92
sg8
VP01375
p6911
sg10
I8
sg11
VTNFalpha
p6912
sg13
I1
sasg23
(lp6913
(dp6914
g7
I19
sg26
VC0003864
p6915
sg10
I9
sg11
Varthritis
p6916
sg13
I1
sa(dp6917
g7
I33
sg26
VC0003509
p6918
sg10
I8
sg11
Vaortitis
p6919
sg13
I1
sasa(dp6920
g2
S"Apolipoprotein E (ApoE) has been extensively studied in Alzheimer's disease (AD), but little is known of apolipoprotein A-I (ApoA-I) in cerebrospinal fluid (CSF).\n"
p6921
sg4
(lp6922
(dp6923
g7
I105
sg8
VP02647
p6924
sg10
I18
sg11
Vapolipoprotein A-I
p6925
sg13
I2
sa(dp6926
g7
I18
sg8
VP02649
p6927
sg10
I4
sg11
VApoE
p6928
sg13
I1
sa(dp6929
g7
I0
sg8
VP02649
p6930
sg10
I16
sg11
VApolipoprotein E
p6931
sg13
I2
sa(dp6932
g7
I125
sg8
VP02647
p6933
sg10
I6
sg11
VApoA-I
p6934
sg13
I1
sasg23
(lp6935
(dp6936
g7
I56
sg26
VC1521724
p6937
sg10
I19
sg11
VAlzheimer's disease
p6938
sg13
I2
sa(dp6939
g7
I77
sg26
VC1521724
p6940
sg10
I2
sg11
VAD
p6941
sg13
I1
sasa(dp6942
g2
S"Objective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.\n"
p6943
sg4
(lp6944
(dp6945
g7
I2137
sg8
VP21579
p6946
sg10
I4
sg11
VSyt1
p6947
sg13
I1
sa(dp6948
g7
I1886
sg8
VP02647
p6949
sg10
I5
sg11
VApoA1
p6950
sg13
I1
sa(dp6951
g7
I1065
sg8
VP00390
p6952
sg10
I10
sg11
VLZ-H group
p6953
sg13
I2
sa(dp6954
g7
I2142
sg8
VP02649
p6955
sg10
I4
sg11
VApoE
p6956
sg13
I1
sa(dp6957
g7
I145
sg8
VP48651
p6958
sg10
I8
sg11
VAPP/PS-1
p6959
sg13
I1
sa(dp6960
g7
I2142
sg8
VP02649
p6961
sg10
I4
sg11
VApoE
p6962
sg13
I1
sa(dp6963
g7
I2603
sg8
g107
sg10
I16
sg11
VABeta-40 protein
p6964
sg13
I2
sa(dp6965
g7
I1886
sg8
VP02647
p6966
sg10
I5
sg11
VApoA1
p6967
sg13
I1
sa(dp6968
g7
I2021
sg8
g107
sg10
I8
sg11
VABeta-40
p6969
sg13
I1
sa(dp6970
g7
I1065
sg8
VP00390
p6971
sg10
I10
sg11
VLZ-H group
p6972
sg13
I2
sa(dp6973
g7
I145
sg8
g107
sg10
I3
sg11
VAPP
p6974
sg13
I1
sa(dp6975
g7
I1065
sg8
VP00390
p6976
sg10
I10
sg11
VLZ-H group
p6977
sg13
I2
sa(dp6978
g7
I149
sg8
VP48651
p6979
sg10
I4
sg11
VPS-1
p6980
sg13
I1
sa(dp6981
g7
I2137
sg8
VP21579
p6982
sg10
I4
sg11
VSyt1
p6983
sg13
I1
sasg23
(lp6984
(dp6985
g7
I102
sg26
VC0004368
p6986
sg10
I12
sg11
Vautoimmunity
p6987
sg13
I1
sa(dp6988
g7
I172
sg26
VC1521724
p6989
sg10
I19
sg11
VAlzheimer's disease
p6990
sg13
I2
sa(dp6991
g7
I2494
sg26
VC0004930
p6992
sg10
I18
sg11
Vbehavior disorders
p6993
sg13
I2
sa(dp6994
g7
I653
sg26
VC0443146
p6995
sg10
I10
sg11
Vautoimmune
p6996
sg13
I1
sa(dp6997
g7
I653
sg26
VC0443146
p6998
sg10
I10
sg11
Vautoimmune
p6999
sg13
I1
sasa(dp7000
g2
S'We aimed to explore the correlations between eukaryotic translation initiation factor 3, subunit A (eIF3a) polymorphisms and susceptibility to and chemoradiotherapy efficacy in cervical carcinoma.\n'
p7001
sg4
(lp7002
(dp7003
g7
I100
sg8
g107
sg10
I5
sg11
VeIF3a
p7004
sg13
I1
sasg23
(lp7005
(dp7006
g7
I177
sg26
VC0302592
p7007
sg10
I18
sg11
Vcervical carcinoma
p7008
sg13
I2
sasa(dp7009
g2
S'Compared with carriers of the CC genotype, carriers of the T genotype of the eIF3a Arg803Lys C&gt;T polymorphism had a higher risk of cervical carcinoma.\n'
p7010
sg4
(lp7011
(dp7012
g7
I77
sg8
g107
sg10
I17
sg11
VeIF3a Arg803Lys C
p7013
sg13
I3
sasg23
(lp7014
(dp7015
g7
I134
sg26
VC0302592
p7016
sg10
I18
sg11
Vcervical carcinoma
p7017
sg13
I2
sasa(dp7018
g2
S'Univariate analysis revealed that age, eIF3a Arg803Lys C&gt;T polymorphism, differentiation degree, FIGO stage, and LNM were prognostic factors of cervical carcinoma, and multivariate analysis showed that age &gt;= 60 years, higher FIGO stage, and LNM, as well as the CT and TT genotypes of the eIF3a Arg803Lys C&gt;T polymorphism, were risk factors related to the prognosis of cervical carcinoma.\n'
p7019
sg4
(lp7020
(dp7021
g7
I39
sg8
g107
sg10
I17
sg11
VeIF3a Arg803Lys C
p7022
sg13
I3
sa(dp7023
g7
I39
sg8
g107
sg10
I17
sg11
VeIF3a Arg803Lys C
p7024
sg13
I3
sasg23
(lp7025
(dp7026
g7
I147
sg26
VC0302592
p7027
sg10
I18
sg11
Vcervical carcinoma
p7028
sg13
I2
sa(dp7029
g7
I147
sg26
VC0302592
p7030
sg10
I18
sg11
Vcervical carcinoma
p7031
sg13
I2
sasa(dp7032
g2
S'The eIF3a Arg803Lys C&gt;T polymorphism is connected with a higher susceptibility to cervical carcinoma and may affect chemoradiotherapy efficacy in and prognosis of cervical carcinoma.\n'
p7033
sg4
(lp7034
(dp7035
g7
I4
sg8
g107
sg10
I17
sg11
VeIF3a Arg803Lys C
p7036
sg13
I3
sasg23
(lp7037
(dp7038
g7
I85
sg26
VC0302592
p7039
sg10
I18
sg11
Vcervical carcinoma
p7040
sg13
I2
sa(dp7041
g7
I85
sg26
VC0302592
p7042
sg10
I18
sg11
Vcervical carcinoma
p7043
sg13
I2
sasa(dp7044
g2
S'These findings suggest that the p185 neu may be a prognostic indicator not only for breast adenocarcinomas but also for lymphoproliferative disorders, and that the transforming p185 protein may be involved in the mechanisms of aggressive expansion of lymphoid neoplasias.\n'
p7045
sg4
(lp7046
(dp7047
g7
I37
sg8
VP04626
p7048
sg10
I3
sg11
Vneu
p7049
sg13
I1
sa(dp7050
g7
I32
sg8
g107
sg10
I4
sg11
Vp185
p7051
sg13
I1
sa(dp7052
g7
I177
sg8
g107
sg10
I12
sg11
Vp185 protein
p7053
sg13
I2
sasg23
(lp7054
(dp7055
g7
I227
sg26
VC0001807
p7056
sg10
I10
sg11
Vaggressive
p7057
sg13
I1
sa(dp7058
g7
I91
sg26
VC0001418
p7059
sg10
I15
sg11
Vadenocarcinomas
p7060
sg13
I1
sa(dp7061
g7
I120
sg26
VC0024314
p7062
sg10
I29
sg11
Vlymphoproliferative disorders
p7063
sg13
I2
sa(dp7064
g7
I260
sg26
VC0027651
p7065
sg10
I10
sg11
Vneoplasias
p7066
sg13
I1
sasa(dp7067
g2
S'The authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor.\n'
p7068
sg4
(lp7069
(dp7070
g7
I215
sg8
g107
sg10
I10
sg11
Vanti- p185
p7071
sg13
I2
sa(dp7072
g7
I110
sg8
VP04626
p7073
sg10
I4
sg11
VHER2
p7074
sg13
I1
sa(dp7075
g7
I105
sg8
g107
sg10
I4
sg11
Vp185
p7076
sg13
I1
sa(dp7077
g7
I313
sg8
g107
sg10
I22
sg11
Vgrowth factor receptor
p7078
sg13
I3
sa(dp7079
g7
I110
sg8
VP04626
p7080
sg10
I4
sg11
VHER2
p7081
sg13
I1
sasg23
(lp7082
(dp7083
g7
I265
sg26
VC0024623
p7084
sg10
I14
sg11
Vgastric cancer
p7085
sg13
I2
sa(dp7086
g7
I126
sg26
VC0278701
p7087
sg10
I22
sg11
Vgastric adenocarcinoma
p7088
sg13
I2
sasa(dp7089
g2
S'We evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years).\n'
p7090
sg4
(lp7091
(dp7092
g7
I43
sg8
VP04626
p7093
sg10
I4
sg11
VHER2
p7094
sg13
I1
sa(dp7095
g7
I38
sg8
g107
sg10
I4
sg11
Vp185
p7096
sg13
I1
sasg23
(lp7097
(dp7098
g7
I117
sg26
VC0278701
p7099
sg10
I22
sg11
Vgastric adenocarcinoma
p7100
sg13
I2
sasa(dp7101
g2
S'To explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed.\n'
p7102
sg4
(lp7103
(dp7104
g7
I43
sg8
VP04626
p7105
sg10
I4
sg11
VHER2
p7106
sg13
I1
sa(dp7107
g7
I23
sg8
g107
sg10
I19
sg11
Vhumanized anti-p185
p7108
sg13
I2
sa(dp7109
g7
I43
sg8
VP04626
p7110
sg10
I4
sg11
VHER2
p7111
sg13
I1
sa(dp7112
g7
I38
sg8
g107
sg10
I4
sg11
Vp185
p7113
sg13
I1
sasg23
(lp7114
(dp7115
g7
I131
sg26
VC0024623
p7116
sg10
I14
sg11
Vgastric cancer
p7117
sg13
I2
sasa(dp7118
g2
S'p185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008).\n'
p7119
sg4
(lp7120
(dp7121
g7
I5
sg8
VP04626
p7122
sg10
I4
sg11
VHER2
p7123
sg13
I1
sa(dp7124
g7
I0
sg8
g107
sg10
I4
sg11
Vp185
p7125
sg13
I1
sasg23
(lp7126
(dp7127
g7
I88
sg26
VC0349530
p7128
sg10
I20
sg11
Vearly gastric cancer
p7129
sg13
I3
sa(dp7130
g7
I68
sg26
VC0024623
p7131
sg10
I14
sg11
Vgastric cancer
p7132
sg13
I2
sasa(dp7133
g2
S'Among several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2).\n'
p7134
sg4
(lp7135
(dp7136
g7
I86
sg8
g107
sg10
I4
sg11
Vp185
p7137
sg13
I1
sa(dp7138
g7
I91
sg8
VP04626
p7139
sg10
I4
sg11
VHER2
p7140
sg13
I1
sasg23
(lp7141
(dp7142
g7
I21
sg26
VC0024623
p7143
sg10
I14
sg11
Vgastric cancer
p7144
sg13
I2
sasa(dp7145
g2
S'Trastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression.\n'
p7146
sg4
(lp7147
(dp7148
g7
I43
sg8
g107
sg10
I4
sg11
Vp185
p7149
sg13
I1
sa(dp7150
g7
I48
sg8
VP04626
p7151
sg10
I4
sg11
VHER2
p7152
sg13
I1
sa(dp7153
g7
I48
sg8
VP04626
p7154
sg10
I4
sg11
VHER2
p7155
sg13
I1
sa(dp7156
g7
I43
sg8
g107
sg10
I4
sg11
Vp185
p7157
sg13
I1
sasg23
(lp7158
(dp7159
g7
I75
sg26
VC0024623
p7160
sg10
I14
sg11
Vgastric cancer
p7161
sg13
I2
sa(dp7162
g7
I26
sg26
VC0334094
p7163
sg10
I13
sg11
Vproliferation
p7164
sg13
I1
sasa(dp7165
g2
S'S: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism.\n'
p7166
sg4
(lp7167
(dp7168
g7
I85
sg8
g107
sg10
I4
sg11
Vp185
p7169
sg13
I1
sa(dp7170
g7
I90
sg8
VP04626
p7171
sg10
I4
sg11
VHER2
p7172
sg13
I1
sasg23
(lp7173
(dp7174
g7
I121
sg26
VC0278701
p7175
sg10
I22
sg11
Vgastric adenocarcinoma
p7176
sg13
I2
sasa(dp7177
g2
S'This suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer.\n'
p7178
sg4
(lp7179
(dp7180
g7
I39
sg8
VP04626
p7181
sg10
I4
sg11
VHER2
p7182
sg13
I1
sa(dp7183
g7
I34
sg8
g107
sg10
I4
sg11
Vp185
p7184
sg13
I1
sasg23
(lp7185
(dp7186
g7
I72
sg26
VC0024623
p7187
sg10
I14
sg11
Vgastric cancer
p7188
sg13
I2
sasa(dp7189
g2
S'Administration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs.\n'
p7190
sg4
(lp7191
(dp7192
g7
I85
sg8
VP01133
p7193
sg10
I40
sg11
Vhuman epidermal growth factor receptor 2
p7194
sg13
I6
sa(dp7195
g7
I127
sg8
VP04626
p7196
sg10
I4
sg11
VHER2
p7197
sg13
I1
sa(dp7198
g7
I133
sg8
g107
sg10
I4
sg11
Vp185
p7199
sg13
I1
sa(dp7200
g7
I127
sg8
VP04626
p7201
sg10
I4
sg11
VHER2
p7202
sg13
I1
sasg23
(lp7203
(dp7204
g7
I194
sg26
VC0024623
p7205
sg10
I14
sg11
Vgastric cancer
p7206
sg13
I2
sa(dp7207
g7
I210
sg26
VC0024623
p7208
sg10
I2
sg11
VGC
p7209
sg13
I1
sa(dp7210
g7
I210
sg26
VC0024623
p7211
sg10
I2
sg11
VGC
p7212
sg13
I1
sasa(dp7213
g2
S'Eukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly expressed in lung cancer.\n'
p7214
sg4
(lp7215
(dp7216
g7
I54
sg8
g107
sg10
I5
sg11
VeIF3a
p7217
sg13
I1
sa(dp7218
g7
I54
sg8
g107
sg10
I5
sg11
VeIF3a
p7219
sg13
I1
sa(dp7220
g7
I0
sg8
g107
sg10
I52
sg11
VEukaryotic translation initiation factor 3 subunit A
p7221
sg13
I7
sasg23
(lp7222
(dp7223
g7
I168
sg26
VC0684249
p7224
sg10
I11
sg11
Vlung cancer
p7225
sg13
I2
sasa(dp7226
g2
S'In this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).\n'
p7227
sg4
(lp7228
(dp7229
g7
I82
sg8
g107
sg10
I5
sg11
VeIF3a
p7230
sg13
I1
sasg23
(lp7231
(dp7232
g7
I206
sg26
VC0007131
p7233
sg10
I5
sg11
VNSCLC
p7234
sg13
I1
sa(dp7235
g7
I178
sg26
VC0007131
p7236
sg10
I26
sg11
Vnon-small cell lung cancer
p7237
sg13
I4
sasa(dp7238
g2
S'The positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.\n'
p7239
sg4
(lp7240
(dp7241
g7
I32
sg8
g107
sg10
I5
sg11
VeIF3a
p7242
sg13
I1
sasg23
(lp7243
(dp7244
g7
I122
sg26
VC0007131
p7245
sg10
I5
sg11
VNSCLC
p7246
sg13
I1
sasa(dp7247
g2
S'To investigate the correlation between eukaryotic translation initiation factor 3, subunit A (eIF3a) and human epididymis protein 4 (HE4) expression and ovarian cancer.\n'
p7248
sg4
(lp7249
(dp7250
g7
I133
sg8
VP01031
p7251
sg10
I3
sg11
VHE4
p7252
sg13
I1
sa(dp7253
g7
I105
sg8
VP01031
p7254
sg10
I26
sg11
Vhuman epididymis protein 4
p7255
sg13
I4
sa(dp7256
g7
I94
sg8
g107
sg10
I5
sg11
VeIF3a
p7257
sg13
I1
sasg23
(lp7258
(dp7259
g7
I153
sg26
VC1140680
p7260
sg10
I14
sg11
Vovarian cancer
p7261
sg13
I2
sasa(dp7262
g2
S'RT-PCR or immunohistochemistry was used to examine eIF3a and HE4 mRNA or protein expression in ovarian tissues from patients with ovarian cancer (n=181) or benign ovarian tumors, or from the healthy women.\n'
p7263
sg4
(lp7264
(dp7265
g7
I51
sg8
g107
sg10
I5
sg11
VeIF3a
p7266
sg13
I1
sasg23
(lp7267
(dp7268
g7
I130
sg26
VC1140680
p7269
sg10
I14
sg11
Vovarian cancer
p7270
sg13
I2
sa(dp7271
g7
I156
sg26
VC0004997
p7272
sg10
I21
sg11
Vbenign ovarian tumors
p7273
sg13
I3
sasa(dp7274
g2
S'There were significant differences in mRNA and protein expression of eIF3a and HE4 among normal ovarian tissues, benign ovarian tumor tissues, and ovarian cancer tissues (P&lt; 0.05).\n'
p7275
sg4
(lp7276
(dp7277
g7
I69
sg8
g107
sg10
I5
sg11
VeIF3a
p7278
sg13
I1
sasg23
(lp7279
(dp7280
g7
I147
sg26
VC1140680
p7281
sg10
I14
sg11
Vovarian cancer
p7282
sg13
I2
sa(dp7283
g7
I113
sg26
VC0004997
p7284
sg10
I20
sg11
Vbenign ovarian tumor
p7285
sg13
I3
sasa(dp7286
g2
S'There were significant differences in mRNA expression of eIF3a and HE4 between the normal tissues and the ovarian cancer tissues, or between the benign ovarian tumor tissues and the normal tissues (P&lt; 0.001).\n'
p7287
sg4
(lp7288
(dp7289
g7
I57
sg8
g107
sg10
I5
sg11
VeIF3a
p7290
sg13
I1
sasg23
(lp7291
(dp7292
g7
I145
sg26
VC0004997
p7293
sg10
I20
sg11
Vbenign ovarian tumor
p7294
sg13
I3
sa(dp7295
g7
I106
sg26
VC1140680
p7296
sg10
I14
sg11
Vovarian cancer
p7297
sg13
I2
sasa(dp7298
g2
S'The mRNA expression of eIF3a in the normal ovarian tissues was significantly higher than that in the benign ovarian tumor tissues or that in the ovarian cancer tissues.\n'
p7299
sg4
(lp7300
(dp7301
g7
I23
sg8
g107
sg10
I5
sg11
VeIF3a
p7302
sg13
I1
sasg23
(lp7303
(dp7304
g7
I101
sg26
VC0004997
p7305
sg10
I20
sg11
Vbenign ovarian tumor
p7306
sg13
I3
sa(dp7307
g7
I145
sg26
VC1140680
p7308
sg10
I14
sg11
Vovarian cancer
p7309
sg13
I2
sasa(dp7310
g2
S'Positive expression rates for eIF3a or HE4 protein in normal, benign tumor, and cancer tissues were 0, 66.7%, and 81.0% or 0, 27.8%, and 56.2%, respectively.\n'
p7311
sg4
(lp7312
(dp7313
g7
I30
sg8
g107
sg10
I5
sg11
VeIF3a
p7314
sg13
I1
sasg23
(lp7315
(dp7316
g7
I62
sg26
VC0086692
p7317
sg10
I12
sg11
Vbenign tumor
p7318
sg13
I2
sa(dp7319
g7
I80
sg26
VC0006826
p7320
sg10
I6
sg11
Vcancer
p7321
sg13
I1
sasa(dp7322
g2
S'There were significant differences in positive expression rates of eIF3a protein and HE4 protein between the ovarian tumor tissues and benign ovarian tumor tissues, between the ovarian cancer tissues and the normal ovarian tissues, or between the benign ovarian tumor tissues and the normal ovarian tissues (P&lt; 0.001).\n'
p7323
sg4
(lp7324
(dp7325
g7
I67
sg8
g107
sg10
I13
sg11
VeIF3a protein
p7326
sg13
I2
sasg23
(lp7327
(dp7328
g7
I135
sg26
VC0004997
p7329
sg10
I20
sg11
Vbenign ovarian tumor
p7330
sg13
I3
sa(dp7331
g7
I109
sg26
VC0919267
p7332
sg10
I13
sg11
Vovarian tumor
p7333
sg13
I2
sa(dp7334
g7
I135
sg26
VC0004997
p7335
sg10
I20
sg11
Vbenign ovarian tumor
p7336
sg13
I3
sa(dp7337
g7
I177
sg26
VC1140680
p7338
sg10
I14
sg11
Vovarian cancer
p7339
sg13
I2
sasa(dp7340
g2
S'The expressions of eIF3a and HE4 are associated with ovarian cancer, and extracellular regulated protein kinases may play a role in the interaction between eIF3a and HE4.\n'
p7341
sg4
(lp7342
(dp7343
g7
I19
sg8
g107
sg10
I5
sg11
VeIF3a
p7344
sg13
I1
sa(dp7345
g7
I73
sg8
VP10398
p7346
sg10
I39
sg11
Vextracellular regulated protein kinases
p7347
sg13
I4
sa(dp7348
g7
I19
sg8
g107
sg10
I5
sg11
VeIF3a
p7349
sg13
I1
sasg23
(lp7350
(dp7351
g7
I53
sg26
VC1140680
p7352
sg10
I14
sg11
Vovarian cancer
p7353
sg13
I2
sasa(dp7354
g2
S'We describe an ultrasensitive electrochemical nucleic acid assay amplified by carbon nanotubes (CNTs)-based labels for the detection of human acute lymphocytic leukemia (ALL)-related p185 BCR-ABL fusion transcript.\n'
p7355
sg4
(lp7356
(dp7357
g7
I192
sg8
VP55157
p7358
sg10
I3
sg11
VABL
p7359
sg13
I1
sa(dp7360
g7
I183
sg8
g107
sg10
I4
sg11
Vp185
p7361
sg13
I1
sa(dp7362
g7
I188
sg8
VP11274
p7363
sg10
I3
sg11
VBCR
p7364
sg13
I1
sasg23
(lp7365
(dp7366
g7
I192
sg26
VC0000744
p7367
sg10
I3
sg11
VABL
p7368
sg13
I1
sa(dp7369
g7
I142
sg26
VC1961102
p7370
sg10
I26
sg11
Vacute lymphocytic leukemia
p7371
sg13
I3
sa(dp7372
g7
I170
sg26
VC1961102
p7373
sg10
I3
sg11
VALL
p7374
sg13
I1
sasa(dp7375
g2
S'Plasma levels of annexin V-MP, endothelial-derived MP, platelet-derived MP (CD61+ and P-Selectin+), leukocyte-derived MP, tissue factor-bearing (TF+) and CD36+MP were prospectively measured in 20 patients with III degree obesity (BMI &gt;= 40 kg/m(2)) before (T0) and 3 (T3) and 12 (T12) months after sleeve gastrectomy (SLG).\n'
p7376
sg4
(lp7377
(dp7378
g7
I100
sg8
VP13726
p7379
sg10
I49
sg11
Vleukocyte-derived MP, tissue factor-bearing (TF+)
p7380
sg13
I5
sa(dp7381
g7
I17
sg8
VP08758
p7382
sg10
I57
sg11
Vannexin V-MP, endothelial-derived MP, platelet-derived MP
p7383
sg13
I6
sa(dp7384
g7
I76
sg8
VP05106
p7385
sg10
I5
sg11
VCD61+
p7386
sg13
I1
sasg23
(lp7387
(dp7388
g7
I221
sg26
VC0028754
p7389
sg10
I7
sg11
Vobesity
p7390
sg13
I1
sasa(dp7391
g2
S'Key messages Bilirubin levels are inversely related to cardiovascular disease, and overexpression of heme oxygenase-1 (the enzyme that determines bilirubin production) has prevented post-infarction ventricular remodeling in experimental animals, but the association between bilirubin levels and the progression of ventricular volumes and function in patients with acute myocardial infarction remained unexplored.\n'
p7392
sg4
(lp7393
(dp7394
g7
I101
sg8
VP09601
p7395
sg10
I16
sg11
Vheme oxygenase-1
p7396
sg13
I2
sasg23
(lp7397
(dp7398
g7
I187
sg26
VC0021308
p7399
sg10
I10
sg11
Vinfarction
p7400
sg13
I1
sa(dp7401
g7
I55
sg26
VC0007222
p7402
sg10
I22
sg11
Vcardiovascular disease
p7403
sg13
I2
sa(dp7404
g7
I364
sg26
VC0155626
p7405
sg10
I27
sg11
Vacute myocardial infarction
p7406
sg13
I3
sasa(dp7407
g2
S'HO-1 is known to be protective in the setting of acute myocardial infarction.\n'
p7408
sg4
(lp7409
(dp7410
g7
I0
sg8
VP09601
p7411
sg10
I4
sg11
VHO-1
p7412
sg13
I1
sasg23
(lp7413
(dp7414
g7
I49
sg26
VC0155626
p7415
sg10
I27
sg11
Vacute myocardial infarction
p7416
sg13
I3
sasa(dp7417
g2
S'In vitro experiments revealed enteropeptidase as a putative substrate for Bace1 suggesting a role in acute pancreatitis.\n'
p7418
sg4
(lp7419
(dp7420
g7
I74
sg8
VP56817
p7421
sg10
I5
sg11
VBace1
p7422
sg13
I1
sa(dp7423
g7
I30
sg8
VP98073
p7424
sg10
I15
sg11
Venteropeptidase
p7425
sg13
I1
sasg23
(lp7426
(dp7427
g7
I101
sg26
VC0001339
p7428
sg10
I18
sg11
Vacute pancreatitis
p7429
sg13
I2
sasa(dp7430
g2
S'acute necrotizing pancreatitis was induced in anesthetized pigs by the retrograde infusion of 1 ml/kg of 5% sodium taurocholate and 8 U/kg enterokinase in the pancreatic duct.\n'
p7431
sg4
(lp7432
(dp7433
g7
I134
sg8
VP98073
p7434
sg10
I17
sg11
VU/kg enterokinase
p7435
sg13
I2
sasg23
(lp7436
(dp7437
g7
I0
sg26
VC0267941
p7438
sg10
I30
sg11
Vacute necrotizing pancreatitis
p7439
sg13
I3
sasa(dp7440
g2
S'Conversely, duodenopancreatic reflux of proteolytically active enteropeptidase may cause acute and chronic pancreatitis.\n'
p7441
sg4
(lp7442
(dp7443
g7
I63
sg8
VP98073
p7444
sg10
I15
sg11
Venteropeptidase
p7445
sg13
I1
sasg23
(lp7446
(dp7447
g7
I99
sg26
VC0149521
p7448
sg10
I20
sg11
Vchronic pancreatitis
p7449
sg13
I2
sa(dp7450
g7
I30
sg26
VC0017168
p7451
sg10
I6
sg11
Vreflux
p7452
sg13
I1
sasa(dp7453
g2
S'A noninvasive model of necrohemorrhagic pancreatitis induced by simultaneous intravenous cerulein/enterokinase (EK) infusion has recently been established in rats.\n'
p7454
sg4
(lp7455
(dp7456
g7
I112
sg8
VP98073
p7457
sg10
I2
sg11
VEK
p7458
sg13
I1
sa(dp7459
g7
I89
sg8
VP98073
p7460
sg10
I21
sg11
Vcerulein/enterokinase
p7461
sg13
I1
sasg23
(lp7462
(dp7463
g7
I40
sg26
VC0030305
p7464
sg10
I12
sg11
Vpancreatitis
p7465
sg13
I1
sasa(dp7466
g2
S'Study hemodynamic pattern and lipoperoxidation during methylene blue (MB) treatment on taurocholate - enterokinase induced acute pancreatitis (AP).\n'
p7467
sg4
(lp7468
(dp7469
g7
I87
sg8
VP98073
p7470
sg10
I27
sg11
Vtaurocholate - enterokinase
p7471
sg13
I3
sasg23
(lp7472
(dp7473
g7
I123
sg26
VC0001339
p7474
sg10
I18
sg11
Vacute pancreatitis
p7475
sg13
I2
sa(dp7476
g7
I143
sg26
VC0001339
p7477
sg10
I2
sg11
VAP
p7478
sg13
I1
sasa(dp7479
g2
S'The HLA-B47,DR7 haplotype in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency contains a deletion of most of the active CYP21 gene and the entire adjacent C4B gene.\n'
p7480
sg4
(lp7481
(dp7482
g7
I141
sg8
VP08686
p7483
sg10
I10
sg11
VCYP21 gene
p7484
sg13
I2
sa(dp7485
g7
I176
sg8
VP04003
p7486
sg10
I8
sg11
VC4B gene
p7487
sg13
I2
sa(dp7488
g7
I12
sg8
VP13761
p7489
sg10
I13
sg11
VDR7 haplotype
p7490
sg13
I2
sa(dp7491
g7
I4
sg8
VP30486
p7492
sg10
I7
sg11
VHLA-B47
p7493
sg13
I1
sa(dp7494
g7
I73
sg8
VP08686
p7495
sg10
I14
sg11
V21-hydroxylase
p7496
sg13
I1
sasg23
(lp7497
(dp7498
g7
I61
sg26
VC0520463
p7499
sg10
I3
sg11
VCAH
p7500
sg13
I1
sa(dp7501
g7
I29
sg26
VC0001627
p7502
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p7503
sg13
I3
sa(dp7504
g7
I73
sg26
VC0852654
p7505
sg10
I25
sg11
V21-hydroxylase deficiency
p7506
sg13
I2
sasa(dp7507
g2
S"The HLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7 is associated with congenital adrenal hyperplasia (CAH), since it only carries the dysfunctional steroid 21-hydroxylase A pseudogene as well as the 5' adjacent complement C4A gene.\n"
p7508
sg4
(lp7509
(dp7510
g7
I4
sg8
VP30486
p7511
sg10
I38
sg11
VHLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7
p7512
sg13
I3
sa(dp7513
g7
I140
sg8
VP08686
p7514
sg10
I35
sg11
Vsteroid 21-hydroxylase A pseudogene
p7515
sg13
I4
sa(dp7516
g7
I191
sg8
g107
sg10
I31
sg11
V5' adjacent complement C4A gene
p7517
sg13
I5
sasg23
(lp7518
(dp7519
g7
I62
sg26
VC0001627
p7520
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p7521
sg13
I3
sa(dp7522
g7
I94
sg26
VC0520463
p7523
sg10
I3
sg11
VCAH
p7524
sg13
I1
sasa(dp7525
g2
S'The mutation of vesicle-associated membrane protein-associated protein B (VAPB) was proved to cause family amyotrophic lateral sclerosis (FALS).\n'
p7526
sg4
(lp7527
(dp7528
g7
I16
sg8
g107
sg10
I56
sg11
Vvesicle-associated membrane protein-associated protein B
p7529
sg13
I5
sa(dp7530
g7
I74
sg8
g107
sg10
I4
sg11
VVAPB
p7531
sg13
I1
sasg23
(lp7532
(dp7533
g7
I138
sg26
VC1862939
p7534
sg10
I4
sg11
VFALS
p7535
sg13
I1
sa(dp7536
g7
I100
sg26
VC1862939
p7537
sg10
I36
sg11
Vfamily amyotrophic lateral sclerosis
p7538
sg13
I4
sa(dp7539
g7
I16
sg26
VC0333262
p7540
sg10
I7
sg11
Vvesicle
p7541
sg13
I1
sasa(dp7542
g2
S'ALS8 is a late-onset familial autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS) caused by a point mutation (P56S) in the VAPB gene (VAMP associated protein isoform B).\n'
p7543
sg4
(lp7544
(dp7545
g7
I0
sg8
g107
sg10
I4
sg11
VALS8
p7546
sg13
I1
sa(dp7547
g7
I134
sg8
g107
sg10
I9
sg11
VVAPB gene
p7548
sg13
I2
sa(dp7549
g7
I145
sg8
g107
sg10
I33
sg11
VVAMP associated protein isoform B
p7550
sg13
I5
sasg23
(lp7551
(dp7552
g7
I0
sg26
VC1837728
p7553
sg10
I4
sg11
VALS8
p7554
sg13
I1
sa(dp7555
g7
I0
sg26
VC0002736
p7556
sg10
I3
sg11
VALS
p7557
sg13
I1
sa(dp7558
g7
I57
sg26
VC0002736
p7559
sg10
I29
sg11
VAmyotrophic Lateral Sclerosis
p7560
sg13
I3
sasa(dp7561
g2
S'This supports the loss of VAPB function in ALS8 pathogenesis and suggests that reducing intracellular PtdIns4P might be an effective therapeutic strategy in delaying progressive loss of motor neurons.\n'
p7562
sg4
(lp7563
(dp7564
g7
I43
sg8
g107
sg10
I4
sg11
VALS8
p7565
sg13
I1
sa(dp7566
g7
I26
sg8
g107
sg10
I4
sg11
VVAPB
p7567
sg13
I1
sa(dp7568
g7
I79
sg8
g107
sg10
I31
sg11
Vreducing intracellular PtdIns4P
p7569
sg13
I3
sasg23
(lp7570
(dp7571
g7
I48
sg26
VC0699748
p7572
sg10
I12
sg11
Vpathogenesis
p7573
sg13
I1
sa(dp7574
g7
I43
sg26
VC1837728
p7575
sg10
I4
sg11
VALS8
p7576
sg13
I1
sasa(dp7577
g2
S"Mutations in VAP-B that have been identified in familial forms of amyotrophic lateral sclerosis (ALS or Lou-Gehrig's disease) cause aggregation of the VAP-B protein, which then impairs its binding to several proteins, including Nir2.\n"
p7578
sg4
(lp7579
(dp7580
g7
I228
sg8
g107
sg10
I4
sg11
VNir2
p7581
sg13
I1
sa(dp7582
g7
I13
sg8
g107
sg10
I5
sg11
VVAP-B
p7583
sg13
I1
sa(dp7584
g7
I151
sg8
g107
sg10
I13
sg11
VVAP-B protein
p7585
sg13
I2
sasg23
(lp7586
(dp7587
g7
I97
sg26
VC0002736
p7588
sg10
I3
sg11
VALS
p7589
sg13
I1
sa(dp7590
g7
I66
sg26
VC0002736
p7591
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p7592
sg13
I3
sa(dp7593
g7
I108
sg26
VC0002736
p7594
sg10
I16
sg11
VGehrig's disease
p7595
sg13
I2
sasa(dp7596
g2
S'A mutation in VAPB causes a familial form of Amyotrophic Lateral Sclerosis.\n'
p7597
sg4
(lp7598
(dp7599
g7
I14
sg8
g107
sg10
I4
sg11
VVAPB
p7600
sg13
I1
sasg23
(lp7601
(dp7602
g7
I45
sg26
VC0002736
p7603
sg10
I29
sg11
VAmyotrophic Lateral Sclerosis
p7604
sg13
I3
sasa(dp7605
g2
S'We present two cases of Peters anomaly (Peters plus syndrome and a maximum manifestation variant) with abnormally thickened cornea and corneal staphyloma.\n'
p7606
sg4
(lp7607
sg23
(lp7608
(dp7609
g7
I24
sg26
VC0344559
p7610
sg10
I14
sg11
VPeters anomaly
p7611
sg13
I2
sa(dp7612
g7
I135
sg26
VC0152440
p7613
sg10
I18
sg11
Vcorneal staphyloma
p7614
sg13
I2
sa(dp7615
g7
I40
sg26
VC0796012
p7616
sg10
I20
sg11
VPeters plus syndrome
p7617
sg13
I3
sasa(dp7618
g2
S'Wnt3a and Wnt5a are ligands orchestrating the canonical and non-canonical pathways, respectively, with involvement in hepatocellular carcinoma (HCC).\n'
p7619
sg4
(lp7620
(dp7621
g7
I10
sg8
VP41221
p7622
sg10
I5
sg11
VWnt5a
p7623
sg13
I1
sa(dp7624
g7
I0
sg8
VP56704
p7625
sg10
I5
sg11
VWnt3a
p7626
sg13
I1
sasg23
(lp7627
(dp7628
g7
I144
sg26
VC2239176
p7629
sg10
I3
sg11
VHCC
p7630
sg13
I1
sa(dp7631
g7
I118
sg26
VC2239176
p7632
sg10
I24
sg11
Vhepatocellular carcinoma
p7633
sg13
I2
sasa(dp7634
g2
S'To investigate member 3a of Wingless-type MMTV integration site family (Wnt3a) expression in cancerous and surrounding tissues and the relationship between clinicopathologic features of hepatocellular carcinoma (HCC) and Wnt3a expression.\n'
p7635
sg4
(lp7636
(dp7637
g7
I15
sg8
VP61587
p7638
sg10
I9
sg11
Vmember 3a
p7639
sg13
I2
sa(dp7640
g7
I72
sg8
VP56704
p7641
sg10
I5
sg11
VWnt3a
p7642
sg13
I1
sa(dp7643
g7
I28
sg8
g107
sg10
I42
sg11
VWingless-type MMTV integration site family
p7644
sg13
I5
sa(dp7645
g7
I72
sg8
VP56704
p7646
sg10
I5
sg11
VWnt3a
p7647
sg13
I1
sasg23
(lp7648
(dp7649
g7
I212
sg26
VC2239176
p7650
sg10
I3
sg11
VHCC
p7651
sg13
I1
sa(dp7652
g7
I186
sg26
VC2239176
p7653
sg10
I24
sg11
Vhepatocellular carcinoma
p7654
sg13
I2
sasa(dp7655
g2
S'We then use a realistic GENESIS model to test two hypothesis about interneuron hypofunction and conclude that a reduction in GAD67 is the most likely candidate as the cause for hypofrontality as observed in Schizophrenia.\n'
p7656
sg4
(lp7657
(dp7658
g7
I125
sg8
VP49419
p7659
sg10
I5
sg11
VGAD67
p7660
sg13
I1
sasg23
(lp7661
(dp7662
g7
I79
sg26
VC0679221
p7663
sg10
I12
sg11
Vhypofunction
p7664
sg13
I1
sa(dp7665
g7
I207
sg26
VC0036341
p7666
sg10
I13
sg11
VSchizophrenia
p7667
sg13
I1
sasa(dp7668
g2
S'The objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients.\n'
p7669
sg4
(lp7670
(dp7671
g7
I74
sg8
g107
sg10
I41
sg11
VATP binding cassette subfamily B member 1
p7672
sg13
I7
sa(dp7673
g7
I117
sg8
VP08183
p7674
sg10
I5
sg11
VABCB1
p7675
sg13
I1
sa(dp7676
g7
I63
sg8
VP20815
p7677
sg10
I6
sg11
VCYP3A5
p7678
sg13
I1
sasg23
(lp7679
(dp7680
g7
I271
sg26
VC0278678
p7681
sg10
I31
sg11
Vmetastatic renal cell carcinoma
p7682
sg13
I4
sasa(dp7683
g2
S'Polymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability.\n'
p7684
sg4
(lp7685
(dp7686
g7
I28
sg8
VP20815
p7687
sg10
I8
sg11
VCYP3A5*1
p7688
sg13
I1
sa(dp7689
g7
I17
sg8
VP35916
p7690
sg10
I6
sg11
VVEGFR3
p7691
sg13
I1
sasg23
(lp7692
(dp7693
g7
I98
sg26
VC0007097
p7694
sg10
I9
sg11
Vcarcinoma
p7695
sg13
I1
sasa(dp7696
g2
S'To examine whether common genetic variation at the SLC10A1 locus is associated with risk of persistent HBV infection, haplotype-tagging and imputed single nucleotide polymorphisms (SNPs) were assessed in two case-control sample sets, totally including 2,550 cases (persistently HBV infected subjects, PIs) and 2,124 controls (spontaneously recovered subjects, SRs) of Southern Chinese ancestry.\n'
p7697
sg4
(lp7698
(dp7699
g7
I360
sg8
VP35270
p7700
sg10
I3
sg11
VSRs
p7701
sg13
I1
sa(dp7702
g7
I51
sg8
g107
sg10
I13
sg11
VSLC10A1 locus
p7703
sg13
I2
sasg23
(lp7704
(dp7705
g7
I107
sg26
VC0009450
p7706
sg10
I9
sg11
Vinfection
p7707
sg13
I1
sa(dp7708
g7
I103
sg26
VC0019163
p7709
sg10
I3
sg11
VHBV
p7710
sg13
I1
sa(dp7711
g7
I103
sg26
VC0019163
p7712
sg10
I3
sg11
VHBV
p7713
sg13
I1
sa(dp7714
g7
I360
sg26
VC0175693
p7715
sg10
I3
sg11
VSRs
p7716
sg13
I1
sasa(dp7717
g2
S'The effectiveness of topical terbinafine (TBF) to tinea pedis was evaluated an animal model in which guinea pigs were experimentally infected through their planta pedis with Trichophyton mentagrophytes, then a 1% TBF or butenafine (BTF) cream was administered topically once daily for 4 consecutive weeks.\n'
p7718
sg4
(lp7719
sg23
(lp7720
(dp7721
g7
I50
sg26
VC0040259
p7722
sg10
I11
sg11
Vtinea pedis
p7723
sg13
I2
sasa(dp7724
g2
S'However, mutations in RecQL4 result in three human disorders: (I) Rothmund-Thomson syndrome (RTS), (II) RAPADILINO and (III) Baller-Gerold syndrome (BGS).\n'
p7725
sg4
(lp7726
(dp7727
g7
I22
sg8
g107
sg10
I6
sg11
VRecQL4
p7728
sg13
I1
sasg23
(lp7729
(dp7730
g7
I66
sg26
VC0032339
p7731
sg10
I25
sg11
VRothmund-Thomson syndrome
p7732
sg13
I2
sa(dp7733
g7
I149
sg26
VC0265308
p7734
sg10
I3
sg11
VBGS
p7735
sg13
I1
sa(dp7736
g7
I93
sg26
VC0032339
p7737
sg10
I3
sg11
VRTS
p7738
sg13
I1
sa(dp7739
g7
I125
sg26
VC0265308
p7740
sg10
I22
sg11
VBaller-Gerold syndrome
p7741
sg13
I2
sasa(dp7742
g2
S'This is in accordance with clinical and epidemiological findings demonstrating that defects in three RecQL helicases, i.e., WRN, BLM, RECQL4, are related to human progeroid and cancer predisposition syndromes, i.e., Werner, Bloom, and Rothmund Thomson syndrome, respectively.\n'
p7743
sg4
(lp7744
(dp7745
g7
I101
sg8
VP46063
p7746
sg10
I15
sg11
VRecQL helicases
p7747
sg13
I2
sa(dp7748
g7
I129
sg8
VP54132
p7749
sg10
I3
sg11
VBLM
p7750
sg13
I1
sa(dp7751
g7
I134
sg8
g107
sg10
I6
sg11
VRECQL4
p7752
sg13
I1
sasg23
(lp7753
(dp7754
g7
I235
sg26
VC0032339
p7755
sg10
I25
sg11
VRothmund Thomson syndrome
p7756
sg13
I3
sa(dp7757
g7
I199
sg26
VC0039082
p7758
sg10
I9
sg11
Vsyndromes
p7759
sg13
I1
sa(dp7760
g7
I124
sg26
VC0043119
p7761
sg10
I3
sg11
VWRN
p7762
sg13
I1
sa(dp7763
g7
I177
sg26
VC0006826
p7764
sg10
I6
sg11
Vcancer
p7765
sg13
I1
sa(dp7766
g7
I129
sg26
VC0005859
p7767
sg10
I3
sg11
VBLM
p7768
sg13
I1
sasa(dp7769
g2
S'Human RecQ homologs include RECQ1, BLM, WRN, RECQ4, and RECQ5Beta, three of which have been linked to diseases with elevated risk of cancer and growth defects (Bloom Syndrome and Rothmund-Thomson Syndrome) or premature aging (Werner Syndrome).\n'
p7770
sg4
(lp7771
(dp7772
g7
I45
sg8
g107
sg10
I5
sg11
VRECQ4
p7773
sg13
I1
sa(dp7774
g7
I40
sg8
VP02545
p7775
sg10
I3
sg11
VWRN
p7776
sg13
I1
sa(dp7777
g7
I0
sg8
g107
sg10
I19
sg11
VHuman RecQ homologs
p7778
sg13
I3
sa(dp7779
g7
I28
sg8
VP46063
p7780
sg10
I5
sg11
VRECQ1
p7781
sg13
I1
sa(dp7782
g7
I35
sg8
VP54132
p7783
sg10
I3
sg11
VBLM
p7784
sg13
I1
sasg23
(lp7785
(dp7786
g7
I226
sg26
VC0043119
p7787
sg10
I15
sg11
VWerner Syndrome
p7788
sg13
I2
sa(dp7789
g7
I209
sg26
VC0231341
p7790
sg10
I15
sg11
Vpremature aging
p7791
sg13
I2
sa(dp7792
g7
I35
sg26
VC0005859
p7793
sg10
I3
sg11
VBLM
p7794
sg13
I1
sa(dp7795
g7
I133
sg26
VC0006826
p7796
sg10
I6
sg11
Vcancer
p7797
sg13
I1
sa(dp7798
g7
I160
sg26
VC0005859
p7799
sg10
I14
sg11
VBloom Syndrome
p7800
sg13
I2
sa(dp7801
g7
I179
sg26
VC0032339
p7802
sg10
I25
sg11
VRothmund-Thomson Syndrome
p7803
sg13
I2
sa(dp7804
g7
I40
sg26
VC0043119
p7805
sg10
I3
sg11
VWRN
p7806
sg13
I1
sasa(dp7807
g2
S'Depletion of PAICS largely cancelled breast cancer expansion, exemplifying a prognostic gene with breast cancer activity.\n'
p7808
sg4
(lp7809
sg23
(lp7810
(dp7811
g7
I37
sg26
VC0678222
p7812
sg10
I13
sg11
Vbreast cancer
p7813
sg13
I2
sa(dp7814
g7
I37
sg26
VC0678222
p7815
sg10
I13
sg11
Vbreast cancer
p7816
sg13
I2
sasa(dp7817
g2
S'We propose that pharmacological inhibition of components within this network, such as PAICS, may be used in conjunction with the Fra-1 prognostic classifier towards personalized management of poor prognosis breast cancer.\n'
p7818
sg4
(lp7819
(dp7820
g7
I129
sg8
VP15407
p7821
sg10
I5
sg11
VFra-1
p7822
sg13
I1
sa(dp7823
g7
I86
sg8
VP22234
p7824
sg10
I5
sg11
VPAICS
p7825
sg13
I1
sasg23
(lp7826
(dp7827
g7
I207
sg26
VC0678222
p7828
sg10
I13
sg11
Vbreast cancer
p7829
sg13
I2
sa(dp7830
g7
I129
sg26
VC1858361
p7831
sg10
I3
sg11
VFra
p7832
sg13
I1
sasa(dp7833
g2
S'Our goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression.\n'
p7834
sg4
(lp7835
sg23
(lp7836
(dp7837
g7
I112
sg26
VC0178874
p7838
sg10
I18
sg11
Vcancer progression
p7839
sg13
I2
sasa(dp7840
g2
S'Next-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer.\n'
p7841
sg4
(lp7842
(dp7843
g7
I130
sg8
VP22234
p7844
sg10
I40
sg11
VPhosphoribosylaminoimidazole Carboxylase
p7845
sg13
I2
sa(dp7846
g7
I232
sg8
VP22234
p7847
sg10
I5
sg11
VPAICS
p7848
sg13
I1
sa(dp7849
g7
I172
sg8
VP22234
p7850
sg10
I58
sg11
VPhosphoribosylaminoimidazole Succinocarboxamide Synthetase
p7851
sg13
I3
sasg23
(lp7852
(dp7853
g7
I266
sg26
VC0600139
p7854
sg10
I15
sg11
Vprostate cancer
p7855
sg13
I2
sasa(dp7856
g2
S'Through several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells.\n'
p7857
sg4
(lp7858
(dp7859
g7
I70
sg8
VP22234
p7860
sg10
I5
sg11
VPAICS
p7861
sg13
I1
sasg23
(lp7862
(dp7863
g7
I93
sg26
VC0334094
p7864
sg10
I13
sg11
Vproliferation
p7865
sg13
I1
sa(dp7866
g7
I123
sg26
VC0600139
p7867
sg10
I15
sg11
Vprostate cancer
p7868
sg13
I2
sa(dp7869
g7
I111
sg26
VC2699153
p7870
sg10
I8
sg11
Vinvasion
p7871
sg13
I1
sasa(dp7872
g2
S'We identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells.\n'
p7873
sg4
(lp7874
(dp7875
g7
I83
sg8
VP12524
p7876
sg10
I3
sg11
VMYC
p7877
sg13
I1
sa(dp7878
g7
I150
sg8
VP22234
p7879
sg10
I5
sg11
VPAICS
p7880
sg13
I1
sasg23
(lp7881
(dp7882
g7
I123
sg26
VC0600139
p7883
sg10
I15
sg11
Vprostate cancer
p7884
sg13
I2
sa(dp7885
g7
I123
sg26
VC0600139
p7886
sg10
I15
sg11
Vprostate cancer
p7887
sg13
I2
sasa(dp7888
g2
S'Here, we report that evaluation of PAICS in prostate cancer progression and its role in prostate cancer cell proliferation and invasion and suggest it as a valid therapeutic target.\n'
p7889
sg4
(lp7890
sg23
(lp7891
(dp7892
g7
I127
sg26
VC2699153
p7893
sg10
I8
sg11
Vinvasion
p7894
sg13
I1
sa(dp7895
g7
I53
sg26
VC0178874
p7896
sg10
I18
sg11
Vcancer progression
p7897
sg13
I2
sa(dp7898
g7
I109
sg26
VC0334094
p7899
sg10
I13
sg11
Vproliferation
p7900
sg13
I1
sa(dp7901
g7
I44
sg26
VC0600139
p7902
sg10
I15
sg11
Vprostate cancer
p7903
sg13
I2
sasa(dp7904
g2
S'We suggest JQ1, a BET-domain inhibitor, as possible therapeutic option in targeting PAICS in prostate cancer.\n'
p7905
sg4
(lp7906
sg23
(lp7907
(dp7908
g7
I93
sg26
VC0600139
p7909
sg10
I15
sg11
Vprostate cancer
p7910
sg13
I2
sasa(dp7911
g2
S'We discovered increased expression of phosphoribosyl amidotransferase (PPAT) and phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzymes of de novo purine biosynthetic pathway in lung adenocarcinomas.\n'
p7912
sg4
(lp7913
(dp7914
g7
I71
sg8
g107
sg10
I4
sg11
VPPAT
p7915
sg13
I1
sa(dp7916
g7
I183
sg8
VP22234
p7917
sg10
I5
sg11
VPAICS
p7918
sg13
I1
sa(dp7919
g7
I38
sg8
g107
sg10
I31
sg11
Vphosphoribosyl amidotransferase
p7920
sg13
I2
sa(dp7921
g7
I81
sg8
VP22234
p7922
sg10
I100
sg11
Vphosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase
p7923
sg13
I5
sasg23
(lp7924
(dp7925
g7
I245
sg26
VC0001418
p7926
sg10
I15
sg11
Vadenocarcinomas
p7927
sg13
I1
sasa(dp7928
g2
S'Transcript analyses from next-generation RNA sequencing and gene expression profiling studies suggested that PPAT and PAICS can serve as prognostic biomarkers for aggressive lung adenocarcinoma.\n'
p7929
sg4
(lp7930
(dp7931
g7
I109
sg8
g107
sg10
I4
sg11
VPPAT
p7932
sg13
I1
sa(dp7933
g7
I118
sg8
VP22234
p7934
sg10
I5
sg11
VPAICS
p7935
sg13
I1
sasg23
(lp7936
(dp7937
g7
I174
sg26
VC0152013
p7938
sg10
I19
sg11
Vlung adenocarcinoma
p7939
sg13
I2
sa(dp7940
g7
I163
sg26
VC0001807
p7941
sg10
I10
sg11
Vaggressive
p7942
sg13
I1
sasa(dp7943
g2
S'Furthermore we identified genomic amplification and aneuploidy of the divergently transcribed PPAT-PAICS genomic region in a subset of lung cancers.\n'
p7944
sg4
(lp7945
(dp7946
g7
I99
sg8
VP22234
p7947
sg10
I5
sg11
VPAICS
p7948
sg13
I1
sa(dp7949
g7
I94
sg8
g107
sg10
I4
sg11
VPPAT
p7950
sg13
I1
sasg23
(lp7951
(dp7952
g7
I135
sg26
VC0242379
p7953
sg10
I12
sg11
Vlung cancers
p7954
sg13
I2
sa(dp7955
g7
I52
sg26
VC0002938
p7956
sg10
I10
sg11
Vaneuploidy
p7957
sg13
I1
sa(dp7958
g7
I34
sg26
VC1705759
p7959
sg10
I13
sg11
Vamplification
p7960
sg13
I1
sasa(dp7961
g2
S'In summary, this study reveals the regulatory mechanisms by which purine biosynthetic pathway enzymes PPAT and PAICS, and pyruvate kinase activity is increased and exposes an existing metabolic vulnerability in lung cancer cells that can be explored for pharmacological intervention.\n'
p7962
sg4
(lp7963
(dp7964
g7
I102
sg8
g107
sg10
I4
sg11
VPPAT
p7965
sg13
I1
sa(dp7966
g7
I122
sg8
VP30613
p7967
sg10
I15
sg11
Vpyruvate kinase
p7968
sg13
I2
sa(dp7969
g7
I111
sg8
VP22234
p7970
sg10
I5
sg11
VPAICS
p7971
sg13
I1
sasg23
(lp7972
(dp7973
g7
I211
sg26
VC0684249
p7974
sg10
I11
sg11
Vlung cancer
p7975
sg13
I2
sasa(dp7976
g2
S'We also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which might deserve further investigations.\n'
p7977
sg4
(lp7978
(dp7979
g7
I58
sg8
g107
sg10
I6
sg11
VRBMXL1
p7980
sg13
I1
sa(dp7981
g7
I44
sg8
g107
sg10
I5
sg11
VMUC19
p7982
sg13
I1
sa(dp7983
g7
I51
sg8
VP22234
p7984
sg10
I5
sg11
VPAICS
p7985
sg13
I1
sa(dp7986
g7
I66
sg8
g107
sg10
I5
sg11
VKIF23
p7987
sg13
I1
sasg23
(lp7988
(dp7989
g7
I91
sg26
VC0025202
p7990
sg10
I8
sg11
Vmelanoma
p7991
sg13
I1
sasa(dp7992
g2
S'Alterations in PAICS expression in humans have been associated with various types of cancer.\n'
p7993
sg4
(lp7994
(dp7995
g7
I15
sg8
VP22234
p7996
sg10
I5
sg11
VPAICS
p7997
sg13
I1
sasg23
(lp7998
(dp7999
g7
I85
sg26
VC0006826
p8000
sg10
I6
sg11
Vcancer
p8001
sg13
I1
sasa(dp8002
g2
S'An IST1 clone, detected for the first time in 2000, was the most prevalent and responsible for the shigellosis epidemic in 2001 to 2003.\n'
p8003
sg4
(lp8004
(dp8005
g7
I3
sg8
VP53990
p8006
sg10
I4
sg11
VIST1
p8007
sg13
I1
sasg23
(lp8008
(dp8009
g7
I99
sg26
VC0013371
p8010
sg10
I11
sg11
Vshigellosis
p8011
sg13
I1
sasa(dp8012
g2
S'Patients with chronic kidney disease have high levels of serum sclerostin.\n'
p8013
sg4
(lp8014
sg23
(lp8015
(dp8016
g7
I14
sg26
VC1561643
p8017
sg10
I22
sg11
Vchronic kidney disease
p8018
sg13
I3
sasa(dp8019
g2
S'Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients.\n'
p8020
sg4
(lp8021
(dp8022
g7
I0
sg8
g107
sg10
I10
sg11
VSclerostin
p8023
sg13
I1
sasg23
(lp8024
(dp8025
g7
I38
sg26
VC0699748
p8026
sg10
I12
sg11
Vpathogenesis
p8027
sg13
I1
sa(dp8028
g7
I54
sg26
VC0342649
p8029
sg10
I22
sg11
Vvascular calcification
p8030
sg13
I2
sa(dp8031
g7
I152
sg26
VC1561643
p8032
sg10
I22
sg11
Vchronic kidney disease
p8033
sg13
I3
sasa(dp8034
g2
S'However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive.\n'
p8035
sg4
(lp8036
(dp8037
g7
I21
sg8
g107
sg10
I10
sg11
Vsclerostin
p8038
sg13
I1
sasg23
(lp8039
(dp8040
g7
I84
sg26
VC1561643
p8041
sg10
I22
sg11
Vchronic kidney disease
p8042
sg13
I3
sa(dp8043
g7
I35
sg26
VC0342649
p8044
sg10
I22
sg11
Vvascular calcification
p8045
sg13
I2
sasa(dp8046
g2
S'Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease.\n'
p8047
sg4
(lp8048
(dp8049
g7
I13
sg8
g107
sg10
I26
sg11
Vanti-sclerostin antibodies
p8050
sg13
I2
sasg23
(lp8051
(dp8052
g7
I112
sg26
VC1561643
p8053
sg10
I22
sg11
Vchronic kidney disease
p8054
sg13
I3
sasa(dp8055
g2
S'This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.\n'
p8056
sg4
(lp8057
sg23
(lp8058
(dp8059
g7
I93
sg26
VC0342649
p8060
sg10
I22
sg11
Vvascular calcification
p8061
sg13
I2
sa(dp8062
g7
I140
sg26
VC1561643
p8063
sg10
I22
sg11
Vchronic kidney disease
p8064
sg13
I3
sa(dp8065
g7
I140
sg26
VC1561643
p8066
sg10
I22
sg11
Vchronic kidney disease
p8067
sg13
I3
sasa(dp8068
g2
S'In this observational, cross-sectional study, circulating levels of sclerostin and other laboratory parameters of mineral and bone disease, including intact parathyroid hormone (PTH), calcium, phosphate, magnesium, 25(OH) D-vitamin, 1,25 (OH)2 D-vitamin, and bone specific alkaline phosphatase (BALP) were assessed in 100 patients with end-stage renal disease recruited from an ongoing longitudinal cohort study in Stockholm, Sweden.\n'
p8069
sg4
(lp8070
(dp8071
g7
I259
sg8
VP10696
p8072
sg10
I34
sg11
Vbone specific alkaline phosphatase
p8073
sg13
I4
sa(dp8074
g7
I178
sg8
VP01270
p8075
sg10
I3
sg11
VPTH
p8076
sg13
I1
sa(dp8077
g7
I150
sg8
VP01270
p8078
sg10
I26
sg11
Vintact parathyroid hormone
p8079
sg13
I3
sa(dp8080
g7
I295
sg8
VP10696
p8081
sg10
I4
sg11
VBALP
p8082
sg13
I1
sasg23
(lp8083
(dp8084
g7
I336
sg26
VC0022661
p8085
sg10
I23
sg11
Vend-stage renal disease
p8086
sg13
I3
sa(dp8087
g7
I126
sg26
VC0005940
p8088
sg10
I12
sg11
Vbone disease
p8089
sg13
I2
sasa(dp8090
g2
S'Findings from research into mineral bone disorder associated with CKD (CKD-MBD) could help the medical community to better understand the vascular actions of certain molecules, such as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their relevance to the management of different pathologies in the general population.\n'
p8091
sg4
(lp8092
(dp8093
g7
I197
sg8
g107
sg10
I27
sg11
Vfibroblast growth factor 23
p8094
sg13
I4
sa(dp8095
g7
I226
sg8
VP01270
p8096
sg10
I19
sg11
Vparathyroid hormone
p8097
sg13
I2
sasg23
(lp8098
(dp8099
g7
I36
sg26
VC0005940
p8100
sg10
I13
sg11
Vbone disorder
p8101
sg13
I2
sasa(dp8102
g2
S'In chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis.\n'
p8103
sg4
(lp8104
(dp8105
g7
I33
sg8
g107
sg10
I10
sg11
Vsclerostin
p8106
sg13
I1
sasg23
(lp8107
(dp8108
g7
I3
sg26
VC1561643
p8109
sg10
I22
sg11
Vchronic kidney disease
p8110
sg13
I3
sa(dp8111
g7
I27
sg26
VC1561643
p8112
sg10
I3
sg11
VCKD
p8113
sg13
I1
sasa(dp8114
g2
S'Clinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.\n'
p8115
sg4
(lp8116
sg23
(lp8117
sa(dp8118
g2
S'(3) Compared with the control group, the expression of CD63 in basophils increased in anaphylactic shock lung tissue.\n'
p8119
sg4
(lp8120
(dp8121
g7
I55
sg8
VP08962
p8122
sg10
I4
sg11
VCD63
p8123
sg13
I1
sasg23
(lp8124
(dp8125
g7
I86
sg26
VC0002792
p8126
sg10
I18
sg11
Vanaphylactic shock
p8127
sg13
I2
sa(dp8128
g7
I99
sg26
VC0035222
p8129
sg10
I10
sg11
Vshock lung
p8130
sg13
I2
sasa(dp8131
g2
S'To elucidate a potential mechanism involving BM88/Cend1, RanBPM and Dyrk1B in cell cycle progression/exit, we transiently co-expressed these proteins in mouse neuroblastoma Neuro 2a cells.\n'
p8132
sg4
(lp8133
(dp8134
g7
I68
sg8
g107
sg10
I6
sg11
VDyrk1B
p8135
sg13
I1
sa(dp8136
g7
I50
sg8
g107
sg10
I5
sg11
VCend1
p8137
sg13
I1
sa(dp8138
g7
I45
sg8
g107
sg10
I4
sg11
VBM88
p8139
sg13
I1
sa(dp8140
g7
I57
sg8
g107
sg10
I6
sg11
VRanBPM
p8141
sg13
I1
sasg23
(lp8142
(dp8143
g7
I153
sg26
VC1524043
p8144
sg10
I19
sg11
Vmouse neuroblastoma
p8145
sg13
I2
sasa(dp8146
g2
S'Calcium imaging experiments revealed that P2Y-induced calcium mobilization is diminished in mouse neuroblastoma Neuro 2a cells stably transfected with BM88 (N2A-BM88 cells) as compared with N2A cells or N2A cells differentiated with retinoic acid.\n'
p8147
sg4
(lp8148
sg23
(lp8149
(dp8150
g7
I92
sg26
VC1524043
p8151
sg10
I19
sg11
Vmouse neuroblastoma
p8152
sg13
I2
sasa(dp8153
g2
S'We report here that trichostatin-A (TSA) specifically induces the transcription of Cend1, a neuronal-lineage specific regulator of cell cycle exit and differentiation, in neuroblastoma Neuro2A cells, but not in non-neuronal cells.\n'
p8154
sg4
(lp8155
(dp8156
g7
I36
sg8
VP32119
p8157
sg10
I3
sg11
VTSA
p8158
sg13
I1
sa(dp8159
g7
I83
sg8
g107
sg10
I5
sg11
VCend1
p8160
sg13
I1
sa(dp8161
g7
I20
sg8
VP32119
p8162
sg10
I14
sg11
Vtrichostatin-A
p8163
sg13
I1
sasg23
(lp8164
(dp8165
g7
I171
sg26
VC0027819
p8166
sg10
I13
sg11
Vneuroblastoma
p8167
sg13
I1
sasa(dp8168
g2
S'Here we have used mouse neuroblastoma Neuro 2a cells as an in vitro model of neuronal differentiation to dissect the functional properties of BM88 by implementing gain- and loss-of-function approaches.\n'
p8169
sg4
(lp8170
sg23
(lp8171
(dp8172
g7
I18
sg26
VC1524043
p8173
sg10
I19
sg11
Vmouse neuroblastoma
p8174
sg13
I2
sasa(dp8175
g2
S'BM88 overexpression also results in increased levels of the cell cycle regulatory protein p53, and accumulation of the hypophosphorylated form of the retinoblastoma protein leading to cell cycle arrest, with concomitant decreased levels and, in many cells, cytoplasmic localization of cyclin D1.\n'
p8176
sg4
(lp8177
(dp8178
g7
I0
sg8
g107
sg10
I4
sg11
VBM88
p8179
sg13
I1
sa(dp8180
g7
I285
sg8
VP24385
p8181
sg10
I9
sg11
Vcyclin D1
p8182
sg13
I2
sa(dp8183
g7
I150
sg8
g107
sg10
I22
sg11
Vretinoblastoma protein
p8184
sg13
I2
sa(dp8185
g7
I82
sg8
VP42771
p8186
sg10
I11
sg11
Vprotein p53
p8187
sg13
I2
sasg23
(lp8188
(dp8189
g7
I150
sg26
VC0035335
p8190
sg10
I14
sg11
Vretinoblastoma
p8191
sg13
I1
sasa(dp8192
g2
S'Previous studies have shown that the BM88 antigen, a neuron-specific molecule, promotes the differentiation of mouse neuroblastoma cells [23] (Mamalaki A., Boutou E., Hurel C., Patsavoudi E., Tzartos S. and Matsas R. (1995) The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells.\n'
p8193
sg4
(lp8194
(dp8195
g7
I37
sg8
g107
sg10
I12
sg11
VBM88 antigen
p8196
sg13
I2
sa(dp8197
g7
I37
sg8
g107
sg10
I12
sg11
VBM88 antigen
p8198
sg13
I2
sasg23
(lp8199
(dp8200
g7
I111
sg26
VC1524043
p8201
sg10
I19
sg11
Vmouse neuroblastoma
p8202
sg13
I2
sa(dp8203
g7
I111
sg26
VC1524043
p8204
sg10
I19
sg11
Vmouse neuroblastoma
p8205
sg13
I2
sasa(dp8206
g2
S'Moreover, they respond differentially to growth factors [10] (Gomez J., Boutou E., Hurel C., Mamalaki A., Kentroti S. , Vernadakis A. and Matsas R. (1998) Overexpression of the neuron-specific molecule BM88 in mouse neuroblastoma cells: Altered responsiveness to growth factors.\n'
p8207
sg4
(lp8208
sg23
(lp8209
(dp8210
g7
I210
sg26
VC1524043
p8211
sg10
I19
sg11
Vmouse neuroblastoma
p8212
sg13
I2
sasa(dp8213
g2
S'Previous studies have shown that the BM88 antigen, a novel neuron-specific molecule, promotes the differentiation of mouse neuroblastoma (Neuro 2a) cells.\n'
p8214
sg4
(lp8215
(dp8216
g7
I37
sg8
g107
sg10
I12
sg11
VBM88 antigen
p8217
sg13
I2
sasg23
(lp8218
(dp8219
g7
I117
sg26
VC1524043
p8220
sg10
I19
sg11
Vmouse neuroblastoma
p8221
sg13
I2
sasa(dp8222
g2
S'In conclusion, our findings show that overexpression of the neuron-specific antigen BM88 in neuroblastoma cells modifies their properties with respect to growth factor sensitivity, and, hence, the Neuro 2a and Neuro 2a-BM88 are suitable cell models to examine the role of growth factors in neuronal differentiation.\n'
p8223
sg4
(lp8224
(dp8225
g7
I60
sg8
VP14209
p8226
sg10
I28
sg11
Vneuron-specific antigen BM88
p8227
sg13
I3
sa(dp8228
g7
I210
sg8
g107
sg10
I13
sg11
VNeuro 2a-BM88
p8229
sg13
I2
sasg23
(lp8230
(dp8231
g7
I92
sg26
VC0027819
p8232
sg10
I13
sg11
Vneuroblastoma
p8233
sg13
I1
sasa(dp8234
g2
S'Here, we investigated the expression stabilities of ten previously recommended reference genes (ABCT, CYP, EF1A, FBOX, GPDH, RPL30, TUA4, TUB4, TUA5, and UNK2) in soybean under biotic stress from Bean pod mottle virus (BPMV), powdery mildew (PMD), soybean aphid (SBA), and two-spotted spider mite (TSSM).\n'
p8235
sg4
(lp8236
(dp8237
g7
I102
sg8
g107
sg10
I3
sg11
VCYP
p8238
sg13
I1
sa(dp8239
g7
I125
sg8
VP62888
p8240
sg10
I5
sg11
VRPL30
p8241
sg13
I1
sa(dp8242
g7
I107
sg8
VP68104
p8243
sg10
I4
sg11
VEF1A
p8244
sg13
I1
sasg23
(lp8245
(dp8246
g7
I242
sg26
VC1832661
p8247
sg10
I3
sg11
VPMD
p8248
sg13
I1
sa(dp8249
g7
I226
sg26
VC1832661
p8250
sg10
I14
sg11
Vpowdery mildew
p8251
sg13
I2
sasa(dp8252
g2
S'In conclusion, the anti-B7-1 antibody approach may provide a novel therapy for allergic asthma.\n'
p8253
sg4
(lp8254
sg23
(lp8255
(dp8256
g7
I79
sg26
VC0155877
p8257
sg10
I15
sg11
Vallergic asthma
p8258
sg13
I2
sasa(dp8259
g2
S'To investigate whether there is altered expression and the clinical significance of soluble co-stimulatory molecules in asthmatic patients, plasma concentrations of sCTLA-4, sCD28, sCD80 and sCD86 in 51 adult allergic asthmatic adults with or without steroid treatment, and 35 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay (ELISA).\n'
p8260
sg4
(lp8261
sg23
(lp8262
(dp8263
g7
I120
sg26
VC0004096
p8264
sg10
I9
sg11
Vasthmatic
p8265
sg13
I1
sa(dp8266
g7
I120
sg26
VC0004096
p8267
sg10
I9
sg11
Vasthmatic
p8268
sg13
I1
sasa(dp8269
g2
S'The surface expression of T cell costimulatory molecules CTLA-4 and CD28 and their counter-ligands, B7 molecules (CD80, CD86), is differentially induced for T cell activation and expansion in allergic asthma.\n'
p8270
sg4
(lp8271
(dp8272
g7
I68
sg8
VP33681
p8273
sg10
I4
sg11
VCD28
p8274
sg13
I1
sa(dp8275
g7
I120
sg8
VP42081
p8276
sg10
I4
sg11
VCD86
p8277
sg13
I1
sa(dp8278
g7
I26
sg8
VP16410
p8279
sg10
I37
sg11
VT cell costimulatory molecules CTLA-4
p8280
sg13
I5
sa(dp8281
g7
I114
sg8
VP33681
p8282
sg10
I4
sg11
VCD80
p8283
sg13
I1
sasg23
(lp8284
(dp8285
g7
I192
sg26
VC0155877
p8286
sg10
I15
sg11
Vallergic asthma
p8287
sg13
I2
sasa(dp8288
g2
S'Plasma concentrations of soluble CTLA-4 (sCTLA-4), CD28, CD80 and CD86 in 51 children with chronic allergic asthma with or without inhaled corticosteroid treatment, and 22 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay.\n'
p8289
sg4
(lp8290
(dp8291
g7
I57
sg8
VP33681
p8292
sg10
I4
sg11
VCD80
p8293
sg13
I1
sa(dp8294
g7
I66
sg8
VP42081
p8295
sg10
I4
sg11
VCD86
p8296
sg13
I1
sa(dp8297
g7
I51
sg8
VP33681
p8298
sg10
I4
sg11
VCD28
p8299
sg13
I1
sa(dp8300
g7
I33
sg8
VP16410
p8301
sg10
I6
sg11
VCTLA-4
p8302
sg13
I1
sasg23
(lp8303
(dp8304
g7
I99
sg26
VC0155877
p8305
sg10
I15
sg11
Vallergic asthma
p8306
sg13
I2
sasa(dp8307
g2
S'Plasma sCTLA-4, sCD28 and sCD80 concentrations are elevated in allergic asthma.\n'
p8308
sg4
(lp8309
sg23
(lp8310
(dp8311
g7
I63
sg26
VC0155877
p8312
sg10
I15
sg11
Vallergic asthma
p8313
sg13
I2
sasa(dp8314
g2
S'The percentage of myoglobin denaturation (PMD) of the CA groups was also increased according to the level of CA during storage.\n'
p8315
sg4
(lp8316
(dp8317
g7
I18
sg8
VP02144
p8318
sg10
I9
sg11
Vmyoglobin
p8319
sg13
I1
sasg23
(lp8320
(dp8321
g7
I42
sg26
VC1832661
p8322
sg10
I3
sg11
VPMD
p8323
sg13
I1
sa(dp8324
g7
I4
sg26
VC1832661
p8325
sg10
I36
sg11
Vpercentage of myoglobin denaturation
p8326
sg13
I4
sasa(dp8327
g2
S'Low expression of (or IHC-negative) COX2, miR-200c, ERCC1 and TS, or high expression of (or IHC-positive) CDC25B and p16 are potential biomarkers for predicting the response of esophageal cancer patients treated with chemo(radio)therapy.\n'
p8328
sg4
(lp8329
(dp8330
g7
I36
sg8
VP35354
p8331
sg10
I4
sg11
VCOX2
p8332
sg13
I1
sa(dp8333
g7
I117
sg8
VP42771
p8334
sg10
I3
sg11
Vp16
p8335
sg13
I1
sa(dp8336
g7
I42
sg8
g107
sg10
I8
sg11
VmiR-200c
p8337
sg13
I1
sa(dp8338
g7
I106
sg8
VP30305
p8339
sg10
I6
sg11
VCDC25B
p8340
sg13
I1
sa(dp8341
g7
I52
sg8
VP07992
p8342
sg10
I5
sg11
VERCC1
p8343
sg13
I1
sasg23
(lp8344
(dp8345
g7
I177
sg26
VC0014859
p8346
sg10
I17
sg11
Vesophageal cancer
p8347
sg13
I2
sasa(dp8348
g2
S'ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.\n'
p8349
sg4
(lp8350
(dp8351
g7
I6
sg8
g107
sg10
I3
sg11
VSNP
p8352
sg13
I1
sa(dp8353
g7
I0
sg8
VP07992
p8354
sg10
I5
sg11
VERCC1
p8355
sg13
I1
sa(dp8356
g7
I52
sg8
VP04626
p8357
sg10
I5
sg11
VERBB2
p8358
sg13
I1
sa(dp8359
g7
I0
sg8
VP07992
p8360
sg10
I5
sg11
VERCC1
p8361
sg13
I1
sasg23
(lp8362
(dp8363
g7
I194
sg26
VC0014859
p8364
sg10
I17
sg11
Vesophageal cancer
p8365
sg13
I2
sasa(dp8366
g2
S'ERCC1 C118T could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for OS in esophageal cancer patients after surgery.\n'
p8367
sg4
(lp8368
(dp8369
g7
I0
sg8
VP07992
p8370
sg10
I5
sg11
VERCC1
p8371
sg13
I1
sasg23
(lp8372
(dp8373
g7
I130
sg26
VC0014859
p8374
sg10
I17
sg11
Vesophageal cancer
p8375
sg13
I2
sasa(dp8376
g2
S'In the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR =  .49, 95% CI = 0.31-0.76, heterogeneity P = 0.480).\n'
p8377
sg4
(lp8378
(dp8379
g7
I55
sg8
VP07992
p8380
sg10
I15
sg11
VERCC1 rs3212986
p8381
sg13
I2
sasg23
(lp8382
(dp8383
g7
I139
sg26
VC0014859
p8384
sg10
I17
sg11
Vesophageal cancer
p8385
sg13
I2
sasa(dp8386
g2
S'Furthermore, a considerable correlation was observed between ERCC1 rs11615 and the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.228, 95% CI = 0.125-0.418, heterogeneity P = 0.291).\n'
p8387
sg4
(lp8388
(dp8389
g7
I61
sg8
VP07992
p8390
sg10
I5
sg11
VERCC1
p8391
sg13
I1
sasg23
(lp8392
(dp8393
g7
I100
sg26
VC0014859
p8394
sg10
I17
sg11
Vesophageal cancer
p8395
sg13
I2
sasa(dp8396
g2
S'These findings indicate that the ERCC1 rs11615 and ERCC1 rs312986 polymorphisms may be candidate pharmacogenomic factors capable of predicting the response rate of esophageal cancer patients who accept neoadjuvant therapy.\n'
p8397
sg4
(lp8398
(dp8399
g7
I33
sg8
VP07992
p8400
sg10
I13
sg11
VERCC1 rs11615
p8401
sg13
I2
sa(dp8402
g7
I33
sg8
VP07992
p8403
sg10
I5
sg11
VERCC1
p8404
sg13
I1
sasg23
(lp8405
(dp8406
g7
I164
sg26
VC0014859
p8407
sg10
I17
sg11
Vesophageal cancer
p8408
sg13
I2
sasa(dp8409
g2
S'The expression levels of melanoma-associated antigen (MAGE) A, MAGE-C1/CT7, cancer/testis antigen 1B (CTAG1B) and G antigen (GAGE) were analyzed by immunohistochemistry.\n'
p8410
sg4
(lp8411
(dp8412
g7
I76
sg8
VP78358
p8413
sg10
I24
sg11
Vcancer/testis antigen 1B
p8414
sg13
I3
sa(dp8415
g7
I125
sg8
VP14209
p8416
sg10
I4
sg11
VGAGE
p8417
sg13
I1
sa(dp8418
g7
I114
sg8
VP14209
p8419
sg10
I9
sg11
VG antigen
p8420
sg13
I2
sa(dp8421
g7
I54
sg8
VP43355
p8422
sg10
I4
sg11
VMAGE
p8423
sg13
I1
sa(dp8424
g7
I25
sg8
VP08962
p8425
sg10
I27
sg11
Vmelanoma-associated antigen
p8426
sg13
I2
sa(dp8427
g7
I54
sg8
VP43355
p8428
sg10
I4
sg11
VMAGE
p8429
sg13
I1
sa(dp8430
g7
I102
sg8
VP78358
p8431
sg10
I6
sg11
VCTAG1B
p8432
sg13
I1
sa(dp8433
g7
I71
sg8
g107
sg10
I3
sg11
VCT7
p8434
sg13
I1
sasg23
(lp8435
(dp8436
g7
I25
sg26
VC0025202
p8437
sg10
I8
sg11
Vmelanoma
p8438
sg13
I1
sa(dp8439
g7
I76
sg26
VC0006826
p8440
sg10
I6
sg11
Vcancer
p8441
sg13
I1
sasa(dp8442
g2
S'In papillary and follicular carcinoma, MAGE-A was present in 8.1% of cases, GAGE in 10.8% and CT/7MAGE-C1 and CTAG1B in 2.7% each.\n'
p8443
sg4
(lp8444
sg23
(lp8445
(dp8446
g7
I3
sg26
VC0206683
p8447
sg10
I34
sg11
Vpapillary and follicular carcinoma
p8448
sg13
I4
sasa(dp8449
g2
S'In medullary carcinoma, CT antigen expression was as follows: MAGE-A in 42.9% of patients; MAGE-C1/CT7 in 46.5%; GAGE in 92.9%; and CTAG1B in 3.6%.\n'
p8450
sg4
(lp8451
(dp8452
g7
I24
sg8
VP14209
p8453
sg10
I10
sg11
VCT antigen
p8454
sg13
I2
sa(dp8455
g7
I62
sg8
VP43355
p8456
sg10
I6
sg11
VMAGE-A
p8457
sg13
I1
sasg23
(lp8458
(dp8459
g7
I3
sg26
VC0238462
p8460
sg10
I19
sg11
Vmedullary carcinoma
p8461
sg13
I2
sasa(dp8462
g2
S'In poorly differentiated and anaplastic carcinoma cases, CT antigen expression was as follows: MAGE-A in 61.8% of cases; MAGE-C1 in 57.1%; GAGE in 66.7%; and CTAG1B in 14.4%.\n'
p8463
sg4
(lp8464
(dp8465
g7
I57
sg8
VP14209
p8466
sg10
I10
sg11
VCT antigen
p8467
sg13
I2
sasg23
(lp8468
(dp8469
g7
I29
sg26
VC0205698
p8470
sg10
I20
sg11
Vanaplastic carcinoma
p8471
sg13
I2
sasa(dp8472
g2
S'In patients with colon cancer, the expression of TSP50, MAGE-A(1-6), and SSX1,2,4 genes was associated with a poor prognosis, that of MAGE-C1 and XAGE1 was related to a favorable prognosis.\n'
p8473
sg4
(lp8474
(dp8475
g7
I73
sg8
g107
sg10
I14
sg11
VSSX1,2,4 genes
p8476
sg13
I2
sa(dp8477
g7
I49
sg8
g107
sg10
I5
sg11
VTSP50
p8478
sg13
I1
sa(dp8479
g7
I146
sg8
g107
sg10
I5
sg11
VXAGE1
p8480
sg13
I1
sa(dp8481
g7
I56
sg8
VP43355
p8482
sg10
I4
sg11
VMAGE
p8483
sg13
I1
sasg23
(lp8484
(dp8485
g7
I17
sg26
VC0699790
p8486
sg10
I12
sg11
Vcolon cancer
p8487
sg13
I2
sasa(dp8488
g2
S'Consequently, the expression of CT antigens MAGE-A1, MAGE-A4, CT7/MAGE-C1, NY-ESO-1, and GAGE was analyzed in a series of pediatric melanomas.\n'
p8489
sg4
(lp8490
(dp8491
g7
I32
sg8
VP43355
p8492
sg10
I19
sg11
VCT antigens MAGE-A1
p8493
sg13
I3
sa(dp8494
g7
I44
sg8
VP43355
p8495
sg10
I4
sg11
VMAGE
p8496
sg13
I1
sa(dp8497
g7
I62
sg8
g107
sg10
I3
sg11
VCT7
p8498
sg13
I1
sa(dp8499
g7
I75
sg8
VP78358
p8500
sg10
I8
sg11
VNY-ESO-1
p8501
sg13
I1
sa(dp8502
g7
I53
sg8
VP43355
p8503
sg10
I7
sg11
VMAGE-A4
p8504
sg13
I1
sasg23
(lp8505
(dp8506
g7
I132
sg26
VC0025202
p8507
sg10
I9
sg11
Vmelanomas
p8508
sg13
I1
sasa(dp8509
g2
S'In this study, we show that the dying myeloma cells treated with chaetocin resulted in the induction of heat shock protein (HSP) 90, which was inhibited by antioxidant N-acetyl cysteine, and showed an increase in the expression of MAGE-A3 and MAGE-C1/CT7.\n'
p8510
sg4
(lp8511
(dp8512
g7
I104
sg8
VP34931
p8513
sg10
I27
sg11
Vheat shock protein (HSP) 90
p8514
sg13
I5
sa(dp8515
g7
I251
sg8
g107
sg10
I3
sg11
VCT7
p8516
sg13
I1
sa(dp8517
g7
I231
sg8
VP43355
p8518
sg10
I4
sg11
VMAGE
p8519
sg13
I1
sa(dp8520
g7
I231
sg8
VP43355
p8521
sg10
I7
sg11
VMAGE-A3
p8522
sg13
I1
sasg23
(lp8523
(dp8524
g7
I124
sg26
VC0034152
p8525
sg10
I3
sg11
VHSP
p8526
sg13
I1
sa(dp8527
g7
I38
sg26
VC0026764
p8528
sg10
I7
sg11
Vmyeloma
p8529
sg13
I1
sa(dp8530
g7
I104
sg26
VC0034152
p8531
sg10
I18
sg11
Vheat shock protein
p8532
sg13
I3
sasa(dp8533
g2
S'We used immunohistochemistry to examine the expression of four CTAs (MAGE-A, NY-ESO-1, CT7, and GAGE7) in various types of salivary gland carcinoma (n = 95).\n'
p8534
sg4
(lp8535
(dp8536
g7
I77
sg8
VP78358
p8537
sg10
I8
sg11
VNY-ESO-1
p8538
sg13
I1
sa(dp8539
g7
I96
sg8
g107
sg10
I5
sg11
VGAGE7
p8540
sg13
I1
sa(dp8541
g7
I87
sg8
g107
sg10
I3
sg11
VCT7
p8542
sg13
I1
sa(dp8543
g7
I69
sg8
VP43355
p8544
sg10
I6
sg11
VMAGE-A
p8545
sg13
I1
sasg23
(lp8546
(dp8547
g7
I123
sg26
VC0948750
p8548
sg10
I24
sg11
Vsalivary gland carcinoma
p8549
sg13
I3
sasa(dp8550
g2
S'When carcinoma cases were divided into low-grade and intermediate/high-grade types, NY-ESO-1 and CT7 were expressed more frequently in intermediate/high-grade carcinomas.\n'
p8551
sg4
(lp8552
(dp8553
g7
I84
sg8
VP78358
p8554
sg10
I8
sg11
VNY-ESO-1
p8555
sg13
I1
sa(dp8556
g7
I97
sg8
g107
sg10
I3
sg11
VCT7
p8557
sg13
I1
sasg23
(lp8558
(dp8559
g7
I159
sg26
VC0007097
p8560
sg10
I10
sg11
Vcarcinomas
p8561
sg13
I1
sa(dp8562
g7
I5
sg26
VC0007097
p8563
sg10
I9
sg11
Vcarcinoma
p8564
sg13
I1
sasa(dp8565
g2
S'The expression of cancer testis antigen MAGE C1 has been linked to the malignant stem cell in this disease, and thus, we investigated the use of both flow cytometric and qRTPCR approaches to monitor its expression as an alternative monitoring methodology in this pilot study.\n'
p8566
sg4
(lp8567
(dp8568
g7
I25
sg8
VP15735
p8569
sg10
I22
sg11
Vtestis antigen MAGE C1
p8570
sg13
I4
sasg23
(lp8571
(dp8572
g7
I18
sg26
VC0153594
p8573
sg10
I13
sg11
Vcancer testis
p8574
sg13
I2
sasa(dp8575
g2
S'These variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA).\n'
p8576
sg4
(lp8577
(dp8578
g7
I152
sg8
g107
sg10
I5
sg11
VMORN2
p8579
sg13
I1
sa(dp8580
g7
I84
sg8
g107
sg10
I4
sg11
VTOX3
p8581
sg13
I1
sa(dp8582
g7
I69
sg8
g107
sg10
I5
sg11
VDNAH9
p8583
sg13
I1
sa(dp8584
g7
I145
sg8
g107
sg10
I5
sg11
VTHSD1
p8585
sg13
I1
sa(dp8586
g7
I76
sg8
g107
sg10
I6
sg11
VMAGEC1
p8587
sg13
I1
sa(dp8588
g7
I159
sg8
g107
sg10
I5
sg11
VPTCRA
p8589
sg13
I1
sa(dp8590
g7
I60
sg8
g107
sg10
I7
sg11
VANKRD35
p8591
sg13
I1
sasg23
(lp8592
(dp8593
g7
I51
sg26
VC0006826
p8594
sg10
I6
sg11
Vcancer
p8595
sg13
I1
sa(dp8596
g7
I51
sg26
VC0006826
p8597
sg10
I7
sg11
Vcancers
p8598
sg13
I1
sasa(dp8599
g2
S'Our study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer.\n'
p8600
sg4
(lp8601
(dp8602
g7
I132
sg8
g107
sg10
I7
sg11
VMAGE-C2
p8603
sg13
I1
sa(dp8604
g7
I120
sg8
VP43355
p8605
sg10
I4
sg11
VMAGE
p8606
sg13
I1
sasg23
(lp8607
(dp8608
g7
I92
sg26
VC0025202
p8609
sg10
I8
sg11
Vmelanoma
p8610
sg13
I1
sa(dp8611
g7
I143
sg26
VC0678222
p8612
sg10
I13
sg11
Vbreast cancer
p8613
sg13
I2
sasa(dp8614
g2
S'Reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated.\n'
p8615
sg4
(lp8616
(dp8617
g7
I126
sg8
VP43355
p8618
sg10
I4
sg11
VMAGE
p8619
sg13
I1
sa(dp8620
g7
I126
sg8
VP43355
p8621
sg10
I4
sg11
VMAGE
p8622
sg13
I1
sasg23
(lp8623
(dp8624
g7
I215
sg26
VC0678222
p8625
sg10
I13
sg11
Vbreast cancer
p8626
sg13
I2
sa(dp8627
g7
I182
sg26
VC0027651
p8628
sg10
I5
sg11
Vtumor
p8629
sg13
I1
sa(dp8630
g7
I296
sg26
VC1458156
p8631
sg10
I10
sg11
Vrecurrence
p8632
sg13
I1
sasa(dp8633
g2
S"We examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines.\n"
p8634
sg4
(lp8635
(dp8636
g7
I122
sg8
VP32119
p8637
sg10
I24
sg11
Vinhibitor trichostatin A
p8638
sg13
I3
sa(dp8639
g7
I168
sg8
VP43355
p8640
sg10
I4
sg11
VMAGE
p8641
sg13
I1
sa(dp8642
g7
I102
sg8
VP56524
p8643
sg10
I19
sg11
Vhistone deacetylase
p8644
sg13
I2
sa(dp8645
g7
I180
sg8
g107
sg10
I7
sg11
VMAGE-C2
p8646
sg13
I1
sasg23
(lp8647
(dp8648
g7
I191
sg26
VC0678222
p8649
sg10
I13
sg11
Vbreast cancer
p8650
sg13
I2
sasa(dp8651
g2
S'Proteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively.\n'
p8652
sg4
(lp8653
(dp8654
g7
I13
sg8
VP43355
p8655
sg10
I4
sg11
VMAGE
p8656
sg13
I1
sa(dp8657
g7
I13
sg8
VP43355
p8658
sg10
I4
sg11
VMAGE
p8659
sg13
I1
sa(dp8660
g7
I13
sg8
VP43355
p8661
sg10
I4
sg11
VMAGE
p8662
sg13
I1
sa(dp8663
g7
I13
sg8
VP43355
p8664
sg10
I4
sg11
VMAGE
p8665
sg13
I1
sasg23
(lp8666
(dp8667
g7
I69
sg26
VC0678222
p8668
sg10
I13
sg11
Vbreast cancer
p8669
sg13
I2
sasa(dp8670
g2
S'MAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.\n'
p8671
sg4
(lp8672
(dp8673
g7
I0
sg8
VP43355
p8674
sg10
I4
sg11
VMAGE
p8675
sg13
I1
sa(dp8676
g7
I0
sg8
VP43355
p8677
sg10
I4
sg11
VMAGE
p8678
sg13
I1
sasg23
(lp8679
(dp8680
g7
I120
sg26
VC0678222
p8681
sg10
I13
sg11
Vbreast cancer
p8682
sg13
I2
sa(dp8683
g7
I48
sg26
VC0027651
p8684
sg10
I5
sg11
Vtumor
p8685
sg13
I1
sasa(dp8686
g2
S'In the present study, we investigated expression patterns of nanog in the rat heart after acute myocardial infarction by semi-quantitative RT-PCR, immunohistochemistry and Western blot analyses.\n'
p8687
sg4
(lp8688
sg23
(lp8689
(dp8690
g7
I90
sg26
VC0155626
p8691
sg10
I27
sg11
Vacute myocardial infarction
p8692
sg13
I3
sasa(dp8693
g2
S'MRI represents the gold standard tool for differential diagnosis (with schwannoma, paraganglioma and haemangioma) and correct staging, while immunohistochemical and cytomorphologic analysis (bcl-2 and CD34 positivity in 90% of cases) is needed for definitive diagnosis.\n'
p8694
sg4
(lp8695
(dp8696
g7
I191
sg8
VP10415
p8697
sg10
I5
sg11
Vbcl-2
p8698
sg13
I1
sa(dp8699
g7
I201
sg8
VP28906
p8700
sg10
I4
sg11
VCD34
p8701
sg13
I1
sasg23
(lp8702
(dp8703
g7
I101
sg26
VC0018916
p8704
sg10
I11
sg11
Vhaemangioma
p8705
sg13
I1
sa(dp8706
g7
I71
sg26
VC0027809
p8707
sg10
I10
sg11
Vschwannoma
p8708
sg13
I1
sa(dp8709
g7
I83
sg26
VC0030421
p8710
sg10
I13
sg11
Vparaganglioma
p8711
sg13
I1
sasa(dp8712
g2
S"L'RMN rappresenta l'esame principale per escludere altre diagnosi (schwannoma, paragangliome ed emangioma) e per una corretta stadiazione mentre l'immunoistochimica e l'analisi citomorfologica (bcl-2 e CD34 positiva nel 90% dei casi) e la base per una diagnosi definitiva.\n"
p8713
sg4
(lp8714
(dp8715
g7
I202
sg8
VP28906
p8716
sg10
I4
sg11
VCD34
p8717
sg13
I1
sa(dp8718
g7
I194
sg8
VP10415
p8719
sg10
I5
sg11
Vbcl-2
p8720
sg13
I1
sasg23
(lp8721
(dp8722
g7
I67
sg26
VC0027809
p8723
sg10
I10
sg11
Vschwannoma
p8724
sg13
I1
sasa(dp8725
g2
S'Disease-specific iPS cells were generated from skin fibroblasts obtained from the indicated PMD patient and two other PMD patients having a 637-kb chromosomal duplication including entire PLP1 and a novel missense mutation (W212C) of PLP1, by transfections of OCT3/4, C-MYC, KLF4 and SOX2 using retro-virus vectors.\n'
p8726
sg4
(lp8727
(dp8728
g7
I188
sg8
VP60201
p8729
sg10
I4
sg11
VPLP1
p8730
sg13
I1
sa(dp8731
g7
I188
sg8
VP60201
p8732
sg10
I4
sg11
VPLP1
p8733
sg13
I1
sa(dp8734
g7
I275
sg8
g107
sg10
I4
sg11
VKLF4
p8735
sg13
I1
sa(dp8736
g7
I268
sg8
VP12524
p8737
sg10
I5
sg11
VC-MYC
p8738
sg13
I1
sa(dp8739
g7
I284
sg8
VP48431
p8740
sg10
I4
sg11
VSOX2
p8741
sg13
I1
sa(dp8742
g7
I260
sg8
g107
sg10
I6
sg11
VOCT3/4
p8743
sg13
I1
sasg23
(lp8744
(dp8745
g7
I147
sg26
VC1516516
p8746
sg10
I23
sg11
Vchromosomal duplication
p8747
sg13
I2
sa(dp8748
g7
I17
sg26
VC1837610
p8749
sg10
I3
sg11
ViPS
p8750
sg13
I1
sa(dp8751
g7
I92
sg26
VC1832661
p8752
sg10
I3
sg11
VPMD
p8753
sg13
I1
sa(dp8754
g7
I92
sg26
VC1832661
p8755
sg10
I3
sg11
VPMD
p8756
sg13
I1
sasa(dp8757
g2
S'Mice with increased KLF4 in NSCs and NSCs-derived ependymal cells developed hydrocephalus-like characteristics, including enlarged ventricles, thinned cortex, agenesis of the corpus callosum, and significantly reduced subcommissural organ.\n'
p8758
sg4
(lp8759
(dp8760
g7
I20
sg8
g107
sg10
I4
sg11
VKLF4
p8761
sg13
I1
sasg23
(lp8762
(dp8763
g7
I76
sg26
VC0020255
p8764
sg10
I13
sg11
Vhydrocephalus
p8765
sg13
I1
sa(dp8766
g7
I159
sg26
VC0175754
p8767
sg10
I31
sg11
Vagenesis of the corpus callosum
p8768
sg13
I5
sasa(dp8769
g2
S'These results indicate that down-regulation of KLF4 is critical for neural development and its dysregulation may lead to hydrocephalus.\n'
p8770
sg4
(lp8771
(dp8772
g7
I47
sg8
g107
sg10
I4
sg11
VKLF4
p8773
sg13
I1
sasg23
(lp8774
(dp8775
g7
I121
sg26
VC0020255
p8776
sg10
I13
sg11
Vhydrocephalus
p8777
sg13
I1
sasa(dp8778
g2
S'Our findings further reveal that activated Akt and STAT3 pathways induce the upregulation of HIF1Alfa and its downstream targets (LDHA and PDK1), leading to increased glycolysis in myeloma cells.\n'
p8779
sg4
(lp8780
(dp8781
g7
I43
sg8
g107
sg10
I3
sg11
VAkt
p8782
sg13
I1
sa(dp8783
g7
I139
sg8
g107
sg10
I4
sg11
VPDK1
p8784
sg13
I1
sa(dp8785
g7
I130
sg8
VP00338
p8786
sg10
I4
sg11
VLDHA
p8787
sg13
I1
sa(dp8788
g7
I51
sg8
VP40763
p8789
sg10
I5
sg11
VSTAT3
p8790
sg13
I1
sasg23
(lp8791
(dp8792
g7
I181
sg26
VC0026764
p8793
sg10
I7
sg11
Vmyeloma
p8794
sg13
I1
sasa(dp8795
g2
S'We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism.\n'
p8796
sg4
(lp8797
(dp8798
g7
I94
sg8
VP00338
p8799
sg10
I4
sg11
VLDHA
p8800
sg13
I1
sa(dp8801
g7
I103
sg8
g107
sg10
I5
sg11
VHIF1A
p8802
sg13
I1
sa(dp8803
g7
I103
sg8
g107
sg10
I5
sg11
VHIF1A
p8804
sg13
I1
sa(dp8805
g7
I94
sg8
VP00338
p8806
sg10
I4
sg11
VLDHA
p8807
sg13
I1
sasg23
(lp8808
(dp8809
g7
I263
sg26
VC0598934
p8810
sg10
I12
sg11
Vtumor growth
p8811
sg13
I2
sa(dp8812
g7
I112
sg26
VC0026764
p8813
sg10
I16
sg11
Vmultiple myeloma
p8814
sg13
I2
sasa(dp8815
g2
S'Novel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.\n'
p8816
sg4
(lp8817
(dp8818
g7
I89
sg8
VP00338
p8819
sg10
I4
sg11
VLDHA
p8820
sg13
I1
sasg23
(lp8821
(dp8822
g7
I48
sg26
VC0026764
p8823
sg10
I16
sg11
Vmultiple myeloma
p8824
sg13
I2
sa(dp8825
g7
I124
sg26
VC0598934
p8826
sg10
I12
sg11
Vtumor growth
p8827
sg13
I2
sasa(dp8828
g2
S'A 36,000-Mr protein purified from mouse myeloma on the basis of selective binding to a single-stranded DNA (ssDNA)-cellulose column has been identified as the lactate dehydrogenase A (LDH-A) subunit.\n'
p8829
sg4
(lp8830
(dp8831
g7
I184
sg8
VP00338
p8832
sg10
I5
sg11
VLDH-A
p8833
sg13
I1
sa(dp8834
g7
I159
sg8
VP49366
p8835
sg10
I23
sg11
Vlactate dehydrogenase A
p8836
sg13
I3
sasg23
(lp8837
(dp8838
g7
I40
sg26
VC0026764
p8839
sg10
I7
sg11
Vmyeloma
p8840
sg13
I1
sasa(dp8841
g2
S"A homogeneous preparation of this mouse myeloma ssDNA-binding protein, termed the 'low-salt-eluting protein', was found to possess LDH activity, and rabbit antiserum prepared against this protein was shown to cross-react with purified 36,000-Mr LDH-A subunits from mouse and bovine sources.\n"
p8842
sg4
(lp8843
(dp8844
g7
I131
sg8
g107
sg10
I3
sg11
VLDH
p8845
sg13
I1
sa(dp8846
g7
I245
sg8
VP00338
p8847
sg10
I14
sg11
VLDH-A subunits
p8848
sg13
I2
sa(dp8849
g7
I34
sg8
g107
sg10
I35
sg11
Vmouse myeloma ssDNA-binding protein
p8850
sg13
I4
sasg23
(lp8851
(dp8852
g7
I40
sg26
VC0026764
p8853
sg10
I7
sg11
Vmyeloma
p8854
sg13
I1
sa(dp8855
g7
I123
sg26
VC0850310
p8856
sg10
I7
sg11
Vpossess
p8857
sg13
I1
sasa(dp8858
g2
S'These enzymic and immunological identities with LDH-A were not observed with purified helix-destabilizing protein 1 from mouse myeloma.\n'
p8859
sg4
(lp8860
(dp8861
g7
I48
sg8
VP00338
p8862
sg10
I5
sg11
VLDH-A
p8863
sg13
I1
sasg23
(lp8864
(dp8865
g7
I127
sg26
VC0026764
p8866
sg10
I7
sg11
Vmyeloma
p8867
sg13
I1
sasa(dp8868
g2
S'Concentrations of total lactate dehydrogenase (LDH; EC 1.1.1.27) and LDH isoenzyme patterns were studied in serum of 19 patients with multiple myeloma and in 19 healthy controls.\n'
p8869
sg4
(lp8870
(dp8871
g7
I24
sg8
VP49366
p8872
sg10
I21
sg11
Vlactate dehydrogenase
p8873
sg13
I2
sa(dp8874
g7
I47
sg8
g107
sg10
I3
sg11
VLDH
p8875
sg13
I1
sa(dp8876
g7
I69
sg8
g107
sg10
I13
sg11
VLDH isoenzyme
p8877
sg13
I2
sasg23
(lp8878
(dp8879
g7
I134
sg26
VC0026764
p8880
sg10
I16
sg11
Vmultiple myeloma
p8881
sg13
I2
sasa(dp8882
g2
S'Defective DNA repair is tightly correlated with worse neurological outcomes after stroke, whereas upregulation of DNA repair enzymes, such as APE1, OGG1, and XRCC1, improves long-term functional recovery following stroke.\n'
p8883
sg4
(lp8884
(dp8885
g7
I158
sg8
VP18887
p8886
sg10
I5
sg11
VXRCC1
p8887
sg13
I1
sa(dp8888
g7
I142
sg8
VP27695
p8889
sg10
I4
sg11
VAPE1
p8890
sg13
I1
sasg23
(lp8891
(dp8892
g7
I184
sg26
VC0599766
p8893
sg10
I19
sg11
Vfunctional recovery
p8894
sg13
I2
sa(dp8895
g7
I82
sg26
VC0038454
p8896
sg10
I6
sg11
Vstroke
p8897
sg13
I1
sa(dp8898
g7
I82
sg26
VC0038454
p8899
sg10
I6
sg11
Vstroke
p8900
sg13
I1
sasa(dp8901
g2
S'Our data showed that OGG1 Ser326Cys and XRCC1 Arg399Gln gene polymorphisms had impacts on the development of stroke.\n'
p8902
sg4
(lp8903
(dp8904
g7
I40
sg8
VP18887
p8905
sg10
I20
sg11
VXRCC1 Arg399Gln gene
p8906
sg13
I3
sasg23
(lp8907
(dp8908
g7
I109
sg26
VC0038454
p8909
sg10
I6
sg11
Vstroke
p8910
sg13
I1
sasa(dp8911
g2
S'Previously, our laboratory showed that mice lacking the BER glycosylases 8-oxoguanine glycosylase 1 (Ogg1) or nei endonuclease VIII-like 1 (Neil1) recover more poorly from focal ischemic stroke than wild-type mice.\n'
p8912
sg4
(lp8913
(dp8914
g7
I140
sg8
g107
sg10
I5
sg11
VNeil1
p8915
sg13
I1
sa(dp8916
g7
I110
sg8
g107
sg10
I28
sg11
Vnei endonuclease VIII-like 1
p8917
sg13
I4
sasg23
(lp8918
(dp8919
g7
I178
sg26
VC3272363
p8920
sg10
I15
sg11
Vischemic stroke
p8921
sg13
I2
sasa(dp8922
g2
S'Genotyping of polymorphisms of the OGG1 (Ser326Cys), XRCC1 (Arg399Gln), ERCC2 (Lys751Gln), and ERCC5 (Asp1104His) genes was performed and used to evaluate LAA stroke susceptibility.\n'
p8923
sg4
(lp8924
(dp8925
g7
I95
sg8
VP28715
p8926
sg10
I24
sg11
VERCC5 (Asp1104His) genes
p8927
sg13
I3
sa(dp8928
g7
I72
sg8
VP18074
p8929
sg10
I5
sg11
VERCC2
p8930
sg13
I1
sa(dp8931
g7
I53
sg8
VP18887
p8932
sg10
I5
sg11
VXRCC1
p8933
sg13
I1
sasg23
(lp8934
(dp8935
g7
I159
sg26
VC0038454
p8936
sg10
I6
sg11
Vstroke
p8937
sg13
I1
sasa(dp8938
g2
S'A joint effect on risk elevation of LAA stroke was seen in those patients with OGG1 and ERCC2 polymorphisms (OR: 2.75, 95%CI: 1.26-6.00).\n'
p8939
sg4
(lp8940
(dp8941
g7
I88
sg8
VP18074
p8942
sg10
I5
sg11
VERCC2
p8943
sg13
I1
sasg23
(lp8944
(dp8945
g7
I40
sg26
VC0038454
p8946
sg10
I6
sg11
Vstroke
p8947
sg13
I1
sasa(dp8948
g2
S'Moreover, among smokers carrying the OGG1 Ser326Cys polymorphism, there was a tendency toward an increased risk of LAA stroke in those patients who had a greater number of high-risk genotypes of XRCC1, ERCC2, and ERCC5 polymorphisms (p(trend)=0.010).\n'
p8949
sg4
(lp8950
(dp8951
g7
I202
sg8
VP18074
p8952
sg10
I5
sg11
VERCC2
p8953
sg13
I1
sa(dp8954
g7
I213
sg8
VP28715
p8955
sg10
I5
sg11
VERCC5
p8956
sg13
I1
sa(dp8957
g7
I195
sg8
VP18887
p8958
sg10
I5
sg11
VXRCC1
p8959
sg13
I1
sasg23
(lp8960
(dp8961
g7
I119
sg26
VC0038454
p8962
sg10
I6
sg11
Vstroke
p8963
sg13
I1
sasa(dp8964
g2
S'Among 22 patients who underwent LP shunt placement for IIH, 16 (72.8%) patients had severe and fulminant opening CSF pressures with values of more than 400 mmH(2)O.\n'
p8965
sg4
(lp8966
sg23
(lp8967
sa(dp8968
g2
S'This study implicates increased I(NaL) in excessive atrial APD prolongation and arrhythmic EAD occurrence in a congenital LQTS3 mouse model.\n'
p8969
sg4
(lp8970
sg23
(lp8971
(dp8972
g7
I91
sg26
VC1864233
p8973
sg10
I3
sg11
VEAD
p8974
sg13
I1
sasa(dp8975
g2
S'(1) To report the different patterns of NAL and discuss the mechanisms encountered; (2) to determine the relationship between a given type of lymphoma and a specific type of neuropathy; and (3) to assess the prognosis of NAL.\n'
p8976
sg4
(lp8977
sg23
(lp8978
(dp8979
g7
I142
sg26
VC0024299
p8980
sg10
I8
sg11
Vlymphoma
p8981
sg13
I1
sa(dp8982
g7
I174
sg26
VC0442874
p8983
sg10
I10
sg11
Vneuropathy
p8984
sg13
I1
sasa(dp8985
g2
S'Two thousand four hundred ninety-three consecutive dermatitis patients in 9 dermatology clinics were patch tested with a TDM 6.6%, consisting of Disperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1 and 17, all 1.0% each, and D Blue 106 and D Blue 124, each 0.3%.\n'
p8986
sg4
(lp8987
(dp8988
g7
I145
sg8
VP16435
p8989
sg10
I59
sg11
VDisperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1
p8990
sg13
I15
sasg23
(lp8991
(dp8992
g7
I51
sg26
VC0011603
p8993
sg10
I10
sg11
Vdermatitis
p8994
sg13
I1
sasa(dp8995
g2
S'The name hydrolethalus refers to the main findings, namely polyhydramnios, hydrocephalus and lethality.\n'
p8996
sg4
(lp8997
sg23
(lp8998
(dp8999
g7
I75
sg26
VC0020255
p9000
sg10
I13
sg11
Vhydrocephalus
p9001
sg13
I1
sa(dp9002
g7
I59
sg26
VC0020224
p9003
sg10
I14
sg11
Vpolyhydramnios
p9004
sg13
I1
sasa(dp9005
g2
S'VACTERL with hydrocephalus appears distinct from hydrolethalus and similar conditions but is itself heterogeneous.\n'
p9006
sg4
(lp9007
sg23
(lp9008
(dp9009
g7
I13
sg26
VC0020255
p9010
sg10
I13
sg11
Vhydrocephalus
p9011
sg13
I1
sasa(dp9012
g2
S'In this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro.\n'
p9013
sg4
(lp9014
(dp9015
g7
I57
sg8
VP42771
p9016
sg10
I6
sg11
Vp53-DC
p9017
sg13
I1
sa(dp9018
g7
I57
sg8
VP42771
p9019
sg10
I4
sg11
Vp53-
p9020
sg13
I1
sa(dp9021
g7
I57
sg8
VP42771
p9022
sg10
I3
sg11
Vp53
p9023
sg13
I1
sa(dp9024
g7
I76
sg8
VP55042
p9025
sg10
I3
sg11
VrAd
p9026
sg13
I1
sasg23
(lp9027
(dp9028
g7
I146
sg26
VC0600139
p9029
sg10
I15
sg11
Vprostate cancer
p9030
sg13
I2
sasa(dp9031
g2
S'In addition, rAd-p53 infection can induce overexpression of p53 and thus the cytotoxicity of CTLs differentiated by the p53-DC vaccine in p53 non-expressing prostate cancer cells.\n'
p9032
sg4
(lp9033
(dp9034
g7
I17
sg8
VP42771
p9035
sg10
I3
sg11
Vp53
p9036
sg13
I1
sa(dp9037
g7
I120
sg8
VP42771
p9038
sg10
I6
sg11
Vp53-DC
p9039
sg13
I1
sa(dp9040
g7
I13
sg8
VP55042
p9041
sg10
I7
sg11
VrAd-p53
p9042
sg13
I1
sa(dp9043
g7
I17
sg8
VP42771
p9044
sg10
I3
sg11
Vp53
p9045
sg13
I1
sasg23
(lp9046
(dp9047
g7
I77
sg26
VC0596402
p9048
sg10
I12
sg11
Vcytotoxicity
p9049
sg13
I1
sa(dp9050
g7
I21
sg26
VC0009450
p9051
sg10
I9
sg11
Vinfection
p9052
sg13
I1
sa(dp9053
g7
I157
sg26
VC0600139
p9054
sg10
I15
sg11
Vprostate cancer
p9055
sg13
I2
sasa(dp9056
g2
S'This study detected the migration of MSCs to high metastasis liver carcinoma cells MHCC-97H in vitro, investigated the inhibitory effect of rAd-NK4-MSCs on the growth and metastasis of MHCC-97H cells, further explored the inhibitory mechanism of rAd-NK4-MSCs to MHCC-97H cell metastasis, and examined the inhibitory effect of rAd-NK4-MSCs on the migration of human umbilical vein endothelial cells (HUVECs) in vitro.\n'
p9057
sg4
(lp9058
(dp9059
g7
I140
sg8
VP55042
p9060
sg10
I12
sg11
VrAd-NK4-MSCs
p9061
sg13
I1
sa(dp9062
g7
I140
sg8
VP55042
p9063
sg10
I3
sg11
VrAd
p9064
sg13
I1
sa(dp9065
g7
I140
sg8
VP55042
p9066
sg10
I12
sg11
VrAd-NK4-MSCs
p9067
sg13
I1
sa(dp9068
g7
I144
sg8
VP24001
p9069
sg10
I3
sg11
VNK4
p9070
sg13
I1
sasg23
(lp9071
(dp9072
g7
I50
sg26
VC0027627
p9073
sg10
I10
sg11
Vmetastasis
p9074
sg13
I1
sa(dp9075
g7
I50
sg26
VC0027627
p9076
sg10
I10
sg11
Vmetastasis
p9077
sg13
I1
sa(dp9078
g7
I61
sg26
VC2239176
p9079
sg10
I15
sg11
Vliver carcinoma
p9080
sg13
I2
sa(dp9081
g7
I50
sg26
VC0027627
p9082
sg10
I10
sg11
Vmetastasis
p9083
sg13
I1
sasa(dp9084
g2
S'The present study was conducted to identify the anti-tumor effects of rAd/p53, which is a recombinant human serotype 5 adenovirus, in cutaneous squamous cell carcinoma (cSCC).\n'
p9085
sg4
(lp9086
(dp9087
g7
I70
sg8
VP55042
p9088
sg10
I3
sg11
VrAd
p9089
sg13
I1
sa(dp9090
g7
I74
sg8
VP42771
p9091
sg10
I3
sg11
Vp53
p9092
sg13
I1
sasg23
(lp9093
(dp9094
g7
I134
sg26
VC0553723
p9095
sg10
I33
sg11
Vcutaneous squamous cell carcinoma
p9096
sg13
I4
sa(dp9097
g7
I119
sg26
VC0001486
p9098
sg10
I10
sg11
Vadenovirus
p9099
sg13
I1
sa(dp9100
g7
I169
sg26
VC0553723
p9101
sg10
I4
sg11
VcSCC
p9102
sg13
I1
sa(dp9103
g7
I53
sg26
VC0027651
p9104
sg10
I5
sg11
Vtumor
p9105
sg13
I1
sasa(dp9106
g2
S'Finally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells.\n'
p9107
sg4
(lp9108
(dp9109
g7
I79
sg8
g107
sg10
I48
sg11
VHistone demethylase Lysine specific demethylase1
p9110
sg13
I5
sa(dp9111
g7
I165
sg8
g107
sg10
I24
sg11
VLarge tumor suppressor 2
p9112
sg13
I4
sa(dp9113
g7
I191
sg8
g107
sg10
I5
sg11
VLATS2
p9114
sg13
I1
sa(dp9115
g7
I202
sg8
VP01116
p9116
sg10
I3
sg11
VRas
p9117
sg13
I1
sasg23
(lp9118
(dp9119
g7
I147
sg26
VC0027651
p9120
sg10
I5
sg11
Vtumor
p9121
sg13
I1
sa(dp9122
g7
I230
sg26
VC0011849
p9123
sg10
I8
sg11
Vdiabetes
p9124
sg13
I1
sa(dp9125
g7
I147
sg26
VC0027651
p9126
sg10
I5
sg11
Vtumor
p9127
sg13
I1
sa(dp9128
g7
I263
sg26
VC0007131
p9129
sg10
I5
sg11
VNSCLC
p9130
sg13
I1
sasa(dp9131
g2
S'To compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC).\n'
p9132
sg4
(lp9133
(dp9134
g7
I97
sg8
VP55042
p9135
sg10
I7
sg11
VrAd-p53
p9136
sg13
I1
sa(dp9137
g7
I146
sg8
VP27797
p9138
sg10
I3
sg11
VCRT
p9139
sg13
I1
sa(dp9140
g7
I53
sg8
VP55042
p9141
sg10
I42
sg11
Vrecombinant human adenovirus-p53 injection
p9142
sg13
I4
sa(dp9143
g7
I127
sg8
VP27797
p9144
sg10
I17
sg11
Vchemoradiotherapy
p9145
sg13
I1
sasg23
(lp9146
(dp9147
g7
I71
sg26
VC0001486
p9148
sg10
I10
sg11
Vadenovirus
p9149
sg13
I1
sa(dp9150
g7
I210
sg26
VC2931822
p9151
sg10
I24
sg11
Vnasopharyngeal carcinoma
p9152
sg13
I2
sa(dp9153
g7
I236
sg26
VC2931822
p9154
sg10
I3
sg11
VNPC
p9155
sg13
I1
sasa(dp9156
g2
S'We used data generated from a haploid hydatidiform mole genome (CHM1) and a diploid human genome (NA12878) to test our approach.\n'
p9157
sg4
(lp9158
(dp9159
g7
I64
sg8
g107
sg10
I4
sg11
VCHM1
p9160
sg13
I1
sasg23
(lp9161
(dp9162
g7
I38
sg26
VC0020217
p9163
sg10
I17
sg11
Vhydatidiform mole
p9164
sg13
I2
sasa(dp9165
g2
S'Our results show the recovery of an allele of the non-coding minisatellite MS1 (located on chromosome 1 at 1p33-35) at greater than 97% identity to reference (GRCh38) from the unprocessed sequence data of a haploid complete hydatidiform mole (CHM1) cell line.\n'
p9166
sg4
(lp9167
sg23
(lp9168
(dp9169
g7
I215
sg26
VC0678213
p9170
sg10
I26
sg11
Vcomplete hydatidiform mole
p9171
sg13
I3
sasa(dp9172
g2
S'We demonstrate the utility of Alpha-CENTAURI in characterizing repeat structure for alpha satellite containing reads in the hydatidiform mole (CHM1, haploid-like) genome.\n'
p9173
sg4
(lp9174
(dp9175
g7
I143
sg8
g107
sg10
I4
sg11
VCHM1
p9176
sg13
I1
sasg23
(lp9177
(dp9178
g7
I124
sg26
VC0020217
p9179
sg10
I17
sg11
Vhydatidiform mole
p9180
sg13
I2
sasa(dp9181
g2
S'In order to overcome the issue of allelic diversity, we used genomic DNA from an essentially haploid hydatidiform mole, CHM1.\n'
p9182
sg4
(lp9183
(dp9184
g7
I120
sg8
g107
sg10
I4
sg11
VCHM1
p9185
sg13
I1
sasg23
(lp9186
(dp9187
g7
I101
sg26
VC0020217
p9188
sg10
I17
sg11
Vhydatidiform mole
p9189
sg13
I2
sasa(dp9190
g2
S'Consistent with these findings, we observed that in an IL-33-administered asthmatic airway inflammation model, IL-13 levels were markedly increased in bronchoalveolar lavage fluid, but its levels were markedly suppressed by treatment with inhibitors of 5-LO, 12-LO or BLT2, further suggesting roles of 5-/12-LO in IL-33-induced IL-13 production.\n'
p9191
sg4
(lp9192
(dp9193
g7
I268
sg8
g107
sg10
I4
sg11
VBLT2
p9194
sg13
I1
sa(dp9195
g7
I111
sg8
VP35225
p9196
sg10
I5
sg11
VIL-13
p9197
sg13
I1
sa(dp9198
g7
I111
sg8
VP35225
p9199
sg10
I5
sg11
VIL-13
p9200
sg13
I1
sasg23
(lp9201
(dp9202
g7
I91
sg26
VC0021368
p9203
sg10
I12
sg11
Vinflammation
p9204
sg13
I1
sa(dp9205
g7
I74
sg26
VC0004096
p9206
sg10
I9
sg11
Vasthmatic
p9207
sg13
I1
sasa(dp9208
g2
S'Our results suggest that "MyD88-5-/12-LO-BLT2-NF-KB" cascade significantly contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus potentially contributing to asthmatic development and exacerbation.\n'
p9209
sg4
(lp9210
(dp9211
g7
I41
sg8
g107
sg10
I4
sg11
VBLT2
p9212
sg13
I1
sa(dp9213
g7
I26
sg8
g107
sg10
I5
sg11
VMyD88
p9214
sg13
I1
sa(dp9215
g7
I121
sg8
VP35225
p9216
sg10
I5
sg11
VIL-13
p9217
sg13
I1
sasg23
(lp9218
(dp9219
g7
I175
sg26
VC0004096
p9220
sg10
I9
sg11
Vasthmatic
p9221
sg13
I1
sasa(dp9222
g2
S'DNA methylation changes at a number of these genes have been linked to various forms of human disease, including cancers, such as asthma and acute myeloid leukemia (ALOX12), gastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia (KCNK15), Wilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L), suggesting a potential etiologic role for MEs in tumorigenesis and underscoring the possible developmental origins of these malignancies.\n'
p9223
sg4
(lp9224
(dp9225
g7
I174
sg8
VP12830
p9226
sg10
I85
sg11
Vgastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia
p9227
sg13
I12
sa(dp9228
g7
I270
sg8
g107
sg10
I80
sg11
VWilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L)
p9229
sg13
I10
sa(dp9230
g7
I261
sg8
g107
sg10
I6
sg11
VKCNK15
p9231
sg13
I1
sasg23
(lp9232
(dp9233
g7
I197
sg26
VC0678222
p9234
sg10
I13
sg11
Vbreast cancer
p9235
sg13
I2
sa(dp9236
g7
I401
sg26
VC0007621
p9237
sg10
I13
sg11
Vtumorigenesis
p9238
sg13
I1
sa(dp9239
g7
I174
sg26
VC0024623
p9240
sg10
I14
sg11
Vgastric cancer
p9241
sg13
I2
sa(dp9242
g7
I141
sg26
VC0023467
p9243
sg10
I22
sg11
Vacute myeloid leukemia
p9244
sg13
I3
sa(dp9245
g7
I236
sg26
VC1961102
p9246
sg10
I23
sg11
Vacute lymphoid leukemia
p9247
sg13
I3
sa(dp9248
g7
I219
sg26
VC0699790
p9249
sg10
I12
sg11
Vcolon cancer
p9250
sg13
I2
sa(dp9251
g7
I130
sg26
VC0004096
p9252
sg10
I6
sg11
Vasthma
p9253
sg13
I1
sa(dp9254
g7
I476
sg26
VC0006826
p9255
sg10
I12
sg11
Vmalignancies
p9256
sg13
I1
sa(dp9257
g7
I323
sg26
VC1527249
p9258
sg10
I17
sg11
Vcolorectal cancer
p9259
sg13
I2
sa(dp9260
g7
I394
sg26
VC0265215
p9261
sg10
I3
sg11
VMEs
p9262
sg13
I1
sa(dp9263
g7
I113
sg26
VC0006826
p9264
sg10
I7
sg11
Vcancers
p9265
sg13
I1
sa(dp9266
g7
I270
sg26
VC0027708
p9267
sg10
I11
sg11
VWilms tumor
p9268
sg13
I2
sasa(dp9269
g2
S'DNA methylation of ALOX12 may be an epigenetic biomarker for the risk of asthma-related phenotypes.\n'
p9270
sg4
(lp9271
(dp9272
g7
I19
sg8
VP18054
p9273
sg10
I6
sg11
VALOX12
p9274
sg13
I1
sasg23
(lp9275
(dp9276
g7
I73
sg26
VC0004096
p9277
sg10
I6
sg11
Vasthma
p9278
sg13
I1
sasa(dp9279
g2
S'We provide evidence that MJD in five pedigrees of Azorean descent is also linked to chromosome 14q in an 18-cM region between the markers D14S67 and AACT (multipoint lod score +7.00 near D14S81).\n'
p9280
sg4
(lp9281
(dp9282
g7
I149
sg8
VP05154
p9283
sg10
I4
sg11
VAACT
p9284
sg13
I1
sasg23
(lp9285
(dp9286
g7
I25
sg26
VC0024408
p9287
sg10
I3
sg11
VMJD
p9288
sg13
I1
sasa(dp9289
g2
S"Here we report linkage disequilibrium of rs2288904 with rs3087969 and the association of these SLC44A2 SNPs with Meniere's disease severity.\n"
p9290
sg4
(lp9291
(dp9292
g7
I95
sg8
g107
sg10
I12
sg11
VSLC44A2 SNPs
p9293
sg13
I2
sasg23
(lp9294
(dp9295
g7
I23
sg26
VC0394006
p9296
sg10
I14
sg11
Vdisequilibrium
p9297
sg13
I1
sa(dp9298
g7
I113
sg26
VC0025281
p9299
sg10
I17
sg11
VMeniere's disease
p9300
sg13
I2
sasa(dp9301
g2
S"The association of SLC44A2 SNPs with VTE suggests that thrombi affecting cochlear vessels could be a factor in Meniere's disease.\n"
p9302
sg4
(lp9303
(dp9304
g7
I19
sg8
g107
sg10
I12
sg11
VSLC44A2 SNPs
p9305
sg13
I2
sasg23
(lp9306
(dp9307
g7
I55
sg26
VC0087086
p9308
sg10
I7
sg11
Vthrombi
p9309
sg13
I1
sa(dp9310
g7
I111
sg26
VC0025281
p9311
sg10
I17
sg11
VMeniere's disease
p9312
sg13
I2
sasa(dp9313
g2
S"A search of PubMed was made using the terms 'triple negative breast cancer' and 'tumor infiltrating lymphocytes', 'CD8', 'CD4', 'B cells', 'natural killer cells', 'macrophages', myeloid derived suppressor cells', 'dendritic cells', 'immune check point inhibitor', 'CTLA-4' and 'PD-L1'.\n"
p9314
sg4
(lp9315
sg23
(lp9316
(dp9317
g7
I61
sg26
VC0678222
p9318
sg10
I13
sg11
Vbreast cancer
p9319
sg13
I2
sa(dp9320
g7
I80
sg26
VC0027651
p9321
sg10
I6
sg11
V'tumor
p9322
sg13
I1
sa(dp9323
g7
I87
sg26
VC0332448
p9324
sg10
I12
sg11
Vinfiltrating
p9325
sg13
I1
sasa(dp9326
g2
S'The aim of this study is to explore cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) distribution and clinical value in liquid biopsy (such as blood) of small cell lung cancer (SCLC) patients.\n'
p9327
sg4
(lp9328
(dp9329
g7
I110
sg8
VP18621
p9330
sg10
I4
sg11
VPD-1
p9331
sg13
I1
sa(dp9332
g7
I131
sg8
g107
sg10
I14
sg11
Vdeath ligand 1
p9333
sg13
I3
sa(dp9334
g7
I90
sg8
VP18621
p9335
sg10
I18
sg11
Vprogrammed death 1
p9336
sg13
I3
sa(dp9337
g7
I36
sg8
VP16410
p9338
sg10
I43
sg11
Vcytotoxic T lymphocyte associated antigen 4
p9339
sg13
I6
sa(dp9340
g7
I81
sg8
VP16410
p9341
sg10
I6
sg11
VCTLA-4
p9342
sg13
I1
sasg23
(lp9343
(dp9344
g7
I246
sg26
VC0149925
p9345
sg10
I4
sg11
VSCLC
p9346
sg13
I1
sa(dp9347
g7
I222
sg26
VC0149925
p9348
sg10
I22
sg11
Vsmall cell lung cancer
p9349
sg13
I4
sasa(dp9350
g2
S'##### ###########T######## (cytotoxic T lymphocyte associated antigen-4, CTLA-4) ####### (programmed death 1, PD-1) ######### (programmed death ligand 1, PD-L1) ###### (small cell lung cancer, SCLC) ###########, ############################ ##290#SCLC###60######, ########2nd###SCLC##EDTA###2 mL##########CTLA-4#PD-1#PD-L1####CD3#CD4#CD8#CD25###, ################################PD-L1#SCLC###H446####### SCLC######CTLA-4+###PD-1+####### (1.56+/-1.24) %# (8.07+/-3.97) %#CTLA-4#CD3###CD4#############, ### (4.87+/-5.18) %# (3.85+/-2.60) %, ###PD-1#CD3+#CD4+###### (26.63+/-9.04) %# (20.79+/-9.41) %, ########, SCLC#CD4+CD25+CTLA-4+######## (1.91+/-1.27) % vs  (7.09+/-5.09) %, P&lt;0.001#PD-1+ (CD8+) ##########, ### (22.56+/-4.21) % vs  (11.47+/-5.85) %, P&lt;0.001#CD4+CD25+CTLA-4+###CD8+PD-1+################################## (P&gt;0.05) #######CD4+CD25+CTLA-4+#CD8+PD-1+##############, ### (5.11+/-2.60) % vs  (6.94+/-4.91) %# (8.74+/-3.39) % vs  (11.48+/-5.91) %, P##&lt;0.000,1, ####################PD-L1####SCLC###H446############, ############# #######SCLC####CTLA4#######T###, #PD-1#######T##, ######SCLC##################, ########################.\n'
p9351
sg4
(lp9352
(dp9353
g7
I73
sg8
VP16410
p9354
sg10
I6
sg11
VCTLA-4
p9355
sg13
I1
sa(dp9356
g7
I73
sg8
VP16410
p9357
sg10
I6
sg11
VCTLA-4
p9358
sg13
I1
sa(dp9359
g7
I552
sg8
VP01730
p9360
sg10
I4
sg11
VCD4+
p9361
sg13
I1
sa(dp9362
g7
I848
sg8
VP01730
p9363
sg10
I26
sg11
VCD4+CD25+CTLA-4+#CD8+PD-1+
p9364
sg13
I1
sa(dp9365
g7
I110
sg8
VP18621
p9366
sg10
I4
sg11
VPD-1
p9367
sg13
I1
sa(dp9368
g7
I38
sg8
VP14209
p9369
sg10
I33
sg11
VT lymphocyte associated antigen-4
p9370
sg13
I4
sa(dp9371
g7
I614
sg8
VP01730
p9372
sg10
I13
sg11
VCD4+CD25+CTLA
p9373
sg13
I1
sa(dp9374
g7
I330
sg8
VP01730
p9375
sg10
I3
sg11
VCD4
p9376
sg13
I1
sa(dp9377
g7
I694
sg8
VP01732
p9378
sg10
I4
sg11
VCD8+
p9379
sg13
I1
sa(dp9380
g7
I330
sg8
VP01730
p9381
sg10
I3
sg11
VCD4
p9382
sg13
I1
sa(dp9383
g7
I1068
sg8
VP16410
p9384
sg10
I5
sg11
VCTLA4
p9385
sg13
I1
sa(dp9386
g7
I138
sg8
g107
sg10
I14
sg11
Vdeath ligand 1
p9387
sg13
I3
sa(dp9388
g7
I338
sg8
VP01589
p9389
sg10
I4
sg11
VCD25
p9390
sg13
I1
sa(dp9391
g7
I110
sg8
VP18621
p9392
sg10
I4
sg11
VPD-1
p9393
sg13
I1
sa(dp9394
g7
I414
sg8
VP16410
p9395
sg10
I7
sg11
VCTLA-4+
p9396
sg13
I1
sa(dp9397
g7
I785
sg8
VP01732
p9398
sg10
I6
sg11
VCD8+PD
p9399
sg13
I1
sa(dp9400
g7
I73
sg8
VP16410
p9401
sg10
I6
sg11
VCTLA-4
p9402
sg13
I1
sa(dp9403
g7
I334
sg8
VP01732
p9404
sg10
I3
sg11
VCD8
p9405
sg13
I1
sa(dp9406
g7
I614
sg8
VP01730
p9407
sg10
I13
sg11
VCD4+CD25+CTLA
p9408
sg13
I1
sa(dp9409
g7
I110
sg8
VP18621
p9410
sg10
I4
sg11
VPD-1
p9411
sg13
I1
sa(dp9412
g7
I424
sg8
VP18621
p9413
sg10
I5
sg11
VPD-1+
p9414
sg13
I1
sasg23
(lp9415
(dp9416
g7
I193
sg26
VC0149925
p9417
sg10
I4
sg11
VSCLC
p9418
sg13
I1
sa(dp9419
g7
I193
sg26
VC0149925
p9420
sg10
I4
sg11
VSCLC
p9421
sg13
I1
sa(dp9422
g7
I193
sg26
VC0149925
p9423
sg10
I4
sg11
VSCLC
p9424
sg13
I1
sa(dp9425
g7
I193
sg26
VC0149925
p9426
sg10
I4
sg11
VSCLC
p9427
sg13
I1
sa(dp9428
g7
I193
sg26
VC0149925
p9429
sg10
I4
sg11
VSCLC
p9430
sg13
I1
sa(dp9431
g7
I193
sg26
VC0149925
p9432
sg10
I4
sg11
VSCLC
p9433
sg13
I1
sa(dp9434
g7
I193
sg26
VC0149925
p9435
sg10
I4
sg11
VSCLC
p9436
sg13
I1
sa(dp9437
g7
I193
sg26
VC0149925
p9438
sg10
I4
sg11
VSCLC
p9439
sg13
I1
sa(dp9440
g7
I193
sg26
VC0149925
p9441
sg10
I4
sg11
VSCLC
p9442
sg13
I1
sa(dp9443
g7
I169
sg26
VC0149925
p9444
sg10
I22
sg11
Vsmall cell lung cancer
p9445
sg13
I4
sasa(dp9446
g2
S'The present study deals with CTLA-4 gene selected polymorphisms (rs11571317 C/T and rs3087243G/A) to explore their relation with breast cancer susceptibility and progression in BC patients.\n'
p9447
sg4
(lp9448
(dp9449
g7
I29
sg8
VP16410
p9450
sg10
I11
sg11
VCTLA-4 gene
p9451
sg13
I2
sasg23
(lp9452
(dp9453
g7
I129
sg26
VC0678222
p9454
sg10
I13
sg11
Vbreast cancer
p9455
sg13
I2
sasa(dp9456
g2
S'Autosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identified in patients with POF.\n'
p9457
sg4
(lp9458
(dp9459
g7
I124
sg8
VP15291
p9460
sg10
I4
sg11
VGALT
p9461
sg13
I1
sa(dp9462
g7
I154
sg8
VP23945
p9463
sg10
I4
sg11
VFSHR
p9464
sg13
I1
sa(dp9465
g7
I140
sg8
VP23945
p9466
sg10
I12
sg11
VFSH receptor
p9467
sg13
I2
sa(dp9468
g7
I67
sg8
g107
sg10
I4
sg11
VPMM2
p9469
sg13
I1
sa(dp9470
g7
I83
sg8
g107
sg10
I39
sg11
Vgalactose-1-phosphate uridyltransferase
p9471
sg13
I2
sa(dp9472
g7
I45
sg8
g107
sg10
I20
sg11
Vphosphomannomutase 2
p9473
sg13
I2
sasg23
(lp9474
(dp9475
g7
I294
sg26
VC0006840
p9476
sg10
I11
sg11
Vcandidiasis
p9477
sg13
I1
sa(dp9478
g7
I317
sg26
VC0333606
p9479
sg10
I9
sg11
Vdystrophy
p9480
sg13
I1
sa(dp9481
g7
I195
sg26
VC0005744
p9482
sg10
I16
sg11
VBlepharophimosis
p9483
sg13
I1
sa(dp9484
g7
I225
sg26
VC0443146
p9485
sg10
I10
sg11
Vautoimmune
p9486
sg13
I1
sa(dp9487
g7
I366
sg26
VC0085215
p9488
sg10
I3
sg11
VPOF
p9489
sg13
I1
sasa(dp9490
g2
S'None exhibited any staining for cathepsin K, HMB-45, or microphthalmia transcription factor.\n'
p9491
sg4
(lp9492
(dp9493
g7
I32
sg8
VP43235
p9494
sg10
I11
sg11
Vcathepsin K
p9495
sg13
I2
sa(dp9496
g7
I45
sg8
g107
sg10
I6
sg11
VHMB-45
p9497
sg13
I1
sasg23
(lp9498
(dp9499
g7
I56
sg26
VC0026010
p9500
sg10
I14
sg11
Vmicrophthalmia
p9501
sg13
I1
sasa(dp9502
g2
S'Osteoclast-specific genes such as Trap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7 (Clcn7), cathepsin K (Ctsk) as well as osteoclast-specific transcription factor and microphthalmia transcription factor (MITF) were up-regulated in the treated cells, whilst the messenger RNA (mRNA) levels of Dspp, Dmp1 and Opg were reduced in the induced cells.\n'
p9503
sg4
(lp9504
(dp9505
g7
I332
sg8
g107
sg10
I4
sg11
VDmp1
p9506
sg13
I1
sa(dp9507
g7
I126
sg8
VP43235
p9508
sg10
I11
sg11
Vcathepsin K
p9509
sg13
I2
sa(dp9510
g7
I118
sg8
VP51798
p9511
sg10
I5
sg11
VClcn7
p9512
sg13
I1
sa(dp9513
g7
I201
sg8
VP35398
p9514
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9515
sg13
I3
sa(dp9516
g7
I326
sg8
g107
sg10
I4
sg11
VDspp
p9517
sg13
I1
sa(dp9518
g7
I139
sg8
VP43235
p9519
sg10
I4
sg11
VCtsk
p9520
sg13
I1
sa(dp9521
g7
I238
sg8
g107
sg10
I4
sg11
VMITF
p9522
sg13
I1
sa(dp9523
g7
I34
sg8
g107
sg10
I82
sg11
VTrap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7
p9524
sg13
I9
sa(dp9525
g7
I341
sg8
g107
sg10
I3
sg11
VOpg
p9526
sg13
I1
sasg23
(lp9527
(dp9528
g7
I40
sg26
VC0029454
p9529
sg10
I13
sg11
Vosteopetrosis
p9530
sg13
I1
sa(dp9531
g7
I201
sg26
VC0026010
p9532
sg10
I14
sg11
Vmicrophthalmia
p9533
sg13
I1
sasa(dp9534
g2
S'Cathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts.\n'
p9535
sg4
(lp9536
(dp9537
g7
I0
sg8
VP43235
p9538
sg10
I11
sg11
VCathepsin K
p9539
sg13
I2
sa(dp9540
g7
I56
sg8
VP35398
p9541
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9542
sg13
I3
sa(dp9543
g7
I93
sg8
g107
sg10
I4
sg11
VMITF
p9544
sg13
I1
sasg23
(lp9545
(dp9546
g7
I56
sg26
VC0026010
p9547
sg10
I14
sg11
Vmicrophthalmia
p9548
sg13
I1
sasa(dp9549
g2
S'Among cell species that infiltrated in perichondral granulation, LCA, CD68 (monocytes/macrophages), and CD4 cells were dominant in number; MMP-8, MMP-9, and elastase were expressed only in the perichondral granulation; whereas MMP-3 and cathepsin K and L were detected in both chondrocytes and granulations.\n'
p9550
sg4
(lp9551
(dp9552
g7
I146
sg8
VP14780
p9553
sg10
I5
sg11
VMMP-9
p9554
sg13
I1
sa(dp9555
g7
I139
sg8
VP22894
p9556
sg10
I5
sg11
VMMP-8
p9557
sg13
I1
sa(dp9558
g7
I237
sg8
VP43235
p9559
sg10
I17
sg11
Vcathepsin K and L
p9560
sg13
I4
sa(dp9561
g7
I104
sg8
VP01730
p9562
sg10
I3
sg11
VCD4
p9563
sg13
I1
sa(dp9564
g7
I157
sg8
VP30740
p9565
sg10
I8
sg11
Velastase
p9566
sg13
I1
sa(dp9567
g7
I227
sg8
VP08254
p9568
sg10
I5
sg11
VMMP-3
p9569
sg13
I1
sa(dp9570
g7
I65
sg8
VP09496
p9571
sg10
I3
sg11
VLCA
p9572
sg13
I1
sa(dp9573
g7
I70
sg8
VP34810
p9574
sg10
I4
sg11
VCD68
p9575
sg13
I1
sasg23
(lp9576
(dp9577
g7
I24
sg26
VC0332448
p9578
sg10
I11
sg11
Vinfiltrated
p9579
sg13
I1
sa(dp9580
g7
I65
sg26
VC0339527
p9581
sg10
I3
sg11
VLCA
p9582
sg13
I1
sasa(dp9583
g2
S'Overexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts.\n'
p9584
sg4
(lp9585
(dp9586
g7
I18
sg8
VP35398
p9587
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9588
sg13
I3
sa(dp9589
g7
I98
sg8
VP43235
p9590
sg10
I11
sg11
Vcathepsin-K
p9591
sg13
I1
sasg23
(lp9592
(dp9593
g7
I18
sg26
VC0026010
p9594
sg10
I14
sg11
Vmicrophthalmia
p9595
sg13
I1
sasa(dp9596
g2
S'We studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas.\n'
p9597
sg4
(lp9598
(dp9599
g7
I55
sg8
VP35398
p9600
sg10
I35
sg11
Vmicrophthalmia transcription factor
p9601
sg13
I3
sasg23
(lp9602
(dp9603
g7
I116
sg26
VC0007134
p9604
sg10
I21
sg11
Vrenal cell carcinomas
p9605
sg13
I3
sa(dp9606
g7
I55
sg26
VC0026010
p9607
sg10
I14
sg11
Vmicrophthalmia
p9608
sg13
I1
sa(dp9609
g7
I102
sg26
VC0040715
p9610
sg10
I13
sg11
Vtranslocation
p9611
sg13
I1
sasa(dp9612
g2
S'Radiographs of the hands of 60 patients with cartilage hair hypoplasia (CHH), 69 with trichorhinophalangeal syndrome I (TRP I) and 11 with TRP II were examined, including 26 longitudinal observations.\n'
p9613
sg4
(lp9614
(dp9615
g7
I139
sg8
VP13686
p9616
sg10
I6
sg11
VTRP II
p9617
sg13
I2
sasg23
(lp9618
(dp9619
g7
I120
sg26
VC0432233
p9620
sg10
I5
sg11
VTRP I
p9621
sg13
I2
sa(dp9622
g7
I45
sg26
VC0220748
p9623
sg10
I25
sg11
Vcartilage hair hypoplasia
p9624
sg13
I3
sa(dp9625
g7
I72
sg26
VC0220748
p9626
sg10
I3
sg11
VCHH
p9627
sg13
I1
sa(dp9628
g7
I86
sg26
VC0432233
p9629
sg10
I32
sg11
Vtrichorhinophalangeal syndrome I
p9630
sg13
I3
sasa(dp9631
g2
S'We report here the new approach of fusing putidaredoxin reductase (PdR) to the carboxy-terminus of CYP101A1 (P450cam) via a linker peptide and reconstituting camphor hydroxylase activity with free putidaredoxin (Pdx).\n'
p9632
sg4
(lp9633
(dp9634
g7
I42
sg8
g107
sg10
I23
sg11
Vputidaredoxin reductase
p9635
sg13
I2
sa(dp9636
g7
I67
sg8
g107
sg10
I3
sg11
VPdR
p9637
sg13
I1
sasg23
(lp9638
(dp9639
g7
I42
sg26
VC1845050
p9640
sg10
I23
sg11
Vputidaredoxin reductase
p9641
sg13
I2
sa(dp9642
g7
I67
sg26
VC1845050
p9643
sg10
I3
sg11
VPdR
p9644
sg13
I1
sasa(dp9645
g2
S'For other diseases, a well-established example relates to CYP1B1 where homozygosity for rare mutations occurs in primary congenital glaucoma.\n'
p9646
sg4
(lp9647
(dp9648
g7
I58
sg8
g107
sg10
I6
sg11
VCYP1B1
p9649
sg13
I1
sasg23
(lp9650
(dp9651
g7
I113
sg26
VC1533041
p9652
sg10
I27
sg11
Vprimary congenital glaucoma
p9653
sg13
I3
sasa(dp9654
g2
S'Rare CYP1B1 mutations and possibly polymorphisms may also contribute to risk for more common forms of glaucoma.\n'
p9655
sg4
(lp9656
(dp9657
g7
I0
sg8
g107
sg10
I11
sg11
VRare CYP1B1
p9658
sg13
I2
sasg23
(lp9659
(dp9660
g7
I102
sg26
VC0017601
p9661
sg10
I8
sg11
Vglaucoma
p9662
sg13
I1
sasa(dp9663
g2
S'However, the effects of the potential herb-drug interactions (HDIs) between LCA and therapeutic drugs on the inhibition of human cytochrome P450 (CYP) enzymes remain unclear.\n'
p9664
sg4
(lp9665
(dp9666
g7
I146
sg8
g107
sg10
I3
sg11
VCYP
p9667
sg13
I1
sa(dp9668
g7
I123
sg8
VP20853
p9669
sg10
I21
sg11
Vhuman cytochrome P450
p9670
sg13
I3
sasg23
(lp9671
(dp9672
g7
I76
sg26
VC0339527
p9673
sg10
I3
sg11
VLCA
p9674
sg13
I1
sasa(dp9675
g2
S'In the present study, the inhibitory effects of LCA on seven major human CYP isoforms, including CYP1A2, 2D6, 2E1, 2C19, 2C8, 2C9 and 3A4, were investigated in human liver microsomes (HLMs).\n'
p9676
sg4
(lp9677
(dp9678
g7
I61
sg8
g107
sg10
I24
sg11
Vmajor human CYP isoforms
p9679
sg13
I4
sa(dp9680
g7
I97
sg8
VP05177
p9681
sg10
I6
sg11
VCYP1A2
p9682
sg13
I1
sasg23
(lp9683
(dp9684
g7
I48
sg26
VC0339527
p9685
sg10
I3
sg11
VLCA
p9686
sg13
I1
sasa(dp9687
g2
S'The results demonstrated that LCA significantly inhibited the activities of CYP1A2, 2C19, 2C8, 2C9 and 3A4 and exhibited weak inhibitory effects on CYP2E1 and CYP2D6.\n'
p9688
sg4
(lp9689
(dp9690
g7
I76
sg8
VP05177
p9691
sg10
I6
sg11
VCYP1A2
p9692
sg13
I1
sa(dp9693
g7
I148
sg8
VP05181
p9694
sg10
I6
sg11
VCYP2E1
p9695
sg13
I1
sa(dp9696
g7
I159
sg8
VP10635
p9697
sg10
I6
sg11
VCYP2D6
p9698
sg13
I1
sasg23
(lp9699
(dp9700
g7
I30
sg26
VC0339527
p9701
sg10
I3
sg11
VLCA
p9702
sg13
I1
sasa(dp9703
g2
S'Dixon and Lineweaver-Burk plots revealed that the inhibition types of LCA against CYP1A2, 2C9, 2C19 and 2C8 were best fit as mixed-type inhibitions, while LCA was a competitive inhibitor towards CYP3A4.\n'
p9704
sg4
(lp9705
(dp9706
g7
I195
sg8
VP08684
p9707
sg10
I6
sg11
VCYP3A4
p9708
sg13
I1
sa(dp9709
g7
I82
sg8
VP05177
p9710
sg10
I6
sg11
VCYP1A2
p9711
sg13
I1
sasg23
(lp9712
(dp9713
g7
I70
sg26
VC0339527
p9714
sg10
I3
sg11
VLCA
p9715
sg13
I1
sa(dp9716
g7
I70
sg26
VC0339527
p9717
sg10
I3
sg11
VLCA
p9718
sg13
I1
sa(dp9719
g7
I118
sg26
VC0036572
p9720
sg10
I3
sg11
Vfit
p9721
sg13
I1
sasa(dp9722
g2
S'Furthermore, the areas under the plasma concentration-time curves (AUCs) of several drugs that are primarily metabolized by CYPs were estimated to increase by 2-398% in the presence of LCA, which suggested that LCA exhibited high HDI potentials via CYP inhibition.\n'
p9723
sg4
(lp9724
sg23
(lp9725
(dp9726
g7
I185
sg26
VC0339527
p9727
sg10
I3
sg11
VLCA
p9728
sg13
I1
sa(dp9729
g7
I185
sg26
VC0339527
p9730
sg10
I3
sg11
VLCA
p9731
sg13
I1
sasa(dp9732
g2
S'To evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC).\n'
p9733
sg4
(lp9734
sg23
(lp9735
(dp9736
g7
I118
sg26
VC0729842
p9737
sg10
I2
sg11
VSC
p9738
sg13
I1
sa(dp9739
g7
I93
sg26
VC0729842
p9740
sg10
I23
sg11
Vserpiginous choroiditis
p9741
sg13
I2
sasa(dp9742
g2
S'Diabetes significantly changed the kidney expression of Rage, Sod2, Tgfb1 and Ctgf, Pdp2, nephrin, and Lias.\n'
p9743
sg4
(lp9744
(dp9745
g7
I68
sg8
VP01137
p9746
sg10
I5
sg11
VTgfb1
p9747
sg13
I1
sa(dp9748
g7
I103
sg8
g107
sg10
I4
sg11
VLias
p9749
sg13
I1
sa(dp9750
g7
I56
sg8
g107
sg10
I4
sg11
VRage
p9751
sg13
I1
sa(dp9752
g7
I62
sg8
VP04179
p9753
sg10
I4
sg11
VSod2
p9754
sg13
I1
sa(dp9755
g7
I84
sg8
g107
sg10
I4
sg11
VPdp2
p9756
sg13
I1
sa(dp9757
g7
I78
sg8
VP29279
p9758
sg10
I4
sg11
VCtgf
p9759
sg13
I1
sa(dp9760
g7
I90
sg8
g107
sg10
I7
sg11
Vnephrin
p9761
sg13
I1
sasg23
(lp9762
(dp9763
g7
I0
sg26
VC0011849
p9764
sg10
I8
sg11
VDiabetes
p9765
sg13
I1
sasa(dp9766
g2
S'The main findings were 1) obesity resulted in a 46% decrease in PDP activity expressed per milligram extracted mitochondrial protein only in RG, while PDP isoform content was unchanged; 2) 8 wk of endurance training led to a significant 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; 3) 8 wk of endurance training led to a trending 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; and 4) PDP2 protein content was not affected by obesity or training.\n'
p9767
sg4
(lp9768
(dp9769
g7
I64
sg8
g107
sg10
I3
sg11
VPDP
p9770
sg13
I1
sa(dp9771
g7
I347
sg8
g107
sg10
I12
sg11
VPDP1 protein
p9772
sg13
I2
sa(dp9773
g7
I347
sg8
g107
sg10
I12
sg11
VPDP1 protein
p9774
sg13
I2
sa(dp9775
g7
I602
sg8
g107
sg10
I4
sg11
VPDP2
p9776
sg13
I1
sasg23
(lp9777
(dp9778
g7
I303
sg26
VC0028754
p9779
sg10
I5
sg11
Vobese
p9780
sg13
I1
sa(dp9781
g7
I303
sg26
VC0028754
p9782
sg10
I5
sg11
Vobese
p9783
sg13
I1
sa(dp9784
g7
I26
sg26
VC0028754
p9785
sg10
I7
sg11
Vobesity
p9786
sg13
I1
sa(dp9787
g7
I26
sg26
VC0028754
p9788
sg10
I7
sg11
Vobesity
p9789
sg13
I1
sasa(dp9790
g2
S'Starvation and streptozotocin-induced diabetes cause decreases in PDP2 mRNA abundance, PDP2 protein amount, and PDP activity in rat heart and kidney.\n'
p9791
sg4
(lp9792
(dp9793
g7
I66
sg8
g107
sg10
I9
sg11
VPDP2 mRNA
p9794
sg13
I2
sa(dp9795
g7
I87
sg8
g107
sg10
I12
sg11
VPDP2 protein
p9796
sg13
I2
sa(dp9797
g7
I66
sg8
g107
sg10
I3
sg11
VPDP
p9798
sg13
I1
sasg23
(lp9799
(dp9800
g7
I38
sg26
VC0011849
p9801
sg10
I8
sg11
Vdiabetes
p9802
sg13
I1
sasa(dp9803
g2
S"This study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013).\n"
p9804
sg4
(lp9805
(dp9806
g7
I73
sg8
VP42771
p9807
sg10
I6
sg11
VCDKN2A
p9808
sg13
I1
sa(dp9809
g7
I81
sg8
g107
sg10
I5
sg11
VSMAD4
p9810
sg13
I1
sa(dp9811
g7
I67
sg8
VP01116
p9812
sg10
I4
sg11
VKRAS
p9813
sg13
I1
sa(dp9814
g7
I92
sg8
VP01893
p9815
sg10
I10
sg11
VTP53 genes
p9816
sg13
I2
sasg23
(lp9817
(dp9818
g7
I195
sg26
VC0027651
p9819
sg10
I6
sg11
Vtumors
p9820
sg13
I1
sa(dp9821
g7
I232
sg26
VC0281361
p9822
sg10
I25
sg11
Vpancreatic adenocarcinoma
p9823
sg13
I2
sa(dp9824
g7
I314
sg26
VC0006826
p9825
sg10
I6
sg11
VCancer
p9826
sg13
I1
sa(dp9827
g7
I314
sg26
VC0006826
p9828
sg10
I6
sg11
VCancer
p9829
sg13
I1
sasa(dp9830
g2
S'We established a genetic diagnosis in six families with autosomal recessive HSP (SPG11 in three families and TFG/SPG57, SACS and ALS2 in one family each).\n'
p9831
sg4
(lp9832
(dp9833
g7
I109
sg8
g107
sg10
I3
sg11
VTFG
p9834
sg13
I1
sa(dp9835
g7
I129
sg8
g107
sg10
I4
sg11
VALS2
p9836
sg13
I1
sa(dp9837
g7
I120
sg8
g107
sg10
I4
sg11
VSACS
p9838
sg13
I1
sa(dp9839
g7
I76
sg8
g107
sg10
I3
sg11
VHSP
p9840
sg13
I1
sasg23
(lp9841
(dp9842
g7
I129
sg26
VC1859807
p9843
sg10
I4
sg11
VALS2
p9844
sg13
I1
sa(dp9845
g7
I120
sg26
VC1849140
p9846
sg10
I4
sg11
VSACS
p9847
sg13
I1
sa(dp9848
g7
I76
sg26
VC0034152
p9849
sg10
I3
sg11
VHSP
p9850
sg13
I1
sa(dp9851
g7
I81
sg26
VC1858479
p9852
sg10
I5
sg11
VSPG11
p9853
sg13
I1
sasa(dp9854
g2
S'We are now performing molecular testing of the HSP patients using Sanger sequencing (SPG4, SPG11, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 20, 21, 31, 33, 39, 42, ABCD1, alsin, and ARSACS), and resequencing microarray (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 17, 20, 21, 31, 33, and ABCD1).\n'
p9855
sg4
(lp9856
(dp9857
g7
I237
sg8
VP33897
p9858
sg10
I5
sg11
VABCD1
p9859
sg13
I1
sa(dp9860
g7
I244
sg8
g107
sg10
I5
sg11
Valsin
p9861
sg13
I1
sa(dp9862
g7
I98
sg8
g107
sg10
I5
sg11
VSPG31
p9863
sg13
I1
sa(dp9864
g7
I85
sg8
g107
sg10
I4
sg11
VSPG4
p9865
sg13
I1
sa(dp9866
g7
I237
sg8
VP33897
p9867
sg10
I5
sg11
VABCD1
p9868
sg13
I1
sasg23
(lp9869
(dp9870
g7
I118
sg26
VC1855900
p9871
sg10
I33
sg11
Vcomparative genomic hybridization
p9872
sg13
I3
sa(dp9873
g7
I98
sg26
VC1853247
p9874
sg10
I5
sg11
VSPG31
p9875
sg13
I1
sa(dp9876
g7
I153
sg26
VC1855900
p9877
sg10
I3
sg11
VCGH
p9878
sg13
I1
sa(dp9879
g7
I109
sg26
VC1849140
p9880
sg10
I6
sg11
VARSACS
p9881
sg13
I1
sa(dp9882
g7
I91
sg26
VC0795953
p9883
sg10
I4
sg11
VSPG1
p9884
sg13
I1
sa(dp9885
g7
I85
sg26
VC1866855
p9886
sg10
I4
sg11
VSPG4
p9887
sg13
I1
sa(dp9888
g7
I91
sg26
VC0795953
p9889
sg10
I4
sg11
VSPG1
p9890
sg13
I1
sa(dp9891
g7
I91
sg26
VC1858479
p9892
sg10
I5
sg11
VSPG11
p9893
sg13
I1
sa(dp9894
g7
I109
sg26
VC1849140
p9895
sg10
I6
sg11
VARSACS
p9896
sg13
I1
sa(dp9897
g7
I47
sg26
VC0034152
p9898
sg10
I3
sg11
VHSP
p9899
sg13
I1
sasa(dp9900
g2
S'Meanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.\n'
p9901
sg4
(lp9902
sg23
(lp9903
(dp9904
g7
I40
sg26
VC1858479
p9905
sg10
I5
sg11
VSPG11
p9906
sg13
I1
sa(dp9907
g7
I50
sg26
VC1849140
p9908
sg10
I6
sg11
VARSACS
p9909
sg13
I1
sasa(dp9910
g2
S'We are now performing molecular testing for the HSP patients using direct sequencing (SPG4, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1/2/3A/4/5/6/7/8/10/11/13/15/17/20/21/31/33/39/42/ABCD1/alsin/SACS), and resequencing microarray (SPG1/2/3A/4/5/6/7/8/10/11/13/17/20/21/31/33/ABCD1).\n'
p9911
sg4
(lp9912
(dp9913
g7
I92
sg8
g107
sg10
I5
sg11
VSPG31
p9914
sg13
I1
sa(dp9915
g7
I212
sg8
VP33897
p9916
sg10
I5
sg11
VABCD1
p9917
sg13
I1
sa(dp9918
g7
I212
sg8
VP33897
p9919
sg10
I5
sg11
VABCD1
p9920
sg13
I1
sa(dp9921
g7
I86
sg8
g107
sg10
I4
sg11
VSPG4
p9922
sg13
I1
sa(dp9923
g7
I105
sg8
g107
sg10
I4
sg11
VSACS
p9924
sg13
I1
sa(dp9925
g7
I218
sg8
g107
sg10
I5
sg11
Valsin
p9926
sg13
I1
sasg23
(lp9927
(dp9928
g7
I92
sg26
VC1853247
p9929
sg10
I5
sg11
VSPG31
p9930
sg13
I1
sa(dp9931
g7
I103
sg26
VC1849140
p9932
sg10
I6
sg11
VARSACS
p9933
sg13
I1
sa(dp9934
g7
I112
sg26
VC1855900
p9935
sg10
I33
sg11
Vcomparative genomic hybridization
p9936
sg13
I3
sa(dp9937
g7
I147
sg26
VC1855900
p9938
sg10
I3
sg11
VCGH
p9939
sg13
I1
sa(dp9940
g7
I48
sg26
VC0034152
p9941
sg10
I3
sg11
VHSP
p9942
sg13
I1
sa(dp9943
g7
I159
sg26
VC0795953
p9944
sg10
I4
sg11
VSPG1
p9945
sg13
I1
sa(dp9946
g7
I159
sg26
VC0795953
p9947
sg10
I4
sg11
VSPG1
p9948
sg13
I1
sa(dp9949
g7
I105
sg26
VC1849140
p9950
sg10
I4
sg11
VSACS
p9951
sg13
I1
sa(dp9952
g7
I86
sg26
VC1866855
p9953
sg10
I4
sg11
VSPG4
p9954
sg13
I1
sasa(dp9955
g2
S'Meanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.\n'
p9956
sg4
(lp9957
sg23
(lp9958
(dp9959
g7
I40
sg26
VC1858479
p9960
sg10
I5
sg11
VSPG11
p9961
sg13
I1
sa(dp9962
g7
I50
sg26
VC1849140
p9963
sg10
I6
sg11
VARSACS
p9964
sg13
I1
sasa(dp9965
g2
S'Autosomal recessive spastic ataxia of Charlevoix-Saguenay is an early onset form of hereditary spastic paraplegia with a peculiar clinical presentation.\n'
p9966
sg4
(lp9967
sg23
(lp9968
(dp9969
g7
I0
sg26
VC1849140
p9970
sg10
I57
sg11
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay
p9971
sg13
I6
sa(dp9972
g7
I84
sg26
VC0037773
p9973
sg10
I29
sg11
Vhereditary spastic paraplegia
p9974
sg13
I3
sasa(dp9975
g2
S'On the basis of our data, we therefore suggest that social avoidance (expressed as social phobia or avoidant personality disorder) has been underestimated in previous studies of carriers with the FMR-1 full mutation or premutation.\n'
p9976
sg4
(lp9977
(dp9978
g7
I196
sg8
g107
sg10
I5
sg11
VFMR-1
p9979
sg13
I1
sasg23
(lp9980
(dp9981
g7
I83
sg26
VC0031572
p9982
sg10
I13
sg11
Vsocial phobia
p9983
sg13
I2
sa(dp9984
g7
I100
sg26
VC0004444
p9985
sg10
I29
sg11
Vavoidant personality disorder
p9986
sg13
I3
sasa(dp9987
g2
S'Analysis of GenBank-derived clones on the Y chromosome revealed the presence of two full-length copies in azoospermia factor region b (AZFb) (PRY1 and PRY2) and two shorter versions of the PRY gene containing exons 3, 4 and 5 in AZFc (PRY3 and PRY4).\n'
p9988
sg4
(lp9989
(dp9990
g7
I151
sg8
g107
sg10
I4
sg11
VPRY2
p9991
sg13
I1
sa(dp9992
g7
I106
sg8
g107
sg10
I27
sg11
Vazoospermia factor region b
p9993
sg13
I4
sa(dp9994
g7
I135
sg8
g107
sg10
I4
sg11
VAZFb
p9995
sg13
I1
sa(dp9996
g7
I189
sg8
g107
sg10
I8
sg11
VPRY gene
p9997
sg13
I2
sa(dp9998
g7
I142
sg8
g107
sg10
I4
sg11
VPRY1
p9999
sg13
I1
sasg23
(lp10000
(dp10001
g7
I106
sg26
VC1384583
p10002
sg10
I18
sg11
Vazoospermia factor
p10003
sg13
I2
sasa(dp10004
g2
S'PRY1 and PRY2, two gene copies that are located in AZFb, a region often deleted in patients with severe male infertility, were shown to be expressed in the testis.\n'
p10005
sg4
(lp10006
(dp10007
g7
I9
sg8
g107
sg10
I4
sg11
VPRY2
p10008
sg13
I1
sa(dp10009
g7
I0
sg8
g107
sg10
I4
sg11
VPRY1
p10010
sg13
I1
sasg23
(lp10011
(dp10012
g7
I104
sg26
VC0021364
p10013
sg10
I16
sg11
Vmale infertility
p10014
sg13
I2
sasa(dp10015
g2
S'Expression of KIR3DL2 on NK and T cells was quantified in peripheral blood (PB) from 35 patients with SpA and 5 patients with juvenile enthesitis-related arthritis (juvenile ERA); samples were compared with samples from healthy and rheumatoid arthritis (RA) controls.\n'
p10016
sg4
(lp10017
(dp10018
g7
I14
sg8
VP43630
p10019
sg10
I7
sg11
VKIR3DL2
p10020
sg13
I1
sasg23
(lp10021
(dp10022
g7
I175
sg26
VC0003873
p10023
sg10
I2
sg11
VRA
p10024
sg13
I1
sa(dp10025
g7
I135
sg26
VC1282952
p10026
sg10
I10
sg11
Venthesitis
p10027
sg13
I1
sa(dp10028
g7
I232
sg26
VC0003873
p10029
sg10
I20
sg11
Vrheumatoid arthritis
p10030
sg13
I2
sa(dp10031
g7
I154
sg26
VC0003864
p10032
sg10
I9
sg11
Varthritis
p10033
sg13
I1
sasa(dp10034
g2
S'NKB1 inhibits cytoxic activity of T lymphocytes mediated by superantigens, which is one of the contributing factors in the pathogenesis of rheumatoid arthritis (RA).\n'
p10035
sg4
(lp10036
(dp10037
g7
I0
sg8
VP43629
p10038
sg10
I4
sg11
VNKB1
p10039
sg13
I1
sasg23
(lp10040
(dp10041
g7
I139
sg26
VC0003873
p10042
sg10
I20
sg11
Vrheumatoid arthritis
p10043
sg13
I2
sa(dp10044
g7
I123
sg26
VC0699748
p10045
sg10
I12
sg11
Vpathogenesis
p10046
sg13
I1
sa(dp10047
g7
I161
sg26
VC0003873
p10048
sg10
I2
sg11
VRA
p10049
sg13
I1
sasa(dp10050
g2
S'Killer Ig-like receptors (KIRs) are expressed on CD4(+)CD28(null) T cells, a highly oligoclonal subset of T cells that is expanded in patients with rheumatoid arthritis.\n'
p10051
sg4
(lp10052
(dp10053
g7
I0
sg8
g107
sg10
I24
sg11
VKiller Ig-like receptors
p10054
sg13
I3
sa(dp10055
g7
I26
sg8
VP55040
p10056
sg10
I4
sg11
VKIRs
p10057
sg13
I1
sa(dp10058
g7
I55
sg8
VP33681
p10059
sg10
I4
sg11
VCD28
p10060
sg13
I1
sa(dp10061
g7
I49
sg8
VP01730
p10062
sg10
I3
sg11
VCD4
p10063
sg13
I1
sasg23
(lp10064
(dp10065
g7
I148
sg26
VC0003873
p10066
sg10
I20
sg11
Vrheumatoid arthritis
p10067
sg13
I2
sasa(dp10068
g2
S'Functional involvement of NKAIN2 in miR-181d-regulated pancreatic cancer development was tested by small interfering RNA-mediated NKAIN2 knockdown in miR-181d-downregulated PANC-1 and AsPC-1 cells.\n'
p10069
sg4
(lp10070
(dp10071
g7
I26
sg8
g107
sg10
I6
sg11
VNKAIN2
p10072
sg13
I1
sa(dp10073
g7
I36
sg8
g107
sg10
I8
sg11
VmiR-181d
p10074
sg13
I1
sa(dp10075
g7
I36
sg8
g107
sg10
I8
sg11
VmiR-181d
p10076
sg13
I1
sasg23
(lp10077
(dp10078
g7
I55
sg26
VC0235974
p10079
sg10
I17
sg11
Vpancreatic cancer
p10080
sg13
I2
sasa(dp10081
g2
S'NKAIN2 was directly targeted by miR-181d in pancreatic cancer.\n'
p10082
sg4
(lp10083
(dp10084
g7
I32
sg8
g107
sg10
I8
sg11
VmiR-181d
p10085
sg13
I1
sa(dp10086
g7
I0
sg8
g107
sg10
I6
sg11
VNKAIN2
p10087
sg13
I1
sasg23
(lp10088
(dp10089
g7
I44
sg26
VC0235974
p10090
sg10
I17
sg11
Vpancreatic cancer
p10091
sg13
I2
sasa(dp10092
g2
S'Small interfering RNA-mediated NKAIN2 knockdown reversed the inhibition of miR-181d downregulation on pancreatic cancer development.\n'
p10093
sg4
(lp10094
(dp10095
g7
I75
sg8
g107
sg10
I8
sg11
VmiR-181d
p10096
sg13
I1
sa(dp10097
g7
I31
sg8
g107
sg10
I6
sg11
VNKAIN2
p10098
sg13
I1
sasg23
(lp10099
(dp10100
g7
I102
sg26
VC0235974
p10101
sg10
I17
sg11
Vpancreatic cancer
p10102
sg13
I2
sasa(dp10103
g2
S'Inhibiting miR-181d may suppress pancreatic cancer development, possibly through the inverse regulation on NKAIN2.\n'
p10104
sg4
(lp10105
(dp10106
g7
I107
sg8
g107
sg10
I6
sg11
VNKAIN2
p10107
sg13
I1
sa(dp10108
g7
I11
sg8
g107
sg10
I8
sg11
VmiR-181d
p10109
sg13
I1
sasg23
(lp10110
(dp10111
g7
I33
sg26
VC0235974
p10112
sg10
I17
sg11
Vpancreatic cancer
p10113
sg13
I2
sasa(dp10114
g2
S'Recurrent chromosome breakpoints at 6q22.31, leading to truncation and potential loss-of-function of the NKAIN2 gene, in Chinese prostate cancer patients were previously identified.\n'
p10115
sg4
(lp10116
(dp10117
g7
I105
sg8
g107
sg10
I11
sg11
VNKAIN2 gene
p10118
sg13
I2
sasg23
(lp10119
(dp10120
g7
I129
sg26
VC0600139
p10121
sg10
I15
sg11
Vprostate cancer
p10122
sg13
I2
sa(dp10123
g7
I56
sg26
VC1706395
p10124
sg10
I10
sg11
Vtruncation
p10125
sg13
I1
sasa(dp10126
g2
S'In this study we investigated genomic, methylation and expression changes of NKAIN2 in a large number of prostate cancer samples and determined its functional role in prostate cancer cells.\n'
p10127
sg4
(lp10128
(dp10129
g7
I77
sg8
g107
sg10
I6
sg11
VNKAIN2
p10130
sg13
I1
sasg23
(lp10131
(dp10132
g7
I105
sg26
VC0600139
p10133
sg10
I15
sg11
Vprostate cancer
p10134
sg13
I2
sa(dp10135
g7
I105
sg26
VC0600139
p10136
sg10
I15
sg11
Vprostate cancer
p10137
sg13
I2
sasa(dp10138
g2
S'Fluorescence in situ hybridization analysis confirmed that NKAIN2 truncation is specific to Chinese while deletion of the gene is frequent in both Chinese and UK prostate cancers.\n'
p10139
sg4
(lp10140
(dp10141
g7
I59
sg8
g107
sg10
I6
sg11
VNKAIN2
p10142
sg13
I1
sasg23
(lp10143
(dp10144
g7
I162
sg26
VC0376358
p10145
sg10
I16
sg11
Vprostate cancers
p10146
sg13
I2
sa(dp10147
g7
I66
sg26
VC1706395
p10148
sg10
I10
sg11
Vtruncation
p10149
sg13
I1
sasa(dp10150
g2
S'Somatic mutations of NKAIN2 in prostate cancer samples exist but at very low frequency, suggesting that it is a putative tumor suppressor gene (TSG) with haploid insufficiency.\n'
p10151
sg4
(lp10152
(dp10153
g7
I21
sg8
g107
sg10
I6
sg11
VNKAIN2
p10154
sg13
I1
sasg23
(lp10155
(dp10156
g7
I31
sg26
VC0600139
p10157
sg10
I15
sg11
Vprostate cancer
p10158
sg13
I2
sa(dp10159
g7
I0
sg26
VC0544886
p10160
sg10
I17
sg11
VSomatic mutations
p10161
sg13
I2
sa(dp10162
g7
I121
sg26
VC0027651
p10163
sg10
I5
sg11
Vtumor
p10164
sg13
I1
sasa(dp10165
g2
S'Our functional studies showed that overexpression of NKAIN2 in prostate cancer cells inhibits cellular growth by promoting cell apoptosis, and decreasing cell migration and invasion.\n'
p10166
sg4
(lp10167
(dp10168
g7
I53
sg8
g107
sg10
I6
sg11
VNKAIN2
p10169
sg13
I1
sasg23
(lp10170
(dp10171
g7
I63
sg26
VC0600139
p10172
sg10
I15
sg11
Vprostate cancer
p10173
sg13
I2
sa(dp10174
g7
I173
sg26
VC2699153
p10175
sg10
I8
sg11
Vinvasion
p10176
sg13
I1
sasa(dp10177
g2
S'Conversely, knockdown of NKAIN2 promotes prostate cancer cell growth by inhibiting cell apoptosis, and increasing cell migration and invasion.\n'
p10178
sg4
(lp10179
(dp10180
g7
I25
sg8
g107
sg10
I6
sg11
VNKAIN2
p10181
sg13
I1
sasg23
(lp10182
(dp10183
g7
I133
sg26
VC2699153
p10184
sg10
I8
sg11
Vinvasion
p10185
sg13
I1
sa(dp10186
g7
I50
sg26
VC1516170
p10187
sg10
I18
sg11
Vcancer cell growth
p10188
sg13
I3
sasa(dp10189
g2
S'These data imply that NKAIN2 is a novel TSG whose activity is commonly reduced in prostate cancer.\n'
p10190
sg4
(lp10191
(dp10192
g7
I40
sg8
g107
sg10
I3
sg11
VTSG
p10193
sg13
I1
sa(dp10194
g7
I22
sg8
g107
sg10
I6
sg11
VNKAIN2
p10195
sg13
I1
sasg23
(lp10196
(dp10197
g7
I82
sg26
VC0600139
p10198
sg10
I15
sg11
Vprostate cancer
p10199
sg13
I2
sasa(dp10200
g2
S'Our recent work detected recurrent chromosomal truncation at the Na(+)/K(+) transporting ATPase interacting 2 (NKAIN2) gene in prostate cancer, which was also found to be truncated in leukemia and lymphoma, suggesting that NKAIN2 is potentially one of the TSGs located in the 6q commonly deleted region in human cancers.\n'
p10201
sg4
(lp10202
(dp10203
g7
I65
sg8
g107
sg10
I44
sg11
VNa(+)/K(+) transporting ATPase interacting 2
p10204
sg13
I5
sa(dp10205
g7
I111
sg8
g107
sg10
I6
sg11
VNKAIN2
p10206
sg13
I1
sa(dp10207
g7
I108
sg8
g107
sg10
I15
sg11
V2 (NKAIN2) gene
p10208
sg13
I3
sasg23
(lp10209
(dp10210
g7
I184
sg26
VC0023418
p10211
sg10
I8
sg11
Vleukemia
p10212
sg13
I1
sa(dp10213
g7
I197
sg26
VC0024299
p10214
sg10
I8
sg11
Vlymphoma
p10215
sg13
I1
sa(dp10216
g7
I47
sg26
VC1706395
p10217
sg10
I10
sg11
Vtruncation
p10218
sg13
I1
sa(dp10219
g7
I312
sg26
VC0006826
p10220
sg10
I7
sg11
Vcancers
p10221
sg13
I1
sa(dp10222
g7
I127
sg26
VC0600139
p10223
sg10
I15
sg11
Vprostate cancer
p10224
sg13
I2
sasa(dp10225
g2
S'Fluorescent in situ hybridisation with BAC/PAC clones and long range polymerase chain reaction products assessed in the human genome sequence localised the chromosome 1 breakpoint to a 9.8 kb segment within a hypothetical gene, LOC388735, and the chromosome 6 breakpoint to a 12.8 kb segment in intron 4 of the T-cell lymphoma breakpoint-associated target 1 (TCBA1) gene.\n'
p10226
sg4
(lp10227
(dp10228
g7
I359
sg8
g107
sg10
I5
sg11
VTCBA1
p10229
sg13
I1
sa(dp10230
g7
I311
sg8
g107
sg10
I46
sg11
VT-cell lymphoma breakpoint-associated target 1
p10231
sg13
I5
sasg23
(lp10232
(dp10233
g7
I311
sg26
VC0079772
p10234
sg10
I15
sg11
VT-cell lymphoma
p10235
sg13
I2
sa(dp10236
g7
I43
sg26
VC0033036
p10237
sg10
I3
sg11
VPAC
p10238
sg13
I1
sasa(dp10239
g2
S'Disruption and/or formation of TCBA1 fusion genes in T cell lymphoma and leukaemia cell lines suggests a role for this gene in tumorigenesis.\n'
p10240
sg4
(lp10241
(dp10242
g7
I31
sg8
g107
sg10
I18
sg11
VTCBA1 fusion genes
p10243
sg13
I3
sasg23
(lp10244
(dp10245
g7
I73
sg26
VC0023418
p10246
sg10
I9
sg11
Vleukaemia
p10247
sg13
I1
sa(dp10248
g7
I127
sg26
VC0007621
p10249
sg10
I13
sg11
Vtumorigenesis
p10250
sg13
I1
sa(dp10251
g7
I53
sg26
VC0079772
p10252
sg10
I15
sg11
VT cell lymphoma
p10253
sg13
I3
sasa(dp10254
g2
S'We identified two T-cell lymphoma/leukemia cell lines with different differentiation stages that had breakpoints within the same novel gene, TCBA1 (T-cell lymphoma breakpoint associated target 1).\n'
p10255
sg4
(lp10256
(dp10257
g7
I18
sg8
g107
sg10
I15
sg11
VT-cell lymphoma
p10258
sg13
I2
sa(dp10259
g7
I148
sg8
g107
sg10
I46
sg11
VT-cell lymphoma breakpoint associated target 1
p10260
sg13
I6
sa(dp10261
g7
I141
sg8
g107
sg10
I5
sg11
VTCBA1
p10262
sg13
I1
sasg23
(lp10263
(dp10264
g7
I18
sg26
VC0079772
p10265
sg10
I15
sg11
VT-cell lymphoma
p10266
sg13
I2
sa(dp10267
g7
I18
sg26
VC0079772
p10268
sg10
I15
sg11
VT-cell lymphoma
p10269
sg13
I2
sa(dp10270
g7
I34
sg26
VC0023418
p10271
sg10
I8
sg11
Vleukemia
p10272
sg13
I1
sasa(dp10273
g2
S'In a T-cell lymphoblastic lymphoma cell line, HT-1, the TCBA1 fused to SUSP1 (SUMO-1-specific protease), creating a SUSP1-TCBA1 chimeric gene.\n'
p10274
sg4
(lp10275
(dp10276
g7
I56
sg8
g107
sg10
I5
sg11
VTCBA1
p10277
sg13
I1
sa(dp10278
g7
I56
sg8
g107
sg10
I5
sg11
VTCBA1
p10279
sg13
I1
sa(dp10280
g7
I71
sg8
g107
sg10
I5
sg11
VSUSP1
p10281
sg13
I1
sa(dp10282
g7
I71
sg8
g107
sg10
I5
sg11
VSUSP1
p10283
sg13
I1
sasg23
(lp10284
(dp10285
g7
I12
sg26
VC0079748
p10286
sg10
I22
sg11
Vlymphoblastic lymphoma
p10287
sg13
I2
sasa(dp10288
g2
S'However, in an adult T-cell leukemia cell line, ATN-1, no chimeric gene was detected, although aberrant TCBA1 transcripts were produced.\n'
p10289
sg4
(lp10290
(dp10291
g7
I104
sg8
g107
sg10
I17
sg11
VTCBA1 transcripts
p10292
sg13
I2
sasg23
(lp10293
(dp10294
g7
I15
sg26
VC0023492
p10295
sg10
I21
sg11
Vadult T-cell leukemia
p10296
sg13
I3
sa(dp10297
g7
I48
sg26
VC0268494
p10298
sg10
I3
sg11
VATN
p10299
sg13
I1
sasa(dp10300
g2
S'The expression levels of TUG1 were determined using Real-Time qPCR in a total of 44 patients with bladder urothelial carcinomas.\n'
p10301
sg4
(lp10302
sg23
(lp10303
(dp10304
g7
I117
sg26
VC0007097
p10305
sg10
I10
sg11
Vcarcinomas
p10306
sg13
I1
sasa(dp10307
g2
S'Bladder urothelial carcinoma T24 and 5637 cells were transfected with TUG1 siRNA or negative control siRNA.\n'
p10308
sg4
(lp10309
sg23
(lp10310
(dp10311
g7
I0
sg26
VC0279680
p10312
sg10
I28
sg11
VBladder urothelial carcinoma
p10313
sg13
I3
sasa(dp10314
g2
S'TUG1 was up-regulated in bladder urothelial carcinoma compared to paired normal urothelium.\n'
p10315
sg4
(lp10316
sg23
(lp10317
(dp10318
g7
I25
sg26
VC0279680
p10319
sg10
I28
sg11
Vbladder urothelial carcinoma
p10320
sg13
I3
sasa(dp10321
g2
S'Cell proliferation inhibition and apoptosis induction were observed in TUG1 siRNA-transfected bladder urothelial carcinoma T24 and 5637 cells.\n'
p10322
sg4
(lp10323
sg23
(lp10324
(dp10325
g7
I5
sg26
VC0334094
p10326
sg10
I13
sg11
Vproliferation
p10327
sg13
I1
sa(dp10328
g7
I94
sg26
VC0279680
p10329
sg10
I28
sg11
Vbladder urothelial carcinoma
p10330
sg13
I3
sasa(dp10331
g2
S'Our data suggest that lincRNA TUG1 is emerging as a novel player in the disease state of bladder urothelial carcinoma.\n'
p10332
sg4
(lp10333
sg23
(lp10334
(dp10335
g7
I89
sg26
VC0279680
p10336
sg10
I28
sg11
Vbladder urothelial carcinoma
p10337
sg13
I3
sasa(dp10338
g2
S'TUG1 may have potential roles as a biomarker and/or a therapeutic target in bladder urothelial carcinoma.\n'
p10339
sg4
(lp10340
sg23
(lp10341
(dp10342
g7
I76
sg26
VC0279680
p10343
sg10
I28
sg11
Vbladder urothelial carcinoma
p10344
sg13
I3
sasa(dp10345
g2
S'Serial samples of serum Cystatin C and urine NGAL were collected from 139 consecutive patients with congenital heart defects aged 3 days to 30 years after admission to the intensive care unit, 2 and 6 hours after the end of cardiopulmonary bypass.\n'
p10346
sg4
(lp10347
(dp10348
g7
I39
sg8
VP80188
p10349
sg10
I10
sg11
Vurine NGAL
p10350
sg13
I2
sa(dp10351
g7
I24
sg8
VP01034
p10352
sg10
I10
sg11
VCystatin C
p10353
sg13
I2
sasg23
(lp10354
(dp10355
g7
I100
sg26
VC0018798
p10356
sg10
I24
sg11
Vcongenital heart defects
p10357
sg13
I3
sasa(dp10358
g2
S'Hyper-IgE syndrome (HIES) is a very rare primary immune deficiency characterized by elevated serum IgE levels, recurrent bacterial infections, chronic dermatitis, and connective tissue abnormalities.\n'
p10359
sg4
(lp10360
(dp10361
g7
I0
sg8
VP01854
p10362
sg10
I9
sg11
VHyper-IgE
p10363
sg13
I1
sa(dp10364
g7
I93
sg8
VP01854
p10365
sg10
I9
sg11
Vserum IgE
p10366
sg13
I2
sasg23
(lp10367
(dp10368
g7
I6
sg26
VC0270850
p10369
sg10
I3
sg11
VIgE
p10370
sg13
I1
sa(dp10371
g7
I0
sg26
VC0022398
p10372
sg10
I18
sg11
VHyper-IgE syndrome
p10373
sg13
I2
sa(dp10374
g7
I20
sg26
VC0022398
p10375
sg10
I4
sg11
VHIES
p10376
sg13
I1
sa(dp10377
g7
I143
sg26
VC0262975
p10378
sg10
I18
sg11
Vchronic dermatitis
p10379
sg13
I2
sa(dp10380
g7
I49
sg26
VC0850497
p10381
sg10
I17
sg11
Vimmune deficiency
p10382
sg13
I2
sa(dp10383
g7
I111
sg26
VC1844383
p10384
sg10
I30
sg11
Vrecurrent bacterial infections
p10385
sg13
I3
sasa(dp10386
g2
S'We describe the clinical course of a 2-month-old infant who was evaluated for autosomal dominant Hyper IgE Syndrome based on eczema, periorbital cellulitis, skin abscesses, increased total IgE levels and blood eosinophilia.\n'
p10387
sg4
(lp10388
(dp10389
g7
I103
sg8
VP01854
p10390
sg10
I3
sg11
VIgE
p10391
sg13
I1
sa(dp10392
g7
I88
sg8
VP01854
p10393
sg10
I18
sg11
Vdominant Hyper IgE
p10394
sg13
I3
sasg23
(lp10395
(dp10396
g7
I97
sg26
VC0022398
p10397
sg10
I18
sg11
VHyper IgE Syndrome
p10398
sg13
I3
sa(dp10399
g7
I125
sg26
VC0013595
p10400
sg10
I6
sg11
Veczema
p10401
sg13
I1
sa(dp10402
g7
I210
sg26
VC0014457
p10403
sg10
I12
sg11
Veosinophilia
p10404
sg13
I1
sa(dp10405
g7
I157
sg26
VC0149777
p10406
sg10
I14
sg11
Vskin abscesses
p10407
sg13
I2
sa(dp10408
g7
I103
sg26
VC0270850
p10409
sg10
I3
sg11
VIgE
p10410
sg13
I1
sa(dp10411
g7
I133
sg26
VC0149754
p10412
sg10
I22
sg11
Vperiorbital cellulitis
p10413
sg13
I2
sasa(dp10414
g2
S'IL-22 induces STAT3 phosphorylation and mediates psoriasis-related gene expression.\n'
p10415
sg4
(lp10416
(dp10417
g7
I14
sg8
VP40763
p10418
sg10
I5
sg11
VSTAT3
p10419
sg13
I1
sa(dp10420
g7
I0
sg8
g107
sg10
I5
sg11
VIL-22
p10421
sg13
I1
sasg23
(lp10422
(dp10423
g7
I49
sg26
VC0033860
p10424
sg10
I9
sg11
Vpsoriasis
p10425
sg13
I1
sasa(dp10426
g2
S'The IL-22-STAT3-Bcl-3 pathway may be important in the pathogenesis of psoriasis.\n'
p10427
sg4
(lp10428
(dp10429
g7
I4
sg8
g107
sg10
I17
sg11
VIL-22-STAT3-Bcl-3
p10430
sg13
I1
sasg23
(lp10431
(dp10432
g7
I54
sg26
VC0699748
p10433
sg10
I12
sg11
Vpathogenesis
p10434
sg13
I1
sa(dp10435
g7
I70
sg26
VC0033860
p10436
sg10
I9
sg11
Vpsoriasis
p10437
sg13
I1
sasa(dp10438
g2
S'By using quantitative real-time polymerase chain reaction, we identified significant upregulation of PMEPA1 gene expression in malignant tissues of patients with gastric adenocarcinoma.\n'
p10439
sg4
(lp10440
(dp10441
g7
I101
sg8
g107
sg10
I11
sg11
VPMEPA1 gene
p10442
sg13
I2
sasg23
(lp10443
(dp10444
g7
I162
sg26
VC0278701
p10445
sg10
I22
sg11
Vgastric adenocarcinoma
p10446
sg13
I2
sasa(dp10447
g2
S'By using developed antibodies, we observed pronounced expression of TMEPAI in normal gastric epithelial cells while tumor cells from gastric adenomas, and adenocarcinoma samples were mostly negative for target protein expression.\n'
p10448
sg4
(lp10449
sg23
(lp10450
(dp10451
g7
I141
sg26
VC0001430
p10452
sg10
I8
sg11
Vadenomas
p10453
sg13
I1
sa(dp10454
g7
I116
sg26
VC0027651
p10455
sg10
I5
sg11
Vtumor
p10456
sg13
I1
sa(dp10457
g7
I155
sg26
VC0001418
p10458
sg10
I14
sg11
Vadenocarcinoma
p10459
sg13
I1
sasa(dp10460
g2
S'Analysis of expressed sequence tag databases showed that STAG1/PMEPA1 also was expressed in pancreatic, endometrial, and prostatic adenocarcinomas.\n'
p10461
sg4
(lp10462
(dp10463
g7
I57
sg8
g107
sg10
I5
sg11
VSTAG1
p10464
sg13
I1
sa(dp10465
g7
I63
sg8
g107
sg10
I6
sg11
VPMEPA1
p10466
sg13
I1
sasg23
(lp10467
(dp10468
g7
I31
sg26
VC0037293
p10469
sg10
I3
sg11
Vtag
p10470
sg13
I1
sa(dp10471
g7
I131
sg26
VC0001418
p10472
sg10
I15
sg11
Vadenocarcinomas
p10473
sg13
I1
sasa(dp10474
g2
S'It is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.\n'
p10475
sg4
(lp10476
(dp10477
g7
I115
sg8
g107
sg10
I5
sg11
VTRPV1
p10478
sg13
I1
sasg23
(lp10479
(dp10480
g7
I85
sg26
VC0242606
p10481
sg10
I16
sg11
Voxidative stress
p10482
sg13
I2
sa(dp10483
g7
I61
sg26
VC0155877
p10484
sg10
I15
sg11
Vallergic asthma
p10485
sg13
I2
sasa(dp10486
g2
S'Our data suggests the involvement of TRPV1 in allergic asthma and thus we feel this target merits further investigation.\n'
p10487
sg4
(lp10488
(dp10489
g7
I37
sg8
g107
sg10
I5
sg11
VTRPV1
p10490
sg13
I1
sasg23
(lp10491
(dp10492
g7
I46
sg26
VC0155877
p10493
sg10
I15
sg11
Vallergic asthma
p10494
sg13
I2
sasa(dp10495
g2
S'TNFAlfa, a proinflammatory cytokine known to be involved in the pathogenesis of allergic asthma, has been shown to induce hyperalgesia in somatic tissue via a sensitizing effect on dorsal root ganglion neurons expressing transient receptor potential vanilloid type 1 receptor (TRPV1).\n'
p10496
sg4
(lp10497
(dp10498
g7
I277
sg8
g107
sg10
I5
sg11
VTRPV1
p10499
sg13
I1
sa(dp10500
g7
I221
sg8
g107
sg10
I54
sg11
Vtransient receptor potential vanilloid type 1 receptor
p10501
sg13
I7
sasg23
(lp10502
(dp10503
g7
I193
sg26
VC1258666
p10504
sg10
I8
sg11
Vganglion
p10505
sg13
I1
sa(dp10506
g7
I64
sg26
VC0699748
p10507
sg10
I12
sg11
Vpathogenesis
p10508
sg13
I1
sa(dp10509
g7
I122
sg26
VC0020429
p10510
sg10
I12
sg11
Vhyperalgesia
p10511
sg13
I1
sa(dp10512
g7
I80
sg26
VC0155877
p10513
sg10
I15
sg11
Vallergic asthma
p10514
sg13
I2
sasa(dp10515
g2
S'Sequencing of genes known to be causative for WS [microphthalmia transcription factor (MITF), Pax3, Sox10, SNAI2 ] failed to show any candidate mutations to explain this complex cutaneous depigmentation phenotype.\n'
p10516
sg4
(lp10517
(dp10518
g7
I87
sg8
g107
sg10
I4
sg11
VMITF
p10519
sg13
I1
sa(dp10520
g7
I100
sg8
VP56693
p10521
sg10
I5
sg11
VSox10
p10522
sg13
I1
sa(dp10523
g7
I49
sg8
g107
sg10
I36
sg11
V[microphthalmia transcription factor
p10524
sg13
I3
sa(dp10525
g7
I107
sg8
g107
sg10
I5
sg11
VSNAI2
p10526
sg13
I1
sa(dp10527
g7
I94
sg8
VP23760
p10528
sg10
I4
sg11
VPax3
p10529
sg13
I1
sasg23
(lp10530
(dp10531
g7
I50
sg26
VC0026010
p10532
sg10
I14
sg11
Vmicrophthalmia
p10533
sg13
I1
sa(dp10534
g7
I188
sg26
VC0162835
p10535
sg10
I14
sg11
Vdepigmentation
p10536
sg13
I1
sasa(dp10537
g2
S'The mice include splotch (Sp), microphthalmia (mi), Slugh-/-, WS4, JF1, lethal-spotting (ls), and Dominant megacolon (Dom).\n'
p10538
sg4
(lp10539
(dp10540
g7
I62
sg8
VP56693
p10541
sg10
I3
sg11
VWS4
p10542
sg13
I1
sasg23
(lp10543
(dp10544
g7
I4
sg26
VC0026010
p10545
sg10
I2
sg11
Vmi
p10546
sg13
I1
sa(dp10547
g7
I62
sg26
VC1848519
p10548
sg10
I3
sg11
VWS4
p10549
sg13
I1
sa(dp10550
g7
I79
sg26
VC0025874
p10551
sg10
I8
sg11
Vspotting
p10552
sg13
I1
sa(dp10553
g7
I107
sg26
VC0235904
p10554
sg10
I9
sg11
Vmegacolon
p10555
sg13
I1
sa(dp10556
g7
I31
sg26
VC0026010
p10557
sg10
I14
sg11
Vmicrophthalmia
p10558
sg13
I1
sasa(dp10559
g2
S"The effect of ELL3 depletion on cell morphology, latent Epstein Barr Virus (EBV) lytic replication and differentiation markers in a Burkitt's lymphoma (BL) cell line cells are presented.\n"
p10560
sg4
(lp10561
(dp10562
g7
I14
sg8
g107
sg10
I4
sg11
VELL3
p10563
sg13
I1
sasg23
(lp10564
(dp10565
g7
I132
sg26
VC0006413
p10566
sg10
I18
sg11
VBurkitt's lymphoma
p10567
sg13
I2
sa(dp10568
g7
I152
sg26
VC0006413
p10569
sg10
I2
sg11
VBL
p10570
sg13
I1
sa(dp10571
g7
I81
sg26
VC0024348
p10572
sg10
I5
sg11
Vlytic
p10573
sg13
I1
sasa(dp10574
g2
S"Burkitt's lymphoma and a sub-set of Diffuse Large B cell lymphoma cell lines abundantly express ELL3.\n"
p10575
sg4
(lp10576
(dp10577
g7
I96
sg8
g107
sg10
I4
sg11
VELL3
p10578
sg13
I1
sasg23
(lp10579
(dp10580
g7
I0
sg26
VC0006413
p10581
sg10
I18
sg11
VBurkitt's lymphoma
p10582
sg13
I2
sa(dp10583
g7
I36
sg26
VC0079744
p10584
sg10
I29
sg11
VDiffuse Large B cell lymphoma
p10585
sg13
I5
sasa(dp10586
g2
S'This article provides a comprehensive review of the syndromes and disorders associated with NTDs, including Pallister-Hall syndrome, Walker-Warburg syndrome and Fukuyama congenital muscular dystrophy, MURCS association, Roberts syndrome, cerebro-costo-mandibular syndrome, laterality sequences, hydrolethalus syndrome, Knobloch syndrome, oculoauriculovertebral spectrum (hemifacial microsomia), cervico-oculo-acoustic syndrome, Fanconi anemia, Miller-Dieker lissencephaly syndrome, Fraser syndrome, frontonasal dysplasia, Adams-Oliver syndrome, CHILD syndrome, dyssegmental dysplasia, and monozygotic twinning.\n'
p10587
sg4
(lp10588
sg23
(lp10589
(dp10590
g7
I328
sg26
VC0220681
p10591
sg10
I32
sg11
Vsyndrome, oculoauriculovertebral
p10592
sg13
I2
sa(dp10593
g7
I52
sg26
VC0039082
p10594
sg10
I9
sg11
Vsyndromes
p10595
sg13
I1
sa(dp10596
g7
I238
sg26
VC0265342
p10597
sg10
I33
sg11
Vcerebro-costo-mandibular syndrome
p10598
sg13
I2
sa(dp10599
g7
I511
sg26
VC0334044
p10600
sg10
I9
sg11
Vdysplasia
p10601
sg13
I1
sa(dp10602
g7
I499
sg26
VC1876203
p10603
sg10
I21
sg11
Vfrontonasal dysplasia
p10604
sg13
I2
sa(dp10605
g7
I201
sg26
VC1832817
p10606
sg10
I17
sg11
VMURCS association
p10607
sg13
I2
sa(dp10608
g7
I52
sg26
VC0039082
p10609
sg10
I8
sg11
Vsyndrome
p10610
sg13
I1
sa(dp10611
g7
I522
sg26
VC0265268
p10612
sg10
I21
sg11
VAdams-Oliver syndrome
p10613
sg13
I2
sa(dp10614
g7
I395
sg26
VC0265239
p10615
sg10
I31
sg11
Vcervico-oculo-acoustic syndrome
p10616
sg13
I2
sa(dp10617
g7
I108
sg26
VC0265220
p10618
sg10
I23
sg11
VPallister-Hall syndrome
p10619
sg13
I2
sa(dp10620
g7
I371
sg26
VC1306710
p10621
sg10
I21
sg11
Vhemifacial microsomia
p10622
sg13
I2
sa(dp10623
g7
I295
sg26
VC2931104
p10624
sg10
I22
sg11
Vhydrolethalus syndrome
p10625
sg13
I2
sa(dp10626
g7
I123
sg26
VC0265221
p10627
sg10
I24
sg11
Vsyndrome, Walker-Warburg
p10628
sg13
I2
sa(dp10629
g7
I161
sg26
VC0410174
p10630
sg10
I38
sg11
VFukuyama congenital muscular dystrophy
p10631
sg13
I4
sa(dp10632
g7
I482
sg26
VC0265233
p10633
sg10
I15
sg11
VFraser syndrome
p10634
sg13
I2
sa(dp10635
g7
I220
sg26
VC0392475
p10636
sg10
I16
sg11
VRoberts syndrome
p10637
sg13
I2
sa(dp10638
g7
I545
sg26
VC0265267
p10639
sg10
I14
sg11
VCHILD syndrome
p10640
sg13
I2
sa(dp10641
g7
I472
sg26
VC0265233
p10642
sg10
I16
sg11
Vsyndrome, Fraser
p10643
sg13
I2
sa(dp10644
g7
I428
sg26
VC3469521
p10645
sg10
I14
sg11
VFanconi anemia
p10646
sg13
I2
sa(dp10647
g7
I444
sg26
VC0265219
p10648
sg10
I36
sg11
VMiller-Dieker lissencephaly syndrome
p10649
sg13
I3
sasa(dp10650
g2
S'Moreover, the Etv5 mutation resulted in several developmental abnormalities including an increased incidence of embryonic and perinatal lethality, postnatal growth restriction, polydactyly and renal asymmetry.\n'
p10651
sg4
(lp10652
(dp10653
g7
I14
sg8
VP41161
p10654
sg10
I13
sg11
VEtv5 mutation
p10655
sg13
I2
sasg23
(lp10656
(dp10657
g7
I177
sg26
VC0152427
p10658
sg10
I11
sg11
Vpolydactyly
p10659
sg13
I1
sasa(dp10660
g2
S'Here, we show that conditional knockout of the FGF-activated transcription factor genes Etv4 and Etv5 in mouse led to ectopic Shh expression in the anterior limb bud and a preaxial polydactyly (PPD) skeletal phenotype.\n'
p10661
sg4
(lp10662
(dp10663
g7
I126
sg8
g107
sg10
I3
sg11
VShh
p10664
sg13
I1
sa(dp10665
g7
I172
sg8
VP32754
p10666
sg10
I20
sg11
Vpreaxial polydactyly
p10667
sg13
I2
sa(dp10668
g7
I194
sg8
VP32754
p10669
sg10
I3
sg11
VPPD
p10670
sg13
I1
sa(dp10671
g7
I47
sg8
VP35398
p10672
sg10
I45
sg11
VFGF-activated transcription factor genes Etv4
p10673
sg13
I5
sa(dp10674
g7
I97
sg8
VP41161
p10675
sg10
I4
sg11
VEtv5
p10676
sg13
I1
sasg23
(lp10677
(dp10678
g7
I172
sg26
VC0345354
p10679
sg10
I20
sg11
Vpreaxial polydactyly
p10680
sg13
I2
sa(dp10681
g7
I194
sg26
VC0432215
p10682
sg10
I3
sg11
VPPD
p10683
sg13
I1
sasa(dp10684
g2
S'Mechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly.\n'
p10685
sg4
(lp10686
(dp10687
g7
I182
sg8
VP00390
p10688
sg10
I4
sg11
VDARC
p10689
sg13
I1
sa(dp10690
g7
I152
sg8
VP00390
p10691
sg10
I28
sg11
VDuffy antigen receptor group
p10692
sg13
I4
sa(dp10693
g7
I121
sg8
VP42857
p10694
sg10
I3
sg11
Vp21
p10695
sg13
I1
sa(dp10696
g7
I56
sg8
VP27701
p10697
sg10
I4
sg11
VCD82
p10698
sg13
I1
sa(dp10699
g7
I237
sg8
g107
sg10
I48
sg11
VIL-8-mediated vascular endothelial (VE)-cadherin
p10700
sg13
I4
sasg23
(lp10701
(dp10702
g7
I198
sg26
VC0027651
p10703
sg10
I5
sg11
Vtumor
p10704
sg13
I1
sa(dp10705
g7
I71
sg26
VC0278883
p10706
sg10
I19
sg11
Vmetastatic melanoma
p10707
sg13
I2
sasa(dp10708
g2
S'Our oneway ANOVA analysis results showed that in all cases from benign diseases to invasive carcinoma, the concentration of CXCL8, CXCR4 and CXCL12 was significantly different; in benign subgroups (benign change, benign change with proliferation, atypia), the concentration of CCL2 and CCR5 was significantly different; in invasive carcinoma cases, DARC concentration was significantly correlated with the relapse risk of patients.\n'
p10709
sg4
(lp10710
(dp10711
g7
I286
sg8
VP32302
p10712
sg10
I4
sg11
VCCR5
p10713
sg13
I1
sa(dp10714
g7
I131
sg8
VP61073
p10715
sg10
I5
sg11
VCXCR4
p10716
sg13
I1
sa(dp10717
g7
I277
sg8
VP13500
p10718
sg10
I4
sg11
VCCL2
p10719
sg13
I1
sa(dp10720
g7
I141
sg8
VP48061
p10721
sg10
I6
sg11
VCXCL12
p10722
sg13
I1
sasg23
(lp10723
(dp10724
g7
I83
sg26
VC1334274
p10725
sg10
I18
sg11
Vinvasive carcinoma
p10726
sg13
I2
sa(dp10727
g7
I83
sg26
VC1334274
p10728
sg10
I18
sg11
Vinvasive carcinoma
p10729
sg13
I2
sa(dp10730
g7
I232
sg26
VC0334094
p10731
sg10
I13
sg11
Vproliferation
p10732
sg13
I1
sa(dp10733
g7
I406
sg26
VC0277556
p10734
sg10
I7
sg11
Vrelapse
p10735
sg13
I1
sasa(dp10736
g2
S'177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.\n'
p10737
sg4
(lp10738
(dp10739
g7
I1876
sg8
VP49366
p10740
sg10
I49
sg11
Vsuccinate dehydrogenase complex assembly factor 2
p10741
sg13
I6
sa(dp10742
g7
I1927
sg8
VP21912
p10743
sg10
I4
sg11
VSDHB
p10744
sg13
I1
sa(dp10745
g7
I1771
sg8
g107
sg10
I3
sg11
VSDH
p10746
sg13
I1
sa(dp10747
g7
I2023
sg8
VP61278
p10748
sg10
I30
sg11
VSSTRs = somatostatin receptors
p10749
sg13
I4
sa(dp10750
g7
I438
sg8
g107
sg10
I5
sg11
VEGLN2
p10751
sg13
I1
sa(dp10752
g7
I2266
sg8
VP40337
p10753
sg10
I3
sg11
VVHL
p10754
sg13
I1
sa(dp10755
g7
I1802
sg8
VP31040
p10756
sg10
I4
sg11
VSDHA
p10757
sg13
I1
sa(dp10758
g7
I1760
sg8
VP33981
p10759
sg10
I9
sg11
VS6 kinase
p10760
sg13
I2
sa(dp10761
g7
I578
sg8
g107
sg10
I5
sg11
VEPAS1
p10762
sg13
I1
sa(dp10763
g7
I1434
sg8
VP13674
p10764
sg10
I33
sg11
Vprolyl hydroxylase domain protein
p10765
sg13
I4
sa(dp10766
g7
I2303
sg8
VP49366
p10767
sg10
I33
sg11
Valpha-ketoglutarate dehydrogenase
p10768
sg13
I2
sa(dp10769
g7
I464
sg8
g107
sg10
I26
sg11
Vhypoxia inducible factor 2
p10770
sg13
I4
sa(dp10771
g7
I1140
sg8
VP42345
p10772
sg10
I4
sg11
VmTOR
p10773
sg13
I1
sa(dp10774
g7
I1754
sg8
VP62753
p10775
sg10
I3
sg11
VS6K
p10776
sg13
I1
sa(dp10777
g7
I592
sg8
g107
sg10
I32
sg11
Vendothelial PAS domain protein 2
p10778
sg13
I5
sa(dp10779
g7
I492
sg8
g107
sg10
I3
sg11
VelF
p10780
sg13
I1
sa(dp10781
g7
I584
sg8
g107
sg10
I5
sg11
VHIF2A
p10782
sg13
I1
sa(dp10783
g7
I2063
sg8
g107
sg10
I21
sg11
Vsuccinyl-CoA synthase
p10784
sg13
I2
sa(dp10785
g7
I231
sg8
VP31947
p10786
sg10
I20
sg11
VO-methyl transferase
p10787
sg13
I2
sa(dp10788
g7
I958
sg8
g107
sg10
I33
sg11
VIGF-1R = growth factor 1 receptor
p10789
sg13
I6
sa(dp10790
g7
I1777
sg8
VP49366
p10791
sg10
I23
sg11
Vsuccinate dehydrogenase
p10792
sg13
I2
sa(dp10793
g7
I926
sg8
VP48735
p10794
sg10
I30
sg11
VIDH = isocitrate dehydrogenase
p10795
sg13
I4
sa(dp10796
g7
I748
sg8
VP84243
p10797
sg10
I5
sg11
VH3F3A
p10798
sg13
I1
sa(dp10799
g7
I900
sg8
VP01116
p10800
sg10
I3
sg11
VRAS
p10801
sg13
I1
sa(dp10802
g7
I1058
sg8
VP49366
p10803
sg10
I27
sg11
VMDH2 = malate dehydrogenase
p10804
sg13
I4
sa(dp10805
g7
I385
sg8
g107
sg10
I7
sg11
VEGLN1/2
p10806
sg13
I1
sa(dp10807
g7
I253
sg8
VP16870
p10808
sg10
I24
sg11
VCPE = carboxypeptidase E
p10809
sg13
I4
sa(dp10810
g7
I1001
sg8
g107
sg10
I7
sg11
Vkinesin
p10811
sg13
I1
sa(dp10812
g7
I756
sg8
VP62805
p10813
sg10
I25
sg11
Vhistone 3.3 encoding gene
p10814
sg13
I4
sa(dp10815
g7
I625
sg8
g107
sg10
I30
sg11
Vhypoxia-inducible factor 2Alfa
p10816
sg13
I3
sa(dp10817
g7
I1648
sg8
VP35125
p10818
sg10
I20
sg11
Vrat sarcoma oncogene
p10819
sg13
I3
sa(dp10820
g7
I1670
sg8
VP07949
p10821
sg10
I3
sg11
VRET
p10822
sg13
I1
sa(dp10823
g7
I657
sg8
VP29323
p10824
sg10
I3
sg11
VERK
p10825
sg13
I1
sa(dp10826
g7
I1027
sg8
VP61244
p10827
sg10
I29
sg11
VMAX = myc-associated factor X
p10828
sg13
I5
sa(dp10829
g7
I408
sg8
g107
sg10
I28
sg11
Vhypoxia inducible factor 1/2
p10830
sg13
I4
sa(dp10831
g7
I2230
sg8
g107
sg10
I34
sg11
Vvascular endothelial growth factor
p10832
sg13
I4
sa(dp10833
g7
I444
sg8
g107
sg10
I4
sg11
VPHD1
p10834
sg13
I1
sasg23
(lp10835
(dp10836
g7
I1771
sg26
VC0018946
p10837
sg10
I3
sg11
VSDH
p10838
sg13
I1
sa(dp10839
g7
I1261
sg26
VC0206754
p10840
sg10
I21
sg11
Vneuroendocrine tumors
p10841
sg13
I2
sa(dp10842
g7
I1477
sg26
VC0031511
p10843
sg10
I16
sg11
VPheochromocytoma
p10844
sg13
I1
sa(dp10845
g7
I1648
sg26
VC1882848
p10846
sg10
I11
sg11
Vrat sarcoma
p10847
sg13
I2
sa(dp10848
g7
I408
sg26
VC0242184
p10849
sg10
I7
sg11
Vhypoxia
p10850
sg13
I1
sa(dp10851
g7
I790
sg26
VC0242184
p10852
sg10
I7
sg11
VHypoxia
p10853
sg13
I1
sa(dp10854
g7
I1213
sg26
VC1850380
p10855
sg10
I3
sg11
VNAd
p10856
sg13
I1
sa(dp10857
g7
I94
sg26
VC1845055
p10858
sg10
I4
sg11
VATRX
p10859
sg13
I1
sa(dp10860
g7
I197
sg26
VC2678439
p10861
sg10
I3
sg11
VCoA
p10862
sg13
I1
sa(dp10863
g7
I1498
sg26
VC0030421
p10864
sg10
I14
sg11
VParagangliomas
p10865
sg13
I1
sa(dp10866
g7
I883
sg26
VC0030421
p10867
sg10
I14
sg11
Vparagangliomas
p10868
sg13
I1
sa(dp10869
g7
I408
sg26
VC0242184
p10870
sg10
I7
sg11
Vhypoxia
p10871
sg13
I1
sa(dp10872
g7
I1284
sg26
VC0027831
p10873
sg10
I3
sg11
VNF1
p10874
sg13
I1
sa(dp10875
g7
I408
sg26
VC0242184
p10876
sg10
I7
sg11
Vhypoxia
p10877
sg13
I1
sa(dp10878
g7
I2266
sg26
VC0019562
p10879
sg10
I3
sg11
VVHL
p10880
sg13
I1
sa(dp10881
g7
I729
sg26
VC1260386
p10882
sg10
I3
sg11
VGSH
p10883
sg13
I1
sa(dp10884
g7
I135
sg26
VC0279702
p10885
sg10
I31
sg11
Vclear cell renal cell carcinoma
p10886
sg13
I5
sa(dp10887
g7
I566
sg26
VC0599156
p10888
sg10
I10
sg11
Vtransition
p10889
sg13
I1
sa(dp10890
g7
I94
sg26
VC1845055
p10891
sg10
I4
sg11
VATRX
p10892
sg13
I1
sa(dp10893
g7
I2144
sg26
VC0040715
p10894
sg10
I13
sg11
Vtranslocation
p10895
sg13
I1
sa(dp10896
g7
I197
sg26
VC2678439
p10897
sg10
I3
sg11
VCoA
p10898
sg13
I1
sa(dp10899
g7
I408
sg26
VC0242184
p10900
sg10
I7
sg11
Vhypoxia
p10901
sg13
I1
sasa(dp10902
g2
S'Immunohistochemistry for phosphorylated-S6, phosphorylated-mTOR, mTOR, phosphorylated-AKT, hypoxia inducible factor-1Alfa, Raptor, phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K), and phosphorylated 4E-binding protein-1 was performed on tissue microarray constructs of patients treated for nonmetastatic kidney cancer from 1997 to 2010.\n'
p10903
sg4
(lp10904
(dp10905
g7
I86
sg8
g107
sg10
I3
sg11
VAKT
p10906
sg13
I1
sa(dp10907
g7
I163
sg8
VP60484
p10908
sg10
I4
sg11
VPTEN
p10909
sg13
I1
sa(dp10910
g7
I59
sg8
VP42345
p10911
sg10
I4
sg11
VmTOR
p10912
sg13
I1
sa(dp10913
g7
I197
sg8
VP42336
p10914
sg10
I4
sg11
VPI3K
p10915
sg13
I1
sa(dp10916
g7
I123
sg8
g107
sg10
I19
sg11
VRaptor, phosphatase
p10917
sg13
I2
sa(dp10918
g7
I131
sg8
VP60484
p10919
sg10
I30
sg11
Vphosphatase and tensin homolog
p10920
sg13
I4
sa(dp10921
g7
I59
sg8
VP42345
p10922
sg10
I4
sg11
VmTOR
p10923
sg13
I1
sa(dp10924
g7
I91
sg8
g107
sg10
I30
sg11
Vhypoxia inducible factor-1Alfa
p10925
sg13
I3
sa(dp10926
g7
I208
sg8
g107
sg10
I35
sg11
Vphosphorylated 4E-binding protein-1
p10927
sg13
I3
sa(dp10928
g7
I170
sg8
g107
sg10
I25
sg11
Vphosphoinositide 3-kinase
p10929
sg13
I2
sasg23
(lp10930
(dp10931
g7
I91
sg26
VC0242184
p10932
sg10
I7
sg11
Vhypoxia
p10933
sg13
I1
sa(dp10934
g7
I328
sg26
VC0740457
p10935
sg10
I13
sg11
Vkidney cancer
p10936
sg13
I2
sasa(dp10937
g2
S'Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA).\n'
p10938
sg4
(lp10939
sg23
(lp10940
(dp10941
g7
I211
sg26
VC1865926
p10942
sg10
I4
sg11
ViCCA
p10943
sg13
I1
sa(dp10944
g7
I0
sg26
VC0206698
p10945
sg10
I18
sg11
VCholangiocarcinoma
p10946
sg13
I1
sa(dp10947
g7
I229
sg26
VC3151140
p10948
sg10
I4
sg11
VpCCA
p10949
sg13
I1
sa(dp10950
g7
I69
sg26
VC0027651
p10951
sg10
I7
sg11
Vtumours
p10952
sg13
I1
sa(dp10953
g7
I125
sg26
VC0206698
p10954
sg10
I19
sg11
Vcholangiocarcinomas
p10955
sg13
I1
sasa(dp10956
g2
S'Cholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) subsets.\n'
p10957
sg4
(lp10958
sg23
(lp10959
(dp10960
g7
I0
sg26
VC0206698
p10961
sg10
I18
sg11
VCholangiocarcinoma
p10962
sg13
I1
sa(dp10963
g7
I168
sg26
VC1865926
p10964
sg10
I4
sg11
ViCCA
p10965
sg13
I1
sa(dp10966
g7
I186
sg26
VC3151140
p10967
sg10
I4
sg11
VpCCA
p10968
sg13
I1
sa(dp10969
g7
I20
sg26
VC0220668
p10970
sg10
I3
sg11
VCCA
p10971
sg13
I1
sa(dp10972
g7
I66
sg26
VC0006826
p10973
sg10
I7
sg11
Vcancers
p10974
sg13
I1
sasa(dp10975
g2
S'Preoperative evaluation of vasculobiliary anatomy in the umbilical fissure (U-point) is pivotal for perihilar cholangiocarcinoma (PCCA) applied to right-sided hepatectomy.\n'
p10976
sg4
(lp10977
sg23
(lp10978
(dp10979
g7
I100
sg26
VC3151140
p10980
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p10981
sg13
I2
sa(dp10982
g7
I130
sg26
VC3151140
p10983
sg10
I4
sg11
VPCCA
p10984
sg13
I1
sasa(dp10985
g2
S'This study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA).\n'
p10986
sg4
(lp10987
sg23
(lp10988
(dp10989
g7
I119
sg26
VC3151140
p10990
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p10991
sg13
I2
sa(dp10992
g7
I149
sg26
VC3151140
p10993
sg10
I4
sg11
VpCCA
p10994
sg13
I1
sasa(dp10995
g2
S'Our goal was to characterize PD-L1 expression in intra-hepatic (iCCA) and perihilar (pCCA) cholangiocarcinomas, and to correlate our results with clinicopathological features, density of tumor-infiltrating lymphocytes (TILs) and PD-1 expression.A series of 58 iCCAs and 41 pCCAs was included in the study.\n'
p10996
sg4
(lp10997
(dp10998
g7
I229
sg8
VP18621
p10999
sg10
I4
sg11
VPD-1
p11000
sg13
I1
sasg23
(lp11001
(dp11002
g7
I91
sg26
VC0206698
p11003
sg10
I19
sg11
Vcholangiocarcinomas
p11004
sg13
I1
sa(dp11005
g7
I193
sg26
VC0332448
p11006
sg10
I12
sg11
Vinfiltrating
p11007
sg13
I1
sa(dp11008
g7
I85
sg26
VC3151140
p11009
sg10
I4
sg11
VpCCA
p11010
sg13
I1
sa(dp11011
g7
I64
sg26
VC1865926
p11012
sg10
I4
sg11
ViCCA
p11013
sg13
I1
sa(dp11014
g7
I187
sg26
VC0027651
p11015
sg10
I5
sg11
Vtumor
p11016
sg13
I1
sasa(dp11017
g2
S'Liver transplantation (LT) provides a good chance of cure for selected patients with hepatocellular carcinoma (HCC) and perihilar cholangiocarcinoma (pCCA).\n'
p11018
sg4
(lp11019
sg23
(lp11020
(dp11021
g7
I150
sg26
VC3151140
p11022
sg10
I4
sg11
VpCCA
p11023
sg13
I1
sa(dp11024
g7
I111
sg26
VC2239176
p11025
sg10
I3
sg11
VHCC
p11026
sg13
I1
sa(dp11027
g7
I120
sg26
VC3151140
p11028
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p11029
sg13
I2
sa(dp11030
g7
I85
sg26
VC2239176
p11031
sg10
I24
sg11
Vhepatocellular carcinoma
p11032
sg13
I2
sasa(dp11033
g2
S'BTC are sub-classified as intrahepatic cholangiocarcinoma (iCCA), perhilar/hilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA), and gallbladder carcinoma.\n'
p11034
sg4
(lp11035
(dp11036
g7
I0
sg8
VP35070
p11037
sg10
I3
sg11
VBTC
p11038
sg13
I1
sasg23
(lp11039
(dp11040
g7
I39
sg26
VC0206698
p11041
sg10
I18
sg11
Vcholangiocarcinoma
p11042
sg13
I1
sa(dp11043
g7
I66
sg26
VC3151140
p11044
sg10
I33
sg11
Vperhilar/hilar cholangiocarcinoma
p11045
sg13
I2
sa(dp11046
g7
I146
sg26
VC0235782
p11047
sg10
I21
sg11
Vgallbladder carcinoma
p11048
sg13
I2
sa(dp11049
g7
I26
sg26
VC0345905
p11050
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p11051
sg13
I2
sa(dp11052
g7
I101
sg26
VC3151140
p11053
sg10
I4
sg11
VpCCA
p11054
sg13
I1
sa(dp11055
g7
I59
sg26
VC1865926
p11056
sg10
I4
sg11
ViCCA
p11057
sg13
I1
sasa(dp11058
g2
S'To evaluate prognostic factors for stent patency and survival in patients with perihilar cholangiocarcinoma (pCCA) who underwent percutaneous biliary stent placement.\n'
p11059
sg4
(lp11060
sg23
(lp11061
(dp11062
g7
I109
sg26
VC3151140
p11063
sg10
I4
sg11
VpCCA
p11064
sg13
I1
sa(dp11065
g7
I79
sg26
VC3151140
p11066
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p11067
sg13
I2
sasa(dp11068
g2
S'Clinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun.\n'
p11069
sg4
(lp11070
(dp11071
g7
I161
sg8
VP05412
p11072
sg10
I3
sg11
VJun
p11073
sg13
I1
sasg23
(lp11074
(dp11075
g7
I147
sg26
VC0086543
p11076
sg10
I8
sg11
Vcataract
p11077
sg13
I1
sa(dp11078
g7
I135
sg26
VC0017601
p11079
sg10
I8
sg11
Vglaucoma
p11080
sg13
I1
sa(dp11081
g7
I67
sg26
VC0027726
p11082
sg10
I18
sg11
Vnephrotic syndrome
p11083
sg13
I2
sa(dp11084
g7
I114
sg26
VC0028840
p11085
sg10
I19
sg11
Vocular hypertension
p11086
sg13
I2
sasa(dp11087
g2
S'c-Jun, c-Jun N-terminal kinase(JNK) and endothelin B (ETB) receptor have been shown to contribute to the pathogenesis of glaucoma.\n'
p11088
sg4
(lp11089
(dp11090
g7
I0
sg8
VP05412
p11091
sg10
I5
sg11
Vc-Jun
p11092
sg13
I1
sa(dp11093
g7
I31
sg8
VP53779
p11094
sg10
I3
sg11
VJNK
p11095
sg13
I1
sa(dp11096
g7
I40
sg8
g107
sg10
I27
sg11
Vendothelin B (ETB) receptor
p11097
sg13
I4
sa(dp11098
g7
I7
sg8
VP53779
p11099
sg10
I23
sg11
Vc-Jun N-terminal kinase
p11100
sg13
I3
sasg23
(lp11101
(dp11102
g7
I105
sg26
VC0699748
p11103
sg10
I12
sg11
Vpathogenesis
p11104
sg13
I1
sa(dp11105
g7
I121
sg26
VC0017601
p11106
sg10
I8
sg11
Vglaucoma
p11107
sg13
I1
sasa(dp11108
g2
S'Ocular hypertension also caused upregulations in the iron-regulating protein ceruloplasmin, the anaerobic glycolytic enzyme lactate dehydrogenase, and the transcription factors cFos and p-cJun.\n'
p11109
sg4
(lp11110
(dp11111
g7
I53
sg8
VP00450
p11112
sg10
I37
sg11
Viron-regulating protein ceruloplasmin
p11113
sg13
I3
sa(dp11114
g7
I124
sg8
VP49366
p11115
sg10
I21
sg11
Vlactate dehydrogenase
p11116
sg13
I2
sa(dp11117
g7
I177
sg8
VP01100
p11118
sg10
I4
sg11
VcFos
p11119
sg13
I1
sasg23
(lp11120
(dp11121
g7
I0
sg26
VC0028840
p11122
sg10
I19
sg11
VOcular hypertension
p11123
sg13
I2
sasa(dp11124
g2
S'JUN is expressed after glaucoma-relevant injuries and Jun deficiency protects RGCs after mechanical injury to the optic nerve.\n'
p11125
sg4
(lp11126
(dp11127
g7
I54
sg8
VP05412
p11128
sg10
I3
sg11
VJun
p11129
sg13
I1
sa(dp11130
g7
I0
sg8
VP05412
p11131
sg10
I3
sg11
VJUN
p11132
sg13
I1
sasg23
(lp11133
(dp11134
g7
I23
sg26
VC0017601
p11135
sg10
I8
sg11
Vglaucoma
p11136
sg13
I1
sasa(dp11137
g2
S'Here, we tested the importance of JNK-JUN signaling for RGC death after ocular hypertensive axonal injury in an age-related, mouse model of ocular hypertension.\n'
p11138
sg4
(lp11139
(dp11140
g7
I38
sg8
VP05412
p11141
sg10
I3
sg11
VJUN
p11142
sg13
I1
sa(dp11143
g7
I34
sg8
VP53779
p11144
sg10
I3
sg11
VJNK
p11145
sg13
I1
sasg23
(lp11146
(dp11147
g7
I140
sg26
VC0028840
p11148
sg10
I19
sg11
Vocular hypertension
p11149
sg13
I2
sasa(dp11150
g2
S'JUN was expressed in a temporal and spatial pattern consistent with a role in glaucomatous injury.\n'
p11151
sg4
(lp11152
(dp11153
g7
I0
sg8
VP05412
p11154
sg10
I3
sg11
VJUN
p11155
sg13
I1
sasg23
(lp11156
sa(dp11157
g2
S'To determine the importance of JUN in ocular hypertension-induced RGC death, a floxed allele of Jun and a retinal expressed cre recombinase (Six3-cre) were backcrossed onto the DBA/2J background.\n'
p11158
sg4
(lp11159
(dp11160
g7
I124
sg8
g107
sg10
I15
sg11
Vcre recombinase
p11161
sg13
I2
sa(dp11162
g7
I141
sg8
g107
sg10
I8
sg11
VSix3-cre
p11163
sg13
I1
sa(dp11164
g7
I96
sg8
VP05412
p11165
sg10
I3
sg11
VJun
p11166
sg13
I1
sasg23
(lp11167
(dp11168
g7
I177
sg26
VC0398550
p11169
sg10
I3
sg11
VDBA
p11170
sg13
I1
sa(dp11171
g7
I38
sg26
VC0028840
p11172
sg10
I19
sg11
Vocular hypertension
p11173
sg13
I2
sasa(dp11174
g2
S'Jun deficiency protected RGC somas from ocular hypertensive injury, but did not protect RGC axons from glaucomatous neurodegeneration.\n'
p11175
sg4
(lp11176
(dp11177
g7
I0
sg8
VP05412
p11178
sg10
I3
sg11
VJun
p11179
sg13
I1
sasg23
(lp11180
(dp11181
g7
I116
sg26
VC0027746
p11182
sg10
I17
sg11
Vneurodegeneration
p11183
sg13
I1
sasa(dp11184
g2
S'Jun is a major regulator of RGC somal degeneration after glaucomatous ocular hypertensive injury.\n'
p11185
sg4
(lp11186
(dp11187
g7
I0
sg8
VP05412
p11188
sg10
I3
sg11
VJun
p11189
sg13
I1
sasg23
(lp11190
(dp11191
g7
I38
sg26
VC0011164
p11192
sg10
I12
sg11
Vdegeneration
p11193
sg13
I1
sasa(dp11194
g2
S'These results suggest in glaucomatous neurodegeneration, JNK-JUN signaling has a major role as a pro-death signaling pathway between axonal injury and somal degeneration.\n'
p11195
sg4
(lp11196
(dp11197
g7
I61
sg8
VP05412
p11198
sg10
I3
sg11
VJUN
p11199
sg13
I1
sa(dp11200
g7
I57
sg8
VP53779
p11201
sg10
I3
sg11
VJNK
p11202
sg13
I1
sasg23
(lp11203
(dp11204
g7
I43
sg26
VC0011164
p11205
sg10
I12
sg11
Vdegeneration
p11206
sg13
I1
sa(dp11207
g7
I38
sg26
VC0027746
p11208
sg10
I17
sg11
Vneurodegeneration
p11209
sg13
I1
sasa(dp11210
g2
S'To our knowledge the co-existence of Pompe disease and thymic neuroendocrine tumor in the same patient has not been previously reported.\n'
p11211
sg4
(lp11212
sg23
(lp11213
(dp11214
g7
I62
sg26
VC0206754
p11215
sg10
I20
sg11
Vneuroendocrine tumor
p11216
sg13
I2
sa(dp11217
g7
I37
sg26
VC0017921
p11218
sg10
I13
sg11
VPompe disease
p11219
sg13
I2
sasa(dp11220
g2
S"Significantly more A-C (block 2: rs230528-rs230521) haplotypes (P = 0.0003 after Bonferroni's corrections) and G-A-A (block 4: rs4648068-rs3774964-rs3774968) haplotypes (P = 0.021) were found in the patients with ovarian cancer.\n"
p11221
sg4
(lp11222
sg23
(lp11223
(dp11224
g7
I213
sg26
VC1140680
p11225
sg10
I14
sg11
Vovarian cancer
p11226
sg13
I2
sasa(dp11227
g2
S'The thyroid conditions for which surgery was indicated were: diffuse toxic goiter in 8 patients; multinodular toxic and nontoxic goiter in 30 patients; autonomous nodule in 2 patients; 2 patients with benign nodules at fine needle aspiration biopsy (FNAB); 4 patients with nodules positive for carcinoma at FNAB, among them 2 with unilateral cervical lymph nodes enlargement; 4 patients with highly suspect nodule on FNAB.\n'
p11228
sg4
(lp11229
sg23
(lp11230
(dp11231
g7
I61
sg26
VC0342122
p11232
sg10
I20
sg11
Vdiffuse toxic goiter
p11233
sg13
I3
sa(dp11234
g7
I163
sg26
VC0028259
p11235
sg10
I6
sg11
Vnodule
p11236
sg13
I1
sa(dp11237
g7
I120
sg26
VC0221777
p11238
sg10
I15
sg11
Vnontoxic goiter
p11239
sg13
I2
sa(dp11240
g7
I163
sg26
VC0028259
p11241
sg10
I6
sg11
Vnodule
p11242
sg13
I1
sa(dp11243
g7
I208
sg26
VC0028259
p11244
sg10
I7
sg11
Vnodules
p11245
sg13
I1
sa(dp11246
g7
I208
sg26
VC0028259
p11247
sg10
I7
sg11
Vnodules
p11248
sg13
I1
sa(dp11249
g7
I363
sg26
VC2711450
p11250
sg10
I11
sg11
Venlargement
p11251
sg13
I1
sa(dp11252
g7
I294
sg26
VC0007097
p11253
sg10
I9
sg11
Vcarcinoma
p11254
sg13
I1
sa(dp11255
g7
I231
sg26
VC0700198
p11256
sg10
I10
sg11
Vaspiration
p11257
sg13
I1
sasa(dp11258
g2
S'The aim of the present study was to comparatively investigate the effects of piroxicam, a selective COX-I inhibitor, and celecoxib, a selective COX-II inhibitor, on cognitive functions in an AlCl3-induced neurotoxicity mouse model to understand the specific role of each COX enzyme in the hippocampus and cortex.\n'
p11259
sg4
(lp11260
(dp11261
g7
I100
sg8
VP00395
p11262
sg10
I5
sg11
VCOX-I
p11263
sg13
I1
sa(dp11264
g7
I144
sg8
VP00403
p11265
sg10
I6
sg11
VCOX-II
p11266
sg13
I1
sasg23
(lp11267
sa(dp11268
g2
S'Of these differentially expressed genes, we elected to further examine the increase in COX1 expression, because of data implicating energy utilization in METH neurotoxicity and the known role of COX1 in energy metabolism.\n'
p11269
sg4
(lp11270
(dp11271
g7
I87
sg8
VP00395
p11272
sg10
I4
sg11
VCOX1
p11273
sg13
I1
sa(dp11274
g7
I87
sg8
VP00395
p11275
sg10
I4
sg11
VCOX1
p11276
sg13
I1
sasg23
(lp11277
sa(dp11278
g2
S'The precise role of COX1 and other genes in METH neurotoxicity remains to be elucidated.\n'
p11279
sg4
(lp11280
(dp11281
g7
I20
sg8
VP00395
p11282
sg10
I4
sg11
VCOX1
p11283
sg13
I1
sasg23
(lp11284
sa(dp11285
g2
S'Various genes involved in the control of cell proliferation and invasion (p16INK4A, RASSF1A, PTEN, Rap1GAP, TIMP3, DAPK, RARBeta2, E-cadherin, and CITED1) as well as genes specific of thyroid differentiation (Na+/I- symport, TSH receptor, pendrin, SL5A8, and TTF-1) present aberrant methylation in thyroid cancer.\n'
p11286
sg4
(lp11287
(dp11288
g7
I93
sg8
VP60484
p11289
sg10
I4
sg11
VPTEN
p11290
sg13
I1
sa(dp11291
g7
I115
sg8
VP53355
p11292
sg10
I4
sg11
VDAPK
p11293
sg13
I1
sa(dp11294
g7
I225
sg8
VP16473
p11295
sg10
I12
sg11
VTSH receptor
p11296
sg13
I2
sa(dp11297
g7
I74
sg8
VP42771
p11298
sg10
I8
sg11
Vp16INK4A
p11299
sg13
I1
sa(dp11300
g7
I108
sg8
VP35625
p11301
sg10
I5
sg11
VTIMP3
p11302
sg13
I1
sa(dp11303
g7
I147
sg8
g107
sg10
I6
sg11
VCITED1
p11304
sg13
I1
sa(dp11305
g7
I99
sg8
VP47736
p11306
sg10
I7
sg11
VRap1GAP
p11307
sg13
I1
sa(dp11308
g7
I259
sg8
VP43699
p11309
sg10
I5
sg11
VTTF-1
p11310
sg13
I1
sa(dp11311
g7
I131
sg8
VP12830
p11312
sg10
I10
sg11
VE-cadherin
p11313
sg13
I1
sa(dp11314
g7
I239
sg8
g107
sg10
I7
sg11
Vpendrin
p11315
sg13
I1
sasg23
(lp11316
(dp11317
g7
I298
sg26
VC0007115
p11318
sg10
I14
sg11
Vthyroid cancer
p11319
sg13
I2
sa(dp11320
g7
I46
sg26
VC0334094
p11321
sg10
I13
sg11
Vproliferation
p11322
sg13
I1
sa(dp11323
g7
I64
sg26
VC2699153
p11324
sg10
I8
sg11
Vinvasion
p11325
sg13
I1
sasa(dp11326
g2
S'Immunohistochemistry was performed using primary antibodies to cytokeratin 19, HBME1, and CITED1 that have been found to be useful in the diagnosis of thyroid carcinoma.\n'
p11327
sg4
(lp11328
(dp11329
g7
I90
sg8
g107
sg10
I6
sg11
VCITED1
p11330
sg13
I1
sa(dp11331
g7
I63
sg8
g107
sg10
I14
sg11
Vcytokeratin 19
p11332
sg13
I2
sasg23
(lp11333
(dp11334
g7
I151
sg26
VC0549473
p11335
sg10
I17
sg11
Vthyroid carcinoma
p11336
sg13
I2
sasa(dp11337
g2
S'Markers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary thyroid carcinomas from follicular adenomas.\n'
p11338
sg4
(lp11339
(dp11340
g7
I27
sg8
g107
sg10
I6
sg11
VCITED1
p11341
sg13
I1
sasg23
(lp11342
(dp11343
g7
I124
sg26
VC0007097
p11344
sg10
I10
sg11
Vcarcinomas
p11345
sg13
I1
sa(dp11346
g7
I140
sg26
VC0205647
p11347
sg10
I19
sg11
Vfollicular adenomas
p11348
sg13
I2
sasa(dp11349
g2
S'These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p &lt; 0.0001).\n'
p11350
sg4
(lp11351
(dp11352
g7
I178
sg8
VP17931
p11353
sg10
I26
sg11
Vgalectin-3, cytokeratin 19
p11354
sg13
I3
sa(dp11355
g7
I210
sg8
VP26447
p11356
sg10
I6
sg11
VS100A4
p11357
sg13
I1
sa(dp11358
g7
I170
sg8
g107
sg10
I6
sg11
VCITED1
p11359
sg13
I1
sasg23
(lp11360
(dp11361
g7
I76
sg26
VC0205647
p11362
sg10
I19
sg11
Vfollicular adenomas
p11363
sg13
I2
sa(dp11364
g7
I141
sg26
VC0007097
p11365
sg10
I10
sg11
Vcarcinomas
p11366
sg13
I1
sasa(dp11367
g2
S'A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.\n'
p11368
sg4
(lp11369
(dp11370
g7
I58
sg8
VP17931
p11371
sg10
I10
sg11
Vgalectin-3
p11372
sg13
I1
sa(dp11373
g7
I101
sg8
g107
sg10
I6
sg11
VCITED1
p11374
sg13
I1
sa(dp11375
g7
I58
sg8
VP17931
p11376
sg10
I10
sg11
Vgalectin-3
p11377
sg13
I1
sasg23
(lp11378
(dp11379
g7
I215
sg26
VC0238463
p11380
sg10
I27
sg11
Vpapillary thyroid carcinoma
p11381
sg13
I3
sa(dp11382
g7
I169
sg26
VC0205647
p11383
sg10
I18
sg11
Vfollicular adenoma
p11384
sg13
I2
sasa(dp11385
g2
S'We examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism.\n'
p11386
sg4
(lp11387
(dp11388
g7
I101
sg8
g107
sg10
I3
sg11
VAPP
p11389
sg13
I1
sa(dp11390
g7
I12
sg8
VP12821
p11391
sg10
I20
sg11
Vacetylcholinesterase
p11392
sg13
I1
sa(dp11393
g7
I34
sg8
VP29475
p11394
sg10
I65
sg11
Vplasma neuronal proteins, secreted beta-amyloid precursor protein
p11395
sg13
I7
sa(dp11396
g7
I111
sg8
g107
sg10
I44
sg11
Vamyloid-beta 40 and amyloid-beta 42 peptides
p11397
sg13
I6
sasg23
(lp11398
(dp11399
g7
I185
sg26
VC0004352
p11400
sg10
I6
sg11
Vautism
p11401
sg13
I1
sa(dp11402
g7
I74
sg26
VC0011560
p11403
sg10
I7
sg11
Vamyloid
p11404
sg13
I1
sa(dp11405
g7
I74
sg26
VC0011560
p11406
sg10
I7
sg11
Vamyloid
p11407
sg13
I1
sa(dp11408
g7
I74
sg26
VC0011560
p11409
sg10
I7
sg11
Vamyloid
p11410
sg13
I1
sasa(dp11411
g2
S'The growth associated protein 43-positive fibres also seemed to be less in six samples of club foot.\n'
p11412
sg4
(lp11413
sg23
(lp11414
(dp11415
g7
I90
sg26
VC0009081
p11416
sg10
I9
sg11
Vclub foot
p11417
sg13
I2
sasa(dp11418
g2
S'Here we showed that miR-342-5p and miR-608 suppressed the tumorigenesis of colon cancer cells in vitro and in vivo by targeting NAA10 mRNA for degradation.\n'
p11419
sg4
(lp11420
(dp11421
g7
I20
sg8
g107
sg10
I10
sg11
VmiR-342-5p
p11422
sg13
I1
sa(dp11423
g7
I128
sg8
VP41227
p11424
sg10
I10
sg11
VNAA10 mRNA
p11425
sg13
I2
sasg23
(lp11426
(dp11427
g7
I75
sg26
VC0699790
p11428
sg10
I12
sg11
Vcolon cancer
p11429
sg13
I2
sa(dp11430
g7
I58
sg26
VC0007621
p11431
sg10
I13
sg11
Vtumorigenesis
p11432
sg13
I1
sasa(dp11433
g2
S'Our results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10.\n'
p11434
sg4
(lp11435
(dp11436
g7
I22
sg8
g107
sg10
I10
sg11
VmiR-342-5p
p11437
sg13
I1
sa(dp11438
g7
I144
sg8
VP41227
p11439
sg10
I5
sg11
VNAA10
p11440
sg13
I1
sa(dp11441
g7
I37
sg8
g107
sg10
I7
sg11
VmiR-608
p11442
sg13
I1
sasg23
(lp11443
(dp11444
g7
I48
sg26
VC0699790
p11445
sg10
I12
sg11
Vcolon cancer
p11446
sg13
I2
sasa(dp11447
g2
S'We demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases).\n'
p11448
sg4
(lp11449
(dp11450
g7
I127
sg8
VP04626
p11451
sg10
I4
sg11
VHER2
p11452
sg13
I1
sa(dp11453
g7
I83
sg8
g107
sg10
I8
sg11
VmiR-744*
p11454
sg13
I1
sa(dp11455
g7
I127
sg8
VP04626
p11456
sg10
I4
sg11
VHER2
p11457
sg13
I1
sa(dp11458
g7
I68
sg8
g107
sg10
I10
sg11
VmiR-342-5p
p11459
sg13
I1
sasg23
(lp11460
(dp11461
g7
I211
sg26
VC0678222
p11462
sg10
I13
sg11
Vbreast cancer
p11463
sg13
I2
sa(dp11464
g7
I141
sg26
VC1458155
p11465
sg10
I13
sg11
Vbreast tumors
p11466
sg13
I2
sa(dp11467
g7
I148
sg26
VC0027651
p11468
sg10
I6
sg11
Vtumors
p11469
sg13
I1
sasa(dp11470
g2
S'Furthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts.\n'
p11471
sg4
(lp11472
(dp11473
g7
I34
sg8
g107
sg10
I10
sg11
VmiR-342-5p
p11474
sg13
I1
sasg23
(lp11475
(dp11476
g7
I89
sg26
VC0678222
p11477
sg10
I13
sg11
Vbreast cancer
p11478
sg13
I2
sasa(dp11479
g2
S'Compromised CN function is a significant cause of erectile dysfunction development following prostatectomy and serves as the primary target for potential neuroprotective or regenerative strategies utilizing NGFs such as BDNF, GDF-5, and NTN, and/or targeted novel therapeutics modulating signaling pathways.\n'
p11480
sg4
(lp11481
(dp11482
g7
I226
sg8
VP43026
p11483
sg10
I5
sg11
VGDF-5
p11484
sg13
I1
sasg23
(lp11485
(dp11486
g7
I50
sg26
VC0242350
p11487
sg10
I20
sg11
Verectile dysfunction
p11488
sg13
I2
sasa(dp11489
g2
S'The manifestation of LHON was associated with increased mortality and increased incidence of several disorders including stroke, demyelinating disorder, dementia, and epilepsy.\n'
p11490
sg4
(lp11491
sg23
(lp11492
(dp11493
g7
I121
sg26
VC0038454
p11494
sg10
I6
sg11
Vstroke
p11495
sg13
I1
sa(dp11496
g7
I153
sg26
VC0497327
p11497
sg10
I8
sg11
Vdementia
p11498
sg13
I1
sa(dp11499
g7
I21
sg26
VC0917796
p11500
sg10
I4
sg11
VLHON
p11501
sg13
I1
sa(dp11502
g7
I129
sg26
VC0011303
p11503
sg10
I22
sg11
Vdemyelinating disorder
p11504
sg13
I2
sa(dp11505
g7
I167
sg26
VC0014544
p11506
sg10
I8
sg11
Vepilepsy
p11507
sg13
I1
sasa(dp11508
g2
S"Leber's Hereditary Optic Neuropathy (LHON) shares features with Multiple Sclerosis (MS).\n"
p11509
sg4
(lp11510
sg23
(lp11511
(dp11512
g7
I0
sg26
VC0917796
p11513
sg10
I35
sg11
VLeber's Hereditary Optic Neuropathy
p11514
sg13
I4
sa(dp11515
g7
I37
sg26
VC0917796
p11516
sg10
I4
sg11
VLHON
p11517
sg13
I1
sa(dp11518
g7
I64
sg26
VC0026769
p11519
sg10
I18
sg11
VMultiple Sclerosis
p11520
sg13
I2
sa(dp11521
g7
I84
sg26
VC0026769
p11522
sg10
I2
sg11
VMS
p11523
sg13
I1
sasa(dp11524
g2
S"Leber's hereditary optic neuropathy (LHON) is a mitochondrial DNA (mtDNA) associated neurodegenerative disorder of retinal ganglion cells.\n"
p11525
sg4
(lp11526
sg23
(lp11527
(dp11528
g7
I0
sg26
VC0917796
p11529
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p11530
sg13
I4
sa(dp11531
g7
I37
sg26
VC0917796
p11532
sg10
I4
sg11
VLHON
p11533
sg13
I1
sa(dp11534
g7
I85
sg26
VC0524851
p11535
sg10
I26
sg11
Vneurodegenerative disorder
p11536
sg13
I2
sa(dp11537
g7
I123
sg26
VC1258666
p11538
sg10
I8
sg11
Vganglion
p11539
sg13
I1
sasa(dp11540
g2
S"MT-ND4: mitochondrially encoded NADH dehydrogenase 4; MT-TL1: mitochondrially encoded tRNA leucine 1 (UUA/G); PCR: polymerase chain reaction; OXPHOS: mitochondrial oxidative phosphorylation; ATP: adenosine triphosphate; mtDNA: mitochondrial DNA; SNPs: single nucleotide substitutions; AD: alzheimer's disease; PD: parkinson's disease; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; ROS: reactive oxygen species.\n"
p11541
sg4
(lp11542
(dp11543
g7
I54
sg8
g107
sg10
I6
sg11
VMT-TL1
p11544
sg13
I1
sa(dp11545
g7
I62
sg8
VP30740
p11546
sg10
I38
sg11
Vmitochondrially encoded tRNA leucine 1
p11547
sg13
I5
sa(dp11548
g7
I8
sg8
VP49366
p11549
sg10
I44
sg11
Vmitochondrially encoded NADH dehydrogenase 4
p11550
sg13
I5
sa(dp11551
g7
I0
sg8
VP03905
p11552
sg10
I6
sg11
VMT-ND4
p11553
sg13
I1
sasg23
(lp11554
(dp11555
g7
I314
sg26
VC0030567
p11556
sg10
I19
sg11
Vparkinson's disease
p11557
sg13
I2
sa(dp11558
g7
I342
sg26
VC1964017
p11559
sg10
I77
sg11
Vmitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
p11560
sg13
I8
sa(dp11561
g7
I335
sg26
VC0162671
p11562
sg10
I5
sg11
VMELAS
p11563
sg13
I1
sa(dp11564
g7
I289
sg26
VC1521724
p11565
sg10
I19
sg11
Valzheimer's disease
p11566
sg13
I2
sasa(dp11567
g2
S"Leber's hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding's disease.\n"
p11568
sg4
(lp11569
sg23
(lp11570
(dp11571
g7
I0
sg26
VC0917796
p11572
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p11573
sg13
I4
sa(dp11574
g7
I37
sg26
VC0917796
p11575
sg10
I4
sg11
VLHON
p11576
sg13
I1
sa(dp11577
g7
I37
sg26
VC0917796
p11578
sg10
I4
sg11
VLHON
p11579
sg13
I1
sa(dp11580
g7
I60
sg26
VC0026769
p11581
sg10
I18
sg11
Vmultiple sclerosis
p11582
sg13
I2
sasa(dp11583
g2
S'The role of oxidative stress in the five most common inherited mitochondrial diseases, Friedreich ataxia, LHON, MELAS, MERRF, and Leigh syndrome (LS), is discussed.\n'
p11584
sg4
(lp11585
(dp11586
g7
I112
sg8
VP03886
p11587
sg10
I5
sg11
VMELAS
p11588
sg13
I1
sa(dp11589
g7
I119
sg8
VP03915
p11590
sg10
I5
sg11
VMERRF
p11591
sg13
I1
sasg23
(lp11592
(dp11593
g7
I63
sg26
VC0751651
p11594
sg10
I22
sg11
Vmitochondrial diseases
p11595
sg13
I2
sa(dp11596
g7
I112
sg26
VC0162671
p11597
sg10
I5
sg11
VMELAS
p11598
sg13
I1
sa(dp11599
g7
I130
sg26
VC0023264
p11600
sg10
I14
sg11
VLeigh syndrome
p11601
sg13
I2
sa(dp11602
g7
I12
sg26
VC0242606
p11603
sg10
I16
sg11
Voxidative stress
p11604
sg13
I2
sa(dp11605
g7
I146
sg26
VC0023264
p11606
sg10
I2
sg11
VLS
p11607
sg13
I1
sa(dp11608
g7
I87
sg26
VC0016719
p11609
sg10
I17
sg11
VFriedreich ataxia
p11610
sg13
I2
sa(dp11611
g7
I106
sg26
VC0917796
p11612
sg10
I4
sg11
VLHON
p11613
sg13
I1
sa(dp11614
g7
I119
sg26
VC0162672
p11615
sg10
I5
sg11
VMERRF
p11616
sg13
I1
sasa(dp11617
g2
S'Of the five most common mitochondrial diseases, the strongest support for oxidative stress is for Friedreich ataxia (6.42%), followed by LHON (2.45%), MELAS (2.18%), MERRF (1.71%), and LS (1.03%).\n'
p11618
sg4
(lp11619
sg23
(lp11620
(dp11621
g7
I137
sg26
VC0917796
p11622
sg10
I4
sg11
VLHON
p11623
sg13
I1
sa(dp11624
g7
I166
sg26
VC0162672
p11625
sg10
I5
sg11
VMERRF
p11626
sg13
I1
sa(dp11627
g7
I24
sg26
VC0751651
p11628
sg10
I22
sg11
Vmitochondrial diseases
p11629
sg13
I2
sa(dp11630
g7
I151
sg26
VC0162671
p11631
sg10
I5
sg11
VMELAS
p11632
sg13
I1
sa(dp11633
g7
I98
sg26
VC0016719
p11634
sg10
I17
sg11
VFriedreich ataxia
p11635
sg13
I2
sa(dp11636
g7
I74
sg26
VC0242606
p11637
sg10
I16
sg11
Voxidative stress
p11638
sg13
I2
sasa(dp11639
g2
S"Leber's hereditary optic neuropathy (LHON) and a multiple sclerosis (MS)-like illness appear to coexist 50 times more frequently than would be expected by chance.\n"
p11640
sg4
(lp11641
sg23
(lp11642
(dp11643
g7
I0
sg26
VC0917796
p11644
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p11645
sg13
I4
sa(dp11646
g7
I37
sg26
VC0917796
p11647
sg10
I4
sg11
VLHON
p11648
sg13
I1
sa(dp11649
g7
I69
sg26
VC0026769
p11650
sg10
I2
sg11
VMS
p11651
sg13
I1
sa(dp11652
g7
I49
sg26
VC0026769
p11653
sg10
I18
sg11
Vmultiple sclerosis
p11654
sg13
I2
sasa(dp11655
g2
S'Mutations in the retinitis pigmentosa 1 (RP1) gene are a common cause of retinitis pigmentosa (RP).\n'
p11656
sg4
(lp11657
(dp11658
g7
I17
sg8
VP56715
p11659
sg10
I22
sg11
Vretinitis pigmentosa 1
p11660
sg13
I3
sa(dp11661
g7
I41
sg8
VP56715
p11662
sg10
I3
sg11
VRP1
p11663
sg13
I1
sasg23
(lp11664
(dp11665
g7
I17
sg26
VC0220701
p11666
sg10
I22
sg11
Vretinitis pigmentosa 1
p11667
sg13
I3
sa(dp11668
g7
I41
sg26
VC0035334
p11669
sg10
I2
sg11
VRP
p11670
sg13
I1
sa(dp11671
g7
I17
sg26
VC0035334
p11672
sg10
I20
sg11
Vretinitis pigmentosa
p11673
sg13
I2
sa(dp11674
g7
I41
sg26
VC0220701
p11675
sg10
I3
sg11
VRP1
p11676
sg13
I1
sasa(dp11677
g2
S'Furthermore, these findings indicate that the RP1 form of inherited retinal degeneration is part of the larger class of neurodegenerative diseases caused by MAP dysfunction.\n'
p11678
sg4
(lp11679
(dp11680
g7
I46
sg8
VP56715
p11681
sg10
I3
sg11
VRP1
p11682
sg13
I1
sasg23
(lp11683
(dp11684
g7
I46
sg26
VC0220701
p11685
sg10
I3
sg11
VRP1
p11686
sg13
I1
sa(dp11687
g7
I120
sg26
VC0524851
p11688
sg10
I26
sg11
Vneurodegenerative diseases
p11689
sg13
I2
sa(dp11690
g7
I68
sg26
VC0035304
p11691
sg10
I20
sg11
Vretinal degeneration
p11692
sg13
I2
sasa(dp11693
g2
S'Our objective was to determine the ethical options of Paediatric Intensive Care Unit (PICU) paediatricians as regards a child with SMA-1 and respiratory failure.\n'
p11694
sg4
(lp11695
(dp11696
g7
I131
sg8
g107
sg10
I5
sg11
VSMA-1
p11697
sg13
I1
sasg23
(lp11698
(dp11699
g7
I141
sg26
VC1145670
p11700
sg10
I19
sg11
Vrespiratory failure
p11701
sg13
I2
sa(dp11702
g7
I131
sg26
VC0026847
p11703
sg10
I3
sg11
VSMA
p11704
sg13
I1
sasa(dp11705
g2
S"Faced with child with SMA-1 and respiratory failure, most paediatricians are in favour of initiating NIV and LET when such support is insufficient, but they would accept the family's decision, even in case of disagreement.\n"
p11706
sg4
(lp11707
(dp11708
g7
I22
sg8
g107
sg10
I5
sg11
VSMA-1
p11709
sg13
I1
sasg23
(lp11710
(dp11711
g7
I22
sg26
VC0026847
p11712
sg10
I3
sg11
VSMA
p11713
sg13
I1
sa(dp11714
g7
I32
sg26
VC1145670
p11715
sg10
I19
sg11
Vrespiratory failure
p11716
sg13
I2
sasa(dp11717
g2
S'A scenario of acute respiratory failure in an infant with SMA-1 has been included in a training program using advanced simulation for Primary Care pediatricians (PCP).\n'
p11718
sg4
(lp11719
(dp11720
g7
I58
sg8
g107
sg10
I5
sg11
VSMA-1
p11721
sg13
I1
sasg23
(lp11722
(dp11723
g7
I58
sg26
VC0026847
p11724
sg10
I3
sg11
VSMA
p11725
sg13
I1
sa(dp11726
g7
I134
sg26
VC2919094
p11727
sg10
I26
sg11
VPrimary Care pediatricians
p11728
sg13
I3
sa(dp11729
g7
I162
sg26
VC2919094
p11730
sg10
I3
sg11
VPCP
p11731
sg13
I1
sa(dp11732
g7
I14
sg26
VC0264490
p11733
sg10
I25
sg11
Vacute respiratory failure
p11734
sg13
I3
sasa(dp11735
g2
S'When faced with a simulated SMA-1 infant with respiratory failure, PCP have difficulties in interacting with the family, and to involve it in the decision making process.\n'
p11736
sg4
(lp11737
sg23
(lp11738
(dp11739
g7
I67
sg26
VC2919094
p11740
sg10
I3
sg11
VPCP
p11741
sg13
I1
sa(dp11742
g7
I46
sg26
VC1145670
p11743
sg10
I19
sg11
Vrespiratory failure
p11744
sg13
I2
sa(dp11745
g7
I28
sg26
VC0026847
p11746
sg10
I3
sg11
VSMA
p11747
sg13
I1
sasa(dp11748
g2
S'TREX1 acts in concert with the SET complex in granzyme A-mediated apoptosis, and mutations in TREX1 cause Aicardi-Goutieres syndrome and familial chilblain lupus.\n'
p11749
sg4
(lp11750
(dp11751
g7
I0
sg8
g107
sg10
I5
sg11
VTREX1
p11752
sg13
I1
sa(dp11753
g7
I0
sg8
g107
sg10
I5
sg11
VTREX1
p11754
sg13
I1
sasg23
(lp11755
(dp11756
g7
I146
sg26
VC0024145
p11757
sg10
I15
sg11
Vchilblain lupus
p11758
sg13
I2
sa(dp11759
g7
I106
sg26
VC0796126
p11760
sg10
I26
sg11
VAicardi-Goutieres syndrome
p11761
sg13
I2
sasa(dp11762
g2
S'Lymphoblastoid cells carrying the D18N mutation are significantly less sensitive to granzyme A-mediated cell death, suggesting a novel role for this caspase-independent form of apoptosis in the pathogenesis of familial chilblain lupus.\n'
p11763
sg4
(lp11764
(dp11765
g7
I149
sg8
VP39880
p11766
sg10
I7
sg11
Vcaspase
p11767
sg13
I1
sasg23
(lp11768
(dp11769
g7
I194
sg26
VC0699748
p11770
sg10
I12
sg11
Vpathogenesis
p11771
sg13
I1
sa(dp11772
g7
I219
sg26
VC0024145
p11773
sg10
I15
sg11
Vchilblain lupus
p11774
sg13
I2
sasa(dp11775
g2
S'A recent article explored protective modifiers, including plastin 3 (PLS3) and coronin 1C (CORO1C), in spinal muscular atrophy (SMA).\n'
p11776
sg4
(lp11777
(dp11778
g7
I58
sg8
VP13797
p11779
sg10
I9
sg11
Vplastin 3
p11780
sg13
I2
sa(dp11781
g7
I69
sg8
VP13797
p11782
sg10
I4
sg11
VPLS3
p11783
sg13
I1
sa(dp11784
g7
I79
sg8
g107
sg10
I10
sg11
Vcoronin 1C
p11785
sg13
I2
sa(dp11786
g7
I91
sg8
g107
sg10
I6
sg11
VCORO1C
p11787
sg13
I1
sasg23
(lp11788
(dp11789
g7
I103
sg26
VC0026847
p11790
sg10
I23
sg11
Vspinal muscular atrophy
p11791
sg13
I3
sa(dp11792
g7
I128
sg26
VC0026847
p11793
sg10
I3
sg11
VSMA
p11794
sg13
I1
sasa(dp11795
g2
S'However, the expression of CYP26C1, another CYP26 family member, in primary breast carcinoma remains to be clarified.\n'
p11796
sg4
(lp11797
(dp11798
g7
I44
sg8
g107
sg10
I19
sg11
VCYP26 family member
p11799
sg13
I3
sa(dp11800
g7
I27
sg8
g107
sg10
I7
sg11
VCYP26C1
p11801
sg13
I1
sasg23
(lp11802
(dp11803
g7
I76
sg26
VC0678222
p11804
sg10
I16
sg11
Vbreast carcinoma
p11805
sg13
I2
sasa(dp11806
g2
S'In the present study, we examined the expression of CYP26C1 by immunohistochemistry, using three different types of microarray, and observed strong cytoplasmic staining of CYP26C1 in 73 of the 219 (33.3 %) breast carcinomas.\n'
p11807
sg4
(lp11808
(dp11809
g7
I52
sg8
g107
sg10
I7
sg11
VCYP26C1
p11810
sg13
I1
sa(dp11811
g7
I52
sg8
g107
sg10
I7
sg11
VCYP26C1
p11812
sg13
I1
sasg23
(lp11813
(dp11814
g7
I206
sg26
VC0678222
p11815
sg10
I17
sg11
Vbreast carcinomas
p11816
sg13
I2
sasa(dp11817
g2
S'In addition, CYP26C1 positivity was independent of the expression status of the hormone receptors and immunohistochemical surrogates for the intrinsic subtypes of breast cancer.\n'
p11818
sg4
(lp11819
(dp11820
g7
I13
sg8
g107
sg10
I7
sg11
VCYP26C1
p11821
sg13
I1
sasg23
(lp11822
(dp11823
g7
I163
sg26
VC0678222
p11824
sg10
I13
sg11
Vbreast cancer
p11825
sg13
I2
sasa(dp11826
g2
S'This report is the first to demonstrate elevated expression of CYP26C1 in primary breast carcinomas.\n'
p11827
sg4
(lp11828
(dp11829
g7
I63
sg8
g107
sg10
I7
sg11
VCYP26C1
p11830
sg13
I1
sasg23
(lp11831
(dp11832
g7
I82
sg26
VC0678222
p11833
sg10
I17
sg11
Vbreast carcinomas
p11834
sg13
I2
sasa(dp11835
g2
S'In the present study we chose to investigate 7 genes involved in the synthesis, degradation and transportation of RA, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1, CYP26C1 and Transthyretin (TTR), for their roles in the development of schizophrenia.\n'
p11836
sg4
(lp11837
(dp11838
g7
I136
sg8
VP47895
p11839
sg10
I7
sg11
VALDH1A3
p11840
sg13
I1
sa(dp11841
g7
I190
sg8
VP02766
p11842
sg10
I3
sg11
VTTR
p11843
sg13
I1
sa(dp11844
g7
I175
sg8
VP02766
p11845
sg10
I13
sg11
VTransthyretin
p11846
sg13
I1
sa(dp11847
g7
I163
sg8
g107
sg10
I7
sg11
VCYP26C1
p11848
sg13
I1
sa(dp11849
g7
I154
sg8
g107
sg10
I7
sg11
VCYP26B1
p11850
sg13
I1
sa(dp11851
g7
I145
sg8
g107
sg10
I7
sg11
VCYP26A1
p11852
sg13
I1
sa(dp11853
g7
I127
sg8
g107
sg10
I7
sg11
VALDH1A2
p11854
sg13
I1
sa(dp11855
g7
I118
sg8
VP00352
p11856
sg10
I7
sg11
VALDH1A1
p11857
sg13
I1
sasg23
(lp11858
(dp11859
g7
I234
sg26
VC0036341
p11860
sg10
I13
sg11
Vschizophrenia
p11861
sg13
I1
sasa(dp11862
g2
S'The index of low SIRT1 and high MMP2 respectively correlated with patients history of MI (p=0.3, p=0.01) and marginally with presence or history of atrial fibrillation (AF) (p=0.213, p=0.076).\n'
p11863
sg4
(lp11864
(dp11865
g7
I17
sg8
g107
sg10
I5
sg11
VSIRT1
p11866
sg13
I1
sasg23
(lp11867
(dp11868
g7
I148
sg26
VC0004238
p11869
sg10
I19
sg11
Vatrial fibrillation
p11870
sg13
I2
sa(dp11871
g7
I169
sg26
VC0004238
p11872
sg10
I2
sg11
VAF
p11873
sg13
I1
sasa(dp11874
g2
S'BACKGROUND To examine changes of mRNA and protein expressions of MMP-2, Bcl-2, and BAX in atrial fibrillation (AF) patients, and investigate the correlations among these 3 biomarkers.\n'
p11875
sg4
(lp11876
(dp11877
g7
I65
sg8
VP08253
p11878
sg10
I5
sg11
VMMP-2
p11879
sg13
I1
sa(dp11880
g7
I72
sg8
VP10415
p11881
sg10
I5
sg11
VBcl-2
p11882
sg13
I1
sasg23
(lp11883
(dp11884
g7
I90
sg26
VC0004238
p11885
sg10
I19
sg11
Vatrial fibrillation
p11886
sg13
I2
sa(dp11887
g7
I111
sg26
VC0004238
p11888
sg10
I2
sg11
VAF
p11889
sg13
I1
sasa(dp11890
g2
S'In conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.\n'
p11891
sg4
(lp11892
(dp11893
g7
I29
sg8
g107
sg10
I6
sg11
VKcnj16
p11894
sg13
I1
sasg23
(lp11895
(dp11896
g7
I147
sg26
VC2748572
p11897
sg10
I13
sg11
VEAST syndrome
p11898
sg13
I2
sasa(dp11899
g2
S'We investigated the localization of KCNJ10 and the homologous KCNJ16 in kidney and the functional consequences of KCNJ10 mutations found in our patients with EAST syndrome.\n'
p11900
sg4
(lp11901
(dp11902
g7
I62
sg8
g107
sg10
I6
sg11
VKCNJ16
p11903
sg13
I1
sa(dp11904
g7
I36
sg8
VP78508
p11905
sg10
I6
sg11
VKCNJ10
p11906
sg13
I1
sa(dp11907
g7
I114
sg8
VP78508
p11908
sg10
I16
sg11
VKCNJ10 mutations
p11909
sg13
I2
sasg23
(lp11910
(dp11911
g7
I158
sg26
VC2748572
p11912
sg10
I13
sg11
VEAST syndrome
p11913
sg13
I2
sasa(dp11914
g2
S'Toxin C13S1C1 was also cytotoxic against breast adenocarcinoma MDA-MB-231 cells (LC50 = 62+/-2myg/ml) and colorectal adenocarcinoma HT-29 cells (LC50 = 110+/-4myg/ml).\n'
p11915
sg4
(lp11916
(dp11917
g7
I0
sg8
g107
sg10
I5
sg11
VToxin
p11918
sg13
I1
sasg23
(lp11919
(dp11920
g7
I106
sg26
VC1319315
p11921
sg10
I25
sg11
Vcolorectal adenocarcinoma
p11922
sg13
I2
sa(dp11923
g7
I41
sg26
VC0858252
p11924
sg10
I21
sg11
Vbreast adenocarcinoma
p11925
sg13
I2
sasa(dp11926
g2
S'We report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.\n'
p11927
sg4
(lp11928
(dp11929
g7
I248
sg8
VP06401
p11930
sg10
I22
sg11
Vprogesterone receptors
p11931
sg13
I2
sa(dp11932
g7
I280
sg8
VP04626
p11933
sg10
I3
sg11
Vneu
p11934
sg13
I1
sa(dp11935
g7
I275
sg8
VP04626
p11936
sg10
I4
sg11
VHer2
p11937
sg13
I1
sasg23
(lp11938
(dp11939
g7
I38
sg26
VC1335320
p11940
sg10
I33
sg11
Vpapillary carcinoma of the breast
p11941
sg13
I5
sa(dp11942
g7
I188
sg26
VC0332448
p11943
sg10
I10
sg11
Vinfiltrate
p11944
sg13
I1
sasa(dp11945
g2
S'Moreover, Sec24bY613 genetically interacts with a loss-of-function Vangl2 allele (Vangl2LP), causing a marked increase in the prevalence of spina bifida.\n'
p11946
sg4
(lp11947
(dp11948
g7
I67
sg8
g107
sg10
I13
sg11
VVangl2 allele
p11949
sg13
I2
sasg23
(lp11950
(dp11951
g7
I140
sg26
VC0080178
p11952
sg10
I12
sg11
Vspina bifida
p11953
sg13
I2
sasa(dp11954
g2
S'The overall goal of TASK2 of the AES/ILAE Translational Task Force is to organize and coordinate systematic reviews on selected topics regarding animal research in epilepsy.\n'
p11955
sg4
(lp11956
(dp11957
g7
I20
sg8
g107
sg10
I5
sg11
VTASK2
p11958
sg13
I1
sasg23
(lp11959
(dp11960
g7
I164
sg26
VC0014544
p11961
sg10
I8
sg11
Vepilepsy
p11962
sg13
I1
sasa(dp11963
g2
S'K2P 5.1 channels (also called TASK-2 or Kcnk5) have already been shown to be relevant in the pathophysiology of autoimmune disease because they are known to be upregulated on peripheral and central T lymphocytes of multiple sclerosis (MS) patients.\n'
p11964
sg4
(lp11965
(dp11966
g7
I0
sg8
g107
sg10
I16
sg11
VK2P 5.1 channels
p11967
sg13
I3
sa(dp11968
g7
I40
sg8
g107
sg10
I5
sg11
VKcnk5
p11969
sg13
I1
sa(dp11970
g7
I30
sg8
g107
sg10
I6
sg11
VTASK-2
p11971
sg13
I1
sasg23
(lp11972
(dp11973
g7
I235
sg26
VC0026769
p11974
sg10
I2
sg11
VMS
p11975
sg13
I1
sa(dp11976
g7
I112
sg26
VC0004364
p11977
sg10
I18
sg11
Vautoimmune disease
p11978
sg13
I2
sa(dp11979
g7
I215
sg26
VC0026769
p11980
sg10
I18
sg11
Vmultiple sclerosis
p11981
sg13
I2
sasa(dp11982
g2
S'Recent studies have indicated the impact of K2P5.1 upregulation in T lymphocytes on the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.\n'
p11983
sg4
(lp11984
(dp11985
g7
I44
sg8
g107
sg10
I6
sg11
VK2P5.1
p11986
sg13
I1
sasg23
(lp11987
(dp11988
g7
I157
sg26
VC0026769
p11989
sg10
I18
sg11
Vmultiple sclerosis
p11990
sg13
I2
sa(dp11991
g7
I132
sg26
VC0003873
p11992
sg10
I20
sg11
Vrheumatoid arthritis
p11993
sg13
I2
sa(dp11994
g7
I88
sg26
VC0699748
p11995
sg10
I12
sg11
Vpathogenesis
p11996
sg13
I1
sa(dp11997
g7
I104
sg26
VC0004364
p11998
sg10
I19
sg11
Vautoimmune diseases
p11999
sg13
I2
sasa(dp12000
g2
S'So far KCNK5 has been described to be up-regulated in T cells in multiple sclerosis patients and to be implicated in the volume regulatory mechanism regulatory volume decrease (RVD) in T cells.\n'
p12001
sg4
(lp12002
(dp12003
g7
I7
sg8
g107
sg10
I5
sg11
VKCNK5
p12004
sg13
I1
sasg23
(lp12005
(dp12006
g7
I65
sg26
VC0026769
p12007
sg10
I18
sg11
Vmultiple sclerosis
p12008
sg13
I2
sasa(dp12009
g2
S'Recent studies highlighted the potential role of the K2P5.1 K(+) channel in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.\n'
p12010
sg4
(lp12011
(dp12012
g7
I53
sg8
g107
sg10
I8
sg11
VK2P5.1 K
p12013
sg13
I2
sasg23
(lp12014
(dp12015
g7
I96
sg26
VC0004364
p12016
sg10
I19
sg11
Vautoimmune diseases
p12017
sg13
I2
sa(dp12018
g7
I149
sg26
VC0026769
p12019
sg10
I18
sg11
Vmultiple sclerosis
p12020
sg13
I2
sa(dp12021
g7
I80
sg26
VC0699748
p12022
sg10
I12
sg11
Vpathogenesis
p12023
sg13
I1
sa(dp12024
g7
I124
sg26
VC0003873
p12025
sg10
I20
sg11
Vrheumatoid arthritis
p12026
sg13
I2
sasa(dp12027
g2
S'Expression levels of K2P5.1 (TASK2; KCNK5) channels belonging to the family of two-pore domain potassium channels have previously been correlated to the activity of autoreactive T lymphocytes in patients with multiple sclerosis and rheumatoid arthritis.\n'
p12028
sg4
(lp12029
(dp12030
g7
I21
sg8
g107
sg10
I6
sg11
VK2P5.1
p12031
sg13
I1
sa(dp12032
g7
I29
sg8
g107
sg10
I5
sg11
VTASK2
p12033
sg13
I1
sa(dp12034
g7
I36
sg8
g107
sg10
I5
sg11
VKCNK5
p12035
sg13
I1
sasg23
(lp12036
(dp12037
g7
I209
sg26
VC0026769
p12038
sg10
I18
sg11
Vmultiple sclerosis
p12039
sg13
I2
sa(dp12040
g7
I232
sg26
VC0003873
p12041
sg10
I20
sg11
Vrheumatoid arthritis
p12042
sg13
I2
sasa(dp12043
g2
S'Thus, we evaluated the effect of serum availability on the expression of commonly used HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in seven colon adenocarcinoma cell lines (Caco-2, DLD-1, HCT116, HT29, Lovo, SW480, and SW620).\n'
p12044
sg4
(lp12045
(dp12046
g7
I110
sg8
VP08236
p12047
sg10
I4
sg11
VGUSB
p12048
sg13
I1
sa(dp12049
g7
I98
sg8
VP61769
p12050
sg10
I3
sg11
VB2M
p12051
sg13
I1
sa(dp12052
g7
I123
sg8
g107
sg10
I4
sg11
VIPO8
p12053
sg13
I1
sa(dp12054
g7
I169
sg8
VP20226
p12055
sg10
I3
sg11
VTBP
p12056
sg13
I1
sa(dp12057
g7
I240
sg8
VP98173
p12058
sg10
I5
sg11
VDLD-1
p12059
sg13
I1
sa(dp12060
g7
I137
sg8
VP00558
p12061
sg10
I4
sg11
VPGK1
p12062
sg13
I1
sa(dp12063
g7
I103
sg8
VP04406
p12064
sg10
I5
sg11
VGAPDH
p12065
sg13
I1
sa(dp12066
g7
I156
sg8
VP62266
p12067
sg10
I5
sg11
VRPS23
p12068
sg13
I1
sa(dp12069
g7
I92
sg8
VP63261
p12070
sg10
I4
sg11
VACTB
p12071
sg13
I1
sa(dp12072
g7
I149
sg8
VP05388
p12073
sg10
I5
sg11
VRPLP0
p12074
sg13
I1
sa(dp12075
g7
I143
sg8
VP62937
p12076
sg10
I4
sg11
VPPIA
p12077
sg13
I1
sa(dp12078
g7
I116
sg8
VP55884
p12079
sg10
I5
sg11
VHPRT1
p12080
sg13
I1
sa(dp12081
g7
I129
sg8
VP49406
p12082
sg10
I6
sg11
VMRPL19
p12083
sg13
I1
sa(dp12084
g7
I163
sg8
VP31040
p12085
sg10
I4
sg11
VSDHA
p12086
sg13
I1
sa(dp12087
g7
I174
sg8
g107
sg10
I3
sg11
VUBC
p12088
sg13
I1
sasg23
(lp12089
(dp12090
g7
I199
sg26
VC0338106
p12091
sg10
I20
sg11
Vcolon adenocarcinoma
p12092
sg13
I2
sasa(dp12093
g2
S'We investigated whether the expression of PGK1 varies between metastatic and non-metastatic colon cancer.\n'
p12094
sg4
(lp12095
(dp12096
g7
I42
sg8
VP00558
p12097
sg10
I4
sg11
VPGK1
p12098
sg13
I1
sasg23
(lp12099
(dp12100
g7
I81
sg26
VC0278484
p12101
sg10
I23
sg11
Vmetastatic colon cancer
p12102
sg13
I3
sasa(dp12103
g2
S'We compared PGK1 expression in colon cancer patients either with or without metastasis via polymerase chain reaction (PCR) and immunohistochemistry.\n'
p12104
sg4
(lp12105
(dp12106
g7
I12
sg8
VP00558
p12107
sg10
I4
sg11
VPGK1
p12108
sg13
I1
sasg23
(lp12109
(dp12110
g7
I31
sg26
VC0699790
p12111
sg10
I12
sg11
Vcolon cancer
p12112
sg13
I2
sa(dp12113
g7
I76
sg26
VC0027627
p12114
sg10
I10
sg11
Vmetastasis
p12115
sg13
I1
sasa(dp12116
g2
S'PCR results showed an increased expression of PGK1 in colon cancer tissue from metastatic patients in comparison to patients with no metastasis (fold change 2.6, p&lt;0.001).\n'
p12117
sg4
(lp12118
(dp12119
g7
I46
sg8
VP00558
p12120
sg10
I4
sg11
VPGK1
p12121
sg13
I1
sasg23
(lp12122
(dp12123
g7
I133
sg26
VC0027627
p12124
sg10
I10
sg11
Vmetastasis
p12125
sg13
I1
sa(dp12126
g7
I54
sg26
VC0699790
p12127
sg10
I12
sg11
Vcolon cancer
p12128
sg13
I2
sasa(dp12129
g2
S'The results indicate that increased expression of PGK1 in colon cancer tissue is associated with metastasis.\n'
p12130
sg4
(lp12131
(dp12132
g7
I50
sg8
VP00558
p12133
sg10
I4
sg11
VPGK1
p12134
sg13
I1
sasg23
(lp12135
(dp12136
g7
I58
sg26
VC0699790
p12137
sg10
I12
sg11
Vcolon cancer
p12138
sg13
I2
sa(dp12139
g7
I97
sg26
VC0027627
p12140
sg10
I10
sg11
Vmetastasis
p12141
sg13
I1
sasa(dp12142
g2
S'TYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.\n'
p12143
sg4
(lp12144
(dp12145
g7
I9
sg8
VP00558
p12146
sg10
I4
sg11
VPGK1
p12147
sg13
I1
sa(dp12148
g7
I9
sg8
VP00558
p12149
sg10
I4
sg11
VPGK1
p12150
sg13
I1
sa(dp12151
g7
I0
sg8
VP04818
p12152
sg10
I4
sg11
VTYMS
p12153
sg13
I1
sa(dp12154
g7
I118
sg8
VP30486
p12155
sg10
I9
sg11
VHLA-A2(+)
p12156
sg13
I1
sa(dp12157
g7
I0
sg8
VP04818
p12158
sg10
I4
sg11
VTYMS
p12159
sg13
I1
sasg23
(lp12160
(dp12161
g7
I128
sg26
VC0699790
p12162
sg10
I12
sg11
Vcolon cancer
p12163
sg13
I2
sa(dp12164
g7
I252
sg26
VC0027651
p12165
sg10
I5
sg11
Vtumor
p12166
sg13
I1
sasa(dp12167
g2
S"In one sample we sequenced 7231 contiguous base pairs that covered completely the region from the 5'end of the 16S rRNA gene to the 5'end of the 23S rRNA gene comprising the whole 16S rRNA (rrs), and the following genes: Ala tRNA (alaT), Ile tRNA (ileT), adenylosuccinate lyase (purB), adenylosuccinate synthetase (purA), methylpurine-DNA glycosylase (mag), hypoxanthine-guanine phosphoribosyltransferase (hpt), an hydrolase (HAD superfamily) and a 135 bp 5' fragment of the 23S rRNA (rrlA) genes.\n"
p12168
sg4
(lp12169
(dp12170
g7
I315
sg8
g107
sg10
I4
sg11
VpurA
p12171
sg13
I1
sa(dp12172
g7
I352
sg8
VP20916
p12173
sg10
I3
sg11
Vmag
p12174
sg13
I1
sa(dp12175
g7
I279
sg8
g107
sg10
I4
sg11
VpurB
p12176
sg13
I1
sa(dp12177
g7
I322
sg8
g107
sg10
I28
sg11
Vmethylpurine-DNA glycosylase
p12178
sg13
I2
sa(dp12179
g7
I255
sg8
VP30566
p12180
sg10
I22
sg11
Vadenylosuccinate lyase
p12181
sg13
I2
sa(dp12182
g7
I406
sg8
VP00738
p12183
sg10
I3
sg11
Vhpt
p12184
sg13
I1
sa(dp12185
g7
I221
sg8
VP00709
p12186
sg10
I25
sg11
VAla tRNA (alaT), Ile tRNA
p12187
sg13
I5
sa(dp12188
g7
I190
sg8
VP49788
p12189
sg10
I3
sg11
Vrrs
p12190
sg13
I1
sa(dp12191
g7
I475
sg8
VP01893
p12192
sg10
I21
sg11
V23S rRNA (rrlA) genes
p12193
sg13
I4
sa(dp12194
g7
I286
sg8
VP30520
p12195
sg10
I27
sg11
Vadenylosuccinate synthetase
p12196
sg13
I2
sa(dp12197
g7
I358
sg8
VP00492
p12198
sg10
I46
sg11
Vhypoxanthine-guanine phosphoribosyltransferase
p12199
sg13
I2
sasg23
(lp12200
(dp12201
g7
I190
sg26
VC1849334
p12202
sg10
I3
sg11
Vrrs
p12203
sg13
I1
sasa(dp12204
g2
S'Additionally, NOLC1 expression was decreased in human hepatocellular carcinoma (HCC) tissue, and the ectopic expression of NOLC1 repressed the proliferation of HCC cells and tumor growth in a HCC xenograft model.\n'
p12205
sg4
(lp12206
(dp12207
g7
I14
sg8
g107
sg10
I5
sg11
VNOLC1
p12208
sg13
I1
sa(dp12209
g7
I14
sg8
g107
sg10
I5
sg11
VNOLC1
p12210
sg13
I1
sasg23
(lp12211
(dp12212
g7
I174
sg26
VC0598934
p12213
sg10
I12
sg11
Vtumor growth
p12214
sg13
I2
sa(dp12215
g7
I80
sg26
VC2239176
p12216
sg10
I3
sg11
VHCC
p12217
sg13
I1
sa(dp12218
g7
I143
sg26
VC0334094
p12219
sg10
I13
sg11
Vproliferation
p12220
sg13
I1
sa(dp12221
g7
I80
sg26
VC2239176
p12222
sg10
I3
sg11
VHCC
p12223
sg13
I1
sa(dp12224
g7
I80
sg26
VC2239176
p12225
sg10
I3
sg11
VHCC
p12226
sg13
I1
sa(dp12227
g7
I54
sg26
VC2239176
p12228
sg10
I24
sg11
Vhepatocellular carcinoma
p12229
sg13
I2
sasa(dp12230
g2
S'CUL3(KBTBD8) monoubiquitylates NOLC1 and its paralogue TCOF1, the mutation of which underlies the neurocristopathy Treacher Collins syndrome.\n'
p12231
sg4
(lp12232
(dp12233
g7
I5
sg8
g107
sg10
I6
sg11
VKBTBD8
p12234
sg13
I1
sa(dp12235
g7
I0
sg8
g107
sg10
I4
sg11
VCUL3
p12236
sg13
I1
sa(dp12237
g7
I55
sg8
g107
sg10
I5
sg11
VTCOF1
p12238
sg13
I1
sa(dp12239
g7
I31
sg8
g107
sg10
I5
sg11
VNOLC1
p12240
sg13
I1
sasg23
(lp12241
(dp12242
g7
I115
sg26
VC0242387
p12243
sg10
I25
sg11
VTreacher Collins syndrome
p12244
sg13
I3
sasa(dp12245
g2
S'Treacher Collins syndrome (TCS), a representative human ribosomopathy with craniofacial abnormalities, is attributed to mutations in the tcof1 gene that has a homologous gene called nopp140.\n'
p12246
sg4
(lp12247
(dp12248
g7
I137
sg8
g107
sg10
I10
sg11
Vtcof1 gene
p12249
sg13
I2
sa(dp12250
g7
I182
sg8
g107
sg10
I7
sg11
Vnopp140
p12251
sg13
I1
sasg23
(lp12252
(dp12253
g7
I27
sg26
VC0242387
p12254
sg10
I3
sg11
VTCS
p12255
sg13
I1
sa(dp12256
g7
I0
sg26
VC0242387
p12257
sg10
I25
sg11
VTreacher Collins syndrome
p12258
sg13
I3
sa(dp12259
g7
I75
sg26
VC0376634
p12260
sg10
I26
sg11
Vcraniofacial abnormalities
p12261
sg13
I2
sasa(dp12262
g2
S'Previous studies suggest that NOLC1 is crucial for normal cell growth, and plays a role in the regulation of tumorigenesis of nasopharyngeal carcinoma (NPC) and demonstrate that both NOLC1 and tumor protein 53 work synergistically to activate the MDM2 promoter in NPC cells.\n'
p12263
sg4
(lp12264
(dp12265
g7
I30
sg8
g107
sg10
I5
sg11
VNOLC1
p12266
sg13
I1
sa(dp12267
g7
I30
sg8
g107
sg10
I5
sg11
VNOLC1
p12268
sg13
I1
sasg23
(lp12269
(dp12270
g7
I109
sg26
VC0007621
p12271
sg10
I13
sg11
Vtumorigenesis
p12272
sg13
I1
sa(dp12273
g7
I126
sg26
VC2931822
p12274
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12275
sg13
I2
sa(dp12276
g7
I152
sg26
VC2931822
p12277
sg10
I3
sg11
VNPC
p12278
sg13
I1
sa(dp12279
g7
I152
sg26
VC2931822
p12280
sg10
I3
sg11
VNPC
p12281
sg13
I1
sa(dp12282
g7
I109
sg26
VC0027651
p12283
sg10
I5
sg11
Vtumor
p12284
sg13
I1
sasa(dp12285
g2
S'Yet, the functioning of NOLC1 in liver cancer remains unknown.\n'
p12286
sg4
(lp12287
(dp12288
g7
I24
sg8
g107
sg10
I5
sg11
VNOLC1
p12289
sg13
I1
sasg23
(lp12290
(dp12291
g7
I33
sg26
VC0345904
p12292
sg10
I12
sg11
Vliver cancer
p12293
sg13
I2
sasa(dp12294
g2
S'In this study, we showed that NOLC1 was silenced or downregulated in liver tumor tissues when compared with that in the matched non-cancer tissues.\n'
p12295
sg4
(lp12296
(dp12297
g7
I30
sg8
g107
sg10
I5
sg11
VNOLC1
p12298
sg13
I1
sasg23
(lp12299
(dp12300
g7
I69
sg26
VC0023903
p12301
sg10
I11
sg11
Vliver tumor
p12302
sg13
I2
sa(dp12303
g7
I132
sg26
VC0006826
p12304
sg10
I6
sg11
Vcancer
p12305
sg13
I1
sasa(dp12306
g2
S'Low expression of NOLC1 in hepatoma cell lines and liver cancer tissues was associated with cyclin D3.\n'
p12307
sg4
(lp12308
(dp12309
g7
I92
sg8
VP30281
p12310
sg10
I9
sg11
Vcyclin D3
p12311
sg13
I2
sa(dp12312
g7
I18
sg8
g107
sg10
I5
sg11
VNOLC1
p12313
sg13
I1
sasg23
(lp12314
(dp12315
g7
I27
sg26
VC0023903
p12316
sg10
I8
sg11
Vhepatoma
p12317
sg13
I1
sa(dp12318
g7
I51
sg26
VC0345904
p12319
sg10
I12
sg11
Vliver cancer
p12320
sg13
I2
sasa(dp12321
g2
S'In conclusion, our study demonstrated that DNA methylation is a key mechanism of silenced NOLC1 expression in human hepatocellular carcinoma cells, and NOLC1 gene hypermethylation of the four CpG dinucleotides is a potential biomarker for hepatocellular carcinoma.\n'
p12322
sg4
(lp12323
(dp12324
g7
I152
sg8
g107
sg10
I10
sg11
VNOLC1 gene
p12325
sg13
I2
sa(dp12326
g7
I90
sg8
g107
sg10
I5
sg11
VNOLC1
p12327
sg13
I1
sasg23
(lp12328
(dp12329
g7
I116
sg26
VC1512411
p12330
sg10
I24
sg11
Vhepatocellular carcinoma
p12331
sg13
I2
sa(dp12332
g7
I116
sg26
VC1512411
p12333
sg10
I24
sg11
Vhepatocellular carcinoma
p12334
sg13
I2
sasa(dp12335
g2
S'Severe combined immunodeficiency mice bearing NPC xenografts derived from NOLC1-short hairpin-RNA-transfected animals were found to have 82% lower levels of tumor growth than control mice as well as marked tumor cell apoptosis.\n'
p12336
sg4
(lp12337
(dp12338
g7
I74
sg8
g107
sg10
I5
sg11
VNOLC1
p12339
sg13
I1
sasg23
(lp12340
(dp12341
g7
I157
sg26
VC0598934
p12342
sg10
I12
sg11
Vtumor growth
p12343
sg13
I2
sa(dp12344
g7
I0
sg26
VC0085110
p12345
sg10
I32
sg11
VSevere combined immunodeficiency
p12346
sg13
I3
sa(dp12347
g7
I157
sg26
VC0027651
p12348
sg10
I5
sg11
Vtumor
p12349
sg13
I1
sa(dp12350
g7
I46
sg26
VC2931822
p12351
sg10
I3
sg11
VNPC
p12352
sg13
I1
sasa(dp12353
g2
S'The aim of the study was to examine the effects of endurance exercise on circulating vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.\n'
p12354
sg4
(lp12355
(dp12356
g7
I133
sg8
VP05362
p12357
sg10
I33
sg11
Vintercellular adhesion molecule-1
p12358
sg13
I3
sa(dp12359
g7
I85
sg8
VP19320
p12360
sg10
I33
sg11
Vvascular cell adhesion molecule-1
p12361
sg13
I4
sasg23
(lp12362
(dp12363
g7
I180
sg26
VC0037054
p12364
sg10
I17
sg11
Vsickle cell trait
p12365
sg13
I3
sa(dp12366
g7
I199
sg26
VC1848934
p12367
sg10
I3
sg11
VSCT
p12368
sg13
I1
sa(dp12369
g7
I99
sg26
VC0001511
p12370
sg10
I8
sg11
Vadhesion
p12371
sg13
I1
sa(dp12372
g7
I99
sg26
VC0001511
p12373
sg10
I8
sg11
Vadhesion
p12374
sg13
I1
sa(dp12375
g7
I229
sg26
VC0002312
p12376
sg10
I17
sg11
Valpha-thalassemia
p12377
sg13
I1
sasa(dp12378
g2
S'The aim of the study was to examine the effects of exercise on soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.\n'
p12379
sg4
(lp12380
(dp12381
g7
I119
sg8
VP05362
p12382
sg10
I33
sg11
Vintercellular adhesion molecule-1
p12383
sg13
I3
sa(dp12384
g7
I71
sg8
VP19320
p12385
sg10
I33
sg11
Vvascular cell adhesion molecule-1
p12386
sg13
I4
sasg23
(lp12387
(dp12388
g7
I85
sg26
VC0001511
p12389
sg10
I8
sg11
Vadhesion
p12390
sg13
I1
sa(dp12391
g7
I85
sg26
VC0001511
p12392
sg10
I8
sg11
Vadhesion
p12393
sg13
I1
sa(dp12394
g7
I215
sg26
VC0002312
p12395
sg10
I17
sg11
Valpha-thalassemia
p12396
sg13
I1
sa(dp12397
g7
I166
sg26
VC0037054
p12398
sg10
I17
sg11
Vsickle cell trait
p12399
sg13
I3
sa(dp12400
g7
I185
sg26
VC1848934
p12401
sg10
I3
sg11
VSCT
p12402
sg13
I1
sasa(dp12403
g2
S'As compared to normal, increased sICAM-1 was found in beta-thal/HbE patients with non-splenectomy; BE-NS (p = 0.002), increased ELAM-1 in beta-thal/HbE patients with splenectomy; BE-S (p = 0.01) and HbH with Hb Constant Spring; HbH/CS (p = 0.001), and increased sVCAM-1 in BE-NS; (p = &lt; 0.0001) and BE-S (p = 0.002).\n'
p12404
sg4
(lp12405
(dp12406
g7
I64
sg8
VP02100
p12407
sg10
I3
sg11
VHbE
p12408
sg13
I1
sa(dp12409
g7
I128
sg8
VP16581
p12410
sg10
I6
sg11
VELAM-1
p12411
sg13
I1
sa(dp12412
g7
I208
sg8
g107
sg10
I18
sg11
VHb Constant Spring
p12413
sg13
I3
sasg23
(lp12414
(dp12415
g7
I199
sg26
VC3161174
p12416
sg10
I3
sg11
VHbH
p12417
sg13
I1
sa(dp12418
g7
I199
sg26
VC3161174
p12419
sg10
I3
sg11
VHbH
p12420
sg13
I1
sasa(dp12421
g2
S'Furthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA-3 and retinoic acid receptor-related orphan nuclear receptor (ROR)Gammat in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis.\n'
p12422
sg4
(lp12423
(dp12424
g7
I173
sg8
VP51843
p12425
sg10
I23
sg11
Vorphan nuclear receptor
p12426
sg13
I3
sa(dp12427
g7
I110
sg8
VP23771
p12428
sg10
I27
sg11
Vtranscription factor GATA-3
p12429
sg13
I3
sa(dp12430
g7
I142
sg8
VP10826
p12431
sg10
I22
sg11
Vretinoic acid receptor
p12432
sg13
I3
sasg23
(lp12433
(dp12434
g7
I282
sg26
VC2607914
p12435
sg10
I17
sg11
Vallergic rhinitis
p12436
sg13
I2
sasa(dp12437
g2
S'The present results suggested that treatment with AST may attenuate OVA-induced allergic rhinitis via regulating the expression of the transcription factors GATA-3, RORGammat, T-bet and Foxp3, which commit T helper cells to the Th1 phenotype.\n'
p12438
sg4
(lp12439
(dp12440
g7
I50
sg8
VP51689
p12441
sg10
I3
sg11
VAST
p12442
sg13
I1
sa(dp12443
g7
I135
sg8
VP19883
p12444
sg10
I28
sg11
Vtranscription factors GATA-3
p12445
sg13
I3
sa(dp12446
g7
I176
sg8
g107
sg10
I5
sg11
VT-bet
p12447
sg13
I1
sa(dp12448
g7
I186
sg8
g107
sg10
I5
sg11
VFoxp3
p12449
sg13
I1
sasg23
(lp12450
(dp12451
g7
I80
sg26
VC2607914
p12452
sg10
I17
sg11
Vallergic rhinitis
p12453
sg13
I2
sasa(dp12454
g2
S'Canagliflozin was associated with a low incidence of hypoglycemia when used with background AHAs that are not associated with hypoglycemia; the incidence was higher among patients on background AHAs associated with hypoglycemia (i.e.\n'
p12455
sg4
(lp12456
sg23
(lp12457
(dp12458
g7
I53
sg26
VC0020615
p12459
sg10
I12
sg11
Vhypoglycemia
p12460
sg13
I1
sa(dp12461
g7
I53
sg26
VC0020615
p12462
sg10
I12
sg11
Vhypoglycemia
p12463
sg13
I1
sa(dp12464
g7
I53
sg26
VC0020615
p12465
sg10
I12
sg11
Vhypoglycemia
p12466
sg13
I1
sasa(dp12467
g2
S'Canagliflozin was associated with a low incidence of hypoglycemia when not used in conjunction with AHAs associated with hypoglycemia (i.e., insulin or sulfonylurea).\n'
p12468
sg4
(lp12469
(dp12470
g7
I141
sg8
VP01308
p12471
sg10
I7
sg11
Vinsulin
p12472
sg13
I1
sasg23
(lp12473
(dp12474
g7
I53
sg26
VC0020615
p12475
sg10
I12
sg11
Vhypoglycemia
p12476
sg13
I1
sa(dp12477
g7
I53
sg26
VC0020615
p12478
sg10
I12
sg11
Vhypoglycemia
p12479
sg13
I1
sasa(dp12480
g2
S'Adding different AHAs to metformin was associated with varying effects on HbA1c, BW, SBP, hypoglycemia, UTI and GTI which should impact clinician choice when selecting adjunctive therapy.\n'
p12481
sg4
(lp12482
sg23
(lp12483
(dp12484
g7
I90
sg26
VC0020615
p12485
sg10
I12
sg11
Vhypoglycemia
p12486
sg13
I1
sa(dp12487
g7
I104
sg26
VC0042029
p12488
sg10
I3
sg11
VUTI
p12489
sg13
I1
sasa(dp12490
g2
S'It has been shown at least four mutations of mitochondrial genome, namely, A1555G in MT-RNR1 gene, C3256T in MT-TL1 gene, G12315A in MT-TL2 gene, and G15059A in MT-CYB gene have significantly higher prevalence and mean value in lipofibrous plaques as compared to non-atherosclerotic intima, and therefore are associated with atherosclerosis.\n'
p12491
sg4
(lp12492
(dp12493
g7
I85
sg8
VP43354
p12494
sg10
I12
sg11
VMT-RNR1 gene
p12495
sg13
I2
sa(dp12496
g7
I133
sg8
VP50591
p12497
sg10
I11
sg11
VMT-TL2 gene
p12498
sg13
I2
sa(dp12499
g7
I109
sg8
g107
sg10
I11
sg11
VMT-TL1 gene
p12500
sg13
I2
sa(dp12501
g7
I161
sg8
g107
sg10
I11
sg11
VMT-CYB gene
p12502
sg13
I2
sasg23
(lp12503
(dp12504
g7
I240
sg26
VC0333463
p12505
sg10
I7
sg11
Vplaques
p12506
sg13
I1
sa(dp12507
g7
I325
sg26
VC0004153
p12508
sg10
I15
sg11
Vatherosclerosis
p12509
sg13
I1
sasa(dp12510
g2
S'Ten mitochondrial mutations belonging to mitochondrial genes MT-RNR1 (rRNA 12S); MT-TL1 (tRNA-Leu, recognizes UUR); MT-TL2 (tRNA-Leu, recognizes CUN); MT-ND1, MT-ND2, MT-ND5, and MT-ND6 (subunits 1, 2, 5, and 6, respectively, of NADH dehydrogenase); and MT-CYB (cytochrome b) were potentially associated with atherosclerosis.\n'
p12511
sg4
(lp12512
(dp12513
g7
I81
sg8
g107
sg10
I6
sg11
VMT-TL1
p12514
sg13
I1
sa(dp12515
g7
I116
sg8
VP50591
p12516
sg10
I6
sg11
VMT-TL2
p12517
sg13
I1
sa(dp12518
g7
I254
sg8
g107
sg10
I6
sg11
VMT-CYB
p12519
sg13
I1
sa(dp12520
g7
I167
sg8
VP03915
p12521
sg10
I6
sg11
VMT-ND5
p12522
sg13
I1
sa(dp12523
g7
I159
sg8
VP03891
p12524
sg10
I6
sg11
VMT-ND2
p12525
sg13
I1
sa(dp12526
g7
I229
sg8
VP49366
p12527
sg10
I18
sg11
VNADH dehydrogenase
p12528
sg13
I2
sa(dp12529
g7
I61
sg8
VP43354
p12530
sg10
I7
sg11
VMT-RNR1
p12531
sg13
I1
sa(dp12532
g7
I124
sg8
VP30740
p12533
sg10
I24
sg11
VtRNA-Leu, recognizes CUN
p12534
sg13
I3
sa(dp12535
g7
I89
sg8
VP30740
p12536
sg10
I24
sg11
VtRNA-Leu, recognizes UUR
p12537
sg13
I3
sa(dp12538
g7
I151
sg8
VP03886
p12539
sg10
I6
sg11
VMT-ND1
p12540
sg13
I1
sasg23
(lp12541
(dp12542
g7
I309
sg26
VC0004153
p12543
sg10
I15
sg11
Vatherosclerosis
p12544
sg13
I1
sasa(dp12545
g2
S'The vectors of chikungunya and dengue virus, Aedes aegypti and Aedes albopictus, the vector of lymphatic filariasis, Culex quinquefasciatus, and that of Japanese encephalitis, Culex tritaeniorhynchus, were found from 70 to 2,000 m asl in eastern Nepal.\n'
p12546
sg4
(lp12547
sg23
(lp12548
(dp12549
g7
I153
sg26
VC0014057
p12550
sg10
I21
sg11
VJapanese encephalitis
p12551
sg13
I2
sa(dp12552
g7
I95
sg26
VC0013884
p12553
sg10
I20
sg11
Vlymphatic filariasis
p12554
sg13
I2
sa(dp12555
g7
I15
sg26
VC0008055
p12556
sg10
I11
sg11
Vchikungunya
p12557
sg13
I1
sa(dp12558
g7
I31
sg26
VC0011311
p12559
sg10
I6
sg11
Vdengue
p12560
sg13
I1
sasa(dp12561
g2
S'The results of an examination of a paraffin block histopathology specimen by fluorescence in-situ hybridization (FISH) showed no mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) (18q21.1), B-cell lymphoma 2 (BCL2) (18q21.3), or BCL6 (3q27) split signals in either the uterus or the greater omentum, however, trisomy 18 was detected in approximately 50%-70% of the tumor cells in both the uterus and the greater omentum.\n'
p12562
sg4
(lp12563
(dp12564
g7
I251
sg8
VP41182
p12565
sg10
I4
sg11
VBCL6
p12566
sg13
I1
sa(dp12567
g7
I231
sg8
VP10415
p12568
sg10
I4
sg11
VBCL2
p12569
sg13
I1
sa(dp12570
g7
I212
sg8
VP10415
p12571
sg10
I17
sg11
VB-cell lymphoma 2
p12572
sg13
I3
sasg23
(lp12573
(dp12574
g7
I172
sg26
VC0040715
p12575
sg10
I13
sg11
Vtranslocation
p12576
sg13
I1
sa(dp12577
g7
I387
sg26
VC0027651
p12578
sg10
I5
sg11
Vtumor
p12579
sg13
I1
sa(dp12580
g7
I129
sg26
VC0242647
p12581
sg10
I42
sg11
Vmucosa associated lymphoid tissue lymphoma
p12582
sg13
I5
sa(dp12583
g7
I212
sg26
VC0079731
p12584
sg10
I15
sg11
VB-cell lymphoma
p12585
sg13
I2
sa(dp12586
g7
I331
sg26
VC0152096
p12587
sg10
I10
sg11
Vtrisomy 18
p12588
sg13
I2
sasa(dp12589
g2
S'The following abnormalities were most frequently observed: rearrangements involving 14q32, 19q13, 19p13, 1p, 3q27, and 8q24; del(6q); dup(1q); and trisomy 18.\n'
p12590
sg4
(lp12591
sg23
(lp12592
(dp12593
g7
I147
sg26
VC0152096
p12594
sg10
I10
sg11
Vtrisomy 18
p12595
sg13
I2
sasa(dp12596
g2
S'Passive avoidance test showed four Group rats shuttle times were 6.8+/-0.6, 1.2+/-0.2, 5.4+/-0.5, 3.6+/-0.3, incubation period were 26.1+/-3.9, 152.2+/-12.9, 65.8+/-7.0, 91.2+/-9.1, and water maze test had the same trend, with values in epilepsy groups significantly lower than the normal group of rats, which meant cognitive dysfunction.The above results also showed Baclofen further inhibited the learning and memory ability of the rats and CGP35348 promoted the learning and memory ability.The results of the Arc/Arg3.1 and GB1, GB2 level detection showed that epilepsy groups had significantly higher expression levels of Arc/Arg3.1 and GB1, GB2 than the normal group.Comparison among epilepsy groups showed that Baclofen group expressed lower levels of Arc/Arg3.1 and expressed higher levels of GB1, GB2, however CGP35348 group expressed higher levels of Arc/Arg3.1 and expressed lower levels of GB1, GB2.\n'
p12597
sg4
(lp12598
(dp12599
g7
I516
sg8
g107
sg10
I6
sg11
VArg3.1
p12600
sg13
I1
sa(dp12601
g7
I532
sg8
g107
sg10
I3
sg11
VGB2
p12602
sg13
I1
sa(dp12603
g7
I527
sg8
VP62873
p12604
sg10
I3
sg11
VGB1
p12605
sg13
I1
sa(dp12606
g7
I516
sg8
g107
sg10
I6
sg11
VArg3.1
p12607
sg13
I1
sa(dp12608
g7
I532
sg8
g107
sg10
I3
sg11
VGB2
p12609
sg13
I1
sa(dp12610
g7
I532
sg8
g107
sg10
I3
sg11
VGB2
p12611
sg13
I1
sa(dp12612
g7
I512
sg8
g107
sg10
I3
sg11
VArc
p12613
sg13
I1
sa(dp12614
g7
I516
sg8
g107
sg10
I6
sg11
VArg3.1
p12615
sg13
I1
sa(dp12616
g7
I512
sg8
g107
sg10
I3
sg11
VArc
p12617
sg13
I1
sa(dp12618
g7
I512
sg8
g107
sg10
I3
sg11
VArc
p12619
sg13
I1
sa(dp12620
g7
I527
sg8
VP62873
p12621
sg10
I3
sg11
VGB1
p12622
sg13
I1
sa(dp12623
g7
I527
sg8
VP62873
p12624
sg10
I3
sg11
VGB1
p12625
sg13
I1
sa(dp12626
g7
I532
sg8
g107
sg10
I3
sg11
VGB2
p12627
sg13
I1
sa(dp12628
g7
I818
sg8
VP00390
p12629
sg10
I14
sg11
VCGP35348 group
p12630
sg13
I2
sa(dp12631
g7
I512
sg8
g107
sg10
I3
sg11
VArc
p12632
sg13
I1
sa(dp12633
g7
I516
sg8
g107
sg10
I6
sg11
VArg3.1
p12634
sg13
I1
sa(dp12635
g7
I527
sg8
VP62873
p12636
sg10
I3
sg11
VGB1
p12637
sg13
I1
sasg23
(lp12638
(dp12639
g7
I237
sg26
VC0014544
p12640
sg10
I8
sg11
Vepilepsy
p12641
sg13
I1
sa(dp12642
g7
I512
sg26
VC0001857
p12643
sg10
I3
sg11
VArc
p12644
sg13
I1
sa(dp12645
g7
I237
sg26
VC0014544
p12646
sg10
I8
sg11
Vepilepsy
p12647
sg13
I1
sa(dp12648
g7
I512
sg26
VC0001857
p12649
sg10
I3
sg11
VArc
p12650
sg13
I1
sa(dp12651
g7
I512
sg26
VC0001857
p12652
sg10
I3
sg11
VArc
p12653
sg13
I1
sa(dp12654
g7
I316
sg26
VC0338656
p12655
sg10
I21
sg11
Vcognitive dysfunction
p12656
sg13
I2
sa(dp12657
g7
I237
sg26
VC0014544
p12658
sg10
I8
sg11
Vepilepsy
p12659
sg13
I1
sa(dp12660
g7
I512
sg26
VC0001857
p12661
sg10
I3
sg11
VArc
p12662
sg13
I1
sasa(dp12663
g2
S"To search for the mechanism causing clinically silent corticotroph adenoma, we immunohistochemically examined the expression of prohormone convertase 1/3 (PC1/3) in this type of adenoma and compared our results with those obtained for Cushing's disease.\n"
p12664
sg4
(lp12665
(dp12666
g7
I155
sg8
VP29120
p12667
sg10
I5
sg11
VPC1/3
p12668
sg13
I1
sa(dp12669
g7
I128
sg8
VP29120
p12670
sg10
I25
sg11
Vprohormone convertase 1/3
p12671
sg13
I3
sasg23
(lp12672
(dp12673
g7
I67
sg26
VC0001430
p12674
sg10
I7
sg11
Vadenoma
p12675
sg13
I1
sa(dp12676
g7
I54
sg26
VC1306214
p12677
sg10
I20
sg11
Vcorticotroph adenoma
p12678
sg13
I2
sa(dp12679
g7
I235
sg26
VC0221406
p12680
sg10
I17
sg11
VCushing's disease
p12681
sg13
I2
sa(dp12682
g7
I155
sg26
VC1706595
p12683
sg10
I3
sg11
VPC1
p12684
sg13
I1
sasa(dp12685
g2
S'In the present study, we tested the therapeutic and immunomodulatory effects of FTS and its derivative 5-fluoro-FTS (F-FTS) in the rat adjuvant-induced arthritis model (AIA).\n'
p12686
sg4
(lp12687
(dp12688
g7
I117
sg8
g107
sg10
I5
sg11
VF-FTS
p12689
sg13
I1
sa(dp12690
g7
I103
sg8
g107
sg10
I12
sg11
V5-fluoro-FTS
p12691
sg13
I1
sasg23
(lp12692
(dp12693
g7
I152
sg26
VC0003864
p12694
sg10
I9
sg11
Varthritis
p12695
sg13
I1
sasa(dp12696
g2
S'MR features were scored (0-3) following the Oslo hand OA score: BMLs, synovitis, cysts, flexor tenosynovitis (FTS).\n'
p12697
sg4
(lp12698
sg23
(lp12699
(dp12700
g7
I110
sg26
VC0744058
p12701
sg10
I3
sg11
VFTS
p12702
sg13
I1
sa(dp12703
g7
I81
sg26
VC0010709
p12704
sg10
I5
sg11
Vcysts
p12705
sg13
I1
sa(dp12706
g7
I70
sg26
VC0039103
p12707
sg10
I9
sg11
Vsynovitis
p12708
sg13
I1
sa(dp12709
g7
I88
sg26
VC0744058
p12710
sg10
I20
sg11
Vflexor tenosynovitis
p12711
sg13
I2
sasa(dp12712
g2
S'BMLs, synovitis, cysts, FTS and ETI were demonstrated in 56%, 90%, 22%, 16% and 30% of patients, respectively.\n'
p12713
sg4
(lp12714
sg23
(lp12715
(dp12716
g7
I17
sg26
VC0010709
p12717
sg10
I5
sg11
Vcysts
p12718
sg13
I1
sa(dp12719
g7
I6
sg26
VC0039103
p12720
sg10
I9
sg11
Vsynovitis
p12721
sg13
I1
sasa(dp12722
g2
S'BMLs (grade 2/3 vs 0: 3.5 (1.6-7.7)) and synovitis (3 vs 0: OR 3.6 (95% CI 1.9-6.6)) were severity-dependent associated with joint pain, but FTS and ETI were not.\n'
p12723
sg4
(lp12724
sg23
(lp12725
(dp12726
g7
I125
sg26
VC0003862
p12727
sg10
I10
sg11
Vjoint pain
p12728
sg13
I2
sa(dp12729
g7
I41
sg26
VC0039103
p12730
sg10
I9
sg11
Vsynovitis
p12731
sg13
I1
sasa(dp12732
g2
S'Infectious flexor tenosynovitis (FTS) is a serious infection of the hand and wrist that can lead to necrosis and amputation without prompt diagnosis and surgical debridement.\n'
p12733
sg4
(lp12734
sg23
(lp12735
(dp12736
g7
I33
sg26
VC0744058
p12737
sg10
I3
sg11
VFTS
p12738
sg13
I1
sa(dp12739
g7
I11
sg26
VC0744058
p12740
sg10
I20
sg11
Vflexor tenosynovitis
p12741
sg13
I2
sa(dp12742
g7
I51
sg26
VC0009450
p12743
sg10
I9
sg11
Vinfection
p12744
sg13
I1
sa(dp12745
g7
I0
sg26
VC0009450
p12746
sg10
I10
sg11
VInfectious
p12747
sg13
I1
sasa(dp12748
g2
S'Our objective in this work was to investigate the anti-inflammatory effects of the Ras inhibitor farnesylthiosalicylic acid (FTS) on adjuvant-induced arthritis (AIA) in rats, an experimental model for RA.\n'
p12749
sg4
(lp12750
(dp12751
g7
I83
sg8
VP01116
p12752
sg10
I3
sg11
VRas
p12753
sg13
I1
sasg23
(lp12754
(dp12755
g7
I150
sg26
VC0003864
p12756
sg10
I9
sg11
Varthritis
p12757
sg13
I1
sasa(dp12758
g2
S'Diabetic patients are susceptible to stenosing flexor tenosynovitis (FTS) and may have a diminished response to treatment.\n'
p12759
sg4
(lp12760
sg23
(lp12761
(dp12762
g7
I47
sg26
VC0744058
p12763
sg10
I20
sg11
Vflexor tenosynovitis
p12764
sg13
I2
sa(dp12765
g7
I69
sg26
VC0744058
p12766
sg10
I3
sg11
VFTS
p12767
sg13
I1
sasa(dp12768
g2
S'With the rising participation of women in sports events, the prevalence of eating disorders and the female athlete triad (FTS), a syndrome of disordered eating, amenorrhea, and osteoporosis, have also increased in recent years.\n'
p12769
sg4
(lp12770
sg23
(lp12771
(dp12772
g7
I161
sg26
VC0002453
p12773
sg10
I10
sg11
Vamenorrhea
p12774
sg13
I1
sa(dp12775
g7
I100
sg26
VC1721053
p12776
sg10
I20
sg11
Vfemale athlete triad
p12777
sg13
I3
sa(dp12778
g7
I75
sg26
VC0013473
p12779
sg10
I16
sg11
Veating disorders
p12780
sg13
I2
sa(dp12781
g7
I130
sg26
VC0039082
p12782
sg10
I8
sg11
Vsyndrome
p12783
sg13
I1
sa(dp12784
g7
I177
sg26
VC0029456
p12785
sg10
I12
sg11
Vosteoporosis
p12786
sg13
I1
sasa(dp12787
g2
S"Dupuytren's contracture (DC) (42 vs. 29.3%, respectively; P=0.01), limited joint mobility (LJM) (39 vs. 28.5%, respectively; P=0.01) and carpal tunnel syndrome (CTS) (5.3 vs. 1%, respectively; P=0.01) were significantly higher in T2DM patients than in the controls, but not stenosing flexor tenosynovitis (FTS, 'trigger finger').\n"
p12788
sg4
(lp12789
sg23
(lp12790
(dp12791
g7
I161
sg26
VC0007286
p12792
sg10
I3
sg11
VCTS
p12793
sg13
I1
sa(dp12794
g7
I137
sg26
VC0007286
p12795
sg10
I22
sg11
Vcarpal tunnel syndrome
p12796
sg13
I3
sa(dp12797
g7
I311
sg26
VC0158328
p12798
sg10
I15
sg11
V'trigger finger
p12799
sg13
I2
sa(dp12800
g7
I25
sg26
VC0013312
p12801
sg10
I2
sg11
VDC
p12802
sg13
I1
sa(dp12803
g7
I0
sg26
VC0013312
p12804
sg10
I23
sg11
VDupuytren's contracture
p12805
sg13
I2
sa(dp12806
g7
I284
sg26
VC0744058
p12807
sg10
I20
sg11
Vflexor tenosynovitis
p12808
sg13
I2
sa(dp12809
g7
I306
sg26
VC0744058
p12810
sg10
I3
sg11
VFTS
p12811
sg13
I1
sasa(dp12812
g2
S'Data from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis.\n'
p12813
sg4
(lp12814
(dp12815
g7
I43
sg8
VP01350
p12816
sg10
I14
sg11
Vgastrin family
p12817
sg13
I2
sa(dp12818
g7
I61
sg8
VP19883
p12819
sg10
I14
sg11
Vgrowth factors
p12820
sg13
I2
sasg23
(lp12821
(dp12822
g7
I88
sg26
VC1527249
p12823
sg10
I17
sg11
Vcolorectal cancer
p12824
sg13
I2
sasa(dp12825
g2
S'The aim of this study was to investigate whether progastrin expression may predict clinical outcome in colorectal cancer.\n'
p12826
sg4
(lp12827
sg23
(lp12828
(dp12829
g7
I103
sg26
VC1527249
p12830
sg10
I17
sg11
Vcolorectal cancer
p12831
sg13
I2
sasa(dp12832
g2
S'This is the first study to show that progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer and supports its clinical relevance and potential use as a biomarker.\n'
p12833
sg4
(lp12834
sg23
(lp12835
(dp12836
g7
I80
sg26
VC0001807
p12837
sg10
I10
sg11
Vaggressive
p12838
sg13
I1
sa(dp12839
g7
I91
sg26
VC0027651
p12840
sg10
I6
sg11
Vtumour
p12841
sg13
I1
sa(dp12842
g7
I125
sg26
VC1527249
p12843
sg10
I17
sg11
Vcolorectal cancer
p12844
sg13
I2
sasa(dp12845
g2
S'The aim of this study was to analyze plasma concentrations of enterohormones (motilin, ghrelin, gastrin and pancreatic polypeptide) and to verify if their abnormal levels may contribute to the severity of dyspeptic symptoms in colorectal cancer patients.\n'
p12846
sg4
(lp12847
(dp12848
g7
I87
sg8
g107
sg10
I7
sg11
Vghrelin
p12849
sg13
I1
sa(dp12850
g7
I96
sg8
VP01350
p12851
sg10
I7
sg11
Vgastrin
p12852
sg13
I1
sa(dp12853
g7
I78
sg8
VP12872
p12854
sg10
I7
sg11
Vmotilin
p12855
sg13
I1
sasg23
(lp12856
(dp12857
g7
I227
sg26
VC1527249
p12858
sg10
I17
sg11
Vcolorectal cancer
p12859
sg13
I2
sasa(dp12860
g2
S'This study examined the expression level, subcellular localization, and binding activity of CacyBP/SIP in human colon cancer cells in the presence and absence of the hormone gastrin.\n'
p12861
sg4
(lp12862
(dp12863
g7
I99
sg8
g107
sg10
I3
sg11
VSIP
p12864
sg13
I1
sa(dp12865
g7
I92
sg8
g107
sg10
I6
sg11
VCacyBP
p12866
sg13
I1
sa(dp12867
g7
I174
sg8
VP01350
p12868
sg10
I7
sg11
Vgastrin
p12869
sg13
I1
sasg23
(lp12870
(dp12871
g7
I112
sg26
VC0699790
p12872
sg10
I12
sg11
Vcolon cancer
p12873
sg13
I2
sasa(dp12874
g2
S'CacyBP/SIP promoted the cell proliferation of colon cancer cells under both basal and gastrin stimulated conditions as shown by knockdown studies.\n'
p12875
sg4
(lp12876
(dp12877
g7
I86
sg8
VP01350
p12878
sg10
I7
sg11
Vgastrin
p12879
sg13
I1
sa(dp12880
g7
I0
sg8
g107
sg10
I6
sg11
VCacyBP
p12881
sg13
I1
sa(dp12882
g7
I7
sg8
g107
sg10
I3
sg11
VSIP
p12883
sg13
I1
sasg23
(lp12884
(dp12885
g7
I46
sg26
VC0699790
p12886
sg10
I12
sg11
Vcolon cancer
p12887
sg13
I2
sa(dp12888
g7
I29
sg26
VC0334094
p12889
sg10
I13
sg11
Vproliferation
p12890
sg13
I1
sasa(dp12891
g2
S"As treatment with proton pump inhibitors (PPIs) increases the biosynthesis and secretion of gastrin, it has been postulated that treatment with PPIs could increase the risk of cancer, especially in Barrett's esophagus, gastric carcinoids, and colorectal cancer (CRC).\n"
p12892
sg4
(lp12893
(dp12894
g7
I92
sg8
VP01350
p12895
sg10
I7
sg11
Vgastrin
p12896
sg13
I1
sasg23
(lp12897
(dp12898
g7
I198
sg26
VC0004763
p12899
sg10
I19
sg11
VBarrett's esophagus
p12900
sg13
I2
sa(dp12901
g7
I243
sg26
VC1527249
p12902
sg10
I17
sg11
Vcolorectal cancer
p12903
sg13
I2
sa(dp12904
g7
I227
sg26
VC0007095
p12905
sg10
I10
sg11
Vcarcinoids
p12906
sg13
I1
sa(dp12907
g7
I262
sg26
VC1527249
p12908
sg10
I3
sg11
VCRC
p12909
sg13
I1
sa(dp12910
g7
I176
sg26
VC0006826
p12911
sg10
I6
sg11
Vcancer
p12912
sg13
I1
sasa(dp12913
g2
S'Pathological studies showed lymph nodes metastasis in 2 patients with pancreatic gastrinomas, and in one patient with duodenal gastrinoma.\n'
p12914
sg4
(lp12915
sg23
(lp12916
(dp12917
g7
I81
sg26
VC0017150
p12918
sg10
I11
sg11
Vgastrinomas
p12919
sg13
I1
sa(dp12920
g7
I118
sg26
VC1333321
p12921
sg10
I19
sg11
Vduodenal gastrinoma
p12922
sg13
I2
sa(dp12923
g7
I40
sg26
VC0027627
p12924
sg10
I10
sg11
Vmetastasis
p12925
sg13
I1
sasa(dp12926
g2
S'A progressive increase in the expression of PD-1 and B7-H1/B7-DC on T cells and APC, respectively, was observed in the pancreatic lymph nodes of female non-obese diabetic (NOD) mice as they developed diabetes.\n'
p12927
sg4
(lp12928
(dp12929
g7
I53
sg8
g107
sg10
I5
sg11
VB7-H1
p12930
sg13
I1
sa(dp12931
g7
I80
sg8
VP25054
p12932
sg10
I3
sg11
VAPC
p12933
sg13
I1
sa(dp12934
g7
I44
sg8
VP18621
p12935
sg10
I4
sg11
VPD-1
p12936
sg13
I1
sa(dp12937
g7
I59
sg8
g107
sg10
I5
sg11
VB7-DC
p12938
sg13
I1
sasg23
(lp12939
(dp12940
g7
I172
sg26
VC0751781
p12941
sg10
I3
sg11
VNOD
p12942
sg13
I1
sa(dp12943
g7
I80
sg26
VC0033036
p12944
sg10
I3
sg11
VAPC
p12945
sg13
I1
sa(dp12946
g7
I200
sg26
VC0011849
p12947
sg10
I8
sg11
Vdiabetes
p12948
sg13
I1
sa(dp12949
g7
I152
sg26
VC0751781
p12950
sg10
I18
sg11
Vnon-obese diabetic
p12951
sg13
I2
sasa(dp12952
g2
S'B7-H1 and B7-DC have negative regulatory effects upon binding PD-1 on activated T cells and B7-H1 deficiency increases severity of both diabetes and EAE.\n'
p12953
sg4
(lp12954
(dp12955
g7
I10
sg8
g107
sg10
I5
sg11
VB7-DC
p12956
sg13
I1
sa(dp12957
g7
I0
sg8
g107
sg10
I5
sg11
VB7-H1
p12958
sg13
I1
sa(dp12959
g7
I62
sg8
VP18621
p12960
sg10
I4
sg11
VPD-1
p12961
sg13
I1
sa(dp12962
g7
I0
sg8
g107
sg10
I5
sg11
VB7-H1
p12963
sg13
I1
sasg23
(lp12964
(dp12965
g7
I136
sg26
VC0011849
p12966
sg10
I8
sg11
Vdiabetes
p12967
sg13
I1
sasa(dp12968
g2
S'These characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sezary syndrome, CD30+ cutaneous lymphoma, and transformed mycosis fungoides.\n'
p12969
sg4
(lp12970
(dp12971
g7
I38
sg8
VP43630
p12972
sg10
I7
sg11
VKIR3DL2
p12973
sg13
I1
sasg23
(lp12974
(dp12975
g7
I132
sg26
VC0036920
p12976
sg10
I15
sg11
VSezary syndrome
p12977
sg13
I2
sa(dp12978
g7
I97
sg26
VC0079773
p12979
sg10
I26
sg11
Vcutaneous T-cell lymphomas
p12980
sg13
I3
sa(dp12981
g7
I70
sg26
VC0038013
p12982
sg10
I22
sg11
Vankylosing spondylitis
p12983
sg13
I2
sa(dp12984
g7
I155
sg26
VC1276146
p12985
sg10
I18
sg11
Vcutaneous lymphoma
p12986
sg13
I2
sa(dp12987
g7
I191
sg26
VC0026948
p12988
sg10
I17
sg11
Vmycosis fungoides
p12989
sg13
I2
sasa(dp12990
g2
S'KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sezary syndrome.\n'
p12991
sg4
(lp12992
(dp12993
g7
I0
sg8
VP43630
p12994
sg10
I7
sg11
VKIR3DL2
p12995
sg13
I1
sa(dp12996
g7
I89
sg8
VP01732
p12997
sg10
I3
sg11
VCD8
p12998
sg13
I1
sasg23
(lp12999
(dp13000
g7
I164
sg26
VC0862196
p13001
sg10
I37
sg11
Vmycosis fungoides and Sezary syndrome
p13002
sg13
I5
sasa(dp13003
g2
S'Not only we confirmed the expression of this marker in the blood and/or skin of mycosis fungoides patients but we also show for the first time CD158k expression (often associated with CD160) on cutaneous CD4+ T cells from healthy individuals (25.3 +/- 15%).\n'
p13004
sg4
(lp13005
(dp13006
g7
I184
sg8
g107
sg10
I5
sg11
VCD160
p13007
sg13
I1
sa(dp13008
g7
I143
sg8
VP43627
p13009
sg10
I6
sg11
VCD158k
p13010
sg13
I1
sasg23
(lp13011
(dp13012
g7
I80
sg26
VC0026948
p13013
sg10
I17
sg11
Vmycosis fungoides
p13014
sg13
I2
sasa(dp13015
g2
S'Therefore, CD4+ CD160+ T cells expressing CD158k might represent specialized cutaneous lymphocytes devoted to immune surveillance, from which could originate cutaneous T-cell lymphomas such as mycosis fungoides.\n'
p13016
sg4
(lp13017
(dp13018
g7
I11
sg8
VP01730
p13019
sg10
I4
sg11
VCD4+
p13020
sg13
I1
sa(dp13021
g7
I42
sg8
VP43627
p13022
sg10
I6
sg11
VCD158k
p13023
sg13
I1
sasg23
(lp13024
(dp13025
g7
I158
sg26
VC0079773
p13026
sg10
I26
sg11
Vcutaneous T-cell lymphomas
p13027
sg13
I3
sa(dp13028
g7
I193
sg26
VC0026948
p13029
sg10
I17
sg11
Vmycosis fungoides
p13030
sg13
I2
sasa(dp13031
g2
S"p140/KIR3DL2 has been identified in malignant cell lines isolated from the skin and blood of patients with transformed mycosis fungoides (MF) and Sezary's syndrome (SS).\n"
p13032
sg4
(lp13033
(dp13034
g7
I5
sg8
VP43630
p13035
sg10
I7
sg11
VKIR3DL2
p13036
sg13
I1
sa(dp13037
g7
I0
sg8
VP43630
p13038
sg10
I4
sg11
Vp140
p13039
sg13
I1
sasg23
(lp13040
(dp13041
g7
I146
sg26
VC0036920
p13042
sg10
I17
sg11
VSezary's syndrome
p13043
sg13
I2
sa(dp13044
g7
I119
sg26
VC0026948
p13045
sg10
I17
sg11
Vmycosis fungoides
p13046
sg13
I2
sasa(dp13047
g2
S'Chromosomal aberration (DS especially) are among the most frequent prenatally diagnosed birth defects, further being heart defects, neural tube defects (anencephaly, encephalocele, spina bifida), hydrocephalus, congenital skeletal system defects, abdominal wall defects (omphalocele, gastroschisis) and renal defects.\n'
p13048
sg4
(lp13049
sg23
(lp13050
(dp13051
g7
I153
sg26
VC0002902
p13052
sg10
I11
sg11
Vanencephaly
p13053
sg13
I1
sa(dp13054
g7
I196
sg26
VC0020256
p13055
sg10
I25
sg11
Vhydrocephalus, congenital
p13056
sg13
I2
sa(dp13057
g7
I166
sg26
VC0014065
p13058
sg10
I13
sg11
Vencephalocele
p13059
sg13
I1
sa(dp13060
g7
I181
sg26
VC0080178
p13061
sg10
I12
sg11
Vspina bifida
p13062
sg13
I2
sa(dp13063
g7
I0
sg26
VC0008625
p13064
sg10
I22
sg11
VChromosomal aberration
p13065
sg13
I2
sa(dp13066
g7
I271
sg26
VC0795690
p13067
sg10
I11
sg11
Vomphalocele
p13068
sg13
I1
sa(dp13069
g7
I284
sg26
VC0265706
p13070
sg10
I13
sg11
Vgastroschisis
p13071
sg13
I1
sa(dp13072
g7
I117
sg26
VC0018798
p13073
sg10
I13
sg11
Vheart defects
p13074
sg13
I2
sa(dp13075
g7
I88
sg26
VC0000768
p13076
sg10
I13
sg11
Vbirth defects
p13077
sg13
I2
sasa(dp13078
g2
S'In some defects, prenatal diagnostics has also significantly influenced their incidence in births (anencephaly, gastroschisis and DS e.g.\n'
p13079
sg4
(lp13080
sg23
(lp13081
(dp13082
g7
I99
sg26
VC0002902
p13083
sg10
I11
sg11
Vanencephaly
p13084
sg13
I1
sa(dp13085
g7
I112
sg26
VC0265706
p13086
sg10
I13
sg11
Vgastroschisis
p13087
sg13
I1
sasa(dp13088
g2
S'The Fxn KO/Mck model reproduces some key features of patients with Friedreich ataxia and provides an opportunity of ameliorating their symptoms with experimental therapies.\n'
p13089
sg4
(lp13090
(dp13091
g7
I4
sg8
VP51587
p13092
sg10
I6
sg11
VFxn KO
p13093
sg13
I2
sasg23
(lp13094
(dp13095
g7
I67
sg26
VC0016719
p13096
sg10
I17
sg11
VFriedreich ataxia
p13097
sg13
I2
sasa(dp13098
g2
S'Further confirmation is obtained with identification of two mutations in the ARSB gene for MPS VI or mutations in the GALNS gene for MPS IVA.We report slowly progressing patients, one with MPS VI and two with MPS IVA, who presented with skeletal changes and hip findings resembling Legg-Calve-Perthes disease or spondyloepiphyseal dysplasia and normal/near normal urine GAG levels.\n'
p13099
sg4
(lp13100
(dp13101
g7
I118
sg8
VP34059
p13102
sg10
I10
sg11
VGALNS gene
p13103
sg13
I2
sa(dp13104
g7
I133
sg8
VP05164
p13105
sg10
I7
sg11
VMPS IVA
p13106
sg13
I2
sa(dp13107
g7
I91
sg8
VP05164
p13108
sg10
I6
sg11
VMPS VI
p13109
sg13
I2
sasg23
(lp13110
(dp13111
g7
I133
sg26
VC0086651
p13112
sg10
I7
sg11
VMPS IVA
p13113
sg13
I2
sa(dp13114
g7
I91
sg26
VC0026709
p13115
sg10
I6
sg11
VMPS VI
p13116
sg13
I2
sa(dp13117
g7
I312
sg26
VC2745959
p13118
sg10
I28
sg11
Vspondyloepiphyseal dysplasia
p13119
sg13
I2
sa(dp13120
g7
I282
sg26
VC0023234
p13121
sg10
I26
sg11
VLegg-Calve-Perthes disease
p13122
sg13
I2
sa(dp13123
g7
I133
sg26
VC0086651
p13124
sg10
I7
sg11
VMPS IVA
p13125
sg13
I2
sa(dp13126
g7
I91
sg26
VC0026709
p13127
sg10
I6
sg11
VMPS VI
p13128
sg13
I2
sasa(dp13129
g2
S"We identified genes that might be truly causative, but GWAS might have failed to identify for 148 out of the GWAS-identified SNPs; for example, TUFM (P = 3.3E-48) was identified for inflammatory bowel disease (early onset); ZFP90 (P = 4.4E-34) for ulcerative colitis; and IDUA (P = 2.2E-11) for Parkinson's disease.\n"
p13130
sg4
(lp13131
(dp13132
g7
I224
sg8
g107
sg10
I5
sg11
VZFP90
p13133
sg13
I1
sasg23
(lp13134
(dp13135
g7
I248
sg26
VC0009324
p13136
sg10
I18
sg11
Vulcerative colitis
p13137
sg13
I2
sa(dp13138
g7
I295
sg26
VC0030567
p13139
sg10
I19
sg11
VParkinson's disease
p13140
sg13
I2
sa(dp13141
g7
I182
sg26
VC0021390
p13142
sg10
I26
sg11
Vinflammatory bowel disease
p13143
sg13
I3
sasa(dp13144
g2
S'Apart from allergic bronchopulmonary aspergillosis (ABPA) and mould-caused mycoses, only sufficient evidence for an association between moisture/mould damage and the following health effects has been established: allergic respiratory disease, asthma (manifestation, progression and exacerbation), allergic rhinitis, hypersensitivity pneumonitis (extrinsic allergic alveolitis), and increased likelihood of respiratory infections/bronchitis.\n'
p13145
sg4
(lp13146
sg23
(lp13147
(dp13148
g7
I346
sg26
VC0002390
p13149
sg10
I29
sg11
Vextrinsic allergic alveolitis
p13150
sg13
I3
sa(dp13151
g7
I429
sg26
VC0006277
p13152
sg10
I10
sg11
Vbronchitis
p13153
sg13
I1
sa(dp13154
g7
I11
sg26
VC0004031
p13155
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p13156
sg13
I3
sa(dp13157
g7
I316
sg26
VC0002390
p13158
sg10
I28
sg11
Vhypersensitivity pneumonitis
p13159
sg13
I2
sa(dp13160
g7
I52
sg26
VC0004031
p13161
sg10
I4
sg11
VABPA
p13162
sg13
I1
sa(dp13163
g7
I75
sg26
VC0026946
p13164
sg10
I7
sg11
Vmycoses
p13165
sg13
I1
sa(dp13166
g7
I213
sg26
VC1504369
p13167
sg10
I28
sg11
Vallergic respiratory disease
p13168
sg13
I3
sa(dp13169
g7
I243
sg26
VC0004096
p13170
sg10
I6
sg11
Vasthma
p13171
sg13
I1
sa(dp13172
g7
I406
sg26
VC0035243
p13173
sg10
I22
sg11
Vrespiratory infections
p13174
sg13
I2
sa(dp13175
g7
I297
sg26
VC2607914
p13176
sg10
I17
sg11
Vallergic rhinitis
p13177
sg13
I2
sasa(dp13178
g2
S'We studied the relationship between GORD and allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), or Aspergillus bronchitis.\n'
p13179
sg4
(lp13180
sg23
(lp13181
(dp13182
g7
I61
sg26
VC2350529
p13183
sg10
I23
sg11
Vpulmonary aspergillosis
p13184
sg13
I2
sa(dp13185
g7
I45
sg26
VC0004031
p13186
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p13187
sg13
I3
sa(dp13188
g7
I135
sg26
VC2919277
p13189
sg10
I22
sg11
VAspergillus bronchitis
p13190
sg13
I2
sa(dp13191
g7
I86
sg26
VC0004031
p13192
sg10
I4
sg11
VABPA
p13193
sg13
I1
sasa(dp13194
g2
S'We reviewed four patients referred with elevated Aspergillus serology markers and marked pulmonary symptoms for ABPA, CPA, and Aspergillus bronchitis, and discussed the underlying pathophysiological relationship with GORD.\n'
p13195
sg4
(lp13196
sg23
(lp13197
(dp13198
g7
I112
sg26
VC0004031
p13199
sg10
I4
sg11
VABPA
p13200
sg13
I1
sa(dp13201
g7
I127
sg26
VC2919277
p13202
sg10
I22
sg11
VAspergillus bronchitis
p13203
sg13
I2
sasa(dp13204
g2
S"Data were collected retrospectively from medical records included age, gender, predisposing factors for ABPA, chronic pulmonary aspergillosis, or Aspergillus bronchitis; presence of nocturnal reflux, nausea, epigastric pain, Medical Research Council dyspnea scale score, pH manometry data, endoscopic results (ulcers, Barrett's esophagus), treatment of GORD [proton-pump inhibitors (PPIs), surgical operation]; history of smoking, alcohol consumption; concomitant COPD; serological markers (anti-Aspergillus IgG, anti-Aspergillus IgE), and antifungal treatment.\n"
p13205
sg4
(lp13206
(dp13207
g7
I513
sg8
VP01854
p13208
sg10
I20
sg11
Vanti-Aspergillus IgE
p13209
sg13
I2
sasg23
(lp13210
(dp13211
g7
I310
sg26
VC0041582
p13212
sg10
I6
sg11
Vulcers
p13213
sg13
I1
sa(dp13214
g7
I200
sg26
VC0027497
p13215
sg10
I6
sg11
Vnausea
p13216
sg13
I1
sa(dp13217
g7
I208
sg26
VC0232493
p13218
sg10
I15
sg11
Vepigastric pain
p13219
sg13
I2
sa(dp13220
g7
I192
sg26
VC0017168
p13221
sg10
I6
sg11
Vreflux
p13222
sg13
I1
sa(dp13223
g7
I530
sg26
VC0270850
p13224
sg10
I3
sg11
VIgE
p13225
sg13
I1
sa(dp13226
g7
I250
sg26
VC0013404
p13227
sg10
I7
sg11
Vdyspnea
p13228
sg13
I1
sa(dp13229
g7
I118
sg26
VC2350529
p13230
sg10
I23
sg11
Vpulmonary aspergillosis
p13231
sg13
I2
sa(dp13232
g7
I464
sg26
VC0024117
p13233
sg10
I4
sg11
VCOPD
p13234
sg13
I1
sa(dp13235
g7
I146
sg26
VC2919277
p13236
sg10
I22
sg11
VAspergillus bronchitis
p13237
sg13
I2
sa(dp13238
g7
I318
sg26
VC0004763
p13239
sg10
I19
sg11
VBarrett's esophagus
p13240
sg13
I2
sa(dp13241
g7
I104
sg26
VC0004031
p13242
sg10
I4
sg11
VABPA
p13243
sg13
I1
sasa(dp13244
g2
S'One had ABPA, one CPA, and two had Aspergillus bronchitis; median age was 57 years [range 39-71]; males-to-females ratio was 1:3.\n'
p13245
sg4
(lp13246
sg23
(lp13247
(dp13248
g7
I8
sg26
VC0004031
p13249
sg10
I4
sg11
VABPA
p13250
sg13
I1
sa(dp13251
g7
I35
sg26
VC2919277
p13252
sg10
I22
sg11
VAspergillus bronchitis
p13253
sg13
I2
sasa(dp13254
g2
S'Apart from the allergic bronchopulmonary aspergillosis (ABPA) and the mycoses caused by mold, there is only sufficient evidence for the following associations between moisture/mold damages and different health effects: Allergic respiratory diseases, asthma (manifestation, progression, exacerbation), allergic rhinitis, exogenous allergic alveolitis and respiratory tract infections/bronchitis.\n'
p13255
sg4
(lp13256
sg23
(lp13257
(dp13258
g7
I383
sg26
VC0006277
p13259
sg10
I10
sg11
Vbronchitis
p13260
sg13
I1
sa(dp13261
g7
I228
sg26
VC0035204
p13262
sg10
I20
sg11
Vrespiratory diseases
p13263
sg13
I2
sa(dp13264
g7
I56
sg26
VC0004031
p13265
sg10
I4
sg11
VABPA
p13266
sg13
I1
sa(dp13267
g7
I301
sg26
VC2607914
p13268
sg10
I17
sg11
Vallergic rhinitis
p13269
sg13
I2
sa(dp13270
g7
I354
sg26
VC0035243
p13271
sg10
I28
sg11
Vrespiratory tract infections
p13272
sg13
I3
sa(dp13273
g7
I15
sg26
VC0004031
p13274
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p13275
sg13
I3
sa(dp13276
g7
I250
sg26
VC0004096
p13277
sg10
I6
sg11
Vasthma
p13278
sg13
I1
sa(dp13279
g7
I70
sg26
VC0026946
p13280
sg10
I7
sg11
Vmycoses
p13281
sg13
I1
sa(dp13282
g7
I330
sg26
VC0002390
p13283
sg10
I19
sg11
Vallergic alveolitis
p13284
sg13
I2
sasa(dp13285
g2
S'can lead to allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitisation and Aspergillus bronchitis in CF.\n'
p13286
sg4
(lp13287
sg23
(lp13288
(dp13289
g7
I12
sg26
VC0004031
p13290
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p13291
sg13
I3
sa(dp13292
g7
I90
sg26
VC2919277
p13293
sg10
I22
sg11
VAspergillus bronchitis
p13294
sg13
I2
sa(dp13295
g7
I53
sg26
VC0004031
p13296
sg10
I4
sg11
VABPA
p13297
sg13
I1
sasa(dp13298
g2
S'Published proportions of ABPA (17.7%), Aspergillus sensitisation (14.6%) and Aspergillus bronchitis (30%) in CF were applied to those &gt;18 years and compared with notified ABPA cases.\n'
p13299
sg4
(lp13300
sg23
(lp13301
(dp13302
g7
I25
sg26
VC0004031
p13303
sg10
I4
sg11
VABPA
p13304
sg13
I1
sa(dp13305
g7
I25
sg26
VC0004031
p13306
sg10
I4
sg11
VABPA
p13307
sg13
I1
sa(dp13308
g7
I77
sg26
VC2919277
p13309
sg10
I22
sg11
VAspergillus bronchitis
p13310
sg13
I2
sasa(dp13311
g2
S'Aspergillus sensitisation, associated with increased bronchiectasis and reduced FEV1, affects an anticipated 5,506 patients without ABPA or Aspergillus bronchitis.\n'
p13312
sg4
(lp13313
sg23
(lp13314
(dp13315
g7
I140
sg26
VC2919277
p13316
sg10
I22
sg11
VAspergillus bronchitis
p13317
sg13
I2
sa(dp13318
g7
I132
sg26
VC0004031
p13319
sg10
I4
sg11
VABPA
p13320
sg13
I1
sa(dp13321
g7
I53
sg26
VC0006267
p13322
sg10
I14
sg11
Vbronchiectasis
p13323
sg13
I1
sasa(dp13324
g2
S'Together ABPA and Aspergillus bronchitis are estimated to affect 17,989 adults, 47.7% of the adult CF population.\n'
p13325
sg4
(lp13326
sg23
(lp13327
(dp13328
g7
I9
sg26
VC0004031
p13329
sg10
I4
sg11
VABPA
p13330
sg13
I1
sa(dp13331
g7
I18
sg26
VC2919277
p13332
sg10
I22
sg11
VAspergillus bronchitis
p13333
sg13
I2
sasa(dp13334
g2
S'Itraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects.\n'
p13335
sg4
(lp13336
sg23
(lp13337
(dp13338
g7
I31
sg26
VC0004031
p13339
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p13340
sg13
I3
sa(dp13341
g7
I81
sg26
VC2919277
p13342
sg10
I22
sg11
VAspergillus bronchitis
p13343
sg13
I2
sa(dp13344
g7
I72
sg26
VC0004031
p13345
sg10
I4
sg11
VABPA
p13346
sg13
I1
sasa(dp13347
g2
S'We selected an average of five serum samples from each of the 17 patients with ABPA (13 proven and 4 probable ABPA) and from 3 patients with Aspergillus bronchitis and rhinosinusitis.\n'
p13348
sg4
(lp13349
sg23
(lp13350
(dp13351
g7
I141
sg26
VC2919277
p13352
sg10
I22
sg11
VAspergillus bronchitis
p13353
sg13
I2
sa(dp13354
g7
I79
sg26
VC0004031
p13355
sg10
I4
sg11
VABPA
p13356
sg13
I1
sa(dp13357
g7
I168
sg26
VC0948780
p13358
sg10
I14
sg11
Vrhinosinusitis
p13359
sg13
I1
sa(dp13360
g7
I79
sg26
VC0004031
p13361
sg10
I4
sg11
VABPA
p13362
sg13
I1
sasa(dp13363
g2
S'Patients were diagnosed with ABPA and Aspergillus bronchitis related to innate immune defects.\n'
p13364
sg4
(lp13365
sg23
(lp13366
(dp13367
g7
I29
sg26
VC0004031
p13368
sg10
I4
sg11
VABPA
p13369
sg13
I1
sa(dp13370
g7
I38
sg26
VC2919277
p13371
sg10
I22
sg11
VAspergillus bronchitis
p13372
sg13
I2
sasa(dp13373
g2
S'Yeasts and filamentous fungi are beginning to emerge as significant microbial pathogens in patients with cystic fibrosis (CF), particularly in relation to allergic-type responses, as seen in patients with allergic bronchopulmonary aspergillosis (ABPA), Aspergillus bronchitis and in invasive fungal disease in lung transplant patients.\n'
p13374
sg4
(lp13375
sg23
(lp13376
(dp13377
g7
I246
sg26
VC0004031
p13378
sg10
I4
sg11
VABPA
p13379
sg13
I1
sa(dp13380
g7
I122
sg26
VC0010674
p13381
sg10
I2
sg11
VCF
p13382
sg13
I1
sa(dp13383
g7
I105
sg26
VC0010674
p13384
sg10
I15
sg11
Vcystic fibrosis
p13385
sg13
I2
sa(dp13386
g7
I253
sg26
VC2919277
p13387
sg10
I22
sg11
VAspergillus bronchitis
p13388
sg13
I2
sa(dp13389
g7
I292
sg26
VC0026946
p13390
sg10
I14
sg11
Vfungal disease
p13391
sg13
I2
sa(dp13392
g7
I205
sg26
VC0004031
p13393
sg10
I39
sg11
Vallergic bronchopulmonary aspergillosis
p13394
sg13
I3
sasa(dp13395
g2
S"On the other hand, a widespread positive reaction for CK 5/8, CK 7, CK 19, and negative reaction for CK 10, was a helpful feature in the differentiation of Paget's disease from Bowen's disease and BAK.\n"
p13396
sg4
(lp13397
(dp13398
g7
I54
sg8
VP02533
p13399
sg10
I6
sg11
VCK 5/8
p13400
sg13
I2
sa(dp13401
g7
I62
sg8
VP08729
p13402
sg10
I4
sg11
VCK 7
p13403
sg13
I2
sa(dp13404
g7
I101
sg8
VP13645
p13405
sg10
I5
sg11
VCK 10
p13406
sg13
I2
sasg23
(lp13407
(dp13408
g7
I177
sg26
VC0006079
p13409
sg10
I15
sg11
VBowen's disease
p13410
sg13
I2
sa(dp13411
g7
I156
sg26
VC0029401
p13412
sg10
I15
sg11
VPaget's disease
p13413
sg13
I2
sasa(dp13414
g2
S'To date, the relation between serum leptin levels of dialysis patients and renal osteodystrophy, defined by histomorphometric and histodynamic parameters of bone, has not been studied.\n'
p13415
sg4
(lp13416
(dp13417
g7
I36
sg8
VP41159
p13418
sg10
I6
sg11
Vleptin
p13419
sg13
I1
sasg23
(lp13420
(dp13421
g7
I75
sg26
VC0035086
p13422
sg10
I20
sg11
Vrenal osteodystrophy
p13423
sg13
I2
sasa(dp13424
g2
S'For 100 years, it has been obvious that Salmonella enterica strains sharing the serotype with the formula 1,4,[5],12:b:1,2-now known as Paratyphi B-can cause diseases ranging from serious systemic infections to self-limiting gastroenteritis.\n'
p13425
sg4
(lp13426
sg23
(lp13427
(dp13428
g7
I225
sg26
VC0017160
p13429
sg10
I15
sg11
Vgastroenteritis
p13430
sg13
I1
sa(dp13431
g7
I40
sg26
VC0036117
p13432
sg10
I10
sg11
VSalmonella
p13433
sg13
I1
sa(dp13434
g7
I188
sg26
VC0243026
p13435
sg10
I19
sg11
Vsystemic infections
p13436
sg13
I2
sasa(dp13437
g2
S'Interestingly, in the case of breast cancer patients, this phenomenon correlated with high expression level of several molecular chaperones belonging to the HSPA, DNAJB and HSPC families.\n'
p13438
sg4
(lp13439
sg23
(lp13440
(dp13441
g7
I30
sg26
VC0678222
p13442
sg10
I13
sg11
Vbreast cancer
p13443
sg13
I2
sasa(dp13444
g2
S'Unexpectedly, conditioning before HSPC infusion was required to protect the mice from lymphoma developing when transplanting small numbers of progenitors.\n'
p13445
sg4
(lp13446
sg23
(lp13447
(dp13448
g7
I86
sg26
VC0024299
p13449
sg10
I8
sg11
Vlymphoma
p13450
sg13
I1
sasa(dp13451
g2
S'Here, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an in vivo-like model system and mouse xenograft model.\n'
p13452
sg4
(lp13453
(dp13454
g7
I70
sg8
VP28906
p13455
sg10
I11
sg11
Vhuman CD34+
p13456
sg13
I2
sasg23
(lp13457
(dp13458
g7
I173
sg26
VC1140680
p13459
sg10
I14
sg11
Vovarian cancer
p13460
sg13
I2
sa(dp13461
g7
I133
sg26
VC0332448
p13462
sg10
I10
sg11
Vinfiltrate
p13463
sg13
I1
sasa(dp13464
g2
S'These CD56+Perforin+ HSPC-NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12, and exerted efficient cytolytic activity and IFNGamma production toward ovarian cancer monolayer cultures.\n'
p13465
sg4
(lp13466
(dp13467
g7
I6
sg8
VP14222
p13468
sg10
I22
sg11
VCD56+Perforin+ HSPC-NK
p13469
sg13
I2
sa(dp13470
g7
I113
sg8
VP40933
p13471
sg10
I5
sg11
VIL-15
p13472
sg13
I1
sasg23
(lp13473
(dp13474
g7
I203
sg26
VC1140680
p13475
sg10
I14
sg11
Vovarian cancer
p13476
sg13
I2
sasa(dp13477
g2
S'Live-imaging confocal microscopy demonstrated that these HSPC-NK cells actively migrate, infiltrate, and mediate tumor cell killing in a three-dimensional multicellular ovarian cancer spheroid.\n'
p13478
sg4
(lp13479
sg23
(lp13480
(dp13481
g7
I113
sg26
VC0027651
p13482
sg10
I5
sg11
Vtumor
p13483
sg13
I1
sa(dp13484
g7
I89
sg26
VC0332448
p13485
sg10
I10
sg11
Vinfiltrate
p13486
sg13
I1
sa(dp13487
g7
I169
sg26
VC1140680
p13488
sg10
I14
sg11
Vovarian cancer
p13489
sg13
I2
sasa(dp13490
g2
S'Furthermore, intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2RGammanull (NSG) mice bearing ovarian carcinoma significantly reduced tumor progression.\n'
p13491
sg4
(lp13492
(dp13493
g7
I59
sg8
VP31785
p13494
sg10
I18
sg11
VSCID-IL2RGammanull
p13495
sg13
I1
sa(dp13496
g7
I55
sg8
VP54259
p13497
sg10
I3
sg11
VNOD
p13498
sg13
I1
sasg23
(lp13499
(dp13500
g7
I97
sg26
VC0029925
p13501
sg10
I17
sg11
Vovarian carcinoma
p13502
sg13
I2
sa(dp13503
g7
I55
sg26
VC0751781
p13504
sg10
I3
sg11
VNOD
p13505
sg13
I1
sa(dp13506
g7
I59
sg26
VC0085110
p13507
sg10
I4
sg11
VSCID
p13508
sg13
I1
sa(dp13509
g7
I137
sg26
VC0178874
p13510
sg10
I17
sg11
Vtumor progression
p13511
sg13
I2
sasa(dp13512
g2
S'These findings demonstrate that highly functional HSPC-NK cells efficiently destruct ovarian carcinoma spheroids in vitro and kill intraperitoneal ovarian tumors in vivo, providing great promise for effective immunotherapy through intraperitoneal HSPC-NK cell adoptive transfer in ovarian carcinoma patients.\n'
p13513
sg4
(lp13514
sg23
(lp13515
(dp13516
g7
I85
sg26
VC0029925
p13517
sg10
I17
sg11
Vovarian carcinoma
p13518
sg13
I2
sa(dp13519
g7
I147
sg26
VC0919267
p13520
sg10
I14
sg11
Vovarian tumors
p13521
sg13
I2
sa(dp13522
g7
I85
sg26
VC0029925
p13523
sg10
I17
sg11
Vovarian carcinoma
p13524
sg13
I2
sasa(dp13525
g2
S'Treatment with vitamin C, a co-factor of Fe2+ and Alfa-KG-dependent dioxygenases, mimics TET2 restoration by enhancing 5-hydroxymethylcytosine formation in Tet2-deficient mouse HSPCs and suppresses human leukemic colony formation and leukemia progression of primary human leukemia PDXs.\n'
p13526
sg4
(lp13527
(dp13528
g7
I156
sg8
g107
sg10
I26
sg11
VTet2-deficient mouse HSPCs
p13529
sg13
I3
sa(dp13530
g7
I89
sg8
g107
sg10
I4
sg11
VTET2
p13531
sg13
I1
sasg23
(lp13532
(dp13533
g7
I234
sg26
VC0023418
p13534
sg10
I8
sg11
Vleukemia
p13535
sg13
I1
sa(dp13536
g7
I234
sg26
VC0023418
p13537
sg10
I8
sg11
Vleukemia
p13538
sg13
I1
sasa(dp13539
g2
S'We quantified extracellular IL-16 protein (ELISA) and intracellular IL-16 in NK cells, T-cells, B-cells, and monocytes (flow cytometry) in blood samples from long-term tobacco smokers with and without chronic obstructive pulmonary disease (COPD) and in never-smokers.\n'
p13540
sg4
(lp13541
(dp13542
g7
I14
sg8
g107
sg10
I27
sg11
Vextracellular IL-16 protein
p13543
sg13
I3
sa(dp13544
g7
I28
sg8
g107
sg10
I5
sg11
VIL-16
p13545
sg13
I1
sasg23
(lp13546
(dp13547
g7
I240
sg26
VC0024117
p13548
sg10
I4
sg11
VCOPD
p13549
sg13
I1
sa(dp13550
g7
I201
sg26
VC0024117
p13551
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13552
sg13
I4
sasa(dp13553
g2
S'In asthmatic children with positive ETC, monocyte hemotactic protein-1 (MCP-1) and IL-16 adjusted to pre-EBC forced expiratory volume in 1 s (FEV1) were significantly higher compared to children with negative ETC (p = 0.022 and p = 0.017 respectively).\n'
p13554
sg4
(lp13555
(dp13556
g7
I83
sg8
g107
sg10
I5
sg11
VIL-16
p13557
sg13
I1
sa(dp13558
g7
I72
sg8
VP41597
p13559
sg10
I5
sg11
VMCP-1
p13560
sg13
I1
sa(dp13561
g7
I36
sg8
VP17980
p13562
sg10
I34
sg11
VETC, monocyte hemotactic protein-1
p13563
sg13
I4
sasg23
(lp13564
(dp13565
g7
I3
sg26
VC0004096
p13566
sg10
I9
sg11
Vasthmatic
p13567
sg13
I1
sasa(dp13568
g2
S'Compared with the control group, silica dust exposed group, the observation group of objects, the pneumosilicosis patients of IL-16 in induced sputum IL-16 (21.40 +/- 9.24) decreased, the content of PDGF [(5.96 +/- 0.51) ng/L], MMP-2 [(447.86 +/- 27.10) ng/L], MMP-9 [(223.91 +/- 12.28) ng/L], MCP-1 [(122.87 +/- 6.08) ng/L] increased, the differences are statistically significant (P &lt; 0.05).\n'
p13569
sg4
(lp13570
(dp13571
g7
I294
sg8
VP41597
p13572
sg10
I5
sg11
VMCP-1
p13573
sg13
I1
sa(dp13574
g7
I126
sg8
g107
sg10
I5
sg11
VIL-16
p13575
sg13
I1
sa(dp13576
g7
I228
sg8
VP08253
p13577
sg10
I5
sg11
VMMP-2
p13578
sg13
I1
sa(dp13579
g7
I261
sg8
VP14780
p13580
sg10
I5
sg11
VMMP-9
p13581
sg13
I1
sa(dp13582
g7
I199
sg8
VP04085
p13583
sg10
I4
sg11
VPDGF
p13584
sg13
I1
sa(dp13585
g7
I143
sg8
g107
sg10
I12
sg11
Vsputum IL-16
p13586
sg13
I2
sasg23
(lp13587
sa(dp13588
g2
S'As silicosis biomarkers, TNF-alpha, TGF-beta, IL-16, PDGF, MMP-2, MMP-9 and MCP-1 have certain significance, further suggesting that early detection rate of patients with silicosis can be improved by employing the multiple indexes discriminate equation.\n'
p13589
sg4
(lp13590
(dp13591
g7
I66
sg8
VP14780
p13592
sg10
I5
sg11
VMMP-9
p13593
sg13
I1
sa(dp13594
g7
I53
sg8
VP04085
p13595
sg10
I4
sg11
VPDGF
p13596
sg13
I1
sa(dp13597
g7
I46
sg8
g107
sg10
I5
sg11
VIL-16
p13598
sg13
I1
sa(dp13599
g7
I25
sg8
VP01375
p13600
sg10
I9
sg11
VTNF-alpha
p13601
sg13
I1
sa(dp13602
g7
I59
sg8
VP08253
p13603
sg10
I5
sg11
VMMP-2
p13604
sg13
I1
sa(dp13605
g7
I76
sg8
VP41597
p13606
sg10
I5
sg11
VMCP-1
p13607
sg13
I1
sa(dp13608
g7
I36
sg8
VP18075
p13609
sg10
I8
sg11
VTGF-beta
p13610
sg13
I1
sasg23
(lp13611
(dp13612
g7
I3
sg26
VC0037116
p13613
sg10
I9
sg11
Vsilicosis
p13614
sg13
I1
sa(dp13615
g7
I3
sg26
VC0037116
p13616
sg10
I9
sg11
Vsilicosis
p13617
sg13
I1
sasa(dp13618
g2
S'By contrast, compared to eosinophil-normal asthma (eosinophils&lt;=0.3%), eosinophil-high asthma (eosinophils&gt;0.3%) had higher levels of IL-5, IL-13, IL-16, and PDGF-bb, but same neutrophil percentage, IL-8, and FEV1.\n'
p13619
sg4
(lp13620
(dp13621
g7
I146
sg8
VP35225
p13622
sg10
I5
sg11
VIL-13
p13623
sg13
I1
sa(dp13624
g7
I164
sg8
VP04085
p13625
sg10
I7
sg11
VPDGF-bb
p13626
sg13
I1
sa(dp13627
g7
I153
sg8
g107
sg10
I5
sg11
VIL-16
p13628
sg13
I1
sa(dp13629
g7
I140
sg8
VP05113
p13630
sg10
I4
sg11
VIL-5
p13631
sg13
I1
sasg23
(lp13632
(dp13633
g7
I43
sg26
VC0004096
p13634
sg10
I6
sg11
Vasthma
p13635
sg13
I1
sa(dp13636
g7
I43
sg26
VC0004096
p13637
sg10
I6
sg11
Vasthma
p13638
sg13
I1
sasa(dp13639
g2
S'Here, we demonstrate that DRG1 is elevated in lung adenocarcinomas while weakly expressed in adjacent lung tissues.\n'
p13640
sg4
(lp13641
(dp13642
g7
I26
sg8
VP55039
p13643
sg10
I4
sg11
VDRG1
p13644
sg13
I1
sasg23
(lp13645
(dp13646
g7
I51
sg26
VC0001418
p13647
sg10
I15
sg11
Vadenocarcinomas
p13648
sg13
I1
sasa(dp13649
g2
S'To this end, we describe the identification of developmentally regulated GTP-binding protein 1 (DRG-1) as a melanoma-associated antigen recognized by HLA-DR11-restricted CD4(+) Th1 cells.\n'
p13650
sg4
(lp13651
(dp13652
g7
I96
sg8
g107
sg10
I5
sg11
VDRG-1
p13653
sg13
I1
sa(dp13654
g7
I150
sg8
VP30486
p13655
sg10
I8
sg11
VHLA-DR11
p13656
sg13
I1
sa(dp13657
g7
I108
sg8
VP08962
p13658
sg10
I27
sg11
Vmelanoma-associated antigen
p13659
sg13
I2
sa(dp13660
g7
I47
sg8
g107
sg10
I47
sg11
Vdevelopmentally regulated GTP-binding protein 1
p13661
sg13
I5
sa(dp13662
g7
I170
sg8
VP01730
p13663
sg10
I3
sg11
VCD4
p13664
sg13
I1
sasg23
(lp13665
(dp13666
g7
I108
sg26
VC0025202
p13667
sg10
I8
sg11
Vmelanoma
p13668
sg13
I1
sasa(dp13669
g2
S'Reverse transcription-polymerase chain reaction revealed that DRG-1 was highly expressed in melanoma cell lines but not in normal tissues.\n'
p13670
sg4
(lp13671
(dp13672
g7
I62
sg8
g107
sg10
I5
sg11
VDRG-1
p13673
sg13
I1
sasg23
(lp13674
(dp13675
g7
I92
sg26
VC0025202
p13676
sg10
I8
sg11
Vmelanoma
p13677
sg13
I1
sasa(dp13678
g2
S'DRG-1 knockdown by lentiviral-based shRNA suppressed melanoma cell proliferation and soft agar colony formation.\n'
p13679
sg4
(lp13680
sg23
(lp13681
(dp13682
g7
I67
sg26
VC0334094
p13683
sg10
I13
sg11
Vproliferation
p13684
sg13
I1
sa(dp13685
g7
I53
sg26
VC0025202
p13686
sg10
I8
sg11
Vmelanoma
p13687
sg13
I1
sasa(dp13688
g2
S'Taken together, these data suggest that DRG-1 plays an important role in melanoma cell growth and transformation, indicating that DRG1 may represent a novel target for CD4(+) T cell-mediated immunotherapy in melanoma.\n'
p13689
sg4
(lp13690
(dp13691
g7
I168
sg8
VP01730
p13692
sg10
I3
sg11
VCD4
p13693
sg13
I1
sa(dp13694
g7
I40
sg8
g107
sg10
I5
sg11
VDRG-1
p13695
sg13
I1
sa(dp13696
g7
I130
sg8
VP55039
p13697
sg10
I4
sg11
VDRG1
p13698
sg13
I1
sasg23
(lp13699
(dp13700
g7
I98
sg26
VC1510411
p13701
sg10
I14
sg11
Vtransformation
p13702
sg13
I1
sa(dp13703
g7
I73
sg26
VC0025202
p13704
sg10
I8
sg11
Vmelanoma
p13705
sg13
I1
sa(dp13706
g7
I73
sg26
VC0025202
p13707
sg10
I8
sg11
Vmelanoma
p13708
sg13
I1
sasa(dp13709
g2
S'FBXW7 mRNA was identified as a direct target of miR-155 in glioma.\n'
p13710
sg4
(lp13711
(dp13712
g7
I0
sg8
g107
sg10
I10
sg11
VFBXW7 mRNA
p13713
sg13
I2
sasg23
(lp13714
(dp13715
g7
I59
sg26
VC0017638
p13716
sg10
I6
sg11
Vglioma
p13717
sg13
I1
sasa(dp13718
g2
S'Finally, we found that MALAT1 positively regulated FBXW7 expression, which was responsible for glioma progression mediated by MALAT1-miR-155 pathway.\n'
p13719
sg4
(lp13720
(dp13721
g7
I51
sg8
g107
sg10
I5
sg11
VFBXW7
p13722
sg13
I1
sa(dp13723
g7
I23
sg8
g107
sg10
I6
sg11
VMALAT1
p13724
sg13
I1
sa(dp13725
g7
I126
sg8
g107
sg10
I10
sg11
VMALAT1-miR
p13726
sg13
I1
sasg23
(lp13727
(dp13728
g7
I95
sg26
VC0017638
p13729
sg10
I6
sg11
Vglioma
p13730
sg13
I1
sasa(dp13731
g2
S'Besides those, Fbxw7 activity is controlled at different levels, resulting in specific and tunable regulation of the abundance and activity of its substrates in a variety of human solid tumor types, including glioma malignancy, nasopharyngeal carcinoma, osteosarcoma, melanoma as well as colorectal, lung, breast, gastric, liver, pancreatic, renal, prostate, endometrial, and esophageal cancers.\n'
p13732
sg4
(lp13733
(dp13734
g7
I15
sg8
g107
sg10
I5
sg11
VFbxw7
p13735
sg13
I1
sasg23
(lp13736
(dp13737
g7
I376
sg26
VC0546837
p13738
sg10
I18
sg11
Vesophageal cancers
p13739
sg13
I2
sa(dp13740
g7
I216
sg26
VC0006826
p13741
sg10
I10
sg11
Vmalignancy
p13742
sg13
I1
sa(dp13743
g7
I228
sg26
VC2931822
p13744
sg10
I24
sg11
Vnasopharyngeal carcinoma
p13745
sg13
I2
sa(dp13746
g7
I209
sg26
VC0017638
p13747
sg10
I6
sg11
Vglioma
p13748
sg13
I1
sa(dp13749
g7
I268
sg26
VC0025202
p13750
sg10
I8
sg11
Vmelanoma
p13751
sg13
I1
sa(dp13752
g7
I254
sg26
VC0029463
p13753
sg10
I12
sg11
Vosteosarcoma
p13754
sg13
I1
sa(dp13755
g7
I180
sg26
VC0280100
p13756
sg10
I11
sg11
Vsolid tumor
p13757
sg13
I2
sasa(dp13758
g2
S'Subsequently, miR-15/16 activities are reduced and many of their direct targets are de-repressed, including ubiquitin ligase FBXW7 that destabilizes Cyclin E. Conversely, GBM cells expressing low p21 level, or after p21 knock-down, exhibit weaker or no E2F1 response to miR-10b inhibition.\n'
p13759
sg4
(lp13760
(dp13761
g7
I270
sg8
g107
sg10
I7
sg11
VmiR-10b
p13762
sg13
I1
sa(dp13763
g7
I14
sg8
g107
sg10
I9
sg11
VmiR-15/16
p13764
sg13
I1
sa(dp13765
g7
I108
sg8
g107
sg10
I22
sg11
Vubiquitin ligase FBXW7
p13766
sg13
I3
sa(dp13767
g7
I196
sg8
VP42857
p13768
sg10
I3
sg11
Vp21
p13769
sg13
I1
sa(dp13770
g7
I253
sg8
g107
sg10
I4
sg11
VE2F1
p13771
sg13
I1
sa(dp13772
g7
I216
sg8
VP42857
p13773
sg10
I9
sg11
Vp21 knock
p13774
sg13
I2
sa(dp13775
g7
I149
sg8
VP24864
p13776
sg10
I8
sg11
VCyclin E
p13777
sg13
I2
sasg23
(lp13778
(dp13779
g7
I171
sg26
VC0017636
p13780
sg10
I3
sg11
VGBM
p13781
sg13
I1
sasa(dp13782
g2
S'Notch pathway genes are overexpressed in ependymomas and gliomas along with FBXW7 downregulation.\n'
p13783
sg4
(lp13784
(dp13785
g7
I0
sg8
VP01893
p13786
sg10
I19
sg11
VNotch pathway genes
p13787
sg13
I3
sa(dp13788
g7
I76
sg8
g107
sg10
I5
sg11
VFBXW7
p13789
sg13
I1
sasg23
(lp13790
(dp13791
g7
I41
sg26
VC0014474
p13792
sg10
I11
sg11
Vependymomas
p13793
sg13
I1
sa(dp13794
g7
I57
sg26
VC0017638
p13795
sg10
I7
sg11
Vgliomas
p13796
sg13
I1
sasa(dp13797
g2
S'We propose that p53 mutations contribute to gliomagenesis by both allowing the overexpression of c-Myc through downregulation of Fbxw7 and by protecting against c-Myc-induced apoptosis.\n'
p13798
sg4
(lp13799
(dp13800
g7
I16
sg8
VP42771
p13801
sg10
I13
sg11
Vp53 mutations
p13802
sg13
I2
sa(dp13803
g7
I97
sg8
VP12524
p13804
sg10
I5
sg11
Vc-Myc
p13805
sg13
I1
sa(dp13806
g7
I129
sg8
g107
sg10
I5
sg11
VFbxw7
p13807
sg13
I1
sa(dp13808
g7
I97
sg8
VP12524
p13809
sg10
I5
sg11
Vc-Myc
p13810
sg13
I1
sasg23
(lp13811
sa(dp13812
g2
S'PMD is located adjacent and medial to the nucleus prepositus hypoglossi (PH) in the dorsal medulla and is distinguished by the pattern of immunoreactivity of cells and fibers to several markers including calcium-binding proteins, a synthetic enzyme for nitric oxide (neuronal nitric oxide synthase, nNOS) and a nonphosphorylated neurofilament protein (antibody SMI-32).\n'
p13813
sg4
(lp13814
(dp13815
g7
I42
sg8
VP61457
p13816
sg10
I29
sg11
Vnucleus prepositus hypoglossi
p13817
sg13
I3
sa(dp13818
g7
I299
sg8
VP29475
p13819
sg10
I4
sg11
VnNOS
p13820
sg13
I1
sasg23
(lp13821
(dp13822
g7
I0
sg26
VC1832661
p13823
sg10
I3
sg11
VPMD
p13824
sg13
I1
sasa(dp13825
g2
S'Cells in PMD are also immunoreactive to nNOS, and immunoreactivity to a neurofilament protein shows many labeled cells and fibers.\n'
p13826
sg4
(lp13827
(dp13828
g7
I40
sg8
VP29475
p13829
sg10
I4
sg11
VnNOS
p13830
sg13
I1
sasg23
(lp13831
(dp13832
g7
I9
sg26
VC1832661
p13833
sg10
I3
sg11
VPMD
p13834
sg13
I1
sasa(dp13835
g2
S'Regardless of the type of surgery (PRE-OP, POS-OP1, POS-OP2), the prevalence of periodontitis proved to be high (81.45%).\n'
p13836
sg4
(lp13837
(dp13838
g7
I43
sg8
VP18075
p13839
sg10
I7
sg11
VPOS-OP1
p13840
sg13
I1
sa(dp13841
g7
I52
sg8
VP34820
p13842
sg10
I7
sg11
VPOS-OP2
p13843
sg13
I1
sasg23
(lp13844
(dp13845
g7
I80
sg26
VC0031099
p13846
sg10
I13
sg11
Vperiodontitis
p13847
sg13
I1
sasa(dp13848
g2
S'There was a statistically significant difference in the prevalence of periodontitis among the PRE-OP, POS-OP1, and POS-OP2 groups (P = 0.040).\n'
p13849
sg4
(lp13850
(dp13851
g7
I94
sg8
VP58743
p13852
sg10
I6
sg11
VPRE-OP
p13853
sg13
I1
sa(dp13854
g7
I102
sg8
VP18075
p13855
sg10
I7
sg11
VPOS-OP1
p13856
sg13
I1
sasg23
(lp13857
(dp13858
g7
I70
sg26
VC0031099
p13859
sg10
I13
sg11
Vperiodontitis
p13860
sg13
I1
sasa(dp13861
g2
S'Long-term studies with gamma-irradiated 0.5 and 2.5mg hOP-1 per gram of xenogeneic bovine collagenous matrix induce the restitutio ad integrum of the periodontal tissues in furcation defects exposed by chronic periodontitis in P. ursinus.\n'
p13862
sg4
(lp13863
sg23
(lp13864
(dp13865
g7
I173
sg26
VC0206306
p13866
sg10
I17
sg11
Vfurcation defects
p13867
sg13
I2
sa(dp13868
g7
I202
sg26
VC0266929
p13869
sg10
I21
sg11
Vchronic periodontitis
p13870
sg13
I2
sasa(dp13871
g2
S'Bone morphogenetic protein-7 (BMP 7) induces cementogenesis in periodontitis-associated periodontal ligament (PDL) defects.\n'
p13872
sg4
(lp13873
(dp13874
g7
I0
sg8
VP18075
p13875
sg10
I28
sg11
VBone morphogenetic protein-7
p13876
sg13
I3
sa(dp13877
g7
I30
sg8
VP18075
p13878
sg10
I5
sg11
VBMP 7
p13879
sg13
I2
sasg23
(lp13880
(dp13881
g7
I63
sg26
VC0031099
p13882
sg10
I13
sg11
Vperiodontitis
p13883
sg13
I1
sasa(dp13884
g2
S'Both KRT19 and ANXA8 mRNA may be useful markers for detecting lymph node metastases in OSCC patients.\n'
p13885
sg4
(lp13886
(dp13887
g7
I15
sg8
VP13928
p13888
sg10
I10
sg11
VANXA8 mRNA
p13889
sg13
I2
sasg23
(lp13890
(dp13891
g7
I62
sg26
VC0686619
p13892
sg10
I21
sg11
Vlymph node metastases
p13893
sg13
I3
sasa(dp13894
g2
S'The clinical data of 98 cases of epidermal growth factor receptor (EGFR), kirsten rat sarcoma viral oncogene (KRAS), V-rafmurine sarcoma viral oncogene homolog B1 (BRAF)-negative patients with advanced lung adenocarcinoma patients who diagnosed by histopathology from January 2015 to April 2016 in the First Affiliated Hospital of Zhengzhou University were collected.\n'
p13895
sg4
(lp13896
(dp13897
g7
I110
sg8
VP01116
p13898
sg10
I4
sg11
VKRAS
p13899
sg13
I1
sa(dp13900
g7
I33
sg8
VP01133
p13901
sg10
I32
sg11
Vepidermal growth factor receptor
p13902
sg13
I4
sa(dp13903
g7
I74
sg8
VP35125
p13904
sg10
I34
sg11
Vkirsten rat sarcoma viral oncogene
p13905
sg13
I5
sa(dp13906
g7
I164
sg8
VP15056
p13907
sg10
I4
sg11
VBRAF
p13908
sg13
I1
sa(dp13909
g7
I117
sg8
VP35125
p13910
sg10
I45
sg11
VV-rafmurine sarcoma viral oncogene homolog B1
p13911
sg13
I6
sa(dp13912
g7
I67
sg8
VP01133
p13913
sg10
I4
sg11
VEGFR
p13914
sg13
I1
sasg23
(lp13915
(dp13916
g7
I202
sg26
VC0152013
p13917
sg10
I19
sg11
Vlung adenocarcinoma
p13918
sg13
I2
sa(dp13919
g7
I86
sg26
VC1261473
p13920
sg10
I7
sg11
Vsarcoma
p13921
sg13
I1
sa(dp13922
g7
I82
sg26
VC1882848
p13923
sg10
I11
sg11
Vrat sarcoma
p13924
sg13
I2
sasa(dp13925
g2
S'##### ######## (anaplastic lymphoma kinase, ALK) ####### (non-small cell lung cancer, NSCLC) #########, ###########ALK##################################ALK################# ###############2015#1#-2016#4##########98######### (epidermal growth factor receptor, EGFR) ########## (kirsten rat sarcoma viral oncogene, KRAS) ###############B1 (V-rafmurine sarcoma viral oncogene homolog B1, BRAF) ####################ALK####################### (progression-free survival, PFS) ######## 98#######ALK####, ALK######34# (34.7%) , #######64# (65.3%) #####################, ##### (objective response rate, ORR) #21.4%, ##### (disease control rate, DCR) #84.7%#ALK########ORR#DCR####### (41.2% vs 10.9%, X2=23.389, P&lt;0.001; 91.2% vs 81.3%, X2=4.153, P=0.042) , #########ALK##########################ALK########PFS#7.1## (95%CI: 6.1-8.1) , ##4.7## (95%CI: 3.818-5.582) , ###PFS######## (X2=13.269, P&lt;0.001) #Cox#####################PFS###########################, ALK#######PFS####### (HR=0.392, 95%CI: 0.243-0.634, P&lt;0.001) ### ALK####ALK###############################.\n'
p13926
sg4
(lp13927
(dp13928
g7
I44
sg8
g107
sg10
I3
sg11
VALK
p13929
sg13
I1
sa(dp13930
g7
I338
sg8
VP35125
p13931
sg10
I45
sg11
VV-rafmurine sarcoma viral oncogene homolog B1
p13932
sg13
I6
sa(dp13933
g7
I225
sg8
VP01133
p13934
sg10
I32
sg11
Vepidermal growth factor receptor
p13935
sg13
I4
sa(dp13936
g7
I44
sg8
g107
sg10
I3
sg11
VALK
p13937
sg13
I1
sa(dp13938
g7
I385
sg8
VP15056
p13939
sg10
I4
sg11
VBRAF
p13940
sg13
I1
sa(dp13941
g7
I313
sg8
VP01116
p13942
sg10
I4
sg11
VKRAS
p13943
sg13
I1
sasg23
(lp13944
(dp13945
g7
I16
sg26
VC1321546
p13946
sg10
I19
sg11
Vanaplastic lymphoma
p13947
sg13
I2
sa(dp13948
g7
I289
sg26
VC1261473
p13949
sg10
I7
sg11
Vsarcoma
p13950
sg13
I1
sa(dp13951
g7
I285
sg26
VC1882848
p13952
sg10
I11
sg11
Vrat sarcoma
p13953
sg13
I2
sa(dp13954
g7
I58
sg26
VC0007131
p13955
sg10
I26
sg11
Vnon-small cell lung cancer
p13956
sg13
I4
sa(dp13957
g7
I86
sg26
VC0007131
p13958
sg10
I5
sg11
VNSCLC
p13959
sg13
I1
sasa(dp13960
g2
S'None of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation.\n'
p13961
sg4
(lp13962
(dp13963
g7
I161
sg8
g107
sg10
I32
sg11
Vtelomerase reverse transcriptase
p13964
sg13
I3
sa(dp13965
g7
I39
sg8
VP48735
p13966
sg10
I26
sg11
Visocitrate dehydrogenase 1
p13967
sg13
I3
sa(dp13968
g7
I136
sg8
VP15056
p13969
sg10
I4
sg11
VBRAF
p13970
sg13
I1
sa(dp13971
g7
I67
sg8
g107
sg10
I4
sg11
VIDH1
p13972
sg13
I1
sa(dp13973
g7
I195
sg8
g107
sg10
I4
sg11
VTERT
p13974
sg13
I1
sa(dp13975
g7
I12
sg8
VP21359
p13976
sg10
I17
sg11
VNF1 glioblastomas
p13977
sg13
I2
sa(dp13978
g7
I88
sg8
VP15056
p13979
sg10
I46
sg11
Vv-RAF murine sarcoma viral oncogene homolog B1
p13980
sg13
I7
sasg23
(lp13981
(dp13982
g7
I101
sg26
VC1261473
p13983
sg10
I7
sg11
Vsarcoma
p13984
sg13
I1
sa(dp13985
g7
I12
sg26
VC0027831
p13986
sg10
I3
sg11
VNF1
p13987
sg13
I1
sa(dp13988
g7
I16
sg26
VC0017636
p13989
sg10
I13
sg11
Vglioblastomas
p13990
sg13
I1
sasa(dp13991
g2
S'Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.\n'
p13992
sg4
(lp13993
(dp13994
g7
I55
sg8
VP15056
p13995
sg10
I4
sg11
VBRAF
p13996
sg13
I1
sa(dp13997
g7
I0
sg8
VP04049
p13998
sg10
I53
sg11
VSomatic v-Raf murine sarcoma viral oncogene homolog B
p13999
sg13
I8
sasg23
(lp14000
(dp14001
g7
I21
sg26
VC1261473
p14002
sg10
I7
sg11
Vsarcoma
p14003
sg13
I1
sa(dp14004
g7
I133
sg26
VC0948380
p14005
sg10
I4
sg11
VmCRC
p14006
sg13
I1
sa(dp14007
g7
I103
sg26
VC0948380
p14008
sg10
I28
sg11
Vmetastatic colorectal cancer
p14009
sg13
I3
sasa(dp14010
g2
S'All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.\n'
p14011
sg4
(lp14012
(dp14013
g7
I42
sg8
VP15056
p14014
sg10
I4
sg11
VBRAF
p14015
sg13
I1
sasg23
(lp14016
(dp14017
g7
I4
sg26
VC1527249
p14018
sg10
I17
sg11
Vcolorectal cancer
p14019
sg13
I2
sasa(dp14020
g2
S'We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.\n'
p14021
sg4
(lp14022
(dp14023
g7
I333
sg8
VP15056
p14024
sg10
I4
sg11
VBRAF
p14025
sg13
I1
sa(dp14026
g7
I241
sg8
VP29401
p14027
sg10
I44
sg11
VROS1 proto-oncogene receptor tyrosine kinase
p14028
sg13
I5
sa(dp14029
g7
I200
sg8
VP01133
p14030
sg10
I4
sg11
VEGFR
p14031
sg13
I1
sa(dp14032
g7
I241
sg8
VP08922
p14033
sg10
I4
sg11
VROS1
p14034
sg13
I1
sa(dp14035
g7
I166
sg8
VP01133
p14036
sg10
I32
sg11
Vepidermal growth factor receptor
p14037
sg13
I4
sa(dp14038
g7
I294
sg8
VP15056
p14039
sg10
I37
sg11
Vserine/threonine-protein kinase b-raf
p14040
sg13
I3
sa(dp14041
g7
I235
sg8
g107
sg10
I3
sg11
VALK
p14042
sg13
I1
sa(dp14043
g7
I207
sg8
g107
sg10
I26
sg11
Vanaplastic lymphoma kinase
p14044
sg13
I3
sasg23
(lp14045
(dp14046
g7
I207
sg26
VC1321546
p14047
sg10
I19
sg11
Vanaplastic lymphoma
p14048
sg13
I2
sa(dp14049
g7
I104
sg26
VC0007131
p14050
sg10
I5
sg11
VNSCLC
p14051
sg13
I1
sasa(dp14052
g2
S'Here, we investigated the response of normal human keratinocytes to the MEK inhibitors trametinib and cobimetinib, alone and in combination with the v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors dabrafenib and vemurafenib, in terms of signal transduction and de novo gene expression.\n'
p14053
sg4
(lp14054
(dp14055
g7
I196
sg8
VP15056
p14056
sg10
I4
sg11
VBRAF
p14057
sg13
I1
sa(dp14058
g7
I149
sg8
VP04049
p14059
sg10
I45
sg11
Vv-Raf murine sarcoma viral oncogene homolog B
p14060
sg13
I7
sa(dp14061
g7
I72
sg8
VP45985
p14062
sg10
I3
sg11
VMEK
p14063
sg13
I1
sasg23
(lp14064
(dp14065
g7
I162
sg26
VC1261473
p14066
sg10
I7
sg11
Vsarcoma
p14067
sg13
I1
sasa(dp14068
g2
S'The prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.\n'
p14069
sg4
(lp14070
(dp14071
g7
I45
sg8
VP15056
p14072
sg10
I92
sg11
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p14073
sg13
I13
sasg23
(lp14074
(dp14075
g7
I132
sg26
VC0948380
p14076
sg10
I4
sg11
VmCRC
p14077
sg13
I1
sa(dp14078
g7
I102
sg26
VC0948380
p14079
sg10
I28
sg11
Vmetastatic colorectal cancer
p14080
sg13
I3
sa(dp14081
g7
I58
sg26
VC1261473
p14082
sg10
I7
sg11
Vsarcoma
p14083
sg13
I1
sasa(dp14084
g2
S'Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF mutational status was assayed using direct sequencing.\n'
p14085
sg4
(lp14086
(dp14087
g7
I104
sg8
VP15056
p14088
sg10
I4
sg11
VBRAF
p14089
sg13
I1
sa(dp14090
g7
I51
sg8
VP01116
p14091
sg10
I40
sg11
Vneuroblastoma RAS viral oncogene homolog
p14092
sg13
I5
sa(dp14093
g7
I0
sg8
VP35125
p14094
sg10
I42
sg11
VKirsten rat sarcoma viral oncogene homolog
p14095
sg13
I6
sa(dp14096
g7
I93
sg8
VP01111
p14097
sg10
I4
sg11
VNRAS
p14098
sg13
I1
sa(dp14099
g7
I44
sg8
VP01116
p14100
sg10
I4
sg11
VKRAS
p14101
sg13
I1
sasg23
(lp14102
(dp14103
g7
I51
sg26
VC0027819
p14104
sg10
I13
sg11
Vneuroblastoma
p14105
sg13
I1
sa(dp14106
g7
I8
sg26
VC1882848
p14107
sg10
I11
sg11
Vrat sarcoma
p14108
sg13
I2
sasa(dp14109
g2
S"We performed an unbiased CRISPR-Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/threonine-protein kinase BRAF, in order to functionally mine their genome for 'addiction genes'.\n"
p14110
sg4
(lp14111
(dp14112
g7
I130
sg8
g107
sg10
I31
sg11
Vserine/threonine-protein kinase
p14113
sg13
I2
sa(dp14114
g7
I162
sg8
VP15056
p14115
sg10
I4
sg11
VBRAF
p14116
sg13
I1
sasg23
(lp14117
(dp14118
g7
I56
sg26
VC0025202
p14119
sg10
I8
sg11
Vmelanoma
p14120
sg13
I1
sa(dp14121
g7
I215
sg26
VC0085281
p14122
sg10
I10
sg11
V'addiction
p14123
sg13
I1
sasa(dp14124
g2
S'In patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch.\n'
p14125
sg4
(lp14126
(dp14127
g7
I150
sg8
VP29401
p14128
sg10
I24
sg11
Vreceptor tyrosine kinase
p14129
sg13
I3
sa(dp14130
g7
I70
sg8
VP15056
p14131
sg10
I4
sg11
VBRAF
p14132
sg13
I1
sa(dp14133
g7
I175
sg8
VP30530
p14134
sg10
I3
sg11
VAXL
p14135
sg13
I1
sasg23
(lp14136
(dp14137
g7
I17
sg26
VC0025202
p14138
sg10
I8
sg11
Vmelanoma
p14139
sg13
I1
sasa(dp14140
g2
S'v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors.\n'
p14141
sg4
(lp14142
(dp14143
g7
I0
sg8
VP15056
p14144
sg10
I46
sg11
Vv-raf murine sarcoma viral oncogene homolog B1
p14145
sg13
I7
sa(dp14146
g7
I48
sg8
VP15056
p14147
sg10
I4
sg11
VBRAF
p14148
sg13
I1
sa(dp14149
g7
I48
sg8
VP15056
p14150
sg10
I4
sg11
VBRAF
p14151
sg13
I1
sa(dp14152
g7
I136
sg8
VP53779
p14153
sg10
I32
sg11
Vmitogen-activated protein kinase
p14154
sg13
I3
sasg23
(lp14155
(dp14156
g7
I13
sg26
VC1261473
p14157
sg10
I7
sg11
Vsarcoma
p14158
sg13
I1
sa(dp14159
g7
I54
sg26
VC0596988
p14160
sg10
I6
sg11
Vmutant
p14161
sg13
I1
sa(dp14162
g7
I95
sg26
VC0206716
p14163
sg10
I14
sg11
Vgangliogliomas
p14164
sg13
I1
sasa(dp14165
g2
S'Mutations in the proto-oncogene B-raf (BRAF) occur in approximately 3% of NSCLC cases.\n'
p14166
sg4
(lp14167
(dp14168
g7
I39
sg8
VP15056
p14169
sg10
I4
sg11
VBRAF
p14170
sg13
I1
sa(dp14171
g7
I17
sg8
VP15056
p14172
sg10
I20
sg11
Vproto-oncogene B-raf
p14173
sg13
I2
sasg23
(lp14174
(dp14175
g7
I74
sg26
VC0007131
p14176
sg10
I5
sg11
VNSCLC
p14177
sg13
I1
sasa(dp14178
g2
S'To our knowledge, this is only the second well-documented case of gastrointestinal metastasis from BRAF-mutated lung cancer.\n'
p14179
sg4
(lp14180
sg23
(lp14181
(dp14182
g7
I83
sg26
VC0027627
p14183
sg10
I10
sg11
Vmetastasis
p14184
sg13
I1
sa(dp14185
g7
I112
sg26
VC0684249
p14186
sg10
I11
sg11
Vlung cancer
p14187
sg13
I2
sasa(dp14188
g2
S'For example, "Mongolism" was changed to Down\'s syndrome; "Australia" antigen to HBsAg; "Mexican" Swine flu to H1N1; "GRID" (Gay Related Immune Deficiency) and 4H-Disease (Haitians, Homosexuals, Haemophiliacs and Heroin Users Disease) to AIDS.\n'
p14189
sg4
(lp14190
sg23
(lp14191
(dp14192
g7
I40
sg26
VC0013080
p14193
sg10
I15
sg11
VDown's syndrome
p14194
sg13
I2
sa(dp14195
g7
I14
sg26
VC0013080
p14196
sg10
I9
sg11
VMongolism
p14197
sg13
I1
sa(dp14198
g7
I97
sg26
VC2076600
p14199
sg10
I9
sg11
VSwine flu
p14200
sg13
I2
sa(dp14201
g7
I136
sg26
VC0850497
p14202
sg10
I17
sg11
VImmune Deficiency
p14203
sg13
I2
sasa(dp14204
g2
S"WHEN IT WAS CALLED 'GRID': One year ago today, I told my colleagues that I was dying of AIDS.\n"
p14205
sg4
(lp14206
sg23
(lp14207
sa(dp14208
g2
S'APL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and comedication with proton-pump inhibitors.\n'
p14209
sg4
(lp14210
(dp14211
g7
I0
sg8
VP10276
p14212
sg10
I3
sg11
VAPL
p14213
sg13
I1
sasg23
(lp14214
(dp14215
g7
I53
sg26
VC0010674
p14216
sg10
I15
sg11
Vcystic fibrosis
p14217
sg13
I2
sa(dp14218
g7
I0
sg26
VC0023487
p14219
sg10
I3
sg11
VAPL
p14220
sg13
I1
sasa(dp14221
g2
S'DMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.\n'
p14222
sg4
(lp14223
(dp14224
g7
I12
sg8
g107
sg10
I4
sg11
VMEN1
p14225
sg13
I1
sasg23
(lp14226
(dp14227
g7
I47
sg26
VC0206754
p14228
sg10
I20
sg11
Vneuroendocrine tumor
p14229
sg13
I2
sa(dp14230
g7
I85
sg26
VC1337011
p14231
sg10
I31
sg11
Vpancreatic neuroendocrine tumor
p14232
sg13
I3
sa(dp14233
g7
I12
sg26
VC0025267
p14234
sg10
I4
sg11
VMEN1
p14235
sg13
I1
sa(dp14236
g7
I180
sg26
VC0025267
p14237
sg10
I35
sg11
Vmultiple endocrine neoplasia type 1
p14238
sg13
I5
sa(dp14239
g7
I47
sg26
VC0206754
p14240
sg10
I20
sg11
Vneuroendocrine tumor
p14241
sg13
I2
sa(dp14242
g7
I47
sg26
VC0206754
p14243
sg10
I20
sg11
Vneuroendocrine tumor
p14244
sg13
I2
sasa(dp14245
g2
S'APL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and co-medication with proton-pump inhibitors.\n'
p14246
sg4
(lp14247
(dp14248
g7
I0
sg8
VP10276
p14249
sg10
I3
sg11
VAPL
p14250
sg13
I1
sasg23
(lp14251
(dp14252
g7
I53
sg26
VC0010674
p14253
sg10
I15
sg11
Vcystic fibrosis
p14254
sg13
I2
sa(dp14255
g7
I0
sg26
VC0023487
p14256
sg10
I3
sg11
VAPL
p14257
sg13
I1
sasa(dp14258
g2
S'In both cases, the diagnosis of multiple endocrine neoplasia type 1 was made after proton pump therapy was discontinued.\n'
p14259
sg4
(lp14260
sg23
(lp14261
(dp14262
g7
I32
sg26
VC0025267
p14263
sg10
I35
sg11
Vmultiple endocrine neoplasia type 1
p14264
sg13
I5
sasa(dp14265
g2
S'Clinical assessment for features of multiple endocrine neoplasia type 1 (eg, serum calcium levels, personal and family history of hypercalcemia, pituitary or pancreatic tumors) could identify patients with higher risk for a tumoral source of hypergastrinemia where imaging studies can help support the diagnosis without the potential side effects of abrupt discontinuation of proton pump inhibitor therapy.\n'
p14266
sg4
(lp14267
sg23
(lp14268
(dp14269
g7
I36
sg26
VC0025267
p14270
sg10
I35
sg11
Vmultiple endocrine neoplasia type 1
p14271
sg13
I5
sa(dp14272
g7
I130
sg26
VC0020437
p14273
sg10
I13
sg11
Vhypercalcemia
p14274
sg13
I1
sa(dp14275
g7
I158
sg26
VC0030297
p14276
sg10
I17
sg11
Vpancreatic tumors
p14277
sg13
I2
sasa(dp14278
g2
S'No correlation was detected between Ki-67 values of HGPs in CLD patients and the presence of portal hypertension, infection with Helicobacter pylori, or proton pump inhibitor use.\n'
p14279
sg4
(lp14280
sg23
(lp14281
(dp14282
g7
I93
sg26
VC0020541
p14283
sg10
I19
sg11
Vportal hypertension
p14284
sg13
I2
sa(dp14285
g7
I52
sg26
VC0033300
p14286
sg10
I4
sg11
VHGPs
p14287
sg13
I1
sa(dp14288
g7
I114
sg26
VC0009450
p14289
sg10
I9
sg11
Vinfection
p14290
sg13
I1
sa(dp14291
g7
I60
sg26
VC0746102
p14292
sg10
I3
sg11
VCLD
p14293
sg13
I1
sasa(dp14294
g2
S'Mutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis-(ALS) and frontotemporal dementia-(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients.\n'
p14295
sg4
(lp14296
(dp14297
g7
I137
sg8
g107
sg10
I7
sg11
VCHCHD10
p14298
sg13
I1
sa(dp14299
g7
I149
sg8
VP68366
p14300
sg10
I6
sg11
VTUBA4A
p14301
sg13
I1
sasg23
(lp14302
(dp14303
g7
I207
sg26
VC1862937
p14304
sg10
I7
sg11
VFTD-ALS
p14305
sg13
I1
sa(dp14306
g7
I114
sg26
VC0338451
p14307
sg10
I3
sg11
VFTD
p14308
sg13
I1
sa(dp14309
g7
I49
sg26
VC0002736
p14310
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p14311
sg13
I3
sa(dp14312
g7
I80
sg26
VC0002736
p14313
sg10
I3
sg11
VALS
p14314
sg13
I1
sa(dp14315
g7
I80
sg26
VC0002736
p14316
sg10
I3
sg11
VALS
p14317
sg13
I1
sa(dp14318
g7
I89
sg26
VC0338451
p14319
sg10
I23
sg11
Vfrontotemporal dementia
p14320
sg13
I2
sa(dp14321
g7
I114
sg26
VC0338451
p14322
sg10
I3
sg11
VFTD
p14323
sg13
I1
sasa(dp14324
g2
S"In TUBA4A, we detected a novel frameshift mutation (p.Arg64Glyfs*90) leading to a truncated protein in 1 FTD patient (1/459 of 0.22%) with family history of Parkinson's disease and cognitive impairment, and a novel missense mutation (p.Thr381Met) in 2 sibs with familial ALS and memory problems (1 index patient/429, 0.23%) in whom we previously identified a pathogenic Chromosome 9 open reading frame 72 repeat expansion mutation.\n"
p14325
sg4
(lp14326
(dp14327
g7
I3
sg8
VP68366
p14328
sg10
I6
sg11
VTUBA4A
p14329
sg13
I1
sasg23
(lp14330
(dp14331
g7
I105
sg26
VC0338451
p14332
sg10
I3
sg11
VFTD
p14333
sg13
I1
sa(dp14334
g7
I31
sg26
VC0079380
p14335
sg10
I19
sg11
Vframeshift mutation
p14336
sg13
I2
sa(dp14337
g7
I181
sg26
VC0338656
p14338
sg10
I20
sg11
Vcognitive impairment
p14339
sg13
I2
sa(dp14340
g7
I279
sg26
VC0233794
p14341
sg10
I15
sg11
Vmemory problems
p14342
sg13
I2
sa(dp14343
g7
I271
sg26
VC0002736
p14344
sg10
I3
sg11
VALS
p14345
sg13
I1
sa(dp14346
g7
I157
sg26
VC0030567
p14347
sg10
I19
sg11
VParkinson's disease
p14348
sg13
I2
sasa(dp14349
g2
S"The present study confirms the role of CHCHD10 and TUBA4A in the FTD-ALS spectrum, although genetic variations in these 2 genes are extremely rare in the Belgian population and often associated with symptomatology of related neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.\n"
p14350
sg4
(lp14351
(dp14352
g7
I51
sg8
VP68366
p14353
sg10
I6
sg11
VTUBA4A
p14354
sg13
I1
sa(dp14355
g7
I39
sg8
g107
sg10
I7
sg11
VCHCHD10
p14356
sg13
I1
sasg23
(lp14357
(dp14358
g7
I225
sg26
VC0524851
p14359
sg10
I26
sg11
Vneurodegenerative diseases
p14360
sg13
I2
sa(dp14361
g7
I262
sg26
VC0030567
p14362
sg10
I19
sg11
VParkinson's disease
p14363
sg13
I2
sa(dp14364
g7
I65
sg26
VC1862937
p14365
sg10
I7
sg11
VFTD-ALS
p14366
sg13
I1
sa(dp14367
g7
I286
sg26
VC1521724
p14368
sg10
I19
sg11
VAlzheimer's disease
p14369
sg13
I2
sasa(dp14370
g2
S'The tubulin alpha 4a (TUBA4A) gene has been recently associated with amyotrophic lateral sclerosis.\n'
p14371
sg4
(lp14372
(dp14373
g7
I22
sg8
VP68366
p14374
sg10
I6
sg11
VTUBA4A
p14375
sg13
I1
sa(dp14376
g7
I4
sg8
VP68366
p14377
sg10
I16
sg11
Vtubulin alpha 4a
p14378
sg13
I3
sasg23
(lp14379
(dp14380
g7
I69
sg26
VC0002736
p14381
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p14382
sg13
I3
sasa(dp14383
g2
S'TUBA4A gene has recently been identified as a potential candidate amyotrophic lateral sclerosis(ALS)-associated gene using exome-wide rare variant burden analysis.\n'
p14384
sg4
(lp14385
(dp14386
g7
I0
sg8
VP68366
p14387
sg10
I11
sg11
VTUBA4A gene
p14388
sg13
I2
sasg23
(lp14389
(dp14390
g7
I66
sg26
VC0002736
p14391
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p14392
sg13
I3
sa(dp14393
g7
I96
sg26
VC0002736
p14394
sg10
I3
sg11
VALS
p14395
sg13
I1
sasa(dp14396
g2
S"Here we studied the physiological function of CLAC-P/collagen XXV, a transmembrane-type collagen originally identified as a component of senile plaque amyloid of Alzheimer's disease brains, by means of generating Col25a1-deficient (KO) mice.\n"
p14397
sg4
(lp14398
(dp14399
g7
I46
sg8
g107
sg10
I6
sg11
VCLAC-P
p14400
sg13
I1
sa(dp14401
g7
I213
sg8
g107
sg10
I7
sg11
VCol25a1
p14402
sg13
I1
sasg23
(lp14403
(dp14404
g7
I151
sg26
VC0011560
p14405
sg10
I7
sg11
Vamyloid
p14406
sg13
I1
sa(dp14407
g7
I137
sg26
VC0333463
p14408
sg10
I13
sg11
Vsenile plaque
p14409
sg13
I2
sa(dp14410
g7
I162
sg26
VC1521724
p14411
sg10
I19
sg11
VAlzheimer's disease
p14412
sg13
I2
sasa(dp14413
g2
S"Collagen XXV alpha 1 (COL25A1) is a collagenous type II transmembrane protein purified from senile plaques of Alzheimer's disease (AD) brains.\n"
p14414
sg4
(lp14415
(dp14416
g7
I0
sg8
VP25100
p14417
sg10
I20
sg11
VCollagen XXV alpha 1
p14418
sg13
I4
sa(dp14419
g7
I36
sg8
VP27037
p14420
sg10
I41
sg11
Vcollagenous type II transmembrane protein
p14421
sg13
I5
sa(dp14422
g7
I22
sg8
g107
sg10
I7
sg11
VCOL25A1
p14423
sg13
I1
sasg23
(lp14424
(dp14425
g7
I131
sg26
VC1521724
p14426
sg10
I2
sg11
VAD
p14427
sg13
I1
sa(dp14428
g7
I92
sg26
VC0333463
p14429
sg10
I14
sg11
Vsenile plaques
p14430
sg13
I2
sa(dp14431
g7
I110
sg26
VC1521724
p14432
sg10
I19
sg11
VAlzheimer's disease
p14433
sg13
I2
sasa(dp14434
g2
S"The COL25A1 gene, located in 4q25, encodes the CLAC protein, which has been implicated in Alzheimer's disease (AD) pathogenesis.\n"
p14435
sg4
(lp14436
(dp14437
g7
I47
sg8
g107
sg10
I12
sg11
VCLAC protein
p14438
sg13
I2
sa(dp14439
g7
I4
sg8
g107
sg10
I12
sg11
VCOL25A1 gene
p14440
sg13
I2
sasg23
(lp14441
(dp14442
g7
I115
sg26
VC0699748
p14443
sg10
I12
sg11
Vpathogenesis
p14444
sg13
I1
sa(dp14445
g7
I111
sg26
VC1521724
p14446
sg10
I2
sg11
VAD
p14447
sg13
I1
sa(dp14448
g7
I90
sg26
VC1521724
p14449
sg10
I19
sg11
VAlzheimer's disease
p14450
sg13
I2
sasa(dp14451
g2
S"Thus, in addition to the biochemical data, there is now genetic evidence of association between COL25A1 and risk for Alzheimer's disease.\n"
p14452
sg4
(lp14453
(dp14454
g7
I96
sg8
g107
sg10
I7
sg11
VCOL25A1
p14455
sg13
I1
sasg23
(lp14456
(dp14457
g7
I117
sg26
VC1521724
p14458
sg10
I19
sg11
VAlzheimer's disease
p14459
sg13
I2
sasa(dp14460
g2
S"Recently, a novel plaque-associated protein, collagenous Alzheimer amyloid plaque component (CLAC), was identified in brains from patients with Alzheimer's disease.\n"
p14461
sg4
(lp14462
sg23
(lp14463
(dp14464
g7
I67
sg26
VC0333463
p14465
sg10
I14
sg11
Vamyloid plaque
p14466
sg13
I2
sa(dp14467
g7
I18
sg26
VC0011389
p14468
sg10
I6
sg11
Vplaque
p14469
sg13
I1
sa(dp14470
g7
I144
sg26
VC1521724
p14471
sg10
I19
sg11
VAlzheimer's disease
p14472
sg13
I2
sasa(dp14473
g2
S"The biological function and the contribution of CLAC to the pathogenesis of Alzheimer's disease and plaque formation are unknown.\n"
p14474
sg4
(lp14475
sg23
(lp14476
(dp14477
g7
I76
sg26
VC1521724
p14478
sg10
I19
sg11
VAlzheimer's disease
p14479
sg13
I2
sa(dp14480
g7
I100
sg26
VC0011389
p14481
sg10
I6
sg11
Vplaque
p14482
sg13
I1
sa(dp14483
g7
I60
sg26
VC0699748
p14484
sg10
I12
sg11
Vpathogenesis
p14485
sg13
I1
sasa(dp14486
g2
S"CLAC (collagenous Alzheimer amyloid plaque component) is a proteolytic fragment derived from a novel membrane-bound collagen, CLAC-P/collagen type XXV, that deposits in senile plaques associated with amyloid beta peptides (Abeta) in the brains of patients with Alzheimer's disease.\n"
p14487
sg4
(lp14488
(dp14489
g7
I200
sg8
g107
sg10
I21
sg11
Vamyloid beta peptides
p14490
sg13
I3
sa(dp14491
g7
I126
sg8
g107
sg10
I6
sg11
VCLAC-P
p14492
sg13
I1
sa(dp14493
g7
I223
sg8
g107
sg10
I5
sg11
VAbeta
p14494
sg13
I1
sasg23
(lp14495
(dp14496
g7
I28
sg26
VC0333463
p14497
sg10
I14
sg11
Vamyloid plaque
p14498
sg13
I2
sa(dp14499
g7
I169
sg26
VC0333463
p14500
sg10
I14
sg11
Vsenile plaques
p14501
sg13
I2
sa(dp14502
g7
I28
sg26
VC0011560
p14503
sg10
I7
sg11
Vamyloid
p14504
sg13
I1
sa(dp14505
g7
I261
sg26
VC1521724
p14506
sg10
I19
sg11
VAlzheimer's disease
p14507
sg13
I2
sasa(dp14508
g2
S"These results suggest the anti-amyloidogenic roles of CLAC in the pathophysiology of Alzheimer's disease.\n"
p14509
sg4
(lp14510
(dp14511
g7
I54
sg8
g107
sg10
I4
sg11
VCLAC
p14512
sg13
I1
sasg23
(lp14513
(dp14514
g7
I85
sg26
VC1521724
p14515
sg10
I19
sg11
VAlzheimer's disease
p14516
sg13
I2
sasa(dp14517
g2
S"The analysis of breast cancer and pancreatic cancer data further shows iSPCA's satisfactory performance.\n"
p14518
sg4
(lp14519
sg23
(lp14520
(dp14521
g7
I16
sg26
VC0678222
p14522
sg10
I13
sg11
Vbreast cancer
p14523
sg13
I2
sa(dp14524
g7
I34
sg26
VC0235974
p14525
sg10
I17
sg11
Vpancreatic cancer
p14526
sg13
I2
sasa(dp14527
g2
S'Tissue factor (TF) is a transmembrane receptor for coagulation factor VII/VIIa and is frequently overexpressed by cancer cells.\n'
p14528
sg4
(lp14529
(dp14530
g7
I51
sg8
VP08709
p14531
sg10
I22
sg11
Vcoagulation factor VII
p14532
sg13
I3
sasg23
(lp14533
(dp14534
g7
I114
sg26
VC0006826
p14535
sg10
I6
sg11
Vcancer
p14536
sg13
I1
sasa(dp14537
g2
S'To identify the location of missed significant prostate cancer (sPCa) lesions by transrectal ultrasound-guided biopsy (TRUSbx) and multiparametric magnetic resonance imaging-guided biopsy (mpMRIbx) in men undergoing repeat biopsies.\n'
p14538
sg4
(lp14539
sg23
(lp14540
(dp14541
g7
I47
sg26
VC0600139
p14542
sg10
I15
sg11
Vprostate cancer
p14543
sg13
I2
sasa(dp14544
g2
S'Of the 289 patients, prostate cancer was detected in 128 (44%) with 88 (30%) having sPCa.\n'
p14545
sg4
(lp14546
(dp14547
g7
I84
sg8
VP08709
p14548
sg10
I4
sg11
VsPCa
p14549
sg13
I1
sasg23
(lp14550
(dp14551
g7
I21
sg26
VC0600139
p14552
sg10
I15
sg11
Vprostate cancer
p14553
sg13
I2
sasa(dp14554
g2
S'Overall, 165 separate prostate cancer lesions were detected with 100 being sPCa.\n'
p14555
sg4
(lp14556
sg23
(lp14557
(dp14558
g7
I22
sg26
VC0600139
p14559
sg10
I15
sg11
Vprostate cancer
p14560
sg13
I2
sasa(dp14561
g2
S'Factor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.\n'
p14562
sg4
(lp14563
(dp14564
g7
I0
sg8
VP08709
p14565
sg10
I37
sg11
VFactor VII (FVII) activating protease
p14566
sg13
I5
sa(dp14567
g7
I39
sg8
g107
sg10
I4
sg11
VFSAP
p14568
sg13
I1
sa(dp14569
g7
I62
sg8
VP57727
p14570
sg10
I15
sg11
Vserine protease
p14571
sg13
I2
sasg23
(lp14572
(dp14573
g7
I150
sg26
VC0038454
p14574
sg10
I6
sg11
Vstroke
p14575
sg13
I1
sa(dp14576
g7
I158
sg26
VC0004153
p14577
sg10
I15
sg11
Vatherosclerosis
p14578
sg13
I1
sa(dp14579
g7
I175
sg26
VC0239946
p14580
sg10
I14
sg11
Vliver fibrosis
p14581
sg13
I2
sa(dp14582
g7
I206
sg26
VC0006826
p14583
sg10
I6
sg11
Vcancer
p14584
sg13
I1
sa(dp14585
g7
I191
sg26
VC0040053
p14586
sg10
I10
sg11
Vthrombosis
p14587
sg13
I1
sasa(dp14588
g2
S'In the absence of factor VII in platelet-free plasma, thrombin generation in solid pancreatic cancer cell lines was significantly reduced unlike in haematological cell lines.\n'
p14589
sg4
(lp14590
(dp14591
g7
I54
sg8
VP00734
p14592
sg10
I8
sg11
Vthrombin
p14593
sg13
I1
sasg23
(lp14594
(dp14595
g7
I83
sg26
VC0235974
p14596
sg10
I17
sg11
Vpancreatic cancer
p14597
sg13
I2
sasa(dp14598
g2
S'SPCA gene expression is significantly elevated in breast cancer subtypes that are associated with microcalcifications.\n'
p14599
sg4
(lp14600
(dp14601
g7
I0
sg8
VP08709
p14602
sg10
I9
sg11
VSPCA gene
p14603
sg13
I2
sasg23
(lp14604
(dp14605
g7
I50
sg26
VC0678222
p14606
sg10
I13
sg11
Vbreast cancer
p14607
sg13
I2
sa(dp14608
g7
I98
sg26
VC0521174
p14609
sg10
I19
sg11
Vmicrocalcifications
p14610
sg13
I1
sasa(dp14611
g2
S'Clinically significant cancer (SPCa) was defined as Gleason score &gt;=3 + 4.\n'
p14612
sg4
(lp14613
sg23
(lp14614
(dp14615
g7
I23
sg26
VC0006826
p14616
sg10
I6
sg11
Vcancer
p14617
sg13
I1
sasa(dp14618
g2
S'Heritable disorders of connective tissue (marfan syndrome, Ehlers-Danlos syndrome, adult polycystic kidney disease, floppy mitral valve/mitral valve prolapse); congenital heart disease (bicuspid aortic valve); inflammatory/immunologic disorders (rheumatic fever, AIDS, Kawasaki disease, syphilis, seronegative spondyloarthropathies, systemic lupus erythematosus, antiphospholipid syndrome); endocardial disorders (nonbacteremic thrombotic endocarditis, infective endocarditis, endomyocardial fibroelastosis); myocardial dysfunction (ischemic heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy); diseases and disorders of other organs (chronic renal failure, carcinoid heart disease); aging (calcific aortic stenosis, mitral annular calcification); postinterventional valvular disease; drugs and physical agents are all clinical entities associated with VHD.\n'
p14619
sg4
(lp14620
sg23
(lp14621
(dp14622
g7
I136
sg26
VC0026267
p14623
sg10
I21
sg11
Vmitral valve prolapse
p14624
sg13
I3
sa(dp14625
g7
I533
sg26
VC0151744
p14626
sg10
I22
sg11
Vischemic heart disease
p14627
sg13
I3
sa(dp14628
g7
I116
sg26
VC0026267
p14629
sg10
I19
sg11
Vfloppy mitral valve
p14630
sg13
I3
sa(dp14631
g7
I160
sg26
VC0152021
p14632
sg10
I24
sg11
Vcongenital heart disease
p14633
sg13
I3
sa(dp14634
g7
I565
sg26
VC0878544
p14635
sg10
I14
sg11
Vcardiomyopathy
p14636
sg13
I1
sa(dp14637
g7
I186
sg26
VC0149630
p14638
sg10
I21
sg11
Vbicuspid aortic valve
p14639
sg13
I3
sa(dp14640
g7
I223
sg26
VC0021053
p14641
sg10
I21
sg11
Vimmunologic disorders
p14642
sg13
I2
sa(dp14643
g7
I611
sg26
VC0012634
p14644
sg10
I22
sg11
Vdiseases and disorders
p14645
sg13
I3
sa(dp14646
g7
I477
sg26
VC0014117
p14647
sg10
I29
sg11
Vendomyocardial fibroelastosis
p14648
sg13
I2
sa(dp14649
g7
I333
sg26
VC0024141
p14650
sg10
I28
sg11
Vsystemic lupus erythematosus
p14651
sg13
I3
sa(dp14652
g7
I674
sg26
VC0007093
p14653
sg10
I23
sg11
Vcarcinoid heart disease
p14654
sg13
I3
sa(dp14655
g7
I565
sg26
VC0007194
p14656
sg10
I28
sg11
Vcardiomyopathy, hypertrophic
p14657
sg13
I2
sa(dp14658
g7
I723
sg26
VC0026269
p14659
sg10
I16
sg11
Vstenosis, mitral
p14660
sg13
I2
sa(dp14661
g7
I439
sg26
VC1541923
p14662
sg10
I23
sg11
Vendocarditis, infective
p14663
sg13
I2
sa(dp14664
g7
I310
sg26
VC0949691
p14665
sg10
I21
sg11
Vspondyloarthropathies
p14666
sg13
I1
sa(dp14667
g7
I246
sg26
VC0035436
p14668
sg10
I15
sg11
Vrheumatic fever
p14669
sg13
I2
sa(dp14670
g7
I439
sg26
VC0014118
p14671
sg10
I12
sg11
Vendocarditis
p14672
sg13
I1
sa(dp14673
g7
I49
sg26
VC0013720
p14674
sg10
I23
sg11
Vsyndrome, Ehlers-Danlos
p14675
sg13
I2
sa(dp14676
g7
I509
sg26
VC0340515
p14677
sg10
I22
sg11
Vmyocardial dysfunction
p14678
sg13
I2
sa(dp14679
g7
I269
sg26
VC0026691
p14680
sg10
I16
sg11
VKawasaki disease
p14681
sg13
I2
sa(dp14682
g7
I83
sg26
VC0085413
p14683
sg10
I31
sg11
Vadult polycystic kidney disease
p14684
sg13
I4
sa(dp14685
g7
I651
sg26
VC0022661
p14686
sg10
I21
sg11
Vchronic renal failure
p14687
sg13
I3
sa(dp14688
g7
I49
sg26
VC0039082
p14689
sg10
I8
sg11
Vsyndrome
p14690
sg13
I1
sa(dp14691
g7
I363
sg26
VC0085278
p14692
sg10
I25
sg11
Vantiphospholipid syndrome
p14693
sg13
I2
sa(dp14694
g7
I287
sg26
VC0039128
p14695
sg10
I8
sg11
Vsyphilis
p14696
sg13
I1
sasa(dp14697
g2
S'Described here is an autopsy case of a 61-year-old man with polycystic kidney disease who had P. multocida bacteremia and acute infective endocarditis with multiple bacterial clumps involving bicuspid aortic valve.\n'
p14698
sg4
(lp14699
sg23
(lp14700
(dp14701
g7
I192
sg26
VC0149630
p14702
sg10
I21
sg11
Vbicuspid aortic valve
p14703
sg13
I3
sa(dp14704
g7
I107
sg26
VC0004610
p14705
sg10
I10
sg11
Vbacteremia
p14706
sg13
I1
sa(dp14707
g7
I122
sg26
VC0155685
p14708
sg10
I28
sg11
Vacute infective endocarditis
p14709
sg13
I3
sa(dp14710
g7
I60
sg26
VC0022680
p14711
sg10
I25
sg11
Vpolycystic kidney disease
p14712
sg13
I3
sasa(dp14713
g2
S'Twenty-five people with COPD + PC (mean (standard deviation (SD)) age 73 (11) years, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II-IV), 25 people with COPD (70 (8) years, GOLD stage II-IV) and 25 controls (70 (7) years) wore the SenseWear Pro3 Armband for 7 days.\n'
p14714
sg4
(lp14715
sg23
(lp14716
(dp14717
g7
I24
sg26
VC0024117
p14718
sg10
I4
sg11
VCOPD
p14719
sg13
I1
sa(dp14720
g7
I141
sg26
VC0024117
p14721
sg10
I4
sg11
VGOLD
p14722
sg13
I1
sa(dp14723
g7
I141
sg26
VC0024117
p14724
sg10
I4
sg11
VGOLD
p14725
sg13
I1
sa(dp14726
g7
I85
sg26
VC0024117
p14727
sg10
I54
sg11
VGlobal Initiative for Chronic Obstructive Lung Disease
p14728
sg13
I7
sa(dp14729
g7
I24
sg26
VC0024117
p14730
sg10
I4
sg11
VCOPD
p14731
sg13
I1
sasa(dp14732
g2
S'Patients with severe atopic dermatitis had a decreased CD4+CD29+: CD4+CD45RA+ ratio (p &lt; 0.01).\n'
p14733
sg4
(lp14734
(dp14735
g7
I66
sg8
VP01730
p14736
sg10
I11
sg11
VCD4+CD45RA+
p14737
sg13
I1
sa(dp14738
g7
I55
sg8
VP01730
p14739
sg10
I9
sg11
VCD4+CD29+
p14740
sg13
I1
sasg23
(lp14741
(dp14742
g7
I21
sg26
VC0011615
p14743
sg10
I17
sg11
Vatopic dermatitis
p14744
sg13
I2
sasa(dp14745
g2
S'No significant changes in the CD4+CD29+: CD4+CD45RA+ ratio were found in the peripheral blood of patients with clinically mild or moderate atopic dermatitis.\n'
p14746
sg4
(lp14747
(dp14748
g7
I30
sg8
VP01730
p14749
sg10
I9
sg11
VCD4+CD29+
p14750
sg13
I1
sa(dp14751
g7
I41
sg8
VP01730
p14752
sg10
I11
sg11
VCD4+CD45RA+
p14753
sg13
I1
sasg23
(lp14754
(dp14755
g7
I139
sg26
VC0011615
p14756
sg10
I17
sg11
Vatopic dermatitis
p14757
sg13
I2
sasa(dp14758
g2
S'Tissue sections from the skin of patients with atopic dermatitis were investigated by means of hematoxylin-eosin staining, the avidin-biotin-peroxidase complex method, and double-labeling immunofluorescence using monoclonal antibodies to cell-surface antigens, including CD45R and CD29.\n'
p14759
sg4
(lp14760
(dp14761
g7
I271
sg8
VP08575
p14762
sg10
I5
sg11
VCD45R
p14763
sg13
I1
sa(dp14764
g7
I141
sg8
VP05164
p14765
sg10
I10
sg11
Vperoxidase
p14766
sg13
I1
sasg23
(lp14767
(dp14768
g7
I47
sg26
VC0011615
p14769
sg10
I17
sg11
Vatopic dermatitis
p14770
sg13
I2
sasa(dp14771
g2
S'These novel data demonstrate the role of HDAC2-mediated epigenetic mechanisms in anxiety and alcoholism.\n'
p14772
sg4
(lp14773
(dp14774
g7
I41
sg8
g107
sg10
I5
sg11
VHDAC2
p14775
sg13
I1
sasg23
(lp14776
(dp14777
g7
I93
sg26
VC0001973
p14778
sg10
I10
sg11
Valcoholism
p14779
sg13
I1
sasa(dp14780
g2
S'The mRNA levels of cholesterol transport regulators ABCA1 and ABCG1 were markedly downregulated by UVB, parallel to the lamellar ichthyosis related glucosylceramide transporter ABCA12 and the suspected sphingosine-1-phosphate and cholesterol sulfate transporter ABCC1.\n'
p14781
sg4
(lp14782
(dp14783
g7
I230
sg8
VP50443
p14784
sg10
I37
sg11
Vcholesterol sulfate transporter ABCC1
p14785
sg13
I4
sasg23
(lp14786
(dp14787
g7
I120
sg26
VC0020758
p14788
sg10
I19
sg11
Vlamellar ichthyosis
p14789
sg13
I2
sasa(dp14790
g2
S'To investigate the potential tumour suppressor functions of glutathione peroxidase 7 (GPX7) and examine the interplay between epigenetic and genetic events in regulating its expression in oesophageal adenocarcinomas (OAC).\n'
p14791
sg4
(lp14792
(dp14793
g7
I86
sg8
g107
sg10
I4
sg11
VGPX7
p14794
sg13
I1
sa(dp14795
g7
I60
sg8
g107
sg10
I24
sg11
Vglutathione peroxidase 7
p14796
sg13
I3
sasg23
(lp14797
(dp14798
g7
I200
sg26
VC0001418
p14799
sg10
I15
sg11
Vadenocarcinomas
p14800
sg13
I1
sa(dp14801
g7
I29
sg26
VC0027651
p14802
sg10
I6
sg11
Vtumour
p14803
sg13
I1
sasa(dp14804
g2
S'The goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor.\n'
p14805
sg4
(lp14806
(dp14807
g7
I102
sg8
g107
sg10
I13
sg11
Vkallikrein 10
p14808
sg13
I2
sasg23
(lp14809
(dp14810
g7
I134
sg26
VC0007133
p14811
sg10
I19
sg11
Vpapillary carcinoma
p14812
sg13
I2
sa(dp14813
g7
I164
sg26
VC0001807
p14814
sg10
I10
sg11
Vaggressive
p14815
sg13
I1
sa(dp14816
g7
I186
sg26
VC0014170
p14817
sg10
I17
sg11
Vendometrial tumor
p14818
sg13
I2
sasa(dp14819
g2
S'Human kallikrein 10 gene expression levels were evaluated in 11 snap-frozen uterine serous papillary carcinoma biopsies and 6 normal endometrial cell biopsies by real-time polymerase chain reaction.\n'
p14820
sg4
(lp14821
(dp14822
g7
I0
sg8
g107
sg10
I24
sg11
VHuman kallikrein 10 gene
p14823
sg13
I4
sasg23
(lp14824
(dp14825
g7
I91
sg26
VC0007133
p14826
sg10
I19
sg11
Vpapillary carcinoma
p14827
sg13
I2
sasa(dp14828
g2
S'Secretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA.\n'
p14829
sg4
(lp14830
(dp14831
g7
I13
sg8
g107
sg10
I21
sg11
Vkallikrein 10 protein
p14832
sg13
I3
sasg23
(lp14833
(dp14834
g7
I171
sg26
VC0027651
p14835
sg10
I6
sg11
Vtumors
p14836
sg13
I1
sa(dp14837
g7
I91
sg26
VC0007133
p14838
sg10
I20
sg11
Vpapillary carcinomas
p14839
sg13
I2
sa(dp14840
g7
I41
sg26
VC0677930
p14841
sg10
I13
sg11
Vprimary tumor
p14842
sg13
I2
sa(dp14843
g7
I115
sg26
VC0206687
p14844
sg10
I23
sg11
Vendometrioid carcinomas
p14845
sg13
I2
sasa(dp14846
g2
S'Finally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied.\n'
p14847
sg4
(lp14848
(dp14849
g7
I9
sg8
g107
sg10
I13
sg11
Vkallikrein 10
p14850
sg13
I2
sasg23
(lp14851
(dp14852
g7
I183
sg26
VC0007133
p14853
sg10
I19
sg11
Vpapillary carcinoma
p14854
sg13
I2
sa(dp14855
g7
I136
sg26
VC0206687
p14856
sg10
I23
sg11
Vendometrioid carcinomas
p14857
sg13
I2
sasa(dp14858
g2
S'Kallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous papillary carcinoma versus endometrioid carcinoma: P &lt; .02).\n'
p14859
sg4
(lp14860
(dp14861
g7
I0
sg8
g107
sg10
I18
sg11
VKallikrein 10 gene
p14862
sg13
I3
sasg23
(lp14863
(dp14864
g7
I81
sg26
VC0007133
p14865
sg10
I19
sg11
Vpapillary carcinoma
p14866
sg13
I2
sa(dp14867
g7
I81
sg26
VC0007133
p14868
sg10
I19
sg11
Vpapillary carcinoma
p14869
sg13
I2
sa(dp14870
g7
I270
sg26
VC0206687
p14871
sg10
I22
sg11
Vendometrioid carcinoma
p14872
sg13
I2
sasa(dp14873
g2
S'In vitro kallikrein 10 secretion was detected in all primary uterine serous papillary carcinoma cell lines tested (mean = 2.7 microg/L), and the secretion levels were not significantly different to those found in primary ovarian serous papillary tumor cultures (mean 4.2 microg/L).\n'
p14874
sg4
(lp14875
(dp14876
g7
I9
sg8
g107
sg10
I13
sg11
Vkallikrein 10
p14877
sg13
I2
sasg23
(lp14878
(dp14879
g7
I76
sg26
VC0007133
p14880
sg10
I19
sg11
Vpapillary carcinoma
p14881
sg13
I2
sa(dp14882
g7
I236
sg26
VC0476073
p14883
sg10
I15
sg11
Vpapillary tumor
p14884
sg13
I2
sasa(dp14885
g2
S'In contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005).\n'
p14886
sg4
(lp14887
(dp14888
g7
I23
sg8
VP03952
p14889
sg10
I17
sg11
Vplasma kallikrein
p14890
sg13
I2
sasg23
(lp14891
(dp14892
g7
I160
sg26
VC0006826
p14893
sg10
I6
sg11
Vcancer
p14894
sg13
I1
sa(dp14895
g7
I69
sg26
VC0007133
p14896
sg10
I19
sg11
Vpapillary carcinoma
p14897
sg13
I2
sa(dp14898
g7
I214
sg26
VC0206687
p14899
sg10
I22
sg11
Vendometrioid carcinoma
p14900
sg13
I2
sasa(dp14901
g2
S'Kallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients.\n'
p14902
sg4
(lp14903
(dp14904
g7
I0
sg8
VP06870
p14905
sg10
I10
sg11
VKallikrein
p14906
sg13
I1
sasg23
(lp14907
(dp14908
g7
I52
sg26
VC0007133
p14909
sg10
I19
sg11
Vpapillary carcinoma
p14910
sg13
I2
sa(dp14911
g7
I52
sg26
VC0007133
p14912
sg10
I19
sg11
Vpapillary carcinoma
p14913
sg13
I2
sasa(dp14914
g2
S'Kallikrein 10 may represent a novel biomarker for uterine serous papillary carcinoma.\n'
p14915
sg4
(lp14916
(dp14917
g7
I0
sg8
VP06870
p14918
sg10
I10
sg11
VKallikrein
p14919
sg13
I1
sasg23
(lp14920
(dp14921
g7
I65
sg26
VC0007133
p14922
sg10
I19
sg11
Vpapillary carcinoma
p14923
sg13
I2
sasa(dp14924
g2
S'The present investigation was designed to clarify the role of the subcommissural organ (SCO) in the pathogenesis of hydrocephalus occurring in the HTx rat.\n'
p14925
sg4
(lp14926
sg23
(lp14927
(dp14928
g7
I116
sg26
VC0020255
p14929
sg10
I13
sg11
Vhydrocephalus
p14930
sg13
I1
sa(dp14931
g7
I100
sg26
VC0699748
p14932
sg10
I12
sg11
Vpathogenesis
p14933
sg13
I1
sasa(dp14934
g2
S'At the same time, it functions as a transcriptional regulator of particular genes and as a cytokine: HMGB-1 released from a defective cell has been reported to induce damage to the adjacent cells.With a view to examine the relationship between neuronal damage caused by hydrocephalus and HMGB-1, we analyzed the expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus of 1-day-old congenitally hydrocephalic H-Tx rats.As opposed to nonhydrocephalic H-Tx rats, the hydrocephalic H-Tx rats were observed to show stronger expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus.\n'
p14935
sg4
(lp14936
(dp14937
g7
I101
sg8
VP09429
p14938
sg10
I6
sg11
VHMGB-1
p14939
sg13
I1
sa(dp14940
g7
I101
sg8
VP09429
p14941
sg10
I6
sg11
VHMGB-1
p14942
sg13
I1
sa(dp14943
g7
I101
sg8
VP09429
p14944
sg10
I6
sg11
VHMGB-1
p14945
sg13
I1
sa(dp14946
g7
I101
sg8
VP09429
p14947
sg10
I6
sg11
VHMGB-1
p14948
sg13
I1
sasg23
(lp14949
(dp14950
g7
I270
sg26
VC0020255
p14951
sg10
I13
sg11
Vhydrocephalus
p14952
sg13
I1
sasa(dp14953
g2
S'All studies utilized an animal model such as AQP4-knockout mice, H-Tx rats, and kaolin and L-Alfa-lysophosphatidylcholine (LPC) stearoyl injection models of hydrocephalus.\n'
p14954
sg4
(lp14955
(dp14956
g7
I45
sg8
VP55087
p14957
sg10
I4
sg11
VAQP4
p14958
sg13
I1
sasg23
(lp14959
(dp14960
g7
I157
sg26
VC0020255
p14961
sg10
I13
sg11
Vhydrocephalus
p14962
sg13
I1
sasa(dp14963
g2
S'The purpose of this study was to determine the efficacy of minocycline, an antibiotic known for its anti-inflammatory properties, to reduce gliosis in the H-Tx rat model of congenital hydrocephalus.\n'
p14964
sg4
(lp14965
sg23
(lp14966
(dp14967
g7
I173
sg26
VC0020256
p14968
sg10
I24
sg11
Vcongenital hydrocephalus
p14969
sg13
I2
sa(dp14970
g7
I140
sg26
VC0017639
p14971
sg10
I7
sg11
Vgliosis
p14972
sg13
I1
sasa(dp14973
g2
S"It has been well documented that up to 70% of H-Tx rats' offspring suffer from severe hydrocephalus, which can be fatal if it remains untreated.\n"
p14974
sg4
(lp14975
sg23
(lp14976
(dp14977
g7
I86
sg26
VC0020255
p14978
sg10
I13
sg11
Vhydrocephalus
p14979
sg13
I1
sa(dp14980
g7
I67
sg26
VC0683278
p14981
sg10
I6
sg11
Vsuffer
p14982
sg13
I1
sasa(dp14983
g2
S'Aside from the well-documented hydrocephalus, H-Tx rats may develop other intracranial malformations that have not yet been documented in the literature.\n'
p14984
sg4
(lp14985
sg23
(lp14986
(dp14987
g7
I31
sg26
VC0020255
p14988
sg10
I13
sg11
Vhydrocephalus
p14989
sg13
I1
sa(dp14990
g7
I87
sg26
VC0000768
p14991
sg10
I13
sg11
Vmalformations
p14992
sg13
I1
sasa(dp14993
g2
S'We investigated the effect of vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO) model.\n'
p14994
sg4
(lp14995
(dp14996
g7
I30
sg8
g107
sg10
I34
sg11
Vvascular endothelial growth factor
p14997
sg13
I4
sa(dp14998
g7
I66
sg8
g107
sg10
I4
sg11
VVEGF
p14999
sg13
I1
sasg23
(lp15000
(dp15001
g7
I164
sg26
VC0041956
p15002
sg10
I20
sg11
Vureteral obstruction
p15003
sg13
I2
sa(dp15004
g7
I114
sg26
VC0016059
p15005
sg10
I8
sg11
Vfibrosis
p15006
sg13
I1
sa(dp15007
g7
I96
sg26
VC0021368
p15008
sg10
I12
sg11
Vinflammation
p15009
sg13
I1
sa(dp15010
g7
I186
sg26
VC0041956
p15011
sg10
I3
sg11
VUUO
p15012
sg13
I1
sasa(dp15013
g2
S'Renal fibrosis was consequently attenuated in the UUO+VEGF-C group.\n'
p15014
sg4
(lp15015
(dp15016
g7
I50
sg8
VP49767
p15017
sg10
I10
sg11
VUUO+VEGF-C
p15018
sg13
I1
sasg23
(lp15019
(dp15020
g7
I0
sg26
VC0151650
p15021
sg10
I14
sg11
VRenal fibrosis
p15022
sg13
I2
sasa(dp15023
g2
S'Enhancement of the VEGF-C signaling pathway in LECs may be a therapeutic strategy for renal fibrosis.Laboratory Investigation advance online publication, 30 October 2017; doi:10.1038/labinvest.2017.77.\n'
p15024
sg4
(lp15025
(dp15026
g7
I19
sg8
VP49767
p15027
sg10
I6
sg11
VVEGF-C
p15028
sg13
I1
sasg23
(lp15029
(dp15030
g7
I86
sg26
VC0151650
p15031
sg10
I14
sg11
Vrenal fibrosis
p15032
sg13
I2
sasa(dp15033
g2
S'However, the relevance of urinary and circulating VEGF-A165b levels in chronic kidney disease patients remains unclear.\n'
p15034
sg4
(lp15035
sg23
(lp15036
(dp15037
g7
I71
sg26
VC1561643
p15038
sg10
I22
sg11
Vchronic kidney disease
p15039
sg13
I3
sasa(dp15040
g2
S'Therefore, the present study aimed to investigate the urinary and circulating VEGF-A165b levels in patients with chronic kidney disease.\n'
p15041
sg4
(lp15042
sg23
(lp15043
(dp15044
g7
I113
sg26
VC1561643
p15045
sg10
I22
sg11
Vchronic kidney disease
p15046
sg13
I3
sasa(dp15047
g2
S'A low urinary VEGF-A165b level reflects renal dysfunction in the chronic kidney disease stage, while a high circulating VEGF-A165b level cannot be attributed to decreased renal clearance.\n'
p15048
sg4
(lp15049
sg23
(lp15050
(dp15051
g7
I65
sg26
VC1561643
p15052
sg10
I22
sg11
Vchronic kidney disease
p15053
sg13
I3
sasa(dp15054
g2
S'By using a novel, advanced, multicolor fluorescence in situ hybridization approach, we enumerated copy numbers of six genes previously identified by array comparative genomic hybridization to be involved in aggressive prostate cancer [TBL1XR1, CTTNBP2, MYC (alias c-myc), PTEN, MEN1, and PDGFB] in six nonrecurrent and seven recurrent radical prostatectomy cases.\n'
p15055
sg4
(lp15056
(dp15057
g7
I264
sg8
VP12524
p15058
sg10
I5
sg11
Vc-myc
p15059
sg13
I1
sa(dp15060
g7
I253
sg8
VP12524
p15061
sg10
I3
sg11
VMYC
p15062
sg13
I1
sa(dp15063
g7
I244
sg8
g107
sg10
I7
sg11
VCTTNBP2
p15064
sg13
I1
sa(dp15065
g7
I235
sg8
g107
sg10
I7
sg11
VTBL1XR1
p15066
sg13
I1
sa(dp15067
g7
I272
sg8
VP60484
p15068
sg10
I4
sg11
VPTEN
p15069
sg13
I1
sa(dp15070
g7
I278
sg8
g107
sg10
I4
sg11
VMEN1
p15071
sg13
I1
sasg23
(lp15072
(dp15073
g7
I278
sg26
VC0025267
p15074
sg10
I4
sg11
VMEN1
p15075
sg13
I1
sa(dp15076
g7
I218
sg26
VC0600139
p15077
sg10
I15
sg11
Vprostate cancer
p15078
sg13
I2
sa(dp15079
g7
I207
sg26
VC0001807
p15080
sg10
I10
sg11
Vaggressive
p15081
sg13
I1
sasa(dp15082
g2
S'The identification of higher NIHSS scores, higher HAMD scores, lower dopamine level, lower 5-hydroxytryptamine level, higher tumor necrosis factor-Alfa level, and lower nerve growth factor level might be useful for clinicians in recognizing and treating depression in patients after a stroke.\n'
p15083
sg4
(lp15084
(dp15085
g7
I125
sg8
VP01375
p15086
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p15087
sg13
I3
sa(dp15088
g7
I169
sg8
VP01138
p15089
sg10
I19
sg11
Vnerve growth factor
p15090
sg13
I3
sasg23
(lp15091
(dp15092
g7
I254
sg26
VC0011581
p15093
sg10
I10
sg11
Vdepression
p15094
sg13
I1
sa(dp15095
g7
I125
sg26
VC0333516
p15096
sg10
I14
sg11
Vtumor necrosis
p15097
sg13
I2
sa(dp15098
g7
I285
sg26
VC0038454
p15099
sg10
I6
sg11
Vstroke
p15100
sg13
I1
sasa(dp15101
g2
S'Other effects include a reduction in the platelet levels of adenosine triphosphate (ATP), serotonin (5-hydroxytryptamine), platelet factor 3 (PF3), PF4 and Beta-thromboglobulin (BTG), decreased platelet adhesiveness in platelets from healthy volunteers and from atherosclerotic patients and an improvement in red blood cell deformability in patients with occlusive vascular disease.\n'
p15102
sg4
(lp15103
(dp15104
g7
I148
sg8
VP02776
p15105
sg10
I3
sg11
VPF4
p15106
sg13
I1
sa(dp15107
g7
I178
sg8
VP02775
p15108
sg10
I3
sg11
VBTG
p15109
sg13
I1
sa(dp15110
g7
I123
sg8
VP14770
p15111
sg10
I17
sg11
Vplatelet factor 3
p15112
sg13
I3
sa(dp15113
g7
I142
sg8
VP14770
p15114
sg10
I3
sg11
VPF3
p15115
sg13
I1
sa(dp15116
g7
I156
sg8
VP02775
p15117
sg10
I20
sg11
VBeta-thromboglobulin
p15118
sg13
I1
sasg23
(lp15119
(dp15120
g7
I355
sg26
VC0750145
p15121
sg10
I26
sg11
Vocclusive vascular disease
p15122
sg13
I3
sasa(dp15123
g2
S'Objective: To explore the effect of trimetazidine pre-treatments on serum 5-hydroxytryptamine (5-HT) and serotonin transporter (SERT), platelet 5-HT and SERT in the Sprague Dawley rats with myocardial infarction(MI), depression, and myocardial infarction co-exist with depression (MI+ depression) and in sham operated rats.\n'
p15124
sg4
(lp15125
(dp15126
g7
I128
sg8
VP31645
p15127
sg10
I4
sg11
VSERT
p15128
sg13
I1
sa(dp15129
g7
I105
sg8
VP31645
p15130
sg10
I21
sg11
Vserotonin transporter
p15131
sg13
I2
sa(dp15132
g7
I128
sg8
VP31645
p15133
sg10
I4
sg11
VSERT
p15134
sg13
I1
sasg23
(lp15135
(dp15136
g7
I217
sg26
VC0011581
p15137
sg10
I10
sg11
Vdepression
p15138
sg13
I1
sa(dp15139
g7
I217
sg26
VC0011581
p15140
sg10
I10
sg11
Vdepression
p15141
sg13
I1
sa(dp15142
g7
I217
sg26
VC0011581
p15143
sg10
I10
sg11
Vdepression
p15144
sg13
I1
sa(dp15145
g7
I190
sg26
VC0027051
p15146
sg10
I21
sg11
Vmyocardial infarction
p15147
sg13
I2
sa(dp15148
g7
I190
sg26
VC0027051
p15149
sg10
I21
sg11
Vmyocardial infarction
p15150
sg13
I2
sasa(dp15151
g2
S'The role of histone deacetylase-3 (HDAC3) in allergic skin inflammation was reported.\n'
p15152
sg4
(lp15153
(dp15154
g7
I35
sg8
g107
sg10
I5
sg11
VHDAC3
p15155
sg13
I1
sa(dp15156
g7
I12
sg8
VP56524
p15157
sg10
I21
sg11
Vhistone deacetylase-3
p15158
sg13
I2
sasg23
(lp15159
(dp15160
g7
I54
sg26
VC0011603
p15161
sg10
I17
sg11
Vskin inflammation
p15162
sg13
I2
sasa(dp15163
g2
S'In this study, we investigated SERPINA3 expression in glioma tissue samples and its significance in predicting the prognosis of glioma patients.\n'
p15164
sg4
(lp15165
sg23
(lp15166
(dp15167
g7
I54
sg26
VC0017638
p15168
sg10
I6
sg11
Vglioma
p15169
sg13
I1
sa(dp15170
g7
I54
sg26
VC0017638
p15171
sg10
I6
sg11
Vglioma
p15172
sg13
I1
sasa(dp15173
g2
S'We found that SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues.\n'
p15174
sg4
(lp15175
sg23
(lp15176
(dp15177
g7
I42
sg26
VC0017638
p15178
sg10
I6
sg11
Vglioma
p15179
sg13
I1
sasa(dp15180
g2
S'We also found that high SERPINA3 expression in glioma tissues correlated significantly with advanced World Health Organization grade.\n'
p15181
sg4
(lp15182
sg23
(lp15183
(dp15184
g7
I47
sg26
VC0017638
p15185
sg10
I6
sg11
Vglioma
p15186
sg13
I1
sasa(dp15187
g2
S'Univariate and multivariate analyses revealed that high SERPINA3 expression was an independent prognostic factor for poor overall survival of glioma patients.\n'
p15188
sg4
(lp15189
sg23
(lp15190
(dp15191
g7
I142
sg26
VC0017638
p15192
sg10
I6
sg11
Vglioma
p15193
sg13
I1
sasa(dp15194
g2
S'Taken together, our results suggest that SERPINA3 plays an oncogenic role in glioma progression and provide an insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma.\n'
p15195
sg4
(lp15196
sg23
(lp15197
(dp15198
g7
I77
sg26
VC0017638
p15199
sg10
I6
sg11
Vglioma
p15200
sg13
I1
sa(dp15201
g7
I77
sg26
VC0017638
p15202
sg10
I6
sg11
Vglioma
p15203
sg13
I1
sasa(dp15204
g2
S'To investigate the expression and prognostic value of Alfa1-ACT (Alpha1-antichymotrypsin) in patients with HCC (hepatocellular carcinoma) and identify the mechanism by which Alfa1-ACT inhibits proliferation and promotes apoptosis of HCC.\n'
p15205
sg4
(lp15206
(dp15207
g7
I54
sg8
VP63267
p15208
sg10
I9
sg11
VAlfa1-ACT
p15209
sg13
I1
sa(dp15210
g7
I54
sg8
VP63267
p15211
sg10
I9
sg11
VAlfa1-ACT
p15212
sg13
I1
sa(dp15213
g7
I72
sg8
VP05154
p15214
sg10
I16
sg11
Vantichymotrypsin
p15215
sg13
I1
sasg23
(lp15216
(dp15217
g7
I112
sg26
VC2239176
p15218
sg10
I24
sg11
Vhepatocellular carcinoma
p15219
sg13
I2
sa(dp15220
g7
I107
sg26
VC2239176
p15221
sg10
I3
sg11
VHCC
p15222
sg13
I1
sa(dp15223
g7
I193
sg26
VC0334094
p15224
sg10
I13
sg11
Vproliferation
p15225
sg13
I1
sa(dp15226
g7
I107
sg26
VC2239176
p15227
sg10
I3
sg11
VHCC
p15228
sg13
I1
sasa(dp15229
g2
S'Deletions were found in LEC1 (9.5% versus 14.3%), LEC2 (4.8% versus 14.3%), cagT (33.3% versus 28.6%), cagE (28.6% versus 28.6%) and the promoter region of the cagA (19.0% versus 42.9%) of gastritis and PUD strains, respectively.\n'
p15230
sg4
(lp15231
(dp15232
g7
I103
sg8
g107
sg10
I4
sg11
VcagE
p15233
sg13
I1
sa(dp15234
g7
I50
sg8
g107
sg10
I4
sg11
VLEC2
p15235
sg13
I1
sa(dp15236
g7
I24
sg8
g107
sg10
I4
sg11
VLEC1
p15237
sg13
I1
sa(dp15238
g7
I160
sg8
VP05109
p15239
sg10
I4
sg11
VcagA
p15240
sg13
I1
sasg23
(lp15241
(dp15242
g7
I203
sg26
VC0030920
p15243
sg10
I3
sg11
VPUD
p15244
sg13
I1
sa(dp15245
g7
I189
sg26
VC0017152
p15246
sg10
I9
sg11
Vgastritis
p15247
sg13
I1
sasa(dp15248
g2
S'In the seven women, increased FDG uptake was due to physiological endometrial uptake (n=2), leiomyoma (n=1), corpus luteum cyst (n=1), physiological ovarian uptake (n=1), urinary leak (n=1), and nonspecific colitis (n=1).\n'
p15249
sg4
(lp15250
sg23
(lp15251
(dp15252
g7
I207
sg26
VC0009319
p15253
sg10
I7
sg11
Vcolitis
p15254
sg13
I1
sa(dp15255
g7
I92
sg26
VC0023267
p15256
sg10
I9
sg11
Vleiomyoma
p15257
sg13
I1
sa(dp15258
g7
I109
sg26
VC0010093
p15259
sg10
I18
sg11
Vcorpus luteum cyst
p15260
sg13
I3
sasa(dp15261
g2
S'The most significant quantitative trait locus, Hsm1 (hereditary spherocytosis modifier 1), localizes to mouse Chromosome 12 and is dominant.\n'
p15262
sg4
(lp15263
(dp15264
g7
I53
sg8
g107
sg10
I35
sg11
Vhereditary spherocytosis modifier 1
p15265
sg13
I4
sa(dp15266
g7
I47
sg8
g107
sg10
I4
sg11
VHsm1
p15267
sg13
I1
sasg23
(lp15268
(dp15269
g7
I53
sg26
VC0037889
p15270
sg10
I24
sg11
Vhereditary spherocytosis
p15271
sg13
I2
sasa(dp15272
g2
S'Rates of noninfective synovitis and effusion ranged from 0.2% in the LARS ACL group to 27.6% in the Gore-Tex ACL group.\n'
p15273
sg4
(lp15274
sg23
(lp15275
(dp15276
g7
I22
sg26
VC0039103
p15277
sg10
I9
sg11
Vsynovitis
p15278
sg13
I1
sa(dp15279
g7
I36
sg26
VC0013687
p15280
sg10
I8
sg11
Veffusion
p15281
sg13
I1
sasa(dp15282
g2
S'Preliminary results for newer-generation devices, specifically the LARS, show lower reported rates of failure, revision, and sterile effusion/synovitis when compared with older devices.\n'
p15283
sg4
(lp15284
sg23
(lp15285
(dp15286
g7
I142
sg26
VC0039103
p15287
sg10
I9
sg11
Vsynovitis
p15288
sg13
I1
sa(dp15289
g7
I133
sg26
VC0013687
p15290
sg10
I8
sg11
Veffusion
p15291
sg13
I1
sa(dp15292
g7
I125
sg26
VC0678108
p15293
sg10
I7
sg11
Vsterile
p15294
sg13
I1
sasa(dp15295
g2
S'The Ligament Augmentation and Reconstruction System (LARS) is a third generation of synthetic ligament, designed to overcome the issues of graft failure and synovitis which led previous generations of synthetic ligaments to fall out of favour.\n'
p15296
sg4
(lp15297
sg23
(lp15298
(dp15299
g7
I139
sg26
VC1262018
p15300
sg10
I13
sg11
Vgraft failure
p15301
sg13
I2
sa(dp15302
g7
I157
sg26
VC0039103
p15303
sg10
I9
sg11
Vsynovitis
p15304
sg13
I1
sasa(dp15305
g2
S'Usher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein.\n'
p15306
sg4
(lp15307
(dp15308
g7
I25
sg8
VP58418
p15309
sg10
I4
sg11
VUSH3
p15310
sg13
I1
sa(dp15311
g7
I184
sg8
VP58418
p15312
sg10
I5
sg11
VCLRN1
p15313
sg13
I1
sa(dp15314
g7
I174
sg8
VP58418
p15315
sg10
I8
sg11
Vclarin-1
p15316
sg13
I1
sasg23
(lp15317
(dp15318
g7
I25
sg26
VC1568248
p15319
sg10
I4
sg11
VUSH3
p15320
sg13
I1
sa(dp15321
g7
I61
sg26
VC0011053
p15322
sg10
I8
sg11
Vdeafness
p15323
sg13
I1
sa(dp15324
g7
I101
sg26
VC0456909
p15325
sg10
I9
sg11
Vblindness
p15326
sg13
I1
sa(dp15327
g7
I0
sg26
VC0271097
p15328
sg10
I14
sg11
VUsher syndrome
p15329
sg13
I2
sa(dp15330
g7
I80
sg26
VC0575090
p15331
sg10
I16
sg11
Vbalance disorder
p15332
sg13
I2
sasa(dp15333
g2
S'Mutations in the CLRN1 gene cause Usher syndrome type 3 (USH3), a human disease characterized by progressive blindness and deafness.\n'
p15334
sg4
(lp15335
(dp15336
g7
I57
sg8
VP58418
p15337
sg10
I4
sg11
VUSH3
p15338
sg13
I1
sa(dp15339
g7
I17
sg8
VP58418
p15340
sg10
I10
sg11
VCLRN1 gene
p15341
sg13
I2
sa(dp15342
g7
I34
sg8
VP58418
p15343
sg10
I21
sg11
VUsher syndrome type 3
p15344
sg13
I4
sasg23
(lp15345
(dp15346
g7
I109
sg26
VC0456909
p15347
sg10
I9
sg11
Vblindness
p15348
sg13
I1
sa(dp15349
g7
I34
sg26
VC1568248
p15350
sg10
I21
sg11
VUsher syndrome type 3
p15351
sg13
I4
sa(dp15352
g7
I57
sg26
VC1568248
p15353
sg10
I4
sg11
VUSH3
p15354
sg13
I1
sa(dp15355
g7
I123
sg26
VC0011053
p15356
sg10
I8
sg11
Vdeafness
p15357
sg13
I1
sasa(dp15358
g2
S'Taken together, CD47 might be a novel target to enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.\n'
p15359
sg4
(lp15360
(dp15361
g7
I16
sg8
g107
sg10
I4
sg11
VCD47
p15362
sg13
I1
sa(dp15363
g7
I70
sg8
VP09496
p15364
sg10
I6
sg11
VCLTA-4
p15365
sg13
I1
sa(dp15366
g7
I56
sg8
VP18621
p15367
sg10
I9
sg11
Vanti-PD-1
p15368
sg13
I1
sasg23
(lp15369
(dp15370
g7
I100
sg26
VC0007137
p15371
sg10
I20
sg11
Vsquamous cell cancer
p15372
sg13
I3
sasa(dp15373
g2
S'Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma.\n'
p15374
sg4
(lp15375
(dp15376
g7
I24
sg8
VP09496
p15377
sg10
I15
sg11
VCLTA-4 antibody
p15378
sg13
I2
sasg23
(lp15379
(dp15380
g7
I91
sg26
VC0025202
p15381
sg10
I8
sg11
Vmelanoma
p15382
sg13
I1
sasa(dp15383
g2
S'The most prominent example of this shift is the management of metastatic melanoma, where BRAF and MEK inhibition and CLTA-4 blockade have established an entirely new standard of care in the last 3 years.\n'
p15384
sg4
(lp15385
(dp15386
g7
I89
sg8
VP15056
p15387
sg10
I4
sg11
VBRAF
p15388
sg13
I1
sa(dp15389
g7
I117
sg8
VP09496
p15390
sg10
I6
sg11
VCLTA-4
p15391
sg13
I1
sa(dp15392
g7
I98
sg8
VP45985
p15393
sg10
I3
sg11
VMEK
p15394
sg13
I1
sasg23
(lp15395
(dp15396
g7
I62
sg26
VC0278883
p15397
sg10
I19
sg11
Vmetastatic melanoma
p15398
sg13
I2
sasa(dp15399
g2
S'This was associated with the decreased protein expression of Notch1, Notch2, Notch3 and Hey1, and the increased expression of the tumor suppressor microRNA (miR or miRNA)-200 family members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) that are typically downregulated in colon cancer.\n'
p15400
sg4
(lp15401
(dp15402
g7
I211
sg8
g107
sg10
I8
sg11
VmiR-200c
p15403
sg13
I1
sa(dp15404
g7
I88
sg8
g107
sg10
I4
sg11
VHey1
p15405
sg13
I1
sa(dp15406
g7
I233
sg8
g107
sg10
I7
sg11
VmiR-429
p15407
sg13
I1
sa(dp15408
g7
I221
sg8
g107
sg10
I7
sg11
VmiR-141
p15409
sg13
I1
sa(dp15410
g7
I201
sg8
g107
sg10
I8
sg11
VmiR-200b
p15411
sg13
I1
sa(dp15412
g7
I77
sg8
g107
sg10
I6
sg11
VNotch3
p15413
sg13
I1
sa(dp15414
g7
I61
sg8
VP46531
p15415
sg10
I6
sg11
VNotch1
p15416
sg13
I1
sa(dp15417
g7
I191
sg8
g107
sg10
I8
sg11
VmiR-200a
p15418
sg13
I1
sa(dp15419
g7
I69
sg8
g107
sg10
I6
sg11
VNotch2
p15420
sg13
I1
sasg23
(lp15421
(dp15422
g7
I130
sg26
VC0027651
p15423
sg10
I5
sg11
Vtumor
p15424
sg13
I1
sa(dp15425
g7
I278
sg26
VC0699790
p15426
sg10
I12
sg11
Vcolon cancer
p15427
sg13
I2
sasa(dp15428
g2
S'Phosphorylated IGF-IR/IR (P-IGF-IR/IR) and its downstream signaling partner phospho-S6 (P-S6) were evaluated immunohistochemically in tumor tissue microarrays representing 438 cases of invasive breast cancer.\n'
p15429
sg4
(lp15430
(dp15431
g7
I15
sg8
VP06213
p15432
sg10
I6
sg11
VIGF-IR
p15433
sg13
I1
sa(dp15434
g7
I19
sg8
VP06213
p15435
sg10
I2
sg11
VIR
p15436
sg13
I1
sa(dp15437
g7
I26
sg8
VP06213
p15438
sg10
I8
sg11
VP-IGF-IR
p15439
sg13
I1
sa(dp15440
g7
I19
sg8
VP06213
p15441
sg10
I2
sg11
VIR
p15442
sg13
I1
sasg23
(lp15443
(dp15444
g7
I185
sg26
VC0853879
p15445
sg10
I22
sg11
Vinvasive breast cancer
p15446
sg13
I3
sa(dp15447
g7
I134
sg26
VC0027651
p15448
sg10
I5
sg11
Vtumor
p15449
sg13
I1
sasa(dp15450
g2
S'Importantly, P-IGF-IR/IR was detected in all breast cancer subtypes (luminal, 48.1%; triple negative, 41.9%; and HER2, 64.3%).\n'
p15451
sg4
(lp15452
(dp15453
g7
I13
sg8
VP06213
p15454
sg10
I8
sg11
VP-IGF-IR
p15455
sg13
I1
sa(dp15456
g7
I19
sg8
VP06213
p15457
sg10
I2
sg11
VIR
p15458
sg13
I1
sasg23
(lp15459
(dp15460
g7
I45
sg26
VC0678222
p15461
sg10
I13
sg11
Vbreast cancer
p15462
sg13
I2
sasa(dp15463
g2
S'Thus, we can determine which patients have the activated receptor and provide evidence that P-IGF-IR/IR is a prognostic factor for breast cancer.\n'
p15464
sg4
(lp15465
(dp15466
g7
I92
sg8
VP06213
p15467
sg10
I8
sg11
VP-IGF-IR
p15468
sg13
I1
sa(dp15469
g7
I98
sg8
VP06213
p15470
sg10
I2
sg11
VIR
p15471
sg13
I1
sasg23
(lp15472
(dp15473
g7
I131
sg26
VC0678222
p15474
sg10
I13
sg11
Vbreast cancer
p15475
sg13
I2
sasa(dp15476
g2
S'Beyond this, P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen.\n'
p15477
sg4
(lp15478
(dp15479
g7
I13
sg8
VP06213
p15480
sg10
I8
sg11
VP-IGF-IR
p15481
sg13
I1
sa(dp15482
g7
I15
sg8
VP06213
p15483
sg10
I6
sg11
VIGF-IR
p15484
sg13
I1
sa(dp15485
g7
I19
sg8
VP06213
p15486
sg10
I2
sg11
VIR
p15487
sg13
I1
sasg23
(lp15488
(dp15489
g7
I152
sg26
VC0678222
p15490
sg10
I13
sg11
Vbreast cancer
p15491
sg13
I2
sasa(dp15492
g2
S'The genes plo, fimA, fimC, fimE, fimG, nanH, nanP, and cbpA were investigated in 71 T. pyogenes strains recovered from cattle, sheep, goats, dogs, equines, and a pig, recovered from mastitis (n = 35), and non-mastitis (n = 36) cases (abscesses, reproductive tract diseases, pneumonia, lymphadenitis, encephalitis).\n'
p15493
sg4
(lp15494
(dp15495
g7
I39
sg8
g107
sg10
I4
sg11
VnanH
p15496
sg13
I1
sa(dp15497
g7
I45
sg8
g107
sg10
I4
sg11
VnanP
p15498
sg13
I1
sasg23
(lp15499
(dp15500
g7
I182
sg26
VC3251795
p15501
sg10
I8
sg11
Vmastitis
p15502
sg13
I1
sa(dp15503
g7
I285
sg26
VC0024205
p15504
sg10
I13
sg11
Vlymphadenitis
p15505
sg13
I1
sa(dp15506
g7
I27
sg26
VC0917800
p15507
sg10
I4
sg11
VfimE
p15508
sg13
I1
sa(dp15509
g7
I274
sg26
VC0032285
p15510
sg10
I9
sg11
Vpneumonia
p15511
sg13
I1
sa(dp15512
g7
I234
sg26
VC0000833
p15513
sg10
I9
sg11
Vabscesses
p15514
sg13
I1
sa(dp15515
g7
I182
sg26
VC3251795
p15516
sg10
I8
sg11
Vmastitis
p15517
sg13
I1
sa(dp15518
g7
I300
sg26
VC0014038
p15519
sg10
I12
sg11
Vencephalitis
p15520
sg13
I1
sasa(dp15521
g2
S'The aim was to assess the prevalence of anaemia among quranic schoolchildren in khalawi Wad EL Magboul village, rural Rufaa, Gezira State, central Sudan.\n'
p15522
sg4
(lp15523
sg23
(lp15524
(dp15525
g7
I40
sg26
VC0002871
p15526
sg10
I7
sg11
Vanaemia
p15527
sg13
I1
sasa(dp15528
g2
S'Thrombophilia was present in 294/482 (60.9%) patients: 189/350 LC (54.0%), 31/47 (66.0%) HCC, 29/39 (74.4%) MPN, 35/38 AD (92.1%), and 10/10 (100%) WAD, and 54/150 (36.0%) in HC.\n'
p15529
sg4
(lp15530
sg23
(lp15531
(dp15532
g7
I0
sg26
VC2827470
p15533
sg10
I13
sg11
VThrombophilia
p15534
sg13
I1
sa(dp15535
g7
I89
sg26
VC2239176
p15536
sg10
I3
sg11
VHCC
p15537
sg13
I1
sasa(dp15538
g2
S'A cross-sectional study was conducted to investigate the prevalence of anaemia, iron, zinc and copper deficiencies among pregnant women in Wad Medani hospital, central Sudan and to examine the relationship of these micronutrients with haemoglobin (Hb) levels.\n'
p15539
sg4
(lp15540
(dp15541
g7
I235
sg8
g107
sg10
I11
sg11
Vhaemoglobin
p15542
sg13
I1
sa(dp15543
g7
I248
sg8
g107
sg10
I2
sg11
VHb
p15544
sg13
I1
sasg23
(lp15545
(dp15546
g7
I71
sg26
VC0002871
p15547
sg10
I7
sg11
Vanaemia
p15548
sg13
I1
sasa(dp15549
g2
S'In the orbivirinae this would result in 2 genera of cyanovirus (bluetongue, epizootic hemorrhagic disease, Eubenangee and Palyam sub-genera) and Kemerovovirus (Chenunda, Great Island, Kemerovo and Wad Medani sub-genera) and a number of ungrouped sub-genera (African horsesickness, Changuinola, Corriparta, equine encephalosis, Wallal and Warrego sub-genera and the remaining ungrouped viruses).\n'
p15550
sg4
(lp15551
sg23
(lp15552
(dp15553
g7
I86
sg26
VC0019087
p15554
sg10
I19
sg11
Vhemorrhagic disease
p15555
sg13
I2
sa(dp15556
g7
I258
sg26
VC0001748
p15557
sg10
I21
sg11
VAfrican horsesickness
p15558
sg13
I2
sa(dp15559
g7
I64
sg26
VC0005866
p15560
sg10
I10
sg11
Vbluetongue
p15561
sg13
I1
sasa(dp15562
g2
S'We examined the expression of CT-1, leukemia inhibitory factor (LIF), and gp130 by competitive RT-PCR and Western blotting in Dahl salt-sensitive (DS) rats with a high-salt diet, which showed a distinct transition from left ventricular hypertrophy (LVH) to congestive heart failure (CHF).\n'
p15563
sg4
(lp15564
(dp15565
g7
I36
sg8
VP15018
p15566
sg10
I26
sg11
Vleukemia inhibitory factor
p15567
sg13
I3
sa(dp15568
g7
I64
sg8
VP15018
p15569
sg10
I3
sg11
VLIF
p15570
sg13
I1
sa(dp15571
g7
I74
sg8
VP40189
p15572
sg10
I5
sg11
Vgp130
p15573
sg13
I1
sa(dp15574
g7
I30
sg8
g107
sg10
I4
sg11
VCT-1
p15575
sg13
I1
sasg23
(lp15576
(dp15577
g7
I249
sg26
VC0149721
p15578
sg10
I3
sg11
VLVH
p15579
sg13
I1
sa(dp15580
g7
I36
sg26
VC0023418
p15581
sg10
I8
sg11
Vleukemia
p15582
sg13
I1
sa(dp15583
g7
I257
sg26
VC0018802
p15584
sg10
I24
sg11
Vcongestive heart failure
p15585
sg13
I3
sa(dp15586
g7
I203
sg26
VC0599156
p15587
sg10
I10
sg11
Vtransition
p15588
sg13
I1
sa(dp15589
g7
I219
sg26
VC0149721
p15590
sg10
I28
sg11
Vleft ventricular hypertrophy
p15591
sg13
I3
sa(dp15592
g7
I283
sg26
VC0018802
p15593
sg10
I3
sg11
VCHF
p15594
sg13
I1
sasa(dp15595
g2
S'New factors signaling independently of the leukemia inhibitory-factor receptor pathway may sustain cardiomyocyte cell proliferation and thus be a future target for gene therapy of cardiomyopathies and cell therapy of the myocardium.\n'
p15596
sg4
(lp15597
(dp15598
g7
I43
sg8
g107
sg10
I35
sg11
Vleukemia inhibitory-factor receptor
p15599
sg13
I3
sasg23
(lp15600
(dp15601
g7
I118
sg26
VC0334094
p15602
sg10
I13
sg11
Vproliferation
p15603
sg13
I1
sa(dp15604
g7
I180
sg26
VC0878544
p15605
sg10
I16
sg11
Vcardiomyopathies
p15606
sg13
I1
sa(dp15607
g7
I43
sg26
VC0023418
p15608
sg10
I8
sg11
Vleukemia
p15609
sg13
I1
sasa(dp15610
g2
S'We propose a model in which P-Rex1 acts as a crucial node for the integration of upstream inputs from HER/ErbB receptors and CXCR4 in luminal breast cancer cells.\n'
p15611
sg4
(lp15612
(dp15613
g7
I125
sg8
VP61073
p15614
sg10
I5
sg11
VCXCR4
p15615
sg13
I1
sa(dp15616
g7
I28
sg8
g107
sg10
I6
sg11
VP-Rex1
p15617
sg13
I1
sa(dp15618
g7
I106
sg8
g107
sg10
I14
sg11
VErbB receptors
p15619
sg13
I2
sasg23
(lp15620
(dp15621
g7
I142
sg26
VC0678222
p15622
sg10
I13
sg11
Vbreast cancer
p15623
sg13
I2
sasa(dp15624
g2
S'Notably, there is a significant association in the expression of P-Rex1 and MMP10 in human luminal breast cancer, and their co-expression is indicative of poor prognosis.\n'
p15625
sg4
(lp15626
(dp15627
g7
I76
sg8
VP09238
p15628
sg10
I5
sg11
VMMP10
p15629
sg13
I1
sa(dp15630
g7
I65
sg8
g107
sg10
I6
sg11
VP-Rex1
p15631
sg13
I1
sasg23
(lp15632
(dp15633
g7
I99
sg26
VC0678222
p15634
sg10
I13
sg11
Vbreast cancer
p15635
sg13
I2
sasa(dp15636
g2
S"Treatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2'-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation.\n"
p15637
sg4
(lp15638
(dp15639
g7
I197
sg8
g107
sg10
I6
sg11
VP-REX1
p15640
sg13
I1
sa(dp15641
g7
I197
sg8
g107
sg10
I6
sg11
VP-REX1
p15642
sg13
I1
sa(dp15643
g7
I163
sg8
VP32119
p15644
sg10
I24
sg11
Vinhibitor trichostatin A
p15645
sg13
I3
sa(dp15646
g7
I143
sg8
VP56524
p15647
sg10
I19
sg11
Vhistone deacetylase
p15648
sg13
I2
sasg23
(lp15649
(dp15650
g7
I240
sg26
VC0678222
p15651
sg10
I13
sg11
Vbreast cancer
p15652
sg13
I2
sa(dp15653
g7
I42
sg26
VC0006826
p15654
sg10
I6
sg11
Vcancer
p15655
sg13
I1
sa(dp15656
g7
I240
sg26
VC0678222
p15657
sg10
I13
sg11
Vbreast cancer
p15658
sg13
I2
sasa(dp15659
g2
S'We identify 112 candidate ciliogenesis and ciliopathy genes, including 44 components of the ubiquitin-proteasome system, 12 G-protein-coupled receptors, and 3 pre-mRNA processing factors (PRPF6, PRPF8 and PRPF31) mutated in autosomal dominant retinitis pigmentosa.\n'
p15660
sg4
(lp15661
(dp15662
g7
I195
sg8
g107
sg10
I5
sg11
VPRPF8
p15663
sg13
I1
sa(dp15664
g7
I121
sg8
g107
sg10
I30
sg11
V12 G-protein-coupled receptors
p15665
sg13
I3
sa(dp15666
g7
I205
sg8
g107
sg10
I6
sg11
VPRPF31
p15667
sg13
I1
sa(dp15668
g7
I188
sg8
g107
sg10
I5
sg11
VPRPF6
p15669
sg13
I1
sa(dp15670
g7
I92
sg8
VP62979
p15671
sg10
I9
sg11
Vubiquitin
p15672
sg13
I1
sasg23
(lp15673
(dp15674
g7
I224
sg26
VC0339525
p15675
sg10
I39
sg11
Vautosomal dominant retinitis pigmentosa
p15676
sg13
I4
sasa(dp15677
g2
S'Mutations in six spliceosomal proteins, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200, cause retinitis pigmentosa (RP), a disease characterized by progressive photoreceptor degeneration.\n'
p15678
sg4
(lp15679
(dp15680
g7
I47
sg8
g107
sg10
I5
sg11
VPRPF4
p15681
sg13
I1
sa(dp15682
g7
I68
sg8
g107
sg10
I6
sg11
VPRPF31
p15683
sg13
I1
sa(dp15684
g7
I79
sg8
g107
sg10
I8
sg11
VSNRNP200
p15685
sg13
I1
sa(dp15686
g7
I54
sg8
g107
sg10
I5
sg11
VPRPF6
p15687
sg13
I1
sa(dp15688
g7
I61
sg8
g107
sg10
I5
sg11
VPRPF8
p15689
sg13
I1
sa(dp15690
g7
I40
sg8
g107
sg10
I5
sg11
VPRPF3
p15691
sg13
I1
sasg23
(lp15692
(dp15693
g7
I41
sg26
VC0035334
p15694
sg10
I2
sg11
VRP
p15695
sg13
I1
sa(dp15696
g7
I95
sg26
VC0035334
p15697
sg10
I20
sg11
Vretinitis pigmentosa
p15698
sg13
I2
sa(dp15699
g7
I161
sg26
VC1998028
p15700
sg10
I26
sg11
Vphotoreceptor degeneration
p15701
sg13
I2
sasa(dp15702
g2
S'In addition, a pAsn477Ser change in the neighboring gene PRPF6, a gene previously found to be associated with retinitis pigmentosa, segregated with the ADKD phenotype.\n'
p15703
sg4
(lp15704
(dp15705
g7
I52
sg8
g107
sg10
I10
sg11
Vgene PRPF6
p15706
sg13
I2
sasg23
(lp15707
(dp15708
g7
I110
sg26
VC0035334
p15709
sg10
I20
sg11
Vretinitis pigmentosa
p15710
sg13
I2
sasa(dp15711
g2
S'Yeast two-hybrid analyses suggest a link between retinitis pigmentosa and an aberrant hPrp31-hPrp6 interaction that blocks U4/U6-U5 tri-snRNP formation.\n'
p15712
sg4
(lp15713
(dp15714
g7
I93
sg8
g107
sg10
I5
sg11
VhPrp6
p15715
sg13
I1
sa(dp15716
g7
I86
sg8
g107
sg10
I6
sg11
VhPrp31
p15717
sg13
I1
sasg23
(lp15718
(dp15719
g7
I49
sg26
VC0035334
p15720
sg10
I20
sg11
Vretinitis pigmentosa
p15721
sg13
I2
sasa(dp15722
g2
S'In humans and in mice, mutations in the Ostm1 gene cause the most severe form of osteopetrosis, a major bone disease, and neuronal degeneration, both of which are associated with early death.\n'
p15723
sg4
(lp15724
(dp15725
g7
I40
sg8
g107
sg10
I10
sg11
VOstm1 gene
p15726
sg13
I2
sasg23
(lp15727
(dp15728
g7
I81
sg26
VC0029454
p15729
sg10
I13
sg11
Vosteopetrosis
p15730
sg13
I1
sa(dp15731
g7
I131
sg26
VC0011164
p15732
sg10
I12
sg11
Vdegeneration
p15733
sg13
I1
sa(dp15734
g7
I104
sg26
VC0005940
p15735
sg10
I12
sg11
Vbone disease
p15736
sg13
I2
sasa(dp15737
g2
S'Genetic defects in OSTM1 (osteopetrosis-associated transmembrane protein 1) cause autosomal recessive osteopetrosis in humans.\n'
p15738
sg4
(lp15739
sg23
(lp15740
(dp15741
g7
I26
sg26
VC0029454
p15742
sg10
I13
sg11
Vosteopetrosis
p15743
sg13
I1
sa(dp15744
g7
I26
sg26
VC0029454
p15745
sg10
I13
sg11
Vosteopetrosis
p15746
sg13
I1
sasa(dp15747
g2
S'Thus, these findings suggest that autosomal recessive osteopetrosis patients with an OSTM1 gene mutation lacking the transmembrane domain produce a secreted form of truncated OSTM1 that inhibits osteoclastogenesis.\n'
p15748
sg4
(lp15749
(dp15750
g7
I85
sg8
g107
sg10
I10
sg11
VOSTM1 gene
p15751
sg13
I2
sasg23
(lp15752
(dp15753
g7
I54
sg26
VC0029454
p15754
sg10
I13
sg11
Vosteopetrosis
p15755
sg13
I1
sasa(dp15756
g2
S'Loss of the lysosomal ClC-7/Ostm1 2Cl(-)/H(+) exchanger causes lysosomal storage disease and osteopetrosis in humans and additionally changes fur colour in mice.\n'
p15757
sg4
(lp15758
(dp15759
g7
I12
sg8
VP51798
p15760
sg10
I15
sg11
Vlysosomal ClC-7
p15761
sg13
I2
sa(dp15762
g7
I28
sg8
g107
sg10
I5
sg11
VOstm1
p15763
sg13
I1
sasg23
(lp15764
(dp15765
g7
I63
sg26
VC0085078
p15766
sg10
I25
sg11
Vlysosomal storage disease
p15767
sg13
I3
sa(dp15768
g7
I93
sg26
VC0029454
p15769
sg10
I13
sg11
Vosteopetrosis
p15770
sg13
I1
sasa(dp15771
g2
S'Loss of Ostm1 leads to the most severe form of osteopetrosis in mice and humans.\n'
p15772
sg4
(lp15773
(dp15774
g7
I8
sg8
g107
sg10
I5
sg11
VOstm1
p15775
sg13
I1
sasg23
(lp15776
(dp15777
g7
I47
sg26
VC0029454
p15778
sg10
I13
sg11
Vosteopetrosis
p15779
sg13
I1
sasa(dp15780
g2
S'Mice lacking either ClC-7 or Ostm1 develop a lysosomal storage disease and mutations in either protein have been found to underlie osteopetrosis in mice and humans.\n'
p15781
sg4
(lp15782
(dp15783
g7
I20
sg8
VP51798
p15784
sg10
I5
sg11
VClC-7
p15785
sg13
I1
sa(dp15786
g7
I29
sg8
g107
sg10
I5
sg11
VOstm1
p15787
sg13
I1
sasg23
(lp15788
(dp15789
g7
I45
sg26
VC0085078
p15790
sg10
I25
sg11
Vlysosomal storage disease
p15791
sg13
I3
sa(dp15792
g7
I131
sg26
VC0029454
p15793
sg10
I13
sg11
Vosteopetrosis
p15794
sg13
I1
sasa(dp15795
g2
S'Mice or humans lacking ClC-7 or Ostm1 display osteopetrosis and lysosomal storage disease.\n'
p15796
sg4
(lp15797
(dp15798
g7
I32
sg8
g107
sg10
I5
sg11
VOstm1
p15799
sg13
I1
sa(dp15800
g7
I23
sg8
VP51798
p15801
sg10
I5
sg11
VClC-7
p15802
sg13
I1
sasg23
(lp15803
(dp15804
g7
I64
sg26
VC0085078
p15805
sg10
I25
sg11
Vlysosomal storage disease
p15806
sg13
I3
sa(dp15807
g7
I46
sg26
VC0029454
p15808
sg10
I13
sg11
Vosteopetrosis
p15809
sg13
I1
sasa(dp15810
g2
S'Here we describe for the first time homozygous microdeletions of different sizes affecting the OSTM1 gene in two unrelated consanguineous families with children suffering from neuronopathic infantile malignant osteopetrosis.\n'
p15811
sg4
(lp15812
(dp15813
g7
I95
sg8
g107
sg10
I10
sg11
VOSTM1 gene
p15814
sg13
I2
sasg23
(lp15815
(dp15816
g7
I161
sg26
VC0683278
p15817
sg10
I9
sg11
Vsuffering
p15818
sg13
I1
sa(dp15819
g7
I190
sg26
VC1318518
p15820
sg10
I33
sg11
Vinfantile malignant osteopetrosis
p15821
sg13
I3
sasa(dp15822
g2
S"Our findings are summarized as follows: i) BPY2 (testis basic protein on Y, 2), DAZ1 (deleted in azoospermia 1), TTY4 (testis transcript Y 4) mRNAs and 23 ESTs were found; ii) Eighteen of 23 ESTs were transcripts of the DAZ gene(s), one EST was a transcript of TTY4 gene, and the remaining 4 probably corresponded to 4 different pseudogenes; iii) DAZ gene(s) were expressed not only in testis, but also in lung carcinoma cells, stomach and Ewing's sarcoma cells; iv) beta-satellite clusters were present around and within the BPY2 and TTY4 gene region; v) In this study, TTY4, BPY2 and DAZ1 genes were mapped precisely to the AC010088 region.\n"
p15823
sg4
(lp15824
(dp15825
g7
I80
sg8
g107
sg10
I4
sg11
VDAZ1
p15826
sg13
I1
sa(dp15827
g7
I49
sg8
VP15735
p15828
sg10
I20
sg11
Vtestis basic protein
p15829
sg13
I3
sa(dp15830
g7
I43
sg8
g107
sg10
I4
sg11
VBPY2
p15831
sg13
I1
sa(dp15832
g7
I220
sg8
g107
sg10
I8
sg11
VDAZ gene
p15833
sg13
I2
sa(dp15834
g7
I220
sg8
g107
sg10
I11
sg11
VDAZ gene(s)
p15835
sg13
I2
sa(dp15836
g7
I43
sg8
g107
sg10
I4
sg11
VBPY2
p15837
sg13
I1
sa(dp15838
g7
I586
sg8
g107
sg10
I10
sg11
VDAZ1 genes
p15839
sg13
I2
sa(dp15840
g7
I43
sg8
g107
sg10
I4
sg11
VBPY2
p15841
sg13
I1
sa(dp15842
g7
I86
sg8
g107
sg10
I24
sg11
Vdeleted in azoospermia 1
p15843
sg13
I4
sasg23
(lp15844
(dp15845
g7
I406
sg26
VC0684249
p15846
sg10
I14
sg11
Vlung carcinoma
p15847
sg13
I2
sa(dp15848
g7
I440
sg26
VC0553580
p15849
sg10
I15
sg11
VEwing's sarcoma
p15850
sg13
I2
sa(dp15851
g7
I97
sg26
VC1321542
p15852
sg10
I11
sg11
Vazoospermia
p15853
sg13
I1
sasa(dp15854
g2
S'Lowered POMC and heightened TRPV3 expressions in the HN and mNTS are involved in development of hyperphagia and obesity in OP rats.\n'
p15855
sg4
(lp15856
(dp15857
g7
I8
sg8
VP01189
p15858
sg10
I4
sg11
VPOMC
p15859
sg13
I1
sa(dp15860
g7
I28
sg8
g107
sg10
I5
sg11
VTRPV3
p15861
sg13
I1
sasg23
(lp15862
(dp15863
g7
I112
sg26
VC0028754
p15864
sg10
I7
sg11
Vobesity
p15865
sg13
I1
sa(dp15866
g7
I96
sg26
VC0020505
p15867
sg10
I11
sg11
Vhyperphagia
p15868
sg13
I1
sasa(dp15869
g2
S'Here, we have shown that it is applicable to 10 human colorectal carcinoma cell lines with a direct correlation between viral toxicity and CPG2 production.\n'
p15870
sg4
(lp15871
sg23
(lp15872
(dp15873
g7
I54
sg26
VC0009402
p15874
sg10
I20
sg11
Vcolorectal carcinoma
p15875
sg13
I2
sasa(dp15876
g2
S"Ten patients with colorectal carcinoma expressing carcinoembryonic antigen received antibody-directed enzyme prodrug therapy with A5B7 F(ab')2 antibody to carcinoembryonic antigen conjugated to carboxypeptidase G2 (CPG2).\n"
p15877
sg4
(lp15878
(dp15879
g7
I194
sg8
VP10619
p15880
sg10
I19
sg11
Vcarboxypeptidase G2
p15881
sg13
I2
sa(dp15882
g7
I50
sg8
VP40198
p15883
sg10
I24
sg11
Vcarcinoembryonic antigen
p15884
sg13
I2
sa(dp15885
g7
I215
sg8
VP10619
p15886
sg10
I4
sg11
VCPG2
p15887
sg13
I1
sasg23
(lp15888
(dp15889
g7
I18
sg26
VC0009402
p15890
sg10
I20
sg11
Vcolorectal carcinoma
p15891
sg13
I2
sasa(dp15892
g2
S'Human tumor cell lines A2780, SK-OV-3 (ovarian adenocarcinomas), LS174T, and WiDr (colon carcinomas) were engineered to express constitutively either CPG2 or bacterial beta-galactosidase.\n'
p15893
sg4
(lp15894
(dp15895
g7
I158
sg8
VP16278
p15896
sg10
I28
sg11
Vbacterial beta-galactosidase
p15897
sg13
I2
sasg23
(lp15898
(dp15899
g7
I6
sg26
VC0027651
p15900
sg10
I5
sg11
Vtumor
p15901
sg13
I1
sa(dp15902
g7
I47
sg26
VC0001418
p15903
sg10
I15
sg11
Vadenocarcinomas
p15904
sg13
I1
sa(dp15905
g7
I52
sg26
VC0007097
p15906
sg10
I10
sg11
Vcarcinomas
p15907
sg13
I1
sasa(dp15908
g2
S'They have been used to treat mouse models of connective tissue disease such as lumican-null (Lum) and mucopolysaccharidosis (Gusb) mice.\n'
p15909
sg4
(lp15910
(dp15911
g7
I93
sg8
VP51884
p15912
sg10
I3
sg11
VLum
p15913
sg13
I1
sa(dp15914
g7
I79
sg8
VP51884
p15915
sg10
I12
sg11
Vlumican-null
p15916
sg13
I1
sasg23
(lp15917
(dp15918
g7
I45
sg26
VC0009782
p15919
sg10
I25
sg11
Vconnective tissue disease
p15920
sg13
I3
sa(dp15921
g7
I102
sg26
VC0026703
p15922
sg10
I21
sg11
Vmucopolysaccharidosis
p15923
sg13
I1
sasa(dp15924
g2
S'Expression of fibromodulin was significantly higher in plaques obtained from patients with diabetes and a high fibromodulin expression was associated with a higher incidence of post-operative cerebrovascular events, whereas no such associations were seen for lumican.\n'
p15925
sg4
(lp15926
(dp15927
g7
I14
sg8
g107
sg10
I12
sg11
Vfibromodulin
p15928
sg13
I1
sa(dp15929
g7
I259
sg8
VP51884
p15930
sg10
I7
sg11
Vlumican
p15931
sg13
I1
sa(dp15932
g7
I14
sg8
g107
sg10
I12
sg11
Vfibromodulin
p15933
sg13
I1
sasg23
(lp15934
(dp15935
g7
I55
sg26
VC0333463
p15936
sg10
I7
sg11
Vplaques
p15937
sg13
I1
sa(dp15938
g7
I91
sg26
VC0011849
p15939
sg10
I8
sg11
Vdiabetes
p15940
sg13
I1
sasa(dp15941
g2
S'This study aimed to identify which myometrial ECM components are affected by diabetes, including fibril-forming collagen types I, III and V, as well as proteoglycans, decorin, lumican, fibromodulin and biglycan.\n'
p15942
sg4
(lp15943
(dp15944
g7
I185
sg8
g107
sg10
I12
sg11
Vfibromodulin
p15945
sg13
I1
sa(dp15946
g7
I176
sg8
VP51884
p15947
sg10
I7
sg11
Vlumican
p15948
sg13
I1
sa(dp15949
g7
I35
sg8
g107
sg10
I25
sg11
Vmyometrial ECM components
p15950
sg13
I3
sa(dp15951
g7
I167
sg8
VP07585
p15952
sg10
I7
sg11
Vdecorin
p15953
sg13
I1
sasg23
(lp15954
(dp15955
g7
I77
sg26
VC0011849
p15956
sg10
I8
sg11
Vdiabetes
p15957
sg13
I1
sasa(dp15958
g2
S'Using the polymicrobial model of murine sepsis, we investigated the role of C5a receptors in septic lymphopenia.\n'
p15959
sg4
(lp15960
(dp15961
g7
I76
sg8
VP21730
p15962
sg10
I13
sg11
VC5a receptors
p15963
sg13
I2
sasg23
(lp15964
(dp15965
g7
I40
sg26
VC0243026
p15966
sg10
I6
sg11
Vsepsis
p15967
sg13
I1
sa(dp15968
g7
I100
sg26
VC0024312
p15969
sg10
I11
sg11
Vlymphopenia
p15970
sg13
I1
sasa(dp15971
g2
S'In wild-type mice, cecal ligation and puncture resulted in splenocyte apoptosis and significant lymphopenia after 3 d, which was not observed in C5aR1(-/-) or C5aR2(-/-) mice.\n'
p15972
sg4
(lp15973
(dp15974
g7
I145
sg8
VP21730
p15975
sg10
I5
sg11
VC5aR1
p15976
sg13
I1
sasg23
(lp15977
(dp15978
g7
I96
sg26
VC0024312
p15979
sg10
I11
sg11
Vlymphopenia
p15980
sg13
I1
sasa(dp15981
g2
S'NDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo.\n'
p15982
sg4
(lp15983
(dp15984
g7
I34
sg8
VP21730
p15985
sg10
I3
sg11
VC5a
p15986
sg13
I1
sasg23
(lp15987
sa(dp15988
g2
S'Nonetheless, topical application of C5aR antagonists produced circulating levels of the drugs that antagonized the LPS-induced systemic responses of neutropenia and hypotension.\n'
p15989
sg4
(lp15990
(dp15991
g7
I36
sg8
VP21730
p15992
sg10
I4
sg11
VC5aR
p15993
sg13
I1
sasg23
(lp15994
(dp15995
g7
I115
sg26
VC0175697
p15996
sg10
I3
sg11
VLPS
p15997
sg13
I1
sasa(dp15998
g2
S'Several of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers.\n'
p15999
sg4
(lp16000
(dp16001
g7
I27
sg8
VP06729
p16002
sg10
I3
sg11
VCD2
p16003
sg13
I1
sa(dp16004
g7
I50
sg8
g107
sg10
I6
sg11
VCD203c
p16005
sg13
I1
sa(dp16006
g7
I32
sg8
VP01589
p16007
sg10
I4
sg11
VCD25
p16008
sg13
I1
sa(dp16009
g7
I44
sg8
VP21730
p16010
sg10
I4
sg11
VCD88
p16011
sg13
I1
sa(dp16012
g7
I38
sg8
VP11274
p16013
sg10
I4
sg11
VCD35
p16014
sg13
I1
sasg23
(lp16015
(dp16016
g7
I86
sg26
VC0036221
p16017
sg10
I3
sg11
VMCs
p16018
sg13
I1
sa(dp16019
g7
I107
sg26
VC0221013
p16020
sg10
I21
sg11
Vsystemic mastocytosis
p16021
sg13
I2
sasa(dp16022
g2
S'This study analysed the expression of various complement-related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non-haematological disorders (control groups).\n'
p16023
sg4
(lp16024
(dp16025
g7
I125
sg8
VP08174
p16026
sg10
I3
sg11
VDAF
p16027
sg13
I1
sa(dp16028
g7
I146
sg8
VP21730
p16029
sg10
I4
sg11
VC5aR
p16030
sg13
I1
sa(dp16031
g7
I46
sg8
g107
sg10
I40
sg11
Vcomplement-related cell surface antigens
p16032
sg13
I4
sa(dp16033
g7
I130
sg8
VP13987
p16034
sg10
I4
sg11
VCD59
p16035
sg13
I1
sa(dp16036
g7
I115
sg8
VP17927
p16037
sg10
I3
sg11
VCR1
p16038
sg13
I1
sa(dp16039
g7
I105
sg8
VP20702
p16040
sg10
I3
sg11
VCR4
p16041
sg13
I1
sa(dp16042
g7
I88
sg8
VP11215
p16043
sg10
I5
sg11
VCD11b
p16044
sg13
I1
sa(dp16045
g7
I110
sg8
VP11274
p16046
sg10
I4
sg11
VCD35
p16047
sg13
I1
sa(dp16048
g7
I120
sg8
VP08174
p16049
sg10
I4
sg11
VCD55
p16050
sg13
I1
sa(dp16051
g7
I94
sg8
VP51864
p16052
sg10
I3
sg11
VCR3
p16053
sg13
I1
sa(dp16054
g7
I135
sg8
VP13987
p16055
sg10
I4
sg11
VMIRL
p16056
sg13
I1
sa(dp16057
g7
I99
sg8
VP20702
p16058
sg10
I5
sg11
VCD11c
p16059
sg13
I1
sa(dp16060
g7
I141
sg8
VP21730
p16061
sg10
I4
sg11
VCD88
p16062
sg13
I1
sasg23
(lp16063
(dp16064
g7
I278
sg26
VC0018939
p16065
sg10
I24
sg11
Vhaematological disorders
p16066
sg13
I2
sa(dp16067
g7
I197
sg26
VC0683278
p16068
sg10
I9
sg11
Vsuffering
p16069
sg13
I1
sa(dp16070
g7
I235
sg26
VC0221013
p16071
sg10
I2
sg11
VSM
p16072
sg13
I1
sa(dp16073
g7
I212
sg26
VC0221013
p16074
sg10
I21
sg11
Vsystemic mastocytosis
p16075
sg13
I2
sasa(dp16076
g2
S'A cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats.\n'
p16077
sg4
(lp16078
(dp16079
g7
I154
sg8
VP21730
p16080
sg10
I4
sg11
VCD88
p16081
sg13
I1
sa(dp16082
g7
I133
sg8
VP21730
p16083
sg10
I3
sg11
VC5a
p16084
sg13
I1
sasg23
(lp16085
(dp16086
g7
I260
sg26
VC0036983
p16087
sg10
I12
sg11
Vseptic shock
p16088
sg13
I2
sa(dp16089
g7
I304
sg26
VC0175697
p16090
sg10
I3
sg11
VLPS
p16091
sg13
I1
sa(dp16092
g7
I284
sg26
VC0175697
p16093
sg10
I18
sg11
Vlipopolysaccharide
p16094
sg13
I1
sasa(dp16095
g2
S'Some in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs).\n'
p16096
sg4
(lp16097
(dp16098
g7
I31
sg8
g107
sg10
I14
sg11
Vcomplement C5a
p16099
sg13
I2
sasg23
(lp16100
sa(dp16101
g2
S'The abnormal C5aR expression on eosinophils and neutrophils became normal after spontaneous resolution of symptoms and blood eosinophilia.\n'
p16102
sg4
(lp16103
(dp16104
g7
I13
sg8
VP21730
p16105
sg10
I4
sg11
VC5aR
p16106
sg13
I1
sasg23
(lp16107
(dp16108
g7
I125
sg26
VC0014457
p16109
sg10
I12
sg11
Veosinophilia
p16110
sg13
I1
sasa(dp16111
g2
S'The therapeutic potential of DPPSC was tested in a wound healing mouse model and in two genetic mouse models of muscular dystrophy (Scid/mdx and Sgcb-null Rag2-null Gammac-null).\n'
p16112
sg4
(lp16113
(dp16114
g7
I145
sg8
VP55895
p16115
sg10
I31
sg11
VSgcb-null Rag2-null Gammac-null
p16116
sg13
I3
sasg23
(lp16117
(dp16118
g7
I112
sg26
VC0026850
p16119
sg10
I18
sg11
Vmuscular dystrophy
p16120
sg13
I2
sa(dp16121
g7
I137
sg26
VC1839839
p16122
sg10
I3
sg11
Vmdx
p16123
sg13
I1
sa(dp16124
g7
I132
sg26
VC0085110
p16125
sg10
I4
sg11
VScid
p16126
sg13
I1
sasa(dp16127
g2
S'Mutations in the RAG1/RAG2 genes are associated with a broad spectrum of clinical phenotypes, ranging from severe combined immunodeficiency to various autoimmune diseases.\n'
p16128
sg4
(lp16129
(dp16130
g7
I22
sg8
VP55895
p16131
sg10
I4
sg11
VRAG2
p16132
sg13
I1
sa(dp16133
g7
I17
sg8
VP15918
p16134
sg10
I4
sg11
VRAG1
p16135
sg13
I1
sasg23
(lp16136
(dp16137
g7
I107
sg26
VC0085110
p16138
sg10
I32
sg11
Vsevere combined immunodeficiency
p16139
sg13
I3
sa(dp16140
g7
I151
sg26
VC0004364
p16141
sg10
I19
sg11
Vautoimmune diseases
p16142
sg13
I2
sasa(dp16143
g2
S'In this review, the molecular pathology of diseases caused by RAG1/RAG2 mutations, in particular Omenn syndrome, will be discussed.\n'
p16144
sg4
(lp16145
(dp16146
g7
I62
sg8
VP15918
p16147
sg10
I4
sg11
VRAG1
p16148
sg13
I1
sa(dp16149
g7
I67
sg8
VP55895
p16150
sg10
I4
sg11
VRAG2
p16151
sg13
I1
sasg23
(lp16152
(dp16153
g7
I30
sg26
VC0677042
p16154
sg10
I9
sg11
Vpathology
p16155
sg13
I1
sa(dp16156
g7
I97
sg26
VC1801959
p16157
sg10
I14
sg11
VOmenn syndrome
p16158
sg13
I2
sasa(dp16159
g2
S'Severe combined immunodeficiency (SCID) is a potentially fatal primary immunodeficiency (PID) that is caused by mutations in genes such as IL2RG, JAK3, IL7RA, RAG1, RAG2, and ADA.\n'
p16160
sg4
(lp16161
(dp16162
g7
I159
sg8
VP15918
p16163
sg10
I4
sg11
VRAG1
p16164
sg13
I1
sa(dp16165
g7
I139
sg8
VP31785
p16166
sg10
I5
sg11
VIL2RG
p16167
sg13
I1
sa(dp16168
g7
I175
sg8
VP00813
p16169
sg10
I3
sg11
VADA
p16170
sg13
I1
sa(dp16171
g7
I165
sg8
VP55895
p16172
sg10
I4
sg11
VRAG2
p16173
sg13
I1
sa(dp16174
g7
I146
sg8
VP52333
p16175
sg10
I4
sg11
VJAK3
p16176
sg13
I1
sasg23
(lp16177
(dp16178
g7
I34
sg26
VC0085110
p16179
sg10
I4
sg11
VSCID
p16180
sg13
I1
sa(dp16181
g7
I63
sg26
VC0398686
p16182
sg10
I24
sg11
Vprimary immunodeficiency
p16183
sg13
I2
sa(dp16184
g7
I0
sg26
VC0085110
p16185
sg10
I32
sg11
VSevere combined immunodeficiency
p16186
sg13
I3
sa(dp16187
g7
I89
sg26
VC0242172
p16188
sg10
I3
sg11
VPID
p16189
sg13
I1
sasa(dp16190
g2
S'Severe combined immunodeficiency can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as recombination-activating gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C).\n'
p16191
sg4
(lp16192
(dp16193
g7
I139
sg8
VP15918
p16194
sg10
I31
sg11
Vrecombination-activating gene 1
p16195
sg13
I3
sa(dp16196
g7
I179
sg8
VP55895
p16197
sg10
I4
sg11
VRAG2
p16198
sg13
I1
sa(dp16199
g7
I172
sg8
VP15918
p16200
sg10
I4
sg11
VRAG1
p16201
sg13
I1
sasg23
(lp16202
(dp16203
g7
I0
sg26
VC0085110
p16204
sg10
I32
sg11
VSevere combined immunodeficiency
p16205
sg13
I3
sasa(dp16206
g2
S'Seven of the 98 cases (7%) of carcinomas showed TLE-1 expression, including 1 each of prostate adenocarcinoma (ADCA), esophageal ADCA, basal cell carcinoma, adrenocortical carcinoma, endometrial ADCA, ovarian serous carcinoma, and small cell carcinoma.\n'
p16207
sg4
(lp16208
sg23
(lp16209
(dp16210
g7
I86
sg26
VC0007112
p16211
sg10
I23
sg11
Vprostate adenocarcinoma
p16212
sg13
I2
sa(dp16213
g7
I231
sg26
VC0262584
p16214
sg10
I20
sg11
Vsmall cell carcinoma
p16215
sg13
I3
sa(dp16216
g7
I111
sg26
VC0007112
p16217
sg10
I4
sg11
VADCA
p16218
sg13
I1
sa(dp16219
g7
I111
sg26
VC0007112
p16220
sg10
I4
sg11
VADCA
p16221
sg13
I1
sa(dp16222
g7
I48
sg26
VC0014556
p16223
sg10
I3
sg11
VTLE
p16224
sg13
I1
sa(dp16225
g7
I146
sg26
VC0206686
p16226
sg10
I25
sg11
Vcarcinoma, adrenocortical
p16227
sg13
I2
sa(dp16228
g7
I30
sg26
VC0007097
p16229
sg10
I10
sg11
Vcarcinomas
p16230
sg13
I1
sa(dp16231
g7
I111
sg26
VC0007112
p16232
sg10
I4
sg11
VADCA
p16233
sg13
I1
sa(dp16234
g7
I172
sg26
VC0476089
p16235
sg10
I22
sg11
Vcarcinoma, endometrial
p16236
sg13
I2
sa(dp16237
g7
I201
sg26
VC1335177
p16238
sg10
I24
sg11
Vovarian serous carcinoma
p16239
sg13
I3
sasa(dp16240
g2
S'Here, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN).\n'
p16241
sg4
(lp16242
(dp16243
g7
I149
sg8
VP31947
p16244
sg10
I6
sg11
VMES-SA
p16245
sg13
I1
sa(dp16246
g7
I77
sg8
VP14679
p16247
sg10
I24
sg11
Vtyrosine kinas inhibitor
p16248
sg13
I3
sa(dp16249
g7
I103
sg8
VP14679
p16250
sg10
I3
sg11
VTKI
p16251
sg13
I1
sa(dp16252
g7
I172
sg8
g107
sg10
I3
sg11
VSKN
p16253
sg13
I1
sasg23
(lp16254
(dp16255
g7
I149
sg26
VC0265215
p16256
sg10
I3
sg11
VMES
p16257
sg13
I1
sa(dp16258
g7
I121
sg26
VC0338113
p16259
sg10
I15
sg11
Vuterine sarcoma
p16260
sg13
I2
sa(dp16261
g7
I149
sg26
VC0265215
p16262
sg10
I3
sg11
VMES
p16263
sg13
I1
sasa(dp16264
g2
S'Previous studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid.\n'
p16265
sg4
(lp16266
(dp16267
g7
I112
sg8
VP07998
p16268
sg10
I7
sg11
VRNase P
p16269
sg13
I2
sasg23
(lp16270
(dp16271
g7
I212
sg26
VC0027651
p16272
sg10
I5
sg11
Vtumor
p16273
sg13
I1
sa(dp16274
g7
I230
sg26
VC0600139
p16275
sg10
I15
sg11
Vprostate cancer
p16276
sg13
I2
sasa(dp16277
g2
S'These results suggest RASP, as a promising lead compound for the treatment of several dermatological disorders and certain cancer types, has apparently minimal toxic side-effects as revealed in this two-generation reproduction study in rats.\n'
p16278
sg4
(lp16279
(dp16280
g7
I22
sg8
g107
sg10
I4
sg11
VRASP
p16281
sg13
I1
sasg23
(lp16282
(dp16283
g7
I86
sg26
VC0037274
p16284
sg10
I24
sg11
Vdermatological disorders
p16285
sg13
I2
sa(dp16286
g7
I123
sg26
VC0006826
p16287
sg10
I6
sg11
Vcancer
p16288
sg13
I1
sasa(dp16289
g2
S'To determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells.\n'
p16290
sg4
(lp16291
(dp16292
g7
I155
sg8
VP03372
p16293
sg10
I2
sg11
VER
p16294
sg13
I1
sa(dp16295
g7
I169
sg8
VP04626
p16296
sg10
I4
sg11
VHER2
p16297
sg13
I1
sa(dp16298
g7
I136
sg8
VP03372
p16299
sg10
I17
sg11
Vestrogen receptor
p16300
sg13
I2
sasg23
(lp16301
(dp16302
g7
I63
sg26
VC0678222
p16303
sg10
I13
sg11
Vbreast cancer
p16304
sg13
I2
sa(dp16305
g7
I63
sg26
VC0678222
p16306
sg10
I13
sg11
Vbreast cancer
p16307
sg13
I2
sasa(dp16308
g2
S'Depletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER positive, but not triple negative, breast cancer cells.\n'
p16309
sg4
(lp16310
sg23
(lp16311
(dp16312
g7
I129
sg26
VC0678222
p16313
sg10
I13
sg11
Vbreast cancer
p16314
sg13
I2
sa(dp16315
g7
I74
sg26
VC0334094
p16316
sg10
I13
sg11
Vproliferation
p16317
sg13
I1
sasa(dp16318
g2
S'These data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.\n'
p16319
sg4
(lp16320
(dp16321
g7
I67
sg8
VP04626
p16322
sg10
I4
sg11
VHER2
p16323
sg13
I1
sasg23
(lp16324
(dp16325
g7
I105
sg26
VC0678222
p16326
sg10
I13
sg11
Vbreast cancer
p16327
sg13
I2
sa(dp16328
g7
I119
sg26
VC0334094
p16329
sg10
I13
sg11
Vproliferation
p16330
sg13
I1
sa(dp16331
g7
I105
sg26
VC0678222
p16332
sg10
I13
sg11
Vbreast cancer
p16333
sg13
I2
sasa(dp16334
g2
S'Hedgehog acyltransferase (HHAT) is the enzyme in the endoplasmic reticulum that palmitoylates Hedgehog proteins, is a member of a small subfamily of membrane-bound O-acyltransferase proteins that acylate secreted proteins, and is an important drug target in cancer.\n'
p16335
sg4
(lp16336
(dp16337
g7
I26
sg8
g107
sg10
I4
sg11
VHHAT
p16338
sg13
I1
sa(dp16339
g7
I164
sg8
VP02649
p16340
sg10
I26
sg11
VO-acyltransferase proteins
p16341
sg13
I2
sa(dp16342
g7
I0
sg8
g107
sg10
I24
sg11
VHedgehog acyltransferase
p16343
sg13
I2
sasg23
(lp16344
(dp16345
g7
I258
sg26
VC0006826
p16346
sg10
I6
sg11
Vcancer
p16347
sg13
I1
sasa(dp16348
g2
S'The STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a cholesterol-binding membrane protein.\n'
p16349
sg4
(lp16350
(dp16351
g7
I51
sg8
VP04626
p16352
sg10
I4
sg11
VHER2
p16353
sg13
I1
sa(dp16354
g7
I4
sg8
g107
sg10
I11
sg11
VSTARD3 gene
p16355
sg13
I2
sa(dp16356
g7
I94
sg8
VP63244
p16357
sg10
I36
sg11
Vcholesterol-binding membrane protein
p16358
sg13
I3
sasg23
(lp16359
(dp16360
g7
I65
sg26
VC0006142
p16361
sg10
I14
sg11
Vbreast cancers
p16362
sg13
I2
sasa(dp16363
g2
S'To study how elevated StAR-related lipid transfer protein 3 (StARD3) expression affects breast cancer cells, we generated MCF-7 cells stably overexpressing StARD3-green fluorescent protein.\n'
p16364
sg4
(lp16365
(dp16366
g7
I156
sg8
g107
sg10
I32
sg11
VStARD3-green fluorescent protein
p16367
sg13
I3
sa(dp16368
g7
I22
sg8
g107
sg10
I37
sg11
VStAR-related lipid transfer protein 3
p16369
sg13
I5
sa(dp16370
g7
I61
sg8
g107
sg10
I6
sg11
VStARD3
p16371
sg13
I1
sasg23
(lp16372
(dp16373
g7
I88
sg26
VC0678222
p16374
sg10
I13
sg11
Vbreast cancer
p16375
sg13
I2
sa(dp16376
g7
I22
sg26
VC2678045
p16377
sg10
I4
sg11
VStAR
p16378
sg13
I1
sasa(dp16379
g2
S'In two Finnish nationwide patient cohorts, approximately 10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly associated with HER2 amplification; several factors related to poor disease outcome and poor breast cancer-specific survival.\n'
p16380
sg4
(lp16381
(dp16382
g7
I160
sg8
VP04626
p16383
sg10
I4
sg11
VHER2
p16384
sg13
I1
sa(dp16385
g7
I102
sg8
g107
sg10
I14
sg11
VStARD3 protein
p16386
sg13
I2
sasg23
(lp16387
(dp16388
g7
I165
sg26
VC1705759
p16389
sg10
I13
sg11
Vamplification
p16390
sg13
I1
sa(dp16391
g7
I72
sg26
VC0006142
p16392
sg10
I14
sg11
Vbreast cancers
p16393
sg13
I2
sa(dp16394
g7
I72
sg26
VC0006142
p16395
sg10
I13
sg11
Vbreast cancer
p16396
sg13
I2
sasa(dp16397
g2
S'In addition, high StARD3 levels in breast cancers were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti-Src-Tyr416 immunoreactivity.\n'
p16398
sg4
(lp16399
(dp16400
g7
I80
sg8
VP04035
p16401
sg10
I52
sg11
V3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA
p16402
sg13
I4
sa(dp16403
g7
I144
sg8
VP12931
p16404
sg10
I8
sg11
Vanti-Src
p16405
sg13
I1
sa(dp16406
g7
I18
sg8
g107
sg10
I6
sg11
VStARD3
p16407
sg13
I1
sasg23
(lp16408
(dp16409
g7
I35
sg26
VC0006142
p16410
sg10
I14
sg11
Vbreast cancers
p16411
sg13
I2
sasa(dp16412
g2
S'These results provide evidence that StARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling.\n'
p16413
sg4
(lp16414
(dp16415
g7
I36
sg8
g107
sg10
I6
sg11
VStARD3
p16416
sg13
I1
sa(dp16417
g7
I108
sg8
VP12931
p16418
sg10
I10
sg11
VSrc kinase
p16419
sg13
I2
sa(dp16420
g7
I36
sg8
g107
sg10
I6
sg11
VStARD3
p16421
sg13
I1
sasg23
(lp16422
(dp16423
g7
I227
sg26
VC0001807
p16424
sg10
I14
sg11
Vaggressiveness
p16425
sg13
I1
sa(dp16426
g7
I131
sg26
VC0678222
p16427
sg10
I13
sg11
Vbreast cancer
p16428
sg13
I2
sa(dp16429
g7
I131
sg26
VC0678222
p16430
sg10
I13
sg11
Vbreast cancer
p16431
sg13
I2
sasa(dp16432
g2
S'In addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.\n'
p16433
sg4
(lp16434
(dp16435
g7
I124
sg8
g107
sg10
I4
sg11
VMED1
p16436
sg13
I1
sa(dp16437
g7
I138
sg8
g107
sg10
I4
sg11
VGRB7
p16438
sg13
I1
sa(dp16439
g7
I144
sg8
VP10827
p16440
sg10
I4
sg11
VTHRA
p16441
sg13
I1
sa(dp16442
g7
I187
sg8
VP01350
p16443
sg10
I4
sg11
VGAST
p16444
sg13
I1
sa(dp16445
g7
I130
sg8
g107
sg10
I6
sg11
VSTARD3
p16446
sg13
I1
sa(dp16447
g7
I164
sg8
VP32248
p16448
sg10
I4
sg11
VCCR7
p16449
sg13
I1
sa(dp16450
g7
I150
sg8
VP10276
p16451
sg10
I4
sg11
VRARA
p16452
sg13
I1
sa(dp16453
g7
I170
sg8
VP35900
p16454
sg10
I5
sg11
VKRT20
p16455
sg13
I1
sasg23
(lp16456
(dp16457
g7
I196
sg26
VC0678222
p16458
sg10
I13
sg11
Vbreast cancer
p16459
sg13
I2
sa(dp16460
g7
I76
sg26
VC1705759
p16461
sg10
I13
sg11
Vamplification
p16462
sg13
I1
sasa(dp16463
g2
S'Using a quantitative polymerase chain reaction method and DNA extracted from frozen tumor specimens, 11 genes (MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19 and GAS), which are localized within Chr17q12-q21 and have a putative role in breast cancer development, were quantified.\n'
p16464
sg4
(lp16465
(dp16466
g7
I156
sg8
VP22692
p16467
sg10
I6
sg11
VIGFBP4
p16468
sg13
I1
sa(dp16469
g7
I131
sg8
g107
sg10
I4
sg11
VGRB7
p16470
sg13
I1
sa(dp16471
g7
I111
sg8
g107
sg10
I4
sg11
VMED1
p16472
sg13
I1
sa(dp16473
g7
I117
sg8
g107
sg10
I6
sg11
VSTARD3
p16474
sg13
I1
sa(dp16475
g7
I170
sg8
VP35900
p16476
sg10
I5
sg11
VKRT20
p16477
sg13
I1
sa(dp16478
g7
I149
sg8
g107
sg10
I5
sg11
VTOP2A
p16479
sg13
I1
sa(dp16480
g7
I164
sg8
VP32248
p16481
sg10
I4
sg11
VCCR7
p16482
sg13
I1
sa(dp16483
g7
I125
sg8
VP04626
p16484
sg10
I4
sg11
VHER2
p16485
sg13
I1
sa(dp16486
g7
I137
sg8
VP10827
p16487
sg10
I4
sg11
VTHRA
p16488
sg13
I1
sa(dp16489
g7
I187
sg8
VP01350
p16490
sg10
I3
sg11
VGAS
p16491
sg13
I1
sa(dp16492
g7
I143
sg8
VP10276
p16493
sg10
I4
sg11
VRARA
p16494
sg13
I1
sasg23
(lp16495
(dp16496
g7
I261
sg26
VC0678222
p16497
sg10
I13
sg11
Vbreast cancer
p16498
sg13
I2
sa(dp16499
g7
I84
sg26
VC0027651
p16500
sg10
I5
sg11
Vtumor
p16501
sg13
I1
sasa(dp16502
g2
S'The metastatic lymph node 64 (MLN64) gene was initially identified as highly expressed in the metastatic lymph node from breast cancer.\n'
p16503
sg4
(lp16504
(dp16505
g7
I30
sg8
g107
sg10
I5
sg11
VMLN64
p16506
sg13
I1
sa(dp16507
g7
I4
sg8
g107
sg10
I24
sg11
Vmetastatic lymph node 64
p16508
sg13
I4
sasg23
(lp16509
(dp16510
g7
I121
sg26
VC0678222
p16511
sg10
I13
sg11
Vbreast cancer
p16512
sg13
I2
sasa(dp16513
g2
S'However, the role played by MLN64 in breast cancer remains unclear.\n'
p16514
sg4
(lp16515
(dp16516
g7
I28
sg8
g107
sg10
I5
sg11
VMLN64
p16517
sg13
I1
sasg23
(lp16518
(dp16519
g7
I37
sg26
VC0678222
p16520
sg10
I13
sg11
Vbreast cancer
p16521
sg13
I2
sasa(dp16522
g2
S'In the present study, the expression of MLN64 was examined in a breast cancer cohort using quantitative real-time PCR and immunohistochemical staining.\n'
p16523
sg4
(lp16524
(dp16525
g7
I40
sg8
g107
sg10
I5
sg11
VMLN64
p16526
sg13
I1
sasg23
(lp16527
(dp16528
g7
I64
sg26
VC0678222
p16529
sg10
I13
sg11
Vbreast cancer
p16530
sg13
I2
sasa(dp16531
g2
S'A panel of breast cancer cell sublines was subsequently developed by knockdown of MLN64 expression.\n'
p16532
sg4
(lp16533
(dp16534
g7
I82
sg8
g107
sg10
I5
sg11
VMLN64
p16535
sg13
I1
sasg23
(lp16536
(dp16537
g7
I11
sg26
VC0678222
p16538
sg10
I13
sg11
Vbreast cancer
p16539
sg13
I2
sasa(dp16540
g2
S'In conclusion, MLN64 is overexpressed in breast cancer, and its level correlates with poor prognosis and patient survival.\n'
p16541
sg4
(lp16542
(dp16543
g7
I15
sg8
g107
sg10
I5
sg11
VMLN64
p16544
sg13
I1
sasg23
(lp16545
(dp16546
g7
I41
sg26
VC0678222
p16547
sg10
I13
sg11
Vbreast cancer
p16548
sg13
I2
sasa(dp16549
g2
S'MLN64 contributes to the development and progression of breast cancer through the regulation of cell proliferation and adhesive capacity.\n'
p16550
sg4
(lp16551
(dp16552
g7
I0
sg8
g107
sg10
I5
sg11
VMLN64
p16553
sg13
I1
sasg23
(lp16554
(dp16555
g7
I101
sg26
VC0334094
p16556
sg10
I13
sg11
Vproliferation
p16557
sg13
I1
sa(dp16558
g7
I56
sg26
VC0678222
p16559
sg10
I13
sg11
Vbreast cancer
p16560
sg13
I2
sasa(dp16561
g2
S'STARD3 and RARA also hold clinical relevance, the former having been shown to function in steroidogenesis and therefore implicated in hormone-receptor-positive breast cancer.\n'
p16562
sg4
(lp16563
(dp16564
g7
I0
sg8
g107
sg10
I6
sg11
VSTARD3
p16565
sg13
I1
sa(dp16566
g7
I11
sg8
VP10276
p16567
sg10
I4
sg11
VRARA
p16568
sg13
I1
sasg23
(lp16569
(dp16570
g7
I160
sg26
VC0678222
p16571
sg10
I13
sg11
Vbreast cancer
p16572
sg13
I2
sasa(dp16573
g2
S'We used a genetic association study design to determine if common genetic variation (frequency&gt;or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk.\n'
p16574
sg4
(lp16575
(dp16576
g7
I169
sg8
g107
sg10
I4
sg11
VCRK7
p16577
sg13
I1
sa(dp16578
g7
I175
sg8
g107
sg10
I7
sg11
VNEUROD2
p16579
sg13
I1
sa(dp16580
g7
I207
sg8
VP11086
p16581
sg10
I4
sg11
VPNMT
p16582
sg13
I1
sa(dp16583
g7
I226
sg8
g107
sg10
I8
sg11
VC17ORF37
p16584
sg13
I1
sa(dp16585
g7
I184
sg8
g107
sg10
I7
sg11
VPPP1R1B
p16586
sg13
I1
sa(dp16587
g7
I236
sg8
g107
sg10
I4
sg11
VGRB7
p16588
sg13
I1
sa(dp16589
g7
I161
sg8
g107
sg10
I6
sg11
VPPARBP
p16590
sg13
I1
sa(dp16591
g7
I213
sg8
g107
sg10
I4
sg11
VCAB2
p16592
sg13
I1
sa(dp16593
g7
I245
sg8
g107
sg10
I13
sg11
VZNFN1A3 genes
p16594
sg13
I2
sa(dp16595
g7
I193
sg8
g107
sg10
I6
sg11
VSTARD3
p16596
sg13
I1
sa(dp16597
g7
I136
sg8
VP04626
p16598
sg10
I5
sg11
VERBB2
p16599
sg13
I1
sa(dp16600
g7
I136
sg8
VP04626
p16601
sg10
I5
sg11
VERBB2
p16602
sg13
I1
sa(dp16603
g7
I201
sg8
g107
sg10
I4
sg11
VTCAP
p16604
sg13
I1
sasg23
(lp16605
(dp16606
g7
I280
sg26
VC0678222
p16607
sg10
I13
sg11
Vbreast cancer
p16608
sg13
I2
sasa(dp16609
g2
S'The applicability of salivary Beta -hexosaminidase (Beta-HEX A%, percentage of Beta-HEX A isoenzyme to total Beta-HEX) and Beta-HEX B% (Beta-HEX B/Beta-HEX) indexes was investigated as a possible marker of periodontitis.\n'
p16610
sg4
(lp16611
(dp16612
g7
I21
sg8
VP04745
p16613
sg10
I29
sg11
Vsalivary Beta -hexosaminidase
p16614
sg13
I3
sa(dp16615
g7
I52
sg8
g107
sg10
I8
sg11
VBeta-HEX
p16616
sg13
I1
sa(dp16617
g7
I52
sg8
g107
sg10
I8
sg11
VBeta-HEX
p16618
sg13
I1
sa(dp16619
g7
I123
sg8
g107
sg10
I11
sg11
VBeta-HEX B%
p16620
sg13
I2
sa(dp16621
g7
I123
sg8
g107
sg10
I10
sg11
VBeta-HEX B
p16622
sg13
I2
sa(dp16623
g7
I52
sg8
g107
sg10
I10
sg11
VBeta-HEX A
p16624
sg13
I2
sasg23
(lp16625
(dp16626
g7
I206
sg26
VC0031099
p16627
sg10
I13
sg11
Vperiodontitis
p16628
sg13
I1
sasa(dp16629
g2
S'Salivary Beta-HEX A% is a promising excellent marker for the diagnosis of periodontitis.\n'
p16630
sg4
(lp16631
sg23
(lp16632
(dp16633
g7
I74
sg26
VC0031099
p16634
sg10
I13
sg11
Vperiodontitis
p16635
sg13
I1
sasa(dp16636
g2
S'To evaluate the prognostic impact of gene expression levels (ELs) of two tumor suppressor genes, sprouty 4 (SPRY4, located on 5q) and lysine methyltransferase 2C (KMT2C, located on 7q) in correlation with clinical characteristics and genetic abnormalities assessed at initial diagnosis in acute myeloid leukemia (AML).\n'
p16637
sg4
(lp16638
(dp16639
g7
I163
sg8
g107
sg10
I5
sg11
VKMT2C
p16640
sg13
I1
sa(dp16641
g7
I134
sg8
g107
sg10
I27
sg11
Vlysine methyltransferase 2C
p16642
sg13
I3
sa(dp16643
g7
I97
sg8
g107
sg10
I9
sg11
Vsprouty 4
p16644
sg13
I2
sa(dp16645
g7
I108
sg8
g107
sg10
I5
sg11
VSPRY4
p16646
sg13
I1
sasg23
(lp16647
(dp16648
g7
I73
sg26
VC0027651
p16649
sg10
I5
sg11
Vtumor
p16650
sg13
I1
sa(dp16651
g7
I313
sg26
VC0023467
p16652
sg10
I3
sg11
VAML
p16653
sg13
I1
sa(dp16654
g7
I289
sg26
VC0023467
p16655
sg10
I22
sg11
Vacute myeloid leukemia
p16656
sg13
I3
sasa(dp16657
g2
S'As a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.\n'
p16658
sg4
(lp16659
(dp16660
g7
I50
sg8
VP29323
p16661
sg10
I3
sg11
VERK
p16662
sg13
I1
sa(dp16663
g7
I46
sg8
VP01116
p16664
sg10
I3
sg11
VRAS
p16665
sg13
I1
sasg23
(lp16666
(dp16667
g7
I143
sg26
VC0006826
p16668
sg10
I7
sg11
Vcancers
p16669
sg13
I1
sa(dp16670
g7
I158
sg26
VC0024623
p16671
sg10
I14
sg11
Vgastric cancer
p16672
sg13
I2
sasa(dp16673
g2
S'Sprouty proteins are modulators of mitogeninduced signal transduction processes and therefore can influence the process of cancerogenesis.\n'
p16674
sg4
(lp16675
sg23
(lp16676
sa(dp16677
g2
S'The encoded protein of Sprouty homolog 4 (SPRY4) is associated with various human cancers.\n'
p16678
sg4
(lp16679
(dp16680
g7
I23
sg8
g107
sg10
I17
sg11
VSprouty homolog 4
p16681
sg13
I3
sa(dp16682
g7
I42
sg8
g107
sg10
I5
sg11
VSPRY4
p16683
sg13
I1
sasg23
(lp16684
(dp16685
g7
I82
sg26
VC0006826
p16686
sg10
I7
sg11
Vcancers
p16687
sg13
I1
sasa(dp16688
g2
S'We show that these retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared by all subtypes, such as SPRY1, and other lineage-specific super-enhancers, such as SOX2 in brain-derived rhabdoid tumors.\n'
p16689
sg4
(lp16690
(dp16691
g7
I202
sg8
VP48431
p16692
sg10
I4
sg11
VSOX2
p16693
sg13
I1
sa(dp16694
g7
I143
sg8
g107
sg10
I5
sg11
VSPRY1
p16695
sg13
I1
sasg23
(lp16696
(dp16697
g7
I224
sg26
VC0206743
p16698
sg10
I15
sg11
Vrhabdoid tumors
p16699
sg13
I2
sa(dp16700
g7
I62
sg26
VC0206743
p16701
sg10
I14
sg11
Vrhabdoid tumor
p16702
sg13
I2
sasa(dp16703
g2
S'As a member of the Sprouty family, Sprouty4 has been previously shown to function as a tumour suppressor in lung and breast cancer.\n'
p16704
sg4
(lp16705
sg23
(lp16706
(dp16707
g7
I117
sg26
VC0678222
p16708
sg10
I13
sg11
Vbreast cancer
p16709
sg13
I2
sa(dp16710
g7
I87
sg26
VC0027651
p16711
sg10
I6
sg11
Vtumour
p16712
sg13
I1
sasa(dp16713
g2
S'In this issue of Blood, Dietrich et al make the first observation of the presence of deleterious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).\n'
p16714
sg4
(lp16715
(dp16716
g7
I97
sg8
VP46527
p16717
sg10
I15
sg11
VCDKN1B mutation
p16718
sg13
I2
sasg23
(lp16719
(dp16720
g7
I137
sg26
VC0023443
p16721
sg10
I19
sg11
Vhairy cell leukemia
p16722
sg13
I3
sa(dp16723
g7
I158
sg26
VC0023443
p16724
sg10
I3
sg11
VHCL
p16725
sg13
I1
sasa(dp16726
g2
S'We previously found that global CypD knockout mice (KO) are protected from diet-induced glucose intolerance; however, the tissue-specific function of CypD and mPTP, particularly in the control of glucose homeostasis, has not been ascertained.\n'
p16727
sg4
(lp16728
(dp16729
g7
I32
sg8
g107
sg10
I4
sg11
VCypD
p16730
sg13
I1
sasg23
(lp16731
(dp16732
g7
I88
sg26
VC0271650
p16733
sg10
I19
sg11
Vglucose intolerance
p16734
sg13
I2
sasa(dp16735
g2
S'Mice lacking CypD were protected from high fat diet-induced glucose intolerance due to increased glucose uptake in skeletal muscle.\n'
p16736
sg4
(lp16737
(dp16738
g7
I13
sg8
g107
sg10
I4
sg11
VCypD
p16739
sg13
I1
sasg23
(lp16740
(dp16741
g7
I60
sg26
VC0271650
p16742
sg10
I19
sg11
Vglucose intolerance
p16743
sg13
I2
sasa(dp16744
g2
S'Adult CypD(-/-) developed hyperglycemia, insulin resistance and glucose intolerance albeit resistant to DIO.\n'
p16745
sg4
(lp16746
(dp16747
g7
I6
sg8
g107
sg10
I4
sg11
VCypD
p16748
sg13
I1
sa(dp16749
g7
I41
sg8
VP01308
p16750
sg10
I7
sg11
Vinsulin
p16751
sg13
I1
sasg23
(lp16752
(dp16753
g7
I64
sg26
VC0271650
p16754
sg10
I19
sg11
Vglucose intolerance
p16755
sg13
I2
sa(dp16756
g7
I26
sg26
VC0020456
p16757
sg10
I13
sg11
Vhyperglycemia
p16758
sg13
I1
sa(dp16759
g7
I41
sg26
VC0021655
p16760
sg10
I18
sg11
Vinsulin resistance
p16761
sg13
I2
sasa(dp16762
g2
S'In elderly patients, atrial fibrillation has a limited effect on VWF, and the age is an important factor affecting the endothelial function.\n'
p16763
sg4
(lp16764
sg23
(lp16765
(dp16766
g7
I21
sg26
VC0004238
p16767
sg10
I19
sg11
Vatrial fibrillation
p16768
sg13
I2
sasa(dp16769
g2
S'von Willebrand factor (VWF) is an independent risk factor for adverse events in patients with non-valvular atrial fibrillation (NVAF).\n'
p16770
sg4
(lp16771
(dp16772
g7
I23
sg8
VP04275
p16773
sg10
I3
sg11
VVWF
p16774
sg13
I1
sa(dp16775
g7
I0
sg8
VP04275
p16776
sg10
I21
sg11
Vvon Willebrand factor
p16777
sg13
I3
sasg23
(lp16778
(dp16779
g7
I107
sg26
VC0004238
p16780
sg10
I19
sg11
Vatrial fibrillation
p16781
sg13
I2
sasa(dp16782
g2
S'Higher VWF level correlated with higher CHADS2 scores and with progressing intensity of blood stasis in the left atrium and thrombus formation in all three time periods of atrial fibrillation duration.\n'
p16783
sg4
(lp16784
sg23
(lp16785
(dp16786
g7
I172
sg26
VC0004238
p16787
sg10
I19
sg11
Vatrial fibrillation
p16788
sg13
I2
sa(dp16789
g7
I94
sg26
VC0333138
p16790
sg10
I6
sg11
Vstasis
p16791
sg13
I1
sa(dp16792
g7
I124
sg26
VC0302148
p16793
sg10
I8
sg11
Vthrombus
p16794
sg13
I1
sasa(dp16795
g2
S'Patients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 levels.\n'
p16796
sg4
(lp16797
(dp16798
g7
I61
sg8
VP04275
p16799
sg10
I3
sg11
VvWF
p16800
sg13
I1
sasg23
(lp16801
(dp16802
g7
I35
sg26
VC0004238
p16803
sg10
I2
sg11
VAF
p16804
sg13
I1
sa(dp16805
g7
I14
sg26
VC0004238
p16806
sg10
I19
sg11
Vatrial fibrillation
p16807
sg13
I2
sasa(dp16808
g2
S"In a multicenter case-control association study, we studied the SNPs rs11136000 (clusterin, CLU), rs541458 (phosphatidylinositol binding clatrin assembly protein, PICALM), and rs1554948 (transcription factor A, and tyrosine kinase, non-receptor, 1, TNK1) according to the three age groups 50-65 years (group 1), 66-80 years (group 2), and 80+ years (group 3) in 569 older subjects without cognitive impairment (NoCI) and 520 Alzheimer's disease (AD) patients.\n"
p16809
sg4
(lp16810
(dp16811
g7
I215
sg8
VP29401
p16812
sg10
I15
sg11
Vtyrosine kinase
p16813
sg13
I2
sa(dp16814
g7
I108
sg8
VP63244
p16815
sg10
I36
sg11
Vphosphatidylinositol binding clatrin
p16816
sg13
I3
sa(dp16817
g7
I232
sg8
g107
sg10
I15
sg11
Vnon-receptor, 1
p16818
sg13
I2
sa(dp16819
g7
I249
sg8
g107
sg10
I4
sg11
VTNK1
p16820
sg13
I1
sasg23
(lp16821
(dp16822
g7
I446
sg26
VC1521724
p16823
sg10
I2
sg11
VAD
p16824
sg13
I1
sa(dp16825
g7
I389
sg26
VC0338656
p16826
sg10
I20
sg11
Vcognitive impairment
p16827
sg13
I2
sa(dp16828
g7
I425
sg26
VC1521724
p16829
sg10
I19
sg11
VAlzheimer's disease
p16830
sg13
I2
sasa(dp16831
g2
S"To study the association of apolipoprotein E (APOE), Clusterin (CLU) and phosphatidylinositol binding clathrin assembly protein (PICALM) polymorphisms in Alzheimer's disease (AD) subjects compared to cognitively normal control subjects in an Indian population.\n"
p16832
sg4
(lp16833
(dp16834
g7
I64
sg8
VP10909
p16835
sg10
I3
sg11
VCLU
p16836
sg13
I1
sa(dp16837
g7
I46
sg8
VP02649
p16838
sg10
I4
sg11
VAPOE
p16839
sg13
I1
sa(dp16840
g7
I28
sg8
VP02649
p16841
sg10
I16
sg11
Vapolipoprotein E
p16842
sg13
I2
sa(dp16843
g7
I73
sg8
VP63244
p16844
sg10
I37
sg11
Vphosphatidylinositol binding clathrin
p16845
sg13
I3
sa(dp16846
g7
I53
sg8
VP10909
p16847
sg10
I9
sg11
VClusterin
p16848
sg13
I1
sasg23
(lp16849
(dp16850
g7
I175
sg26
VC1521724
p16851
sg10
I2
sg11
VAD
p16852
sg13
I1
sa(dp16853
g7
I154
sg26
VC1521724
p16854
sg10
I19
sg11
VAlzheimer's disease
p16855
sg13
I2
sasa(dp16856
g2
S"Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.\n"
p16857
sg4
(lp16858
(dp16859
g7
I292
sg8
g107
sg10
I6
sg11
VPICALM
p16860
sg13
I1
sa(dp16861
g7
I176
sg8
g107
sg10
I5
sg11
VCD2AP
p16862
sg13
I1
sa(dp16863
g7
I270
sg8
g107
sg10
I6
sg11
VMS4A4E
p16864
sg13
I1
sa(dp16865
g7
I255
sg8
g107
sg10
I5
sg11
VMEF2C
p16866
sg13
I1
sa(dp16867
g7
I227
sg8
VP30486
p16868
sg10
I3
sg11
VHLA
p16869
sg13
I1
sa(dp16870
g7
I206
sg8
g107
sg10
I4
sg11
VDSG2
p16871
sg13
I1
sa(dp16872
g7
I189
sg8
g107
sg10
I5
sg11
VCELF1
p16873
sg13
I1
sa(dp16874
g7
I157
sg8
VP02649
p16875
sg10
I4
sg11
VAPOE
p16876
sg13
I1
sa(dp16877
g7
I150
sg8
g107
sg10
I5
sg11
VABCA7
p16878
sg13
I1
sa(dp16879
g7
I313
sg8
g107
sg10
I4
sg11
VRIN3
p16880
sg13
I1
sa(dp16881
g7
I328
sg8
g107
sg10
I5
sg11
VSORL1
p16882
sg13
I1
sa(dp16883
g7
I319
sg8
g107
sg10
I7
sg11
VSLC24A4
p16884
sg13
I1
sa(dp16885
g7
I247
sg8
g107
sg10
I6
sg11
VINPP5D
p16886
sg13
I1
sa(dp16887
g7
I262
sg8
g107
sg10
I6
sg11
VMS4A4A
p16888
sg13
I1
sa(dp16889
g7
I183
sg8
VP20138
p16890
sg10
I4
sg11
VCD33
p16891
sg13
I1
sa(dp16892
g7
I300
sg8
g107
sg10
I4
sg11
VPLD3
p16893
sg13
I1
sa(dp16894
g7
I219
sg8
g107
sg10
I6
sg11
VFERMT2
p16895
sg13
I1
sa(dp16896
g7
I169
sg8
g107
sg10
I5
sg11
VCASS4
p16897
sg13
I1
sa(dp16898
g7
I196
sg8
VP10909
p16899
sg10
I3
sg11
VCLU
p16900
sg13
I1
sa(dp16901
g7
I306
sg8
g107
sg10
I5
sg11
VPTK2B
p16902
sg13
I1
sa(dp16903
g7
I212
sg8
VP21709
p16904
sg10
I5
sg11
VEPHA1
p16905
sg13
I1
sa(dp16906
g7
I278
sg8
g107
sg10
I6
sg11
VMS4A6E
p16907
sg13
I1
sa(dp16908
g7
I227
sg8
VP30486
p16909
sg10
I3
sg11
VHLA
p16910
sg13
I1
sa(dp16911
g7
I201
sg8
VP17927
p16912
sg10
I3
sg11
VCR1
p16913
sg13
I1
sa(dp16914
g7
I339
sg8
g107
sg10
I12
sg11
VZCWPW1 genes
p16915
sg13
I2
sa(dp16916
g7
I286
sg8
g107
sg10
I4
sg11
VNME8
p16917
sg13
I1
sa(dp16918
g7
I231
sg8
g107
sg10
I4
sg11
VDRB1
p16919
sg13
I1
sasg23
(lp16920
(dp16921
g7
I95
sg26
VC0002395
p16922
sg10
I20
sg11
VAlzheimer's diseases
p16923
sg13
I2
sa(dp16924
g7
I117
sg26
VC0002395
p16925
sg10
I2
sg11
VAD
p16926
sg13
I1
sasa(dp16927
g2
S"The PICALM rs541458 T allele has been recognized as a risk factor for late-onset Alzheimer's disease, and age might modulate the effects that genetic factors have on cognitive functions and brain.\n"
p16928
sg4
(lp16929
(dp16930
g7
I4
sg8
g107
sg10
I24
sg11
VPICALM rs541458 T allele
p16931
sg13
I4
sasg23
(lp16932
(dp16933
g7
I81
sg26
VC1521724
p16934
sg10
I19
sg11
VAlzheimer's disease
p16935
sg13
I2
sasa(dp16936
g2
S"The association of variants in CLU, CR1, PICALM, BIN1, ABCA7, and CD33 genes with late-onset Alzheimer's disease (LOAD) was evaluated and confirmed through genome-wide association study.\n"
p16937
sg4
(lp16938
(dp16939
g7
I31
sg8
VP10909
p16940
sg10
I3
sg11
VCLU
p16941
sg13
I1
sa(dp16942
g7
I41
sg8
g107
sg10
I6
sg11
VPICALM
p16943
sg13
I1
sa(dp16944
g7
I55
sg8
g107
sg10
I5
sg11
VABCA7
p16945
sg13
I1
sa(dp16946
g7
I66
sg8
VP20138
p16947
sg10
I10
sg11
VCD33 genes
p16948
sg13
I2
sa(dp16949
g7
I36
sg8
VP17927
p16950
sg10
I3
sg11
VCR1
p16951
sg13
I1
sasg23
(lp16952
(dp16953
g7
I93
sg26
VC1521724
p16954
sg10
I19
sg11
VAlzheimer's disease
p16955
sg13
I2
sasa(dp16956
g2
S'In vivo, depletion of GDF-15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor development.\n'
p16957
sg4
(lp16958
(dp16959
g7
I22
sg8
g107
sg10
I6
sg11
VGDF-15
p16960
sg13
I1
sa(dp16961
g7
I32
sg8
VP01116
p16962
sg10
I3
sg11
VRas
p16963
sg13
I1
sasg23
(lp16964
(dp16965
g7
I43
sg26
VC0027651
p16966
sg10
I5
sg11
Vtumor
p16967
sg13
I1
sa(dp16968
g7
I90
sg26
VC0235974
p16969
sg10
I17
sg11
Vpancreatic cancer
p16970
sg13
I2
sa(dp16971
g7
I43
sg26
VC0027651
p16972
sg10
I5
sg11
Vtumor
p16973
sg13
I1
sasa(dp16974
g2
S'Further, production of GDF-15 is directly regulated by NF-KB, and the colocalization of activated NF-KB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of this observation.\n'
p16975
sg4
(lp16976
(dp16977
g7
I23
sg8
g107
sg10
I6
sg11
VGDF-15
p16978
sg13
I1
sa(dp16979
g7
I23
sg8
g107
sg10
I6
sg11
VGDF-15
p16980
sg13
I1
sasg23
(lp16981
(dp16982
g7
I144
sg26
VC0281361
p16983
sg10
I25
sg11
Vpancreatic adenocarcinoma
p16984
sg13
I2
sasa(dp16985
g2
S'The present study investigated the association between cancer-associated weight loss and plasma GDF-15 concentration, as well as other biomarkers, in patients with metastatic lung or exocrine pancreatic cancer.\n'
p16986
sg4
(lp16987
(dp16988
g7
I89
sg8
g107
sg10
I13
sg11
Vplasma GDF-15
p16989
sg13
I2
sasg23
(lp16990
(dp16991
g7
I183
sg26
VC0346648
p16992
sg10
I26
sg11
Vexocrine pancreatic cancer
p16993
sg13
I3
sa(dp16994
g7
I55
sg26
VC0006826
p16995
sg10
I6
sg11
Vcancer
p16996
sg13
I1
sasa.